PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Carey, JR; Liedo, P; Muller, HG; Wang, JL; Vaupel, JW				Carey, JR; Liedo, P; Muller, HG; Wang, JL; Vaupel, JW			Dual modes of aging in Mediterranean fruit fly females	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; LIFE; MORTALITY; FLIES; RATS; DIET; AGE	The life history of medflies is characterized by two physiological modes with different demographic schedules of fertility and survival: a waiting mode in which both mortality and reproduction are low and a reproductive mode in which mortality is very low at the onset of egg laying but accelerates as eggs are laid. Medflies stay in waiting mode when they are fed only sugar. When fed protein, a scarce resource in the wild, medflies switch to reproductive mode. Medflies that switch from waiting to reproductive mode survive longer than medflies kept in either mode exclusively. An understanding of the physiological shift that occurs between the waiting and reproductive modes may yield information about the fundamental processes that determine longevity.	Univ Calif Davis, Dept Entomol, Livermore, CA 95616 USA; Univ Calif Berkeley, Ctr Econ & Demog Aging, Berkeley, CA 94720 USA; Colegio Frontera Sur, Tapachula 30700, Chiapas, Mexico; Univ Calif Davis, Div Stat, Livermore, CA 95616 USA; Max Planck Inst Demog Res, D-18057 Rostock, Germany; Odense Univ, Sch Med, DK-5000 Odense C, Denmark; Duke Univ, Sanford Inst, Durham, NC 27706 USA; Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA	University of California System; University of California Davis; University of California System; University of California Berkeley; El Colegio de la Frontera Sur (ECOSUR); University of California System; University of California Davis; Max Planck Society; University of Southern Denmark; Duke University; University of Southern California	Carey, JR (corresponding author), Univ Calif Davis, Dept Entomol, 1 Shields Ave, Livermore, CA 95616 USA.	jrcarey@ucdavis.edu	Liedo, Pablo/E-9313-2010	Liedo, Pablo/0000-0002-0004-1721; Vaupel, James/0000-0003-0783-3905	NIA NIH HHS [AG-08761] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIGAKI T, 1984, EXP GERONTOL, V19, P267, DOI 10.1016/0531-5565(84)90022-6; Audesirk T., 1996, BIOL LIFE EARTH; BALL ZB, 1947, AM J PHYSIOL, V150, P511, DOI 10.1152/ajplegacy.1947.150.3.511; Bell G., 1986, Oxford Surveys in Evolutionary Biology, V3, P83; BOULETREAU J, 1978, OECOLOGIA, V35, P319, DOI 10.1007/BF00345140; Carey JR, 1998, FUNCT ECOL, V12, P359, DOI 10.1046/j.1365-2435.1998.00197.x; CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CAREY JR, 1986, ENTOMOL EXP APPL, V42, P159, DOI 10.1007/BF00343543; CAREY JR, 1997, ZEUS SALMON BIODEMOG, P127; CAREY JR, 1985, OIKOS, V44, P257; DEPAOLA LV, 1994, MODULATION AGING PRO, pCH10; Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407; Finch CE, 1990, LONGEVITY SENESCENCE; HOLEHAN AM, 1985, MECH AGEING DEV, V33, P19, DOI 10.1016/0047-6374(85)90106-X; HOLLIDAY R, 1989, BIOESSAYS, V10, P4; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; Lotka AJ, 1907, SCIENCE, V26, P21, DOI 10.1126/science.26.653.21-a; Masoro EJ, 1996, J GERONTOL A-BIOL, V51, pB387, DOI 10.1093/gerona/51A.6.B387; MASORO EJ, 1988, J GERONTOL, V43, pB59, DOI 10.1093/geronj/43.3.B59; MERRY BJ, 1979, J REPROD FERTIL, V57, P253, DOI 10.1530/jrf.0.0570253; Muller HG, 1997, P NATL ACAD SCI USA, V94, P2762, DOI 10.1073/pnas.94.6.2762; Muller HG, 1997, BIOMETRIKA, V84, P881, DOI 10.1093/biomet/84.4.881; Partridge L., 1986, P45; PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; ROITBERG BD, 1989, EVOL ECOL, V3, P183, DOI 10.1007/BF02270920; TATAR M, 1995, ECOLOGY, V76, P2066, DOI 10.2307/1941681; TULJAPURKAR S, 1989, THEOR POPUL BIOL, V35, P227, DOI 10.1016/0040-5809(89)90001-4; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; VISSCHER MB, 1952, AM J PHYSIOL, V170, P72, DOI 10.1152/ajplegacy.1952.170.1.72; Wachter K. W., 1997, ZEUS SALMON BIODEMOG, P1; Weindruch R, 1996, SCI AM, V274, P46, DOI 10.1038/scientificamerican0196-46; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	33	126	131	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					996	998		10.1126/science.281.5379.996	http://dx.doi.org/10.1126/science.281.5379.996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703516				2022-12-28	WOS:000075412700049
J	Olivieri, NF; Brittenham, GM; McLaren, CE; Templeton, DM; Cameron, RG; McClelland, RA; Burt, AD; Fleming, KA				Olivieri, NF; Brittenham, GM; McLaren, CE; Templeton, DM; Cameron, RG; McClelland, RA; Burt, AD; Fleming, KA			Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-THALASSEMIA; L1; 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE; OVERLOAD; EFFICACY; DESFERRIOXAMINE; TRIAL	Background Deferiprone is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major. Studies in an animal model showed that prolonged treatment is associated with a decline in the effectiveness of deferiprone and exacerbation of hepatic fibrosis. Methods Hepatic iron stores were determined yearly by chemical analysis of liver-biopsy specimens, magnetic susceptometry, or both. Three hepatopathologists who were unaware of the patients' clinical status, the time at which the specimens were obtained, and the iron content of the specimens examined 72 biopsy specimens from 19 patients treated with deferiprone for more than one year. For comparison, 48 liver-biopsy specimens obtained from 20 patients treated with parenteral deferoxamine far more than one year were similarly reviewed. Results Of the 19 patients treated with deferiprone, 18 had received the drug continuously for a mean (+/-SE) of 4.6+/-0.3 years. At the final analysis, 7 of the 18 had hepatic iron concentrations of at least 80 mu mol per gram of liver, wet weight (the value above which there is an increased risk of cardiac disease and early death in patients with thalassemia major). Of 19 patients in whom multiple biopsies were performed over a period of more than one year, 14 could be evaluated for progression of hepatic fibrosis; of the 20 deferoxamine-treated patients, 12 could be evaluated for progression. Five deferiprone-treated patients had progression of fibrosis, as compared with none of those given deferoxamine (P=0.04). By the life-table method, we estimated that the median time to progression of fibrosis was 3.2 years in deferiprone-treated patients. After adjustment for the initial hepatic iron concentration, the estimated odds of progression of fibrosis increased by a factor of 5.8 (95 percent confidence interval, 1.1 to 29.6) with each additional year of deferiprone treatment. Conclusions Deferiprone does not adequately control body iron burden in patients with thalassemia and may worsen hepatic fibrosis. (N Engl J Med 1998;339:417-23.) (C)1998, Massachusetts Medical Society.	Univ Toronto, Dept Med & Pediat, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A1, Canada; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ Calif Irvine, Dept Med, Div Epidemiol, Irvine, CA 92717 USA; Newcastle Univ, Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Dept Pathol, Oxford OX3 9DU, England	University of Toronto; University of Toronto; University of Toronto; Columbia University; Columbia University; University of California System; University of California Irvine; Newcastle University - UK; University of Oxford	Olivieri, NF (corresponding author), Hosp Sick Children, Hemoglobinopathy Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Olivieri, Nancy/AAI-2250-2020; Burt, Alastair D/D-3634-2013	Burt, Alastair D/0000-0002-3011-7774; Templeton, Douglas/0000-0003-0693-662X; Fleming, Kenneth/0000-0002-3200-1302	NHLBI NIH HHS [HL61219, HL58203] Funding Source: Medline; NIDDK NIH HHS [DK49108] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL058203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049108, R01DK049108] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL MB, 1992, BRIT J HAEMATOL, V82, P460, DOI 10.1111/j.1365-2141.1992.tb06445.x; ALDOURI MA, 1987, J CLIN PATHOL, V40, P1353, DOI 10.1136/jcp.40.11.1353; ALREFAIE FN, 1992, BLOOD, V80, P593; ALREFAIE FN, 1995, BRIT J HAEMATOL, V91, P224, DOI 10.1111/j.1365-2141.1995.tb05274.x; BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; Bergeron RJ, 1993, DEV IRON CHELATORS C; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; CARTHEW P, 1994, BIOMETALS, V7, P267; *COOL AN PROGR REV, 1995, COOL AN PROGR BIOL M; Cragg L., 1996, Blood, V88, p646A; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V262, P1472; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FOSBURG MT, 1990, BLOOD, V76, P435; HALLIWELL B, 1994, DEVELOPMENT OF IRON CHELATORS FOR CLINICAL USE, P33; HALLIWELL B, 1991, DRUGS, V42, P569, DOI 10.2165/00003495-199142040-00003; Hershko C., 1997, Blood, V90, p11A; Hoffbrand AV, 1998, BLOOD, V91, P295, DOI 10.1182/blood.V91.1.295.295_295_300; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KONTOGHIORGHES GJ, 1987, LANCET, V1, P1294; KONTOGHIORGHES GJ, 1990, BRIT J HAEMATOL, V76, P295, DOI 10.1111/j.1365-2141.1990.tb07887.x; MOTEKAITIS RJ, 1991, INORG CHIM ACTA, V183, P71, DOI 10.1016/S0020-1693(00)82997-7; NATHAN DG, 1995, NEW ENGL J MED, V332, P1315; Olivieri, 1997, BLOOD, V89, P2621; Olivieri NF, 1997, BLOOD, V89, P739, DOI 10.1182/blood.V89.3.739; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056/NEJM199504063321404; OLIVIERI NF, 1990, LANCET, V336, P1275, DOI 10.1016/0140-6736(90)92962-H; OVERMOYER BA, 1987, ARCH PATHOL LAB MED, V111, P549; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RISDON RA, 1973, GUT, V14, P421; RISDON RA, 1975, J PATHOL, V116, P83, DOI 10.1002/path.1711160204; TONDURY P, 1990, BRIT J HAEMATOL, V76, P550; Wong A, 1997, BIOMETALS, V10, P247, DOI 10.1023/A:1018312113969	36	313	334	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					417	423		10.1056/NEJM199808133390701	http://dx.doi.org/10.1056/NEJM199808133390701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700174				2022-12-28	WOS:000075342500001
J	Borch-Johnsen, K; Eriksson, J; Qiao, Q; Tuomilehto, J; Balkau, B; Nordisk, N				Borch-Johnsen, K; Eriksson, J; Qiao, Q; Tuomilehto, J; Balkau, B; Nordisk, N		DECODE Study Grp	Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; RISK-FACTORS; FOLLOW-UP; MEN; PREVALENCE; POPULATION; FINLAND; NIDDM	Objective: To evaluate the impact of the revised diagnostic criteria far diabetes mellitus adopted by the American Diabetes Association on prevalence of diabetes and on classification of patients. For epidemiological purposes the American criteria use a fasting plasma glucose concentration greater than or equal to 7.0 mmol/l in contrast with the current World Health Organisation criteria of 2 hour glucose concentration greater than or equal to 11.1 mmol/l. Design: Data were collected from 13 populations and three occupational based studies from eight European countries. Ail studies used a 75 g oral glucose tolerance test to measure fasting and 2 hour glucose concentrations. Subjects: 17 881 men; 8309 women; age range 17-92 years. Main outcome measures: Classification of diabetes according to both sets of criteria. Results: The application of the American criteria on European populations induced changes in prevalence of diabetes ranging from a reduction of 4.0% to an increase of 13.2%. A total of 1517 previously undiagnosed individuals had diabetes according to either the WHO or the American criteria. Among 1044 with diabetes according to American criteria, only 45% had 2 hour values fulfilling the WHO criteria. The risk of disagreement of classification decreased with increasing body mass index (P < 0.00001) and increasing age (P < 0.0001); the impact of sex was not significant (P = 0.08). Conclusions: This shift in strategy from using 2 hour to fasting plasma glucose will cause an increase in the prevalence of diabetes in some European populations. A high degree of disagreement in the classification was observed between the two recommendations. Prospective data are needed to evaluate whether the WHO or the American criteria best identify individuals at risk of developing microvascular complications and cardiovascular disease. Wider implementation of revised diagnostic criteria should await prospective data.	Steno Diabet Ctr, DK-2820 Gentofte, Denmark	Steno Diabetes Center	Borch-Johnsen, K (corresponding author), Steno Diabet Ctr, Steensens Vej 2, DK-2820 Gentofte, Denmark.	kbjo@novo.dk		Eriksson, Johan/0000-0002-2516-2060				[Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; Charles MA, 1996, LANCET, V348, P1657, DOI 10.1016/S0140-6736(05)65719-4; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; FESKENS EJM, 1994, ARTERIOSCLER THROMB, V14, P1641, DOI 10.1161/01.ATV.14.10.1641; FONTBONNE A, 1992, DIABETES, V41, P1385, DOI 10.2337/diabetes.41.11.1385; GARANCINI MP, 1995, DIABETOLOGIA, V38, P306, DOI 10.1007/BF00400635; Gavin JR, 1997, DIABETES CARE, V20, P1183; HAGERUP L, 1987, SYGDOM SUNDHED BEFOL; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HITUNEN L, 1994, DIABETIC MED, V11, P241; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; Kangas T, 1996, DIABETES CARE, V19, P494, DOI 10.2337/diacare.19.5.494; KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157; KLEINMAN JC, 1981, AM J PUBLIC HEALTH, V71, P73, DOI 10.2105/AJPH.71.1.73; Lindberg O, 1997, J AM GERIATR SOC, V45, P407, DOI 10.1111/j.1532-5415.1997.tb05163.x; McCance DR, 1997, DIABETOLOGIA, V40, P247, DOI 10.1007/s001250050671; MOOY JM, 1995, DIABETES CARE, V18, P1270, DOI 10.2337/diacare.18.9.1270; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Pajak Andrzej, 1995, European Heart Journal, V16, P143; PYRALA K, 1979, J CHRON DIS, V32, P45; RAJALA U, 1995, SCAND J PRIM HEALTH, V13, P222, DOI 10.3109/02813439508996765; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; STENGARD JH, 1993, DIABETES METAB, V19, P121; Unwin N, 1997, J EPIDEMIOL COMMUN H, V51, P160, DOI 10.1136/jech.51.2.160; Vanhala M J, 1997, J Cardiovasc Risk, V4, P291, DOI 10.1097/00043798-199708000-00010; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; World Health Organization, 1980, WHO TECHN REP SER, V646, P1; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232	31	346	351	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1998	317	7155					371	375						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694750				2022-12-28	WOS:000075409600021
J	Wright, JC; Weinstein, MC				Wright, JC; Weinstein, MC			Gains in life expectancy from medical interventions - Standardizing data on outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; COST-EFFECTIVENESS ANALYSIS; CELL LUNG-CANCER; DECISION-ANALYSIS; ADJUVANT CHEMOTHERAPY; RANDOMIZED TRIAL; BREAST-CANCER; HEPATITIS-B; THERAPY; RISKS	Background The gain in life expectancy is an important measure of the effectiveness of medical interventions, but its interpretation requires that it be placed in context. The interpretation of gains in life expectancy is particularly problematic for preventive interventions, for which the gains are often just weeks or even days when averaged across the entire target population. Methods We tabulated the gains in life expectancy from a variety of medical interventions as reported in 83 published sources and categorized them according to target population and disease. We considered prevention in populations at average risk for particular diseases, prevention in populations at elevated risk, and treatments in populations with established disease. Results The gains in life expectancy from preventive interventions in populations at average risk ranged from less than one month to slightly more than one year per person receiving the intervention, but the gains were as high as five yea rs or more if the prevention was targeted at persons at especially high risk. The gains in life expectancy from treatments of established disease ranged from several months (for coronary thrombolysis and revascularization to treat heart disease) to as long as nine years (for chemotherapy to treat advanced testicular cancer). Conclusions A gain in life expectancy from a medical intervention can be categorized as large or small by comparing it with gains from other interventions aimed at the same target population. A gain in life expectancy of a month from a preventive intervention targeted at populations at average risk and a gain of a year from a preventive intervention targeted at populations at elevated risk can both be considered large. The framework we developed for standardizing gains in life expectancy can be used in the interpretation of data on the outcomes of interventions. (N Engl J Med 1998;339:380-6.) (C)1998, Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Weinstein, MC (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 718 Huntington Ave, Boston, MA 02115 USA.							BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; CARSON JL, 1992, AM J MED, V92, P45, DOI 10.1016/0002-9343(92)90014-3; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; FELDMAN S, 1993, OBSTET GYNECOL, V81, P968; Fleming C, 1993, JAMA, V269, P2650; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GOODWIN PJ, 1988, J CLIN ONCOL, V6, P1537, DOI 10.1200/JCO.1988.6.10.1537; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HATZIANDREU EI, 1989, AM J PUBLIC HEALTH, V79, P273; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; HINMAN AR, 1984, JAMA-J AM MED ASSOC, V251, P3109, DOI 10.1001/jama.251.23.3109; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; KASSIRER JP, 1987, ANN INTERN MED, V106, P275, DOI 10.7326/0003-4819-106-2-275; LARSEN GC, 1992, J AM COLL CARDIOL, V19, P1323, DOI 10.1016/0735-1097(92)90341-J; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEVIN LA, 1992, EUR HEART J, V13, P2, DOI 10.1093/oxfordjournals.eurheartj.a060041; Lindfors KK, 1996, JAMA-J AM MED ASSOC, V275, P112; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; MARK DB, 1995, NEW ENGL J MED, V333, P267; Messori A, 1996, EUR J CLIN PHARMACOL, V51, P111, DOI 10.1007/s002280050169; Messori A, 1997, EUR J CLIN PHARMACOL, V51, P427, DOI 10.1007/s002280050225; Messori A, 1997, BONE MARROW TRANSPL, V19, P275, DOI 10.1038/sj.bmt.1700642; NAIMARK D, 1994, J GEN INTERN MED, V9, P702, DOI 10.1007/BF02599016; Neutra R., 1977, COSTS RISKS BENEFITS, P277; OBRIEN BJ, 1987, J CHRON DIS, V40, pS137, DOI 10.1016/S0021-9681(87)80043-7; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; RANSOHOFF DF, 1993, ANN INTERN MED, V119, P606, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00010; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; Schrag D, 1997, NEW ENGL J MED, V337, P434; SHIBLEY L, 1990, J NATL CANCER I, V82, P186, DOI 10.1093/jnci/82.3.186; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; TSEVAT J, 1991, CIRCULATION, V84, P2610; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004	40	280	281	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1998	339	6					380	386		10.1056/NEJM199808063390606	http://dx.doi.org/10.1056/NEJM199808063390606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107MD	9691106				2022-12-28	WOS:000075212300006
J	Dearwater, SR; Coben, JH; Campbell, JC; Nah, G; Glass, N; McLoughlin, E; Bekemeier, B				Dearwater, SR; Coben, JH; Campbell, JC; Nah, G; Glass, N; McLoughlin, E; Bekemeier, B			Prevalence of intimate partner abuse in women treated at community hospital emergency departments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOMESTIC VIOLENCE; BATTERED WOMEN; PREGNANCY	Context. - The majority of prior studies examining intimate partner abuse in the emergency department (ED) setting have been conducted in large, urban tertiary care settings and may not reflect the experiences of women seen at community hospital EDs, which treat the majority of ED patients in the United States. Objective. - To determine the prevalence of intimate partner abuse among female patients presenting for treatment in community hospital EDs and describe their characteristics. Design. - An anonymous survey conducted from 1995 through 1997 inquiring about physical, sexual, and emotional abuse. Setting. - Eleven community EDs in Pennsylvania and California. Participants. - All women aged 18 years or older who came to the ED during selected shifts. Main Outcome Measures. - Reported acute trauma from abuse, past-year physical or sexual abuse, and lifetime physical or emotional abuse. Results. - Surveys were completed by 3455 (74%) of 4641 women seen. The prevalence of reported abuse by an intimate partner was 2.2% (95% confidence interval [CI], 1.7%-2.7%) for acute trauma from abuse, 14.4% (95% CI, 13.2%-15.6%) for past-year physical or sexual abuse, and 36.9% (95% CI, 35.3%-38.6%) for lifetime emotional or physical abuse. California had significantly higher reported rates of past-year physical or sexual abuse (17% vs 12%, P < .001) and lifetime abuse (44% vs 31%, P < .001) than Pennsylvania. Logistic regression modeling identified 4 risk factors for reported physical, sexual, or acute trauma from abuse within the past year: age, 18 to 39 years (odds ratio [OR], 2.2; 95% CI, 1.7-3.0); monthly income less than $1000 (OR, 1.7; 95% CI, 1.3-2.1); children younger than 18 years living in the home (OR, 2.0; 95% CI, 1.5-2.6); and ending a relationship within the past year (OR, 7.0; 95% CI, 5.5-8.9). Conclusion. - If the prevalence of abuse in community hospitals throughout the United States is similar to the range of prevalence estimates found in this study, then heightened awareness of intimate partner abuse is warranted for patients presenting to the ED.	Allegheny Univ Hlth Sci, Ctr Violence & Injury Control, Dept Emergency Med, Pittsburgh, PA 15212 USA; Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA; San Francisco Injury Ctr Res & Prevent, San Francisco, CA USA; Tacoma Pierce Cty Hlth Dept, Tacoma, WA USA	Johns Hopkins University	Dearwater, SR (corresponding author), Allegheny Univ Hlth Sci, Ctr Violence & Injury Control, Dept Emergency Med, 1 Allegheny Ctr,Suite 510, Pittsburgh, PA 15212 USA.			Glass, Nancy/0000-0002-6691-3684	PHS HHS [R49/CCR310285-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; BACHMAN R, 1995, NCJ154348 US DEP JUS; BERGMAN B, 1991, AM J PUBLIC HEALTH, V81, P1468; Bullock L, 1989, Nurse Pract, V14, P53; Campbell J, 1996, J Am Med Womens Assoc (1972), V51, P106; CAMPBELL JC, 1992, RES NURS HEALTH, V15, P219, DOI 10.1002/nur.4770150308; Crowell N. A., 1996, UNDERSTANDING VIOLEN; Feldhaus KM, 1997, JAMA-J AM MED ASSOC, V277, P1357, DOI 10.1001/jama.277.17.1357; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; HAREL Y, 1994, AM J PUBLIC HEALTH, V84, P599, DOI 10.2105/AJPH.84.4.599; Klein E, 1997, ENDING DOMESTIC VIOL; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; Muelleman RL, 1996, ANN EMERG MED, V28, P486, DOI 10.1016/S0196-0644(96)70110-5; RINGLE C, 1997, NCJ165812 US DEP JUS; SOEKEN K, IN PRESS DIAGNOSIS C; STARK E, 1981, WIFE ABUSE MED SETTI; Varvaro F., 1989, AM COLL EMERG PHYS, V11, P8	18	220	222	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					433	438		10.1001/jama.280.5.433	http://dx.doi.org/10.1001/jama.280.5.433			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105AR	9701078	Bronze			2022-12-28	WOS:000075050200030
J	Beecham, L				Beecham, L			More women hold top NHS jobs	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					286	286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677242				2022-12-28	WOS:000075081900063
J	Miskin, JE; Abrams, CC; Goatley, LC; Dixon, LK				Miskin, JE; Abrams, CC; Goatley, LC; Dixon, LK			A viral mechanism for inhibition of the cellular phosphatase calcineurin	SCIENCE			English	Article							SWINE FEVER VIRUS; TRANSCRIPTION FACTOR NFAT1; NF-KAPPA-B; CONSTRUCTION	The transcription factor NFAT (nuclear factor of activated T cells) controls the expression of many immunomodulatory proteins. African swine Fever virus inhibits proinflammatory cytokine expression in infected macrophages, and a viral protein A238L was found to display the activity of the immunosuppressive drug cyclosporin A by inhibiting NFAT-regulated gene transcription in vivo. This it does by binding the catalytic subunit of calcineurin and inhibiting calcineurin phosphatase activity.	AFRC, Inst Anim Hlth, Pirbright Lab, Pirbright GU24 0NF, Surrey, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Dixon, LK (corresponding author), AFRC, Inst Anim Hlth, Pirbright Lab, Pirbright GU24 0NF, Surrey, England.		Goatley, Lynnette/ABI-1426-2020; Dixon, Linda K/B-9063-2019	Goatley, Lynnette/0000-0001-6792-2235; Dixon, Linda/0000-0003-3845-3016				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; DavisPoynter NJ, 1996, IMMUNOL CELL BIOL, V74, P513, DOI 10.1038/icb.1996.84; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HARPER JW, 1993, CELL, V75, P805; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MISKIN JE, UNPUB; Neilan JG, 1997, VIROLOGY, V235, P377, DOI 10.1006/viro.1997.8693; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RODRIGUEZ JM, 1992, VIROLOGY, V188, P67, DOI 10.1016/0042-6822(92)90735-8; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149	17	112	118	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					562	565		10.1126/science.281.5376.562	http://dx.doi.org/10.1126/science.281.5376.562			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677199				2022-12-28	WOS:000075012300041
J	Gordon, LK; Levin, LA				Gordon, LK; Levin, LA			Visual loss in giant cell arteritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TEMPORAL ARTERITIS; POLYMYALGIA-RHEUMATICA; BIOPSY FINDINGS; PROGNOSIS; DIAGNOSIS		Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53792 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA; W Los Angeles Vet Affairs Hosp, Los Angeles, CA USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Levin, LA (corresponding author), Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 600 Highland Ave, Madison, WI 53792 USA.							ACHKAR AA, 1994, ANN INTERN MED, V120, P987, DOI 10.7326/0003-4819-120-12-199406150-00003; AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ALBERT DM, 1976, ARCH OPHTHALMOL-CHIC, V94, P2072; Boehme MWJ, 1996, AM J MED, V101, P387, DOI 10.1016/S0002-9343(96)00230-6; Cornblath WT, 1997, OPHTHALMOLOGY, V104, P854, DOI 10.1016/S0161-6420(97)30222-X; FAUCHALD P, 1972, ANN INTERN MED, V77, P845, DOI 10.7326/0003-4819-77-6-845; Fineman MS, 1996, AM J OPHTHALMOL, V122, P428, DOI 10.1016/S0002-9394(14)72073-2; Font C, 1997, BRIT J RHEUMATOL, V36, P251; Ghanchi FD, 1997, SURV OPHTHALMOL, V42, P99, DOI 10.1016/S0039-6257(97)00052-0; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; Hayreh SS, 1997, AM J OPHTHALMOL, V123, P285, DOI 10.1016/S0002-9394(14)70123-0; JONASSON F, 1979, SCOT MED J, V24, P111, DOI 10.1177/003693307902400203; Lauwerys BR, 1997, J RHEUMATOL, V24, P1570; Levin LA, 1996, INVEST OPHTH VIS SCI, V37, P2744; LIU GT, 1994, OPHTHALMOLOGY, V101, P1779; MELBERG NS, 1995, OPHTHALMOLOGY, V102, P1611; Myklebust G, 1996, BRIT J RHEUMATOL, V35, P1161; RodriguezValverde V, 1997, AM J MED, V102, P331, DOI 10.1016/S0002-9343(97)00117-4; SALVARANI C, 1995, ANN INTERN MED, V123, P192, DOI 10.7326/0003-4819-123-3-199508010-00006; Schmidt WA, 1997, NEW ENGL J MED, V337, P1336, DOI 10.1056/NEJM199711063371902; SLAVIN ML, 1994, AM J OPHTHALMOL, V117, P81, DOI 10.1016/S0002-9394(14)73018-1; Sorbi D, 1996, ARTHRITIS RHEUM-US, V39, P1747, DOI 10.1002/art.1780391019; Sudlow C, 1997, BRIT MED J, V315, P549, DOI 10.1136/bmj.315.7107.549; Wagner AD, 1996, AM J PATHOL, V148, P1925; Weyand CM, 1997, ARTHRITIS RHEUM, V40, P19, DOI 10.1002/art.1780400105	25	36	37	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					385	386		10.1001/jama.280.4.385	http://dx.doi.org/10.1001/jama.280.4.385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686559				2022-12-28	WOS:000074804200044
J	Sjostrom, L; Rissanen, A; Andersen, T; Boldrin, M; Golay, A; Koppeschaar, HPF; Krempf, M				Sjostrom, L; Rissanen, A; Andersen, T; Boldrin, M; Golay, A; Koppeschaar, HPF; Krempf, M		European Multicentre Orlistat Study Grp	Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients	LANCET			English	Article							GASTROINTESTINAL LIPASE INHIBITOR; DIETARY-FAT ABSORPTION; HEALTHY-VOLUNTEERS; RO-18-0647; PREVALENCE	Background We undertook a randomised controlled trial to assess the efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, in promoting weight loss and preventing weight regain in obese patients over a 2-year period. Methods 743 patients (body-mass index 28-47 kg/m(2)), recruited at 15 European centres, entered a 4-week, single-blind, placebo lead-in period on a slightly hypocaloric diet (600 kcal/day deficit). 688 patients who completed the lead-in were assigned double-blind treatment with orlistat 120 mg (three times a day) or placebo for 1 year in conjunction with the hypocaloric diet. In a second 52-week double-blind period patients were reassigned orlistat or placebo with a weight maintenance (eucaloric) diet. Findings From the start of lead-in to the end of year 1, the orlistat group lost, on average, more bodyweight than the placebo group (10.2% [10.3 kg] vs 6.1% [6.1 kg]; LSM difference 3.9 kg [p<0.001] from randomisation to the end of year 1). During year 2, patients who continued with orlistat regained, on average, half as much weight as those patients switched to placebo (p<0.001). Patients switched from placebo to orlistat lost an additional 0.9 hg during year 2, compared with a mean regain of 2.5 kg in patients who continued on placebo (p<0 001). Total cholesterol, low-density lipoprotein (LDL) cholesterol, LDL/high-density lipoprotein ratio, and concentrations of glucose and insulin decreased more in the orlistat group than in the placebo group. Gastrointestinal adverse events were more common in the orlistat group. Other adverse symptoms occurred at a similar frequency during both treatments. Interpretation Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period. The use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.	Sahlgrens Univ Hosp, Dept Med, S-41345 Gothenburg, Sweden; Univ Helsinki, Cent Hosp, Helsinki, Finland; Hvidovre Univ Hosp, Copenhagen, Denmark; Hoffmann La Roche, Nutley, NJ USA; Univ Hosp Geneva, Geneva, Switzerland; Acad Ziekenhuis, Utrecht, Netherlands; Hotel Dieu, Nantes, France	Sahlgrenska University Hospital; University of Helsinki; Helsinki University Central Hospital; University of Copenhagen; Roche Holding; University of Geneva	Sjostrom, L (corresponding author), Sahlgrens Univ Hosp, Dept Med, S-41345 Gothenburg, Sweden.			Krempf, Michel/0000-0002-4353-9511				Curfman GD, 1997, NEW ENGL J MED, V337, P629, DOI 10.1056/NEJM199708283370909; *DEP HLTH, 1995, NUTR PHYS ACT TASK F; DRENT ML, 1995, INT J OBESITY, V19, P221; DRENT ML, 1993, INT J OBESITY, V17, P241; FOREYT J, 1995, LANCET, V346, P34; Golay A, 1997, INT J OBESITY, V21, pS2; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; GUYGRAND B, 1989, LANCET, V2, P1142; HAUPTMAN J B, 1992, American Journal of Clinical Nutrition, V55, p309S, DOI 10.1093/ajcn/55.1.309s; James W. P. T., 1990, HUMAN ENERGY REQUIRE; KROTKIEWSKI M, 1977, INT J OBESITY, V1, P395; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUSKOWSKAWOLK A, 1993, J EPIDEMIOL COMMUN H, V47, P195, DOI 10.1136/jech.47.3.195; LISSNER L, 1995, EUR J CLIN NUTR, V49, P79; Melia AT, 1996, J CLIN PHARMACOL, V36, P647, DOI 10.1002/j.1552-4604.1996.tb04230.x; PRESCOTTCLARK P, 1997, HLTH SURVEY ENGLAND; Seidell JC, 1997, HORM METAB RES, V29, P155, DOI 10.1055/s-2007-979011; Sjostrom CD, 1997, OBES RES, V5, P519; TONSTAD S, 1994, EUR J CLIN PHARMACOL, V46, P405, DOI 10.1007/BF00191901; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907; ZHI J, 1994, CLIN PHARMACOL THER, V56, P82, DOI 10.1038/clpt.1994.104; Zhi JG, 1996, J CLIN PHARMACOL, V36, P152, DOI 10.1002/j.1552-4604.1996.tb04180.x; [No title captured]	23	765	804	2	72	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					167	172		10.1016/S0140-6736(97)11509-4	http://dx.doi.org/10.1016/S0140-6736(97)11509-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683204				2022-12-28	WOS:000074859800008
J	Kros, CJ; Ruppersberg, JP; Rusch, A				Kros, CJ; Ruppersberg, JP; Rusch, A			Expression of a potassium current in inner hair cells during development of hearing in mice	NATURE			English	Article							GUINEA-PIG; COCHLEA; CALCIUM; SODIUM; CHICK; NERVE	Excitable cells use ion channels to tailor their biophysical properties to the functional demands made upon them(1). During development, these demands may alter considerably, often associated with a change in the cells' complement of ion channels(2-4). Here we present evidence for such a change in inner hair cells, the primary sensory receptors in the mammalian cochlea. In mice, responses to sound can first be recorded from the auditory nerve and observed behaviourally from 10-12 days after birth; these responses mature rapidly over the next 4 days(5-8). Before this time, mouse inner hair cells have slow voltage responses and fire spontaneous and evoked action potentials. During development of auditory responsiveness a large, fast potassium conductance is expressed, greatly speeding up the membrane time constant and preventing action potentials. This change in potassium channel expression turns the inner hair cell from a regenerative, spiking pacemaker into a high-frequency signal transducer.	Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, ENT Hosp, Div Sensory Biophys, D-72076 Tubingen, Germany	University of Bristol; University of Sussex; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Kros, CJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Physiol, Univ Walk, Bristol BS8 1TD, Avon, England.		Huisman, Jeroen/B-7859-2009					Appenrodt P, 1997, J PHYSIOL-LONDON, V501P, pP147; ART JJ, 1987, J PHYSIOL-LONDON, V385, P207, DOI 10.1113/jphysiol.1987.sp016492; Ehret G, 1983, DEV AUDITORY VESTIBU, P211; EVANS MG, 1987, BIOPHYS J, V52, P649, DOI 10.1016/S0006-3495(87)83256-3; FUCHS PA, 1990, P ROY SOC B-BIOL SCI, V241, P122, DOI 10.1098/rspb.1990.0075; FUCHS PA, 1988, J NEUROSCI, V8, P2460; Geleoc GSG, 1997, P ROY SOC B-BIOL SCI, V264, P611, DOI 10.1098/rspb.1997.0087; GUMMER AW, 1994, NEUROREPORT, V5, P685, DOI 10.1097/00001756-199402000-00006; Hille B., 1992, IONIC CHANNELS EXCIT; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KETTNER RE, 1985, J NEUROSCI, V5, P275; Kirkwood NK, 1997, J PHYSIOL-LONDON, V504P, pP127; KROS CJ, 1990, J PHYSIOL-LONDON, V421, P263, DOI 10.1113/jphysiol.1990.sp017944; KROS CJ, 1993, J PHYSIOL-LONDON, V473, pP231; Kros CJ, 1996, COCHLEA, P318; LIPPE WR, 1994, J NEUROSCI, V14, P1486, DOI 10.1523/JNEUROSCI.14-03-01486.1994; Mikaelian D, 1965, ACTA OTO-LARYNGOL, V59, P451, DOI DOI 10.3109/00016486509124579; Mu MY, 1997, DEV BRAIN RES, V99, P29, DOI 10.1016/S0165-3806(96)00194-0; ODOWD DK, 1988, J NEUROSCI, V8, P792; PALMER AR, 1986, HEARING RES, V24, P1, DOI 10.1016/0378-5955(86)90002-X; PUJOL R, 1998, DEV AUDITORY SYSTEM, P146; Romand R., 1983, DEV AUDITORY VESTIBU, P47; RUBSAMEN R, 1998, DEV AUDITORY SYSTEM, P193; RUSSELL IJ, 1987, HEARING RES, V31, P9, DOI 10.1016/0378-5955(87)90210-3; SHNERSON A, 1982, DEV BRAIN RES, V2, P65; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; SUGIHARA I, 1989, J NEUROPHYSIOL, V62, P1330, DOI 10.1152/jn.1989.62.6.1330; Walsh Edward J., 1992, P161	29	301	306	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					281	284		10.1038/28401	http://dx.doi.org/10.1038/28401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685158				2022-12-28	WOS:000074851900049
J	Clarke, M; Chalmers, I				Clarke, M; Chalmers, I			Discussion sections in reports of controlled trials published in general medical journals - Islands in search of continents?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			QUALITY; BIAS	Context.-Several journals have adopted the Consolidated Standards of Reporting Trials (CONSORT) recommendations to make assessment of the quality of randomized controlled trials (RCTs) easier. One of these recommendations is that the trial's results be discussed in light of the totality of the available evidence. Objective.-To assess the extent to which reports of RCTs published in 5 general medical journals have discussed new results in light of all available evidence. Design.-Assessment of the discussion sections in all 26 reports of RCTs published during May 1997 in Annals of Infernal Medicine, BMJ, JAMA, The Lancet, and The New England Journal of Medicine. Main Outcome Measure.-The inclusion or mention of a systematic review in the discussion section of each article. Results.-ln only 2 articles were the RCT's results discussed in the context of an updated systematic review of earlier trials. In a further 4 articles, references were made to relevant systematic reviews, but no attempts were made to integrate the results of the new trials in updated versions of these reviews. One article was probably the first published trial to address the question studied. The remaining 19 articles included no evidence that any systematic attempt had been made to set the reported trial's results in the context of previous trials. Conclusion.-There is little evidence that journals have adequately implemented the CONSORT recommendation that results of an RCT be discussed in light of the totality of the available evidence.	Univ Oxford, Clin Trial Serv Unit, Oxford OX1 2JD, England; United Kingdom Cochrane Ctr, Oxford, England	University of Oxford; Cochrane Centre	Clarke, M (corresponding author), Radcliffe Infirm, Imperial Canc Res Fund, Clin Trial Serv Unit, Oxford OX2 6HE, England.	mike.clarke@ctsu.ox.ac.uk						Abraham E, 1997, JAMA-J AM MED ASSOC, V277, P1531, DOI 10.1001/jama.277.19.1531; [Anonymous], 1986, Lancet, V2, P57; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bishop NJ, 1997, NEW ENGL J MED, V336, P1557, DOI 10.1056/NEJM199705293362203; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; CAMPBELL FM, 1990, B MED LIBR ASSOC, V78, P376; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; Chung SSC, 1997, BMJ-BRIT MED J, V314, P1307, DOI 10.1136/bmj.314.7090.1307; *COCHR CONTR TRIAL, 1997, COCHR LIB DAT CD ROM; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COUNSELL C, 1997, COCHRANE LIB DATABAS; Creed F, 1997, BRIT MED J, V314, P1381; DONNE J, MEDITATION, V17; Gasche C, 1997, ANN INTERN MED, V126, P782, DOI 10.7326/0003-4819-126-10-199705150-00006; Gianni AM, 1997, NEW ENGL J MED, V336, P1290, DOI 10.1056/NEJM199705013361804; GIBBS WW, 1995, SCI AM, V273, P92, DOI 10.1038/scientificamerican0895-92; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; Grossman DC, 1997, JAMA-J AM MED ASSOC, V277, P1605, DOI 10.1001/jama.277.20.1605; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; HEMMINKI E, 1982, METHOD INFORM MED, V21, P81; HILL AB, 1965, BRIT MED J, V4, P870; Jacobson JM, 1997, NEW ENGL J MED, V336, P1487, DOI 10.1056/NEJM199705223362103; Khan WA, 1997, ANN INTERN MED, V126, P697, DOI 10.7326/0003-4819-126-9-199705010-00004; Liem MSL, 1997, NEW ENGL J MED, V336, P1541, DOI 10.1056/NEJM199705293362201; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; MULROW CD, 1996, COCHRANE COLLABORATI; Perez V, 1997, LANCET, V349, P1594, DOI 10.1016/S0140-6736(96)08007-5; Quinn J, 1997, JAMA-J AM MED ASSOC, V277, P1527; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Sandercock P, 1997, LANCET, V349, P1569; SAUNDERS MC, 1985, LANCET, V2, P793, DOI 10.1016/S0140-6736(85)90792-5; Schuman P, 1997, ANN INTERN MED, V126, P689, DOI 10.7326/0003-4819-126-9-199705010-00003; Simoons ML, 1997, LANCET, V349, P1429; Smith AJ, 1997, CAN J ANAESTH, V44, P9, DOI 10.1007/BF03014316; Spruance SL, 1997, JAMA-J AM MED ASSOC, V277, P1374, DOI 10.1001/jama.277.17.1374; Tcheng JE, 1997, LANCET, V349, P1422; Tingle AJ, 1997, LANCET, V349, P1277, DOI 10.1016/S0140-6736(96)12031-6; TYSON JE, 1983, J PEDIATR-US, V102, P10, DOI 10.1016/S0022-3476(83)80277-7; *UPD SOFTW, 1997, COCHR LIB DAT CD ROM; WESSELY S, 1997, 3 INT C PEER REV BIO; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; Winters JC, 1997, BRIT MED J, V314, P1320, DOI 10.1136/bmj.314.7090.1320; 1986, LANCET, V2, P79	45	109	112	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					280	282		10.1001/jama.280.3.280	http://dx.doi.org/10.1001/jama.280.3.280			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZZ204	9676682	Bronze			2022-12-28	WOS:000074706000027
J	Hatch, CL; Goodman, SN				Hatch, CL; Goodman, SN			Perceived value of providing peer reviewers with abstracts and preprints of related published and unpublished papers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			QUALITY	Context.-Many journals provide peer reviewers with written instructions regarding review criteria,such as the originality of results, but little research has been done to investigate ways to improve or facilitate the peer review task. Objective.-To assess the value that peer reviewers place on receipt of supplemental materials (eg, abstracts of related papers and preprints of related unpublished manuscripts). Design.-Questionnaire survey sent to all 733 peer reviewers recruited by the Journal of the National Cancer Institute to review 356 manuscripts consecutively sent out for review from February 24, 1997, through January 16, 1998. The inclusion of supplemental materials with manuscript review packages was optional. Main Outcome Measure.-The peer reviewers' assessment of the actual or potential usefulness of supplemental materials on the performance of peer review. Results.-A total of 481 (66%) of 733 questionnaires were returned, Of the 471 respondents' questionnaires that could be used, 217 (46%) indicated that they received abstracts, and 44 (10%) of 458 respondents indicated that they received preprints. Higher proportions of peer reviewers who received supplemental materials than those who had not received them felt that they were (or would be) useful to them when reviewing the manuscript (63% [95% confidence interval (CI), 57%-69%] vs 45% [95% CI, 38%-52%]; P < .001) and to the peer review process in general (80% [95% CI, 75%-85%] vs 64% [95% CI, 58%-70%]; P <,001). Conclusion.-The majority of respondents indicated that supplemental materials helped (or would have helped) them evaluate manuscripts and valued them more highly when they actually received them.	Journal Natl Canc Inst, Bethesda, MD USA; Johns Hopkins Univ, Div Biostat, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Hatch, CL (corresponding author), Execut Plaza N,Room 635H,6130 Execut Blvd, Rockville, MD 20892 USA.			Goodman, Steven/0000-0002-3872-5723				ANGELL M, 1989, NEW ENGL J MED, V320, P1212, DOI 10.1056/NEJM198905043201812; [Anonymous], 1969, N Engl J Med, V281, P676; EVANS AT, 1993, J GEN INTERN MED, V8, P422, DOI 10.1007/BF02599618; Frank E, 1996, PREV MED, V25, P102, DOI 10.1006/pmed.1996.0035; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; KASSIRER JP, 1994, JAMA-J AM MED ASSOC, V272, P96, DOI 10.1001/jama.272.2.96; LIKERT RA, 1952, EDUC PSYCHOL MEAS, V12, P313	7	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					273	274		10.1001/jama.280.3.273	http://dx.doi.org/10.1001/jama.280.3.273			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676679				2022-12-28	WOS:000074706000024
J	Hoen, WP; Walvoort, HC; Overbeke, AJPM				Hoen, WP; Walvoort, HC; Overbeke, AJPM			What are the factors determining authorship and the order of the authors' names? - A study among authors of the Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-Although criteria justifying authorship of scientific medical articles have been formulated, it is not well known how authorship is established in practice. Objectives.-To assess the criteria for authorship used by authors of original articles in Nederlands Tijdschrift voor Geneeskunde (NTVG, the Dutch Journal of Medicine), and to determine whether the criteria for authorship of the International Committee of Medical Journal Editors (ICMJE) are known and applied. Design.-Survey questionnaire, Setting.-Editorial office of the NTVG. Participants.-All 450 authors of 115 original articles published in 1995. Main Outcome Measures.-Author's contribution to study design, material, collection of data, statistics, and writing. Results.-Of 362 forms returned, 352 could be analyzed (78.2% response rate). The 5 questions most frequently answered affirmatively were ICMJE criteria: critical reading (86.1% of the authors), approval of the final version (84.7%), study design (74.7%), study conception (64.2%), and revision (63.4%). Authors rated their contribution 2 points higher than did their coauthors. Interestingly, 64% of the respondents met the ICMJE criteria, although 60% of the respondents did not know them. Conclusion.-Authorship was mostly in accordance with ICMJE criteria although many authors were not familiar with them.	Nederlands Tijdschrift Geneeskunde, NL-1070 AZ Amsterdam, Netherlands		Overbeke, AJPM (corresponding author), Nederlands Tijdschrift Geneeskunde, POB 75971, NL-1070 AZ Amsterdam, Netherlands.	ntvg@sara.nl						Bhopal R, 1997, BRIT MED J, V314, P1009, DOI 10.1136/bmj.314.7086.1009; Clever LH, 1997, ANN INTERN MED, V126, P36, DOI 10.7326/0003-4819-126-1-199701010-00006; GOODMAN NW, 1994, BRIT MED J, V309, P1482, DOI 10.1136/bmj.309.6967.1482; *INT COMM MED J ED, 1985, BRIT MED J, V291, P722; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438	5	84	93	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					217	218		10.1001/jama.280.3.217	http://dx.doi.org/10.1001/jama.280.3.217			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZZ204	9676659	Bronze			2022-12-28	WOS:000074706000004
J	Topol, EJ; Lincoff, AM; Califf, RM; Tcheng, JE; Kleiman, NS; Adelman, AG; Burton, JR; Talley, JD; Ivanhoe, RJ; Ducas, C; Cheung, PK; Schick, U; Badard, D; Kramer, J; Leary, J; Snyder, H; Wilson, R; Dearen, M; Caramori, P; Webber, S; Taylor, J; Ferrando, T; Cohen, E; Balleza, L; Rouse, C; Hogg, N; Kelly, T; Alston, S; Webb, J; Buller, E; Ricci, DR; Mockman, S; Tanguay, JF; Poitras, AM; Timis, G; Davey, D; Coleman, P; Herrold-Runge, P; O'Neill, BJ; Foshey, K; Fitzgerald, N; Almond, D; Kostuk, W; White, J; Oskalns, R; Gottlieb, R; Koren, P; Palazzo, D; Azrin, M; Barry, MB; Blankenship, J; Demko, SL; Kraft, P; Dvorak, L; Brown, R; Colclough, M; Stevens, K; Sarembock, I; Snyder, L; Sayre, S; Browne, K; Roy, M; Reen, B; Short, R; Thompson, M; Chiodo, V; Hoffman, D; Bass, TA; Zenni, M; Rohman, G; Marquis, JF; Labinaz, M; Jelley, J; French, W; Goldberg, S; Wang, S; Gradman, A; Boltey, L; Collins, J; Worley, S; Hollywood, L; Frey, L; Yakubov, S; Gilliland, C; Rodriguez, A; Potter, K; Taylor, M; Aji, J; Cleary, E; Tannenbaum, M; Hartz, A; Rund, M; Smigley, R; Lopez, J; Kunny, P; Hochman, J; Slater, J; Termey, D; Bates, E; Fox-Bruenger, P; Gonzalez, M; Jopperri, L; Runyon, JP; Higby, N; Krucoft, M; Booth, T; Aguirre, F; Bach, R; Mechem, C; Azrin, M; Murphy, D; Cummins, FE; Nonweiler, J; Sanz, M; Cole, C; Weston, MW; Anderson, HV; Weigelt, L; Larkin, T; Jackson, BJ; Rosenberg, MJ; Tully, S; Hartman, C; Lunow, S; Lucore, C; Mishkel, G; McShane, K; Muhlestein, B; Jerman, J; Sander, G; Stevens, A; Chisholm, R; Del Core, M; Stengel, L; Cannata, R; Castle, V; DeLuca, S; Balog, C; Knuth, T; McCollough, T; Godfrey, N; Melton, J; Miller, D; Pulliam, M; Sapp, S; Sigmon, KN; Templin, M; Montague, E; Carlson, J; Heil, L; Zovkic, V; Malone, K; Rodkey, S; Haas, G; Harrington, R; Kapadis, S; Campbell, L; Mukherjee, D; Deedy, M; Augostini, R; Alexander, J; Whellan, D; Bajzer, C; Rabbani, R; Clemons, P; Baishnab, R; Randall, R; Underwood, D; Lauer, MA; Lauer, MS; Roe, M; Farhy, R; Schweikert, R; Grady, T; Ellis, S; Moliterno, D; Debowey, D; Ivanc, T; Ols, L; Poliszcuk, R; Balazs, E; Witherspoon, B; Anderson, KM; Barnathan, E; Cabot, CF; Stoner, GL; Weisman, HF				Topol, EJ; Lincoff, AM; Califf, RM; Tcheng, JE; Kleiman, NS; Adelman, AG; Burton, JR; Talley, JD; Ivanhoe, RJ; Ducas, C; Cheung, PK; Schick, U; Badard, D; Kramer, J; Leary, J; Snyder, H; Wilson, R; Dearen, M; Caramori, P; Webber, S; Taylor, J; Ferrando, T; Cohen, E; Balleza, L; Rouse, C; Hogg, N; Kelly, T; Alston, S; Webb, J; Buller, E; Ricci, DR; Mockman, S; Tanguay, JF; Poitras, AM; Timis, G; Davey, D; Coleman, P; Herrold-Runge, P; O'Neill, BJ; Foshey, K; Fitzgerald, N; Almond, D; Kostuk, W; White, J; Oskalns, R; Gottlieb, R; Koren, P; Palazzo, D; Azrin, M; Barry, MB; Blankenship, J; Demko, SL; Kraft, P; Dvorak, L; Brown, R; Colclough, M; Stevens, K; Sarembock, I; Snyder, L; Sayre, S; Browne, K; Roy, M; Reen, B; Short, R; Thompson, M; Chiodo, V; Hoffman, D; Bass, TA; Zenni, M; Rohman, G; Marquis, JF; Labinaz, M; Jelley, J; French, W; Goldberg, S; Wang, S; Gradman, A; Boltey, L; Collins, J; Worley, S; Hollywood, L; Frey, L; Yakubov, S; Gilliland, C; Rodriguez, A; Potter, K; Taylor, M; Aji, J; Cleary, E; Tannenbaum, M; Hartz, A; Rund, M; Smigley, R; Lopez, J; Kunny, P; Hochman, J; Slater, J; Termey, D; Bates, E; Fox-Bruenger, P; Gonzalez, M; Jopperri, L; Runyon, JP; Higby, N; Krucoft, M; Booth, T; Aguirre, F; Bach, R; Mechem, C; Azrin, M; Murphy, D; Cummins, FE; Nonweiler, J; Sanz, M; Cole, C; Weston, MW; Anderson, HV; Weigelt, L; Larkin, T; Jackson, BJ; Rosenberg, MJ; Tully, S; Hartman, C; Lunow, S; Lucore, C; Mishkel, G; McShane, K; Muhlestein, B; Jerman, J; Sander, G; Stevens, A; Chisholm, R; Del Core, M; Stengel, L; Cannata, R; Castle, V; DeLuca, S; Balog, C; Knuth, T; McCollough, T; Godfrey, N; Melton, J; Miller, D; Pulliam, M; Sapp, S; Sigmon, KN; Templin, M; Montague, E; Carlson, J; Heil, L; Zovkic, V; Malone, K; Rodkey, S; Haas, G; Harrington, R; Kapadis, S; Campbell, L; Mukherjee, D; Deedy, M; Augostini, R; Alexander, J; Whellan, D; Bajzer, C; Rabbani, R; Clemons, P; Baishnab, R; Randall, R; Underwood, D; Lauer, MA; Lauer, MS; Roe, M; Farhy, R; Schweikert, R; Grady, T; Ellis, S; Moliterno, D; Debowey, D; Ivanc, T; Ols, L; Poliszcuk, R; Balazs, E; Witherspoon, B; Anderson, KM; Barnathan, E; Cabot, CF; Stoner, GL; Weisman, HF		EPISTENT Investigators	Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade	LANCET			English	Article							ARTERY DISEASE; INTERVENTIONS; IMPLANTATION; PLACEMENT; THERAPY; ASPIRIN	Background Coronary stenting with use of heparin, aspirin, and ticlopidine for thromboprophylaxis is performed in more than 500 000 patients per year worldwide. We did a randomised controlled trial to assess the role of platelet glycoprotein-IIb/IIIa blockade for use in elective stenting. Methods At 63 hospitals in the USA and Canada, 2399 patients with ischaemic heart disease and suitable coronary-artery lesions were randomly assigned stenting plus placebo (n=809), stenting plus abciximab, a IIb/IIIa inhibitor (n=794), or balloon angioplasty plus abciximab (n=796). The primary endpoint was a combination of death, myocardial infarction, or need for urgent revascularisation in the first 30 says, All patients received heparin, aspirin, and standard pharmacological therapy. Findings The primary endpoint occurred in 87 (10.8%) of 809 patients in the stent plus placebo group, 42 (5.3%) of 794 in the stent plus abciximab group (hazard ratio 0.48 [95% CI 0.33-0.69] p<0.001), and 55 (6.9%) of 796 in the balloon plus abciximab group (0.63 [0.45-0.88] p=0.007). The main outcomes that occurred less with abciximab were death and large myocardial infarction-7.8% in the placebo group, 3.0% for stent plus abciximab (p<0.001), and 4.7% for balloon angioplasty plus abciximab (p=0.01). Major bleeding complications occurred in 2.2% of patients assigned stent plus placebo, 1.5% assigned stent plus abciximab, and 1.4% assigned balloon angioplasty plus abciximab (p=0 38). Interpretation Platelet glycoprotein-IIb/IIIa blockade with abciximab substantially improves the safety of coronary-stenting procedures. Balloon angioplasty with abciximab is safer than stenting without abciximab.	Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Univ Manitoba, Winnipeg, MB, Canada; Cardiovasc Associates Delaware Valley, Cherry Hill, NJ USA; Univ Arkansas, Little Rock, AR 72204 USA; Toronto Hosp, Toronto, ON, Canada; Baylor Coll Med, Houston, TX 77030 USA; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Alberta Hosp, Edmonton, AB, Canada; Moses Cone Mem Hosp, Greensboro, NC USA; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada; Inst Cardiol Montreal, Montreal, PQ, Canada; William Beaumont Hosp, Royal Oak, MI 48072 USA; No Calif Med Assoc, Santa Rosa, CA USA; Victoria Gen Hosp, Halifax, NS, Canada; London Hlth Sci Ctr, London, ON, Canada; Univ Penn, Grad Hosp, Philadelphia, PA 19104 USA; Univ Connecticut, Ctr Hlth, Farmington, CT USA; Geisinger Med Ctr, Danville, PA 17822 USA; Henry Ford Hosp, Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA; Royal Columbian Hosp, New Westminster, BC, Canada; Univ Virginia, Charlottesville, VA USA; Watson Clin, Lakeland, FL USA; Rochester Gen Hosp, Rochester, NY 14621 USA; Presbyterian Hosp, Charlotte, NC USA; Univ Med Ctr, Jacksonville, FL USA; Ottawa Civic Hosp, Ottawa, ON, Canada; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Western PA Hosp, Pittsburgh, PA USA; Lancaster Heart Fdn, Lancaster, PA USA; Midwest Cardiol Res Fdn, Columbus, OH USA; Florida Hosp, Orlando, FL USA; Deborah Heart & Lung Ctr, Browns Mills, NJ 08015 USA; Iowa Heart Ctr, Des Moines, IA USA; Duke Univ, Med Ctr, Durham, NC USA; Royal Univ Hosp, Saskatoon, SK S7N 0W8, Canada; St Lukes Roosevelt Hosp, New York, NY 10025 USA; Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA; Orlando Reg Med Ctr Columbia, Orlando, FL USA; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Durham VA Med Ctr, Durham, NC USA; St Louis Univ Hosp, St Louis, MO USA; Hartford Hosp, Farmington, CT USA; Milwaukee Heart & Vasc Clin, Milwaukee, WI USA; Christ Hosp, Cincinnati, OH 45219 USA; Western Montana Clin, Missoula, MT USA; Harbor Side Med Tower, Tampa, FL USA; Univ Texas, Sch Med, Houston, TX USA; Northwestern Univ, Evanston Hosp, Evanston, IL 60201 USA; Lutheran Gen Hosp, Park Ridge, IL 60068 USA; Sentra Norfolk Gen Hosp, Norfolk, VA USA; Prairie Cardiovasc Consult, Springfield, IL USA; LDS Hosp, Salt Lake City, UT USA; Louisiana State Univ, Med Ctr, New Orleans, LA USA; St Michaels Hosp, Toronto, ON, Canada; Creighton Cardiac Ctr, Omaha, NE USA	Cleveland Clinic Foundation; University of Manitoba; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Baylor College of Medicine; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Alberta; Moses Cone Memorial Hospital; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; Universite de Montreal; Institut de Cardiologie de Montreal; Beaumont Health; Dalhousie University; University of Victoria; London Health Sciences Centre; University of Pennsylvania; Pennsylvania Medicine; University of Connecticut; Geisinger Medical Center; Henry Ford Health System; Henry Ford Hospital; University of Virginia; Rochester General Hospital; University of Ottawa; Ottawa Hospital Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Adventist Health Services; AdventHealth; Duke University; University of Saskatchewan; Mount Sinai St. Luke's; Mount Sinai West; University of Michigan System; University of Michigan; Orlando Regional Medical Center; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Saint Louis University; Hartford Hospital; Christ Hospital - Ohio; University of Texas System; NorthShore University Health System; Northwestern University; Louisiana State University System; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Creighton University	Topol, EJ (corresponding author), Cleveland Clin Fdn, Dept Cardiol, F-25,9500 Euclid Ave, Cleveland, OH 44195 USA.	topole@cesmtp.ccf.org	Bach, Richard/AAI-2515-2021; haas, gretchen/GQP-4644-2022; Bach, Richard G/G-9764-2011; Caramori, Paulo/I-1370-2012; Lauer, Michael S/L-9656-2013; Mukherjee, Debabrata/AAG-1486-2019; Blankenship, James/AAX-4084-2020	Lauer, Michael S/0000-0002-9217-8177; Mukherjee, Debabrata/0000-0002-5131-3694; Blankenship, James/0000-0003-4966-533X; Topol, Eric/0000-0002-1478-4729				Abdelmeguid AE, 1996, AM HEART J, V131, P1097, DOI 10.1016/S0002-8703(96)90083-6; Abdelmeguid AE, 1996, CIRCULATION, V94, P1528, DOI 10.1161/01.CIR.94.7.1528; Abdelmeguid AE, 1996, CIRCULATION, V94, P3369, DOI 10.1161/01.CIR.94.12.3369; BERTRAND M, 1996, CIRCULATION S1, V94, P1; BRENER SJ, IN PRESS CIRCULATION; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Califf RM, 1998, J AM COLL CARDIOL, V31, P241, DOI 10.1016/S0735-1097(97)00506-8; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Gawaz M, 1996, CIRCULATION, V93, P229, DOI 10.1161/01.CIR.93.2.229; Hall P, 1996, CIRCULATION, V93, P215, DOI 10.1161/01.CIR.93.2.215; Hanrath P, 1997, CIRCULATION, V96, P1445; Kereiakes DJ, 1998, CIRCULATION, V97, P857, DOI 10.1161/01.CIR.97.9.857; Kong TQ, 1997, JAMA-J AM MED ASSOC, V277, P461, DOI 10.1001/jama.277.6.461; KUTRYK MJ, 1998, TXB CARDIOVASCULAR M, P2033; LEON MB, 1996, CIRCULATION S1, V94, P1; Mak KH, 1996, J AM COLL CARDIOL, V27, P494, DOI 10.1016/0735-1097(95)00466-1; Makkar RR, 1997, CIRCULATION, V95, P1015; MALONE AP, 1998, SS BARNEY EQUITY RES; Masotti M., 1996, European Heart Journal, V17, P120; NEUMANN FJ, IN PRESS CIRCULATION; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SERRUYS PW, 1997, CIRCULATION S1, V96, P653; Simoons ML, 1997, LANCET, V349, P1429; TARDIFF BE, 1997, EUR HEART J, V18, P857; Tcheng JE, 1997, LANCET, V349, P1422; TOPOL EJ, 1995, AM J CARDIOL, V76, P307, DOI 10.1016/S0002-9149(99)80087-3; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Urban P, 1998, J AM COLL CARDIOL, V31, p397A, DOI 10.1016/S0735-1097(97)85427-7	30	1273	1291	0	34	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1998	352	9122					87	92		10.1016/S0140-6736(98)85010-1	http://dx.doi.org/10.1016/S0140-6736(98)85010-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672272				2022-12-28	WOS:000074775100010
J	Price, JL; Blau, J; Rothenfluh, A; Abodeely, M; Kloss, B; Young, MW				Price, JL; Blau, J; Rothenfluh, A; Abodeely, M; Kloss, B; Young, MW			Double-time is a novel Drosophila clock gene that regulates PERIOD protein accumulation	CELL			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; BIOLOGICAL CLOCK; NERVOUS-SYSTEM; NUCLEAR ENTRY; MUTANTS; MELANOGASTER; EXPRESSION; MUTATION; REVEALS; BRAIN	We have isolated three alleles of a novel Drosophila clock gene, double-time (dbt). Short- (dbts) and long-period (dbt(L)) mutants after both behavioral rhythmicity and molecular oscillations from previously identified clock genes, period and timeless. A third allele, dbf(P), causes pupal lethality and eliminates circadian cycling of per and tim gene products in larvae. In dbt(P) mutants, PER proteins constitutively accumulate, remain hypophosphorylated, and no longer depend on TIM proteins for their accumulation. We propose that the normal function of DOUBLETIME protein is to reduce the stability and thus the level of accumulation of monomeric PER proteins. This would promote a delay between per/tim transcription and PER/TIM complex function, which is essential for molecular rhythmicity.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Natl Sci Fdn, Sci & Technol Ctr Biol Timing, New York, NY 10021 USA	Rockefeller University; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University	Blau, J (corresponding author), Rockefeller Univ, Genet Lab, 1230 York Ave, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Kloss, Brian/0000-0003-0130-8739; Rothenfluh, Adrian/0000-0002-3813-5723	NIGMS NIH HHS [GM 54339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; BRUCE VG, 1972, GENETICS, V70, P537; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Kaneko M, 1997, J NEUROSCI, V17, P6745; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1994, J BIOL RHYTHM, V9, P189, DOI 10.1177/074873049400900303; KUNES S, 1993, J NEUROSCI, V13, P752; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Myers MP, 1997, NUCLEIC ACIDS RES, V25, P4710, DOI 10.1093/nar/25.23.4710; PITTENDRIGH CS, 1967, P NATL ACAD SCI USA, V58, P1762, DOI 10.1073/pnas.58.4.1762; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Stanewsky R, 1997, J NEUROSCI, V17, P676; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	57	651	670	2	91	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					83	95		10.1016/S0092-8674(00)81224-6	http://dx.doi.org/10.1016/S0092-8674(00)81224-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674430	Bronze			2022-12-28	WOS:000074790800012
J	Tattersall, M; Ellis, P				Tattersall, M; Ellis, P			Communication is a vital part of care	BRITISH MEDICAL JOURNAL			English	Article							EARLY BREAST-CANCER; INFORMATION; SURROGATE; DISEASE		Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia	University of Sydney	Tattersall, M (corresponding author), Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia.							CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; *LINC LOUTH NHS TR, 1997, BREAK BAD NEWS GUID; MCINTOSH J, 1976, LANCET, V2, P300; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; *NAT BREAST CANC C, IN PRESS PSYCH CLIN; *NAT HLTH MRC, 1995, MAN EARL BREAST CANC; PALMER MJ, 1990, RADIOTHER ONCOL, V19, P17, DOI 10.1016/0167-8140(90)90162-P; *PROF ED TRAIN COM, 1994, BREAK BAD NEWS; STREET RL, 1995, CANCER, V76, P2275, DOI 10.1002/1097-0142(19951201)76:11<2275::AID-CNCR2820761115>3.0.CO;2-S; Turner S, 1996, BRIT J CANCER, V73, P222, DOI 10.1038/bjc.1996.39	12	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1891	1892						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9669846				2022-12-28	WOS:000074686500033
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			PCR on a roller coaster	SCIENCE			English	Editorial Material									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							KOPP MK, COMMUNICATION; Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046	2	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1956	1956						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669952				2022-12-28	WOS:000074323800070
J	Resti, M; Azzari, C; Manelli, AF; Moriondo, M; Novembre, E; de Martino, M; Vierucci, A				Resti, M; Azzari, C; Manelli, AF; Moriondo, M; Novembre, E; de Martino, M; Vierucci, A		Tuscany Study Grp Hepatitis C Virus Infect Chil	Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TO-INFANT TRANSMISSION; HCV RNA; GENOTYPES	Objective: To determine the risk factors for and timing of vertical transmission of hepatitis C virus in women who are not infected with HIV-1. Design: Follow up for a median of 28 (range 24-38) months of babies born to women with antibodies to hepatitis C virus but not HIV-1. Subjects: 442 mothers and babies, of whom 403 completed the study. Main outcome measures: Presence of antibodies to hepatitis C virus and viral RNA and alanine aminotransferase activity in babies. Presence of viral RNA, method of infection with hepatitis C, method of delivery, and type of infant feeding in mothers. Results: 13 of the 403 children had acquired hepatitis C virus infection at the end of follow up. All these children were born to women positive for hepatitis C virus RNA; none of the 128 RNA negative mothers passed on the infection (difference 5%, 95% confidence interval 2% to 7%). 6 children had viral RNA immediately after birth. 111 women had used intravenous drugs and 20 had received blood transfusions. 11 of the infected children were born to these women compared with 2 to the 144 with no known risk factor (difference 7%, 2% to 12%). Conclusions: This study suggests that in women not infected with HIV only those with hepatitis C virus RNA are at risk of infecting their babies. Transmission does seem to occur in utero, and the rate of transmission is higher in women who have had blood transfusions or used intravenous drugs than in women with no known risk factor for infection.	Univ Florence, Dept Paediat, I-50132 Florence, Italy; Univ G dAnnunzio, Dept Med, Paediat Sect, Chieti, Italy	University of Florence; G d'Annunzio University of Chieti-Pescara	Azzari, C (corresponding author), Univ Florence, Dept Paediat, I-50132 Florence, Italy.	vierucci@cesit1.unifi.it	Azzari, Chiara/AAB-8584-2019; Moriondo, Maria/AAB-7883-2019; Resti, Massimo/AAB-8756-2019	Azzari, Chiara/0000-0001-7236-1655; Moriondo, Maria/0000-0001-9653-8371; Resti, Massimo/0000-0001-6350-1361				Bortolotti F, 1997, J PEDIATR-US, V130, P990, DOI 10.1016/S0022-3476(97)70289-0; DEMARTINO M, 1992, AIDS, V6, P991, DOI 10.1097/00002030-199209000-00013; DEMARTINO M, 1991, ARCH DIS CHILD, V66, P1235, DOI 10.1136/adc.66.10.1235; Detmer J, 1996, J CLIN MICROBIOL, V34, P901, DOI 10.1128/JCM.34.4.901-907.1996; Hawkins A, 1997, J CLIN MICROBIOL, V35, P187, DOI 10.1128/JCM.35.1.187-192.1997; LAM JPH, 1993, J INFECT DIS, V167, P572, DOI 10.1093/infdis/167.3.572; LIN HH, 1995, J PEDIATR-US, V126, P589, DOI 10.1016/S0022-3476(95)70356-X; MANZINI P, 1995, HEPATOLOGY, V21, P328, DOI 10.1016/0270-9139(95)90088-8; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; PACCAGNINI S, 1995, PEDIATR INFECT DIS J, V14, P195, DOI 10.1097/00006454-199503000-00005; PAWLOTSKY JM, 1995, J INFECT DIS, V171, P1607, DOI 10.1093/infdis/171.6.1607; RESTI M, 1995, ACTA PAEDIATR, V84, P251, DOI 10.1111/j.1651-2227.1995.tb13624.x; Rodriguez EM, 1996, AIDS, V10, P273, DOI 10.1097/00002030-199603000-00006; SHINDO M, 1995, HEPATOLOGY, V22, P418, DOI 10.1002/hep.1840220208; SILINI E, 1995, HEPATOLOGY, V21, P285, DOI 10.1016/0270-9139(95)90082-9; SONI P, 1995, LANCET, V345, P562, DOI 10.1016/S0140-6736(95)90470-0; WEINER AJ, 1993, J VIROL, V67, P4365, DOI 10.1128/JVI.67.7.4365-4368.1993; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5	19	192	196	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1998	317	7156					437	440						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703524	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075490200017
J	Shrestha, NM; Sharma, B; Van Ommeren, M; Regmi, S; Makaju, R; Komproe, I; Shrestha, GB; de Jong, JTVM				Shrestha, NM; Sharma, B; Van Ommeren, M; Regmi, S; Makaju, R; Komproe, I; Shrestha, GB; de Jong, JTVM			Impact of torture on refugees displaced within the developing world - Symptomatology among Bhutanese refugees in Nepal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SOUTHEAST ASIAN REFUGEES; MENTAL-HEALTH STATUS; VIETNAMESE REFUGEES; UNITED-STATES; SURVIVORS; WAR; SEQUELAE; SYMPTOMS; TRAUMA	Context. - Most of the world's refugees are displaced within the developing world. The impact of torture on such refugees is unknown. Objective. - To examine the impact of torture on Bhutanese refugees in Nepal. Design. - Case-control survey. Interviews were conducted by local physicians and included demographics, questions related to the torture experienced, a checklist of 40 medical complaints, and measures of posttraumatic stress disorder (PTSD), anxiety, and depression. Setting. - Bhutanese refugee community in the United Nations refugee camps in the Terai in eastern Nepal. Participants. - A random sample of 526 tortured refugees and a control group of 526 nontortured refugees matched for age and sex. Main Outcome Measures. - The Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R) criteria for PTSD and the Hopkins Symptom Checklist-25 (HSCL-25) for depression and anxiety. Results. - The 2 groups were similar on most demographic variables. The tortured refugees, as a group, suffered more on 15 of 17 DSM-III-R PTSD symptoms (P < .005) acid had higher HSCL-25 anxiety and depression scores (P < .001) than nontortured refugees. Logistic regression analysis showed that history of torture predicted PTSD symptoms (odds ratio [OR], 4.6; 95% confidence interval [CI], 2.7-8.0), depression symptoms (OR, 1.9; 95% CI, 1.4-2,6), and anxiety symptoms (OR, 1.5; 95% CI, 1.1-1.9). Torture survivors who were Buddhist were less likely to be depressed (OR, 0.5; 95% CI, 0.3-0.9) or anxious (OR, 0.7; 95% CI, 0.4-1.0). Those who were male were less likely to experience anxiety (OR, 0.66; 95% CI, 0.44-1.00). Tortured refugees also presented more musculoskeletal system - and respiratory system-related complaints (P<.001 for both). Conclusion. - Torture plays a significant role in the development of PTSD, depression, and anxiety symptoms among refugees from Bhutan living in the developing world.	Ctr Victims Torture, Kathmandu, Nepal; Free Univ Amsterdam, NL-1081 HV Amsterdam, Netherlands; Transcultural Psychosocial Org, Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Sharma, B (corresponding author), MBBS, POB 5839, Kathmandu, Nepal.		Komproe, Ivan/AAJ-8699-2021					Ager A., 1993, MENTAL HLTH REFUGEE; ALLODI F, 1982, CAN J PSYCHIAT, V27, P98, DOI 10.1177/070674378202700203; *AMN INT, 1994, BHUD FORC EX; Amnesty International, 1992, BHUT HUM RIGHTS VIOL; [Anonymous], 1993, SPSS WINDOWS BASE SY; [Anonymous], 1997, COMP INT DIAGN INT C; BASOGLU M, 1994, JAMA-J AM MED ASSOC, V272, P357, DOI 10.1001/jama.272.5.357; BASOGLU M, 1993, JAMA-J AM MED ASSOC, V270, P606, DOI 10.1001/jama.270.5.606; BASOGLU M, 1994, AM J PSYCHIAT, V151, P76; BEISER M, 1986, PSYCHOL MED, V16, P627, DOI 10.1017/S0033291700010382; Boehnlein J.K., 1995, TRANSCULTURAL PSYCHI, V32, P223; CARLSON EB, 1991, AM J PSYCHIAT, V148, P1548; de Girolamo G., 1996, ETHNOCULTURAL ASPECT, P33, DOI [DOI 10.1037/10555-002, 10.1037/10555-002]; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DESJARALAIS R, 1995, WORLD MENTAL HLTH PR; DOERRZEGERS O, 1992, PSYCHIATRY, V55, P177; Ekblad S, 1997, J NERV MENT DIS, V185, P102, DOI 10.1097/00005053-199702000-00006; ElSarraj E, 1996, J TRAUMA STRESS, V9, P595; FAWZI MCS, 1997, JAMA-J AM MED ASSOC, V350, P371; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; HAUFF E, 1993, ACTA PSYCHIAT SCAND, V88, P162, DOI 10.1111/j.1600-0447.1993.tb03432.x; Herman J. L., 1993, POSTTRAUMATIC STRESS, P213; HOLST E, 1994, NEED FUNDING REHABIL; HOUGEN HP, 1988, FORENSIC SCI INT, V36, P153, DOI 10.1016/0379-0738(88)90229-0; HOUGEN HP, 1988, FORENSIC SCI INT, V39, P5, DOI 10.1016/0379-0738(88)90113-2; Hutt M., 1996, Journal of Refugee Studies, V9, P397, DOI 10.1093/jrs/9.4.397; Jaranson JM, 1995, TRANSCULT PSYCHIATRY, V32, P253; KANTEMIR E, 1994, JAMA-J AM MED ASSOC, V272, P400, DOI 10.1001/jama.272.5.400; Lavik NJ, 1996, BRIT J PSYCHIAT, V169, P726, DOI 10.1192/bjp.169.6.726; LIN KM, 1979, ARCH GEN PSYCHIAT, V36, P955; Marsella A.J., 1996, ETHNOCULTURAL ASPECT; Meehl P. E., 1954, CLIN VS STAT PREDICT; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P1567; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Mollica RF, 1996, TORTURE S, V1, P35; MOORE LJ, 1991, J NERV MENT DIS, V179, P728, DOI 10.1097/00005053-199112000-00003; Nice DS, 1996, JAMA-J AM MED ASSOC, V276, P375, DOI 10.1001/jama.276.5.375; Orley J., 1994, AMIDST PERIL PAIN ME, P193; Paker M., 1992, TORTURE ITS CONSEQUE, Vxxiii, P72; Pelcovitz D, 1997, J TRAUMA STRESS, V10, P3, DOI 10.1002/jts.2490100103; PETERSEN HD, 1985, FORENSIC SCI INT, V29, P179, DOI 10.1016/0379-0738(85)90111-2; PETERSEN HD, 1989, SCAND J SOC MED, V17, P13, DOI 10.1177/140349488901700104; Priebe S, 1997, J NERV MENT DIS, V185, P74, DOI 10.1097/00005053-199702000-00002; RASMUSSEN OV, 1984, DAN MED B, V37, P1; Sharma B., 1998, TRANSCULT PSYCHIATRY, V35, P85, DOI DOI 10.1177/136346159803500104; Shrestha NM, 1995, TORTURE TORTURE VICT; Silove D, 1997, BRIT J PSYCHIAT, V170, P351, DOI 10.1192/bjp.170.4.351; SOMNIER F, 1992, TORTURE ITS CONSEQUE, P151; SUMMERFIELD D, 1990, LANCET, V336, P678, DOI 10.1016/0140-6736(90)92163-C; Sundquist J, 1996, SOC PSYCH PSYCH EPID, V31, P21; SUNDQUIST J, 1993, ACTA PSYCHIAT SCAND, V87, P208, DOI 10.1111/j.1600-0447.1993.tb03357.x; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; VanOmmeren M, 1997, LANCET, V350, P595, DOI 10.1016/S0140-6736(05)63188-1; VanVelsen C, 1996, J TRAUMA STRESS, V9, P181, DOI 10.1002/jts.2490090203; WESTERMEYER J, 1989, PSYCHOSOMATICS, V30, P34, DOI 10.1016/S0033-3182(89)72315-X; WESTERMEYER J, 1988, AM J PSYCHIAT, V145, P197; WESTERMEYER J, 1989, J TRAUMA STRESS, V2, P515; WILLIAMS CL, 1991, AM PSYCHOL, V46, P632, DOI 10.1037/0003-066X.46.6.632; World Health Organization, 1992, PSYCH CONS DIS PREV; YOUNG A, 1995, TRANSCULT PSYCHIAT, V32, P286	60	174	175	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					443	448		10.1001/jama.280.5.443	http://dx.doi.org/10.1001/jama.280.5.443			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105AR	9701080	Bronze			2022-12-28	WOS:000075050200032
J	von Hippel, PH				von Hippel, PH			Transcription - An integrated model of the transcription complex in elongation, termination, and editing	SCIENCE			English	Review							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; CHAIN ELONGATION; DNA-REPLICATION; FACTOR-RHO; CLEAVAGE; CONFORMATIONS; PROCESSIVITY; MECHANISMS	Recent findings now allow the development of an integrated model of the thermodynamic, kinetic, and structural properties of the transcription complex in the elongation. termination, and editing phases of transcript formation. This model provides an operational framework for placing known facts and can be extended and modified to incorporate new advances. The most complete information about transcriptional mechanisms and their control continues to come from the Escherichia coli system, upon which most of the explicit descriptions provided here are based. The transcriptional machinery of higher organisms, despite its greater inherent complexity, appears to use many of the same general principles. Thus, the Lessons of E, coli continue to be relevant.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Oregon; University of Oregon	von Hippel, PH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R01GM015792, R37GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KATO KI, 1967, J BIOL CHEM, V242, P2780; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; Rees WA, 1997, J MOL BIOL, V273, P797, DOI 10.1006/jmbi.1997.1327; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RICHARDSON JP, 1975, J MOL BIOL, V98, P565, DOI 10.1016/S0022-2836(75)80087-8; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; ROZOVSKAYA TA, 1982, FEBS LETT, V137, P100, DOI 10.1016/0014-5793(82)80323-2; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SIDORENKOV I, IN PRESS MOL CELL; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; vonHippel PH, 1996, BIOPHYS CHEM, V59, P231, DOI 10.1016/0301-4622(96)00006-3; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7980, DOI 10.1021/bi963179s; WILSON KG, UNPUB; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; WILSON KS, 1994, J MOL BIOL, V244, P36, DOI 10.1006/jmbi.1994.1702; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YAGER TD, UNPUB; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; ZHU AQ, IN PRESS	61	195	196	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					660	665		10.1126/science.281.5377.660	http://dx.doi.org/10.1126/science.281.5377.660			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685251				2022-12-28	WOS:000075107900030
J	Russmann, H; Shams, H; Poblete, F; Fu, YX; Galan, JE; Donis, RO				Russmann, H; Shams, H; Poblete, F; Fu, YX; Galan, JE; Donis, RO			Delivery of epitopes by the Salmonella type III secretion system for vaccine development	SCIENCE			English	Article							LYMPHOCYTES-T; TYPHIMURIUM; CELLS; IDENTIFICATION; IMMUNIZATION; RESPONSES; CARRIERS; VECTORS; STRAINS; GENE	Avirulent strains of Salmonella typhimurium are being considered as antigen delivery vectors. During its intracellular stage in the host, S. typhimurium resides within a membrane-bound compartment and is not an efficient inducer of class I-restricted immune responses. Viral epitopes were successfully delivered to the host-cell cytosol by using the type III protein secretion system of S. typhimurium. This resulted in class I-restricted immune responses that protected vaccinated animals against lethal infection. This approach may allow the efficient use of S. typhimurium as an antigen delivery system to control infections by pathogens that require this type of immune response for protection.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Nebraska System; University of Nebraska Lincoln	Galan, JE (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	galan@asterix.bio.sunysb.edu						ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; COLLAZO CM, 1995, MOL MICROBIOL, V15, P25, DOI 10.1111/j.1365-2958.1995.tb02218.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; CURTISS R, 1994, DEV BIOL STAND, V82, P23; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; DECKHUT AM, 1993, J IMMUNOL, V151, P2658; Fu YX, 1998, J BACTERIOL, V180, P3393, DOI 10.1128/JB.180.13.3393-3399.1998; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; GALAN JE, 1990, GENE, V94, P29, DOI 10.1016/0378-1119(90)90464-3; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1996, CELLULAR MOL BIOL, P2757; GAO XM, 1992, INFECT IMMUN, V60, P3780, DOI 10.1128/IAI.60.9.3780-3789.1992; Hackett Jim, 1993, Current Opinion in Biotechnology, V4, P611, DOI 10.1016/0958-1669(93)90085-B; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KANIGA K, 1995, J BACTERIOL, V177, P7078, DOI 10.1128/jb.177.24.7078-7085.1995; KAREM KL, 1997, J GEN VIROL, V78, P27; Katz SL, 1997, LANCET, V350, P1767, DOI 10.1016/S0140-6736(97)05358-0; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; Lambert PH, 1996, DEV BIOL STAND, V87, P45; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; OSSEVOORT MA, 1995, J IMMUNOTHER, V18, P86, DOI 10.1097/00002371-199508000-00002; Paoletti E, 1996, P NATL ACAD SCI USA, V93, P11349, DOI 10.1073/pnas.93.21.11349; Ringrose JH, 1996, CLIN RHEUMATOL, V15, P79, DOI 10.1007/BF03342653; Rolph MS, 1997, CURR OPIN IMMUNOL, V9, P517, DOI 10.1016/S0952-7915(97)80104-5; Schlom J, 1996, BREAST CANCER RES TR, V38, P27, DOI 10.1007/BF01803781; Schmidt W, 1997, P NATL ACAD SCI USA, V94, P3262, DOI 10.1073/pnas.94.7.3262; SCHODEL F, 1995, DEV BIOL STAND, V84, P245; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; Vitiello A, 1996, J IMMUNOL, V157, P5555; Weiskirch LM, 1997, IMMUNOL REV, V158, P159, DOI 10.1111/j.1600-065X.1997.tb01002.x; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WUNDERLICH J, 1991, CURRENT PROTOCOLS IM; YANG DM, 1990, J IMMUNOL, V145, P2281; 1997, WHOVRDGEN9701	35	227	260	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					565	568		10.1126/science.281.5376.565	http://dx.doi.org/10.1126/science.281.5376.565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677200				2022-12-28	WOS:000075012300042
J	Torigoe, C; Inman, JK; Metzger, H				Torigoe, C; Inman, JK; Metzger, H			An unusual mechanism for ligand antagonism	SCIENCE			English	Article							T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; RECEPTOR LIGANDS; LEUKEMIA-CELLS; IGE; ANTIGEN; PHOSPHORYLATION; AGGREGATION; COMPLEXES; KINASE	The ratio of late to early events stimulated by the mast cell receptor for immunoglobulin E (IgE) correlated with the affinity of a ligand for the receptor-bound IgE. Because excess receptors clustered by a weakly binding ligand could hoard a critical initiating kinase, they prevented the outnumbered clusters engendered by the high-affinity ligands from launching the more complete cascade. A similar mechanism could explain the antagonistic action of some peptides on the activation of T cells.	NIAMSD, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Torigoe, C (corresponding author), NIAMSD, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA.							ALBER G, 1992, J IMMUNOL, V149, P2428; ASHMAN RF, 1969, J BIOL CHEM, V244, P3405; BARSUMIAN EL, 1985, CELL IMMUNOL, V90, P131, DOI 10.1016/0008-8749(85)90175-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLLINS AM, 1995, INT ARCH ALLERGY IMM, V107, P547, DOI 10.1159/000237098; DAY LA, 1963, ANN NY ACAD SCI, V103, P611, DOI 10.1111/j.1749-6632.1963.tb53721.x; ELIOT CW, 1985, FOLKLORE FABLES, P27; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; HABA S, 1991, J IMMUNOL METHODS, V138, P15, DOI 10.1016/0022-1759(91)90059-O; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; LIU FT, 1980, J IMMUNOL, V124, P2728; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; METZGER H, 1982, MOL IMMUNOL, V19, P1071, DOI 10.1016/0161-5890(82)90316-9; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; Rabinowitz JD, 1996, IMMUNITY, V5, P125, DOI 10.1016/S1074-7613(00)80489-6; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; RACIOPPI L, 1995, CHEM IMMUNOL, V60, P79; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIN KE, 1980, J IMMUNOL METHODS, V37, P83, DOI 10.1016/0022-1759(80)90183-0; SUBRAMANIAN K, 1995, THESIS CORNELL U ITH; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; TORIGOE C, UNPUB; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; WOFSY C, 1997, J IMMUNOL, V159, P5985; WOLDEMUSSIE E, 1986, J IMMUNOL, V137, P1674; Wulfing C, 1997, J EXP MED, V185, P1815, DOI 10.1084/jem.185.10.1815; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	39	134	137	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					568	572		10.1126/science.281.5376.568	http://dx.doi.org/10.1126/science.281.5376.568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677201				2022-12-28	WOS:000075012300043
J	Young, A; Willatts, S				Young, A; Willatts, S			Controversies in management of acute brain trauma	LANCET			English	Editorial Material							CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; METABOLISM		Bristol Royal Infirm & Gen Hosp, Dept Anaesthesia, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary	Young, A (corresponding author), Bristol Royal Infirm & Gen Hosp, Dept Anaesthesia, Bristol BS2 8HW, Avon, England.		Young, Amber/H-2988-2018	Young, Amber/0000-0001-7205-492X				ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 1995, MAN SEV HEAD INJ; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DeWitt D S, 1995, New Horiz, V3, P376; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031	20	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1998	352	9123					164	166		10.1016/S0140-6736(05)77803-X	http://dx.doi.org/10.1016/S0140-6736(05)77803-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683202				2022-12-28	WOS:000074859800006
J	Trentham, DE; Le, CH				Trentham, DE; Le, CH			Relapsing polychondritis	ANNALS OF INTERNAL MEDICINE			English	Review							ANTI-CD4 MONOCLONAL-ANTIBODY; SEVERE AORTIC-INSUFFICIENCY; RHEUMATOID-ARTHRITIS; II COLLAGEN; AURICULAR CHONDRITIS; MYELODYSPLASTIC SYNDROMES; INFLAMED CARTILAGE; GENITAL ULCERS; MAGIC SYNDROME; INVOLVEMENT	Relapsing polychondritis, an uncommon, chronic, multisystem disorder characterized by recurrent episodes of inflammation of cartilaginous tissues, can be life-threatening, debilitating, and difficult to diagnose. This review is based on the authors' experience with 36 patients with relapsing polychondritis who were followed from 1980 to 1997, 30 patients located elsewhere who completed a detailed questionnaire and interview, and a perusal of English-language textbooks and papers located by a systematic search of the MEDLINE database. Relapsing polychondritis can present in a highly ambiguous fashion; therefore, in the authors' series, the mean delay from the time medical attention was sought because of symptom onset until diagnosis was 2.9 years. Although prednisone was the main form of treatment, methotrexate seemed to be of additional value. Survival was much more favorable than previously thought. Greater awareness of relapsing polychondritis would probably lead to earlier diagnosis and better outcomes.	Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Trentham, DE (corresponding author), Beth Israel Deaconess Med Ctr, Div Rheumatol, 330 Brookline Ave, Boston, MA 02215 USA.							ARKIN C R, 1975, Seminars in Arthritis and Rheumatism, V5, P41, DOI 10.1016/0049-0172(75)90022-0; BALSACRIADO A, 1990, J RHEUMATOL, V17, P1426; BALSACRIADO A, 1987, INT J CARDIOL, V14, P381, DOI 10.1016/0167-5273(87)90214-2; BARRANCO VP, 1976, ARCH DERMATOL, V112, P1286, DOI 10.1001/archderm.112.9.1286; BELLAMY N, 1990, J RHEUMATOL, V17, P1525; BOTEY A, 1984, AM J NEPHROL, V4, P375, DOI 10.1159/000166856; BOWNESS P, 1991, ARTHRITIS RHEUM, V34, P97, DOI 10.1002/art.1780340115; BUCKLEY LM, 1992, ARTHRITIS RHEUM-US, V35, P812, DOI 10.1002/art.1780350716; CHANGMILLER A, 1987, MEDICINE, V66, P202, DOI 10.1097/00005792-198705000-00004; CHOY EHS, 1991, LANCET, V338, P450, DOI 10.1016/0140-6736(91)91076-7; CLARK LJ, 1992, J LARYNGOL OTOL, V106, P841, DOI 10.1017/S002221510012105X; CONTI JA, 1988, ANN INTERN MED, V109, P163, DOI 10.7326/0003-4819-109-2-163; CREMER MA, 1981, J EXP MED, V154, P535, DOI 10.1084/jem.154.2.535; CROCKFORD MP, 1988, CLIN RADIOL, V39, P386, DOI 10.1016/S0009-9260(88)80277-0; DAMIANI JM, 1979, LARYNGOSCOPE, V89, P929; DAVIS SD, 1989, AM J ROENTGENOL, V153, P953, DOI 10.2214/ajr.153.5.953; DIEBOLD J, 1995, BRIT J HAEMATOL, V89, P820; DOLAN DL, 1966, AM J MED, V41, P285, DOI 10.1016/0002-9343(66)90023-4; DUNNE JA, 1994, CHEST, V105, P864, DOI 10.1378/chest.105.3.864; ENG J, 1991, ANN THORAC SURG, V51, P686, DOI 10.1016/0003-4975(91)90348-T; ESDAILE J, 1977, CAN MED ASSOC J, V116, P1019; ESPINOZA LR, 1981, AM J MED, V71, P181, DOI 10.1016/0002-9343(81)90291-6; ESTES SA, 1983, CUTIS, V32, P471; FIRESTEIN GS, 1985, AM J MED, V79, P65, DOI 10.1016/0002-9343(85)90547-9; FOIDART JM, 1978, NEW ENGL J MED, V299, P1203, DOI 10.1056/NEJM197811302992202; GIMOVSKY ML, 1989, AM J OBSTET GYNECOL, V161, P332, DOI 10.1016/0002-9378(89)90513-9; HAGER MH, 1987, J RHEUMATOL, V14, P162; HANDROCK K, 1993, ANN RHEUM DIS, V52, P895, DOI 10.1136/ard.52.12.895-c; HEBBAR M, 1995, LEUKEMIA, V9, P731; HUGHES RAC, 1972, Q J MED, V41, P363; ISAAK BL, 1986, OPHTHALMOLOGY, V93, P681; LANG B, 1993, ARTHRITIS RHEUM, V36, P660, DOI 10.1002/art.1780360513; LIPNICK RN, 1991, J RHEUMATOL, V18, P98; MANNA R, 1985, CLIN RHEUMATOL, V4, P474, DOI 10.1007/BF02031904; MARSHALL DAS, 1992, ANN RHEUM DIS, V51, P413, DOI 10.1136/ard.51.3.413; MARTIN J, 1976, ARCH DERMATOL, V112, P1272, DOI 10.1001/archderm.112.9.1272; *MASS GEN HOSP, 1982, NEW ENGL J MED, V307, P1631; MCADAM LP, 1976, MEDICINE, V55, P193, DOI 10.1097/00005792-197605000-00001; MCCUNE WJ, 1982, ARTHRITIS RHEUM, V25, P266, DOI 10.1002/art.1780250304; MCKAY DAR, 1974, BRIT J OPHTHALMOL, V58, P600, DOI 10.1136/bjo.58.6.600; MESTRES CA, 1983, THORAC CARDIOV SURG, V31, P307, DOI 10.1055/s-2007-1022003; MICHELSON JB, 1984, SURV OPHTHALMOL, V29, P148, DOI 10.1016/0039-6257(84)90172-3; MICHET CJ, 1990, RHEUM DIS CLIN N AM, V16, P441; MICHET CJ, 1986, ANN INTERN MED, V104, P74, DOI 10.7326/0003-4819-104-1-74; MOHNESIFAR Z, 1982, CHEST, V81, P711; NEILD GH, 1978, BRIT MED J, V1, P743, DOI 10.1136/bmj.1.6115.743; NEILLY JB, 1985, THORAX, V40, P78, DOI 10.1136/thx.40.1.78; OHANLAN M, 1976, ARTHRITIS RHEUM, V19, P191, DOI 10.1002/art.1780190210; ORME RL, 1990, ARCH DERMATOL, V126, P940, DOI 10.1001/archderm.126.7.940; PAPO T, 1993, ANN RHEUM DIS, V52, P384, DOI 10.1136/ard.52.5.384-b; PAZIRANDEH M, 1988, J RHEUMATOL, V15, P630; PIEPKORN M, 1983, ANN INTERN MED, V98, P49, DOI 10.7326/0003-4819-98-1-49; PURCELLI FM, 1962, ANN OTO RHINOL LARYN, V71, P1120, DOI 10.1177/000348946207100426; RAJAEE A, 1989, J RHEUMATOL, V16, P1263; RIDGWAY HB, 1979, ARCH DERMATOL, V115, P43, DOI 10.1001/archderm.115.1.43; ROGERS PH, 1973, AM J MED, V55, P243, DOI 10.1016/0002-9343(73)90175-7; RUHLEN JL, 1981, JAMA-J AM MED ASSOC, V245, P847, DOI 10.1001/jama.245.8.847; SANE DC, 1987, CHEST, V91, P268, DOI 10.1378/chest.91.2.268; SELF J, 1967, ARCH INTERN MED, V120, P109; SILVA J, 1991, J RHEUMATOL, V18, P908; STEWART KA, 1992, J RHEUMATOL, V19, P498; STEWART SS, 1988, NEUROLOGY, V38, P150, DOI 10.1212/WNL.38.1.150; STROBEL ES, 1992, J RHEUMATOL, V19, P1482; SUNDARAM MBM, 1983, NEUROLOGY, V33, P513, DOI 10.1212/WNL.33.4.513; SVENSON KLG, 1984, SCAND J RHEUMATOL, V13, P329, DOI 10.3109/03009748409111304; TERATO K, 1990, ARTHRITIS RHEUM, V33, P1493, DOI 10.1002/art.1780331006; TISHLER M, 1987, J RHEUMATOL, V14, P367; Trentham David E., 1993, P1369; TRENTHAM DE, 1995, RHEUM DIS CLIN N AM, V21, P817; TRENTHAM DE, 1996, CLIN IMMUNOLOGY PRIN, P1395; VANBESIEN K, 1992, AM J HEMATOL, V40, P47, DOI 10.1002/ajh.2830400110; VANDECKER W, 1988, ANN INTERN MED, V109, P340, DOI 10.7326/0003-4819-109-4-340; VANDERLUBBE PA, 1991, LANCET, V337, P1349, DOI 10.1016/0140-6736(91)93023-3; WASSERFALLEN JB, 1992, ANN RHEUM DIS, V51, P1184, DOI 10.1136/ard.51.10.1184; WEST PDB, 1988, J LARYNGOL OTOL, V102, P254, DOI 10.1017/S0022215100104657; WILLIS J, 1984, CAN J NEUROL SCI, V11, P402, DOI 10.1017/S0317167100045819	76	259	282	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					114	122		10.7326/0003-4819-129-2-199807150-00011	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669970				2022-12-28	WOS:000074852000007
J	Cox, NLT; Abdul-Hamid, AR; Mulley, GP				Cox, NLT; Abdul-Hamid, AR; Mulley, GP			Why deny ACE inhibitors to patients with aortic stenosis?	LANCET			English	Article									St James Univ Hosp, Dept Med Elderly, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Cox, NLT (corresponding author), St James Univ Hosp, Dept Med Elderly, Leeds LS9 7TF, W Yorkshire, England.							AWAN NA, 1981, AM HEART J, V101, P386, DOI 10.1016/0002-8703(81)90126-5; GROSE R, 1979, AM J CARDIOL, V44, P1371, DOI 10.1016/0002-9149(79)90455-7; MCGRATH BP, 1981, AUST NZ J MED, V11, P639, DOI 10.1111/j.1445-5994.1981.tb03538.x; RIEGGER GAJ, 1988, J CARDIOVASC PHARM, V11, P538, DOI 10.1097/00005344-198805000-00005; WONG SS, 1992, ACTA DERM-VENEREOL, V72, P357	5	21	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					111	112		10.1016/S0140-6736(98)85016-2	http://dx.doi.org/10.1016/S0140-6736(98)85016-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672278				2022-12-28	WOS:000074775100016
J	Ogryzko, VV; Kotani, T; Zhang, XL; Schiltz, RL; Howard, T; Yang, XJ; Howard, BH; Qin, J; Nakatani, Y				Ogryzko, VV; Kotani, T; Zhang, XL; Schiltz, RL; Howard, T; Yang, XJ; Howard, BH; Qin, J; Nakatani, Y			Histone-like TAFs within the PCAF histone acetylase complex	CELL			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; TFIID COMPLEX; MOLECULAR-CLONING; CELL-CYCLE; ADA2; ACETYLTRANSFERASE; COACTIVATOR; INTERACTS; TAF(II)40	PCAF histone acetylase plays a role in regulation of transcription, cell cycle progression, and differentiation. Here, we show that PCAF is found in a complex consisting of more than 20 distinct polypeptides. Strikingly, some polypeptides are identical to TBP-associated factors (TAFs), which are subunits of TFIID. Like TFIID, histone fold-containing factors are present within the PCAF complex. The histone H3- and H2B-like subunits within the PCAF complex are identical to those within TFIID, namely, hTAF(II)31 and hTAF(II)20/15, respectively. The PCAF complex has a novel histone H4-like subunit with similarity to hTAF(II)80 that interacts with the histone H3-like domain of hTAF(II)31. Moreover, the PCAF complex has a novel subunit with WD40 repeats having a similarity to hTAF(II)100.	NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Nakatani, Y (corresponding author), NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BLEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Candau R, 1996, MOL CELL BIOL, V16, P593; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; Eckner R, 1996, BIOL CHEM, V377, P685; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; FENYO D, 1998, IN PRESS ELECTROPHOR; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACKSON V, 1975, J BIOL CHEM, V250, P4856; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Qin J, 1998, RAPID COMMUN MASS SP, V12, P209, DOI 10.1002/(SICI)1097-0231(19980314)12:5<209::AID-RCM141>3.0.CO;2-S; Roberts SM, 1997, GENETICS, V147, P451; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	51	463	479	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					35	44		10.1016/S0092-8674(00)81219-2	http://dx.doi.org/10.1016/S0092-8674(00)81219-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674425	Bronze			2022-12-28	WOS:000074790800007
J	Oda, Y; Kawasaki, K; Morita, M; Korn, H; Matsui, H				Oda, Y; Kawasaki, K; Morita, M; Korn, H; Matsui, H			Inhibitory long-term potentiation underlies auditory conditioning of goldfish escape behaviour	NATURE			English	Article							MAUTHNER CELL; STARTLE REFLEX; TRANSMISSION; SYNAPSES; RESPONSES; NETWORK	Long-term potentiation (LTP), the increase in synaptic strength evoked by high-frequency stimulation, is often considered to be a cellular model for learning and memory. The validity of this model depends on the assumptions that physiological stimuli can induce LTP in vivo and that the resulting: synaptic modifications correlate with behavioural changes. However, modifiable synapses are generally embedded deep in complex circuits. In contrast, the goldfish Mauthner (M)-cell and its afferent synapses are easily accessible for electrophysiological studies, and firing of this neuron is sufficient to trigger fast escape behaviour in response to sudden stimuli(1,2). We have previously shown that tetanic stimulation can induce LTP of the feedforward inhibitory synapses that control the excitability of the M-ceIl(3,4). Here we report that natural sensory stimulation can induce potentiation of this inhibitory connection that resembles the LTP induced by afferent tetanization. Furthermore, comparable acoustic stimulation produced a parallel decrease in the probability of the sound-evoked escape reflex Thus we demonstrate for the first time, to our knowledge, a behavioural role for the long-term synaptic strengthening of inhibitory synapses.	Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Neurosci Lab, Osaka 5608531, Japan; Inst Pasteur, INSERM, U261, Biol Cellulaire & Mol Lab, F-75724 Paris, France	Osaka University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Oda, Y (corresponding author), Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Neurosci Lab, Machikaneyama 1-3, Osaka 5608531, Japan.							ALJURE E, 1980, BRAIN RES, V188, P261, DOI 10.1016/0006-8993(80)90574-0; Blaxter J.H.S., 1988, P203; Brunskill R.W, 1978, ILLUSTRATED HDB VERN; Canfield JG, 1996, BRAIN BEHAV EVOLUT, V48, P137, DOI 10.1159/000113193; EATON RC, 1991, J EXP BIOL, V161, P469; EATON RC, 1988, J NEUROSCI, V8, P2758; FABER DS, 1975, BRAIN RES, V96, P349, DOI 10.1016/0006-8993(75)90746-5; FABER DS, 1988, J NEUROPHYSIOL, V60, P1982, DOI 10.1152/jn.1988.60.6.1982; FABER DS, 1982, J NEUROPHYSIOL, V48, P654, DOI 10.1152/jn.1982.48.3.654; FAY RR, 1995, BRAIN BEHAV EVOLUT, V46, P141, DOI 10.1159/000113267; FETCHO JR, 1991, BRAIN BEHAV EVOLUT, V37, P298, DOI 10.1159/000114367; FISHER TM, 1995, J NEUROSCI, V15, P762; FURUKAWA T, 1967, J NEUROPHYSIOL, V30, P1377, DOI 10.1152/jn.1967.30.6.1377; FURUKAWA T, 1963, J NEUROPHYSIOL, V26, P140, DOI 10.1152/jn.1963.26.1.140; GROVES P M, 1970, Psychological Review, V77, P419, DOI 10.1037/h0029810; KANDEL ER, 1978, GRASS LECT MONOGR J; KORN H, 1992, P NATL ACAD SCI USA, V89, P440, DOI 10.1073/pnas.89.1.440; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; ODA Y, 1995, J NEUROPHYSIOL, V74, P1056, DOI 10.1152/jn.1995.74.3.1056; RODGERS WL, 1963, J COMP PHYSIOL PSYCH, V56, P917, DOI 10.1037/h0039700; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; VU ET, 1993, J NEUROSCI, V13, P4379; Wilson MA, 1997, TRENDS NEUROSCI, V20, P102, DOI 10.1016/S0166-2236(96)01023-5; YANG XD, 1990, NATURE, V348, P542, DOI 10.1038/348542a0; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299; ZOTTOLI SJ, 1977, J EXP BIOL, V66, P243	27	69	69	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					182	185		10.1038/28172	http://dx.doi.org/10.1038/28172			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671301				2022-12-28	WOS:000074705900054
J	Mullins, ME; Horowitz, BZ; Linden, DHJ; Smith, GW; Norton, RL; Stump, J				Mullins, ME; Horowitz, BZ; Linden, DHJ; Smith, GW; Norton, RL; Stump, J			Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCAGON; OVERDOSE	Mibefradil is a T-type and L-type calcium channel blocker (CCB) released in the United States in 1997 for management of hypertension and chronic stable angina. Postmarketing surveillance revealed a potential serious interaction between mibefradil and beta-blockers, digoxin, verapamil, and diltiazem, especially in elderly patients. The manufacturer voluntarily withdrew mibefradil on June 8, 1998. We describe 4 cases of cardiogenic shock in patients taking mibefradil and beta-blockers who began taking dihydropyridine CCBs. One case resulted in death; the other 3 survived episodes of cardiogenic shock with intensive support of heart rate and blood pressure. Physicians who are preparing to switch patients' medications from mibefradil to other antihypertensive agents should be aware of these potentially life-threatening drug-drug interactions.	Oregon Poison Ctr, Portland, OR USA; Rogue Valley Med Ctr, Medford, OR USA; Louisiana Poison Control Ctr, Monroe, LA USA		Mullins, ME (corresponding author), Mail Code CB 550,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Mullins, Michael E./H-7831-2019; Horowitz, B./AAM-6947-2020	Mullins, Michael E./0000-0001-8605-0217; Horowitz, Zane/0000-0002-6172-0461				Alpert JS, 1997, AM J CARDIOL, V79, P1025, DOI 10.1016/S0002-9149(97)00041-6; Bey TA, 1997, ANN EMERG MED, V30, P353; BURSZTYN M, 1997, AM HEART J, V134, P288; DOYON S, 1993, ANN EMERG MED, V22, P1229, DOI 10.1016/S0196-0644(05)80997-7; HOROWITZ BZ, 1989, AM J EMERG MED, V7, P624, DOI 10.1016/0735-6757(89)90287-8; KOBRIN I, 1997, AM J CARDIOL, V80, pC10; NEERGAARD L, 1998, ASS PRESS       0608; *ROCH LAB INC, 1998, DEAR DOCT LETT  0608; *ROCH LAB INC, 1998, DEAR DOCT LETT  0612; *ROCH LAB INC, 1997, DEAR DOCT LETT  1218; WALTER FG, 1993, ANN EMERG MED, V22, P1234, DOI 10.1016/S0196-0644(05)80998-9; WOLF LR, 1993, ANN EMERG MED, V22, P1225, DOI 10.1016/S0196-0644(05)80996-5; 1997, MED LETT, V39, P103	13	114	119	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					157	158		10.1001/jama.280.2.157	http://dx.doi.org/10.1001/jama.280.2.157			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669789	Bronze			2022-12-28	WOS:000074608400031
J	Kaelin, WG				Kaelin, WG			Carcinogenesis - Another p53 Doppelganger?	SCIENCE			English	Editorial Material									Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Kaelin, WG (corresponding author), Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA.	William_Kaelin@dfci.harvard.edu						COLBRINIK D, 1996, GENE DEV, V10, P1633; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LECOUTER JE, COMMUNICATION; MARIN MC, COMMUNICATION; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; YANG A, COMMUNICATION	11	30	30	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					57	58		10.1126/science.281.5373.57	http://dx.doi.org/10.1126/science.281.5373.57			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9679018				2022-12-28	WOS:000074685800034
J	Chou, IM; Blank, JG; Goncharov, AF; Mao, HK; Hemley, RJ				Chou, IM; Blank, JG; Goncharov, AF; Mao, HK; Hemley, RJ			In situ observations of a high-pressure phase of H2O ice	SCIENCE			English	Article							DIAMOND-ANVIL CELL; SUPERCOOLED WATER; BEHAVIOR; VI	A previously unknown solid phase of H2O has been identified by its peculiar growth patterns, distinct pressure-temperature melting relations, and vibrational Rama? spectra. Morphologies of ice crystals and their pressure-temperature melting relations were directly observed in a hydrothermal diamond-anvil cell for H2O bulk densities between 1203 and 1257 kilograms per cubic meter at temperatures between - 10 degrees and 50 degrees C. Under these conditions, four different ice forms were observed-to melt: two stable phases, ice V and ice VI, and two metastable phases, ice IV and the new ice phase. The Raman spectra and crystal morphology are consistent with a disordered anisotropic structure with some similarities to ice VI.	US Geol Survey, Natl Ctr 955, Reston, VA 22091 USA; Carnegie Inst Sci, Geophys Lab, Washington, DC 20015 USA; Carnegie Inst Sci, Ctr High Pressure Res, Washington, DC 20015 USA	United States Department of the Interior; United States Geological Survey; Carnegie Institution for Science; Carnegie Institution for Science	Chou, IM (corresponding author), US Geol Survey, Natl Ctr 955, Reston, VA 22091 USA.		Goncharov, Alexander F./AAX-9943-2020	Goncharov, Alexander F./0000-0002-6422-8819				BANSIL R, 1982, J CHEM PHYS, V76, P2221, DOI 10.1063/1.443295; BASSETT WA, 1993, REV SCI INSTRUM, V64, P2340, DOI 10.1063/1.1143931; BIZHIGITOV TB, 1986, JETP LETT+, V44, P417; Bridgman PW, 1935, J CHEM PHYS, V3, P597, DOI 10.1063/1.1749561; Bridgman PW, 1912, P AM ACAD ARTS SCI, V47, P441, DOI 10.2307/20022754; Chou I-M., 1998, REV HIGH PRES SCI TE, V7, P1132; CHOU IM, 1997, WORKSH HYDR BONDS HI, P11; DARRIGO G, 1981, J CHEM PHYS, V75, P4264, DOI 10.1063/1.442629; ENGELHAR.H, 1972, J CHEM PHYS, V56, P2678, DOI 10.1063/1.1677596; EVANS LF, 1967, J APPL PHYS, V38, P4930, DOI 10.1063/1.1709255; Goncharov AF, 1996, SCIENCE, V273, P218, DOI 10.1126/science.273.5272.218; Haselton HT, 1995, AM MINERAL, V80, P1302; HEMLEY RJ, 1989, NATURE, V338, P638, DOI 10.1038/338638a0; HOBBS PV, 1974, ICE PHYSICS; Kamb B., 1973, PHYSICS CHEM ICE, P28; KUHS WF, 1984, J CHEM PHYS, V81, P3612, DOI 10.1063/1.448109; Lobban C, 1998, NATURE, V391, P268, DOI 10.1038/34622; Mishima O, 1996, NATURE, V384, P546, DOI 10.1038/384546a0; MISHIMA O, 1985, NATURE, V314, P76, DOI 10.1038/314076a0; MISHIMA O, 1984, NATURE, V310, P393, DOI 10.1038/310393a0; Mishima O., 1998, REV HIGH PRESSURE SC, V7, P1103; POOLE PH, 1992, NATURE, V360, P324, DOI 10.1038/360324a0; SAUL A, 1989, J PHYS CHEM REF DATA, V18, P1537, DOI 10.1063/1.555836; SIVAKUMAR TC, 1978, J CHEM PHYS, V69, P3468, DOI 10.1063/1.437079; Tammann G, 1900, ANN PHYS-BERLIN, V2, P1; WAGNER W, 1994, J PHYS CHEM REF DATA, V23, P515, DOI 10.1063/1.555947; YEH Y, 1982, J CHEM PHYS, V77, P2317, DOI 10.1063/1.444142	27	106	111	3	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					809	812		10.1126/science.281.5378.809	http://dx.doi.org/10.1126/science.281.5378.809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694649				2022-12-28	WOS:000075295600045
J	Springer, S; Schekman, R				Springer, S; Schekman, R			Nucleation of COPII vesicular coat complex by endoplasmic reticulum to Golgi vesicle SNAREs	SCIENCE			English	Article							TRANSPORT VESICLES; SORTING SIGNALS; PROTEINS; RECEPTORS; GLYCOPROTEIN; FUSION; YEAST	Protein trafficking from the endoplasmic reticulum (ER) to the Golgi apparatus involves specific uptake into coat protein complex II (COPII)-coated vesicles of secretory and of vesicle targeting (V-SNARE) proteins. Here, two ER to Golgi v-SNAREs, Bet1p and Bos1p, were shown to interact specifically with Sar1p, Sec23p, and Sec24p, components of the COPII coat, in a guanine nucleotide-dependent fashion. Other v-SNAREs, Sec22p and Ykt6p, might interact more weakly with the COPII coat or interact indirectly by binding to Bet1p or Bos1p. The data suggest that transmembrane proteins can be taken up into COPII vesicles by direct interactions with the coat proteins and may play a structural role in the assembly of the COPII coat complex.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	schekman@uclink4.berkeley.edu	Springer, Sebastian/AAJ-7036-2021	Springer, Sebastian/0000-0002-5527-6149				Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SPRINGER S, UNPUB; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	32	172	178	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					698	700		10.1126/science.281.5377.698	http://dx.doi.org/10.1126/science.281.5377.698			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685263				2022-12-28	WOS:000075107900042
J	Utley, RT; Ikeda, K; Grant, PA; Cote, J; Steger, DJ; Eberharter, A; John, S; Workman, JL				Utley, RT; Ikeda, K; Grant, PA; Cote, J; Steger, DJ; Eberharter, A; John, S; Workman, JL			Transcriptional activators direct histone acetyltransferase complexes to nucleosomes	NATURE			English	Article							TATA-BINDING PROTEIN; BASAL TRANSCRIPTION; VP16; ADA2; DOMAINS; ADAPTER; INVITRO; GENE; CBP	Transcriptional co-activators were originally identified as proteins that act as intermediaries between upstream activators and the basal transcription machinery. The discovery that co-activators such as Tetrahymena and yeast Gcn5( >)(1,2), as well as human p300/CBP3,4, pCAF(5), Src-1(6), ACTR(7) and TAFII250(8), can acetylate histones suggests that activators may be involved in targeting acetylation activity to promoters. Several histone deacetylases have been linked to transcriptional co-repressor proteins(9), suggesting that the action of both acetylases and deacetylases is important in the regulation of many genes. Here we demonstrate the binding of two native yeast histone acetyltransferase (HAT) complexes to the herpesvirus VP16 activation domain and the yeast transcriptional activator Gcn4 and show that it is their interaction with the VP16 activation domain that targets Gal4-VP16-bound nucleosomes for acetylation. We find that Gal4-VP16-driven transcription from chromatin templates is stimulated by both HAT complexes in an acetyl CoA-dependent reaction. Our results demonstrate the targeting of native HAT complexes by a transcription-activation domain to nucleosomes in order to activate transcription.	Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA; Penn State Univ, Ctr Gene Regulat, Althouse Lab 306, University Pk, PA 16802 USA; Jichi Med Sch, Dept Biol, Minami Kawachi, Tochigi 32904, Japan; Univ Laval, Hotel Dieu Quebec, Ctr Canc Res, Quebec City, PQ G1R 2J6, Canada	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Jichi Medical University; Laval University	Workman, JL (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA.	jlw10@psu.edu	Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Juan LJ, 1997, J BIOL CHEM, V272, P3635, DOI 10.1074/jbc.272.6.3635; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STEGER DJ, UNPUB P NATL ACAD SC; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Utley RT, 1996, METHOD ENZYMOL, V274, P276; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	31	428	439	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					498	502		10.1038/28886	http://dx.doi.org/10.1038/28886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697775				2022-12-28	WOS:000075080400057
J	McKendrick, O				McKendrick, O			A memorable patient - Mountain power	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					276	276		10.1136/bmj.317.7153.276	http://dx.doi.org/10.1136/bmj.317.7153.276			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677227	Green Published			2022-12-28	WOS:000075081900033
J	Conti, E; Uy, M; Leighton, L; Blobel, G; Kuriyan, J				Conti, E; Uy, M; Leighton, L; Blobel, G; Kuriyan, J			Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha	CELL			English	Article							AMINO-ACID MOTIF; LARGE-T-ANTIGEN; LOCATION SEQUENCE; PORE COMPLEXES; PROTEIN IMPORT; IDENTIFICATION; BINDING; TRANSPORT; BETA; SUBSTRATE	Selective nuclear import is mediated by nuclear localization signals (NLSs) and cognate transport factors known as karyopherins or importins. Karyopherin alpha recognizes "classical" monopartite and bipartite NLSs. We report the crystal structure of a 50 kDa fragment of the 60 kDa yeast karyopherin alpha, in the absence and presence of a monopartite NLS peptide at 2.2 Angstrom and 2.8 Angstrom resolution, respectively. The structure shows a tandem array of ten armadillo repeats, organized in a right-handed superhelix of helices. Binding of the NLS peptide occurs at two sites within a helical surface groove that is lined by conserved residues. The structure reveals the determinants of NLS specificity and suggests a model for the recognition of bipartite NLSs.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.			Conti, Elena/0000-0003-1254-5588				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUNGER AT, 1998, CRYSTALLOGRAPHIC NMR; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Naismith JH, 1996, J MOL RECOGNIT, V9, P113, DOI 10.1002/(SICI)1099-1352(199603)9:2<113::AID-JMR253>3.0.CO;2-H; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WOZNIAK RW, 1998, IN PRESS TRENDS CELL; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	50	651	669	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					193	204		10.1016/S0092-8674(00)81419-1	http://dx.doi.org/10.1016/S0092-8674(00)81419-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695948	Bronze			2022-12-28	WOS:000075020100008
J	Williams, Q; Revenaugh, J; Garnero, E				Williams, Q; Revenaugh, J; Garnero, E			A correlation between ultra-low basal velocities in the mantle and hot spots	SCIENCE			English	Article							HOTSPOT DISTRIBUTION; PLATE BOUNDARIES; FLOOD BASALTS; PLUMES; TECTONICS; PACIFIC; TRACKS; LAYER; D''	The statistical correlation between the locations of hot spots at the surface of Earth and the distribution of ultra-low-velocity zones at the base of the mantle has about a 1 percent chance of arising randomly. This correlation is more significant than that between hot spots and negative velocity anomalies in tomographic models of deep mantle compressional and shear velocity. This correlation is consistent with the notion that many hot. spots originate in a low-velocity, probably partially molten layer at the core-mantle boundary and undergo little lateral deflection on ascent.	Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Inst Tecton, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Williams, Q (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA.		Revenaugh, Justin/GVR-8368-2022	Revenaugh, Justin/0000-0002-7855-5159				ANDERSON DL, 1992, SCIENCE, V256, P1645, DOI 10.1126/science.256.5064.1645; CAMPBELL IH, 1990, EARTH PLANET SC LETT, V99, P79, DOI 10.1016/0012-821X(90)90072-6; CHASE CG, 1983, EARTH PLANET SC LETT, V62, P314, DOI 10.1016/0012-821X(83)90002-X; CHASE CG, 1979, NATURE, V282, P464, DOI 10.1038/282464a0; CROUGH ST, 1979, TECTONOPHYSICS, V61, P321, DOI 10.1016/0040-1951(79)90304-4; FISCHER KM, 1996, EOS T AGU, V77, pF678; GARNERO E, IN PRESS CORE MANTLE; GARNERO EJ, 1995, PHYS EARTH PLANET IN, V91, P161, DOI 10.1016/0031-9201(95)03039-Y; HAGER BH, 1985, NATURE, V313, P541, DOI 10.1038/313541a0; JURDY DM, 1990, GEOPHYS RES LETT, V17, P1965, DOI 10.1029/GL017i011p01965; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; LOPER DE, 1984, PHYS EARTH PLANET IN, V34, P57, DOI 10.1016/0031-9201(84)90084-0; Morgan W.J., 1972, GEOL SOC AM MEM, V132, P7, DOI [DOI 10.1130/MEM132-P7, 10.1130/MEM132-p7]; MORGAN WJ, 1983, TECTONOPHYSICS, V94, P123, DOI 10.1016/0040-1951(83)90013-6; MORGAN WJ, 1978, J GEOPHYS RES, V83, P5355, DOI 10.1029/JB083iB11p05355; MORI J, 1995, J GEOPHYS RES-SOL EA, V100, P20359, DOI 10.1029/95JB02243; OLSON P, 1986, J GEOPHYS RES-SOLID, V91, P7181, DOI 10.1029/JB091iB07p07181; RAY TW, 1994, J GEOPHYS RES-SOL EA, V99, P9605, DOI 10.1029/94JB00340; Revenaugh J, 1997, SCIENCE, V277, P670, DOI 10.1126/science.277.5326.670; RIBE NM, 1994, GEOPHYS RES LETT, V21, P1507, DOI 10.1029/94GL01168; RICHARDS MA, 1989, SCIENCE, V246, P103, DOI 10.1126/science.246.4926.103; SHERIDAN RE, 1987, TECTONOPHYSICS, V143, P59, DOI 10.1016/0040-1951(87)90078-3; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; SLEEP NH, 1992, J GEOPHYS RES-SOL EA, V97, P20007, DOI 10.1029/92JB01468; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; Vidale JE, 1998, NATURE, V391, P682, DOI 10.1038/35601; WALKER RJ, 1995, SCIENCE, V269, P819, DOI 10.1126/science.269.5225.819; WEINSTEIN SA, 1989, GEOPHYS RES LETT, V16, P433, DOI 10.1029/GL016i005p00433; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; Wysession ME, 1996, NATURE, V382, P244, DOI 10.1038/382244a0	30	138	145	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					546	549		10.1126/science.281.5376.546	http://dx.doi.org/10.1126/science.281.5376.546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677194				2022-12-28	WOS:000075012300036
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 56-year-old woman with chronic fatigue syndrome, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Komaroff AL, 1997, JAMA-J AM MED ASSOC, V278, P1179	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					372	372		10.1001/jama.280.4.372	http://dx.doi.org/10.1001/jama.280.4.372			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686556				2022-12-28	WOS:000074804200039
J	Lesko, SM; Corwin, MJ; Vezina, RM; Hunt, CE; Mandell, F; McClain, M; Heeren, T; Mitchell, AA				Lesko, SM; Corwin, MJ; Vezina, RM; Hunt, CE; Mandell, F; McClain, M; Heeren, T; Mitchell, AA			Changes in sleep position during infancy - A prospective longitudinal assessment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; COT DEATH; PROGRAM; PREVALENCE; COHORT; REDUCE; SIDS; RISK	Context.-Prone sleeping by infants has been associated with an increased risk of sudden infant death syndrome. Objective.-To document the prevalence of and identify risk factors for prone sleeping during the first 6 months of life. Design.-Prospective cohort study. Setting.-Eastern Massachusetts and northwest Ohio. Study Participants.-A total of 7796 mothers of infants weighing 2500 g or more at birth. Main Outcome Measures.-Maternal and infant characteristics related to prone sleeping at 1 month and 3 months of age. Results.-Between 1 month and 3 months of age, prone sleeping increased from 18% to 29%. At 1 month, prone sleeping was associated with the following maternal characteristics: non-Hispanic black or Hispanic race/ethnicity, younger age, less education, and higher parity. At 3 months, switching from nonprone to prone position was associated with mother's race/ethnicity of non-Hispanic black (odds ratio [OR], 1.7, 95% confidence interval [CI], 1.2-2.3) or Hispanic (OR, -1.5; 95% CI, 1.1-2.2); younger maternal age (compared with mothers >34 years: 18-24 years, OR, 1.6; 95% CI, 1.2-2,2; <18 years, OR, 2.2; 95% CI, 1.2-4.3); increasing parity (compared with 1 child: 2 children, OR, 1.5; 95% CI, 1.2-1.8; greater than or equal to 3 children, OR, 1.7; 95% CI, 1.4-2.2); and infant sex (male sex, OR, 1.4, 95% CI, 1.2-1.7). Conclusions.-If infant sleeping practices in the study communities are representative of practices throughout the United States, a substantial number of infants who slept nonprone at 1 month sleep prone at 3 months.	Boston Univ, Sch Med, Sch Publ Hlth, Slone Epidemiol Unit, Brookline, MA 02146 USA	Boston University	Lesko, SM (corresponding author), Boston Univ, Sch Med, Sch Publ Hlth, Slone Epidemiol Unit, 1371 Beacon St, Brookline, MA 02146 USA.	leskos@bu.edu		Corwin, Michael/0000-0002-6591-209X; Heeren, Timothy/0000-0001-5643-3559; Mitchell, Allen/0000-0003-0950-6799	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD043221] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-4-3221] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON RN, 1997, MON VITAL STAT RE S2, V45, P68; ARMITAGE P, 1971, STATISTICAL METHODS, P319; CHESSARE JB, 1995, PEDIATRICS, V96, P893; DEJONGE GA, 1993, ARCH DIS CHILD, V69, P660, DOI 10.1136/adc.69.6.660; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GIBSON E, 1995, PEDIATRICS, V96, P69; GILBERT R, 1994, ARCH DIS CHILD, V70, P445, DOI 10.1136/adc.70.5.445; HILEY CMH, 1994, BRIT MED J, V309, P703, DOI 10.1136/bmj.309.6956.703; HUNT CE, 1992, RESP CONTROL DISORDE, P190; IRGENS LM, 1995, ARCH DIS CHILD, V72, P478, DOI 10.1136/adc.72.6.478; Johnson CM, 1996, PEDIATRICS, V98, P163; Kattwinkel J, 1996, PEDIATRICS, V98, P1216; MARKESTAD T, 1995, ACTA PAEDIATR, V84, P375, DOI 10.1111/j.1651-2227.1995.tb13653.x; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MITCHELL EA, 1993, BRIT MED J, V306, P858, DOI 10.1136/bmj.306.6881.858-b; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; Nelson EAS, 1996, NEW ZEAL MED J, V109, P144; PONSONBY AL, 1994, PREV MED, V23, P402, DOI 10.1006/pmed.1994.1055; PONSONBY AL, 1995, ARCH DIS CHILD, V72, P204, DOI 10.1136/adc.72.3.204; SCRAGG LK, 1993, NEW ZEAL MED J, V106, P8; Taylor JA, 1996, ARCH PEDIAT ADOL MED, V150, P834, DOI 10.1001/archpedi.1996.02170330060010	24	66	66	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					336	340		10.1001/jama.280.4.336	http://dx.doi.org/10.1001/jama.280.4.336			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686550	Bronze			2022-12-28	WOS:000074804200033
J	Furuta, T; Hotta, O; Yusa, N; Horigome, I; Chiba, S; Taguma, Y				Furuta, T; Hotta, O; Yusa, N; Horigome, I; Chiba, S; Taguma, Y			Lymphocytapheresis to treat rapidly progressive glomerulonephritis: a randomised comparison with steroid-pulse treatment	LANCET			English	Article									Sendai Shakaihoken Hosp, Dept Nephrol, Aoba Ku, Sendai, Miyagi 9818501, Japan		Furuta, T (corresponding author), Sendai Shakaihoken Hosp, Dept Nephrol, Aoba Ku, 3-16-1 Tsutsumimachi, Sendai, Miyagi 9818501, Japan.							BOLTON WK, 1984, CONTROVERSIES NEPHRO, P421; FRASCA GM, 1992, INT J ARTIF ORGANS, V15, P181, DOI 10.1177/039139889201500308; HOTTA O, 1994, KIDNEY INT S47, V46, P117; TENENBAUM J, 1979, ANN RHEUM DIS, V38, P40, DOI 10.1136/ard.38.1.40	4	30	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					203	204		10.1016/S0140-6736(05)77809-0	http://dx.doi.org/10.1016/S0140-6736(05)77809-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683216				2022-12-28	WOS:000074859800020
J	Scherer, RW; Crawley, B				Scherer, RW; Crawley, B			Reporting of randomized clinical trial descriptors and use of structured abstracts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			QUALITY	Context.-Structured abstracts, that is, abstracts that describe a study using requisite content headings, provide more informative content. Concomitant reporting in the text of the report might improve with structured abstract use because of increased awareness by authors or editors of important study areas associated with content headings. Objective.-To assess whether structured abstract use is associated with improved reporting of randomized clinical trials. Design and Setting.-Survey of trial reports published the year preceding, of, and following new use of structured abstracts, found by hand searching Archives of Ophthalmology (1992-1994) and Ophthalmology (1991-1993), as well as trial reports published concurrently without change in abstract format (American Journal of Ophthalmology, 1991-1994). Main Outcome Measures.-We measured the inclusion of 56 criteria derived from Consolidated Standards of Reporting Trials (CONSORT) descriptors (JAMA 1996;276:637-639) in the text of each report and calculated the number of criteria included per report and the proportion of reports including individual criteria. Reports with structured abstracts were compared with those without, and reports published in 1993 and 1994 in the American Journal of Ophthalmology were compared with those published in 1991 and 1992. Results.-The mean (SEM) number of criteria included by authors was 15.8 (0.4) per report in 125 trial reports, We found no difference in the mean number of criteria included or the proportion of reports that included specific criteria by journal. Following structured abstract use, there was no difference in either the mean number of criteria per report or the proportion of reports including a majority of criteria within each CONSORT subheading. Four criteria were included more often and 2 less often following structured abstract use in individual journals. Conclusion.-Using CONSORT descriptor criteria to evaluate reporting quality, we found no difference in text reporting associated with structured abstract use in the journals examined.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Scherer, RW (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Century Bldg,1st Floor,506 W Fayette St, Baltimore, MD 21201 USA.							*AD HOC WORK GROUP, 1987, ANN INTERN MED, V106, P595; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FROOM P, 1993, J CLIN EPIDEMIOL, V46, P591, DOI 10.1016/0895-4356(93)90029-Z; GOLDBERG MF, 1998, ARCH OPHTHALMOL-CHIC, V111, P39; GRANT A, 1989, BRIT J OBSTET GYNAEC, V96, P397, DOI 10.1111/j.1471-0528.1989.tb02412.x; HARCOURT AM, 1995, B MED LIB ASS, V83, P190; HAYNES RB, 1990, ANN INTERN MED, V113, P69, DOI 10.7326/0003-4819-113-1-69; LICHTER PR, 1991, OPHTHALMOLOGY, V98, P1611; MAHON WA, 1964, CAN MED ASSOC J, V90, P565; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; RENNIE D, 1991, JAMA-J AM MED ASSOC, V266, P116; STRAASTSMA BR, 1994, AM J OPHTHALMOL, V117, P104; TADDIO A, 1994, CAN MED ASSOC J, V150, P1611; 1996, COCHR HAND SEARCH MA	16	54	55	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					269	272		10.1001/jama.280.3.269	http://dx.doi.org/10.1001/jama.280.3.269			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676678				2022-12-28	WOS:000074706000023
J	Sieburth, DS; Sun, Q; Han, M				Sieburth, DS; Sun, Q; Han, M			SUR-8, a conserved Ras-binding protein with leucine-rich repeats, positively regulates Ras-mediated signaling in C-elegans	CELL			English	Article							VULVAL CELL LINEAGES; KSR-1 GENE ENCODES; CAENORHABDITIS-ELEGANS; LET-60 RAS; RIBONUCLEASE INHIBITOR; TRANSDUCTION PATHWAY; ADENYLATE-CYCLASE; MAP KINASE; IDENTIFICATION; INDUCTION	We describe the identification and characterization of a novel gene, sur-8, that positively regulates Ras-mediated signal transduction during C. elegans Vulval development. Reduction of sur-8 function suppresses an activated ras mutation and dramatically enhances phenotypes of mpk-1 MAP kinase and ksr-1 mutations, while increase of sur-8 dosage enhances an activated ras mutation. sur-8 appears to act downstream of or in parallel to ras but upstream of raf. sur-8 encodes a conserved protein that is composed predominantly of leucine-rich repeats. The SUR-8 protein interacts directly with Ras but not with the Ras(P34G) mutant protein, suggesting that SURd may mediate its effects through Ras binding. A structural and functional SUR-8 homolog in humans specifically binds K-Ras and N-Ras but not H-Ras in vitro.	Univ Colorado, Howard Hughes Med Inst, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Han, M (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.				NIGMS NIH HHS [GM47869] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOS JL, 1989, CANCER RES, V49, P4682; BRENNER S, 1974, GENETICS, V77, P71; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FURTH ME, 1987, ONCOGENE, V1, P47; Gutch MJ, 1998, GENE DEV, V12, P571, DOI 10.1101/gad.12.4.571; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MADURO M, 1995, GENETICS, V141, P977; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; RIDRIGUEZVICIAN.P, 1997, CELL, V89, P457; ROGALSKI TM, 1988, GENETICS, V118, P61; Sundaram M, 1996, DEVELOPMENT, V122, P2823; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; Yochem J, 1997, MOL CELL BIOL, V17, P2716, DOI 10.1128/MCB.17.5.2716; ZHANG XF, 1995, METHOD ENZYMOL, V255, P323	45	162	183	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					119	130		10.1016/S0092-8674(00)81227-1	http://dx.doi.org/10.1016/S0092-8674(00)81227-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674433	Bronze			2022-12-28	WOS:000074790800015
J	Hasegawa, I; Fukushima, T; Ihara, T; Miyashita, Y				Hasegawa, I; Fukushima, T; Ihara, T; Miyashita, Y			Callosal window between prefrontal cortices: Cognitive interaction to retrieve long-term memory	SCIENCE			English	Article							CORPUS-CALLOSUM; MONKEYS; CORTEX; COMMISSUROTOMY; ASSOCIATION; ACTIVATION; NEURONS; RETINA	A perceptual image can be recalled from memory without sensory stimulation. However, the neural origin of memory retrieval remains unsettled. To examine whether memory retrieval can be regulated by top-down processes originating from the prefrontal cortex, a visual associative memory task was introduced into the partial split-brain paradigm in monkeys. Long-term memory acquired through stimulus-stimulus association did not transfer via the anterior corpus callosum, a key part interconnecting prefrontal cortices. Nonetheless, when a visual cue was presented to one hemisphere, the anterior callosum could instruct the other hemisphere to retrieve the correct stimulus specified by the cue. Thus, although visual Long-term memory is stored in the temporal cortex, memory retrieval is under the executive control of the prefrontal cortex.	Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 113, Japan; Japan Sci & Technol Corp, ICORP, Mind Articulat Project, Bunkyo Ku, Tokyo 113, Japan; Natl Inst Physiol Sci, Okazaki, Aichi 444, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Hasegawa, I (corresponding author), Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Miyashita, Yasushi/B-7171-2019; Hasegawa, Isao/AAW-5682-2021	Miyashita, Yasushi/0000-0003-3496-8637; Hasegawa, Isao/0000-0002-8633-2502				BLACK P, 1964, SCIENCE, V146, P799, DOI 10.1126/science.146.3645.799; Buckner RL, 1996, J NEUROSCI, V16, P6219; DOTY RW, 1988, BEHAV BRAIN RES, V29, P267, DOI 10.1016/0166-4328(88)90031-9; EACOTT MJ, 1992, EUR J NEUROSCI, V4, P1320, DOI 10.1111/j.1460-9568.1992.tb00157.x; EACOTT MJ, 1990, BEHAV BRAIN RES, V38, P109, DOI 10.1016/0166-4328(90)90009-4; FENDRICH R, 1989, NEUROPSYCHOLOGIA, V27, P273, DOI 10.1016/0028-3932(89)90018-3; Fuster JM, 1995, MEMORY CEREBRAL CORT; GAZZANIGA MS, 1995, NEURON, V14, P217, DOI 10.1016/0896-6273(95)90280-5; GAZZANIGA MS, 1969, EXP NEUROL, V23, P11, DOI 10.1016/0014-4886(69)90029-6; GAZZANIGA MS, 1966, NEUROPSYCHOLOGIA, V4, P183, DOI 10.1016/0028-3932(66)90047-9; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; HALSBAND U, 1985, BEHAV BRAIN RES, V18, P269, DOI 10.1016/0166-4328(85)90035-X; HAMILTON CR, 1986, 2 HEMISPHERES ONE BR, P315; Higuchi S, 1996, P NATL ACAD SCI USA, V93, P739, DOI 10.1073/pnas.93.2.739; HOLTZMAN JD, 1984, VISION RES, V24, P801, DOI 10.1016/0042-6989(84)90151-2; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MATSUDA K, 1996, NEUROSCI RES       S, V20, pS270; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MURRAY EA, 1993, J NEUROSCI, V13, P4549; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; NOBLE J, 1973, BRAIN RES, V50, P147, DOI 10.1016/0006-8993(73)90601-X; Pandya DN., 1986, 2 HEMISPHERES ONE BR, P47; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; PETRIDES M, 1987, FRONTAL LOBES REVISI, P91; SAKAI K, 1995, MAGNET RESON MED, V33, P736, DOI 10.1002/mrm.1910330521; SIDTIS JJ, 1981, SCIENCE, V212, P344, DOI 10.1126/science.6782673; STONE J, 1973, J COMP NEUROL, V150, P333, DOI 10.1002/cne.901500306; STUSS DT, 1989, FRONTAL LOBES; SUGISHITA M, 1978, NEUROPSYCHOLOGIA, V16, P417, DOI 10.1016/0028-3932(78)90065-9; SUGISHITA M, 1994, NEUROPSYCHOLOGIA, V32, P399, DOI 10.1016/0028-3932(94)90086-8; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; ZEKI SM, 1973, J COMP NEUROL, V148, P167, DOI 10.1002/cne.901480204	34	114	117	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					814	818		10.1126/science.281.5378.814	http://dx.doi.org/10.1126/science.281.5378.814			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694651				2022-12-28	WOS:000075295600047
J	Wijnhoven, JEGJ; Vos, WL				Wijnhoven, JEGJ; Vos, WL			Preparation of photonic crystals made of air spheres in titania	SCIENCE			English	Article								Three-dimensional crystals of air spheres in titania (TiO2) with radii between 120 and 1000 nanometers were made by filling the Voids in artificial opals by precipitation from a Liquid-phase chemical reaction and subsequently removing the original opal material by calcination. These macroporous materials are a new class of photonic band gap crystals for the optical spectrum. Scanning electron microscopy, Raman spectroscopy, and optical microscopy confirm the quality of the samples, and optical reflectivity demonstrates that the crystals are strongly photonic and near that needed to exhibit band gap behavior.	Univ Amsterdam, VanderWaals Zeeman Inst, NL-1018 XE Amsterdam, Netherlands	University of Amsterdam	Vos, WL (corresponding author), Univ Amsterdam, VanderWaals Zeeman Inst, Valckenierstr 65, NL-1018 XE Amsterdam, Netherlands.	wvos@phys.uva.nl	Vos, Willem L./B-7489-2012	Vos, Willem L./0000-0003-3066-859X				ARBETENGELS V, 1996, MICROCAVITIES PHOTON; BARTELS J, 1962, LANDOLTBORNSTEIN ZAH; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; Bogomolov VN, 1997, PHYS REV E, V55, P7619, DOI 10.1103/PhysRevE.55.7619; BOWDEN CM, 1993, J OPT SOC AM B, V10, P280, DOI 10.1364/JOSAB.10.000280; BUSCH K, IN PRESS PHYS REV E; ECONOMOU EN, 1993, PHYS REV B, V48, P13434, DOI 10.1103/PhysRevB.48.13434; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; Kimerling LC, 1997, SOLID STATE PHYS, V50, P333; Krauss TF, 1996, NATURE, V383, P699, DOI 10.1038/383699a0; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; MAMMONE JF, 1980, SOLID STATE COMMUN, V34, P799, DOI 10.1016/0038-1098(80)91055-8; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; Megens M, 1997, J APPL CRYSTALLOGR, V30, P637, DOI 10.1107/S002188989700191X; Megens M, 1997, LANGMUIR, V13, P6120, DOI 10.1021/la970422v; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Raman NK, 1996, CHEM MATER, V8, P1682, DOI 10.1021/cm960138+; Romanov SG, 1997, PHYS STATUS SOLIDI A, V164, P169, DOI 10.1002/1521-396X(199711)164:1<169::AID-PSSA169>3.0.CO;2-D; Snigirev A, 1996, NATURE, V384, P49, DOI 10.1038/384049a0; SOZUER HS, 1992, PHYS REV B, V45, P13962, DOI 10.1103/PhysRevB.45.13962; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; Vos WL, 1997, LANGMUIR, V13, P6004, DOI 10.1021/la970423n; Vos WL, 1996, PHYS REV B, V53, P16231, DOI 10.1103/PhysRevB.53.16231; Vos WL, 1997, PHYS REV B, V55, P1903, DOI 10.1103/PhysRevB.55.1903; Vos WL, 1996, J PHYS-CONDENS MAT, V8, P9503, DOI 10.1088/0953-8984/8/47/052; VOS WL, 1998, C LAS EL OPT GLASG 1; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548	30	1669	1750	14	475	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					802	804		10.1126/science.281.5378.802	http://dx.doi.org/10.1126/science.281.5378.802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694646				2022-12-28	WOS:000075295600042
J	Brater, DC				Brater, DC			Diuretic therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGESTIVE-HEART-FAILURE; CHRONIC RENAL-INSUFFICIENCY; DRUG-PROTEIN-BINDING; NEPHROTIC SYNDROME; HEPATIC CIRRHOSIS; FUROSEMIDE DISPOSITION; SODIUM RETENTION; REFRACTORY EDEMA; COLLECTING DUCT; LOOP DIURETICS		Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Brater, DC (corresponding author), Indiana Univ, Sch Med, Dept Med, Emerson Hall 317,545 Barnhill Dr, Indianapolis, IN 46202 USA.				NCRR NIH HHS [MO1RR00750] Funding Source: Medline; NIA NIH HHS [R01 AG 07631] Funding Source: Medline; NIDDK NIH HHS [R01 DK 37994] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007631] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER WD, 1977, POSTGRAD MED J, V53, P117, DOI 10.1136/pgmj.53.617.117; ALMESHARI K, 1993, J AM SOC NEPHROL, V3, P1878; ANDREASEN F, 1977, EUR J CLIN PHARMACOL, V12, P15, DOI 10.1007/BF00561400; BAILIE GR, 1987, CLIN PHARMACOKINET, V12, P440, DOI 10.2165/00003088-198712060-00004; BEERMANN B, 1984, ACTA PHARMACOL TOX, V54, P17; BESSEGHIR K, 1981, J PHARMACOL EXP THER, V219, P435; BORGES HF, 1982, ARCH INTERN MED, V142, P63, DOI 10.1001/archinte.142.1.63; Brater D. C., 1992, IN VIVO STUDY DRUG A, P253; BRATER DC, 1980, CLIN PHARMACOL THER, V28, P182, DOI 10.1038/clpt.1980.148; BRATER DC, 1983, CLIN PHARMACOL THER, V34, P207, DOI 10.1038/clpt.1983.154; BRATER DC, 1983, J PHARMACOL EXP THER, V227, P92; BRATER DC, 1987, CLIN PHARMACOL THER, V42, P187, DOI 10.1038/clpt.1987.131; BRATER DC, 1984, KIDNEY INT, V26, P183, DOI 10.1038/ki.1984.153; Brater DG, 1996, FLUIDS ELECTROLYTES, P693; CHATURVEDI PR, 1987, INT J CLIN PHARM TH, V25, P123; CHENNAVASIN P, 1980, J PHARMACOL EXP THER, V215, P77; CHENNAVASIN P, 1979, KIDNEY INT, V16, P187, DOI 10.1038/ki.1979.120; Chertow GM, 1996, AM J MED, V101, P49, DOI 10.1016/S0002-9343(96)00075-7; COOPERMAN LB, 1973, AM HEART J, V85, P831, DOI 10.1016/0002-8703(73)90434-1; DAVIES DL, 1974, CLIN PHARMACOL THER, V15, P141; Denton MD, 1996, KIDNEY INT, V50, P4, DOI 10.1038/ki.1996.280; EARLEY LE, 1970, CIRCULATION, V42, P323, DOI 10.1161/01.CIR.42.2.323; ELLISON DH, 1989, J CLIN INVEST, V83, P113, DOI 10.1172/JCI113847; ELLISON DH, 1991, ANN INTERN MED, V114, P886, DOI 10.7326/0003-4819-114-10-886; EPSTEIN M, 1977, CURR THER RES CLIN E, V21, P656; Ferguson JA, 1997, CLIN PHARMACOL THER, V62, P203, DOI 10.1016/S0009-9236(97)90069-2; FLISER D, 1994, KIDNEY INT, V46, P482, DOI 10.1038/ki.1994.298; FULLER R, 1981, CLIN PHARMACOL THER, V30, P461, DOI 10.1038/clpt.1981.189; GALLAGHER KL, 1979, ANN INTERN MED, V91, P744, DOI 10.7326/0003-4819-91-5-744; GEHR TWB, 1994, CLIN PHARMACOL THER, V56, P31, DOI 10.1038/clpt.1994.98; GERLAG PGG, 1991, ANN INTERN MED, V115, P360; GIBSON DG, 1970, BRIT HEART J, V32, P399; GREEN TP, 1981, J PHARMACOL EXP THER, V218, P122; GREEN TP, 1980, LIFE SCI, V26, P623, DOI 10.1016/0024-3205(80)90238-6; GREITHER A, 1979, PHARMACOLOGY, V19, P121, DOI 10.1159/000137299; HAMMARLUND MM, 1985, J PHARMACOL EXP THER, V233, P447; HOLAZO AA, 1984, J PHARM SCI, V73, P1108, DOI 10.1002/jps.2600730821; INOUE M, 1987, KIDNEY INT, V32, P198, DOI 10.1038/ki.1987.192; KAISSLING B, 1988, AM J PHYSIOL, V255, pF1256, DOI 10.1152/ajprenal.1988.255.6.F1256; KAOJARERN S, 1983, AM J PHYSIOL, V244, pF134, DOI 10.1152/ajprenal.1983.244.2.F134; KAU ST, 1978, J PHARMACOL EXP THER, V206, P701; KELLER E, 1982, CLIN PHARMACOL THER, V32, P442, DOI 10.1038/clpt.1982.187; KELLER E, 1981, EUR J CLIN PHARMACOL, V20, P27, DOI 10.1007/BF00554663; KELLY RA, 1983, KIDNEY INT, V24, P233, DOI 10.1038/ki.1983.149; KIRCHNER KA, 1990, J PHARMACOL EXP THER, V252, P1097; KITCHNER KA, 1991, KIDNEY INT, V40, P418; KITCHNER KA, 1992, J AM SOC NEPHROL, V2, P201; KNAUF H, 1983, EUR J CLIN PHARMACOL, V24, P453, DOI 10.1007/BF00609885; KNAUF H, 1995, J CARDIOVASC PHARM, V26, P394, DOI 10.1097/00005344-199509000-00008; KOBAYASHI S, 1995, KIDNEY INT, V47, P818, DOI 10.1038/ki.1995.124; LAU HSH, 1983, J PHARMACOL EXP THER, V227, P51; LOON NR, 1989, KIDNEY INT, V36, P682, DOI 10.1038/ki.1989.246; MAREN TH, 1958, J PHARMACOL EXP THER, V123, P311; Murray M. D., 1998, JGIM, V13, P18; NAKAHAMA H, 1988, NEPHRON, V49, P223, DOI 10.1159/000185059; OCHS HR, 1978, AM HEART J, V96, P389, DOI 10.1016/0002-8703(78)90052-2; ODLIND B, 1980, CLIN PHARMACOL THER, V27, P784, DOI 10.1038/clpt.1980.111; OLESEN KH, 1971, ACTA MED SCAND, V190, P233; OSTER JR, 1983, ANN INTERN MED, V99, P405, DOI 10.7326/0003-4819-99-3-405; OVERDIEK HWPM, 1985, CLIN PHARMACOL THER, V38, P469, DOI 10.1038/clpt.1985.206; PEREZ J, 1980, BRIT J CLIN PHARMACO, V9, P471, DOI 10.1111/j.1365-2125.1980.tb05842.x; PETERSEN JS, 1992, PHARMACOL TOXICOL, V70, P3, DOI 10.1111/j.1600-0773.1992.tb00417.x; Pichette V, 1996, J AM SOC NEPHROL, V7, P345; RANE A, 1978, CLIN PHARMACOL THER, V24, P199; RODICIO JL, 1977, REV ESP FISIOL, V33, P113; ROSE LI, 1977, ANN INTERN MED, V87, P398, DOI 10.7326/0003-4819-87-4-398; RUDY DW, 1994, CLIN PHARMACOL THER, V56, P39, DOI 10.1038/clpt.1994.99; SAHN H, 1987, EUR J CLIN PHARMACOL, V33, P493; SCHWARTZ S, 1993, CLIN PHARMACOL THER, V54, P90, DOI 10.1038/clpt.1993.116; SHEAR L, 1970, NEW ENGL J MED, V282, P1391, DOI 10.1056/NEJM197006182822502; SHEFFIELD PA, 1971, SOUTH MED J, V64, P359, DOI 10.1097/00007611-197103000-00022; Sica DA, 1996, CLIN PHARMACOKINET, V30, P229, DOI 10.2165/00003088-199630030-00004; SMITH AJ, 1973, BRIT J PHARMACOL, V48, P646, DOI 10.1111/j.1476-5381.1973.tb08252.x; STANTON BA, 1988, AM J PHYSIOL, V255, pF1269, DOI 10.1152/ajprenal.1988.255.6.F1269; SZERLIP HM, 1991, ANN INTERN MED, V115, P153, DOI 10.7326/0003-4819-115-2-153; TRAEGER A, 1985, INT J CLIN PHARM TH, V23, P129; VANMEYEL JJM, 1992, CLIN PHARMACOKINET, V22, P308, DOI 10.2165/00003088-199222040-00006; VANOLDEN RW, 1995, EUR J CLIN PHARMACOL, V47, P483, DOI 10.1007/BF00193698; VANVLIET AA, 1993, AM J CARDIOL, V71, pA21, DOI 10.1016/0002-9149(93)90241-4; Vargo DL, 1996, J AM SOC NEPHROL, V7, P1032; VARGO DL, 1995, CLIN PHARMACOL THER, V57, P601, DOI 10.1016/0009-9236(95)90222-8; VASKO MR, 1985, ANN INTERN MED, V102, P314, DOI 10.7326/0003-4819-102-3-314; VERBEECK RK, 1982, CLIN PHARMACOL THER, V31, P719, DOI 10.1038/clpt.1982.101; VILLENEUVE JP, 1986, CLIN PHARMACOL THER, V40, P14, DOI 10.1038/clpt.1986.132; VILLENEUVE JP, 1984, CLIN PHARMACOL THER, V35, P831, DOI 10.1038/clpt.1984.121; VOELKER JR, 1987, KIDNEY INT, V32, P572, DOI 10.1038/ki.1987.246; Wakelkamp M, 1996, CLIN PHARMACOL THER, V60, P75, DOI 10.1016/S0009-9236(96)90170-8; WALDORFF S, 1978, CLIN PHARMACOL THER, V24, P162; WARREN SE, 1981, ARCH INTERN MED, V141, P493, DOI 10.1001/archinte.141.4.493; WILCOX CS, 1983, J LAB CLIN MED, V102, P450; WILCOX CS, 1987, KIDNEY INT, V31, P135, DOI 10.1038/ki.1987.20; WOLLAM GL, 1982, AM J MED, V72, P929, DOI 10.1016/0002-9343(82)90854-3	92	393	425	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1998	339	6					387	395		10.1056/NEJM199808063390607	http://dx.doi.org/10.1056/NEJM199808063390607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107MD	9691107				2022-12-28	WOS:000075212300007
J	Krug, EG; Ikeda, RM; Qualls, ML; Anderson, MA; Rosenberg, ML; Jackson, RJ				Krug, EG; Ikeda, RM; Qualls, ML; Anderson, MA; Rosenberg, ML; Jackson, RJ			Preventing land mine-related injury and disability - A public health perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ANTIPERSONNEL MINES; MOZAMBIQUE; CAMBODIA		Natl Ctr Injury Prevent & Control, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Krug, EG (corresponding author), CDC, Div Violence Prevent & Control, 4770 Buford Hwy,Mailstop K-6, Atlanta, GA 30341 USA.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; *CDC, 1994, MMWR-MORBID MORTAL W, V43, P37; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P724; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; Forjuoh S N, 1993, J Public Health Policy, V14, P355, DOI 10.2307/3343044; HOGDEN HC, 1987, CDC SMALLPOX CRUSADE; *HUM RIGHTS WAT PH, 1993, LANDM DEADL LEG; Jeffrey SJ, 1996, J ACCID EMERG MED, V13, P343; KAKAR F, 1996, PREHOSPITAL DISASTER, V11, P41; Meddings DR, 1997, BRIT MED J, V315, P1417, DOI 10.1136/bmj.315.7120.1417; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; MURRAY CJL, 1996, GLOBAL BURDEN DIS, P361; *OFF INT SEC PEAC, 1994, HIDD KILL GLOB LANDM; QUALLS M, 1996, MIL MED, V161, P760; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P331, DOI 10.1001/jama.272.5.331; *WORLD HLTH ASS, 1998, PUBL WHA, V518	17	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					465	466		10.1001/jama.280.5.465	http://dx.doi.org/10.1001/jama.280.5.465			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701084				2022-12-28	WOS:000075050200036
J	Kiser, PF; Wilson, G; Needham, D				Kiser, PF; Wilson, G; Needham, D			A synthetic mimic of the secretory granule for drug delivery	NATURE			English	Article							MAST-CELL; VESICLES; ACCUMULATION; PRODUCTS	Secretory cells contain submicroscopic granules composed of a polyanionic polymer network that is collapsed owing to the presence of hydronium ions and weak base cations(1-3). The network is encapsulated within a lipid membrane, and functions as a vehicle for the osmotically inert storage of a variety of granule-bound endogenous mediator species, such as histamine, serotonin and proteases. These species are excreted from the granule and thence from the cell in response to external biochemical signals(1-4) Hydrogels that swell and shrink in response to external stimuli might serve as synthetic analogues of secretory granules(5,6). Here we describe the systematic engineering of multi-component, environmentally responsive hydrogel microspheres, coated with a lipid bilayer to mimic more closely the natural secretory granule. These microspheres exhibit pH- and ion-dependent volume phase transitions and ion-sensitive exchange of bound cations when the encapsulating lipid membrane is porated. We stimulated poration electrically in individual microgel particles immobilized and manipulated with a micropipette. This system could find use for the triggered release of encapsulated drugs in the body.	Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA; Access Pharmaceut, Dallas, TX 75207 USA; Glynn Wilson Grp, Issaquah, WA 98027 USA	Duke University	Needham, D (corresponding author), Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA.	david.needham@duke.edu	Kiser, Patrick F/C-2843-2014	Kiser, Patrick F/0000-0002-3868-7122; Needham, David/0000-0002-0082-9148				CHEN Y, 1994, MICROSPHERES REGIONA, P2; CURRAN MJ, 1991, J GEN PHYSIOL, V98, P771, DOI 10.1085/jgp.98.4.771; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; EICHENBAUM G, IN PRESS MACROMOLECU; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERNANDEZ JM, 1997, Patent No. 5654006; Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218; KASHIWABARA M, 1995, COLLOID POLYM SCI, V273, P339, DOI 10.1007/BF00652347; KISER P, 1997, P AM CHEM SOC DIV PO, V76, P226; MADDEN TD, 1990, CHEM PHYS LIPIDS, V53, P37, DOI 10.1016/0009-3084(90)90131-A; Marszalek PE, 1997, BIOPHYS J, V73, P1160, DOI 10.1016/S0006-3495(97)78148-7; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; NEEDHAM D, 1989, BIOPHYS J, V55, P1001, DOI 10.1016/S0006-3495(89)82898-X; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; RICKA J, 1984, MACROMOLECULES, V17, P2916, DOI 10.1021/ma00142a081; VERDUGO P, 1995, P INT S CONTR REL BI, P114; WU NZ, 1993, CANCER RES, V53, P3765	20	239	244	5	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					459	462		10.1038/28822	http://dx.doi.org/10.1038/28822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697768				2022-12-28	WOS:000075080400046
J	Mulrow, CD				Mulrow, CD			Evidence based case report - Helping an obese patient make informed choices	BRITISH MEDICAL JOURNAL			English	Review							WEIGHT-LOSS; WOMEN; MORTALITY		Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Mulrow, CD (corresponding author), Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA.	mulrowc@uthscsa.edu						Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; *COMM DEV CRIT EV, 1995, WEIGHT OPT CRIT EV W; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Dennis KE, 1996, ADDICT BEHAV, V21, P103, DOI 10.1016/0306-4603(95)00042-9; FRASER L, 1997, LOSING IT AM OBSESSE; GARROW JS, 1995, EUR J CLIN NUTR, V45, P1; Graham DJ, 1997, NEW ENGL J MED, V337, P635, DOI 10.1056/NEJM199708283370911; James WPT, 1997, INT J OBESITY, V21, pS24; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; NHS Centre for Reviews and Dissemination University of York, 1997, EFFECTIVE HLTH CARE, V3, P1; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; Shaper AG, 1997, BRIT MED J, V314, P1311, DOI 10.1136/bmj.314.7090.1311; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907; 1997, AM J HLTH SYSTEM PHA, V54, P2269	16	3	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					266	267		10.1136/bmj.317.7153.266	http://dx.doi.org/10.1136/bmj.317.7153.266			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677222	Green Published			2022-12-28	WOS:000075081900029
J	Wan, L; Molloy, SS; Thomas, L; Liu, GP; Xiang, Y; Rybak, SL; Thomas, G				Wan, L; Molloy, SS; Thomas, L; Liu, GP; Xiang, Y; Rybak, SL; Thomas, G			PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization	CELL			English	Article							CASEIN KINASE-II; MANNOSE 6-PHOSPHATE RECEPTOR; CYTOPLASMIC DOMAIN; INTRACELLULAR TRAFFICKING; PHOSPHORYLATION SITE; PROPROTEIN CONVERTASE; MESSENGER-RNAS; CELL-SURFACE; FURIN; IDENTIFICATION	We report the role of one member of a novel gene family, PACS-1, in the localization of trans-Golgi network (TGN) membrane proteins. PACS-1 directs the TGN localization of furin by binding to the protease's phosphorylated cytosolic domain. Antisense studies show TGN localization of furin and mannose-6-phosphate receptor, but not TGN46, is strictly dependent on PACS-1.Analyses in vitro and in vivo show PACS-1 has properties of a coat protein and connects furin to components of the clathrin-sorting machinery. Cell-free assays indicate TGN localization of furin is directed by a PACS-1-mediated retrieval step. Together, these findings explain a mechanism by which membrane proteins in mammalian cells are localized to the TGN.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Thomas, G (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.				NIDDK NIH HHS [DK09394, DK44629, DK37274, R01 DK037274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044629, F32DK009394, R01DK037274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BENNETT MK, 1993, J NEUROSCI, V13, P1701; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Hartmann C, 1997, DEV GENES EVOL, V207, P186, DOI 10.1007/s004270050106; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Ikonen E, 1997, J CELL SCI, V110, P2155; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KORNER C, 1994, J BIOL CHEM, V269, P16529; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mallet WG, 1996, J CELL SCI, V109, P3059; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; Norais N, 1996, J VIROL, V70, P5716, DOI 10.1128/JVI.70.8.5716-5719.1996; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Sambrook J., 1989, MOL CLONING, V1; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seaman MNJ, 1996, J BIOL CHEM, V271, P25446, DOI 10.1074/jbc.271.41.25446; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WONG SH, 1993, J BIOL CHEM, V268, P22853; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YAO ZB, 1993, J VIROL, V67, P4464, DOI 10.1128/JVI.67.8.4464-4473.1993	47	306	316	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					205	216		10.1016/S0092-8674(00)81420-8	http://dx.doi.org/10.1016/S0092-8674(00)81420-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695949	Bronze			2022-12-28	WOS:000075020100009
J	Ding, JM; Buchanan, GF; Tischkau, SA; Chen, D; Kuriashkina, L; Faiman, LE; Alster, JM; McPherson, PS; Campbell, KP; Gillette, MU				Ding, JM; Buchanan, GF; Tischkau, SA; Chen, D; Kuriashkina, L; Faiman, LE; Alster, JM; McPherson, PS; Campbell, KP; Gillette, MU			A neuronal ryanodine receptor mediates light-induced phase delays of the circadian clock	NATURE			English	Article							CALCIUM-RELEASE CHANNEL; CA2+ RELEASE; CAFFEINE; PROTEIN; SHIFTS; THAPSIGARGIN; RAPAMYCIN; RETICULUM; MUSCLE; RIBOSE	Circadian clocks are complex biochemical systems that cycle with a period of approximately 24 hours. They integrate temporal information regarding phasing of the solar cycle, and adjust their phase so as to synchronize an organism's internal state to the local environmental day and night(1,2). Nocturnal light is the dominant regulator of this entrainment. In mammals, information about nocturnal light is transmitted by glutamate released om retinal projections to the circadian clock in the suprachiasmatic nucleus of the hypothalamus. Clock resetting requires the activation of ionotropic glutamate receptors, which mediate Ca2+ influx(3). The response induced by such activation depends on the clock's temporal state: during early night it delays the clock phase, whereas in late night the clock phase is advanced. To investigate this differential response, we sought signalling elements that contribute solely to phase delay. We analysed intracellular calcium-channel ryanodine receptors, which mediate coupled Ca2+ signalling, Depletion of intracellular Ca2+ stores during early night blocked the effects of glutamate. Activators of ryanodine receptors induced phase resetting only in early night; inhibitors selectively blocked delays induced by light and glutamate. These findings implicate the release of intracellular Ca2+ through ryanodine receptors in the light-induced phase delay of the circadian clock restricted to the early night.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Neurosci Program, Urbana, IL 61801 USA; Univ Illinois, Comp & Commun Serv Off, Urbana, IL 61801 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol, Iowa City, IA 52242 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; McGill University; Howard Hughes Medical Institute; University of Iowa; University of Iowa	Gillette, MU (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Buchanan, Gordon/0000-0003-2371-4455; Campbell, Kevin/0000-0003-2066-5889				BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; DECOURSEY PJ, 1960, SCIENCE, V131, P33, DOI 10.1126/science.131.3392.33; DENT M, 1996, NEUR ABSTR, V22; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; Liu C, 1997, J NEUROSCI, V17, P659; Mathur A, 1996, AM J PHYSIOL-REG I, V270, pR1031, DOI 10.1152/ajpregu.1996.270.5.R1031; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; OBENAUS A, 1989, NEUROSCI LETT, V98, P172, DOI 10.1016/0304-3940(89)90505-3; OMARA SM, 1995, NEUROSCIENCE, V68, P621, DOI 10.1016/0306-4522(95)00233-9; PARNESS J, 1995, J BIOL CHEM, V270, P18465, DOI 10.1074/jbc.270.31.18465; Pawlikowska L, 1996, J NEUROSCI, V16, P5372; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6812, DOI 10.1073/pnas.86.17.6812; PROSSER RA, 1989, J NEUROSCI, V9, P1073; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEBER ET, 1995, BRAIN RES, V692, P137; WEBER ET, 1995, NEUROSCI LETT, V197, P227, DOI 10.1016/0304-3940(95)11961-U; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; ZATZ M, 1995, J NEUROCHEM, V65, P1332	27	182	184	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					381	384		10.1038/28639	http://dx.doi.org/10.1038/28639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690474				2022-12-28	WOS:000074968800054
J	Zhang, NA; Gridley, T				Zhang, NA; Gridley, T			Defects in somite formation in lunatic fringe deficient mice	NATURE			English	Article							EXPRESSION; DORSAL; BOUNDARY; DELTA; NOTCH	Segmentation in vertebrates first arises when the unsegmented paraxial mesoderm subdivides to form paired epithelial spheres called somites(1,2). The Notch signalling pathway is important in regulating the formation and anterior-posterior patterning of the vertebrate somite(3-7). One component of the Notch signalling pathway in Drosophila is the fringe gene, which encodes a secreted signalling molecule required for activation of Notch during specification of the wing margins-(8-11). Here we show that mice homozygous for a targeted mutation of the lunatic fringe (Lfng) gene, one of the mouse homologues(12,13) of fringe, have defects in somite formation and anterior-posterior patterning of the somites. Somites in the mutant embryos are irregular in size and shape, and their anterior-posterior patterning is disturbed. Marker analysis revealed that in the presomitic mesoderm of the mutant embryos, sharply demarcated domains of expression of several components of the Notch signalling pathway are replaced by even gradients of gene expression. These results indicate that Lfng encodes an essential component of the Notch signalling pathway during somitogenesis in mice.	Jackson Lab, Bar Harbor, ME 04609 USA	Jackson Laboratory	Gridley, T (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	gridley@jax.org						BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BLAIR SS, 1997, CURR BIOL, V7, pR636; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; deCelis JF, 1996, DEVELOPMENT, V122, P359; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; GOSSLER A, 1997, CURR TOP DEV BIOL, V33, P225; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; MONTARRAS D, 1991, NEW BIOL, V3, P592; Neidhardt LM, 1997, DEV GENES EVOL, V207, P330, DOI 10.1007/s004270050120; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Saga Y, 1997, GENE DEV, V11, P1827, DOI 10.1101/gad.11.14.1827; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SWIATEK P, 1993, GENE DEV, P2071; Tannahill D, 1997, CELL TISSUE RES, V290, P275, DOI 10.1007/s004410050932; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WONG C, 1997, NATURE, V387, P288	27	344	352	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					374	377		10.1038/28625	http://dx.doi.org/10.1038/28625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690472				2022-12-28	WOS:000074968800052
J	Flanagin, A; Carey, LA; Fontanarosa, PB; Phillips, SG; Pace, BP; Lundberg, GD; Rennie, D				Flanagin, A; Carey, LA; Fontanarosa, PB; Phillips, SG; Pace, BP; Lundberg, GD; Rennie, D			Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-Authorship in biomedical publications establishes accountability, responsibility, and credit. Misappropriation of authorship undermines the integrity of the authorship system, but accurate data on its prevalence are limited. Objectives.-To determine the prevalence of articles with honorary authors (named authors who have not met authorship criteria) and ghost authors (individuals not named as authors but who contributed substantially to the work) in peer-reviewed medical journals and to identify journal characteristics and article types associated with such authorship misappropriation. Design.-Mailed, self-administered, confidential survey. Participants.-A total of 809 corresponding authors (1179 surveyed, 69% response rate) of articles published in 1996 in 3 peer-reviewed, large-circulation general medical journals (Annals of Internal Medicine, JAMA, and The New England Journal of Medicine) and 3 peer-reviewed, smaller-circulation journals that publish supplements (American Journal of Cardiology, American Journal of Medicine, and American Journal of Obstetrics and Gynecology). Main Outcome Measures.-Prevalence of articles with honorary authors and ghost authors, as reported by corresponding authors. Results.-Of the 809 articles, 492 were original research reports, 240 were reviews and articles not reporting original data, and 77 were editorials. A total of 156 articles (19%) had evidence of honorary authors (range, 11%-25% among journals); 93 articles (11%) had evidence of ghost authors (range, 7%-16% among journals) and 13 articles (2%) had evidence of both. The prevalence of articles with honorary authors was greater among review articles than research articles (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-2.6) but did not differ significantly between large-circulation and smaller-circulation journals (OR, 1.4; 95% CI, 0.96-2.03). Compared with similar-type articles in large-circulation journals, articles with ghost authors in smaller-circulation journals were more likely to be reviews (OR, 4.2; 95% CI, 1.5-13.5) and less likely to be research articles (OR, 0.49; 95% CI, 0.27-0.88). Conclusion.-A substantial proportion of articles in peer-reviewed medical journals demonstrate evidence of honorary authors or ghost authors.	JAMA, Chicago, IL 60610 USA; Marymount Manhattan Coll, New York, NY USA; Project House Inc, Hackensack, NJ USA		Fontanarosa, PB (corresponding author), JAMA, 515 N State St, Chicago, IL 60610 USA.							BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; Bhopal R, 1997, BRIT MED J, V314, P1009, DOI 10.1136/bmj.314.7086.1009; *CDCP, 1994, EP INF COMP PROGR VE; GOODMAN NW, 1994, BRIT MED J, V309, P1482, DOI 10.1136/bmj.309.6967.1482; *I SCI INF, 1996, J CIT REP CD ROM SCI; *INT COMM MED J ED, 1993, JAMA-J AM MED ASSOC, V269, P2282; *INT COMM MED J ED, 1985, BRIT MED J, V291, P722; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; Sloan R, 1996, AM J ROENTGENOL, V167, P571; SMITH J, 1994, BRIT MED J, V309, P1456, DOI 10.1136/bmj.309.6967.1456; *SPSS INC, 1994, SPSS ADV STAT COMP P; *SRDS, 1998, STAND RAT DAT SERV B, V80; 1995, AM J OBSTET GYNECOL, V173, pA23	17	374	387	1	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					222	224		10.1001/jama.280.3.222	http://dx.doi.org/10.1001/jama.280.3.222			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676661	Bronze			2022-12-28	WOS:000074706000006
J	Garrow, J; Butterfield, M; Marshall, J; Williamson, A				Garrow, J; Butterfield, M; Marshall, J; Williamson, A			The reported training and experience of editors in chief of specialist clinical medical journals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-The majority of the peer-reviewed clinical literature is edited by editors whose training in editorial matters may be limited or nonexistent. We suspect that editors are selected for their clinical or academic rather than editorial ability. Objective.-To test the hypothesis that editors of medical specialist clinical journals were recruited from active clinicians rather than those with evident ability or training as editors. Design, Setting, and Subjects.-Anonymous mail survey to editors of the 262 peer-reviewed clinical journals that had received at least 1000 citations in the 1994 Science Citation Index. Main Outcome Measures.-Training and editorial practices of editors. Results.-Replies were received from 191 editors (73%): in 1994 the journals they edited had 6060 (27300/1000 [maximum/minimum]) citations, 234 (740/31) source items, and an impact factor of 2.10 (18.3/0.2); nonresponders' journals had similar characteristics. Of the responding editors, 181 (95%) were part-time, 132 (69%) treated patients, and 164 (86%) were recruited by one of the following methods: election by a scientific society (49 [30%]), nomination by the previous editor (41 [25%]), or response to an advertisement (29 [18%]). There was no strong association between method of recruitment or formal editorial training and the status of the journal. Only 9% of editors in the United States send at least half of the papers to reviewers outside their own country, compared with 41% of editors in the United Kingdom and 73% in other countries, and 69% do not feel bound to follow the advice they receive concerning acceptance of papers. Conclusions.-Clinical journals are usually edited by practicing clinicians who are self-taught part-time editors, but willing to accept further training. They usually consult 2 reviewers, but exercise independent judgment on the acceptability of papers.	BMJ Publishing Grp Specialist Journals, London WC1H 9JR, England	BMJ Publishing Group Ltd	Williamson, A (corresponding author), BMJ Publishing Grp Specialist Journals, BMA House,Tavistock Sq, London WC1H 9JR, England.								0	31	31	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					286	287		10.1001/jama.280.3.286	http://dx.doi.org/10.1001/jama.280.3.286			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676684				2022-12-28	WOS:000074706000029
J	Imai, Y; Kawata, S; Tamura, S; Yabuuchi, I; Noda, S; Inada, M; Maeda, Y; Shirai, Y; Fukuzaki, T; Kaji, I; Ishikawa, H; Matsuda, Y; Nishikawa, M; Seki, K; Matsuzawa, Y				Imai, Y; Kawata, S; Tamura, S; Yabuuchi, I; Noda, S; Inada, M; Maeda, Y; Shirai, Y; Fukuzaki, T; Kaji, I; Ishikawa, H; Matsuda, Y; Nishikawa, M; Seki, K; Matsuzawa, Y		Osaka Hepatocellular Carcinoma Prevention Stud	Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	CHRONIC ACTIVE HEPATITIS; CHRONIC LIVER-DISEASE; B VIRAL-HEPATITIS; CHRONIC NON-A; ALPHA-INTERFERON; CONTROLLED TRIAL; RISK-FACTORS; RANDOMIZED TRIAL; ALFA THERAPY; VIRUS	Background: The effect of interferon therapy on the incidence of hepatocellular carcinoma in chronic hepatitis C is poorly defined. Objective: To compare the incidence of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C to that of historical controls and to examine whether response to therapy is related to incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Design: Retrospective cohort study. Setting: One university hospital and seven university-affiliated hospitals. Patients: 419 consecutive patients with chronic hepatitis C who started interferon therapy between January 1992 and December 1993 (interferon group) and 144 patients with chronic hepatitis C who had liver biopsy between January 1986 and December 1989 and did not receive interferon (controls). Intervention: Patients in the interferon group received human lymphoblastoid interferon, recombinant interferon-alpha 2a, or recombinant interferon-alpha 2b for 6 months. Measurements: The end point was development of hepatocellular carcinoma on abdominal ultrasonography or computed tomography. Sustained response was defined as persistent normalization of alanine aminotransferase (ALT) levels during interferon therapy and follow-up. Relapse was defined as a normal serum ALT revel at the end of treatment with an increase to an abnormal level after cessation of treatment. Nonresponse included all other ALT patterns. Results: Median follow-up in the interferon and control groups was 47.6 and 46.8 months, respectively. During follow-up, hepatocellular carcinoma was found in 28 interferon-treated patients and 19 controls. Cox proportional hazards regression analysis that included all patients revealed that interferon therapy (P = 0.041), older age (P = 0.003), greater histologic activity (P = 0.029), and higher histologic stage (P = 0.049) were independent factors associated with the development of hepatocellular carcinoma. The risk ratios for development of hepatocellular carcinoma in patients with sustained response, relapse, and nonresponse were 0.06 (95% CI, 0.01 to 0.46), 0.51 (CI, 0.20 to 1.27), and 0.95 (CI, 0.48 to 1.84), respectively, compared with controls. Conclusions: The incidence of hepatocellular carcinoma was lower in patients with sustained response to interferon therapy than historical controls and nonresponders. Interferon therapy may decrease the risk for hepatocellular carcinoma in patients with chronic hepatitis C.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan	Osaka University	Kawata, S (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							BRUIX J, 1989, LANCET, V2, P1004; Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAVID E, 1992, AM J CLIN PATHOL, V98, P397, DOI 10.1093/ajcp/98.4.397; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1995, SEMIN LIVER DIS, V15, P64, DOI 10.1055/s-2007-1007263; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIODATI G, 1991, J MED VIROL, V35, P151, DOI 10.1002/jmv.1890350302; Fattovich G, 1997, J HEPATOL, V27, P201, DOI 10.1016/S0168-8278(97)80302-9; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MANABE N, 1993, HEPATOLOGY, V18, P1344, DOI 10.1016/0270-9139(93)90222-9; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; MURAKAMI R, 1990, INT J CANCER, V46, P159, DOI 10.1002/ijc.2910460203; MURAKAMI R, 1990, CANCER, V65, P1255, DOI 10.1002/1097-0142(19900301)65:5<1255::AID-CNCR2820650536>3.0.CO;2-P; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OKUDA K, 1987, CANCER RES, V47, P4967; Poynard T, 1996, HEPATOLOGY, V24, P778; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502	31	296	304	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					94	99		10.7326/0003-4819-129-2-199807150-00005	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669992				2022-12-28	WOS:000074852000003
J	Pittet, D; Harbarth, S				Pittet, D; Harbarth, S			What techniques for diagnosis of ventilator-associated pneumonia?	LANCET			English	Editorial Material									Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, Geneva 14, Switzerland; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Geneva; Harvard University; Harvard T.H. Chan School of Public Health	Pittet, D (corresponding author), Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, Geneva 14, Switzerland.							Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; Flaherty JP, 1996, INFECT CONT HOSP EP, V17, P236; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; Pittet D, 1998, HOSP INFECT, P381; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Sanchez-Nieto JM, 1998, AM J RESP CRIT CARE, V157, P371, DOI 10.1164/ajrccm.157.2.97-02039; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349	9	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					83	84		10.1016/S0140-6736(98)85005-8	http://dx.doi.org/10.1016/S0140-6736(98)85005-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672269				2022-12-28	WOS:000074775100005
J	Veronesi, U; Maisonneuve, P; Costa, A; Sacchini, V; Maltoni, C; Robertson, C; Rotmensz, N; Boyle, P				Veronesi, U; Maisonneuve, P; Costa, A; Sacchini, V; Maltoni, C; Robertson, C; Rotmensz, N; Boyle, P		Italian Tamoxifen Prevention Study	Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women	LANCET			English	Article							THERAPY	Background Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer. Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive. Methods In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy. Women were randomised to receive tamoxifen 20 mg per day or placebo, both orally for 5 years. The original plan was to follow the intervention phase by 5 years' follow-up. In June, 1997, the trialists and the data-monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study. Recruitment ended on July 11, 1997, and the study will continue as planned. The primary endpoints are the occurrence of and deaths from breast cancer, This preliminary interim analysis is based on intention-to-treat. Findings 5408 women were randomised; participating women have a median follow-up of 46 months for major endpoints. 41 cases of breast cancer occurred so far; there have been no deaths from breast cancer, There is no difference in breast-cancer frequency between the placebo (22 cases) and tamoxifen (19) arms, There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen. Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen. Interpretation Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent. Women using hormone replacement therapy appear to have benefited from use of tamoxifen, There were no deaths from breast cancer recorded in women in the study. It is essential to continue follow-up to quantify the long-term risks and benefits of tamoxifen therapy.	European Inst Oncol, I-20141 Milan, Italy; Fdn Europea B Rammazini, Bologna, Italy	IRCCS European Institute of Oncology (IEO)	Boyle, P (corresponding author), European Inst Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pboyle@eio.it	Maisonneuve, Patrick/U-9789-2018; Boyle, Peter/A-4380-2014	Maisonneuve, Patrick/0000-0002-5309-4704; Boyle, Peter/0000-0001-6251-0610				BAUM M, 1988, BRIT J CANCER, V57, P608; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BONADONNA G, 1991, SEMIN ONCOL, V18, P515; BOYLE P, 1988, BAILLIERE CLIN ONCOL, V2, P1; BRUN LD, 1986, CANCER, V57, P2123, DOI 10.1002/1097-0142(19860601)57:11<2123::AID-CNCR2820571106>3.0.CO;2-2; Clarke M, 1998, LANCET, V351, P1451; COLLETTA AA, 1994, BREAST CANCER RES TR, V31, P5, DOI 10.1007/BF00689672; Creasman William T., 1997, Seminars in Oncology, V24, P140; CUZICK J, 1985, LANCET, V2, P282; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; FISHER B, 1991, J NATL CANCER I, V83, P1278, DOI 10.1093/jnci/83.18.1278; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Forbes John F., 1997, Seminars in Oncology, V24, P5; GLUECK CJ, 1994, J LAB CLIN MED, V123, P59; Jordan V C, 1980, Recent Results Cancer Res, V71, P30; Kanel KT, 1997, NEW ENGL J MED, V337, P281, DOI 10.1056/NEJM199707243370417; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; MacMahon Brian, 1997, Seminars in Oncology, V24, P122; THANGARAJU M, 1994, CANCER, V73, P659, DOI 10.1002/1097-0142(19940201)73:3<659::AID-CNCR2820730325>3.0.CO;2-H; Veronesi U, 1995, BREAST, V4, P267, DOI 10.1016/S0960-9776(95)80002-6	20	649	661	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					93	97						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672273				2022-12-28	WOS:000074775100011
J	Kloss, B; Price, JL; Saez, L; Blau, J; Rothenfluh, A; Wesley, CS; Young, MW				Kloss, B; Price, JL; Saez, L; Blau, J; Rothenfluh, A; Wesley, CS; Young, MW			The Drosophila clock gene double-time encodes a protein closely related to human casein kinase I epsilon	CELL			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; PERIOD PROTEIN; EXPRESSION; MUTANT; MUTATION; LIGHT; CELLS; PHOSPHORYLATION; HYBRIDIZATION; MELANOGASTER	The cloning of double-time (dbt) is reported. DOUBLETIME protein (DBT) is most closely related to human casein kinase le. dbt(s) and dbt(L) mutations, which alter period length of Drosophila circadian rhythms, produce single amino acid changes in conserved regions of the predicted kinase. dbf(P) mutants, which eliminate rhythms of per and tim expression and constitutively overproduce hypophosphorylated PER proteins, abolish most dbt expression. dbt mRNA appears to be expressed in the same cell types as are per and tim and shows no evident oscillation in wild-type heads. DBT is capable of binding to PER in vitro and in Drosophila cells, suggesting that a physical association of PER and DBT regulates PER phosphorylation and accumulation in vivo.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Natl Sci Fdn, Sci & Technol Ctr Biol Timing, New York, NY 10021 USA; W Virginia Univ, Dept Biol, Morgantown, WV 26506 USA	Rockefeller University; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University; West Virginia University	Young, MW (corresponding author), Rockefeller Univ, Genet Lab, 1230 York Ave, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Kloss, Brian/0000-0003-0130-8739; Rothenfluh, Adrian/0000-0002-3813-5723	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056895, R01MH056895] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54339] Funding Source: Medline; NIMH NIH HHS [MH 56895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COMOLLI J, 1994, J BIOL RHYTHM, V9, P13, DOI 10.1177/074873049400900102; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Fourney R.M., 1988, FOCUS, V10, P5; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; JOWETT T, 1986, DROSOPHILA PRACTICAL; Kaneko M, 1997, J NEUROSCI, V17, P6745; KELLEY MR, 1987, MOL CELL BIOL, V7, P1545, DOI 10.1128/MCB.7.4.1545; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; Majercak J, 1997, MOL CELL BIOL, V17, P5915, DOI 10.1128/MCB.17.10.5915; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; MEGGIO F, 1991, FEBS LETT, V283, P303, DOI 10.1016/0014-5793(91)80614-9; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Moore DD, 1995, GLOB MOB SURV; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; NEWBY LM, 1993, GENETICS, V135, P1077; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PIRROTTA V, 1986, DROSOPHILA PRACTICAL; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; ROBERTS MH, 1989, BRAIN RES, V504, P211, DOI 10.1016/0006-8993(89)91359-0; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schulz R, 1985, Chronobiol Int, V2, P223, DOI 10.3109/07420528509055883; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZWARTJES RE, 1989, J NEUROBIOL, V21, P376	57	585	600	2	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					97	107		10.1016/S0092-8674(00)81225-8	http://dx.doi.org/10.1016/S0092-8674(00)81225-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674431	Bronze			2022-12-28	WOS:000074790800013
J	Basgoz, N; Frosch, MP				Basgoz, N; Frosch, MP			A 32-year-old woman with pharyngeal spasms and paresthesias after a dog bite - Rabies, involving the central and peripheral nervous systems, salivary glands, and heart (epicardium)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							VIRUS-INFECTION; PATHOPHYSIOLOGY; ENCEPHALITIS; PATHOGENESIS		Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Med Sch, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Basgoz, N (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.		Frosch, Matthew P/ABD-7456-2021	Frosch, Matthew P/0000-0002-3940-9861				Aubert M. F. A., 1994, V187, P219; BUDKA H, 1981, VIRCHOWS ARCH A, V390, P353, DOI 10.1007/BF00496565; CONSTANTINE DG, 1962, PUBLIC HEALTH REP, V77, P287, DOI 10.2307/4591470; DIETZSCHOLD B, 1992, P NATL ACAD SCI USA, V89, P7252, DOI 10.1073/pnas.89.15.7252; DUPONT JR, 1965, NEUROLOGY, V15, P1023, DOI 10.1212/WNL.15.11.1023; FEIDEN W, 1985, CLIN NEUROPATHOL, V4, P156; FISHBEIN DB, 1993, NEW ENGL J MED, V329, P1632, DOI 10.1056/NEJM199311253292208; Hemachudha T, 1994, Curr Top Microbiol Immunol, V187, P121; Human rabies-Connecticut, 1995, MMWR MORB MORTAL WKL, V45, P207; IWASAKI Y, 1985, J NEUROPATH EXP NEUR, V44, P185, DOI 10.1097/00005072-198503000-00007; LENTZ TL, 1982, SCIENCE, V215, P182, DOI 10.1126/science.7053569; LYCKE E, 1987, J VIROL, V61, P2733, DOI 10.1128/JVI.61.9.2733-2741.1987; MRAK RE, 1994, J NEUROPATH EXP NEUR, V53, P1, DOI 10.1097/00005072-199401000-00001; SMITH JS, 1991, NEW ENGL J MED, V324, P205, DOI 10.1056/NEJM199101243240401; SMITH JS, 1989, ADV VIRUS RES, V36, P215; SMITH JS, 1993, PROG MED VIROL, V40, P82; SUNG JH, 1976, J NEUROPATH EXP NEUR, V35, P541, DOI 10.1097/00005072-197609000-00006; Tordo N., 1996, P28; TSIANG H, 1993, ADV VIRUS RES, V42, P375, DOI 10.1016/S0065-3527(08)60090-1; TSIANG H, 1979, J NEUROPATH EXP NEUR, V38, P286, DOI 10.1097/00005072-197905000-00008; TYLER KL, 1989, J EXP MED, V170, P887, DOI 10.1084/jem.170.3.887; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; WARRELL DA, 1977, RABIES FACTS, P35; WINKLER WG, 1973, JAMA-J AM MED ASSOC, V226, P1219, DOI 10.1001/jama.226.10.1219; 1977, MMWR MORB MORTAL WKL, V26, P183	25	26	28	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					105	112		10.1056/NEJM199807093390208	http://dx.doi.org/10.1056/NEJM199807093390208			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9669896				2022-12-28	WOS:000074665300008
J	Fisahn, A; Pike, FG; Buhl, EH; Paulsen, O				Fisahn, A; Pike, FG; Buhl, EH; Paulsen, O			Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro	NATURE			English	Article							GABAERGIC INTERNEURONS; PYRAMIDAL CELLS; NEURONS; RAT; CORTEX; SLICE; SYNCHRONIZATION; EXCITATION; RHYTHMS; MODEL	Acetylcholine is vital for cognitive functions of the brain. Although its actions in the individual cell are known in some detail(1), its effects at the network level are poorly understood(2). The hippocampus, which receives a major cholinergic input from the medial septum/diagonal band(3), is important in memory(4,5) and exhibits network activity at 40 Hz during relevant behaviours(6). Here we show that cholinergic activation is sufficient to induce 40-Hz network oscillations(7) in the hippocampus in vitro. Oscillatory activity is generated spontaneously in the CA3 subfield and can persist for hours. During the oscillatory state, principal neurons fire action potentials that are phase-related to the extracellular oscillation, but each neuron fires in only a small proportion of the cycles. Both excitatory and inhibitory synaptic events participate during the network oscillation in a precise temporal pattern. These results indicate that subcortical cholinergic input can control hippocampal memory processing by inducing fast network oscillations.	Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England	University of Oxford	Fisahn, A (corresponding author), Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Mansfield Rd, Oxford OX1 3TH, England.		Paulsen, Ole/ABB-4843-2020	Paulsen, Ole/0000-0002-2258-5455	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENARDO LS, 1982, BRAIN RES, V249, P315, DOI 10.1016/0006-8993(82)90066-X; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAGIN A, 1995, J NEUROSCI, V15, P47; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Cobb SR, 1997, NEUROSCIENCE, V79, P629, DOI 10.1016/S0306-4522(97)00055-9; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; COLE AE, 1983, SCIENCE, V221, P1299, DOI 10.1126/science.6612345; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; FELLOUS JM, IN PRESS P COMP NEUR; FREEMAN WJ, 1968, J NEUROPHYSIOL, V31, P337, DOI 10.1152/jn.1968.31.3.337; Gray CM, 1996, SCIENCE, V274, P109, DOI 10.1126/science.274.5284.109; HASSELMO ME, 1994, J NEUROSCI, V14, P3898; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KONOPACKI J, 1987, BRAIN RES, V405, P196, DOI 10.1016/0006-8993(87)91009-2; LILJENSTROM H, 1995, J NEUROPHYSIOL, V74, P288, DOI 10.1152/jn.1995.74.1.288; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MILLES R, 1990, J PHYSL, V428, P61; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PITLER TA, 1992, J PHYSIOL-LONDON, V450, P127, DOI 10.1113/jphysiol.1992.sp019119; SHUTE CCD, 1963, NATURE, V199, P1160, DOI 10.1038/1991160a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; Whittington MA, 1997, P NATL ACAD SCI USA, V94, P12198, DOI 10.1073/pnas.94.22.12198; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Williams JH, 1997, J NEUROPHYSIOL, V78, P2631, DOI 10.1152/jn.1997.78.5.2631; WILSON M, 1992, J NEUROPHYSIOL, V67, P981, DOI 10.1152/jn.1992.67.4.981	30	656	666	2	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					186	189		10.1038/28179	http://dx.doi.org/10.1038/28179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671302				2022-12-28	WOS:000074705900055
J	Kemp, M				Kemp, M			Lane's landscapes	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					135	135		10.1038/28072	http://dx.doi.org/10.1038/28072			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671295	Bronze			2022-12-28	WOS:000074705900035
J	Purnell, JQ; Hokanson, JE; Marcovina, SM; Steffes, MW; Cleary, PA; Brunzell, JD				Purnell, JQ; Hokanson, JE; Marcovina, SM; Steffes, MW; Cleary, PA; Brunzell, JD			Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure - Results from the DCCT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; LIPOPROTEIN LEVELS; APOLIPOPROTEIN-B; RISK-FACTORS; IDDM; ASSOCIATION; COMPLICATIONS; POPULATION; PHENOTYPE; MELLITUS	Context.-Intensive treatment of type 1 diabetes results in greater weight gain than conventional treatment. Objective.-To determine the effect of this weight gain on lipid levels and blood pressure. Design.-Randomized controlled trial; ancillary study of the Diabetes Control and Complications Trial (DCCT). Setting.-Twenty-one clinical centers. Participants.-The 1168 subjects enrolled in DCCT with type 1 diabetes who were aged 18 years or older at baseline. Intervention.-Randomized to receive either intensive (n = 586) or conventional (n = 582) diabetes treatment with a mean follow-up of 6.1 years. Main Outcome Measures.-Plasma lipid levels and blood pressure in each treatment group categorized by quartile of weight gain. Results.-With intensive treatment, subjects in the fourth quartile of weight gain had the highest body mass index (BMI) (a measure of weight adjusted for height), blood pressure, and levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B compared with the other weight gain quartiles with the greatest difference seen when compared with the first quartile (mean values for the highest and lowest quartiles: BMI, 31 vs 24 kg/m(2); blood pressure, 120/77 mm Hg vs 113/73 mm Hg; triglyceride, 0.99 mmol/L vs 0.79 mmol/L [88 mg/dL vs 70 mg/dL]; LDL-C, 3.15 mmol/L vs 2.74 mmol/L [122 mg/dL vs 106 mg/dL]; and apolipoprotein B, 0.89 g/L vs 0.78 g/L; all P<.001). In addition, the fourth quartile group had a higher waist-to-hip ratio; more cholesterol in the very low density lipoprotein, intermediate dense lipoprotein, and dense LDL fractions; and lower high-density lipoprotein cholesterol and apolipoprotein A-I levels compared with the first quartile. Baseline characteristics were not different between the first and fourth quartiles of weight gain with intensive therapy except for a higher hemoglobin A,, in the fourth quartile. Weight gain with conventional therapy resulted in smaller increases in BMI, lipids, and systolic blood pressure. Conclusions.-The changes in lipid levels and blood pressure that occur with excessive weight gain with intensive therapy are similar to those seen in the insulin resistance syndrome and may increase the risk of coronary artery disease in this subset of subjects with time.	Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; George Washington Univ, Ctr Biostat, Diabet Control & Complicat Trial Coordinating Ctr, Rockville, MD USA; Univ Minnesota, Dept Lab Med, Minneapolis, MN 55455 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; George Washington University; University of Minnesota System; University of Minnesota Twin Cities	Purnell, JQ (corresponding author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Box 356426, Seattle, WA 98195 USA.	purnell@u.washington.edu	Hramiak, Irene/G-3305-2011; Purnell, Jonathan Q/GVS-8854-2022	Purnell, Jonathan Q/0000-0001-5505-6333	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK002456, N01DK062204] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 37] Funding Source: Medline; NIDDK NIH HHS [DK 2456, N01 DK062204-007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM DIAB ASS, 1996, DIABETES CARE S1, V19, pS96; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; BRUNZELL JD, 1983, CONT ISSUES CLIN NUT, P3; Brunzell La, 1997, ELLENBERG RIFKINS DI, P1077; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1988, DIABETES CARE, V11, P567; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; Diabet Control Complications Trial Res Grp, 1995, DIABETES CARE, V18, P1415; DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; Fujimoto W Y, 1994, Obes Res, V2, P364; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; Koivisto VA, 1996, DIABETES CARE, V19, P689, DOI 10.2337/diacare.19.7.689; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAAKSO M, 1990, METABOLISM, V39, P117, DOI 10.1016/0026-0495(90)90062-H; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; MARCOVINA SM, 1994, CLIN CHEM, V40, P586; *METR LIF INS CO, 1993, STAT B METR LIF INC, V43, P410; PURNELL JQ, 1995, DIABETES, V44, P1218, DOI 10.2337/diabetes.44.10.1218; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; STUHLDREHER WL, 1992, DIABETES RES CLIN PR, V17, P99, DOI 10.1016/0168-8227(92)90155-K; Tchernof A, 1996, DIABETES CARE, V19, P629, DOI 10.2337/diacare.19.6.629; *US DEP COMM, 1993, US DEP COMM NAT TECH; *US DEP HHS, 1980, PREVALENCE STUDY, V1; WING RR, 1990, DIABETES CARE, V13, P1106, DOI 10.2337/diacare.13.11.1106	27	348	355	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					140	146		10.1001/jama.280.2.140	http://dx.doi.org/10.1001/jama.280.2.140			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669786	Green Accepted, Bronze			2022-12-28	WOS:000074608400028
J	Piot, P				Piot, P			The science of AIDS: A tale of two worlds	SCIENCE			English	Editorial Material									UNAIDS, CH-1211 Geneva 27, Switzerland	UNAIDS	Piot, P (corresponding author), UNAIDS, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.								0	29	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1844	1845		10.1126/science.280.5371.1844	http://dx.doi.org/10.1126/science.280.5371.1844			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669936				2022-12-28	WOS:000074323800028
J	Farrell, L				Farrell, L			Seize the day	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					419	419						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694779				2022-12-28	WOS:000075409600065
J	Gunstone, C				Gunstone, C			Nostalgia - In praise of on call?	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					375	375						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694751				2022-12-28	WOS:000075409600022
J	Willinger, M; Hoffman, HJ; Wu, KT; Hou, JR; Kessler, RC; Ward, SL; Keens, TG; Corwin, MJ				Willinger, M; Hoffman, HJ; Wu, KT; Hou, JR; Kessler, RC; Ward, SL; Keens, TG; Corwin, MJ			Factors associated with the transition to nonprone sleep positions of infants in the United States - The National Infant Sleep Position Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; RISK-FACTORS; NEW-ZEALAND; SIDS; EPIDEMIOLOGY; MORTALITY; TASMANIA; COHORT	Context.-Studies have demonstrated strong associations between the prone sleep position (on the stomach) and sudden infant death syndrome (SIDS), In 1992, the American Academy of Pediatrics recommended that infants be placed to sleep laterally (on their side) or supine (on their back) to reduce SIDS risk, and in 1994, the national public education campaign "Back to Sleep" was launched. Objective.-To determine the typical sleep position of infants younger than 8 months in the United States, the changes that occurred after these recommendations, and the factors associated with the placement of infants prone or supine. Design.-Annual nationally representative telephone surveys. Setting.-The 48 contiguous states of the United States. Participants.-Nighttime caregivers of infants born within the last 7 months between 1992 and 1996, Approximately 1000 interviews were conducted per year. Main Outcome Measures.-The position the infant was usually placed in for sleep, and the position the infant was most commonly found in when checked during the night's sleep. Results.-Ninety-seven percent of respondents in each wave of the survey usually placed their infant to sleep in a specific position. Infants were placed in the prone position by 70% of caregivers in 1992, prior to the campaign, but only 24% in 1996, Supine and lateral placements increased during this time period, from 13% in 1992 to 35% in 1996 and from 15% in 1992 to 39% in 1996, respectively. Significant predictors of prone placement included maternal race reported as black (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.68-3.26), mother's age 20 to 29 years (OR, 1.28; 95% CI, 1.09-1.50), region reported as the mid-Atlantic (OR, 1.41; 95% CI, 1.12-1.78) or southern states (OR, 1.47; 95% CI, 1.22-1.70), mothers with a previous child (OR, 1.68; 95% CI, 1.43-1.97), and infants younger than 8 weeks (OR, 0.63; 95% CI, 0.46-0.85), Infants aged 8 to 15 weeks were significantly more likely to be placed nonprone over time compared with the other age groups. Most of the risk factors for prone were significantly related in the opposite direction to supine placement. Conclusions.-The prevalence of infants placed in the prone sleep position declined by 66% between 1992 and 1996, Although causality cannot be proved, SIDS rates declined approximately 38% during this period. To achieve further reduction in prone sleeping, efforts to promote the supine sleep position should be aimed at groups at high risk for prone placement.	NICHHD, Ctr Res Mothers & Children, Pregnancy & Perinatol Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, Epidemiol Stat & Data Syst Branch, NIH, Bethesda, MD USA; Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Neonatol & Pediat Pulmonol, Los Angeles, CA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Boston Univ, Med Ctr, Sch Med, Dept Pediat, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Children's Hospital Los Angeles; University of Southern California; Harvard University; Harvard Medical School; Boston University	Willinger, M (corresponding author), NICHHD, Ctr Res Mothers & Children, Pregnancy & Perinatol Branch, NIH, Execut Bldg,Room 4B03,6100 Execut Blvd,MSC 7510, Bethesda, MD 20892 USA.	mw75q@nih.gov		Corwin, Michael/0000-0002-6591-209X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022996, U10HD029067] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-2-9067, HD-2-2996] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON RN, 1997, MON VITAL STAT RE S2, V45, P66; [Anonymous], 1990, SAS STAT US GUID VER; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P859; CHESSARE JB, 1995, PEDIATRICS, V96, P893; CHIODINI BA, 1993, J PEDIATR-US, V123, P686, DOI 10.1016/S0022-3476(05)80841-8; DAVIES DP, 1989, BMJ-BRIT MED J, V298, P1518; DEJONGE GA, 1993, ARCH DIS CHILD, V69, P660, DOI 10.1136/adc.69.6.660; DOLLFUS C, 1990, PEDIATRICS, V86, P176; DWYER T, 1991, J PAEDIATR CHILD H, V27, P340, DOI 10.1111/j.1440-1754.1991.tb00415.x; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; GIBSON E, 1995, PEDIATRICS, V96, P69; GILBERT R, 1994, ARCH DIS CHILD, V70, P445, DOI 10.1136/adc.70.5.445; Guyer B, 1996, PEDIATRICS, V98, P1007; Hiley CMH, 1996, BRIT MED J, V312, P1397, DOI 10.1136/bmj.312.7043.1397a; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; HOFFMAN HJ, 1996, 4 SIDS INT C JUN 23; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUNT CE, 1992, PEDIATRICS, V90, P115; IRGENS LM, 1995, ARCH DIS CHILD, V72, P478, DOI 10.1136/adc.72.6.478; KATTWINKEL J, 1994, PEDIATRICS, V93, P820; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; Kattwinkel J, 1996, PEDIATRICS, V98, P1216; KOCHANEK KD, 1995, MON VITAL STAT REP S, V43, P62; LEVIN ML, 1978, AM J EPIDEMIOL, V108, P78; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; ORENSTEIN SR, 1993, PEDIATRICS, V91, P497; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; Platt MJ, 1996, ARCH DIS CHILD, V75, P527, DOI 10.1136/adc.75.6.527; PONSONBY AL, 1995, PAEDIATR PERINAT EP, V9, P256, DOI 10.1111/j.1365-3016.1995.tb00141.x; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; Ray BJ, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e12; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; Ventura S. J., 1994, MONTHLY VITAL STAT R, V43, P1; VENTURA SJ, 1997, MON VITAL STAT REP S, V45, P38; VENTURA SJ, 1997, MON VITAL STAT RE S2, V46, P28; VENTURA SJ, 1997, MON VITAL STAT REP S, V45, P49; WILLINGER M, 1994, PEDIATRICS, V93, P814; WILLINGER M, 1991, Pediatric Pathology, V11, P677	43	183	186	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					329	335		10.1001/jama.280.4.329	http://dx.doi.org/10.1001/jama.280.4.329			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686549	Bronze			2022-12-28	WOS:000074804200032
J	Olson, MF; Paterson, HF; Marshall, CJ				Olson, MF; Paterson, HF; Marshall, CJ			Signals from Ras and Rho GTPases interact to regulate expression of p21(Waf1/Cip1)	NATURE			English	Article							CELL-TRANSFORMATION; KINASE; ACTIVATION; GROWTH; NIH-3T3-CELLS; REQUIREMENT; ONCOGENES	Small GTPases act as molecular switches in intracellular signal-transduction pathways(1). In the case of the Ras family of GTPases, one of their most important roles is as regulators of cell proliferation, and the mitogenic response to a variety of growth factors and oncogenes can be blocked by inhibiting Ras function(23). But in certain situations, activation of Ras signalling pathways arrests the cell cycle rather than causing cell proliferation(4-6). Extracellular signals may trigger different cellular responses by activating Ras-dependent signalling pathways to varying degrees(7-9). Other signalling pathways could also influence the consequences of Ras signalling. Here we show that when signalling through the Ras-related GTPase Rho is inhibited, constitutively active Ras induces the cyclin-dependent-kinase inhibitor p2I(Waf1/Cip1) and entry into the DNA-synthesis phase of the cell cycle is blocked. When Rho is active, induction of p21(Waf1/Cip1) by Ras is suppressed and Ras induces DNA synthesis. Cells that lack p21(Watl/Cip1) do not require Rho signalling for the induction of DNA synthesis by activated Ras, indicating that, once Ras has become activated, the primary requirement for Rho signalling is the suppression of p21(Waf1/Cip1) induction.	Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.		Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507				AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1987, ONCOGENE, V2, P41; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zeng YX, 1996, ONCOGENE, V12, P1557	29	390	402	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					295	299		10.1038/28425	http://dx.doi.org/10.1038/28425			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685162				2022-12-28	WOS:000074851900053
J	Clarke, PBS				Clarke, PBS			Tobacco smoking, genes, and dopamine	LANCET			English	Editorial Material							NICOTINE; SYSTEM; REWARD		McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1YC, Canada	McGill University	Clarke, PBS (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1YC, Canada.							CLARKE PBS, 1985, BRAIN RES, V348, P355, DOI 10.1016/0006-8993(85)90456-1; Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; IMPERATO A, 1986, EUR J PHARMACOL, V132, P337, DOI 10.1016/0014-2999(86)90629-1; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LAWFORD BR, 1995, NAT MED, V1, P337, DOI 10.1038/nm0495-337; Noble EP, 1998, JNCI-J NATL CANCER I, V90, P343, DOI 10.1093/jnci/90.5.343; Rose JE, 1997, PSYCHOPHARMACOLOGY, V130, P28, DOI 10.1007/s002130050209; Spitz MR, 1998, J NATL CANCER I, V90, P358, DOI 10.1093/jnci/90.5.358; True WR, 1997, ADDICTION, V92, P1277, DOI 10.1111/j.1360-0443.1997.tb02847.x; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203	12	18	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					84	85		10.1016/S0140-6736(98)85006-X	http://dx.doi.org/10.1016/S0140-6736(98)85006-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672270				2022-12-28	WOS:000074775100006
J	Kushnirov, VV; Ter-Avanesyan, MD				Kushnirov, VV; Ter-Avanesyan, MD			Structure and replication of yeast prions	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; PROTEIN HSP104; PROPAGATION; SCRAPIE; PSI(+)		Inst Expt Cardiol, Moscow 121552, Russia	National Medical Research Center of Cardiology	Kushnirov, VV (corresponding author), Inst Expt Cardiol, 3rd Cherepkovskaya St 15A, Moscow 121552, Russia.		Vitaly, Kushnirov/AAU-6003-2021	Kushnirov, Vitaly/0000-0003-0316-0766				Asakura S, 1970, Adv Biophys, V1, P99; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	20	146	151	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					13	16		10.1016/S0092-8674(00)81216-7	http://dx.doi.org/10.1016/S0092-8674(00)81216-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674422	Bronze			2022-12-28	WOS:000074790800004
J	Williams, CHV				Williams, CHV			Tree bug	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					456	456						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703529				2022-12-28	WOS:000075490200022
J	Abbasi, K				Abbasi, K			Kabul diary	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					401	405						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694761				2022-12-28	WOS:000075409600033
J	McKinney, FK; Lidgard, S; Sepkoski, JJ; Taylor, PD				McKinney, FK; Lidgard, S; Sepkoski, JJ; Taylor, PD			Decoupled temporal patterns of evolution and ecology in two post-Paleozoic clades	SCIENCE			English	Article							DIVERSITY; DIVERSIFICATION; HISTORY; DOMINANCE; CRINOIDS; BIOMASS; TIME	Counts of taxonomic diversity are the prevailing standards for documenting Large-scall patterns of evolution in the fossil record, However, the secular pattern of relative ecological importance between the bryozoan clades Cyclostomata and Cheilostomata is not reflected fully in compilations of generic diversity or within-fauna species richness, and the delayed ecological recovery of the Cheilostomata after the mass extinction at the Cretaceous-Tertiary boundary is missed entirely. These observations demonstrate that evolutionary success and ecological dominance can be decoupled and profoundly different, even over tons of millions of years.	Appalachian State Univ, Dept Geol, Boone, NC 28608 USA; Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England	University of North Carolina; Appalachian State University; Field Museum of Natural History (Chicago); University of Chicago; Natural History Museum London	McKinney, FK (corresponding author), Appalachian State Univ, Dept Geol, Boone, NC 28608 USA.	mckinneyfk@appstate.edu		Taylor, Paul/0000-0002-3127-080X	NIDCR NIH HHS [DEB 9306729] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		[Anonymous], 1975, COMMUNITIES ECOSYSTE; AUSICH WI, 1981, OHIO J SCI, V81, P268; AUSICH WI, 1982, SCIENCE, V216, P173, DOI 10.1126/science.216.4542.173; BAMBACH RK, 1993, PALEOBIOLOGY, V19, P372, DOI 10.1017/S0094837300000336; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BERGLUND BE, 1996, PALEOECOLOGICAL EVEN; BROWN JH, 1986, NATURE, V324, P248, DOI 10.1038/324248a0; Cheetham A. H., 1971, Smithsonian Contributions to Paleobiology, V6, P1; FOOTE M, 1991, PALAEONTOLOGY, V34, P461; FOOTE M, 1991, Contributions from the Museum of Paleontology University of Michigan, V28, P101; Foote M, 1996, SCIENCE, V274, P1492, DOI 10.1126/science.274.5292.1492; FOOTE M, 1992, P NATL ACAD SCI USA, V89, P7325, DOI 10.1073/pnas.89.16.7325; FOOTE M, 1993, PALEOBIOLOGY, V19, P185, DOI 10.1017/S0094837300015864; FOOTE M, 1995, PALEOBIOLOGY, V21, P273, DOI 10.1017/S0094837300013300; FOWELL SJ, 1993, TECTONOPHYSICS, V222, P361, DOI 10.1016/0040-1951(93)90359-R; Gaston K.J, 1996, BIODIVERSITY BIOL NU; GORDON DP, 1996, BRYOZOANS SPACE TIME, P213; HAKANSSON E, 1962, DANMARKS GEOL UNDERS, V83, P1; Jackson J.B.C., 1988, PALEOBIOLOGY, V14, P307; Krause D. W., 1986, CONTRIBUTIONS GEOLOG, V3, P95; LIDGARD S, 1989, PALEOBIOLOGY, V15, P255, DOI 10.1017/S0094837300009441; LIDGARD S, 1993, PALEOBIOLOGY, V19, P352, DOI 10.1017/S0094837300000324; LUPIA R, IN PRESS BIOTIC RESP; McKinney F.K., 1989, BRYOZOAN EVOLUTION; MCNAUGHTON SJ, 1970, SCIENCE, V167, P131, DOI 10.1126/science.167.3915.131; PHILLIPS TL, 1984, INT J COAL GEOL, V3, P205, DOI 10.1016/0166-5162(84)90019-3; Sepkoski J.J. Jr, 1985, P11; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; Sepkoski JJ, 1997, J PALEONTOL, V71, P533, DOI 10.1017/S0022336000040026; SEPKOSKI JJ, 1988, PALEOBIOLOGY, V14, P221, DOI 10.1017/S0094837300011969; SEPKOSKI JJ, 1995, GLOBAL EVENTS EVENT, P35; SIGNOR PW, 1990, ANNU REV ECOL SYST, V21, P509, DOI 10.1146/annurev.es.21.110190.002453; SMITH AM, 1992, PALAEOGEOGR PALAEOCL, V93, P213, DOI 10.1016/0031-0182(92)90098-P; SMITH AM, 1994, OLSEN INT S, P177; Speijer RP, 1996, GEOL SOC SP, P343, DOI 10.1144/GSL.SP.1996.001.01.26; STAFF G, 1985, LETHAIA, V18, P209, DOI 10.1111/j.1502-3931.1985.tb00700.x; TAYLOR PD, 1988, EXTINCTION SURVIVAL, P99; THAYER CW, 1983, BIOTIC INTERACTIONS, P480; Upchurch G.R. Jr, 1989, P195; Vermeij G.J., 1987, EVOLUTION ESCALATION; Wilkinson L., 1990, SYSTAT SYSTEM STAT; WILSON E O, 1992	42	65	67	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					807	809		10.1126/science.281.5378.807	http://dx.doi.org/10.1126/science.281.5378.807			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694648				2022-12-28	WOS:000075295600044
J	Slepnev, VI; Ochoa, GC; Butler, MH; Grabs, D; De Camilli, P				Slepnev, VI; Ochoa, GC; Butler, MH; Grabs, D; De Camilli, P			Role of phosphorylation in regulation of the assembly of endocytic coat complexes	SCIENCE			English	Article							PROTEIN-KINASE-C; FROG NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLE MEMBRANE; NERVE-TERMINALS; TRANSMITTER RELEASE; CLATHRIN; DYNAMIN; AMPHIPHYSIN; INHIBITOR; POTENT	Clathrin-mediated endocytosis involves cycles of assembly and disassembly of clathrin coat components and their accessory proteins. Dephosphorylation of rat brain extract was shown to promote the assembly of dynamin 1, synaptojanin 1, and amphiphysin into complexes that also included clathrin and AP-2, Phosphorylation of dynamin 1 and synaptojanin 1 inhibited their binding to amphiphysin, whereas phosphorylation of amphiphysin inhibited its binding to AP-2 and clathrin. Thus, phosphorylation regulates the association and dissociation cycle of the clathrin-based endocytic machinery, and calcium-dependent dephosphorylation of endocytic proteins could prepare nerve terminals for a burst of endocytosis.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu			NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Floyd S, 1998, MOL MED, V4, P29, DOI 10.1007/BF03401727; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Merisko E M, 1986, Pancreas, V1, P110, DOI 10.1097/00006676-198603000-00002; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Ramjaun A. R., 1997, Molecular Biology of the Cell, V8, p93A; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHOOK WJ, 1985, P NATL ACAD SCI USA, V82, P8039, DOI 10.1073/pnas.82.23.8039; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	39	269	273	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					821	824		10.1126/science.281.5378.821	http://dx.doi.org/10.1126/science.281.5378.821			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694653				2022-12-28	WOS:000075295600049
J	Whybrew, K; Murray, M; Morley, C				Whybrew, K; Murray, M; Morley, C			Diagnosing fever by touch: observational study	BRITISH MEDICAL JOURNAL			English	Article							AXILLARY		Univ Cambridge, Dept Paediat, Neonatal Intens Care Unit, Cambridge CB2 2QQ, England	University of Cambridge	Morley, C (corresponding author), Univ Cambridge, Dept Paediat, Neonatal Intens Care Unit, Box 226, Cambridge CB2 2QQ, England.			Morley, Colin/0000-0001-5388-0214				CLARKE S, 1992, BRIT MED J, V304, P961, DOI 10.1136/bmj.304.6832.961; Einterz EM, 1997, LANCET, V350, P781, DOI 10.1016/S0140-6736(97)24037-7; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; Shann F, 1996, ARCH PEDIAT ADOL MED, V150, P74, DOI 10.1001/archpedi.1996.02170260078013	5	21	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					321	321		10.1136/bmj.317.7154.321	http://dx.doi.org/10.1136/bmj.317.7154.321			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685279	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000075409500023
J	Duncan, SA; Navas, MA; Dufort, D; Rossant, J; Stoffel, M				Duncan, SA; Navas, MA; Dufort, D; Rossant, J; Stoffel, M			Regulation of a transcription factor network required for differentiation and metabolism	SCIENCE			English	Article							PYRUVATE-KINASE GENE; DEFINITIVE ENDODERM; EXPRESSION; MOUSE; INSULIN; HNF-3-BETA; NOTOCHORD; PROMOTER	Hepatocyte nuclear factors (HNFs) are a heterogeneous class of evolutionarily conserved transcription factors that are required for cellular differentiation and metabolism. Mutations in HNF-1 alpha and HNF-4 alpha genes impair insulin secretion and cause type 2 diabetes. Regulation of HNF-4/HNF-1 expression by HNF-3 alpha and HNF-3 beta was studied in embryoid bodies in which one or both HNF-3 alpha or HNF-3 beta alleles were inactivated. HNF-3 beta positively regulated the expression of HNF-4 alpha/HNF-1 alpha and their downstream targets, implicating a role in diabetes. HNF-3 beta was also necessary for expression of HNF-3 alpha. In contrast, HNF-3 alpha acts as a negative regulator of HNF-4 alpha/HNF-1 alpha demonstrating that HNF-3 alpha. and HNF-3 beta have antagonistic transcriptional regulatory functions in vivo. HNF-3 alpha does not appear to act as a classic biochemical repressor but rather exerts its negative effect by competing for HNF-3 binding sites with the more efficient activator HNF-3 beta. In addition, the HNF-3 alpha/HNF-3 beta ratio is modulated by the presence of insulin, providing evidence that the HNF network may have important roles in mediating the action of insulin.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Rockefeller University; Rockefeller University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Stoffel, M (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.	stoffel@rockvax.rockefeller.edu		Stoffel, Markus/0000-0003-1304-5817; Navas, Maria Angeles/0000-0001-6858-2172; Duncan, Stephen/0000-0002-2507-7827; Dufort, Daniel/0000-0002-6477-596X				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DUNCAN S, UNPUB; Duncan SA, 1997, DEVELOPMENT, V124, P279; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Nagy A., 1993, Gene targeting: a practical approach., P147; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Peterson RS, 1997, CELL GROWTH DIFFER, V8, P69; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; SASAKI H, 1993, DEVELOPMENT, V118, P47; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; Tronche F., 1994, LIVER GENE EXPRESSIO; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Vaisse C, 1997, DIABETES, V46, P1364, DOI 10.2337/diabetes.46.8.1364; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	29	281	295	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					692	695		10.1126/science.281.5377.692	http://dx.doi.org/10.1126/science.281.5377.692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685261				2022-12-28	WOS:000075107900040
J	Huber, C; Wachtershauser, G				Huber, C; Wachtershauser, G			Peptides by activation of amino acids with CO on (Ni,Fe)S surfaces: Implications for the origin of life	SCIENCE			English	Article								In experiments modeling volcanic or hydrothermal settings amino acids were converted into their peptides by use of coprecipitated (Ni,Fe)S and CO in conjunction with H2S (or CH3SH) as a catalyst and condensation agent at 100 degrees C and pH 7 to 10 under anaerobic, aqueous conditions. These results demonstrate that amino acids can be activated under geochemically relevant conditions. They support a thermophilic origin of Life and an early appearance of peptides in the evolution of a primordial metabolism.	Tech Univ Munich, Dept Organ Chem & Biochem, D-85747 Munich, Germany	Technical University of Munich	Wachtershauser, G (corresponding author), Tal 29, D-80331 Munich, Germany.							BRACK A, 1984, ORIGINS LIFE EVOL B, V14, P229, DOI 10.1007/BF00933662; Bujdak J, 1996, J INORG BIOCHEM, V63, P119, DOI 10.1016/0162-0134(95)00186-7; Bujdak J, 1997, J MOL EVOL, V45, P457, DOI 10.1007/PL00006250; Fox S. W., 1977, MOL EVOLUTION ORIGIN; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; HULSHOF J, 1976, ORIGINS LIFE EVOL B, V7, P197, DOI 10.1007/BF00926938; LAHAV N, 1978, SCIENCE, V201, P67, DOI 10.1126/science.663639; ORGEL LE, 1989, J MOL EVOL, V29, P465, DOI 10.1007/BF02602917; RABINOWI.J, 1969, NATURE, V224, P795, DOI 10.1038/224795a0; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHWENDINGER MG, 1995, INORG CHIM ACTA, V228, P207, DOI 10.1016/0020-1693(94)04186-Y; SHOCK EL, 1992, GEOCHIM COSMOCHIM AC, V56, P3481, DOI 10.1016/0016-7037(92)90392-V; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Williams RJP, 1997, CELL MOL LIFE SCI, V53, P816, DOI 10.1007/s000180050102	16	443	456	4	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					670	672		10.1126/science.281.5377.670	http://dx.doi.org/10.1126/science.281.5377.670			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685253				2022-12-28	WOS:000075107900032
J	Stern, EA; Jaeger, D; Wilson, CJ				Stern, EA; Jaeger, D; Wilson, CJ			Membrane potential synchrony of simultaneously recorded striatal spiny neurons in vivo	NATURE			English	Article							MICROEXCITABLE ZONES; PRIMATE NEOSTRIATUM; PROJECTION NEURONS; RAT NEOSTRIATUM; FIRING PATTERNS; IN-VIVO; RESPONSES; MICROSTIMULATION; ORGANIZATION; OSCILLATION	The basal ganglia are an interconnected set of subcortical regions whose established role in cognition and motor control remains poorly understood An important nucleus within the basal ganglia, the striatum, receives cortical afferents that convey sensorimotor, limbic and Cognitive information(1). The activity of medium-sized spiny neurons in the striatum seems to depend on convergent input within these information channels(2). To determine the degree of correlated input, both below and at threshold for the generation of action potentials, we recorded intracellularly from pairs of spiny neurons in vivo. Here we report that the transitions between depolarized and hyperpolarized states were highly Correlated among neurons. Within individual depolarized states, some significant synchronous fluctuations in membrane potential occurred, but action potentials were not synchronized. Therefore, although the mean afferent signal across fibres is highly correlated among striatal neurons, the moment-to-moment variations around the mean, which determine the timing of action potentials, are not. We propose that the precisely timed, synchronous component of the membrane potential signals activation of cell assemblies and enables firing to occur. The asynchronous component, with low redundancy, determines the fine temporal pattern of spikes.	Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	University of Tennessee System; University of Tennessee Health Science Center; Emory University	Stern, EA (corresponding author), Univ Tennessee, Coll Med, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.	edstern@marlin.utmem.edu	Wilson, Charles/D-2529-2011	Wilson, Charles/0000-0002-9004-2145; Jaeger, Dieter/0000-0002-5122-1319				ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; ALEXANDER GE, 1985, J NEUROPHYSIOL, V53, P1417, DOI 10.1152/jn.1985.53.6.1417; ALEXANDER GE, 1985, J NEUROPHYSIOL, V53, P1401, DOI 10.1152/jn.1985.53.6.1401; AMZICA F, 1995, J NEUROPHYSIOL, V73, P20, DOI 10.1152/jn.1995.73.1.20; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Choi SK, 1997, J NEUROSCI, V17, P8613; Contreras D, 1997, NEUROSCIENCE, V76, P25; DIGGLE PJ, 1990, TIME SERIES; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; FLAHERTY AW, 1993, J NEUROSCI, V13, P1120; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; HULL CD, 1970, BRAIN RES, V22, P163, DOI 10.1016/0006-8993(70)90002-8; JAEGER D, 1995, BRAIN RES, V694, P111, DOI 10.1016/0006-8993(95)00780-T; JAEGER D, 1994, J NEUROPHYSIOL, V72, P2555, DOI 10.1152/jn.1994.72.5.2555; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; ONN SP, 1994, J NEUROPHYSIOL, V71, P1917, DOI 10.1152/jn.1994.71.5.1917; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; Plenz D, 1998, J NEUROSCI, V18, P266; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; Stern EA, 1997, J NEUROPHYSIOL, V77, P1697, DOI 10.1152/jn.1997.77.4.1697; STERN EA, 1993, ADV NEURAL INF PROCE, V5, P377; Wickens JR, 1998, J NEUROPHYSIOL, V79, P2358, DOI 10.1152/jn.1998.79.5.2358; Wilson C. J., 1992, SINGLE NEURON COMPUT, P141, DOI [10.1016/B978-0-12-484815-3.50012-8, DOI 10.1016/B978-0-12-484815-3.50012-8]; WILSON CJ, 1981, BRAIN RES, V220, P67, DOI 10.1016/0006-8993(81)90211-0; WILSON CJ, 1993, PROG BRAIN RES, V99, P277; WILSON CJ, 1986, BRAIN RES, V367, P201, DOI 10.1016/0006-8993(86)91593-3; Wilson CJ, 1996, J NEUROSCI, V16, P2397; WILSON CJ, 1997, SYNAPTIC ORG BRAIN, P329	30	265	269	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					475	478		10.1038/28848	http://dx.doi.org/10.1038/28848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697769				2022-12-28	WOS:000075080400051
J	Berger, A				Berger, A			Why albumin may not work	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	17	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					240	240		10.1136/bmj.317.7153.240	http://dx.doi.org/10.1136/bmj.317.7153.240			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677210	Green Published			2022-12-28	WOS:000075081900018
J	Naoumov, NV; Petrova, EP; Thomas, MG; Williams, R				Naoumov, NV; Petrova, EP; Thomas, MG; Williams, R			Presence of a newly described human DNA virus (TTV) in patients with liver disease	LANCET			English	Article							HEPATITIS-G VIRUS; PARVOVIRUS B19; INFECTION; CLONING; AGENT	Background A newly described DNA virus, named transfusion-transmitted virus (TTV), was recently detected with high prevalence in Japanese patients with fulminant hepatitis end chronic liver disease of unknown aetiology. We investigated the presence of this virus in patients with liver disease in the UK to find out whether TTV infection is associated with liver damage. Methods We used semi-nested PCR to amplify TTV DNA from serum samples from 126 adults, of whom 72 were patients with a range of chronic liver diseases, 24 had spontaneous resolution of infection with hepatitis C virus (HCV), and 30 were normal controls. Direct DNA sequencing and phylogenetic analysis were used to characterise the TTV isolates. Findings We detected TTV DNA in 18 (25%) of the 72 patients with chronic liver disease, which was not different from the 10% prevalence in normal controls (p=0.15). The rate of TTV DNA was similar among patients with various liver diseases. The majority of TTV-positive cases had no biochemical or histological evidence of significant liver damage. TTV DNA sequencing of nine isolates showed the same genotypic groups as in Japan: three patients were infected with genotype 1, which showed 4% nucleotide divergence, and six patients were infected with genotype 2 with 15-27% divergence. Interpretation The high prevalence of active TTV infection in the general population, both in the UK and in Japan, and the lack of significant liver damage, suggest that TTV, similar to hepatitis G virus (HGV), may be an example of a human virus with no clear disease association.	UCL, Sch Med, Inst Hepatol, Dept Med, London WC1E 6HX, England; UCL, Sch Med, Dept Biol, London WC1E 6HX, England; UCL, Sch Med, Dept Anthropol, London WC1E 6HX, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Naoumov, NV (corresponding author), UCL, Sch Med, Inst Hepatol, Dept Med, London WC1E 6HX, England.	n.naoumov@ucl.ac.uk	Thomas, Mark G/A-2219-2012	Thomas, Mark G/0000-0002-2452-981X				ALTER HJ, 1995, SEMIN LIVER DIS, V15, P110, DOI 10.1055/s-2007-1007268; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; ANDERSON MJ, 1987, J VIROL METHODS, V17, P175, DOI 10.1016/0166-0934(87)90080-2; ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; FELSENSTEIN J, 1995, PHYLIP PHYLOGENY INF; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hillingso JG, 1998, LANCET, V351, P955, DOI 10.1016/S0140-6736(00)80016-1; Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X; Langnas AN, 1995, HEPATOLOGY, V22, P1661, DOI 10.1002/hep.1840220608; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X; Yoto Y, 1996, LANCET, V347, P1563	14	262	273	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					195	197		10.1016/S0140-6736(98)04069-0	http://dx.doi.org/10.1016/S0140-6736(98)04069-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683209				2022-12-28	WOS:000074859800013
J	Miesenbock, G; De Angelis, DA; Rothman, JE				Miesenbock, G; De Angelis, DA; Rothman, JE			Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins	NATURE			English	Article							SIMPLEX VIRUS VECTORS; FUSION EVENTS; MAST-CELLS; MUTATIONS; SIGNAL	In neural systems, information is often carried by ensembles of cells rather than by individual units. Optical indicators(1) provide a powerful means to reveal such distributed activity, particularly when protein-based and encodable in DNA(2-4): encodable probes can be introduced into cells, tissues, or transgenic organisms by genetic manipulation, selectively expressed in anatomically or functionally defined groups of cells, and, ideally, recorded in situ, without a requirement for exogenous cofactors, Here we describe sensors for secretion and neurotransmission that fulfill these criteria We have developed pH-sensitive mutants of green fluorescent protein ('pHluorins') by structure-directed combinatorial mutagenesis, with the aim of exploiting the acidic pH inside secretory vesicles(5,6) to monitor vesicle exocytosis and recycling. When linked to a vesicle membrane protein, pHluorins were sorted to secretory and synaptic vesicles and reported transmission at individual synaptic boutons, as well as secretion and fusion pore 'flicker' of single secretory granules.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Oka, Yoshitaka/C-9670-2010; Wood, David W/B-2992-2012	Oka, Yoshitaka/0000-0002-3482-3051; Miesenboeck, Gero/0000-0003-2940-3228				ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHANDLER DE, 1980, J CELL BIOL, V86, P666, DOI 10.1083/jcb.86.2.666; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; LAWRENCE MS, 1995, P NATL ACAD SCI USA, V92, P7247, DOI 10.1073/pnas.92.16.7247; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Marconi P, 1996, P NATL ACAD SCI USA, V93, P11319, DOI 10.1073/pnas.93.21.11319; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; RAO M, 1997, J IMMUNOL, V159, P2815; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARD WW, 1982, PHOTOCHEM PHOTOBIOL, V35, P803, DOI 10.1111/j.1751-1097.1982.tb02651.x; Ward WW., 1981, BIOLUMINESCENCE CHEM, DOI 10.1016/b978-0-12-208820-9.50035-5; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; YU SS, 1993, J BIOL CHEM, V268, P337	27	1839	1891	9	313	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					192	195		10.1038/28190	http://dx.doi.org/10.1038/28190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671304				2022-12-28	WOS:000074705900057
J	Fingerhut, LA; Ingram, DD; Feldman, JJ				Fingerhut, LA; Ingram, DD; Feldman, JJ			Homicide rates among US teenagers and young adults - Differences by mechanism, level of urbanization, race, and sex, 1987 through 1995	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context. - Homicide rates for persons 15 through 24 years old began to decline between 1993 and 1994, but recent trends in homicide rates by mechanism of homicide and urbanization group have not been described. Objective. - To examine homicide trends from 1987 through 1995 for persons 15 through 24 years old by urbanization level. Design. - Homicide rates by urbanization level were analyzed using the Compressed Mortality File, a county-level mortality and population database maintained by the National Center for Health Statistics, Centers for Disease Control and Prevention, and the rural-urban continuum codes developed by the Economic Research Service, US Department of Agriculture. Setting. - United States, 1987 through 1995, according to 5 urbanization strata, core, counties with the primary central city of a metropolitan statistical area (MSA) of 1 million or more; fringe, remaining counties within an MSA of 1 million or more; medium, counties within an MSA of 250000 to 999999; small, counties in an MSA of less than 250 000; and nonmetropolitan, counties not in an MSA. Subjects. - All persons 15 through 24 years old by race whose cause of death was homicide (International Classification of Diseases, Ninth Revision codes E960-E969). Main Outcome Measures. - Firearm and nonfirearm homicide rates and average annual percentage changes by 5 urbanization levels, race, and sex. Results. - From 1987 through 1991, the average annual firearm homicide rates among persons 15 through 24 years old among all 5 urbanization strata increased between 10.7% in small counties and 19.8% in fringe counties. From 1991 through 1993, the rates increased between 3.3% in core counties and 11.7% in small counties. From 1993 through 1995, the rates declined between 4.4% in fringe counties and 15.3% in medium counties. By 1995, firearm homicide rates among persons 15 through 24 years old ranged from 6.5 and 7.3 per 100000 in the nonmetropolitan and small counties, respectively, to 9.6 and 13.3 per 100000 in the fringe and medium strata, respectively, to 33.5 per 100000 in the core stratum. During 1987 through 1990, nonfirearm homicide rates either were stable or increased, acid from 1990 through 1995, nonfirearm homicide rates declined in all 5 strata, on average 3.7% to 8.0% per year, with rates in 1995 ranging from 2.1 to 4.7 per 100000 across the strata. Conclusions. - After increasing since 1987, firearm and nonfirearm homicide rates began declining between 1993 and 1995 among persons 15 through 24 years old. These declines are taking place across all urbanization strata and among white and black males and females.	Natl Ctr Hlth Stat, Off Anal Epidemiol & Hlth Promot, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Fingerhut, LA (corresponding author), Natl Ctr Hlth Stat, Off Anal Epidemiol & Hlth Promot, 6525 Belcrest Rd,750, Hyattsville, MD 20782 USA.							ANDERSON RN, 1997, MON VITAL STAT RE S2, V45, P77; Butler Margaret A., 1993, RURAL URBAN CONTINUU; *CDCP, 1998, CDC WOND PUBL HLTH R; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P26; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; *NAT CTR HLTH STAT, 1997, HLTH US 1996 97 INJ; *NAT CTR HLTH STAT, 1998, MON VITAL STAT REP, V46, P14; SORLIE PD, 1992, EPIDEMIOLOGY, V3, P181, DOI 10.1097/00001648-199203000-00018; World Health Organization, INT CLASS DIS	9	58	59	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					423	427		10.1001/jama.280.5.423	http://dx.doi.org/10.1001/jama.280.5.423			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105AR	9701076	Bronze			2022-12-28	WOS:000075050200028
J	Proctor, CJ				Proctor, CJ			Tobacco industry research: collaboration, not confrontation, is the best approach	BRITISH MEDICAL JOURNAL			English	Article									Bristish Amer Tobacco, Staines TW18 1DY, Middx, England	British American Tobacco	Proctor, CJ (corresponding author), Bristish Amer Tobacco, Knowle Green, Staines TW18 1DY, Middx, England.							Proctor C, 1997, LANCET, V349, P1329, DOI 10.1016/S0140-6736(05)62549-4; SWANN C, 1996, TOBACCO PRODUCTS RES	2	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					333	334		10.1136/bmj.317.7154.333	http://dx.doi.org/10.1136/bmj.317.7154.333			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685285				2022-12-28	WOS:000075409500030
J	Forbes, GB				Forbes, GB			A memorable patient - A death on the rock	BMJ-BRITISH MEDICAL JOURNAL			English	Article																		EYKYN SJ, 1989, SCAND J INFECT DIS, P41; Forbes GB, 1944, LANCET, V1, P399	2	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					262	262		10.1136/bmj.317.7153.262	http://dx.doi.org/10.1136/bmj.317.7153.262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677219	Green Published			2022-12-28	WOS:000075081900026
J	Gray, NS; Wodicka, L; Thunnissen, AMWH; Norman, TC; Kwon, SJ; Espinoza, FH; Morgan, DO; Barnes, G; LeClerc, S; Meijer, L; Kim, SH; Lockhart, DJ; Schultz, PG				Gray, NS; Wodicka, L; Thunnissen, AMWH; Norman, TC; Kwon, SJ; Espinoza, FH; Morgan, DO; Barnes, G; LeClerc, S; Meijer, L; Kim, SH; Lockhart, DJ; Schultz, PG			Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; GENE-EXPRESSION; YEAST; TRANSCRIPTION; PROTEIN; ANALOGS	Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the adenosine triphosphate- binding site of the human cyclin-dependent kinase 2 (CDK2). By iterating chemical Library synthesis and biological screening, potent inhibitors of the human CDK2-cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified. The structural basis for the binding affinity and selectivity was determined by analysis of a three-dimensional crystal structure of a CDK2-inhibitor complex. The cellular effects of these compounds were characterized in mammalian cells and yeast. In the Latter case the effects were characterized on a genome-wide scale by monitoring changes in messenger RNA Levels in treated cells with high-density oligonucleotide probe arrays. Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may Lead to the development of new therapeutics.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Affymetrix, Santa Clara, CA 95051 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; CNRS, Biol Stn, F-29682 Roscoff, France	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Affymetrix; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS)	Schultz, PG (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.		Thunnissen, Andy-Mark/A-1777-2010; MEIJER, Laurent/ABE-7465-2021	Thunnissen, Andy-Mark/0000-0002-1915-9850; Morgan, David/0000-0001-8753-4416; , laurent/0000-0003-3511-4916				ANDREWS B, 1997, MOL CELL BIOL, V17, P1212; BACKES BJ, 1994, J AM CHEM SOC, V116, P11171, DOI 10.1021/ja00103a048; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; Gray NS, 1997, TETRAHEDRON LETT, V38, P1161, DOI 10.1016/S0040-4039(97)00014-2; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MITSUNOBU O, 1981, SYNTHESIS-STUTTGART, P1, DOI 10.1055/s-1981-29317; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Norman TC, 1996, J AM CHEM SOC, V118, P7430, DOI 10.1021/ja9614934; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Timblin BK, 1997, MOL MICROBIOL, V26, P981, DOI 10.1046/j.1365-2958.1997.6352004.x; Timblin BK, 1996, GENETICS, V143, P57; TOYOTA A, 1993, HETEROCYCLES, V36, P1625, DOI 10.3987/COM-93-6371; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wahl MC, 1997, TRENDS BIOCHEM SCI, V22, P97, DOI 10.1016/S0968-0004(97)01004-9; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; 1368002	30	783	844	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					533	538		10.1126/science.281.5376.533	http://dx.doi.org/10.1126/science.281.5376.533			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677190	Green Submitted			2022-12-28	WOS:000075012300032
J	Link, AM				Link, AM			US and non-US submissions - An analysis of reviewer bias	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-Reviewers increasingly are asked to review manuscripts from outside their own country, but whether they are more likely to recommend acceptance of such manuscripts is not known. Objective.-To assess whether US reviewers or non-US reviewers evaluate manuscripts differently, depending on whether the manuscripts are submitted from outside the United States or from the United States. Design and Setting.-A retrospective analysis of all original submissions received by Gastroenterology in 1995 and 1996. Reviewers ranked manuscripts in 4 decision categories: accept, provisionally accept, reject with resubmission, or reject. Main Outcome Measure.-Ranking of papers based on nationality of authors and reviewers. Results.-The percentage of non-US manuscripts placed in each decision category by US (n=2355) and non-US reviewers (n=1297) was nearly identical (P=.31). However, US reviewers recommended acceptance of papers submitted by US authors more often than did non-US reviewers (P=.001). Non-US reviewers ranked US papers slightly more favorably than non-US papers (P=.09), while US reviewers ranked US papers much more favorably (P=.001). Conclusions.-Reviewers from the United States and outside the United States evaluate non-US papers similarly and evaluate papers submitted by US authors more favorably, with US reviewers having a significant preference for US papers.	Journal Immunol, Bethesda, MD USA		Link, AM (corresponding author), Journal Immunol, 9650 Rockville Pike, Bethesda, MD 20814 USA.							Berk PD, 1996, HEPATOLOGY, V24, P1530, DOI 10.1053/jhep.1996.v24.ajhep0241530; LARUSSO NF, 1995, GASTROENTEROLOGY, V108, P625, DOI 10.1016/0016-5085(95)90432-8; STOSSEL TP, 1990, NEW ENGL J MED, V322, P739, DOI 10.1056/NEJM199003153221106	3	228	234	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					246	247		10.1001/jama.280.3.246	http://dx.doi.org/10.1001/jama.280.3.246			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676670				2022-12-28	WOS:000074706000015
J	van Rooyen, S; Godlee, F; Evans, S; Smith, R; Black, N				van Rooyen, S; Godlee, F; Evans, S; Smith, R; Black, N			Effect of blinding and unmasking on the quality of peer review - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-Little research has been conducted into the quality of peer review and, in particular, the effects of blinding peer reviewers to authors' identities or masking peer reviewers' identities. Objective.-To determine whether concealing authors' identities from reviewers (blinding) and/or revealing the reviewer's identity to a coreviewer (unmasking) affects the quality of reviews, the time taken to carry out reviews, and the recommendation regarding publication. Design and Setting.-Randomized trial of 527 consecutive manuscripts submitted to BMJ, which were randomized and each sent to 2 peer reviewers. Interventions.-Manuscripts were randomized as to whether the reviewers were unmasked, masked, or uninformed that a study was taking place. Two reviewers for each manuscript were randomized to receive either a blinded or an unblinded version. Main Outcome Measures.-Mean total quality score, time taken to carry out the review, and recommendation regarding publication. Results.-Of the 527 manuscripts entered into the study, 467 (89%) were successfully randomized and followed up. The mean total quality score was 2.87. There was little or no difference in review quality between the masked and unmasked groups (scores of 2.82 and 2.96, respectively) and between the blinded and unblinded groups (scores of 2.87 and 2.90, respectively). There was no apparent Hawthorne effect. There was also no significant difference between groups in the recommendations regarding publication or time taken to review. Conclusions.-Blinding and unmasking made no editorially significant difference to review quality, reviewers' recommendations, or time taken to review. Other considerations should guide decisions as to the form of peer review adopted by a journal, and improvements in the quality of peer review should be sought via other means.	BMJ Editorial, London WC1H 9JR, England; London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	van Rooyen, S (corresponding author), BMJ Editorial, BMA House,Tavistock Sq, London WC1H 9JR, England.			Evans, Stephen/0000-0002-1474-2596				Black N, 1998, JAMA-J AM MED ASSOC, V280, P231, DOI 10.1001/jama.280.3.231; FEINSTEIN AR, 1986, J CHRON DIS, V39, P491, DOI 10.1016/0021-9681(86)90193-1; FISHER M, 1994, JAMA-J AM MED ASSOC, V272, P143, DOI 10.1001/jama.272.2.143; INGELFINGER FJ, 1974, AM J MED, V56, P686, DOI 10.1016/0002-9343(74)90635-4; KASSIRER JP, 1994, JAMA-J AM MED ASSOC, V272, P96, DOI 10.1001/jama.272.2.96; LABAND DN, 1994, JAMA-J AM MED ASSOC, V272, P147; Lock S., 1985, DIFFICULT BALANCE ED; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; ROBIN ED, 1987, CHEST, V91, P252, DOI 10.1378/chest.91.2.252; SHAPIRO S, 1985, J CHRON DIS, V38, P365, DOI 10.1016/0021-9681(85)90082-7; STRASBURGER VC, 1985, JAMA-J AM MED ASSOC, V254, P1789, DOI 10.1001/jama.254.13.1789; YANKAUER A, 1982, AM J PUBLIC HEALTH, V72, P239, DOI 10.2105/AJPH.72.3.239	12	198	202	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					234	237		10.1001/jama.280.3.234	http://dx.doi.org/10.1001/jama.280.3.234			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676666	Green Published, Bronze			2022-12-28	WOS:000074706000011
J	Caraballo, RS; Giovino, GA; Pechacek, TF; Mowery, PD; Richter, PA; Strauss, WJ; Sharp, DJ; Eriksen, MP; Pirkle, JL; Maurer, KR				Caraballo, RS; Giovino, GA; Pechacek, TF; Mowery, PD; Richter, PA; Strauss, WJ; Sharp, DJ; Eriksen, MP; Pirkle, JL; Maurer, KR			Racial and ethnic differences in serum cotinine levels of cigarette smokers - Third National Health and Nutrition Examination Survey, 1988-1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; NONMENTHOL CIGARETTES; WHITE SMOKERS; YOUNG-ADULTS; SELF-REPORT; NICOTINE; EXPOSURE; MENTHOL; METABOLISM; CHILDREN	Context.-Cotinine, a metabolite of nicotine, is a marker of exposure to tobacco smoke. Previous studies suggest that non-Hispanic blacks have higher levels of serum cotinine than non-Hispanic whites who report similar levels of cigarette smoking. Objective.-To investigate differences in levels of serum cotinine in black, white, and Mexican American cigarette smokers in the US adult population. Design.-Third National Health and Nutrition Examination Survey, 1988-1991. Participants.-A nationally representative sample of persons aged 17 years or older who participated in the survey. Outcome Measures.-Serum cotinine levels by reported number of cigarettes smoked per day and by race and ethnicity. Results.-A total of 7182 subjects were involved in the study; 2136 subjects reported smoking at least 1 cigarette in the last 5 days, Black smokers had cotinine concentrations substantially higher at all levels of cigarette smoking than did white or Mexican American smokers (P<.001). Serum cotinine levels for blacks were 125 nmol/L (22 ng/mL) (95% confidence interval [CI], 79-176 nmol/L. [14-31 ng/mL]) to 539 nmol/L (95 ng/mL) (95% CI, 289-630 nmol/L [51-111 ng/mL]) higher than for whites and 136 nmol/L (24 ng/mL) (95% CI, 85-182 nmol/L [15-32 ng/mL]) to 641 nmol/L (113 ng/mL) (95% CI, 386-897 nmol/L [68-158 ng/mL]I) higher than for Mexican Americans, These differences do not appear to be attributable to differences in environmental tobacco smoke exposure or in number of cigarettes smoked. Conclusions.-To our knowledge, this study provides the first evidence from a national study that serum cotinine levels are higher among black smokers than among white or Mexican American smokers. If higher cotinine levels among blacks indicate higher nicotine intake or differential pharmacokinetics and possibly serve as a marker of higher exposure to cigarette carcinogenic components, they may help explain why blacks find it harder to quit and are more likely to experience higher rates of lung cancer than white smokers.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Battelle Mem Inst, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Bethesda, MD USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Caraballo, RS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.							Ahijevych K, 1996, PHARMACOL BIOCHEM BE, V53, P355, DOI 10.1016/0091-3057(95)02034-9; ARMITAGE AK, 1975, BRIT MED J, V4, P313, DOI 10.1136/bmj.4.5992.313; BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483, DOI 10.1038/clpt.1994.169; BENOWITZ NL, 1982, J PHARMACOL EXP THER, V221, P368; BENOWITZ NL, 1994, J PHARMACOL EXP THER, V268, P296; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188, DOI 10.1093/oxfordjournals.epirev.a017925; Bernert JT, 1997, CLIN CHEM, V43, P2281; CASKEY NH, 1993, PHARMACOL BIOCHEM BE, V46, P259, DOI 10.1016/0091-3057(93)90350-3; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P671; Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V42, P504; Clark PI, 1996, ANN EPIDEMIOL, V6, P483, DOI 10.1016/S1047-2797(96)00049-X; Clark PI, 1996, CHEST, V110, P1194, DOI 10.1378/chest.110.5.1194; COULTAS DB, 1988, AM REV RESPIR DIS, V137, P810, DOI 10.1164/ajrccm/137.4.810; CRAWFORD FG, 1994, J NATL CANCER I, V86, P1398, DOI 10.1093/jnci/86.18.1398; ENGLISH PB, 1994, AM J PUBLIC HEALTH, V84, P1439, DOI 10.2105/AJPH.84.9.1439; HENNINGFIELD JE, 1990, AM J PUBLIC HEALTH, V80, P1040, DOI 10.2105/AJPH.80.9.1040; HERNING RI, 1983, CLIN PHARMACOL THER, V33, P84, DOI 10.1038/clpt.1983.12; ISAAC PF, 1972, NATURE, V236, P308, DOI 10.1038/236308a0; JARVIK ME, 1994, PHYSIOL BEHAV, V56, P563, DOI 10.1016/0031-9384(94)90302-6; Knight JM, 1996, CHEST, V109, P446, DOI 10.1378/chest.109.2.446; LEADERER BP, 1991, ENVIRON SCI TECHNOL, V25, P770, DOI 10.1021/es00016a023; MCCARTHY WJ, 1992, AM J PUBLIC HEALTH, V82, P1171, DOI 10.2105/AJPH.82.8.1171; MCCARTHY WJ, 1995, AM J PUBLIC HEALTH, V85, P67, DOI 10.2105/AJPH.85.1.67; Miller BA, 1996, NIH PUBLICATION, V96-4104; PATTISHALL EN, 1985, AM J DIS CHILD, V139, P1101, DOI 10.1001/archpedi.1985.02140130039026; PEREZSTABLE EJ, 1995, PREV MED, V24, P171, DOI 10.1006/pmed.1995.1031; PEREZSTABLE EJ, 1990, AM J PUBLIC HEALTH, V80, P1057, DOI 10.2105/AJPH.80.9.1057; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; SHAH BV, 1995, SOFTWARE SURVEY DATA; TURNER JAM, 1977, BMJ-BRIT MED J, V2, P1387, DOI 10.1136/bmj.2.6099.1387; *US DEP HHS, 1989, RED HLTH CONS SMOK 2; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; WAGENKNECHT LE, 1990, AM J PUBLIC HEALTH, V80, P1053, DOI 10.2105/AJPH.80.9.1053; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WAGENKNECHT LE, 1993, ENVIRON RES, V63, P39, DOI 10.1006/enrs.1993.1124; Wagenknecht LE, 1992, AM J PUBLIC HEALTH, V82, P1173	37	376	377	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					135	139		10.1001/jama.280.2.135	http://dx.doi.org/10.1001/jama.280.2.135			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669785				2022-12-28	WOS:000074608400027
J	Gowen, LC; Avrutskaya, AV; Latour, AM; Koller, BH; Leadon, SA				Gowen, LC; Avrutskaya, AV; Latour, AM; Koller, BH; Leadon, SA			RETRACTED: BRCA1 required for transcription-coupled repair of oxidative DNA damage (Retracted article. See vol 300, pg 1657, June 13 2003)	SCIENCE			English	Article; Retracted Publication							RNA POLYMERASE-II; PREFERENTIAL REPAIR; OVARIAN-CANCER; STRAND; GENE; CELLS; BREAST	The breast and ovarian cancer susceptibility gene BRCA1 encodes a zinc finger protein of unknown function. Association of the BRCA1 protein with the DNA repair protein Rad51 and changes in the phosphorylation and cellular Localization of the protein after exposure to DNA-damaging agents are consistent with a role for BRCA1 in DNA repair. Here, it is shown that mouse embryonic stem cells deficient in BRCA1 are defective in the ability to tarry out transcription-coupled repair of oxidative DNA damage, and are hypersensitive to ionizing radiation and hydrogen peroxide. These results suggest that BRCA1 participates, directly or indirectly, in transcription-coupled repair of oxidative DNA damage.	Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Leadon, SA (corresponding author), Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.	saleadon@radonc.unc.edu			NATIONAL CANCER INSTITUTE [P50CA058223, R01CA040453, R03CA070490] Funding Source: NIH RePORTER; NCI NIH HHS [IP50CA58223, CA70490, CA40453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; EASTON DF, 1993, AM J HUM GENET, V52, P678; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HTUN H, 1992, METHOD ENZYMOL, V212, P272; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Leadon SA, 1997, CANCER RES, V57, P3784; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Snouwaert JN, 1998, CURRENT TOPICS ON BRCA1, P33, DOI 10.3233/BD-1998-101-206; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; WARD JF, 1985, RADIAT RES, V103, P383, DOI 10.2307/3576760	22	425	437	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1998	281	5379					1009	1012		10.1126/science.281.5379.1009	http://dx.doi.org/10.1126/science.281.5379.1009			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703501				2022-12-28	WOS:000075412700053
J	Majeed, A; Lehmann, P; Kirby, L; Coleman, MP				Majeed, A; Lehmann, P; Kirby, L; Coleman, MP			Mortality from dementias and neurodegenerative disorders in people aged 15-64 in England and Wales in 1979-96	BRITISH MEDICAL JOURNAL			English	Article									Off Natl Stat, London SW1V 2QQ, England		Majeed, A (corresponding author), Off Natl Stat, London SW1V 2QQ, England.		Coleman, Michel/AAA-9543-2020	Coleman, Michel/0000-0001-8940-3807; Majeed, Azeem/0000-0002-2357-9858				Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HOMER AC, 1988, BMJ-BRIT MED J, V297, P894, DOI 10.1136/bmj.297.6653.894; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	5	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					320	321		10.1136/bmj.317.7154.320	http://dx.doi.org/10.1136/bmj.317.7154.320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685278	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075409500022
J	Fountain, GO; Khakhar, DV; Ottino, JM				Fountain, GO; Khakhar, DV; Ottino, JM			Visualization of three-dimensional chaos	SCIENCE			English	Article							STOKES FLOWS; ADVECTION; STREAMLINES; TRANSPORT; SYMMETRY; MANTLE; OCEAN; ORDER	Most chaotic mixing experiments have been restricted to two-dimensional, time-periodic flows, and this has shaped advances in theory as well. A prototypical, bounded, three-dimensional flow with a moderate Reynolds number is presented; this system lends itself to detailed experimental observation and allows for high-precision computational inspection. The flow structure, captured by means of cuts with a Laser sheet (experimental Poincare section), was visualized with the use of continuously injected fluorescent dye streams and revealed detailed chaotic structures with high-period islands.	Northwestern Univ, McCormick Sch Engn & Sci, Dept Chem Engn, Lab Fluid Mech Chaos & Mixing, Evanston, IL 60208 USA; Indian Inst Technol, Dept Chem Engn, Bombay 400076, Maharashtra, India	Northwestern University; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Ottino, JM (corresponding author), Northwestern Univ, McCormick Sch Engn & Sci, Dept Chem Engn, Lab Fluid Mech Chaos & Mixing, Evanston, IL 60208 USA.		Khakhar, Devang V/B-6143-2012; Ottino, Julio/B-6682-2009	Khakhar, Devang/0000-0001-7179-0909				AREF H, 1984, J FLUID MECH, V143, P1, DOI 10.1017/S0022112084001233; Ashwin P, 1997, J FLUID MECH, V338, P341, DOI 10.1017/S0022112097004990; BAJER K, 1990, J FLUID MECH, V212, P337, DOI 10.1017/S0022112090001999; BATCHELOR GK, 1967, INTRO FLUID DYNAMICS, P290; BROWN MG, 1991, PHYS FLUIDS A-FLUID, V3, P1186, DOI 10.1063/1.858047; Di Prima R., 1985, TOP APPL PHYS, V45, P139; Haller G, 1998, NONLINEARITY, V11, P319, DOI 10.1088/0951-7715/11/2/008; HENON M, 1966, CR ACAD SCI A MATH, V262, P312; KELLOGG LH, 1993, ADV GEOPHYS, V34, P1, DOI 10.1016/S0065-2687(08)60433-1; KUSCH HA, 1992, J FLUID MECH, V236, P319, DOI 10.1017/S0022112092001435; Lamberto DJ, 1996, CHEM ENG SCI, V51, P733, DOI 10.1016/0009-2509(95)00203-0; MACKAY RS, 1994, J NONLINEAR SCI, V4, P329, DOI 10.1007/BF02430637; Manga M, 1996, GEOPHYS RES LETT, V23, P403, DOI 10.1029/96GL00242; Nagata S., 1975, MIXING PRINCIPLES AP; OTTINO JM, 1988, NATURE, V333, P419, DOI 10.1038/333419a0; OTTINO JM, 1992, SCIENCE, V257, P754, DOI 10.1126/science.257.5071.754; OTTINO JM, 1990, ANNU REV FLUID MECH, V22, P207, DOI 10.1146/annurev.fl.22.010190.001231; OTTINO JM, 1989, KINETMATICS MIXING S, P146; PIERCE RB, 1993, J GEOPHYS RES-ATMOS, V98, P18589, DOI 10.1029/93JD01619; PIERREHUMBERT RT, 1993, J ATMOS SCI, V50, P2462, DOI 10.1175/1520-0469(1993)050<2462:GCMOIS>2.0.CO;2; STONE HA, 1991, J FLUID MECH, V232, P629, DOI 10.1017/S002211209100383X; SWANSON PD, 1990, J FLUID MECH, V213, P227, DOI 10.1017/S0022112090002300; Tatterson G.B., 1991, FLUID MIXING GAS DIS; TATTERSON GB, 1991, CHEM ENG PROG, V87, P45; WIGGINS S, 1992, CHAOTIC TRANSPORT DY; WILLERT CE, 1991, EXP FLUIDS, V10, P181; YANG HJ, 1994, GEOPHYS RES LETT, V21, P545, DOI 10.1029/94GL00306	28	74	79	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					683	686		10.1126/science.281.5377.683	http://dx.doi.org/10.1126/science.281.5377.683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685258				2022-12-28	WOS:000075107900037
J	Levin, ER; Gardner, DG; Samson, WK				Levin, ER; Gardner, DG; Samson, WK			Mechanisms of disease - Natriuretic peptides	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MEDULLARY COLLECTING DUCT; CONGESTIVE-HEART-FAILURE; RAT DIENCEPHALIC NEURONS; CYCLASE-A RECEPTOR; TRANSGENIC MICE; ATRIOPEPTIN-II; BLOOD-PRESSURE; ATRIAL; ANTAGONIST; SODIUM		Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA; Vet Affairs Med Ctr, Long Beach, CA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ N Dakota, Sch Med, Dept Physiol, Grand Forks, ND 58202 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of North Dakota Grand Forks	Levin, ER (corresponding author), Long Beach Vet Hosp, Med Serv 111 I, 5901 E 7th St, Long Beach, CA 90822 USA.		Levin, Ellis/J-5402-2013					Allgren RL, 1997, NEW ENGL J MED, V336, P828, DOI 10.1056/NEJM199703203361203; ANGELI P, 1994, HEPATOLOGY, V20, P948, DOI 10.1002/hep.1840200425; BLACKBURN RE, 1995, AM J PHYSIOL, V269, pRI45; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; BURRELL LM, 1991, AM J PHYSIOL, V260, pR475, DOI 10.1152/ajpregu.1991.260.3.R475; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHARLES CJ, 1993, AM J PHYSIOL, V264, pR533, DOI 10.1152/ajpregu.1993.264.3.R533; Charles CJ, 1996, AM J PHYSIOL-REG I, V271, pR373, DOI 10.1152/ajpregu.1996.271.2.R373; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DILLINGHAM MA, 1986, SCIENCE, V231, P1572, DOI 10.1126/science.3006248; FIFER MA, 1990, AM J CARDIOL, V65, P211, DOI 10.1016/0002-9149(90)90087-H; FRIED TA, 1986, AM J PHYSIOL, V250, P1119; FURUYA M, 1993, BIOCHEM BIOPH RES CO, V193, P248, DOI 10.1006/bbrc.1993.1616; GOTTLIEB SS, 1989, J AM COLL CARDIOL, V13, P1534, DOI 10.1016/0735-1097(89)90344-6; GOTTLIEB SS, 1989, J AM COLL CARDIOL, V14, P812; Greenberg RN, 1997, J INVEST MED, V45, P276; GREENWALD JE, 1988, J CLIN INVEST, V81, P1036, DOI 10.1172/JCI113414; GU J, 1989, ENDOCRINOLOGY, V125, P2066, DOI 10.1210/endo-125-4-2066; HARRIS PJ, 1987, NATURE, V326, P697, DOI 10.1038/326697a0; HIRATA Y, 1993, CIRCULATION, V87, P554, DOI 10.1161/01.CIR.87.2.554; HONRATH U, 1994, REGUL PEPTIDES, V49, P211, DOI 10.1016/0167-0115(94)90143-0; HUANG WQ, 1992, ENDOCRINOLOGY, V130, P2426, DOI 10.1210/en.130.4.2426; Hunt PJ, 1996, J CLIN ENDOCR METAB, V81, P3871, DOI 10.1210/jc.81.11.3871; HUNT PJ, 1994, J CLIN ENDOCR METAB, V78, P1428, DOI 10.1210/jc.78.6.1428; IGAKI T, 1996, KIDNEY INT S, V49, pS144; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; JOHN SWM, 1995, SCIENCE, V267, P1753; John SWM, 1996, AM J PHYSIOL-REG I, V271, pR109, DOI 10.1152/ajpregu.1996.271.1.R109; KANGAWA K, 1984, BIOCHEM BIOPH RES CO, V118, P131, DOI 10.1016/0006-291X(84)91077-5; Kentsch M, 1996, EUR J CLIN PHARMACOL, V51, P269, DOI 10.1007/s002280050196; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; LANGUB MC, 1995, J NEUROENDOCRINOL, V7, P305, DOI 10.1111/j.1365-2826.1995.tb00762.x; LAPPE RW, 1985, CIRC RES, V56, P606, DOI 10.1161/01.RES.56.4.606; LEVIN ER, 1992, ENDOCRINOLOGY, V131, P1417, DOI 10.1210/en.131.3.1417; LEVIN ER, 1991, ENDOCRINOLOGY, V128, P2925, DOI 10.1210/endo-128-6-2925; LEVIN ER, 1991, AM J PHYSIOL, V261, pF453; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MARINGREZ M, 1986, NATURE, V324, P473, DOI 10.1038/324473a0; MORISHITA Y, 1992, EUR J PHARM-MOLEC PH, V225, P203, DOI 10.1016/0922-4106(92)90021-M; MORWANI JG, 1993, LANCET, V341, P1109; MUNZEL T, 1992, CIRCULATION, V86, P1089, DOI 10.1161/01.CIR.86.4.1089; OGAWA Y, 1994, J CLIN INVEST, V93, P1911, DOI 10.1172/JCI117182; RAHMAN SN, 1994, KIDNEY INT, V45, P1731, DOI 10.1038/ki.1994.225; SAITO Y, 1989, J CLIN INVEST, V83, P298, DOI 10.1172/JCI113872; SAMSON WK, 1992, TRENDS ENDOCRIN MET, V3, P86, DOI 10.1016/1043-2760(92)90018-V; SANO T, 1992, J PHARMACOL EXP THER, V260, P825; SAXENHOFER H, 1990, AM J PHYSIOL, V259, pF832, DOI 10.1152/ajprenal.1990.259.5.F832; SCHULTZ HD, 1988, AM J PHYSIOL, V155, pR6; SCHULZKNAPPE P, 1988, KLIN WOCHENSCHR, V66, P752, DOI 10.1007/BF01726570; SMITH JB, 1987, AM J PHYSIOL, V253, pC147, DOI 10.1152/ajpcell.1987.253.1.C147; SONNENBERG H, 1986, AM J PHYSIOL, V250, pF963, DOI 10.1152/ajprenal.1986.250.6.F963; STEELE MK, 1991, AM J PHYSIOL, V260, pR1145, DOI 10.1152/ajpregu.1991.260.6.R1145; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; STEVENS TL, 1995, J CLIN INVEST, V95, P1101, DOI 10.1172/JCI117757; Stockand JD, 1997, AM J KIDNEY DIS, V29, P971, DOI 10.1016/S0272-6386(97)90476-5; VESELY DL, 1994, CIRCULATION, V90, P1129, DOI 10.1161/01.CIR.90.3.1129; WADA A, 1994, CIRCULATION, V89, P2232, DOI 10.1161/01.CIR.89.5.2232; WEDER AB, 1987, HYPERTENSION, V10, P582, DOI 10.1161/01.HYP.10.6.582; WIJEYARATNE CN, 1993, J CLIN ENDOCR METAB, V76, P343, DOI 10.1210/jc.76.2.343; Wu CF, 1997, J BIOL CHEM, V272, P14860, DOI 10.1074/jbc.272.23.14860; YANG RH, 1992, HYPERTENSION, V19, P198, DOI 10.1161/01.HYP.19.2.198; YOKOTA N, 1994, J CLIN INVEST, V94, P1938, DOI 10.1172/JCI117544; ZEIDEL ML, 1995, CLIN EXP PHARMACOL P, V22, P121, DOI 10.1111/j.1440-1681.1995.tb01967.x; ZEIDEL ML, 1988, J CLIN INVEST, V82, P1067, DOI 10.1172/JCI113663; ZHANG PL, 1994, J AM SOC NEPHROL, V4, P1564	68	1802	1909	3	41	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1998	339	5					321	328						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104TL	9682046				2022-12-28	WOS:000075031400007
J	McLellan, NJ				McLellan, NJ			Robert Hooke (1635-1703): recognising a sound imagination	LANCET			English	Biographical-Item									Birmingham Childrens Hosp, Dept Paediat & Child Hlth, Birmingham B4 6NH, W Midlands, England	University of Birmingham	McLellan, NJ (corresponding author), Birmingham Childrens Hosp, Dept Paediat & Child Hlth, Steelhouse Lane, Birmingham B4 6NH, W Midlands, England.							COMROE J, 1977, RETROSPECTROSCOPE IN, P99; Drake E.T., 1996, RESTLESS GENIUS R HO; GOUK P, 1980, ANN SCI, V37, P573, DOI 10.1080/00033798000200401; Hooke R, 1667, PHILOS T ROY SOC LON, V28, P539; Hooke R., 1705, POSTHUMOUS WORK ROBE, P39; Hooke Robert, 1665, MICROGRAPHIA SOME PH; Laennec RTH., 1819, AUSCULTATION MEDIATE; MIDDLETON WILLIAM S., 1927, ANN MED HIST, V9, P227; NICHOLS R, 1994, DIARIES R HOOKE LEON, P158; OConnor J J, MACTUTOR HIST MATH; TYNDALL J, 1884, SOUND, P41; Wear Andrew, 1995, W MED TRADITION 800, P215; 1956, ESPINASSE M R HOOKE; 1956, ESPINASSE M R HOOKE, P83	14	1	1	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					312	313		10.1016/S0140-6736(98)01320-8	http://dx.doi.org/10.1016/S0140-6736(98)01320-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690426				2022-12-28	WOS:000074974500044
J	Petticrew, M				Petticrew, M			Miscellany - Heroic medicine in the Iron Age	BRITISH MEDICAL JOURNAL			English	Article													Petticrew, Mark/AAY-6274-2021					Jackson Kenneth Hurlstone, 1971, CELTIC MISCELLANY TR	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					288	288		10.1136/bmj.317.7153.288	http://dx.doi.org/10.1136/bmj.317.7153.288			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677245	Green Published			2022-12-28	WOS:000075081900068
J	Pollock, AM; Vickers, N				Pollock, AM; Vickers, N			Deprivation and emergency admissions for cancers of colorectum, lung, and breast in south east England: ecological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; RATES; CONSULTATION; SURVIVAL; SURGERY; IMPACT	Objectives: To examine the relation between deprivation and acute emergency admissions for cancers of the colon, rectum, lung, and breast in south east England. Design: Ecological analysis with data from hospital episode statistics and 1991 census. Setting: North and South Thames Regional Health Authorities (population about 14 million), divided into 10 aggregations of 31 470 census enumeration districts (median population 462). Subjects: 146 639 admissions relating to 76 552 patients aged < 100 years on admission, resident in the Thames regions, admitted between 1 April 1992 and 31 March 1995. Results: Residents living in deprived areas were more likely to be admitted as emergencies and has ordinary inpatient admissions and less likely to be admitted as day cases. Adjusted odds of ordinary admissions from the most deprived tenth occurring as emergencies (relative to admissions from the most affluent tenth) were 2.29 (95% confidence interval 2.09 to 2.52) for colorectal cancer, 2.20 (1.99 to 2.43) for lung cancer, and 2.41 (2.17 to 2.67) for female breast cancer; adjusted odds of admissions as day cases were 0.70 (0.64 to 0.76), 0.50 (0.44 to 0.56), and 0.56 (0.50 to 0.62), respectively. Patients from deprived areas with lung or breast cancers were less likely to be recorded as having surgical interventions. Adjusted odds of patients fi-om the most deprived tenth receiving surgery were 0.88 (0.78 to 1.00), 0.58 (0.48 to 0.70), and 0.63 (0.56 to 0.71), respectively. Admissions for colorectal cancer from the most deprived areas were less likely to be to hospitals admitting 100 or more new patients a year; the opposite held true for breast cancer admissions. No association was found for lung cancer admissions. Conclusions: Earlier diagnostic and referral procedures in primary care in deprived areas are required if there are to be significant reductions in mortality from these cancers. A national information strategy is required to ensure the continued availability of population based data on NHS patients and to mandate standardised datasets from the private sector. Rationalisation of acute services, hospital mergers, and plans for bed closures must take into account the increased healthcare needs and inequities in access to treatment and care of residents in areas with high levels of deprivation Health authorities and primary care groups should re-examine their purchasing intentions, service reviews, and monitoring arrangements in the light of these findings.	St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	St Georges University London	Pollock, AM (corresponding author), UCL, Sch Publ Hlth, London WC1E 7HN, England.			pollock, allyson/0000-0002-7388-3110				BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BLAXTER M, 1984, BRIT MED J, V288, P1963, DOI 10.1136/bmj.288.6435.1963; CALLE EE, 1993, AM J PUBLIC HEALTH, V83, P53, DOI 10.2105/AJPH.83.1.53; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; CHATURVEDI N, 1995, BRIT J GEN PRACT, V45, P127; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; *EXP ADV GROUP CAN, 1994, POL FRAM COMM CANC S; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GILL L, 1993, J EPIDEMIOL COMMUN H, V47, P316, DOI 10.1136/jech.47.4.316; *GOV STAT SERV, 1993, HOSP EP STAT 1989 19; LAMDEN KH, 1995, J PUBLIC HEALTH MED, V17, P63; *LIANG BUISS, 1996, LIANGS REV PRIV HLTH; MAJEED F, 1995, BRIT MED J, V310, P1674, DOI 10.1136/bmj.310.6995.1674a; Majeed F A, 1995, J Med Screen, V2, P119; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MCCORMICK A, 1994, MORBIDITY STAT GEN P; SCHRIJVERS CTM, 1995, CANCER-AM CANCER SOC, V75, P2946, DOI 10.1002/1097-0142(19950615)75:12<2946::AID-CNCR2820751223>3.0.CO;2-6; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403; SCHRIJVERS CTM, 1995, EUR J CANCER, V31A, P1660, DOI 10.1016/0959-8049(95)00272-K; SCHRIJVERS CTM, 1995, INT J CANCER, V63, P324, DOI 10.1002/ijc.2910630303; SLOGGETT A, 1994, BRIT MED J, V309, P1470, DOI 10.1136/bmj.309.6967.1470; Townsend P, 1988, HLTH DEPRIVATION INQ	24	67	68	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					245	252		10.1136/bmj.317.7153.245	http://dx.doi.org/10.1136/bmj.317.7153.245			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677214	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075081900021
J	Sakai, DH				Sakai, DH			A visit from my daughter	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					321	321		10.1001/jama.280.4.321	http://dx.doi.org/10.1001/jama.280.4.321			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686541				2022-12-28	WOS:000074804200018
J	Reijers, MHE; Weverling, GJ; Jurriaans, S; Wit, FWNM; Weigel, HM; Ten Kate, RW; Mulder, JW; Frissen, PHJ; van Leeuwen, R; Reiss, P; Schuitemaker, H; de Wolf, F; Lange, JMA				Reijers, MHE; Weverling, GJ; Jurriaans, S; Wit, FWNM; Weigel, HM; Ten Kate, RW; Mulder, JW; Frissen, PHJ; van Leeuwen, R; Reiss, P; Schuitemaker, H; de Wolf, F; Lange, JMA			Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study	LANCET			English	Article							ANALOGS	Background Highly active antiretroviral therapy (HAART) has led to health benefits for patients infected with HIV-1. However, long-term use of multidrug regimens is difficult to sustain, Simplifying antiretroviral treatment regimens would increase patients' adherence and minimise toxicity. We investigated the feasibility of a strategy of induction therapy followed by maintenance therapy with HAART in a randomised open-label study. Methods From March, 1997, we enrolled patients infected with HIV-1 with at least 200 CD4cells/mu L, at least 1000 HIV-1 RNA copies/mL in plasma, and no previous exposure to antiretroviral drugs. After 26 weeks of induction therapy (stavudine, lamivudine, saquinavir, and nelflnavir) patients were randomly allocated maintenance therapy (either stavudine and nelfinavir or saquinivir and nelfinavir) or prolonged induction therapy (if the plasma HIV-1 RNA concentration at weeks 24 and 25 was <50 copies/mL). Findings In February, 1998, we discontinued randomisation after an interim analysis. 62 patients had been enrolled. 39 (91%) of the 43 patients who were followed up for at least 26 weeks had an undetectable plasma HIV-1 RNA concentration at week 16. At week 26, 31 patients were randomly allocated treatment. Of these patients 25 had a total follow-up of at least 36 weeks. At week 36, a higher proportion of patients on maintenance therapy (nine [64%] of 14) had a detectable HIV-1 RNA than patients on prolonged induction therapy tone [9%] of 11, p=0.01). The initial virion-clearance rate during induction therapy was higher in five patients on maintenance therapy with a sustained undetectable plasma HIV-1 RNA concentration than in nine patients with recurrence of a detectable plasma HIV-1 RNA concentration at week 36 (0.35 vs 0.19 per day, respectively; p=0.008). Interpretation The induction regimen provided a rapid suppression of Viral replication to below 50 copies/mL. However, suppression was not sustained in a considerable number of patients who went onto maintenance therapy. It is currently inadvisable to continue attempts at moving from induction to maintenance therapy in day-to-day practice.	Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Natl AIDS Therapy Evauat Ctr, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Natl AIDS Therapy Evauat Ctr, NL-1105 AZ Amsterdam, Netherlands; Onze Lieve Vrouwe Gasthuis, Dept Internal Med, Amsterdam, Netherlands; Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Clin Viroimmunol, Amsterdam, Netherlands; Slotervaart Ziekenhuis, Dept Internal Med, Amsterdam, Netherlands; Kennemer Gasthuis, Dept Internal Med, Haarlem, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital; Spaarne Hospital	Lange, JMA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Natl AIDS Therapy Evauat Ctr, NL-1105 AZ Amsterdam, Netherlands.		Reijers, M.H.E./L-4594-2015; Wit, Ferdinand/AAC-3803-2019					Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; deJong MD, 1997, AIDS, V11, pF79, DOI 10.1097/00002030-199711000-00002; EMINI EA, 1997, ANTIVIRAL THERAPY, V2, P128; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hall DB, 1998, AIDS, V12, pF41, DOI 10.1097/00002030-199807000-00001; HAMMER SM, 1997, NEW ENGL J MED, V337, P724; HAVLIR DV, 1998, 5 NAT C RETR OPP INF; HOETELMANS RMW, IN PRESS AIDS; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; LANG EJMA, 1998, ANTIVIRAL THERAPY, V3, P4; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; Merry C, 1997, AIDS, V11, pF117, DOI 10.1097/00002030-199715000-00001; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Notermans DW, 1998, AIDS, V12, P167, DOI 10.1097/00002030-199802000-00006; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIALOUX G, 1997, 4 NAT C RETR OPP INF, P393; RADBOUD JM, IN PRESS AIDS; RAFFI F, 1998, 5 NAT C RETR OPP INF; SHIRASAKA T, 1995, ANTIMICROB AGENTS CH, V39, P2555, DOI 10.1128/AAC.39.11.2555; SOMMADOSSI JP, 1993, CLIN INFECT DIS, V16, pS7, DOI 10.1093/clinids/16.Supplement_1.S7; Stellbrink HJ, 1997, AIDS, V11, P1655; Tamalet C, 1997, AIDS, V11, P895, DOI 10.1097/00002030-199707000-00009; WEVERLING GJ, IN PRESS AIDS; WHO, 1979, WHO HDB REP RES CANC; WONG JK, 1997, P NATL ACAD SCI USA, V94, P12754	31	133	133	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					185	190		10.1016/S0140-6736(98)06193-5	http://dx.doi.org/10.1016/S0140-6736(98)06193-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683207				2022-12-28	WOS:000074859800011
J	Carpenter, EP; Hawkins, AR; Frost, JW; Brown, KA				Carpenter, EP; Hawkins, AR; Frost, JW; Brown, KA			Structure of dehydroquinate synthase reveals an active site capable of multistep catalysis	NATURE			English	Article							PENTAFUNCTIONAL AROM PROTEIN; ASPERGILLUS-NIDULANS; 3-DEHYDROQUINATE; SHIKIMATE	Dehydroquinate synthase (DHQS) has long been regarded as a catalytic marvel because of its ability to perform several consecutive chemical reactions in one active site(1-7). There has been considerable debate as to whether DHQS is actively involved in all these steps(1,2), or whether several steps occur spontaneously, making DHQS a spectator in its own mechanism(3-5). DHQS performs the second step in the shikimate pathway, which is required for the synthesis of aromatic compounds in bacteria, microbial eukaryotes and plants(8). This enzyme is a potential target for new antifungal and antibacterial drugs(9,10) as the shikimate pathway is absent from mammals and DHQS is required for pathogen virulence(11). Here we report the crystal structure of DHQS, which has several unexpected features, including a previously unobserved mode for NAD(+)-binding and an active-site organization that is surprisingly similar to that of alcohol dehydrogenase, in a new protein fold, The structure reveals interactions between the active site and a substrate-analogue inhibitor, which indicate how DHQS can perform multistep catalysis without the formation of unwanted by-products.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Med Sch Newcastle Upon Tyne, New Med Sch, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Imperial College London; MRC National Institute for Medical Research; Newcastle University - UK; Michigan State University	Brown, KA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Exhibit Rd, London SW7 2AY, England.	k.brown@ic.ac.uk		Carpenter, Liz/0000-0001-9138-2937				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTLETT PA, 1988, J AM CHEM SOC, V110, P1628, DOI 10.1021/ja00213a049; BARTLETT PA, 1994, J ORG CHEM, V59, P2082, DOI 10.1021/jo00087a024; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7560, DOI 10.1021/bi00445a010; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CASE ME, 1971, P NATL ACAD SCI USA, V68, P58, DOI 10.1073/pnas.68.1.58; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gunel- Ozcan A., 1997, MICROBIAL PATHOGEN, V17, P169; HAWKINS AR, 1993, J GEN MICROBIOL, V139, P2891, DOI 10.1099/00221287-139-12-2891; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P27; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; LAMBERT JM, 1985, BIOCHEM J, V226, P817, DOI 10.1042/bj2260817; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Montchamp JL, 1997, J AM CHEM SOC, V119, P7645, DOI 10.1021/ja961771z; MOORE JD, 1994, BIOCHEM J, V301, P297, DOI 10.1042/bj3010297; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pittard AJ, 1987, ESCHERICHIA COLI SAL, P368; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SRINIVASAN PR, 1963, J BIOL CHEM, V238, P3176; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; TRONRUD DE, 1993, TNT REFINEMENT PACKA, P1; VANDENHOMBERGH JPTW, 1992, BIOCHEM J, V284, P861, DOI 10.1042/bj2840861; WIDLANSKI T, 1989, J AM CHEM SOC, V111, P2299, DOI 10.1021/ja00188a052; [No title captured]	29	113	138	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					299	302		10.1038/28431	http://dx.doi.org/10.1038/28431			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685163				2022-12-28	WOS:000074851900054
J	Girardi, E; Petrosillo, N; Aloisi, MS; Rava, L; Ippolito, G				Girardi, E; Petrosillo, N; Aloisi, MS; Rava, L; Ippolito, G			Peer-reviewed articles and public health - The Mad Cow affair in Italian newspapers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			SCIENCE	Context.-It has been suggested that early announcements of research works to be published in peer-reviewed journals may diminish newsworthiness of scientific articles, but this issue has not been widely studied. Objective.-To analyze the impact on the news media, in terms of volume and prominence of coverage, of a scientific article published in peer-reviewed journals about issues with relevance to public health compared with the impact of preliminary release of information on the same issue. Design.-Analysis of press coverage of Creutzfeldt-Jakob disease (CJD) and bovine spongiform encephalopathy (mad cow disease) in the 7 newspapers with the widest circulation in Italy, between March 20, 1996, when the British secretary of state for health announced the identification of 10 cases of a new-variant CJD, described April 6, 1996, in The Lancet, and May 10, 1996. Related newspaper articles were identified by hand search. Main Outcome Measures.-Numbers of newspaper articles published before and after publication of the Lancet article. Results.-We collected 535 articles, of which 62 (11.6%) appeared on the front page. The number of articles published daily peaked on March 26 with 48 items and 1 article on the front page of all the newspapers. A total of 386 (72%) of the 535 articles and 56 (88.7%) of the 62 published on the front page were published in the first 2 weeks of the study period, before the Lancet publication. Conclusions.-Our analysis suggests that, in the case of issues of public health importance, when peer-reviewed research is published after a health risk is disclosed to the public, its impact in the media is small. Coordination between news release by public health authorities and publication by peer-reviewed journals may improve the quality of public information.	Ist Ricovero & Cura Carattere Sci L Spallanzari, Ctr Riferimento AIDS, I-00149 Rome, Italy; Ist Ricovero & Cura Carattere Sci L Spallanzari, Serv Epidemiol Malattie Infett, I-00149 Rome, Italy		Petrosillo, N (corresponding author), Ist Ricovero & Cura Carattere Sci L Spallanzari, Ctr Riferimento AIDS, Via Portuense 292, I-00149 Rome, Italy.		Ippolito, Giuseppe/J-7207-2017; Petrosillo, Nicola/AAZ-2095-2021	Ippolito, Giuseppe/0000-0002-1076-2979; petrosillo, nicola/0000-0002-2585-7567; Girardi, Enrico/0000-0001-8182-5896				Altman LK, 1996, LANCET, V347, P1382, DOI 10.1016/S0140-6736(96)91016-8; COLLEE JG, 1990, LANCET, V336, P1300, DOI 10.1016/0140-6736(90)92976-O; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; DEALLER S F, 1990, Food Microbiology (London), V7, P253, DOI 10.1016/0740-0020(90)90032-D; HOUN F, 1995, AM J PUBLIC HEALTH, V85, P1082, DOI 10.2105/AJPH.85.8_Pt_1.1082; Kassirer JP, 1997, NEW ENGL J MED, V337, P1762, DOI 10.1056/NEJM199712113372409; Turney J, 1996, LANCET, V347, P1087, DOI 10.1016/S0140-6736(96)90283-4; Wilkie T, 1996, LANCET, V347, P1308, DOI 10.1016/S0140-6736(96)90947-2; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; 1996, PRIMA, V250, P160; 1996, LANCET, V348, P1599; 1996, LANCET, V347, P915	12	12	12	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					292	294		10.1001/jama.280.3.292	http://dx.doi.org/10.1001/jama.280.3.292			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676687	Bronze			2022-12-28	WOS:000074706000032
J	Weber, EJ; Callaham, ML; Wears, RL; Barton, C; Young, G				Weber, EJ; Callaham, ML; Wears, RL; Barton, C; Young, G			Unpublished research from a medical specialty meeting - Why investigators fail to publish	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			PUBLICATION BIAS; ABSTRACTS; TRIALS; FATE	Context.-It is not known whether peer review of research abstracts submitted to scientific meetings influences subsequent attempts at publication. Objective.-To determine why research submitted to a scientific meeting is not subsequently published. We hypothesized that authors of abstracts rejected by a meeting are less likely to pursue publication than those whose abstracts are accepted, regardless of research quality. Design and Participants.-Blinded review of abstracts submitted to a medical specialty meeting in 1991 and not published as full manuscripts within 5 years. In 1996, authors of 266 unpublished studies were asked to complete questionnaires. Main Outcome Measures.-Submission of a full manuscript to a journal between 1991 and 1996; failure to submit a manuscript to a journal because the investigator believed it would not be accepted for publication. Results.-A total of 223 (84%) of the unpublished investigators returned the questionnaire. Only 44 (20%) had submitted manuscripts to a journal. Manuscript submission was not associated with abstract quality (odds ratio [OR], 1.16; 95% confidence interval [CI], 0.80-1.64), positive results (OR, 0.75; 95% CI, 0.31-1.57), or other study characteristics. Having an abstract accepted for presentation at the meeting weakly predicted submission of a manuscript to a journal (OR, 1.88; 95% CI, 0.84-4.10), Authors of accepted abstracts were significantly less likely to believe a journal would not publish their manuscript than were authors of rejected abstracts (OR, 0.23; 95% CI, 0.0001-0.61). Conclusions.-Study characteristics do not predict attempts to publish research submitted to a scientific meeting. Investigators whose research is rejected by a meeting are pessimistic about chances for publication and may make less effort to publish.	Univ Calif San Francisco, Div Emergency Med, San Francisco, CA 94143 USA; Univ Florida, Ctr Hlth, Div Emergency Med, Jacksonville, FL USA; Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA; Highland Hosp, Dept Emergency Med, Alameda Cty Med Ctr, Oakland, CA USA	University of California System; University of California San Francisco; State University System of Florida; University of Florida; University of North Carolina; University of North Carolina Chapel Hill	Weber, EJ (corresponding author), Univ Calif San Francisco, Div Emergency Med, Box 0208, San Francisco, CA 94143 USA.	weber@itsa.ucsf.edu	Weber, Ellen/GRR-9967-2022; Wears, Robert/N-5959-2014	Wears, Robert/0000-0001-9826-954X; Callaham, Michael/0000-0003-2284-256X; Weber, Ellen/0000-0002-0094-1973				CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; DEBELLEFEUILLE C, 1992, ANN ONCOL, V3, P187, DOI 10.1093/oxfordjournals.annonc.a058147; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Gallagher E J, 1994, Acad Emerg Med, V1, P41; GALLAHAM ML, 1998, JAMA-J AM MED ASSOC, V280, P254; GOLDMAN L, 1980, NEW ENGL J MED, V303, P255, DOI 10.1056/NEJM198007313030504; GORMAN RL, 1990, VET HUM TOXICOL, V32, P470; JUZYCH MS, 1993, INVEST OPHTH VIS SCI, V34, P1879; MCCORMICK MC, 1985, AM J DIS CHILD, V139, P122, DOI 10.1001/archpedi.1985.02140040020017; NYLENNA M, 1994, JAMA-J AM MED ASSOC, V272, P149, DOI 10.1001/jama.272.2.149; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; SCHERER RW, 1994, JAMA-J AM MED ASSOC, V272, P158, DOI 10.1001/jama.272.2.158; WUERZ R, 1994, ACAD EMERG MED, V1, pA59; YENTIS SM, 1993, CAN J ANAESTH, V40, P632, DOI 10.1007/BF03009700	17	199	203	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					257	259		10.1001/jama.280.3.257	http://dx.doi.org/10.1001/jama.280.3.257			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZZ204	9676674	Bronze			2022-12-28	WOS:000074706000019
J	Lamberts, SWJ; de Herder, WW; van der Lely, AJ				Lamberts, SWJ; de Herder, WW; van der Lely, AJ			Pituitary insufficiency	LANCET			English	Article							GROWTH-HORMONE DEFICIENCY; ISOLATED HYPOGONADOTROPIC HYPOGONADISM; GLUCOCORTICOID REPLACEMENT THERAPY; RECOMBINANT HUMAN GH; BODY-COMPOSITION; HYPOPITUITARY ADULTS; POSTMENOPAUSAL WOMEN; GONADOTROPIN THERAPY; ESTROGEN REPLACEMENT; INSULIN SENSITIVITY		Erasmus Univ, Univ Hosp Dijkzigt, Dept Med, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Lamberts, SWJ (corresponding author), Erasmus Univ, Univ Hosp Dijkzigt, Dept Med, 40 Dr Molewaterplein, NL-3015 GD Rotterdam, Netherlands.		de+Herder, Wouter/AAN-8429-2021					AlShoumer KAS, 1996, CLIN ENDOCRINOL, V45, P171, DOI 10.1046/j.1365-2265.1996.d01-1552.x; ALSHOUMER KAS, 1995, CLIN ENDOCRINOL, V42, P85, DOI 10.1111/j.1365-2265.1995.tb02602.x; ARAFAH BM, 1994, J CLIN ENDOCR METAB, V79, P348, DOI 10.1210/jc.79.2.348; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Bagatell CJ, 1996, NEW ENGL J MED, V334, P707, DOI 10.1056/NEJM199603143341107; Baird DT, 1997, LANCET, V350, P275, DOI 10.1016/S0140-6736(97)06297-1; Bates AS, 1996, J CLIN ENDOCR METAB, V81, P1169, DOI 10.1210/jc.81.3.1169; BATES AS, 1997, J ENDOCRINOL S1, V155; BAYLIS PH, 1988, CLIN ENDOCRINOL, V29, P549, DOI 10.1111/j.1365-2265.1988.tb03704.x; BAYLIS PH, 1995, PRINCIPLES PRACTICE, P257; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BEVAN JS, 1992, ENDOCR REV, V13, P220, DOI 10.1210/er.13.2.220; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P3, DOI 10.1210/jc.82.1.3; BHASIN S, 1992, J CLIN ENDOCR METAB, V74, P75, DOI 10.1210/jc.74.1.75; BHASIN S, 1997, CURRENT THERAPY ENDO, P349; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918, DOI 10.1093/ajcn/55.5.918; BINNERTS A, 1992, CLIN ENDOCRINOL, V37, P79, DOI 10.1111/j.1365-2265.1992.tb02287.x; BRADA M, 1993, CLIN ENDOCRINOL, V38, P571, DOI 10.1111/j.1365-2265.1993.tb02137.x; Bulow B, 1997, CLIN ENDOCRINOL, V46, P75, DOI 10.1046/j.1365-2265.1997.d01-1749.x; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; BURRIS AS, 1988, J CLIN ENDOCR METAB, V66, P1144, DOI 10.1210/jcem-66-6-1144; BURRIS AS, 1988, FERTIL STERIL, V50, P343; CACCIARI E, 1992, J CLIN ENDOCR METAB, V74, P1284, DOI 10.1210/jc.74.6.1284; Chipman JJ, 1997, CLIN ENDOCRINOL, V46, P473, DOI 10.1046/j.1365-2265.1997.1660984.x; Clayton RN, 1996, CLIN ENDOCRINOL, V44, P147, DOI 10.1046/j.1365-2265.1996.666478.x; CLAYTON RN, 1997, DIAGNOSIS TREATMENT, P3; COBB WE, 1978, ANN INTERN MED, V88, P183, DOI 10.7326/0003-4819-88-2-183; CONSTINE LS, 1993, NEW ENGL J MED, V328, P87, DOI 10.1056/NEJM199301143280203; CRUNFELD C, 1988, J CLIN ENDOCR METAB, V67, P111; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; deBoer H, 1997, J CLIN ENDOCR METAB, V82, P2032, DOI 10.1210/jc.82.7.2032; ESTEBAN NV, 1991, J CLIN ENDOCR METAB, V72, P39, DOI 10.1210/jcem-72-1-39; FAGLIA G, 1979, J CLIN ENDOCR METAB, V48, P989, DOI 10.1210/jcem-48-6-989; FINDLAY JC, 1989, J CLIN ENDOCR METAB, V68, P369, DOI 10.1210/jcem-68-2-369; FINKEL DM, 1985, NEW ENGL J MED, V313, P651, DOI 10.1056/NEJM198509123131102; FOWLEN J, 1993, METABOLISM, V42, P1443; FRANKLYN JA, 1997, DIAGNOSIS TREATMENT, P99; Ghigo E, 1996, J CLIN ENDOCR METAB, V81, P3323, DOI 10.1210/jc.81.9.3323; GHIGO E, 1994, J ENDOCRINOL INVEST, V17, P113, DOI 10.1007/BF03347695; GOOREN LJG, 1994, J ANDROL, V15, P212; GREENMAN Y, 1995, J CLIN ENDOCR METAB, V80, P1577, DOI 10.1210/jc.80.5.1577; Hajjar RR, 1997, J CLIN ENDOCR METAB, V82, P3793, DOI 10.1210/jc.82.11.3793; HALL JE, 1994, J CLIN ENDOCR METAB, V79, P1166, DOI 10.1210/jc.79.4.1166; HO KKY, 1992, J BONE MINER RES, V7, P821; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; HOMBURG R, 1990, FERTIL STERIL, V53, P254; Howlett TA, 1997, CLIN ENDOCRINOL, V46, P263, DOI 10.1046/j.1365-2265.1997.1340955.x; JACOBS HS, 1995, FERTIL STERIL, V64, P917; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P2877, DOI 10.1210/jc.82.9.2877; JORGENSEN JOL, 1989, LANCET, V1, P1221; JORGENSEN JOL, 1994, CLIN ENDOCRINOL, V41, P609, DOI 10.1111/j.1365-2265.1994.tb01826.x; JORGENSEN JOL, 1994, EUR J ENDOCRINOL, V130, P224, DOI 10.1530/eje.0.1300224; JUDD A, 1997, J CLIN ENDOCR METAB, V82, P1195; KELLY JJ, 1993, CLIN ENDOCRINOL, V39, P561, DOI 10.1111/j.1365-2265.1993.tb02410.x; LAMBERTS S, 1997, DIAGNOSIS TREATMENT; Lamberts SWJ, 1997, NEW ENGL J MED, V337, P1285, DOI 10.1056/NEJM199710303371807; Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419; LAMBERTS SWJ, 1997, J ENDOCRINOL S1, V155, P67; LELY AJ, 1997, DIAGNOSIS TREATMENT, P241; Lindsay RS, 1997, LANCET, V349, P413, DOI 10.1016/S0140-6736(97)80050-5; LITTLEY MD, 1989, Q J MED, V70, P145; MILLER M, 1970, ANN INTERN MED, V73, P721, DOI 10.7326/0003-4819-73-5-721; Mukherjee JJ, 1997, CLIN ENDOCRINOL, V47, P51, DOI 10.1046/j.1365-2265.1997.2151035.x; MURRAY FT, 1984, J CLIN ENDOCR METAB, V59, P79, DOI 10.1210/jcem-59-1-79; Nieschlag E, 1996, CLIN ENDOCRINOL, V45, P261, DOI 10.1046/j.1365-2265.1996.00823.x; OSULLIVAN AJ, 1995, J CLIN ENDOCR METAB, V80, P1783, DOI 10.1210/jc.80.6.1783; Peacey SR, 1997, CLIN ENDOCRINOL, V46, P255, DOI 10.1046/j.1365-2265.1997.780907.x; PFAFFLE R, 1997, DIAGNOSIS TREATMENT, P21; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; Robertson G.L., 1985, FRONTIERS HORMONE RE, P176; RodriguezArnao J, 1996, CLIN ENDOCRINOL, V45, P33, DOI 10.1111/j.1365-2265.1996.tb02057.x; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; Rosenfeld RG, 1997, J CLIN ENDOCR METAB, V82, P349, DOI 10.1210/jc.82.2.349; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SHALET SM, 1993, NEW ENGL J MED, V328, P131, DOI 10.1056/NEJM199301143280211; SNYDER PJ, 1986, AM J MED, V81, P457, DOI 10.1016/0002-9343(86)90299-8; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; SPIGER M, 1975, ARCH INTERN MED, V135, P698, DOI 10.1001/archinte.135.5.698; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; TOFT AD, 1994, NEW ENGL J MED, V331, P174; TOOGOOD AA, 1994, CLIN ENDOCRINOL, V41, P511, DOI 10.1111/j.1365-2265.1994.tb02583.x; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306; WEAVER JU, 1994, CLIN ENDOCRINOL, V41, P639, DOI 10.1111/j.1365-2265.1994.tb01830.x; WEAVER JU, 1995, J CLIN ENDOCR METAB, V80, P153, DOI 10.1210/jc.80.1.153; WEISSBERGER AJ, 1991, J CLIN ENDOCR METAB, V72, P374, DOI 10.1210/jcem-72-2-374; WOOD DF, 1998, CLIN ENDOCRINOL, P702; Wu FCW, 1996, TESTOSTERONE REPLACEMENT THERAPY, P1; ZELISSEN PMJ, 1994, ANN INTERN MED, V120, P207, DOI 10.7326/0003-4819-120-3-199402010-00005	92	126	129	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					127	134						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672293				2022-12-28	WOS:000074775100042
J	Glover, JR; Lindquist, S				Glover, JR; Lindquist, S			Hsp104, Hsp70, and Hsp40: A novel chaperone system that rescues previously aggregated proteins	CELL			English	Article							HEAT-SHOCK PROTEINS; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; RNA-POLYMERASE; YEAST; DNAJ; THERMOTOLERANCE; HOMOLOG	Hsp104 is a stress tolerance factor that promotes the reactivation of heat-damaged proteins in yeast by an unknown mechanism. Herein, we demonstrate that Hsp104 functions in this process directly. Unlike other chaperones, Hsp104 does not prevent the aggregation of denatured proteins. However, in concert with Hsp40 and Hsp70, Hsp104 can reactivate proteins that have been denatured and allowed to aggregate, substrates refractory to the action of other chaperones. Hsp104 cooperates with the chaperones present in reticulocyte lysates but not with DnaK of E. coli. We conclude that Hsp104 has a protein remodeling activity that acts on trapped, aggregated proteins and requires specific interactions with conventional chaperones to promote refolding of the intermediates it produces.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker J, 1996, MOL CELL BIOL, V16, P4378; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Bush GL, 1996, J CELL BIOL, V135, P1229, DOI 10.1083/jcb.135.5.1229; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HORWICH AL, 1995, CURR BIOL, V5, P455, DOI 10.1016/S0960-9822(95)00089-3; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; LEE YRJ, 1994, PLANT CELL, V6, P1889, DOI 10.1105/tpc.6.12.1889; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Xie YS, 1996, PROTEIN SCI, V5, P517; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	49	1068	1106	3	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					73	82		10.1016/S0092-8674(00)81223-4	http://dx.doi.org/10.1016/S0092-8674(00)81223-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674429	Bronze			2022-12-28	WOS:000074790800011
J	Struhl, K; Moqtaderi, Z				Struhl, K; Moqtaderi, Z			The TAFs in the HAT	CELL			English	Review									Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.							Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GRANT PA, 1998, GENE DEV, V94, P45; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	19	121	131	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					1	4		10.1016/S0092-8674(00)81213-1	http://dx.doi.org/10.1016/S0092-8674(00)81213-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674419	Bronze			2022-12-28	WOS:000074790800001
J	Takei, K; Haucke, V; Slepnev, V; Farsad, K; Salazar, M; Chen, H; De Camilli, P				Takei, K; Haucke, V; Slepnev, V; Farsad, K; Salazar, M; Chen, H; De Camilli, P			Generation of coated intermediates of clathrin-mediated endocytosis on protein-free liposomes	CELL			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; HIGH-AFFINITY BINDING; NERVE-TERMINALS; ALPHA-ADAPTIN; GOLGI STACK; IN-VITRO; DYNAMIN; MEMBRANE; DOMAIN; TRANSPORT	Clathrin-coated buds and dynamin-coated tubules morphologically similar to corresponding structures observed in synaptic membranes can be generated on protein-free liposomes by incubation with cytosol, or with clathrin coat proteins and purified dynamin, respectively. Dynamin- and clathrin-coated intermediates may form independently of each other, despite the coupling between the two processes typically observed in synaptic membranes. Formation of both structures on liposomes can occur in the absence of nucleotides. These findings indicate that interfaces between lipids and cytosolic proteins are fully sufficient to deform lipids bilayers into buds and tubules. They suggest that a main function of membrane proteins is to act as positive and negative regulators of coat assembly, therefore controlling these processes in time and space.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.			Haucke, Volker/0000-0003-3119-6993; Takei, Kohji/0000-0002-6555-9425	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHEN H, 1998, IN PRESS NATURE; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; HAMA K, 1977, J NEUROCYTOL, V6, P361, DOI 10.1007/BF01178223; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HEUSER J, 1971, PROC R SOC SER B-BIO, V179, P247, DOI 10.1098/rspb.1971.0096; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1994, J BIOL CHEM, V269, P21043; LOVAS B, 1971, Z ZELLFORSCH MIK ANA, V121, P341, DOI 10.1007/BF00337638; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; MORRIS MB, 1992, J CELL BIOCHEM, V48, P356, DOI 10.1002/jcb.240480404; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; RAPAPORT I, 1997, EMBO J, V16, P2240; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617; YE W, 1991, J BIOL CHEM, V266, P4442; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	60	279	283	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					131	141		10.1016/S0092-8674(00)81228-3	http://dx.doi.org/10.1016/S0092-8674(00)81228-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674434	hybrid			2022-12-28	WOS:000074790800016
J	Annas, GJ				Annas, GJ			Why we should ban human cloning	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							POLITICS		Boston Univ, Sch Med, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA	Boston University; Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				Annas George J., 1994, Kennedy Institute of Ethics Journal, V4, P235; Annas GJ, 1996, NEW ENGL J MED, V334, P1329, DOI 10.1056/NEJM199605163342012; ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; ANNAS GJ, 1998, SOME CHOICE LAW MED, P14; Butler D, 1998, NATURE, V391, P825, DOI 10.1038/35934; Chomsky Noam, 1988, LANGUAGE PROBLEMS KN; Cross Frank B., 1996, WASHINGTON LEE LAW R, V53, p[851, 851]; JONAS H, 1974, PHILOS ESSAYS ANCIEN, P162; KADREY R, 1998, WIRED            MAR, P146; Kassirer JP, 1998, NEW ENGL J MED, V338, P905, DOI 10.1056/NEJM199803263381309; KNOX RA, 1998, BOSTON GLOBE    0107, pA3; Kolata Gina, 1998, CLONE ROAD DOLLY PAT; LEDERBERG J, 1966, AM NAT, V100, P519, DOI 10.1086/282446; LEWONTIN RC, 1997, NEW YORK REV BO 1023, P20; MONTALBANO W, 1997, LOS ANGELES TIM 0225, pA7; National Bioethics Advisory Commission, 1997, CLON HUM BEINGS REP; ROBERTSON J, 1994, CHILDREN CHOICE FREE, P169; Rorvik, 1978, HIS IMAGE CLONING MA; Silver LeeM., 1997, REMAKING EDEN CLONIN; WATSON JD, 1971, ATLANTIC MONTHLY MAY, P50; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	21	25	25	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					122	125		10.1056/NEJM199807093390213	http://dx.doi.org/10.1056/NEJM199807093390213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9669897				2022-12-28	WOS:000074665300013
J	Becker, S; Groner, B; Muller, CW				Becker, S; Groner, B; Muller, CW			Three-dimensional structure of the Stat3 beta homodimer bound to DNA	NATURE			English	Article							B P50 HOMODIMER; ELECTRON-DENSITY MAPS; TRANSCRIPTIONAL ACTIVITY; SIGNAL TRANSDUCERS; TROPONIN-C; BINDING; STAT; DOMAIN; RECOGNITION; ACTIVATION	STAT proteins are a family of eukaryotic transcription factors that mediate the response to a large number of cytokines and growth factors. Upon activation by cell-surface receptors or their associated kinases, STAT proteins dimerize, translocate to the nucleus and bind to specific promoter sequences on their target genes. Here we report the first crystal structure of a STAT protein bound to its DNA recognition site at 2.25 Angstrom resolution. The structure provides insight into the various steps by which STAT proteins deliver a response signal directly from the cell membrane to their target genes in the nucleus.	European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; Inst Expt Canc Res, Tumor Biol Ctr, D-79106 Freiburg, Germany	European Molecular Biology Laboratory (EMBL)	Muller, CW (corresponding author), European Mol Biol Lab, Grenoble Outstn, ILL BP 156, F-38042 Grenoble 9, France.	mueller@embl-grenoble.fr	Müller, Christoph W/I-7420-2012	Müller, Christoph W/0000-0003-2176-8337				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FOTELLE EDL, 1997, METHOD ENZYMOL, V276, P472; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HELM MH, 1995, SCIENCE, V267, P1347; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Muller CW, 1996, NAT STRUCT BIOL, V3, P224, DOI 10.1038/nsb0396-224; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P189; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1996, J BIOL CHEM, V271, P4134; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794	46	650	690	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					145	151		10.1038/28101	http://dx.doi.org/10.1038/28101			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671298				2022-12-28	WOS:000074705900043
J	Zhang, Y; Suenaga, K; Colliex, C; Iijima, S				Zhang, Y; Suenaga, K; Colliex, C; Iijima, S			Coaxial nanocable: Silicon carbide and silicon oxide sheathed with boron nitride and carbon	SCIENCE			English	Article							NANOTUBES	Multielement nanotubes comprising multiple phases, with diameters of a few tens of nanometers and lengths up to 50 micrometers, were successfully synthesized by means of reactive laser ablation. The experimentally determined structure consists of a beta-phase silicon carbide core, an amorphous silicon oxide intermediate layer, and graphitic outer shells made of boron nitride and carbon layers separated in the radial direction. The structure resembles a coaxial nanocable with a semiconductor-insulator-metal (or semiconductor-insulator-semiconductor) geometry and suggests applications in nanoscale electronic devices that take advantage of this self-organization mechanism for multielement nanotube formation.	NEC Corp Ltd, Fundamental Res Labs, Tsukuba, Ibaraki 3050805 3058501, Japan; Univ Paris 11, Phys Solides Lab, URA 002, F-91405 Orsay, France; Meijo Univ, Dept Phys, Nagoya, Aichi 4688502, Japan	NEC Corporation; UDICE-French Research Universities; Universite Paris Saclay; Meijo University	Zhang, Y (corresponding author), NEC Corp Ltd, Fundamental Res Labs, 34 Miyukigaoka, Tsukuba, Ibaraki 3050805 3058501, Japan.	zhang@frl.cl.nec.co.jp	Zhang, Y/E-6600-2011; Suenaga, Kazu/E-2339-2014	Zhang, Y/0000-0003-0344-8399; Suenaga, Kazu/0000-0002-6107-1123				AJAYAN PM, 1993, NATURE, V361, P333, DOI 10.1038/361333a0; AJAYAN PM, 1993, NATURE, V362, P522, DOI 10.1038/362522a0; BARTNITSKAYA TS, 1994, POWDER METALL MET C+, V33, P335, DOI 10.1007/BF00559576; BLASE X, 1994, EUROPHYS LETT, V28, P335, DOI 10.1209/0295-5075/28/5/007; Blase X, 1997, APPL PHYS LETT, V70, P197, DOI 10.1063/1.118354; CHOPRA NG, 1995, SCIENCE, V269, P966, DOI 10.1126/science.269.5226.966; Colliex C, 1996, J ELECTRON MICROSC, V45, P44, DOI 10.1093/oxfordjournals.jmicro.a023411; DIA H, 1995, NATURE, V375, P769; Dresselhaus M, 1996, PHYS WORLD, V9, P18; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Egerton R.F., 2011, ELECT ENERGY LOSS SP; Golberg D, 1996, APPL PHYS LETT, V69, P2045, DOI 10.1063/1.116874; GUERRET-PIECOURT C, 1994, NATURE, V372, P761, DOI 10.1038/372761a0; Han WQ, 1997, SCIENCE, V277, P1287, DOI 10.1126/science.277.5330.1287; Han WQ, 1997, CHEM PHYS LETT, V265, P374, DOI 10.1016/S0009-2614(96)01441-8; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Loiseau A, 1996, CHEM PHYS LETT, V256, P246, DOI 10.1016/0009-2614(96)00459-9; Loiseau A, 1996, PHYS REV LETT, V76, P4737, DOI 10.1103/PhysRevLett.76.4737; MIYAMOTO Y, 1994, PHYS REV B, V50, P18360, DOI 10.1103/PhysRevB.50.18360; MIYAMOTO Y, 1994, PHYS REV B, V50, P4976, DOI 10.1103/PhysRevB.50.4976; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; REDICYH P, 1996, CHEM PHYS LETT, V260, P465; RUBIO A, 1994, PHYS REV B, V49, P5081, DOI 10.1103/PhysRevB.49.5081; Seo WS, 1996, J AM CERAM SOC, V79, P1777, DOI 10.1111/j.1151-2916.1996.tb07995.x; SERAPHIN S, 1993, NATURE, V362, P503, DOI 10.1038/362503a0; STEPHAN O, 1994, SCIENCE, V266, P1683, DOI 10.1126/science.266.5191.1683; Suenaga K, 1997, SCIENCE, V278, P653, DOI 10.1126/science.278.5338.653; Terrones M, 1996, CHEM PHYS LETT, V259, P568, DOI 10.1016/0009-2614(96)00773-7; Terrones M, 1996, CHEM PHYS LETT, V257, P576, DOI 10.1016/0009-2614(96)00594-5; TSANG SC, 1994, NATURE, V372, P159, DOI 10.1038/372159a0; Ugarte D, 1996, SCIENCE, V274, P1897, DOI 10.1126/science.274.5294.1897; WENGSIEH Z, 1995, PHYS REV B, V51, P11229, DOI 10.1103/PhysRevB.51.11229; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Zhang Y, 1997, CHEM PHYS LETT, V279, P264, DOI 10.1016/S0009-2614(97)01048-8; ZHOU D, 1994, CHEM PHYS LETT, V222, P233, DOI 10.1016/0009-2614(94)00342-4	35	545	574	5	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					973	975		10.1126/science.281.5379.973	http://dx.doi.org/10.1126/science.281.5379.973			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703508				2022-12-28	WOS:000075412700041
J	Gider, S; Runge, BU; Marley, AC; Parkin, SSP				Gider, S; Runge, BU; Marley, AC; Parkin, SSP			The magnetic stability of spin-dependent tunneling devices	SCIENCE			English	Article							ENHANCED MAGNETORESISTANCE; EXCHANGE; MULTILAYERS	The tunneling resistance between two ferromagnetic metal Layers that are separated by a thin insulator depends on the relative orientation of the magnetization M of each Layer. In a memory device, independent switching of the magnetically soft Layer is achieved by making the other Layer either exchange-biased or magnetically hard. The repeated reversal of M of the soft Layer by field cycling can demagnetize the other magnetically hard Layer and thus erase the tunnel junction's memory. The M of exchange-biased structures was stable at Least to 10(7) cycles, whereas in hard structures, M generally decayed Logarithmically with the number of field cycles. The decay was very sensitive to the thickness of the hard Layer and the composition of the soft layer. However, no decay was observed when the moment reversal was accomplished by coherent rotation, establishing that demagnetization results from the formation and motion of domain walls in the soft layer during field cycling.	IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA	International Business Machines (IBM)	Parkin, SSP (corresponding author), IBM Corp, Storage Syst Div, 5600 Cottle Rd,N17A-142, San Jose, CA 95193 USA.		Parkin, Stuart/D-2521-2012	Parkin, Stuart/0000-0003-4702-6139				Ashar K.G., 1997, MAGNETIC DISK DRIVE; BINASCH G, 1989, PHYS REV B, V39, P4828, DOI 10.1103/PhysRevB.39.4828; Chiu A, 1996, IBM J RES DEV, V40, P283, DOI 10.1147/rd.403.0283; DIENY B, 1991, PHYS REV B, V43, P1297, DOI 10.1103/PhysRevB.43.1297; Kools JCS, 1996, IEEE T MAGN, V32, P3165, DOI 10.1109/20.508381; NEEL L, 1962, CR HEBD ACAD SCI, V255, P1545; PARKIN SSP, 1993, PHYS REV LETT, V71, P1641, DOI 10.1103/PhysRevLett.71.1641; PARKIN SSP, 1991, PHYS REV LETT, V66, P2152, DOI 10.1103/PhysRevLett.66.2152; PARKIN SSP, 1990, PHYS REV LETT, V64, P2304, DOI 10.1103/PhysRevLett.64.2304; SIRNONDS JL, 1995, PHYS TODAY, V48, P26; SLONCZEWSKI JC, 1989, PHYS REV B, V39, P6995, DOI 10.1103/PhysRevB.39.6995	11	123	123	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					797	799		10.1126/science.281.5378.797	http://dx.doi.org/10.1126/science.281.5378.797			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694644				2022-12-28	WOS:000075295600040
J	Shapiro, RL; Hatheway, C; Swerdlow, DL				Shapiro, RL; Hatheway, C; Swerdlow, DL			Botulism in the United States: A clinical and epidemiologic review	ANNALS OF INTERNAL MEDICINE			English	Review							NUCLEOTIDE-SEQUENCE ANALYSIS; AMINO-ACID-SEQUENCE; TOXIN TYPE-A; CLOSTRIDIUM-BOTULINUM; FOODBORNE BOTULISM; INFANT BOTULISM; ADULT BOTULISM; ENCODING GENE; NEUROTOXIN; ANTITOXIN		Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Swerdlow, DL (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA.							Arnon S. S., 1998, TXB PEDIAT INFECT DI, P1570; AURELI P, 1986, J INFECT DIS, V154, P207, DOI 10.1093/infdis/154.2.207; Bakheit AMO, 1997, J NEUROL NEUROSUR PS, V62, P198, DOI 10.1136/jnnp.62.2.198; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BLACK RE, 1980, AM J MED, V69, P567, DOI 10.1016/0002-9343(80)90469-6; BOWMER EJ, 1963, B WORLD HEALTH ORGAN, V29, P701; Brin MF, 1997, MUSCLE NERVE, pS146; CAMPBELL K, 1993, BIOCHIM BIOPHYS ACTA, V1216, P487, DOI 10.1016/0167-4781(93)90020-E; Cato E., 1986, BERGEYS MANUAL SYSTE, P1141; *CDCP, 1978, PUBL CDC, P3; CHIA JK, 1986, NEW ENGL J MED, V315, P239, DOI 10.1056/NEJM198607243150407; Cole LA, 1996, SCI AM, V275, P60, DOI 10.1038/scientificamerican1296-60; Danzig R., 1996, STRATEGIC FORUM, V58, P1; DOWELL VR, 1977, JAMA-J AM MED ASSOC, V238, P1829, DOI 10.1001/jama.238.17.1829; DUCHEN LW, 1971, J NEUROL SCI, V14, P47, DOI 10.1016/0022-510X(71)90129-8; EAST AK, 1992, FEMS MICROBIOL LETT, V96, P225, DOI 10.1016/0378-1097(92)90408-G; EISENBERG MS, 1976, JAMA-J AM MED ASSOC, V235, P35, DOI 10.1001/jama.235.1.35; EITZEN LT, 1993, PUBLICATION US ARMY; EKEUS R, 1991, REPORT SECRETARY GEN; ELMORE MJ, 1995, SYST APPL MICROBIOL, V18, P23, DOI [10.1016/S0723-2020(11)80444-3, 10.1078/072320203322337272]; Griffin PM, 1997, J INFECT DIS, V175, P633, DOI 10.1093/infdis/175.3.633; HALL JD, 1985, J CLIN MICROBIOL, V21, P654, DOI 10.1128/JCM.21.4.654-655.1985; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; Hatheway C.L., 1988, LAB DIAGNOSIS INFECT, P111; HATHEWAY CH, 1984, J INFECT DIS, V150, P407, DOI 10.1093/infdis/150.3.407; Hatheway CL, 1995, CURR TOP MICROBIOL, V195, P55; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HATHEWAY CL, 1996, NAT TOXINS, V2, P481; HAUSER D, 1990, NUCLEIC ACIDS RES, V18, P4924, DOI 10.1093/nar/18.16.4924; HORWITZ MA, 1977, J INFECT DIS, V136, P153, DOI 10.1093/infdis/136.1.153; Hughes James M., 1997, P615; HUGHES JM, 1981, ANN INTERN MED, V95, P442, DOI 10.7326/0003-4819-95-4-442; LUND BM, 1990, LANCET, V336, P982, DOI 10.1016/0140-6736(90)92431-G; MACDONALD KL, 1986, AM J EPIDEMIOL, V124, P794, DOI 10.1093/oxfordjournals.aje.a114455; MACDONALD KL, 1985, JAMA-J AM MED ASSOC, V253, P1275, DOI 10.1001/jama.253.9.1275; MCCROSKEY LM, 1988, J CLIN MICROBIOL, V26, P1052, DOI 10.1128/JCM.26.5.1052-1054.1988; MCCROSKEY LM, 1991, J CLIN MICROBIOL, V29, P2618, DOI 10.1128/JCM.29.11.2618-2620.1991; MCNALLY RE, 1994, EFFECTIVENESS MED DE; MERSON MH, 1973, NEW ENGL J MED, V289, P1005, DOI 10.1056/NEJM197311082891904; MEYER KF, 1973, CALIF MED, V118, P63; Passaro DJ, 1998, JAMA-J AM MED ASSOC, V279, P859, DOI 10.1001/jama.279.11.859; Schiavo G, 1995, CURR TOP MICROBIOL, V195, P257; SEALS JE, 1981, AM J EPIDEMIOL, V113, P436, DOI 10.1093/oxfordjournals.aje.a113111; Smith L. D. S., 1988, BOTULISM ORGANISM IT; SPIKA JS, 1989, AM J DIS CHILD, V143, P828, DOI 10.1001/archpedi.1989.02150190078026; STLOUIS ME, 1988, ANN INTERN MED, V108, P363, DOI 10.7326/0003-4819-108-3-363; STLOUIS ME, 1991, BACTERIAL INFECT HUM, P115; SZABO EA, 1994, J APPL BACTERIOL, V76, P539, DOI 10.1111/j.1365-2672.1994.tb01650.x; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; Townes JM, 1996, ANN INTERN MED, V125, P558, DOI 10.7326/0003-4819-125-7-199610010-00004; TSUJIHATA M, 1987, J NEUROL SCI, V81, P197, DOI 10.1016/0022-510X(87)90096-7; van Ermengem E., 1897, Z HYG INFEKTIONSKR, V26, P1, DOI [10.1007/BF02220526, DOI 10.1007/BF02220526]; VANERMENGEM E, 1979, REV INFECT DIS, V1, P701; WAINWRIGHT RB, 1988, J INFECT DIS, V157, P1158, DOI 10.1093/infdis/157.6.1158; WHELAN SM, 1992, EUR J BIOCHEM, V204, P657, DOI 10.1111/j.1432-1033.1992.tb16679.x; WHELAN SM, 1992, APPL ENVIRON MICROB, V58, P2345, DOI 10.1128/AEM.58.8.2345-2354.1992; WILSON R, 1982, PEDIATR INFECT DIS J, V1, P148, DOI 10.1097/00006454-198205000-00003; WOODRUFF BA, 1992, J INFECT DIS, V166, P1281, DOI 10.1093/infdis/166.6.1281; 1995, MMWR MORB MORTAL WKL, V43, P22; 1995, MMWR MORB MORTAL WKL, V44, P889; 1979, MMWR MORB MORTAL WKL, V28, P73	63	310	330	0	36	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					221	228		10.7326/0003-4819-129-3-199808010-00011	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696731				2022-12-28	WOS:000075032700008
J	Cox, CL; Zhou, Q; Sherman, SM				Cox, CL; Zhou, Q; Sherman, SM			Glutamate locally activates dendritic outputs of thalamic interneurons	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; PATCH-CLAMP RECORDINGS; CAT; NEURONS; CELLS; GABA	The relay of information through thalamus to cortex is dynamically gated, as illustrated by the retinogeniculocortical pathway(1). Important to this is the inhibitory interneuron in the lateral geniculate nucleus (LGN). For the typical neuron, synaptic information arrives through postsynaptic dendrites and is transmitted by axon terminals. However, the typical thalamic interneuron, in addition to conventional axonal outputs, has distal dendrites that serve both pre- and postsynaptic roles(2-6). These dendritic terminals participate in curious and enigmatic triadic arrangements, in which each contacts a relay cell dendrite and is contacted by a glutamatergic retinal terminal that innervates the same relay cell dendrite. Here we show that agonists of the metabotropic glutamate receptor (mGluR) activate dendritic terminals of interneurons in the absence of action potentials, thereby inhibiting the postsynaptic relay neuron. Somatic recordings from LGN interneurons reveal that there is no response to mGluR agonists, suggesting that their dendritic terminals are electrically isolated from their somata and axons, consistent with anatomical modelling of these cells', Our results offer insight into the functioning of triadic circuitry and indicate that thalamic interneurons can perform independent computations expressed through axonal as opposed to dendritic outputs.	SUNY Stony Brook, Dept Neurobiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sherman, SM (corresponding author), SUNY Stony Brook, Dept Neurobiol, Stony Brook, NY 11794 USA.	ssherman@neurobio.sunysb.edu		Cox, Charles/0000-0002-1179-7014				Arcelli P, 1997, BRAIN RES BULL, V42, P27, DOI 10.1016/S0361-9230(96)00107-4; BLOOMFIELD SA, 1989, P NATL ACAD SCI USA, V86, P3911, DOI 10.1073/pnas.86.10.3911; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FAMIGLIETTI EV, 1972, J COMP NEUROL, V144, P285, DOI 10.1002/cne.901440304; FRIEDLANDER MJ, 1981, J NEUROPHYSIOL, V46, P80, DOI 10.1152/jn.1981.46.1.80; Godwin DW, 1996, J NEUROSCI, V16, P8181; GUILLERY RW, 1966, J COMP NEUROL, V128, P21, DOI 10.1002/cne.901280104; GUILLERY RW, 1969, Z ZELLFORSCH MIK ANA, V96, P1, DOI 10.1007/BF00321474; HAMOS JE, 1985, NATURE, V317, P618, DOI 10.1038/317618a0; Lee KH, 1997, NEUROSCIENCE, V77, P335, DOI 10.1016/S0306-4522(96)00481-2; LEVAY S, 1977, J COMP NEUROL, V172, P563, DOI 10.1002/cne.901720402; MCCORMICK DA, 1992, P NATL ACAD SCI USA, V89, P2774, DOI 10.1073/pnas.89.7.2774; MONTERO VM, 1986, J COMP NEUROL, V254, P228, DOI 10.1002/cne.902540207; OTTERSEN OP, 1984, ANAT EMBRYOL, V170, P197, DOI 10.1007/BF00319005; PAPE HC, 1995, NEUROSCIENCE, V68, P1105, DOI 10.1016/0306-4522(95)00205-W; RALSTON HJ, 1971, NATURE, V230, P585, DOI 10.1038/230585a0; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SHERMAN SM, 1997, SOC NEUR ABSTR, V23; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; WILSON JR, 1984, PROC R SOC SER B-BIO, V221, P411, DOI 10.1098/rspb.1984.0042	21	70	71	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					478	482		10.1038/28855	http://dx.doi.org/10.1038/28855			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697770				2022-12-28	WOS:000075080400052
J	Holland, BT; Blanford, CF; Stein, A				Holland, BT; Blanford, CF; Stein, A			Synthesis of macroporous minerals with highly ordered three-dimensional arrays of spheroidal voids	SCIENCE			English	Article								Titania, zirconia, and alumina samples with periodic three-dimensional arrays of macropores were synthesized from the corresponding metal alkoxides, using latex spheres as templates. In a fast, single-step reaction, the monomeric alkoxide precursors permeate the array of bulk polystyrene spheres and condense in air at room temperature. Close packed, open-pore structures with 320- to 360-nanometer voids are obtained after calcination of the organic component at 575 degrees C. The examples presented demonstrate the compositional diversity possible with this technique. The resulting highly structured ceramics could have applications in areas ranging from quantum electronics ro photocatalysis to battery materials.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Stein, A (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.		Blanford, Christopher/C-1061-2008	Blanford, Christopher/0000-0002-0112-7818				Antonietti M, 1998, ADV MATER, V10, P154, DOI 10.1002/(SICI)1521-4095(199801)10:2<154::AID-ADMA154>3.0.CO;2-I; BLANFORD CF, UNPUB; BRINKER CJ, 1990, SOL GEL SCI PHYSICS; FEDIE RL, 1996, THESIS U MINNESOTA M; Hearn M.T.W., 1991, HPLC PROTEINS PEPTID; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Jansen J.C., 1994, ADV ZEOLITE SCI APPL; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Lim MH, 1997, J AM CHEM SOC, V119, P4090, DOI 10.1021/ja9638824; Lim MH, 1998, CHEM MATER, V10, P467, DOI 10.1021/cm970713p; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; OZIN GA, 1992, ADV MATER, V4, P612, DOI 10.1002/adma.19920041003; Perry RH., 1984, PERRYS CHEM ENG HDB; Templin M, 1997, SCIENCE, V278, P1795, DOI 10.1126/science.278.5344.1795; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; YABLONOVITCH E, 1993, J OPT SOC AM B, V10, P283, DOI 10.1364/JOSAB.10.000283; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548	19	1392	1499	11	485	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					538	540		10.1126/science.281.5376.538	http://dx.doi.org/10.1126/science.281.5376.538			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677191				2022-12-28	WOS:000075012300033
J	Brahams, D				Brahams, D			My kidney as property	LANCET			English	Editorial Material									Old Square Chambers, London WC1R 5LQ, England		Brahams, D (corresponding author), Old Square Chambers, 1 Verulam Bldgs,Grays Inn, London WC1R 5LQ, England.							ANDERSON R, IN PRESS WORKSH 30 I; Brahams D, 1998, Med Leg J, V66 ( Pt 2), P45; Radcliffe-Richards J, 1998, LANCET, V351, P1950, DOI 10.1016/S0140-6736(97)08211-1	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					166	166		10.1016/S0140-6736(05)77804-1	http://dx.doi.org/10.1016/S0140-6736(05)77804-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683203				2022-12-28	WOS:000074859800007
J	Horton, R				Horton, R			The journal ombudsperson - A step toward scientific press oversight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			LANCET OMBUDSMAN	In 1994, Doug Altman invited the International Committee of Medical Journal Editors to consider how it might help authors who had complaints about editors. The concern that editors abuse the power and trust invested in them by authors, readers, and publishers had grown with the careful documentation of instances of unambiguous editorial misconduct. One obstacle to their proposal was the logistic complexity of coordinating, at the international level, an appeals procedure through a single body. In an effort to open a wider discussion about editorial accountability, The Lancet established an ombudsperson in July 1996. Clear criteria, based on the UK Parliamentary Commissioner for Administration, were drawn up. Our ombudsman could investigate delays in handling manuscripts and letters; editorial discourtesy; failure to follow stated editorial procedures; failure to take reasonable account of representations by authors and readers; and challenges to the publishing ethics of the journal. Complaints about the substance of editorial decisions were ruled out of the ombudsman's remit. Twenty complaints were recorded in the first 18 months, 11 of which were upheld. The appointment of an ombudsperson should be considered by editors of all scientific journals. Benefits go well beyond immediate complaints, drawing an editor's attention, for example, to the importance of efficient and courteous journal processes. No discernible harm was discovered. A case still remains for wider oversight of the biomedical press.	The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, 42 Bedford Sq, London WC1B 3SL, England.							Albert T, 1997, LANCET, V350, P822, DOI 10.1016/S0140-6736(05)62628-1; ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P166, DOI 10.1001/jama.272.2.166; Horton R, 1996, LANCET, V348, P6, DOI 10.1016/S0140-6736(05)64352-8; *OFF PARL COMM ADM, 1996, PARL OMB; RELMAN AS, 1997, LANCET, V348, P885; RIIS P, 1992, J INTERN MED, V232, P207, DOI 10.1111/j.1365-2796.1992.tb00574.x; Sherwood T, 1997, LANCET, V350, P4, DOI 10.1016/S0140-6736(05)66235-6; Smith GD, 1996, LANCET, V348, P411, DOI 10.1016/S0140-6736(05)65034-9	8	15	17	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					298	299		10.1001/jama.280.3.298	http://dx.doi.org/10.1001/jama.280.3.298			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676690	Bronze			2022-12-28	WOS:000074706000035
J	Jefferson, T; Smith, R; Yee, Y; Drummond, M; Pratt, M; Gale, R				Jefferson, T; Smith, R; Yee, Y; Drummond, M; Pratt, M; Gale, R			Evaluating the BMJ guidelines for economic submissions - Prospective audit of economic submissions to BMJ and The Lancet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			POLICY	Context.-Editorial management of articles on health economics may benefit from guidelines for peer review and revision. Objective.-To assess whether publication (in August 1996) of the BMJ guidelines on peer review of economics submissions made any difference to editorial and peer review processes, quality of submitted manuscripts, and quality of published manuscripts. Design and Setting.-Before-after study conducted in the editorial offices of BMJ and The Lancet of the effect of the BMJ guidelines on review and revision of economics submissions, defined as those making explicit comments about resource allocation and/or costs of interventions. Main Outcome Measures.-Editorial fate and changes in the quality of submissions. Results.-A total of 2982 manuscripts were submitted to the 2 journals during the before periods, 105 (3.5%) of which were economics submissions. Of these, 27 (24.3%) were full economics evaluations, and 78 (75.7%) were other economics submissions. Overall acceptance rate was 11.6% (12/105). During the after period 2077 manuscripts were submitted to the 2 journals, 87 (4.2%) of which were economics submissions. Eighteen (20.7%) were full economics evaluations, and 69 (79.3%) were other economics submissions. Overall acceptance rate was 6.9% (6/87), Although a number of manuscripts could not be traced to determine whether they were economics submissions, there appeared to be little difference between the 2 journals in numbers or editorial fate of the manuscripts. There was no change in the quality of submitted manuscripts, but BMJ editors found the guidelines and checklists useful and sent fewer economics submissions for external peer review in the after phase. Conclusions.-Publication of the guidelines helped the BMJ editors improve the efficiency of the editorial process but had no impact on the quality of economics evaluations submitted or published.	Minist Def, London, England; BMJ, London, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of York - UK	Jefferson, T (corresponding author), Army Med Directorate, Keogh Barracks, Ash Vale GU12 5RR, Hants, England.							ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; *CAN COORD OFF HLT, 1994, GUID EC EV PHARM; Commonwealth Department of Health Housing and Community Services, 1992, GUID PHARM IND PREP; Detsky A S, 1993, Pharmacoeconomics, V3, P354, DOI 10.2165/00019053-199303050-00003; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; ELIXHAUSER A, 1993, MED CARE S, V31, P1; GERARD K, 1992, HEALTH POLICY, V21, P249, DOI 10.1016/0168-8510(92)90022-4; GOLD MR, 1996, COST EFFECTIVENESS; JEFFERSON T, 1994, HEALTH ECON, V3, P25, DOI 10.1002/hec.4730030105; JEFFERSON T, 1995, BRIT MED J, V311, P393, DOI 10.1136/bmj.311.7001.393c; JEFFERSON T, 1995, HEALTH ECON, V4, P383, DOI 10.1002/hec.4730040504; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; UDVARHELYI S, 1992, ANN INTERN MED, V116, P238	13	58	58	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					275	277		10.1001/jama.280.3.275	http://dx.doi.org/10.1001/jama.280.3.275			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZZ204	9676680	Bronze			2022-12-28	WOS:000074706000025
J	Purcell, GP; Donovan, SL; Davidoff, F				Purcell, GP; Donovan, SL; Davidoff, F			Changes to manuscripts during the editorial process - Characterizing the evolution of a clinical paper	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			INTERNAL-MEDICINE; ANNALS	Context.-Biomedical manuscripts undergo substantive change as a result of the peer review and editorial revision processes. Objective.-To characterize quantitatively problems in manuscripts identified during peer review and changes made to address these problems. Design and Setting.-Descriptive analysis of manuscripts submitted to and articles published by the Annals of Internal Medicine. A taxonomy of problems that occur in reporting clinical research was developed from analysis of changes made to 7 manuscripts between submission and publication (published October 15, 1996, and November 1, 1996), The taxonomy was used to characterize changes to 12 additional manuscripts (published January 15, 1997, to April 1, 1997). Main Outcome Measure.-Types of problems necessitating changes to manuscripts during peer review and revision. Results.-Changes occurred because of 5 types of problems: too much information, too little information, inaccurate information, misplaced Information, and structural problems. Changes most often occurred because information was missing or extraneous. The distribution of changes seemed to be influenced by the type of information involved (such as background or conclusions). Conclusion.-The proposed framework may be useful for characterizing quantitatively the effects of peer review and for comparing those effects across editors, journals, and specialties.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Amer Coll Phys, Annals Internal Med, Editorial Off, Philadelphia, PA USA	Duke University; American College of Physicians	Purcell, GP (corresponding author), Duke Univ, Med Ctr, Dept Surg, 31134, Durham, NC 27710 USA.							GARDNER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1355, DOI 10.1001/jama.263.10.1355; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; KASSIRER JP, 1994, JAMA-J AM MED ASSOC, V272, P96, DOI 10.1001/jama.272.2.96; PURCELL CP, 1997, INT J DIGITAL LIB, V1, P288; ROBERTS JC, 1994, JAMA-J AM MED ASSOC, V272, P119, DOI 10.1001/jama.272.2.119; VOYTOVICH AE, 1986, EVAL HLTH PROFESSION, V9, P91	6	41	41	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					227	228		10.1001/jama.280.3.227	http://dx.doi.org/10.1001/jama.280.3.227			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676663	Bronze			2022-12-28	WOS:000074706000008
J	Boutros, M; Paricio, N; Strutt, DI; Mlodzik, M				Boutros, M; Paricio, N; Strutt, DI; Mlodzik, M			Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling	CELL			English	Article							TISSUE POLARITY; DROSOPHILA EYE; BETA-CATENIN; IN-VIVO; PROTEIN; GENE; WNT; XENOPUS; EMBRYOGENESIS; CONSERVATION	Frizzled family proteins have been described as receptors of Wnt signaling molecules. In Drosophila, the two known Frizzled proteins are associated with distinct developmental processes. Genesis of epithelial planar polarity requires Frizzled, whereas Dfz2 affects morphogenesis by wingless-mediated signaling. Dishevelled is required in both signaling pathways. Here, we use genetic and overexpression assays to show that Dishevelled activates JNK cascades. Rescue analysis reveals different protein domain requirements in Dishevelled far the two pathways; the C-terminal DEP domain is essential to rescue planar polarity defects and induce JNK signaling. Furthermore, the planar polarity-specific dsh(1) allele is mutated in the DEP domain. Our results indicate that different Wnt/Fz signals activate distinct intracellular pathways, and Dishevelled discriminates among them by distinct domain interactions.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mlodzik, M (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Strutt, David/E-6196-2010; Paricio, Nuria/K-2184-2014; Boutros, Michael/C-3566-2008	Strutt, David/0000-0001-8185-4515; Paricio, Nuria/0000-0001-7193-2532; Boutros, Michael/0000-0002-9458-817X				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1994, GENETICS, V137, P1; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; AXELROD JD, 1998, IN PRESS GENES DEV; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Fahmy O. G., 1959, DIS, V33, P83; Fehon RG, 1997, GENETICS, V146, P245; GUBB D, 1993, DEVELOPMENT, P269; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MOON RT, 1993, DEVELOPMENT, V119, P97; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; SOKOL SY, 1995, DEVELOPMENT, V121, P3487; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; XU T, 1993, DEVELOPMENT, V117, P1223; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZHENG L, 1995, DEVELOPMENT, V121, P3045; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	61	653	660	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					109	118		10.1016/S0092-8674(00)81226-X	http://dx.doi.org/10.1016/S0092-8674(00)81226-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674432	Bronze			2022-12-28	WOS:000074790800014
J	Nakamura, S				Nakamura, S			The roles of structural imperfections in InGaN-Based blue light-emitting diodes and laser diodes	SCIENCE			English	Review							GROWN GAN FILMS; GALLIUM NITRIDE; BUFFER LAYER; HYDROGENATION; SUPERLATTICES; LUMINESCENCE; SAPPHIRE; MG	High-efficiency light-emitting diodes emitting amber, green, blue, and ultraviolet light have been obtained through the use of an InGaN active layer instead of a GaN active layer. The localized energy states caused by In composition fluctuation in the InGaN active layer are related to the high efficiency of the InGaN-based emitting devices. The blue and green InCaN quantum-well structure light-emitting diodes with luminous efficiencies of 5 and 30 lumens per watt, respectively, can be made despite the large number of threading dislocations (1 X 10(8) to 1 X 10(12) cm(-2)). Epitaxially laterally overgrown GaN on sapphire reduces the number of threading dislocations originating from the interface of the GaN epilayer with the sapphire substrate; InGaN multi-quantum-well structure laser diodes formed on the GaN layer above the SiO2 mask area can have a lifetime of more than 10,000 hours. Dislocations increase the threshold current density of the laser diodes.	Nichia Chem Ind, Dept Res & Dev, Tokushima 774, Japan	Nichia Corporation	Nakamura, S (corresponding author), Nichia Chem Ind, Dept Res & Dev, 491 Oka, Tokushima 774, Japan.	shuji@nichia.co.jp						AMANO H, 1989, JPN J APPL PHYS 2, V28, pL2112, DOI 10.1143/JJAP.28.L2112; AMANO H, 1986, APPL PHYS LETT, V48, P353, DOI 10.1063/1.96549; BRANDT MS, 1994, APPL PHYS LETT, V64, P2264, DOI 10.1063/1.111639; Bulman GE, 1997, ELECTRON LETT, V33, P1556, DOI 10.1049/el:19971025; Chen Y, 1998, APPL PHYS LETT, V72, P710, DOI 10.1063/1.120853; Chichibu S, 1997, APPL PHYS LETT, V71, P2346, DOI 10.1063/1.120025; Chichibu S, 1997, APPL PHYS LETT, V70, P2822, DOI 10.1063/1.119013; Chichibu S, 1996, APPL PHYS LETT, V69, P4188, DOI 10.1063/1.116981; CHICHIBU SF, UNPUB; Crowell PA, 1998, APPL PHYS LETT, V72, P927, DOI 10.1063/1.120875; Garni B, 1996, APPL PHYS LETT, V68, P1380, DOI 10.1063/1.116086; Hansen PJ, 1998, APPL PHYS LETT, V72, P2247, DOI 10.1063/1.121268; Heying B, 1996, APPL PHYS LETT, V68, P643, DOI 10.1063/1.116495; Itaya K, 1996, JPN J APPL PHYS 2, V35, pL1315, DOI 10.1143/JJAP.35.L1315; KAPOLNEK D, 1995, APPL PHYS LETT, V67, P1541, DOI 10.1063/1.114486; Katoh H, 1998, JPN J APPL PHYS 2, V37, pL444, DOI 10.1143/JJAP.37.L444; Keller S, 1998, JPN J APPL PHYS 2, V37, pL431, DOI 10.1143/JJAP.37.L431; Kneissl M, 1998, APPL PHYS LETT, V72, P1539, DOI 10.1063/1.120575; Kuramata A, 1997, JPN J APPL PHYS 2, V36, pL1130, DOI 10.1143/JJAP.36.L1130; LAGERSTE.O, 1974, J APPL PHYS, V45, P2266, DOI 10.1063/1.1663574; LESTER SD, 1995, APPL PHYS LETT, V66, P1249, DOI 10.1063/1.113252; Mack MP, 1997, MRS INTERNET J N S R, V2, part. no.; MARUSKA HP, 1972, MATER RES BULL, V7, P777, DOI 10.1016/0025-5408(72)90127-4; MATSUOKA T, 1992, J CRYST GROWTH, V124, P433, DOI 10.1016/0022-0248(92)90496-6; McCluskey MD, 1998, APPL PHYS LETT, V72, P2725, DOI 10.1063/1.121072; Mukai T, 1998, J CRYST GROWTH, V189, P778, DOI 10.1016/S0022-0248(98)00292-9; NAGATOMO T, 1989, JPN J APPL PHYS 2, V28, pL1334, DOI 10.1143/JJAP.28.L1334; Nakamura S, 1997, IEEE J SEL TOP QUANT, V3, P712, DOI 10.1109/2944.640626; NAKAMURA S, 1994, APPL PHYS LETT, V64, P1687, DOI 10.1063/1.111832; NAKAMURA S, 1993, J APPL PHYS, V74, P3911, DOI 10.1063/1.354486; NAKAMURA S, 1992, JPN J APPL PHYS 2, V31, pL139, DOI 10.1143/JJAP.31.L139; Nakamura S, 1998, JPN J APPL PHYS 2, V37, pL309, DOI 10.1143/JJAP.37.L309; NAKAMURA S, 1992, JPN J APPL PHYS 1, V31, P2883, DOI 10.1143/JJAP.31.2883; Nakamura S, 1998, APPL PHYS LETT, V72, P211, DOI 10.1063/1.120688; NAKAMURA S, 1992, JPN J APPL PHYS 1, V31, P1258, DOI 10.1143/JJAP.31.1258; NAKAMURA S, 1992, JPN J APPL PHYS 2, V31, pL1457, DOI 10.1143/JJAP.31.L1457; Nakamura S, 1996, JPN J APPL PHYS 2, V35, pL74, DOI 10.1143/JJAP.35.L74; Nakamura S, 1998, JPN J APPL PHYS 2, V37, pL627, DOI 10.1143/JJAP.37.L627; NAKAMURA S, 1995, JPN J APPL PHYS 2, V34, pL1332, DOI 10.1143/JJAP.34.L1332; NAKAMURA S, 1991, JPN J APPL PHYS 2, V30, pL1705, DOI 10.1143/JJAP.30.L1705; Nakamura S, 1997, JPN J APPL PHYS 2, V36, pL1568, DOI 10.1143/JJAP.36.L1568; NAKAMURA S, 1993, JPN J APPL PHYS 2, V32, pL16, DOI 10.1143/JJAP.32.L16; Nakamura S., 1997, BLUE LASER DIODE GAN; Nardelli MB, 1997, APPL PHYS LETT, V71, P3135, DOI 10.1063/1.120269; Narukawa Y, 1997, APPL PHYS LETT, V70, P981, DOI 10.1063/1.118455; Narukawa Y, 1997, PHYS REV B, V55, pR1938, DOI 10.1103/PhysRevB.55.R1938; NEUGEBAUER J, 1994, PHYS REV B, V50, P8067, DOI 10.1103/PhysRevB.50.8067; Osinsky A, 1997, APPL PHYS LETT, V71, P2334, DOI 10.1063/1.120023; Pankove J. I., 1973, Journal of Luminescence, V8, P89, DOI 10.1016/0022-2313(73)90038-0; PANKOVE JI, 1971, RCA REV, V32, P383; Ponce FA, 1997, NATURE, V386, P351, DOI 10.1038/386351a0; Ponce FA, 1996, APPL PHYS LETT, V68, P57, DOI 10.1063/1.116756; QIAN W, 1995, APPL PHYS LETT, V67, P2284, DOI 10.1063/1.115127; Rosner SJ, 1997, APPL PHYS LETT, V70, P420, DOI 10.1063/1.118322; RUBIN M, 1994, APPL PHYS LETT, V64, P64, DOI 10.1063/1.110870; Sakai A, 1997, APPL PHYS LETT, V71, P2259, DOI 10.1063/1.120044; Sasaoka C, 1998, J CRYST GROWTH, V189, P61, DOI 10.1016/S0022-0248(98)00169-9; Sato H, 1998, JPN J APPL PHYS 1, V37, P2013, DOI 10.1143/JJAP.37.2013; SMITH DL, 1987, PHYS REV LETT, V58, P1264, DOI 10.1103/PhysRevLett.58.1264; STRITE S, 1992, J VAC SCI TECHNOL B, V10, P1237, DOI 10.1116/1.585897; Sugahara T, 1998, JPN J APPL PHYS 2, V37, pL398, DOI 10.1143/JJAP.37.L398; SUN CK, 1993, APPL PHYS LETT, V63, P96, DOI 10.1063/1.109709; Takeuchi T, 1997, JPN J APPL PHYS 2, V36, pL177, DOI 10.1143/JJAP.36.L177; TAKEUCHI T, 1997, JPN J APPL PHYS, V36, pL1059; Tarsa EJ, 1997, J APPL PHYS, V82, P5472, DOI 10.1063/1.365575; Weimann NG, 1998, J APPL PHYS, V83, P3656, DOI 10.1063/1.366585; Wu XH, 1996, JPN J APPL PHYS 2, V35, pL1648, DOI 10.1143/JJAP.35.L1648; Wu XH, 1998, APPL PHYS LETT, V72, P692, DOI 10.1063/1.120844; Wu XH, 1996, J APPL PHYS, V80, P3228, DOI 10.1063/1.363264; YOSHIDA S, 1983, APPL PHYS LETT, V42, P427, DOI 10.1063/1.93952; ZAVADA JM, 1994, APPL PHYS LETT, V64, P2724, DOI 10.1063/1.111455; Zheleva TS, 1997, APPL PHYS LETT, V71, P2472, DOI 10.1063/1.120091	72	1677	1768	29	744	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1998	281	5379					956	961		10.1126/science.281.5379.956	http://dx.doi.org/10.1126/science.281.5379.956			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703504				2022-12-28	WOS:000075412700037
J	Xiang, ZX; Huguenard, JR; Prince, DA				Xiang, ZX; Huguenard, JR; Prince, DA			Cholinergic switching within neocortical inhibitory networks	SCIENCE			English	Article							RAT CEREBRAL-CORTEX; GABAERGIC NEURONS; MORPHOLOGICAL-CHARACTERISTICS; MONOCLONAL-ANTIBODY; ALZHEIMERS-DISEASE; PYRAMIDAL CELLS; VISUAL-CORTEX; GABA NEURONS; GUINEA-PIG; ACETYLTRANSFERASE	Differential actions of acetylcholine on the excitability of two subtypes of interneurons in layer V of the rat visual cortex were examined. Acetylcholine excited low-threshold spike (LTS) cells through nicotinic receptors, whereas it elicited hyperpolarization in fast spiking (FS) cells through muscarinic receptors. Axons of LTS cells were mainly distributed vertically to upper Layers, and those of FS cells were primarily confined to layer V. Thus, cortical cholinergic activation may reduce some forms of intralaminar inhibition, promote intracolumnar inhibition, and change the direction of information flow within cortical circuits.	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University	Prince, DA (corresponding author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	daprince@leland.Stanford.edu	Huguenard, John/K-6429-2019; Huguenard, John/I-5016-2012	Huguenard, John/0000-0002-6950-1191; Huguenard, John/0000-0002-6950-1191; Xiang, Zixiu/0000-0002-1678-209X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS012151, P01NS012151] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 06477, NS 12151, NS 07280] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIGNER TG, 1986, BEHAV NEURAL BIOL, V45, P81, DOI 10.1016/S0163-1047(86)80008-5; Alkondon M, 1997, J PHARMACOL EXP THER, V283, P1396; BARKER JL, 1988, J PHYSIOL-LONDON, V403, P41, DOI 10.1113/jphysiol.1988.sp017237; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BEAULIEU C, 1991, J COMP NEUROL, V304, P666, DOI 10.1002/cne.903040412; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DAVIES P, 1976, LANCET, V2, P1403; ECKENSTEIN F, 1983, NEUROSCI LETT, V36, P211, DOI 10.1016/0304-3940(83)90002-2; FOEHRING RC, 1991, J NEUROPHYSIOL, V66, P1825, DOI 10.1152/jn.1991.66.6.1825; Frazier CJ, 1998, J NEUROSCI, V18, P1187; HASSELMO ME, 1995, BEHAV BRAIN RES, V67, P1, DOI 10.1016/0166-4328(94)00113-T; HENDRY SHC, 1989, EXP BRAIN RES, V76, P467; HOUSER CR, 1983, J NEUROCYTOL, V12, P617, DOI 10.1007/BF01181527; HOUSER CR, 1983, BRAIN RES, V266, P97, DOI 10.1016/0006-8993(83)91312-4; HOUSER CR, 1985, J COMP NEUROL, V234, P17, DOI 10.1002/cne.902340103; JONES BE, 1984, CEREB CORTEX, P309; KAWAGUCHI Y, 1995, TRENDS NEUROSCI, V18, P527, DOI 10.1016/0166-2236(95)98374-8; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; KAWAGUCHI Y, 1993, J NEUROPHYSIOL, V69, P416, DOI 10.1152/jn.1993.69.2.416; KRNJEVIC K, 1974, PHYSIOL REV, V54, P418, DOI 10.1152/physrev.1974.54.2.418; LARKMAN AU, 1992, J COMP NEUROL, V323, P137, DOI 10.1002/cne.903230202; LEE KH, 1995, J NEUROPHYSIOL, V73, P2123, DOI 10.1152/jn.1995.73.5.2123; MCCORMICK DA, 1985, P NATL ACAD SCI USA, V82, P6344, DOI 10.1073/pnas.82.18.6344; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; MCCORMICK DA, 1986, NATURE, V319, P402, DOI 10.1038/319402a0; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MCCORMICK DA, 1986, J PHYSIOL-LONDON, V375, P169, DOI 10.1113/jphysiol.1986.sp016112; MCCORMICK DA, 1987, J NEUROSCI, V7, P742; McQuiston A. R., 1996, Society for Neuroscience Abstracts, V22, P786; McQuiston A. R., 1997, Society for Neuroscience Abstracts, V23, P2009; Mesulam Marek-Marsel, 1995, P135; PHILLIS J W, 1968, Brain Research, V10, P297, DOI 10.1016/0006-8993(68)90201-1; PITLER TA, 1992, J PHYSIOL-LONDON, V450, P127, DOI 10.1113/jphysiol.1992.sp019119; PRINCE DA, 1967, ARCH NEUROL-CHICAGO, V16, P194, DOI 10.1001/archneur.1967.00470200082007; REECE LJ, 1991, BRAIN RES, V540, P287, DOI 10.1016/0006-8993(91)90520-6; REECE LJ, 1991, BRAIN RES, V566, P115, DOI 10.1016/0006-8993(91)91688-W; RUBERG M, 1982, BRAIN RES, V232, P129, DOI 10.1016/0006-8993(82)90615-1; Sannita WG, 1995, EEG CL N SU, P156; SAPER CB, 1984, J COMP NEUROL, V222, P313, DOI 10.1002/cne.902220302; SHUTE CCD, 1967, BRAIN, V90, P497, DOI 10.1093/brain/90.3.497; SOMOGYI P, 1984, J NEUROSCI, V4, P2590; STEWART DJ, 1985, BRAIN RES, V358, P404, DOI 10.1016/0006-8993(85)90994-1; SZERB JC, 1967, J PHYSIOL-LONDON, V192, P329, DOI 10.1113/jphysiol.1967.sp008303; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; WAINER BH, 1984, BRAIN RES, V308, P69, DOI 10.1016/0006-8993(84)90918-1; Xiang Z., 1997, Society for Neuroscience Abstracts, V23, P359; Xiang ZX, 1998, J PHYSIOL-LONDON, V506, P715, DOI 10.1111/j.1469-7793.1998.715bv.x	47	352	357	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					985	988		10.1126/science.281.5379.985	http://dx.doi.org/10.1126/science.281.5379.985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703513				2022-12-28	WOS:000075412700046
J	Dematte, JE; O'Mara, K; Buescher, J; Whitney, CG; Forsythe, S; McNamee, T; Adiga, RB; Ndukwu, IM				Dematte, JE; O'Mara, K; Buescher, J; Whitney, CG; Forsythe, S; McNamee, T; Adiga, RB; Ndukwu, IM			Near-fatal heat stroke during the 1995 heat wave in Chicago	ANNALS OF INTERNAL MEDICINE			English	Article						heat stroke; intensive care units; outcome assessment (health care); health status; activities of daily living	RHEUMATOID-ARTHRITIS; ST-LOUIS; HEATSTROKE; COAGULATION; MORBIDITY; MORTALITY; DEATHS; LIVER	Background: In July 1995, Chicago sustained a heat wave that resulted in more than 600 excess deaths, 3300 excess emergency department visits, and a substantial number of intensive care unit admissions for near-fatal heat stroke. Objective: To describe the clinical features of patients admitted to an intensive care unit with near-fatal classic heat stroke. Patients were followed for 1 year to assess delayed functional outcome and mortality. Design: Observational study. Setting: Intensive care units in the Chicago area. Patients: 58 patients admitted to the hospital from 12 July to 20 July 1995 who met the case definition of classic heat stroke. Measurements: The data collection tool was designed to compile demographic and survival data and to permit analysis of organ system function by abstracting data on physical examination findings, electrocardiography and echocardiography results, fluid resuscitation, radiography results, and laboratory findings. Data on functional status at discharge and at 1 year were collected by using a modified Stanford Health Assessment Questionnaire. Results: Patients experienced multiorgan dysfunction with neurologic impairment (100%), moderate to severe renal insufficiency (53%), disseminated intravascular coagulation (45%), and the acute respiratory distress syndrome (10%); Fifty-seven percent of patients had evidence of infection on admission. In-hospital mortality was 21%. Most survivors recovered near-normal renal, hematologic, and respiratory status, but disability persisted, resulting in moderate to severe functional-impairment in 33% of patients at hospital discharge. At 1 year, no patient had improved functional status, and an additional 28% of patients had died. Conclusions: Near-fatal classic heat stroke is associated with multiorgan dysfunction. A high percentage of patients had infection at presentation. A high mortality rate was observed during acute hospitalization and at 1 year, in addition, substantial functional impairment at discharge persisted 1 year. The degree of functional disability correlated highly with survival at 1 year.	Univ Chicago, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Michael Reese Hosp & Med Ctr, Chicago, IL 60521 USA; Resurrect Med Ctr, Crit Care Unit, Chicago, IL 60631 USA; Univ Chicago, Pritzker Sch Med, Dean Students Off, Chicago, IL 60637 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Illinois, Chicago, IL USA	University of Chicago; Michael Reese Hospital & Medical Center; University of Chicago; Centers for Disease Control & Prevention - USA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ndukwu, IM (corresponding author), Univ Chicago, Pulm & Crit Care Med Sect, 5481 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00055] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AUSTIN MG, 1956, JAMA-J AM MED ASSOC, V161, P1525, DOI 10.1001/jama.1956.02970160005002; BEDRAK E, 1964, J APPL PHYSIOL, V19, P469, DOI 10.1152/jappl.1964.19.3.469; BOUCHAMA A, 1993, CHEST, V104, P1498, DOI 10.1378/chest.104.5.1498; Bouchama A, 1996, CRIT CARE MED, V24, P1173, DOI 10.1097/00003246-199607000-00018; BOUCHAMA A, 1992, J APPL PHYSIOL, V73, P405, DOI 10.1152/jappl.1992.73.2.405; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P577; CHAO TC, 1981, PATHOLOGY, V13, P145, DOI 10.3109/00313028109086837; CLOWES GHA, 1974, NEW ENGL J MED, V291, P564, DOI 10.1056/NEJM197409122911106; ELKASSIMI FA, 1986, CHEST, V90, P571, DOI 10.1378/chest.90.4.571; ELLIS FP, 1980, Q J MED, V49, P1; Ferris EB, 1938, J CLIN INVEST, V17, P249, DOI 10.1172/JCI100949; FOGOROS RN, 1980, JAMA-J AM MED ASSOC, V243, P1743, DOI 10.1001/jama.243.17.1743; GRABER CD, 1971, J AMER MED ASSOC, V216, P1195, DOI 10.1001/jama.216.7.1195; Hammami MM, 1997, CRIT CARE MED, V25, P1314, DOI 10.1097/00003246-199708000-00017; HART GR, 1982, MEDICINE, V61, P189, DOI 10.1097/00005792-198205000-00005; HASSANEIN T, 1992, AM J GASTROENTEROL, V87, P1382; HUBBARD RW, 1995, WILDERNESS MED MANAG, P167; JONES TS, 1982, JAMA-J AM MED ASSOC, V247, P3327, DOI 10.1001/jama.247.24.3327; Kaarisalo MM, 1997, STROKE, V28, P311, DOI 10.1161/01.STR.28.2.311; KEW M, 1970, AM J MED, V49, P192, DOI 10.1016/S0002-9343(70)80075-4; KEW MC, 1967, Q J MED, V36, P277; KILBOURNE EM, 1982, JAMA-J AM MED ASSOC, V247, P3332, DOI 10.1001/jama.247.24.3332; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNOCHEL JP, 1974, ARCH INTERN MED, V133, P841, DOI 10.1001/archinte.133.5.841; KNOCHEL JP, 1961, AM J MED, V30, P299, DOI 10.1016/0002-9343(61)90101-2; KNOCHEL JP, 1989, DM-DIS MON, V35, P306; Ladell WSS, 1944, LANCET, V2, P527; Ladell WSS, 1944, LANCET, V2, P491; LEVINE JA, 1969, AM J MED, V47, P251, DOI 10.1016/0002-9343(69)90151-X; MALAMUD N, 1946, Mil Surg, V99, P397; *METR CHIC HEALTHC, 1995, MCHC UPD AR HOSP RES, V6, P3; ODONNELL TF, 1975, JAMA-J AM MED ASSOC, V234, P824, DOI 10.1001/jama.234.8.824; ODONNELL TF, 1972, NEW ENGL J MED, V287, P734, DOI 10.1056/NEJM197210122871502; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PINCUS T, 1986, J RHEUMATOL, V13, P841; RAJU SF, 1973, SOUTH MED J, V66, P330, DOI 10.1097/00007611-197303000-00012; REEBACK J, 1984, J ROY SOC MED, V77, P1002, DOI 10.1177/014107688407701203; ROWELL LB, 1970, J APPL PHYSIOL, V28, P415, DOI 10.1152/jappl.1970.28.4.415; ROWELL LB, 1971, J APPL PHYSIOL, V31, P864, DOI 10.1152/jappl.1971.31.6.864; SCHUMAN SH, 1972, ENVIRON RES, V5, P59, DOI 10.1016/0013-9351(72)90020-5; SHAPIRO Y, 1990, MED SCI SPORT EXER, V22, P6; SHAPIRO Y, 1979, ANN INTERN MED, V90, P913, DOI 10.7326/0003-4819-90-6-913; SHIBOLET S, 1967, Q J MED, V36, P525; SHIBOLET S, 1962, NEW ENGL J MED, V266, P169, DOI 10.1056/NEJM196201252660404; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; SOHAL RS, 1968, ARCH INTERN MED, V122, P43, DOI 10.1001/archinte.122.1.43; STINE RJ, 1979, JACEP-J AM COLL EMER, V8, P154, DOI 10.1016/S0361-1124(79)80343-3; TEK D, 1992, Emergency Medicine Clinics of North America, V10, P299; THAYSEN JH, 1955, J CLIN INVEST, V34, P1719, DOI 10.1172/JCI103225; WOLFE F, 1988, J RHEUMATOL, V15, P1480; ZAHGER D, 1989, CHEST, V95, P1089, DOI 10.1378/chest.95.5.1089; 1995, MMWR MORB MORTAL WKL, V44, P465; 1995, AM J RESP CRIT CARE, V151, pA323	53	278	299	4	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					173	+		10.7326/0003-4819-129-3-199808010-00001	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696724				2022-12-28	WOS:000075032700001
J	Kavanagh, S; Knapp, M				Kavanagh, S; Knapp, M			The impact on general practitioners of the changing balance of care for elderly people living in institutions	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To describe utilisation of general practitioners by elderly people resident in communal establishments; to examine variations in general practitioner utilisation and estimate the likely impact of the "downsizing'' of long stay provision in NHS hospitals. Design: Secondary analyses of the survey of disability among adults in communal establishments conducted by the Office of Population Censuses and Surveys in 1986, and projection to present day. Setting: Nationally representative sample of Communal establishments in Great Britain. Subjects: Disabled residents aged 65 or more without mental handicap. Results: Residents with higher levels of disability, disorders of the digestive system, resident in smaller local authority homes or larger voluntary residential homes were more likely to consult a general practitioner. For those who consulted, higher levels of disability and morbidity and residence in a private nursing home or a larger private residential home were all associated with greater general practitioner utilisation. Overall, when residents' characteristics and size of home was controlled for, residents in nursing homes had greater predicted utilisation than those in residential care homes. People who would previously have been cared for in NHS hospitals and are now cared for in nursing homes have high predicted utilisation due to their greater morbidity and disability. Conclusion: The "downsizing" of NHS provision for elderly people has increased demand on general practitioners by 160 whole time equivalents per year in Britain.	Univ Kent, Personal Serv Res Unit, Canterbury CT2 7NF, Kent, England; London Sch Econ, Personal Social Serv Res Unit, London WC2A 2AE, England	University of Kent; University of London; London School Economics & Political Science	Kavanagh, S (corresponding author), Univ Kent, Personal Serv Res Unit, Canterbury CT2 7NF, Kent, England.		Knapp, Martin RJ/G-3011-2011	Knapp, Martin/0000-0003-1427-0215				ATKIN K, 1993, CENSUS PRACTICE NURS; Black D, 1997, BRIT MED J, V315, P441, DOI 10.1136/bmj.315.7106.441; *BRIT MED ASS DEP, 1994, GEN MED PRACT WORKL; DARTON R, 1998, MENTAL HLTH RES REV, V5, P31; DARTON RA, 1995, PSSRU CHE SURVEYS RE; *DEP HLTH, 1996, STAT GEN MED PRACT E; Department of Health, 1997, NEWS NHS MOD DEP; Department of Health, 1996, PRIM CAR DEL FUT; Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; FRANK RG, 1995, HLTH AFFAIRS, V14, P65; Knapp M., 1992, CARE COMMUNITY CHALL; LAING, 1996, LAINGS REV PRIVATE H; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin D, 1997, Health Serv J, V107, P28; MARTIN J, 1989, OPCS SURVEYS DISABIL; MARTIN J, 1988, 1 OPGS; MATSAGANIS M, 1994, J HEALTH ECON, V13, P31, DOI 10.1016/0167-6296(94)90003-5; MCCORMICK A, 1995, MORBIDITY STAT GEN P; MECHANIC D, 1995, MILBANK Q, V73, P19, DOI 10.2307/3350312; MECHANIC D, 1996, MENTAL HLTH US; NETTEN A, 1997, 13392 U KENT SOC SER; Newhouse JP, 1993, FREE ALL LESSONS RAN; Pedersen LL, 1997, BMJ-BRIT MED J, V314, P1337, DOI 10.1136/bmj.314.7090.1337; Rowlands O., 1997, LIVING BRITAIN RESUL; SHEFFLER, 1989, LANCET, V1, P950; Taylor DH, 1997, BRIT MED J, V314, P1806, DOI 10.1136/bmj.314.7097.1806; WELLWOOD I, 1995, AGE AGEING, V24, P54, DOI 10.1093/ageing/24.1.54; [No title captured]	28	33	33	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					322	327		10.1136/bmj.317.7154.322	http://dx.doi.org/10.1136/bmj.317.7154.322			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685280	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075409500024
J	Feldman, M; Cryer, B; Lee, E; Peterson, WL				Feldman, M; Cryer, B; Lee, E; Peterson, WL			Role of seroconversion in confirming cure of Helicobacter pylori infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTRITIS; SEROLOGY; HUMANS; ACID	Context.-The role of serologic testing to confirm cure of Helicobacter pylori infection after antimicrobial therapy is not completely defined. Objective.-To determine the utility of serologic testing in confirming cure of H pylori infection more than 1 year after therapy. Design.-A prospective, before-after interventional trial. Setting.-An outpatient clinical research laboratory in an academic, urban Veterans Affairs medical center. Participants.-Twenty-three otherwise healthy men and women with active H pylori infection demonstrated by gastric biopsy and with positive H pylori serologic findings. Intervention.-A 14-day course of bismuth, tetracycline, and metronidazole. Main Outcome Measures.-Determination of IgG serum antibodies to H pylori at baseline, 1 month, 3 months, and approximately 18 months after completion of therapy compared with serial gastric mucosal biopsy specimens with stains for H pylori and for histologic examination as the criterion standard. Results.-Fifteen (65%) of 23 subjects were cured of their H pylori infection as assessed by gastric biopsy, with elimination of gastritis; median antibody levels declined from 92.5 U/mL at baseline to undetectable levels at 18 months. The other 8 subjects (35%) were not cured and had persistent gastritis at 18 months; median antibody levels declined from 130.6 U/mL at baseline to 89.7 U/mL at 18 months. Sensitivity and specificity of seroconversion (from a positive to negative test result) in detecting cure of H pylori infection were 60% and 100%, respectively. Conclusion.-Undetectable antibody levels beyond the first year of therapy accurately confirm cure of H pylori infection in initially seropositive healthy subjects, with reasonable sensitivity.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, Dallas, TX 75235 USA; Dept Vet Affairs Med Ctr, Med Serv, Dallas, TX USA; Dept Vet Affairs Med Ctr, Lab Serv, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	Feldman, M (corresponding author), Vet Adm Med Ctr, Med Serv 111, 4500 S Lancaster Rd, Dallas, TX 75216 USA.	feldman.mark@dallas.va.gov						Cryer B, 1996, GASTROINTEST ENDOSC, V44, P317, DOI 10.1016/S0016-5107(96)70171-2; CUTLER A, 1993, DIGEST DIS SCI, V38, P2262, DOI 10.1007/BF01299906; Cutler AF, 1996, AM J GASTROENTEROL, V91, P85; FELDMAN M, 1994, JAMA-J AM MED ASSOC, V272, P70; Feldman M, 1996, GASTROENTEROLOGY, V110, P1043, DOI 10.1053/gast.1996.v110.pm8612992; Graham DY, 1997, GASTROENTEROLOGY, V113, pS113, DOI 10.1016/S0016-5085(97)80023-6; Hopkins RJ, 1997, GASTROENTEROLOGY, V113, pS126, DOI 10.1016/S0016-5085(97)80026-1; Howden CW, 1997, GASTROENTEROLOGY, V113, pS107, DOI 10.1016/S0016-5085(97)80022-4; Lee J, 1997, GASTROENTEROLOGY, V113, pS99, DOI 10.1016/S0016-5085(97)80021-2; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; Unge P, 1997, GASTROENTEROLOGY, V113, pS131, DOI 10.1016/S0016-5085(97)80027-3; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	12	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					363	365		10.1001/jama.280.4.363	http://dx.doi.org/10.1001/jama.280.4.363			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686554	Bronze			2022-12-28	WOS:000074804200037
J	Helfand, M; Redfern, CC				Helfand, M; Redfern, CC			Screening for thyroid disease: An update	ANNALS OF INTERNAL MEDICINE			English	Article							STIMULATING HORMONE ASSAY; L-THYROXINE TREATMENT; MIDDLE-AGED WOMEN; SUBCLINICAL HYPOTHYROIDISM; SERUM THYROTROPIN; FOLLOW-UP; ASYMPTOMATIC ADULTS; ELDERLY POPULATION; OLDER PERSONS; DOUBLE-BLIND	Purpose: To review information on the benefits of screening with a sensitive thyroid-stimulating hormone (TSH) test for thyroid dysfunction in asymptomatic patients seeking primary care for other reasons. This paper focuses on whether screening should be aimed at detection of subclinical thyroid dysfunction and whether persons with mildly abnormal TSH levels can benefit. Data Sources: A MEDLINE search for studies of screening for thyroid dysfunction and of treatment for complications of subclinical thyroid dysfunction. Study Selection: Studies of screening with thyroid function tests in the general adult population or in patients seen in the general office setting were selected (n = 33). All controlled studies of treatment in patients with subclinical hypothyroidism or subclinical hyperthyroidism were also included (n = 23). Data Extraction: The prevalence of overt and subclinical thyroid dysfunction, the evidence for the efficacy of treatment, and the incidence of complications in defined age and sex groups were extracted from each study. Data Synthesis: Screening can detect symptomatic but unsuspected overt thyroid dysfunction. The yield is highest for women older than 50 years of age: In this group, 1 in 71 women screened could benefit from relief of symptoms. Evidence of the efficacy of treatment for subclinical thyroid dysfunction is inconclusive. Conclusions: Even though treatment for subclinical thyroid dysfunction is controversial, office-based screening to detect overt thyroid dysfunction may be indicated in women older than 50 years of age. Large randomized trials are needed to determine the likelihood that treatment will improve quality of life in otherwise healthy patients who have mildly elevated TSH levels.	Vet Affairs Med Ctr, Dept Med 111P, Portland, OR 97201 USA; Providence Portland Med Ctr, Portland, OR USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence Portland Medical Center	Helfand, M (corresponding author), Vet Affairs Med Ctr, Dept Med 111P, Box 1034, Portland, OR 97201 USA.							ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; ANDERSEN EM, 1995, J AM GERIATR SOC, V43, P1030, DOI 10.1111/j.1532-5415.1995.tb05569.x; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BANNISTER P, 1989, GERONTOLOGY, V35, P225, DOI 10.1159/000213027; BAUER DC, 1995, J BONE MINER RES, P10; BEMBEN DA, 1994, J FAM PRACTICE, V38, P577; BERLOWITZ I, 1990, ISRAEL J MED SCI, V26, P496; BJORO T, 1989, Tidsskrift for den Norske Laegeforening, V109, P1048; BOGNER U, 1993, ACTA ENDOCRINOL-COP, V128, P202, DOI 10.1530/acta.0.1280202; BROCHMANN H, 1988, ACTA ENDOCRINOL-COP, V117, P7, DOI 10.1530/acta.0.1170007; Canadian Task Force on the Periodic Health Examination, 1994, CAN GUID CLIN PREV H, P611; Ching GW, 1996, HEART, V75, P363, DOI 10.1136/hrt.75.4.363; CHRISTENSEN SB, 1984, ACTA CHIR SCAND, V150, P13; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; Corti MC, 1997, ANN INTERN MED, V126, P753, DOI 10.7326/0003-4819-126-10-199705150-00001; Danese MD, 1996, JAMA-J AM MED ASSOC, V276, P285, DOI 10.1001/jama.276.4.285; DIEKMAN T, 1995, ARCH INTERN MED, V155, P1490, DOI 10.1001/archinte.155.14.1490; DOSREMEDIOS LV, 1980, ARCH INTERN MED, V140, P1045, DOI 10.1001/archinte.140.8.1045; EDDY DM, 1992, FAST PRO SOFTWARE ME; EDDY DM, 1991, COMMON SCREENING TES, P179; Eden S, 1988, Compr Gerontol A, V2, P40; EDWARDS Y, 1991, BRIT J GEN PRACT, V41, P496; EGGERTSEN R, 1988, BRIT MED J, V297, P1586, DOI 10.1136/bmj.297.6663.1586; FOLDES J, 1993, CLIN ENDOCRINOL, V39, P521, DOI 10.1111/j.1365-2265.1993.tb02403.x; FRANKLYN J, 1995, CLIN ENDOCRINOL, V43, P443, DOI 10.1111/j.1365-2265.1995.tb02615.x; FRANKLYN JA, 1993, CLIN ENDOCRINOL, V38, P453, DOI 10.1111/j.1365-2265.1993.tb00339.x; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; GEUL KW, 1993, CLIN ENDOCRINOL, V39, P275, DOI 10.1111/j.1365-2265.1993.tb02366.x; Glenn GC, 1996, ARCH PATHOL LAB MED, V120, P929; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V277, P1232; HASSELBLAD VIC, 1995, MED DECIS MAKING, V15, P81, DOI 10.1177/0272989X9501500112; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HELFAND M, 1990, ANN INTERN MED, V112, P840, DOI 10.7326/0003-4819-112-11-840; HELFAND M, 1990, COMMON DIAGNOSTIC TE, P148; HELFAND M, 1992, ADV ENDOCRINOL METAB, V3, P271; Hintze G, 1991, Aging (Milano), V3, P325; Jaeschke R, 1996, J GEN INTERN MED, V11, P744, DOI 10.1007/BF02598988; KAGEDAL B, 1981, SCAND J CLIN LAB INV, V41, P403, DOI 10.3109/00365518109092063; KANNEL WB, 1996, ATHEROSCLEROSIS CORO, P13; KONNO N, 1994, J CLIN ENDOCR METAB, V78, P393, DOI 10.1210/jc.78.2.393; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MIURA S, 1994, INTERNAL MED, V33, P413, DOI 10.2169/internalmedicine.33.413; MUDDE AH, 1992, CLIN ENDOCRINOL, V37, P35, DOI 10.1111/j.1365-2265.1992.tb02280.x; NOLAN JP, 1985, AM J CLIN PATHOL, V83, P346, DOI 10.1093/ajcp/83.3.346; NYSTROM E, 1986, CLIN CHEM, V32, P603; NYSTROM E, 1981, ACTA MED SCAND, V210, P39; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; OKAMURA K, 1989, J AM GERIATR SOC, V37, P317, DOI 10.1111/j.1532-5415.1989.tb05497.x; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PARLE JV, 1992, CLIN ENDOCRINOL, V37, P411, DOI 10.1111/j.1365-2265.1992.tb02351.x; PETERSEN K, 1991, J INTERN MED, V229, P407, DOI 10.1111/j.1365-2796.1991.tb00367.x; RODRIGUEZ JC, 1990, MED CLIN-BARCELONA, V95, P89; Salabe-Lotz H, 1990, Thyroidology, V2, P107; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SAWIN CT, 1991, ARCH INTERN MED, V151, P165, DOI 10.1001/archinte.151.1.165; SCHAAF L, 1993, CLIN INVESTIGATOR, V71, P126; SPENCER CA, 1995, CLIN CHEM, V41, P367; STOTT DJ, 1991, Q J MED, V78, P77; SUNDBECK G, 1991, AGE AGEING, V20, P291, DOI 10.1093/ageing/20.4.291; SUNDBECK G, 1991, ARCH INTERN MED, V151, P549, DOI 10.1001/archinte.151.3.549; Tanis BC, 1996, CLIN ENDOCRINOL, V44, P643, DOI 10.1046/j.1365-2265.1996.739560.x; TENERZ A, 1990, J INTERN MED, V228, P229; TUNBRIDGE WMG, 1981, BRIT MED J, V282, P258, DOI 10.1136/bmj.282.6260.258; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Uzzan B, 1996, J CLIN ENDOCR METAB, V81, P4278, DOI 10.1210/jc.81.12.4278; VALDEMARSSON S, 1983, ACTA ENDOCRINOL-COP, V104, P50, DOI 10.1530/acta.0.1040050; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; WEDJA B, 1995, J INTERN MED, V237, P241; WIERSINGA WM, 1995, NETH J MED, V46, P197, DOI 10.1016/0300-2977(94)00089-R; 1993, 1990 CENS POP HOUS P	72	211	231	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					144	158		10.7326/0003-4819-129-2-199807150-00020	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00020			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669977				2022-12-28	WOS:000074852000014
J	Lundberg, GD; Paul, MC				Lundberg, GD; Paul, MC			A comparison of the opinions of experts and readers as to what topics a general medical journal (JAMA) should address	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-Journal editors are responsible to many publics, and their choices of articles to publish are a frequent source of dispute. Objective.-To assess the extent of agreement between topics identified by experts and by JAMA readers as most important for publication. Design and Participants.-Modified Delphi process of polling of JAMA Editorial Board members and senior staff (ie, experts) in 1996, and masked direct mail survey of a stratified sample of JAMA readers in late 1996 and early 1997. Main Outcome Measures.-Agreement between experts and readers on the topics most important for JAMA to deal with in 1997. Results.-Of 55 experts polled, the 40 respondents (73% response rate) proposed 178 topics. Editing to combine similar topics left 73. The same 55 persons were asked to stratify all 73 alphabetically arranged topics on a scale of 1 to 5 (85% [47/55] response rate). They were then given the results of this ballot and asked to vote again (76% [42/55] response rate). Of the 55 experts, 40 attending the annual editorial board meeting were given all results; 39 attendees voted on the final topics. In response to the mail survey, a single pass of the same 73 topics yielded a response rate of 41.6% (208 returns). Nonresponders were roughly equivalent to responders demographically. Readers agreed with the experts on only 3 of the top 10 subjects: managed care, cancer, and aging. Conclusion.-Expert opinion and the opinion of readers as to what JAMA should emphasize vary widely.	JAMA, Chicago, IL 60610 USA; HCI Inc, Princeton, NJ USA		Lundberg, GD (corresponding author), JAMA, 515 N State St, Chicago, IL 60610 USA.							JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; Lundberg GD, 1997, JAMA-J AM MED ASSOC, V278, P1615, DOI 10.1001/jama.278.19.1615; MURNINGHAM J, 1981, MANAGEMENT REV   FEB, P55; PILL J, 1971, SOCIO ECON PLAN SCI, V5, P57, DOI 10.1016/0038-0121(71)90041-3; Winker MA, 1997, JAMA-J AM MED ASSOC, V278, P1377, DOI 10.1001/jama.278.16.1377; Winker MA, 1996, JAMA-J AM MED ASSOC, V275, P245, DOI 10.1001/jama.275.3.245	6	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					288	290		10.1001/jama.280.3.288	http://dx.doi.org/10.1001/jama.280.3.288			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676685				2022-12-28	WOS:000074706000030
J	Duda, RL				Duda, RL			Protein chainmail: Catenated protein in viral capsids	CELL			English	Article							RECOMBINANT BOVINE SOMATOTROPIN; VIRUS; HEAD; BACTERIOPHAGE-T4; RESOLUTION; SEQUENCE; SYSTEM	The capsid shells of bacteriophage HK97 and several other phages contain polypeptides that are covalently linked into complexes so large that they do not enter polyacrylamide gels after denaturation. The enormous apparent size of these protein complexes in HK97 derives from a novel protein topology. HK97 subunits cross-link via isopeptide bonds into oligomers that are closed rings of five or six members. However, polypeptides from neighboring pentamer and hexamer rings intertwine before the covalent cross-links form. As a result, adjacent protein rings catenate into a network similar to chainmail armor. In vitro linking and unlinking experiments provide strong support for the chainmail model, which explains the unusual properties of these bacteriophages and may apply to other macromolecular structures.	Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duda, RL (corresponding author), Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA.			Duda, Robert/0000-0002-9517-2731	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047795] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047795, GM47795] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Casjens SR, 1988, BACTERIOPHAGES, P1; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; DHILLON EKS, 1980, J GEN VIROL, V50, P217, DOI 10.1099/0022-1317-50-1-217; DUDA RL, 1995, J MOL BIOL, V247, P636, DOI 10.1006/jmbi.1994.0169; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; FORD ME, 1998, IN PRESS J MOL BIOL; HATFULL GF, 1993, MOL MICROBIOL, V7, P395, DOI 10.1111/j.1365-2958.1993.tb01131.x; HERUTH DP, 1994, J BACTERIOL, V176, P3559, DOI 10.1128/JB.176.12.3559-3567.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIMBERGER RJ, 1994, J BACTERIOL, V176, P3631, DOI 10.1128/JB.176.12.3631-3637.1994; LUBBERS MW, 1995, APPL ENVIRON MICROB, V61, P4348, DOI 10.1128/AEM.61.12.4348-4356.1995; Murphy F.A., 1995, 6 REP INT COMM TAX V; OLSON AJ, 1983, J MOL BIOL, V171, P61, DOI 10.1016/S0022-2836(83)80314-3; POND FR, 1989, MICROBIOL REV, V53, P25, DOI 10.1128/MMBR.53.1.25-67.1989; POPA MP, 1991, J VIROL, V65, P3227, DOI 10.1128/JVI.65.6.3227-3237.1991; SCHAFER R, 1977, EUR J BIOCHEM, V73, P239, DOI 10.1111/j.1432-1033.1977.tb11312.x; SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6; STERNBERG N, 1977, J MOL BIOL, V117, P733, DOI 10.1016/0022-2836(77)90067-5; STEVEN AC, 1992, J MOL BIOL, V228, P870, DOI 10.1016/0022-2836(92)90871-G; TOU JS, 1993, J PROTEIN CHEM, V12, P237, DOI 10.1007/BF01026046; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; vanSinderen D, 1996, MOL MICROBIOL, V19, P1343, DOI 10.1111/j.1365-2958.1996.tb02478.x; VIOLAND BN, 1989, J PROTEIN CHEM, V8, P619, DOI 10.1007/BF01025602; Wikoff WR, 1998, VIROLOGY, V243, P113, DOI 10.1006/viro.1998.9040; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XIE ZH, 1995, J MOL BIOL, V253, P74, DOI 10.1006/jmbi.1995.0537	27	124	125	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					55	60		10.1016/S0092-8674(00)81221-0	http://dx.doi.org/10.1016/S0092-8674(00)81221-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674427	Bronze			2022-12-28	WOS:000074790800009
J	Perez-Stable, EJ; Herrera, B; Jacob, P; Benowitz, NL				Perez-Stable, EJ; Herrera, B; Jacob, P; Benowitz, NL			Nicotine metabolism and intake in black and white smokers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; RACIAL-DIFFERENCES; CARBON-MONOXIDE; COTININE LEVELS; CONSUMPTION; EXPOSURE; MENTHOL; HUMANS; RACE	Context.-Racial differences in tobacco-related diseases are not fully explained by cigarette-smoking behavior. Despite smoking fewer cigarettes per day, blacks have higher levels of serum cotinine, the proximate metabolite of nicotine. Objective.-To compare the rates of metabolism and the daily intake of nicotine in black smokers and white smokers. Design.-Participants received simultaneous infusions of deuterium-labeled nicotine and cotinine. Urine was collected for determination of total clearance of nicotine and cotinine, fractional conversion of nicotine to cotinine, and cotinine elimination rate. Using cotinine levels during ad libitum smoking and clearance data, the daily intake of nicotine from smoking was estimated. Setting.-Metabolic ward of a university-affiliate public hospital. Participants.-A total of 40 black and 39 white smokers, average consumption of 14 and 14.7 cigarettes per day, respectively, of similar age (mean, 32.5 and 32.3 years, respectively) and body weight (mean, 73.3 and 68.8 kg, respectively). Main Outcome Measures.-Clearance (renal and nonrenal), half-life, and volume of distribution of nicotine and cotinine and the calculated daily intake of nicotine. Results.-The total and nonrenal clearances of nicotine were not significantly different, respectively, in blacks (17.7 and 17.2 mL.min(-1).kg(-1)) compared with whites (19.6 and 18.9 mL.min(-1).kg(-1)) (P=.11 and .20). However, the total and nonrenal clearances of cotinine were significantly lower, respectively, in blacks (0.56 and 0.47 mL.min(-1).kg(-1)) than in whites (0.68 vs 0.61 mL.min(-1).kg(-1); P=.009 for each comparison). The nicotine intake per cigarette was 30% greater in blacks compared with whites (1.41 vs 1.09 mg per cigarette, respectively; P=.02), Volume of distribution did not differ for the 2 groups, but cotinine half-life was higher in blacks than in whites (1064 vs 950 minutes, respectively; P=.07). Conclusions.-Higher levels of cotinine per cigarette smoked by blacks compared with whites can be explained by both slower clearance of cotinine and higher intake of nicotine per cigarette in blacks. Greater nicotine and therefore greater tobacco smoke intake per cigarette could, in part, explain some of the ethnic differences in smoking-related disease risks.	Univ Calif San Francisco, Dept Med, Div Gen Internal Med, Med Effectiveness Res Ctr Diverse Populat, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Med Ctr, Div Clin Pharmacol & Expt Therapeut,Med Serv, San Francisco, CA USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Perez-Stable, EJ (corresponding author), 400 Parnassus Ave,Room A-405,Box 0320, San Francisco, CA 94143 USA.	eliseo_perez-stable@ucsfdgim.ucsf.edu			NATIONAL CANCER INSTITUTE [R18CA039260, R01CA032389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA002277, R01DA002277] Funding Source: NIH RePORTER; NCI NIH HHS [CA32389, CA39260] Funding Source: Medline; NIDA NIH HHS [DA02277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AHIJEVYCH KL, 1994, AM J RESP CRIT CARE, V150, P1229, DOI 10.1164/ajrccm.150.5.7952545; BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483, DOI 10.1038/clpt.1994.169; BENOWITZ NL, 1982, J PHARMACOL EXP THER, V221, P368; BENOWITZ NL, 1994, J PHARMACOL EXP THER, V268, P296; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; CASHMAN JR, 1992, CHEM RES TOXICOL, V5, P639, DOI 10.1021/tx00029a008; CASTRO LC, 1993, OBSTET GYNECOL, V81, P396; Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P588; Clark PI, 1996, ANN EPIDEMIOL, V6, P483, DOI 10.1016/S1047-2797(96)00049-X; Clark PI, 1996, CHEST, V110, P1194, DOI 10.1378/chest.110.5.1194; COULTAS DB, 1994, AM J RESP CRIT CARE, V149, pS93, DOI 10.1164/ajrccm/149.3_Pt_2.S93; Desenclos Jean-Claude A., 1992, Morbidity and Mortality Weekly Report, V41, P13; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; Giovino Gary A., 1994, Morbidity and Mortality Weekly Report, V43, P1; HARRIS RE, 1993, INT J EPIDEMIOL, V22, P592, DOI 10.1093/ije/22.4.592; JACOB P, 1988, PHARMACOL BIOCHEM BE, V30, P249, DOI 10.1016/0091-3057(88)90453-4; JACOB P, 1988, J LABELLED COMPD RAD, V25, P1117, DOI 10.1002/jlcr.2580251009; JACOB P, 1991, BIOL MASS SPECTROM, V20, P247, DOI 10.1002/bms.1200200503; JACOB P, 1981, J CHROMATOGR, V222, P61, DOI 10.1016/S0378-4347(00)81033-6; JARVIK ME, 1994, PHYSIOL BEHAV, V56, P563, DOI 10.1016/0031-9384(94)90302-6; JOHNSON JA, 1992, CLIN PHARMACOL THER, V51, P495, DOI 10.1038/clpt.1992.53; KABAT G, 1991, AM J PUBLIC HEALTH, V11, P1483; KLEIN AE, 1978, EUR J DRUG METAB PH, V1, P51; KYEREMATEN GA, 1982, CLIN PHARMACOL THER, V32, P769, DOI 10.1038/clpt.1982.235; Martin RV, 1990, AM J PREV MED, V6, DOI [10.1016/S0749-3797(18)31005-5, DOI 10.1016/S0749-3797(18)31005-5]; MCCARTHY WJ, 1995, AM J PUBLIC HEALTH, V85, P67, DOI 10.2105/AJPH.85.1.67; MILLER HC, 1987, YALE J BIOL MED, V60, P221; Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212; NOVOTNY TE, 1988, AM J PUBLIC HEALTH, V78, P1187, DOI 10.2105/AJPH.78.9.1187; PEREZSTABLE EJ, 1990, AM J PUBLIC HEALTH, V80, P1057, DOI 10.2105/AJPH.80.9.1057; *SAS I INC, 1988, SAS STAT US REL 6 03; STERLING TD, 1989, AM J IND MED, V15, P319, DOI 10.1002/ajim.4700150307; *US DEP HHS, 1989, RED HLTH CONS SMOK R; WAGENKNECHT LE, 1990, AM J PUBLIC HEALTH, V80, P1053, DOI 10.2105/AJPH.80.9.1053; Wills TA, 1997, AM J PUBLIC HEALTH, V87, P56, DOI 10.2105/AJPH.87.1.56	38	500	507	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					152	156		10.1001/jama.280.2.152	http://dx.doi.org/10.1001/jama.280.2.152			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZY321	9669788	Bronze			2022-12-28	WOS:000074608400030
J	Gilch, P; Pollinger-Dammer, F; Musewald, C; Michel-Beyerle, ME; Steiner, UE				Gilch, P; Pollinger-Dammer, F; Musewald, C; Michel-Beyerle, ME; Steiner, UE			Magnetic field effect on picosecond electron transfer	SCIENCE			English	Article							GEMINATE RECOMBINATION; QUANTUM BEATS; PHOTOOXIDATION; COMPLEXES; PAIRS	The recombination dynamics of a transition metal redox system monitored by femtosecond pump-probe spectroscopy are shown to be sensitive to high magnetic fields at times shorter than 10 picoseconds. The effect, based on coherent population beats of different spin states, is quantitatively accounted for and allows direct access to spin relaxation rates far beyond the time resolution of the fastest electron paramagnetic resonance technique. The presence of this ultrafast magnetic field effect helps in understanding complex reaction schemes in transition metal chemistry, which occur in a wide range of fields, such as bioinorganic chemistry and catalysis.	Tech Univ Munich, Inst Phys & Theoret Chem, D-85748 Garching, Germany; Univ Konstanz, Fak Chem, D-78434 Konstanz, Germany	Technical University of Munich; University of Konstanz	Michel-Beyerle, ME (corresponding author), Tech Univ Munich, Inst Phys & Theoret Chem, D-85748 Garching, Germany.		Maria Elisabeth, Michel-Beyerle/F-7869-2012	Steiner, Ulrich/0000-0001-5176-0948				Anderson SE, 1973, CHEM PHYS, V2, P216, DOI 10.1016/0301-0104(73)80007-2; BENKESER RA, 1964, J AM CHEM SOC, V86, P890, DOI 10.1021/ja01059a029; BURSSNER D, 1993, Z PHYS CHEM, V182, P297; Gilch P, 1997, CHEM PHYS LETT, V275, P339, DOI 10.1016/S0009-2614(97)00755-0; Gilch P, 1996, CHEM PHYS LETT, V254, P384, DOI 10.1016/0009-2614(96)00330-2; KIVELSON D, 1966, J CHEM PHYS, V45, P1324, DOI 10.1063/1.1727756; MICHELBEYERLE ME, 1976, CHEM PHYS, V17, P139, DOI 10.1016/0301-0104(76)80097-3; PRINS R, 1970, J ORGANOMET CHEM, V25, pC74, DOI 10.1016/S0022-328X(00)87818-3; Salikhov K.M., 1984, SPIN POLARIZATION MA, V1st ed.; SCHULTEN K, 1976, Z PHYS CHEM NEUE FOL, V101, P371, DOI 10.1524/zpch.1976.101.1-6.371; STEHLIK D, 1989, J PHYS CHEM-US, V93, P1612, DOI 10.1021/j100341a084; STEINER UE, 1989, CHEM REV, V89, P51, DOI 10.1021/cr00091a003; STEINER UE, 1990, Z PHYS CHEM NEUE FOL, V169, P159, DOI 10.1524/zpch.1990.169.Part_2.159; Turro N.J, 1991, MODERN MOL PHOTOCHEM; vanDijk B, 1996, PHYS REV LETT, V77, P4478, DOI 10.1103/PhysRevLett.77.4478; VESELOV AV, 1987, CHEM PHYS LETT, V136, P263, DOI 10.1016/0009-2614(87)80248-8; Volk M., 1995, ANOXYGENIC PHOTOSYNT, P595; WEBER S, 1995, P NATL ACAD SCI USA, V92, P7789, DOI 10.1073/pnas.92.17.7789	18	59	60	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					982	984		10.1126/science.281.5379.982	http://dx.doi.org/10.1126/science.281.5379.982			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703512	Green Submitted			2022-12-28	WOS:000075412700045
J	Queisser, HJ; Haller, EE				Queisser, HJ; Haller, EE			Defects in semiconductors: Some fatal, some vital	SCIENCE			English	Review							DX CENTERS; ELECTRONIC-STRUCTURE; NATIVE DEFECTS; GAAS; GERMANIUM; DONOR; SPECTROSCOPY; ALXGA1-XAS; ANTISITE; STATE	The role of defects as essential entities in semiconductor materials is reviewed. Early experiments with semiconductors were hampered by the extreme sensitivity of the, electronic properties to minute concentrations of impurities. Semiconductors were viewed as a family of solids with irreproducible properties. Scientific efforts overcame this idiosyncrasy and turned the art of impurity doping into today's exceedingly useful and reproducible technology that is used to control precisely electrical conductivity, composition, and minority carrier lifetimes over wide ranges. Native defects such as vacancies and self-interstitials control basic processes, foremost self- and dopant diffusion. The structural properties of dislocations and higher dimensional defects have been studied with atomic resolution, but a thorough theoretical understanding of their electronic properties is incomplete. Reactions between defects within the host Lattices are increasingly better understood and are used for gettering and electrical passivation of unwanted impurities. Metastable defects such as DX centers and the EL2-related arsenic antisite are briefly discussed. The recent development of isotopically controlled semiconductors has created new research opportunities in this field.	Univ Calif Berkeley, Dept Mat Sci & Mineral Engn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Queisser, HJ (corresponding author), Univ Calif Berkeley, Dept Mat Sci & Mineral Engn, Berkeley, CA 94720 USA.							Bracht H, 1998, PHYS REV LETT, V81, P393, DOI 10.1103/PhysRevLett.81.393; CHADI DJ, 1988, PHYS REV LETT, V60, P2187, DOI 10.1103/PhysRevLett.60.2187; CHADI DJ, 1988, PHYS REV LETT, V61, P873, DOI 10.1103/PhysRevLett.61.873; DABROWSKI J, 1988, PHYS REV LETT, V60, P2183, DOI 10.1103/PhysRevLett.60.2183; GEBALLE TH, 1958, PHYS REV, V110, P773, DOI 10.1103/PhysRev.110.773; GILLES D, 1998, ELECTROCHEMICAL SOC, V981, P1047; Graff K., 1995, METAL IMPURITIES SIL; HALLER EE, 1995, J APPL PHYS, V77, P2857, DOI 10.1063/1.358700; HALLER EE, 1977, IEEE T NUCL SCI, V24, P48, DOI 10.1109/TNS.1977.4328641; HALLER EE, 1978, PHYS REV LETT, V40, P584, DOI 10.1103/PhysRevLett.40.584; HALLER EE, 1986, ADV SOLID STATE PHYS, V26, P203; HALLER EE, 1993, HANDB SEMIC, V4, P937; Hirth J. P., 1972, THEORY DISLOCATIONS; Huff HR, 1998, JPN J APPL PHYS 1, V37, P1210, DOI 10.1143/JJAP.37.1210; LANG DV, 1977, PHYS REV LETT, V39, P635, DOI 10.1103/PhysRevLett.39.635; MAYUR AJ, 1994, PHYS REV B, V49, P16293, DOI 10.1103/PhysRevB.49.16293; MIZUTA M, 1985, JPN J APPL PHYS 2, V24, pL143, DOI 10.1143/JJAP.24.L143; MOONEY PM, 1990, J APPL PHYS, V67, pR1, DOI 10.1063/1.345628; MOONEY PM, 1991, SEMICOND SCI TECH, V6, pB1, DOI 10.1088/0268-1242/6/10B/001; Murarka S.P, 1983, SILICIDES VLSI APPL; Nakamura S, 1998, SCIENCE, V281, P956, DOI 10.1126/science.281.5379.956; Nakamura S., 1997, BLUE LASER DIODE GAN; NEUGEBAUER J, 1994, PHYS REV B, V50, P8067, DOI 10.1103/PhysRevB.50.8067; Obermeier G, 1997, J APPL PHYS, V82, P595, DOI 10.1063/1.365586; PANKOVE JI, 1991, HYDROGEN SEMICONDUCT, V34; PANTELIDES ST, 1992, DEEP CTR SEMIONDUCTO; Pomeranchuk I, 1942, J PHYS-USSR, V6, P237; QUEISSER HJ, IN PRESS MAT RES SOC; QUEISSER HJ, 1983, MATER RES SOC S P, V14, P323; RAMDAS AK, 1981, REP PROG PHYS, V44, P1297, DOI 10.1088/0034-4885/44/12/002; SHOCKLEY W, 1976, IEEE T ELECTRON DEV, V23, P611; Smith AR, 1997, PHYS REV LETT, V79, P3934, DOI 10.1103/PhysRevLett.79.3934; STOLK PA, 1995, APPL PHYS LETT, V66, P1370, DOI 10.1063/1.113204; Stoneham A.M, 1975, THEORY DEFECTS SOLID, P555; UFTRING SJ, 1995, PHYS REV B, V51, P9612, DOI 10.1103/PhysRevB.51.9612; WALTON JR, 1984, ZBL VET MED B, V31, P1; WALUKIEWICZ W, 1989, APPL PHYS LETT, V54, P2094, DOI 10.1063/1.101174; Watkins G. D., 1989, Materials Science Forum, V38-41, P39, DOI 10.4028/www.scientific.net/MSF.38-41.39; Wetzel C, 1997, PHYS REV LETT, V78, P3923, DOI 10.1103/PhysRevLett.78.3923; WOLK J, 1991, PHYS REV LETT, V38, P774; WOLK JA, 1991, PHYS REV LETT, V66, P774, DOI 10.1103/PhysRevLett.66.774; 1997, MAT SCI FORUM, V258; 1998, IN PRESS PHYS STAT B	43	367	373	7	187	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					945	950		10.1126/science.281.5379.945	http://dx.doi.org/10.1126/science.281.5379.945			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703502				2022-12-28	WOS:000075412700035
J	Ganguly, J; Tirone, M; Hervig, RL				Ganguly, J; Tirone, M; Hervig, RL			Diffusion kinetics of samarium and neodymium in garnet, and a method for determining cooling rates of rocks	SCIENCE			English	Article							CLOSURE TEMPERATURE; EQUILIBRIA; HISTORY; SYSTEMS	Experimental determinations of the diffusion coefficients of samarium and neodymium in almandine garnet and theoretical considerations show that one cannot assign a sufficiently restricted range of closure temperature, T-c, to the samarium-neodymium decay system in garnet for the purpose of constraining the cooling rate. However, it is shown that the samarium-neodymium cooling age of garnet can be used to calculate both cooling rate and T-c if the temperature and age at the peak metamorphic conditions are known.	Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Arizona State Univ, Ctr Solid State Sci, Tempe, AZ 85287 USA	University of Arizona; Arizona State University; Arizona State University-Tempe	Ganguly, J (corresponding author), Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA.		tirone, massimiliano/B-6520-2016; Ganguly, Jibamitra/K-6795-2012					Becker H, 1997, CONTRIB MINERAL PETR, V127, P224; BURTON K, 1992, EARTH PLANET SC LETT, V133, P199; CHAKRABORTY S, 1992, CONTRIB MINERAL PETR, V111, P74, DOI 10.1007/BF00296579; Chakraborty S., 1991, ADV PHYS GE, V8, P120; Cherniak DJ, 1997, CHEM GEOL, V134, P289, DOI 10.1016/S0009-2541(96)00098-8; CLEMENT SWJ, 1991, P INT SEC ION MASS S, P289; COGHLAN RAN, 1990, THESIS BROWN U PROVI; COHEN AS, 1988, CONTRIB MINERAL PETR, V98, P303, DOI 10.1007/BF00375181; Crank J., 1975, MATH DIFFUSION; Dodson M. H., 1986, MAT SCI FORUM, V7, P145; DODSON MH, 1973, CONTRIB MINERAL PETR, V40, P259, DOI 10.1007/BF00373790; Ganguly J, 1998, CONTRIB MINERAL PETR, V131, P171, DOI 10.1007/s004100050386; GANGULY J, UNPUB; HARRISON WJ, 1980, CONTRIB MINERAL PETR, V72, P145, DOI 10.1007/BF00399474; HENSEN BJ, 1995, GEOLOGY, V23, P225, DOI 10.1130/0091-7613(1995)023<0225:ROIMIG>2.3.CO;2; HUMPHRIES FJ, 1982, NATURE, V295, P515, DOI 10.1038/295515a0; JAMES F, 1975, COMPUT PHYS COMMUN, V10, P343, DOI 10.1016/0010-4655(75)90039-9; MEZGER K, 1992, EARTH PLANET SC LETT, V113, P387; MORIOKA M, 1991, ADV PHYS GE, V8, P176; ONEILL HS, 1988, AM MINERAL, V73, P470; SHANNON RD, 1969, ACTA CRYSTALL B-STRU, VB 25, P925, DOI 10.1107/S0567740869003220; TANNHAUSER DS, 1956, J APPL PHYS, V27, P662, DOI 10.1063/1.1722460; ZINNER E, 1986, INT J MASS SPECTROM, V69, P17, DOI 10.1016/0168-1176(86)87039-2	23	188	199	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					805	807		10.1126/science.281.5378.805	http://dx.doi.org/10.1126/science.281.5378.805			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694647				2022-12-28	WOS:000075295600043
J	Sit, TL; Vaewhongs, AA; Lommel, SA				Sit, TL; Vaewhongs, AA; Lommel, SA			RNA-mediated trans-activation of transcription from a viral RNA	SCIENCE			English	Article							NECROTIC MOSAIC-VIRUS; INFECTIOUS TRANSCRIPTS; SUBGENOMIC RNA; PLANTS; INVITRO; REGION	The red clover necrotic mosaic virus genome is composed of two single-stranded RNA components, RNA-1 and RNA-2. The viral capsid protein is translated from a subgenomic RNA (sgRNA) that is transcribed from genomic RNA-1, Here, a 34-nucleotide sequence in RNA-2 is shown to be required for transcription of sgRNA. Mutations that prevent base-pairing between the RNA-1 subgenomic promoter and the 34-nucleotide trans-activator prevent expression of a reporter gene. A model is proposed in which direct binding of RNA-2 to RNA-1 trans-activates sgRNA synthesis. This RNA-mediated regulation of transcription is unusual among RNA viruses, which typically rely on protein regulators.	N Carolina State Univ, Dept Plant Pathol, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Lommel, SA (corresponding author), N Carolina State Univ, Dept Plant Pathol, Box 7616, Raleigh, NC 27695 USA.	steve_lommel@ncsu.edu		Sit, Tim/0000-0001-7302-823X				Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CRESPI MD, 1994, EMBO J, V13, P5099, DOI 10.1002/j.1460-2075.1994.tb06839.x; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Gallie DR, 1996, PLANT MOL BIOL, V32, P145, DOI 10.1007/BF00039381; GE ZM, 1993, P JPN ACAD B-PHYS, V69, P113, DOI 10.2183/pjab.69.113; GE ZM, 1992, J GEN VIROL, V73, P2483, DOI 10.1099/0022-1317-73-9-2483; Giesman-Cookmeyer D., 1995, PATHOGENESIS HOST SP, V3, P157; Jaeger L, 1997, CURR OPIN STRUC BIOL, V7, P324, DOI 10.1016/S0959-440X(97)80047-4; Jupe ER, 1996, CELL GROWTH DIFFER, V7, P871; KENDALL TL, 1992, J GEN VIROL, V73, P2479, DOI 10.1099/0022-1317-73-9-2479; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li SL, 1997, BIOTECHNIQUES, V23, P588, DOI 10.2144/97234bm05; Liebhaber S A, 1997, Nucleic Acids Symp Ser, P29; Miller WA, 1997, SEMIN VIROL, V8, P3, DOI 10.1006/smvy.1997.0101; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; MILLER WS, COMMUNICATION; Scholthof HB, 1996, ANNU REV PHYTOPATHOL, V34, P299, DOI 10.1146/annurev.phyto.34.1.299; Siegel RW, 1997, P NATL ACAD SCI USA, V94, P11238, DOI 10.1073/pnas.94.21.11238; SIT TL, UNPUB; VAEWHONGS AA, 1995, VIROLOGY, V212, P607, DOI 10.1006/viro.1995.1518; XIONG ZG, 1991, VIROLOGY, V182, P388, DOI 10.1016/0042-6822(91)90687-7; Zavriev SK, 1996, VIROLOGY, V216, P407, DOI 10.1006/viro.1996.0076; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375	24	174	177	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					829	832		10.1126/science.281.5378.829	http://dx.doi.org/10.1126/science.281.5378.829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694655				2022-12-28	WOS:000075295600051
J	Sato, K; Wickner, W				Sato, K; Wickner, W			Functional reconstitution of Ypt7p GTPase and a purified vacuole SNARE complex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ALKALINE-PHOSPHATASE; ALPHA-SNAP; PROTEIN; FUSION; TRANSPORT; DOCKING; INHERITANCE; SYNTAXIN-1	Membrane trafficking has heretofore been studied with intact organelles. Here, fusion-competent proteoliposomes were reconstituted from a yeast vacuole detergent extract. Homotypic vacuole fusion requires many membrane proteins, including the Ypt7p guanosine triphosphatase and a "SNARE complex" with Vam3p and Nyv1p. Proteoliposomes from extracts immunodepleted of either Vam3p or Ypt7p could not fuse, but vesicles reconstituted from a mixture of these depleted extracts had restored fusion activity. Purified preassembled vacuolar SNARE complex, when reconstituted with a SNARE-depleted extract, was fully functional for fusion. Thus, solubilized integral membrane components can be reconstituted for priming, docking, and fusion steps of organelle trafficking.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.							CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; KANEKO Y, 1987, GENE, V58, P137; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; SATO K, UNPUB; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; YAMADA H, 1989, J BIOL CHEM, V264, P1723; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	23	38	38	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					700	702		10.1126/science.281.5377.700	http://dx.doi.org/10.1126/science.281.5377.700			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685264				2022-12-28	WOS:000075107900043
J	Confavreux, C; Hutchinson, M; Hours, MM; Cortinovis-Tourniaire, P; Moreau, T				Confavreux, C; Hutchinson, M; Hours, MM; Cortinovis-Tourniaire, P; Moreau, T		Pregnancy Multiple Sclerosis Grp	Rate of pregnancy-related relapse in multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUERPERIUM	Background and Methods Multiple sclerosis often occurs in young women, and the effect of pregnancy on the disease is poorly understood. We studied 254 women with multiple sclerosis during 269 pregnancies in 12 European countries, The women were followed during their pregnancies and for up to 12 months after delivery to determine the rate of relapse per trimester and the score on the Kurtzke Expanded Disability Status Scale (range, 0 to 10, with higher scores indicating more severe disability). The relapse rate in each trimester was compared with the rate during the year before the pregnancy. The effects of epidural analgesia and breast-feeding on the frequency of relapse during the first three months post partum and the disability score at 12 months post partum were also determined. Results The mean (+/-SD) rate of relapse was 0.7+/-0.9 per woman per year in the year before pregnancy; it was 0.5+/-1.3 during the first trimester (P=0.03 for the comparison with the rate before pregnancy), 0.6+/-1.6 during the second trimester (P=0.17), and 0.2+/-1.0 during the third (P<0.001). The rate increased to 1.2+/-2.0 during the first three months post partum (P<0.001) and then returned to the prepregnancy rate. The mean Kurtzke disability score worsened by 0.7 point during 33 months of follow-up, with no apparent acceleration during the postpartum period. Neither breast-feeding nor epidural analgesia had an adverse effect on the rate of relapse or on the progression of disability in multiple sclerosis. Conclusions In women with multiple sclerosis, the rate of relapse declines during pregnancy, especially in the third trimester, and increases during the first three months post partum before returning to the prepregnancy rate. (N Engl J Med 1998;339:285-91.) (C)1998, Massachusetts Medical Society.	Hop Antiqualle, EDMUS Coodinating Ctr, F-69321 Lyon, France; Hop Antiqualle, Serv Neurol, F-69321 Lyon, France; St Vincents Hosp, Dept Neurol, Dublin, Ireland	University College Dublin	Confavreux, C (corresponding author), Hop Antiqualle, EDMUS Coodinating Ctr, 1 Rue Antiquaille, F-69321 Lyon, France.		Aladro, Yolanda/GSE-3319-2022	Aladro, Yolanda/0000-0001-9459-5452; hutchinson, michael/0000-0002-8675-1723; amato, Maria Pia/0000-0003-3325-3760				ABRAMSKY O, 1994, ANN NEUROL, V36, pS38, DOI 10.1002/ana.410360712; BERNARDI S, 1991, ACTA NEUROL SCAND, V84, P403, DOI 10.1111/j.1600-0404.1991.tb04977.x; BIRK K, 1986, ARCH NEUROL-CHICAGO, V43, P719, DOI 10.1001/archneur.1986.00520070075022; BIRK K, 1990, ARCH NEUROL-CHICAGO, V47, P738, DOI 10.1001/archneur.1990.00530070026007; CONFAVREUX C, 1992, J NEUROL NEUROSUR PS, V55, P671, DOI 10.1136/jnnp.55.8.671; CONFAVREUX C, 1980, BRAIN, V103, P281, DOI 10.1093/brain/103.2.281; DOUGLASS LH, 1948, AM J OBSTET GYNECOL, V55, P332, DOI 10.1016/S0002-9378(16)39356-5; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; FOG T, 1970, ACTA NEUROL SCAND, V46, P1; FRITH JA, 1988, J NEUROL NEUROSUR PS, V51, P495, DOI 10.1136/jnnp.51.4.495; GHEZZI A, 1981, EUR NEUROL, V20, P115, DOI 10.1159/000115217; Hench P.S., 1938, P STAFF M MAYO CLIN, V13, P161; HUGHES RAC, 1988, LANCET, V2, P179; HUTCHINSON M, 1993, J NEUROL NEUROSUR PS, V56, P1043, DOI 10.1136/jnnp.56.10.1043; Jacobs LD, 1996, ANN NEUROL, V40, P480; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; KORNLUBETZKI I, 1984, ANN NEUROL, V16, P229, DOI 10.1002/ana.410160211; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LEIBOWITZ U, 1967, J NEUROL NEUROSUR PS, V30, P354, DOI 10.1136/jnnp.30.4.354; MILLAR JHD, 1959, BRAIN, V82, P417, DOI 10.1093/brain/82.3.417; NELSON LM, 1988, JAMA-J AM MED ASSOC, V259, P3441, DOI 10.1001/jama.259.23.3441; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POSER S, 1979, ACTA NEUROL SCAND, V59, P108; POSER S, 1983, NEUROLOGY, V33, P1422, DOI 10.1212/WNL.33.11.1422; ROULLET E, 1993, J NEUROL NEUROSUR PS, V56, P1062, DOI 10.1136/jnnp.56.10.1062; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SADOVNICK AD, 1994, ARCH NEUROL-CHICAGO, V51, P1120, DOI 10.1001/archneur.1994.00540230058013; SCHAPIRA K, 1966, BRAIN, V89, P419, DOI 10.1093/brain/89.3.419; *SPSS, 1994, STAT PCK SOC SCI REL; SWEENEY WJ, 1953, AM J OBSTET GYNECOL, V66, P124, DOI 10.1016/0002-9378(53)90294-4; TILLMAN A J B, 1950, Res Publ Assoc Res Nerv Ment Dis, V28, P548; TINCANI A, 1991, LANCET, V338, P756, DOI 10.1016/0140-6736(91)91474-9; VANWALDERVEEN MAA, 1994, NEUROLOGY, V44, P327, DOI 10.1212/WNL.44.2.327; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WEI LJ, 1985, BIOMETRIKA, V72, P359; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; WORTHINGTON J, 1994, J NEUROL, V241, P228, DOI 10.1007/BF00863773	38	1073	1098	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1998	339	5					285	291		10.1056/NEJM199807303390501	http://dx.doi.org/10.1056/NEJM199807303390501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104TL	9682040				2022-12-28	WOS:000075031400001
J	Thorogood, M; Armstrong, B; Nichols, T; Hollowell, J				Thorogood, M; Armstrong, B; Nichols, T; Hollowell, J			Mortality in people taking selegiline: observational study	BRITISH MEDICAL JOURNAL			English	Article								Objective: To evaluate mortality among patients with Parkinson's disease receiving different treatment Design: Cohort study based on computerised medical records. Setting: UK General Practice Research Database, Subjects: 12 621 patients aged between 35 and 90 years who had received a prescription for an antiparkinsonian drug, whether or not a diagnosis of Parkinson's disease had been recorded. Patients prescribed an antipsychotic drug before or at the same time as their first antiparkinsonian drug or before age 35 were excluded to avoid including drug-induced Parkinsonism. Main outcome measure: Death from any cause. Results: 1720 deaths occurred during 14 000 person-pars of observation. There was a non-significant 11% (95% confidence interval 0% to 23%) increase in the risk of death associated with taking selegiline either alone or in combination with levodopa. The death rate was higher among younger patients (aged under 80 years) and these with a recorded diagnosis of Parkinson's disease taking selegiline alone. Conclusions: The results are compatible with a small excess mortality in people taking selegiline and suggest a larger excess in patients under SO years of age and those with a confirmed diagnosis of Parkinson's disease taking selegiline without levodopa.	Univ London London Sch Hyg & Trop Med, Hlth Promot Res Unit, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Environm Epidemiol Unit, London WC1E 7HT, England; Off Natl Stat, London SW1V 2QQ, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Thorogood, M (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Promot Res Unit, Keppel St, London WC1E 7HT, England.		Hollowell, Jennifer/B-5052-2009	Hollowell, Jennifer/0000-0002-4041-5732; armstrong, benedict/0000-0003-4407-0409				Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; HOLLOWELL J, 1997, POPULATION TRENDS, P87; Lees AJ, 1995, BRIT MED J, V311, P1602, DOI 10.1136/bmj.311.7020.1602; McCormick A, 1995, SERIES MB5, V3; *OFF POP CENS SURV, 1990, LONG STUD MORT SOC O; *PARK DIS RES GROU, 1993, BRIT MED J, V307, P169	6	32	32	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					252	254		10.1136/bmj.317.7153.252	http://dx.doi.org/10.1136/bmj.317.7153.252			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677215	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000075081900022
J	Hendrix, RW				Hendrix, RW			Bacteriophage DNA packaging: RNA gears in a DNA transport machine	CELL			English	Review							PORTAL PROTEIN; SYMMETRY; ATPASE; GENE		Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hendrix, RW (corresponding author), Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA.							Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BLACK LW, 1988, BACTERIOPHAGES, V2, P321; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; CASJENS S, 1992, J MOL BIOL, V224, P1055, DOI 10.1016/0022-2836(92)90469-Z; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; KAISER D, 1975, J MOL BIOL, V91, P175, DOI 10.1016/0022-2836(75)90158-8; LUFTIG RB, 1971, J MOL BIOL, V57, P555, DOI 10.1016/0022-2836(71)90109-4; Luria SE, 1942, P NATL ACAD SCI USA, V28, P127, DOI 10.1073/pnas.28.4.127; TAVARES P, 1992, J MOL BIOL, V225, P81, DOI 10.1016/0022-2836(92)91027-M; Trottier M, 1997, J VIROL, V71, P487, DOI 10.1128/JVI.71.1.487-494.1997; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9	16	88	97	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					147	150		10.1016/S0092-8674(00)81413-0	http://dx.doi.org/10.1016/S0092-8674(00)81413-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695942	Bronze			2022-12-28	WOS:000075020100002
J	Keenan, RJ; Freymann, DM; Walter, P; Stroud, RM				Keenan, RJ; Freymann, DM; Walter, P; Stroud, RM			Crystal structure of the signal sequence binding subunit of the signal recognition particle	CELL			English	Article							METHIONINE-RICH DOMAIN; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; DNA RECOGNITION; PEPTIDE COMPLEX; GTP HYDROLYSIS; 4.5S RNA; SRP; CALMODULIN	The crystal structure of the signal sequence binding subunit of the signal recognition particle (SRP) from Thermus aquaticus reveals a deep groove bounded by a flexible loop and lined with side chains of conserved hydrophobic residues. The groove defines a flexible, hydrophobic environment that is likely to contribute to the structural plasticity necessary for SRP to bind signal sequences of different lengths and amino acid sequence. The structure also reveals a helix-turn-helix motif containing an arginine-rich alpha helix that is required for binding to SRP RNA and is implicated in forming the core of an extended RNA binding surface.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Keenan, RJ (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda M./0000-0001-5242-8015; Keenan, Robert/0000-0003-1466-0889; Freymann, Douglas/0000-0002-5231-8841	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024485, R37GM032384, R01GM032384] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09270] Funding Source: Medline; NIGMS NIH HHS [GM-32384, GM-24485] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHOFF S, 1994, NUCLEIC ACIDS RES, V22, P1933, DOI 10.1093/nar/22.11.1933; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BRENNAN R, 1992, CURR OPIN STRUC BIOL, V2, P100; BRUNGER AT, 1996, XPLOR VERSION 3843; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KLEYWEGT GJ, 1994, 1 MAP FINAL MODEL; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurita K, 1996, J BIOL CHEM, V271, P13140, DOI 10.1074/jbc.271.22.13140; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lentzen G, 1996, RNA, V2, P244; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MILLER MS, 1994, INT J ONCOL, V4, P5; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Newitt JA, 1997, EUR J BIOCHEM, V245, P720, DOI 10.1111/j.1432-1033.1997.00720.x; NICHOLLS A, 1992, GRASP MANUAL; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Schmitz U, 1996, RNA, V2, P1213; STEITZ TA, 1982, P NATL ACAD SCI-BIOL, V79, P3097, DOI 10.1073/pnas.79.10.3097; Takamatsu H, 1997, EUR J BIOCHEM, V248, P575, DOI 10.1111/j.1432-1033.1997.00575.x; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	63	227	229	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					181	191		10.1016/S0092-8674(00)81418-X	http://dx.doi.org/10.1016/S0092-8674(00)81418-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695947	Bronze, Green Published			2022-12-28	WOS:000075020100007
J	McNiven, MA				McNiven, MA			Dynamin: A molecular motor with pinchase action	CELL			English	Review							ENDOCYTOSIS; VESICLES; RINGS		Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA.							Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; Llorente A, 1998, J CELL BIOL, V140, P553, DOI 10.1083/jcb.140.3.553; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; RAMBOURG A, 1981, METHOD CELL BIOL, V23, P155, DOI 10.1016/S0091-679X(08)61497-1; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	22	156	159	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					151	154		10.1016/S0092-8674(00)81414-2	http://dx.doi.org/10.1016/S0092-8674(00)81414-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695943	Bronze			2022-12-28	WOS:000075020100003
J	Pivniouk, V; Tsitsikov, E; Swinton, P; Rathbun, G; Alt, FW; Geha, RS				Pivniouk, V; Tsitsikov, E; Swinton, P; Rathbun, G; Alt, FW; Geha, RS			Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76	CELL			English	Article							T-CELL DEVELOPMENT; TYROSINE KINASE; MUTANT MICE; ALPHA-BETA; LYMPHOCYTE DEVELOPMENT; THYMIC SELECTION; TCR-BETA; B-CELLS; GENE; DIFFERENTIATION	The adaptor protein SLP-76 is expressed in T lymphocytes and myeloid cells and is a substrate for ZAP-70 and Syk. We generated a SLP-76 null mutation in mice by homologous recombination in embryonic stem cells to evaluate the role of SLP-76 in T cell development and activation. SLP-76-deficient mice exhibited subcutaneous and intraperitoneal hemorrhaging and impaired viability. Analysis of lymphoid cells revealed a profound block in thymic development with absence of double-positive CD4(+)8(+) thymocytes and of peripheral T cells. This block could not be overcome by in vivo treatment with anti-CD3. V-D-J rearrangement of the TCR beta locus was not obviously affected. B cell development was normal. These results indicate that SLP-76 collects all pre-TCR signals that drive the development and expansion of double-positive thymocytes.	Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute	Geha, RS (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aifantis I, 1997, IMMUNITY, V7, P601, DOI 10.1016/S1074-7613(00)80381-7; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Ardouin L, 1998, J EXP MED, V187, P105, DOI 10.1084/jem.187.1.105; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; daSilva AJ, 1997, BIOCHEM SOC T, V25, P361, DOI 10.1042/bst0250361; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fehling HJ, 1997, IMMUNITY, V6, P703, DOI 10.1016/S1074-7613(00)80446-X; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hollander GA, 1996, P NATL ACAD SCI USA, V93, P4994, DOI 10.1073/pnas.93.10.4994; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; LEVELT CN, 1995, IMMUNITY, V3, P215, DOI 10.1016/1074-7613(95)90091-8; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WALLACE VA, 1995, EUR J IMMUNOL, V25, P1312, DOI 10.1002/eji.1830250527; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	53	317	323	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					229	238		10.1016/S0092-8674(00)81422-1	http://dx.doi.org/10.1016/S0092-8674(00)81422-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695951	Bronze			2022-12-28	WOS:000075020100011
J	Liefers, GJ; Cleton-Jansen, AM; van de Velde, CJH; Hermans, J; van Krieken, JHJM; Cornelisse, CJ; Tollenaar, RAEM				Liefers, GJ; Cleton-Jansen, AM; van de Velde, CJH; Hermans, J; van Krieken, JHJM; Cornelisse, CJ; Tollenaar, RAEM			Micrometastases and survival in stage II colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; LYMPH-NODE MICROMETASTASES; PROGNOSTIC-SIGNIFICANCE; REVERSE-TRANSCRIPTASE; GENETIC DIAGNOSIS; ALLELIC LOSS; TUMOR-CELLS; CARCINOMA; IDENTIFICATION; THERAPY	Background Standard treatment of colorectal cancer includes adjuvant chemotherapy for patients with stage III disease (defined by the presence of lymphnode metastases), but not for patients with stage II tumors (who have no lymph-node metastases). However, 20 percent of patients with stage II tumors die of recurrent disease. We investigated whether the detection of micrometastases can be used to identify patients with stage II disease who are at high risk for recurrence. Methods We analyzed 192 lymph nodes from 26 consecutive patients with stage II colorectal cancer, using a carcinoembryonic antigen-specific nested reverse-transcriptase polymerase chain reaction. Five-year follow-up information was obtained on all patients. Observed and adjusted survival rates were assessed in the patients with and the patients without micrometastases. Results Micrometastases were detected in one or more lymph nodes from 14 of 26 patients (54 percent). The adjusted five-year survival rate (for which only cancer-related deaths were considered) was 50 percent in this group, whereas in the 12 patients without micrometastases, the survival rate was 91 percent (P=0.02 by the log-rank test). The observed five-year survival rates were 36 percent and 75 percent, respectively (P=0.03). The groups were similar with respect to age, sex, tumor side (location in relation to the flexura lienalis), degree of tumor differentiation (grade), and diameter of the primary tumor. Conclusions Molecular detection of micrometastases is a prognostic tool in stage II colorectal cancer. (N Engl J Med 1998;339:223-8.) (C)1998, Massachusetts Medical Society.	Leiden Univ, Med Ctr, Dept Surg K6R, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Tollenaar, RAEM (corresponding author), Leiden Univ, Med Ctr, Dept Surg K6R, POB 9600, NL-2300 RC Leiden, Netherlands.		van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040				Adell G, 1996, EUR J SURG, V162, P637; [Anonymous], 1997, J CLIN PATHOL; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX DR, 1972, J R STAT SOC B, V34, P187; CUTAIT R, 1991, DIS COLON RECTUM, V34, P917, DOI 10.1007/BF02049708; GERHARD M, 1994, J CLIN ONCOL, V12, P725, DOI 10.1200/JCO.1994.12.4.725; GOLDHIRSCH A, 1990, LANCET, V335, P1565; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; Gunn J, 1996, LAB INVEST, V75, P611; HAYASHI N, 1994, CANCER RES, V54, P3853; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; HERMANEK P, 1995, WORLD J SURG, V19, P184, DOI 10.1007/BF00308624; Izbicki JR, 1997, NEW ENGL J MED, V337, P1188, DOI 10.1056/NEJM199710233371702; JASS JR, 1986, HISTOPATHOLOGY, V10, P437, DOI 10.1111/j.1365-2559.1986.tb02497.x; JEFFERS MD, 1994, J PATHOL, V172, P183, DOI 10.1002/path.1711720205; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KERN SE, 1989, JAMA-J AM MED ASSOC, V262, P1952; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MORI M, 1995, CANCER RES, V55, P3417; Nakamori S, 1997, DIS COLON RECTUM, V40, pS29, DOI 10.1007/BF02062017; NEUMAIER M, 1995, GENE, V159, P43, DOI 10.1016/0378-1119(94)00522-T; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; SCHOENFELD A, 1994, CANCER RES, V54, P2986; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G	31	528	556	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					223	228		10.1056/NEJM199807233390403	http://dx.doi.org/10.1056/NEJM199807233390403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673300				2022-12-28	WOS:000074918700003
J	Goldman, L				Goldman, L			A 75-year-old woman with an abdominal aortic aneurysm and emphysema	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC RISK ASSESSMENT; VASCULAR-SURGERY; SURGICAL-PROCEDURES; CORONARY-DISEASE; MANAGEMENT; PREDICTION; MORTALITY; COMPLICATIONS; MORBIDITY; INDEX		Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goldman, L (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							Aadahl P, 1997, J ENDOVASC SURG, V4, P56, DOI 10.1583/1074-6218(1997)004<0056:RAFETO>2.0.CO;2; BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; Blum U, 1997, NEW ENGL J MED, V336, P13, DOI 10.1056/NEJM199701023360103; BROWN PM, 1992, J VASC SURG, V15, P21, DOI 10.1016/0741-5214(92)70009-A; Coselli JS, 1997, ANN THORAC SURG, V64, P639, DOI 10.1016/S0003-4975(97)00618-8; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; Eagle KA, 1997, CIRCULATION, V96, P1882, DOI 10.1161/01.CIR.96.6.1882; Eagle KA, 1996, CIRCULATION, V93, P1278; Ellis SG, 1996, AM J CARDIOL, V77, P1126, DOI 10.1016/S0002-9149(96)00130-0; ERNST CB, 1993, NEW ENGL J MED, V328, P1167; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; Gorecka D, 1997, THORAX, V52, P674, DOI 10.1136/thx.52.8.674; HOLLIER LH, 1992, J VASC SURG, V15, P1046, DOI 10.1016/0741-5214(92)90462-H; Isselbacher E, 1997, HEART DIS TXB CARDIO, P1546; JEFFREY CC, 1983, ANESTHESIOLOGY, V58, P462, DOI 10.1097/00000542-198305000-00013; JOHNSTON KW, 1989, J VASC SURG, V9, P437, DOI 10.1067/mva.1989.vs0090437; KATZ DA, 1994, J VASC SURG, V19, P980, DOI 10.1016/S0741-5214(94)70209-8; KATZ DA, 1992, JAMA-J AM MED ASSOC, V268, P2678, DOI 10.1001/jama.268.19.2678; Koskas F, 1997, ANN VASC SURG, V11, P473, DOI 10.1007/s100169900078; Koskas F, 1997, ANN VASC SURG, V11, P90, DOI 10.1007/s100169900016; KROENKE K, 1992, ARCH INTERN MED, V152, P967, DOI 10.1001/archinte.152.5.967; LARSEN SF, 1987, EUR HEART J, V8, P179, DOI 10.1093/oxfordjournals.eurheartj.a062246; Lawrence VA, 1996, CHEST, V110, P744, DOI 10.1378/chest.110.3.744; LETTE J, 1992, ANN SURG, V216, P192, DOI 10.1097/00000658-199208000-00010; LItalien GJ, 1996, J AM COLL CARDIOL, V27, P779, DOI 10.1016/0735-1097(95)00566-8; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Mangione CM, 1997, J GEN INTERN MED, V12, P686, DOI 10.1046/j.1525-1497.1997.07142.x; Martin E, 1997, ANESTHESIOLOGY, V86, P346; Mialhe C, 1997, J VASC SURG, V26, P199, DOI 10.1016/S0741-5214(97)70180-0; MICHEL LA, 1990, J THORAC CARDIOV SUR, V100, P595; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; Paty PSK, 1997, J VASC SURG, V25, P442, DOI 10.1016/S0741-5214(97)70253-2; POLDERMANS D, 1995, J AM COLL CARDIOL, V26, P648, DOI 10.1016/0735-1097(95)00240-5; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; Reed WW, 1997, ARCH INTERN MED, V157, P2064, DOI 10.1001/archinte.157.18.2064; SCOTT RAP, 1993, LANCET, V342, P1395, DOI 10.1016/0140-6736(93)92756-J; STEYERBERG EW, 1995, ARCH INTERN MED, V155, P1998, DOI 10.1001/archinte.155.18.1998; Tsevat J, 1998, JAMA-J AM MED ASSOC, V279, P371, DOI 10.1001/jama.279.5.371; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; vanderVliet JA, 1997, LANCET, V349, P863; ZELDIN RA, 1984, CAN J SURG, V27, P402; Zielinski J, 1997, Monaldi Arch Chest Dis, V52, P43	45	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					366	372		10.1001/jama.280.4.366	http://dx.doi.org/10.1001/jama.280.4.366			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686555				2022-12-28	WOS:000074804200038
J	Winkleby, MA; Kraemer, HC; Ahn, DK; Varady, AN				Winkleby, MA; Kraemer, HC; Ahn, DK; Varady, AN			Ethnic and socioeconomic differences in cardiovascular disease risk factors - Findings for women from the third national health and nutrition examination survey, 1988-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DEPENDENT DIABETES-MELLITUS; STANFORD 5-CITY PROJECT; NON-HISPANIC WHITES; MEXICAN-AMERICANS; UNITED-STATES; COMMUNITY INTERVENTION; SOCIAL INEQUALITIES; PREVALENCE; MORTALITY	Context.-Cardiovascular disease (CVD) risk factors are higher among ethnic minority women than among white women in the United States. However, because ethnic minority women are disproportionately poor, socioeconomic status (SES) may substantially explain these risk factor differences. Objective.-To determine whether differences in CVD risk factors by ethnicity could be attributed to differences in SES. Design.-Third National Health and Nutrition Examination Survey conducted between 1988 and 1994. Setting.-Eighty-nine mobile examination centers. Participants.-A total of 1762 black, 1481 Mexican American, and 2023 white women, aged 25 to 64 years, who completed both the home questionnaire and medical examination. Main Outcome Measures.-Ethnicity and years of education (SES) in relation to systolic blood pressure, cigarette smoking, body mass index (BMI, a measure of weight in kilograms divided by the square of height in meters), physical inactivity, non-high-density lipoprotein cholesterol (non-HDL-C [the difference between total cholesterol and HDL-C]), and non-insulin-dependent diabetes mellitus. Results.-As expected, most CVD risk factors were higher among ethnic minority women than among white women. After adjusting for years of education, highly significant differences in blood pressure, BMI, physical inactivity, and diabetes remained for both black and Mexican American women compared with white women (P<.001). In addition, women of lower SES from each of the 3 ethnic groups had significantly higher prevalences of smoking and physical inactivity and higher levels of BMI and non-HDL-C than women of higher SES (P<.001). Conclusions.-These findings provide the greatest evidence to date of higher CVD risk factors among black and Mexican American women than among white women of comparable SES. The striking differences by both ethnicity and SES underscore the critical need to improve screening, early detection, and treatment of CVD-related conditions for black and Mexican American women, as well as for women of lower SES in all ethnic groups.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Winkleby, MA (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, 1000 Welch Rd, Palo Alto, CA 94304 USA.	marilyn_winkleby@scrdp.stanford.edu			NHLBI NIH HHS [1-RO3-HL-57100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL057100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Anderson NB, 1995, HEALTH PSYCHOL, V14, P589, DOI 10.1037/0278-6133.14.7.589; ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; BOYKO EJ, 1991, DIABETES, V40, P509, DOI 10.2337/diabetes.40.4.509; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CARLETON RA, 1995, AM J PUBLIC HEALTH, V85, P777, DOI 10.2105/AJPH.85.6.777; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; COWIE CC, 1993, AM J EPIDEMIOL, V137, P719, DOI 10.1093/oxfordjournals.aje.a116732; CUMMINGS SR, 1988, AM J PUBLIC HEALTH, V78, P574, DOI 10.2105/AJPH.78.5.574; DAY JC, 1996, P251130 US BUR CENS; DIEHL AK, 1989, ADV INTERNAL MED, V34, P79; DIEZROUX AV, 1995, AM J EPIDEMIOL, V141, P960, DOI 10.1093/oxfordjournals.aje.a117363; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FINUCANE TE, 1990, J GEN INTERN MED, V5, P120, DOI 10.1007/BF02600511; FORTMANN SP, 1995, AM J EPIDEMIOL, V142, P576, DOI 10.1093/oxfordjournals.aje.a117678; FRANCO LJ, 1985, AM J EPIDEMIOL, V121, P684, DOI 10.1093/aje/121.5.684; FRANK E, 1992, JAMA-J AM MED ASSOC, V268, P1566, DOI 10.1001/jama.268.12.1566; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gidding SS, 1996, AM J CARDIOL, V78, P304, DOI 10.1016/S0002-9149(96)00282-2; GILES WH, 1993, JAMA-J AM MED ASSOC, V269, P1133, DOI 10.1001/jama.269.9.1133; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; Goff DC, 1997, CIRCULATION, V95, P1433; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAFFNER SM, 1993, HYPERTENSION, V21, P83, DOI 10.1161/01.HYP.21.1.83; HAMMAN RF, 1989, AM J EPIDEMIOL, V129, P295, DOI 10.1093/oxfordjournals.aje.a115134; HAVEL RJ, 1995, NEW ENGL J MED, V332, P1491, DOI 10.1056/NEJM199506013322207; HENDEE WR, 1991, JAMA-J AM MED ASSOC, V265, P248; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KAUTZ JA, 1981, CIRCULATION, V64, P730, DOI 10.1161/01.CIR.64.4.730; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KELSEY JL, 1986, METHODS OBSERVATIONA; KRIEGER N, 1993, AM J PUBLIC HEALTH, V83, P1086, DOI 10.2105/AJPH.83.8.1086; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUMANYIKA SK, 1993, ANN INTERN MED, V119, P650, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00005; LIAO Y, 1995, PUBLIC HEALTH REP, V110, P572; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; LUEPKER RV, 1993, CIRCULATION, V88, P2172, DOI 10.1161/01.CIR.88.5.2172; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; LYNCH J, 1995, CIRCULATION, V92, P1786, DOI 10.1161/01.CIR.92.7.1786; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MARIN G, 1993, PUBLIC HEALTH REP, V108, P546; MARMOT MG, 1986, LANCET, V2, P274; MARTIN DC, 1993, STAT MED, V12, P329, DOI 10.1002/sim.4780120315; MCDOWELL A, 1981, VITAL HLTH STAT, V1; MILLER HW, 1977, VITAL HLTH STAT, V1; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; Mitchell BD, 1996, CIRCULATION, V94, P2159, DOI 10.1161/01.CIR.94.9.2159; Molina C, 1994, LATINO HLTH US GROWI, P23; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V1; *NAT HEART LUNG BL, 1995, C SOC STAT CARD HLTH; NAUMBURG EH, 1993, J FAM PRACTICE, V36, P425; *PHS, 1990, DHHS PUBL; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; PUGH JA, 1988, J GEN INTERN MED, V3, P331, DOI 10.1007/BF02595790; Ramirez AG, 1996, PUBLIC HEALTH REP, V111, P25; REESE JW, 1977, HEW CDC PUBLICATION; REYNES JF, 1993, AM J PREV MED, V9, P365, DOI 10.1016/S0749-3797(18)30689-5; SHAH BV, 1991, SUDAAN USERS MANUAL; SHEA S, 1991, AM J EPIDEMIOL, V134, P567, DOI 10.1093/oxfordjournals.aje.a116130; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SORLIE PD, 1993, JAMA-J AM MED ASSOC, V270, P2464, DOI 10.1001/jama.270.20.2464; SPRAFKA JM, 1988, AM J PUBLIC HEALTH, V78, P1546, DOI 10.2105/AJPH.78.12.1546; Stafford RS, 1997, J AM COLL CARDIOL, V29, P139, DOI 10.1016/S0735-1097(96)00441-X; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STERN MP, 1984, AM J EPIDEMIOL, V120, P834, DOI 10.1093/oxfordjournals.aje.a113956; Syme SL, 1996, ANN EPIDEMIOL, V6, P463, DOI 10.1016/S1047-2797(96)00097-X; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEPT HHS, 1989, DHHS PUBL, pCH6; VEGA WA, 1994, ANNU REV PUBL HEALTH, V15, P39, DOI 10.1146/annurev.pu.15.050194.000351; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WENNEKER MB, 1987, JAMA-J AM MED ASSOC, V261, P253; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025; Winkleby MA, 1997, ANN EPIDEMIOL, V7, pS96, DOI 10.1016/S1047-2797(97)80012-9; Winkleby MA, 1997, J CLIN EPIDEMIOL, V50, P645, DOI 10.1016/S0895-4356(97)00020-6; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P1369, DOI 10.2105/AJPH.84.9.1369; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Winkleby MA, 1996, PREV MED, V25, P203, DOI 10.1006/pmed.1996.0047	87	438	441	1	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					356	362		10.1001/jama.280.4.356	http://dx.doi.org/10.1001/jama.280.4.356			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	100FC	9686553	Bronze			2022-12-28	WOS:000074804200036
J	Poortmans, JR; Francaux, M				Poortmans, JR; Francaux, M			Renal dysfunction accompanying oral creatine supplements - reply	LANCET			English	Letter									Free Univ Brussels, Inst Super Educ Phys & Kinesitherapie, B-1000 Brussels, Belgium; Univ Catholique Louvain, Inst Educ & Readaptat, B-1348 Louvain La Neuve, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain	Poortmans, JR (corresponding author), Free Univ Brussels, Inst Super Educ Phys & Kinesitherapie, 808 Route Lennik, B-1000 Brussels, Belgium.		Francaux, Marc/C-5594-2008	Francaux, Marc/0000-0001-8182-1588				MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Mujika I, 1997, INT J SPORTS MED, V18, P491, DOI 10.1055/s-2007-972670; Poortmans JR, 1997, EUR J APPL PHYSIOL O, V76, P566, DOI 10.1007/s004210050291; Pritchard NR, 1998, LANCET, V351, P1252, DOI 10.1016/S0140-6736(05)79319-3	4	33	37	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					234	234		10.1016/S0140-6736(05)77836-3	http://dx.doi.org/10.1016/S0140-6736(05)77836-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683236				2022-12-28	WOS:000074859800053
J	Wang, QA; Zhang, BH				Wang, QA; Zhang, BH			Research design and statistical methods in Chinese medical journals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			CLINICAL RESEARCH; ARTICLES; BIOSTATISTICS	Context.-Study design and statistical analyses have improved in journals published in Western countries, but the type of research designs and statistical methods used in medical journals outside Western countries has not been assessed. Objectives.-To determine the frequency of research designs and statistical techniques used in Chinese medical journals, types of statistical errors present, and trends over a 10-year period. Design.-Evaluation of all original articles published in 5 leading journals in 1985 (N = 640) and in 1995 (N = 954). Main Outcome Measures.-Research designs and statistical methods. Results.-Compared with 1985, significant improvement was seen in 1995; the percentages of original articles reporting clinical trials, prospective studies, or basic science research increased from 18% to 31% (P < .001), the proportion of papers using statistical tests increased from 40% to 60% (P < .001), more sophisticated statistical methods were used, and of those articles using statistics, the proportion using appropriate methods increased from 22% to 46% (P < .001). In both years, the most commonly used statistical methods were t tests and contingency tables. The most common errors were presentation of P values without specifying the test used, use of multiple t tests instead of analysis of variance, and use of unpaired t tests when paired tests were required. Conclusions.-The use of statistical methods in Chinese medical journals research is improving, and by 1995, the frequency of using statistical methods in published articles was similar to the results determined in previous studies of journals. However, the lack of or inappropriate use of statistics remains a serious problem.	Shanghai Med Univ, Hua Shan Hosp, Clin Epidemiol Unit, Shanghai 200040, Peoples R China; Zhong Shan Hosp, Liver Canc Inst, Shanghai, Peoples R China; Shanghai Med Univ, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Wang, QA (corresponding author), Shanghai Med Univ, Hua Shan Hosp, Clin Epidemiol Unit, Shanghai 200040, Peoples R China.							AVRAM MJ, 1985, ANESTH ANALG, V64, P607; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; EMERSON JD, 1983, NEW ENGL J MED, V309, P709, DOI 10.1056/NEJM198309223091206; FEINSTEIN AR, 1974, CLIN PHARMACOL THER, V15, P97; FLETCHER RH, 1979, NEW ENGL J MED, V301, P180, DOI 10.1056/NEJM197907263010403; JUZYCH MS, 1992, ARCH OPHTHALMOL-CHIC, V110, P1225, DOI 10.1001/archopht.1992.01080210043020; KANTER MH, 1994, TRANSFUSION, V34, P697, DOI 10.1046/j.1537-2995.1994.34894353466.x; MCDERMOTT MM, 1995, J GEN INTERN MED, V10, P13, DOI 10.1007/BF02599570; MORRIS RW, 1988, J BONE JOINT SURG BR, V70, P242, DOI 10.1302/0301-620X.70B2.3346297; ROSENFELD RM, 1991, ARCH OTOLARYNGOL, V117, P1172; Schwartz SJ, 1996, ARCH PHYS MED REHAB, V77, P497, DOI 10.1016/S0003-9993(96)90040-4; Wainapel SF, 1985, ARCH PHYS MED REHAB, V66, P332	12	33	40	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					283	285		10.1001/jama.280.3.283	http://dx.doi.org/10.1001/jama.280.3.283			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676683	Bronze			2022-12-28	WOS:000074706000028
J	Stables, RH				Stables, RH			Routine use of abciximab in coronary stenting?	LANCET			English	Editorial Material							BALLOON ANGIOPLASTY; ARTERY DISEASE; PLACEMENT		Royal Brompton Hosp, London SW3 6NP, England	Royal Brompton Hospital	Stables, RH (corresponding author), Royal Brompton Hosp, London SW3 6NP, England.			Stables, Rodney Hilton/0000-0002-9244-7015				CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; *CAPTURE INV, 1997, LANCET, V349, P435; *CAPTURE INV, 1997, LANCET, V350, P744; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Topol EJ, 1997, NEW ENGL J MED, V336, P1689	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					81	82		10.1016/S0140-6736(98)85003-4	http://dx.doi.org/10.1016/S0140-6736(98)85003-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672267				2022-12-28	WOS:000074775100003
J	Bradley, KA; Boyd-Wickizer, J; Powell, SH; Burman, ML				Bradley, KA; Boyd-Wickizer, J; Powell, SH; Burman, ML			Alcohol screening questionnaires in women - A critical review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRIMARY-CARE PATIENTS; RISK-DRINKING; INTERVIEW SCHEDULE; LABORATORY TESTS; EMERGENCY ROOM; DSM-IV; ABUSE; CONSUMPTION; DEPENDENCE; POPULATION	Objective.-To describe the performance of alcohol screening questionnaires in female patients. Data Sources.-We searched MEDLINE from 1966 to July 1997 for alcoholism or alcohol-drinking and for CAGE, AUDIT, BMAST, TWEAK, T-ACE, MAST, SMAST, or SAAST; Citations Indexes for newer screening questionnaires and those without acronyms; and MEDLINE from 1996 to July 1997 for alcoholism or alcohol-drinking and screening. Study Selection and Data Extraction.-Reviewed studies presented data for women comparing brief alcohol screening questionnaires with valid criterion standards for heavy drinking (greater than or equal to 2 drinks per day) or alcohol abuse or dependence in US general clinical populations. Sensitivities, specificities, and areas under receiver operating characteristic curves (AUROCs) were extracted. Data Synthesis.-Thirteen articles (9 studies) were reviewed. The CAGE questionnaire had AUROCs of 0.84 to 0.92 for alcohol abuse and dependence in predominantly black populations of women, but using the traditional cut point of 2 or more resulted in low sensitivities (38%-50%) in predominantly white female populations. The TWEAK and Alcohol Use Disorders Identification Test (AUDIT) questionnaires had high AUROCs (0.87-0.93) for past-year alcohol abuse or dependence in black or white women, but had sensitivities less than 80% at traditional cut points. For detecting heavy drinking, the AUDIT questionnaire had AUROCs of at least 0.87 in female primary care patients. The TWEAK and T-ACE questionnaires had higher AUROCs (0.84-0.87) than the CAGE questionnaire (0.76-0.78) for detecting heavy drinking before pregnancy was recognized in black obstetric patients. Conclusions.-The CAGE questionnaire was relatively insensitive in predominantly white female populations. The TWEAK and AUDIT questionnaires have performed adequately in black or white women, using lower cut points than usual.	VA Puget Sound Hlth Care Syst, Seattle Div, Hlth Serv Res & Dev, Seattle, WA 98108 USA; VA Puget Sound Hlth Care Syst, Seattle Div, Med Serv, Seattle, WA 98108 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bradley, KA (corresponding author), VA Puget Sound Hlth Care Syst, Seattle Div, Hlth Serv Res & Dev, 1660 S Columbian Way,Mail Stop 152, Seattle, WA 98108 USA.	bradley.katharine_a@seattle.va.gov						Adams WL, 1996, JAMA-J AM MED ASSOC, V276, P1964; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; Barry K L, 1990, J Am Board Fam Pract, V3, P93; Becker U, 1996, HEPATOLOGY, V23, P1025, DOI 10.1002/hep.510230513; Bradley KA, 1998, J GEN INTERN MED, V13, P379, DOI 10.1046/j.1525-1497.1998.00118.x; BUCHSBAUM D, 1992, ANN INTERN MED, V116, P1032, DOI 10.7326/0003-4819-116-12-1032; BUCHSBAUM DG, 1991, ALCOHOL ALCOHOLISM, V26, P215, DOI 10.1093/oxfordjournals.alcalc.a045103; BUCHSBAUM DG, 1992, J GEN INTERN MED, V7, P517, DOI 10.1007/BF02599456; BUCHSBAUM DG, 1992, J AM GERIATR SOC, V40, P662, DOI 10.1111/j.1532-5415.1992.tb01956.x; BUCHSBAUM DG, 1995, ARCH INTERN MED, V155, P104, DOI 10.1001/archinte.155.1.104; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; BUCHSBAUM DG, 1993, ARCH INTERN MED, V153, P1573, DOI 10.1001/archinte.153.13.1573; CHAN AWK, 1993, ALCOHOL CLIN EXP RES, V17, P1188, DOI 10.1111/j.1530-0277.1993.tb05226.x; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; CHERPITEL CJ, 1995, ALCOHOL CLIN EXP RES, V19, P628, DOI 10.1111/j.1530-0277.1995.tb01559.x; CHERPITEL CJ, 1995, J STUD ALCOHOL, V56, P695, DOI 10.15288/jsa.1995.56.695; CONNORS GJ, 1995, ASSESSING ALCOHOL PR, P17; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; DAHLGREN L, 1989, ALCOHOL CLIN EXP RES, V13, P499, DOI 10.1111/j.1530-0277.1989.tb00366.x; DAWSON DA, 1994, ADDICTION, V89, P345, DOI 10.1111/j.1360-0443.1994.tb00901.x; FLEMING MF, 1991, ALCOHOL ALCOHOLISM, V26, P81; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; GOMBERG ESL, 1988, ALCOHOL ALCOHOLISM, V23, P507; GRANT BF, 1994, ALCOHOL HEALTH RES W, V18, P243; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P37, DOI 10.1016/0376-8716(95)01134-K; GRODSTEIN F, 1994, AM J PUBLIC HEALTH, V84, P1429, DOI 10.2105/AJPH.84.9.1429; HALLIDAY A, 1986, OBSTET GYNECOL, V68, P322, DOI 10.1097/00006250-198609000-00006; HARFORD TC, 1994, ADDICTION, V89, P421, DOI 10.1111/j.1360-0443.1994.tb00916.x; HOEKSEMA HL, 1993, J FAM PRACTICE, V37, P268; Holman CDJ, 1996, MED J AUSTRALIA, V164, P141, DOI 10.5694/j.1326-5377.1996.tb122011.x; MORROWTLUCAK M, 1989, ALCOHOL CLIN EXP RES, V13, P399, DOI 10.1111/j.1530-0277.1989.tb00343.x; PERPER MM, 1993, ALCOHOL CLIN EXP RES, V17, P272, DOI 10.1111/j.1530-0277.1993.tb00762.x; ROBBINS C, 1989, J HEALTH SOC BEHAV, V30, P117, DOI 10.2307/2136917; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; RUSSELL M, 1994, ALCOHOL CLIN EXP RES, V18, P1156, DOI 10.1111/j.1530-0277.1994.tb00097.x; Russell M, 1996, AM J PUBLIC HEALTH, V86, P1435, DOI 10.2105/AJPH.86.10.1435; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; SCHUCKIT MA, 1994, ADDICTION, V89, P1629, DOI 10.1111/j.1360-0443.1994.tb03764.x; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; SOKOL RJ, 1989, AM J OBSTET GYNECOL, V160, P863, DOI 10.1016/0002-9378(89)90302-5; SOX HC, 1986, ANN INTERN MED, V104, P60, DOI 10.7326/0003-4819-104-1-60; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; TOBIN MB, 1994, AM J PSYCHIAT, V151, P1503; Volk RJ, 1997, ADDICTION, V92, P197, DOI 10.1046/j.1360-0443.1997.9221978.x; WALKER E, 1988, AM J PSYCHIAT, V145, P75; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WECHSLER H, 1995, AM J PUBLIC HEALTH, V85, P982, DOI 10.2105/AJPH.85.7.982; WEISNER C, 1992, JAMA-J AM MED ASSOC, V268, P1872, DOI 10.1001/jama.268.14.1872; WEISNER C, 1990, DRUG ALCOHOL DEPEN, V26, P93, DOI 10.1016/0376-8716(90)90116-V; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; World Health Organization, 1992, INT CLASS DIS CLIN D; YERSIN B, 1995, ARCH INTERN MED, V155, P1907, DOI 10.1001/archinte.155.17.1907	54	287	290	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					166	171		10.1001/jama.280.2.166	http://dx.doi.org/10.1001/jama.280.2.166			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZY321	9669791				2022-12-28	WOS:000074608400033
J	Gimzewski, JK; Joachim, C; Schlittler, RR; Langlais, V; Tang, H; Johannsen, I				Gimzewski, JK; Joachim, C; Schlittler, RR; Langlais, V; Tang, H; Johannsen, I			Rotation of a single molecule within a supramolecular bearing	SCIENCE			English	Article							RATCHETS	Experimental visualization and verification of a single-molecule rotor operating within a supramolecular bearing is reported. Using a scanning tunneling microscope, single molecules were observed to exist in one of two spatially defined states Laterally separated by 0.26 nanometers. One was identified as a rotating state and the other as an immobilized state. Calculations of the energy barrier for rotation of these two states show that it is below the thermal energy at room temperature for the rotating state and above it for the immobilized state.	IBM Corp, Div Res, Zurich Res Lab, CH-8803 Ruschlikon, Switzerland; CNRS, CEMES, F-31055 Toulouse, France; Riso Natl Lab, Condensed Matter Phys & Chem Dept, DK-4000 Roskilde, Denmark	International Business Machines (IBM); Centre National de la Recherche Scientifique (CNRS); Technical University of Denmark	Gimzewski, JK (corresponding author), IBM Corp, Div Res, Zurich Res Lab, Saumerstr 4, CH-8803 Ruschlikon, Switzerland.	gim@zurich.ibm.com		gimzewski, james/0000-0003-4333-6957				ANELLI PL, 1991, J AM CHEM SOC, V113, P5131, DOI 10.1021/ja00013a096; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; BALLARDINI R, 1993, ANGEW CHEM INT EDIT, V32, P1301, DOI 10.1002/anie.199313011; CHAVY C, 1993, CHEM PHYS LETT, V214, P569, DOI 10.1016/0009-2614(93)85685-H; Cuberes MT, 1997, SURF SCI, V383, P37, DOI 10.1016/S0039-6028(97)00156-8; DREXLER KE, 1995, NANOSYSTEMS MOL MACH; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V1, pCH46; Gimzewski JK, 1997, SURF SCI, V386, P101, DOI 10.1016/S0039-6028(97)00301-4; HO DM, 1993, CHEM MATER, V5, P1358, DOI 10.1021/cm00033a029; HOWE RT, 1990, IEEE SPECTRUM, V27, P29, DOI 10.1109/6.58424; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; Joachim C, 1998, P IEEE, V86, P184, DOI 10.1109/5.658770; Jung TA, 1997, NATURE, V386, P696, DOI 10.1038/386696a0; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; Leff H., 1990, MAXWELLS DEMON ENTRO; LIVOREIL A, 1994, J AM CHEM SOC, V116, P9399, DOI 10.1021/ja00099a095; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; MIYATA H, 1995, BIOPHYS J, V68, pS286; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ROBERTSON DH, 1994, MATER RES SOC SYMP P, V349, P283, DOI 10.1557/PROC-349-283; Sohlberg K, 1997, NANOTECHNOLOGY, V8, P103, DOI 10.1088/0957-4484/8/3/002; STANICK SJ, 1994, SCIENCE, V266, P99; Stipe BC, 1998, SCIENCE, V279, P1907, DOI 10.1126/science.279.5358.1907	25	346	349	1	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					531	533		10.1126/science.281.5376.531	http://dx.doi.org/10.1126/science.281.5376.531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677189				2022-12-28	WOS:000075012300031
J	Rignot, EJ				Rignot, EJ			Fast recession of a West Antarctic glacier	SCIENCE			English	Article							ICE-SHEET; RETREAT	Satellite radar interferometry observations of Pine Island Glacier, West Antarctica, reveal that the glacier hinge-line position retreated 1.2 +/- 0.3 kilometers per year between 1992 and 1996, which in turn implies that the ice thinned by 3.5 +/- 0.9 meters per year. The fast recession of Pine Island Glacier, predicted to be a possible trigger for the disintegration of the West Antarctic Ice Sheet, is attributed to enhanced basal melting of the glacier floating tongue by warm ocean waters.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Rignot, EJ (corresponding author), CALTECH, Jet Prop Lab, MS 300-235, Pasadena, CA 91109 USA.	eric@adelie.jpl.nasa.gov	Rignot, Eric/A-4560-2014	Rignot, Eric/0000-0002-3366-0481				Bamber JL, 1997, ANN GLACIOL, V25, P439, DOI 10.3189/S0260305500014427; Crabtree RD, 1982, ANN GLACIOL, V3, P65, DOI DOI 10.1017/S0260305500002548; DENTON GH, 1979, J GLACIOL, V24, P495; HELLMER HH, ANTARCTIC RES SERIES, V75; HUGHES TJ, 1981, J GLACIOL, V27, P518, DOI 10.3189/S002214300001159X; HUGHES TJ, 1979, J GLACIOL, V24, P493; Jacobs SS, 1996, GEOPHYS RES LETT, V23, P957, DOI 10.1029/96GL00723; Jenkins A, 1997, J GLACIOL, V43, P114, DOI 10.3189/S0022143000002872; KELLOGG TB, 1987, J GEOPHYS RES-SOLID, V92, P8859, DOI 10.1029/JB092iB09p08859; KELLOGG TB, 1985, ANTARCT J US, V20, P79; Lindstrom D., 1984, ANTARCT J US, V19, P53; LINDSTROM D, 1997, ANTARCT J US, V43, P56; LINGLE CS, 1979, J GLACIOL, V24, P213; LUCCHITTA BK, 1995, ANNALS OF GLACIOLOGY, VOL 21, 1995, P277; Rignot E, 1996, J GLACIOL, V42, P476, DOI 10.3189/S0022143000003464; RIGNOT E, IN PRESS J GLACIOL; RIGNOT E, IN PRESS ANN CLACIOL; Rignot EJ, 1997, SCIENCE, V276, P934, DOI 10.1126/science.276.5314.934; Stuiver M., 1981, LAST GREAT ICE SHEET, P319; SWIFT JH, 1995, INT WOCE NEWSLETTER, V18, P15; Thomas R., 1979, J GLACIOL, V24, P167, DOI DOI 10.3189/S0022143000014726; THOMAS RH, 1979, NATURE, V277, P355, DOI 10.1038/277355a0; THOMAS RH, 1978, QUATERNARY RES, V10, P150, DOI 10.1016/0033-5894(78)90098-4; THOMPSON RJ, 1984, ADV DEV BEHAVIORAL P, V5, P265; Weertman J., 1974, J GLACIOL, V13, P3, DOI [DOI 10.3189/S0022143000023327, 10.3189/S0022143000023327]	25	263	267	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					549	551		10.1126/science.281.5376.549	http://dx.doi.org/10.1126/science.281.5376.549			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677195	Green Submitted			2022-12-28	WOS:000075012300037
J	Pearson, GS				Pearson, GS			How to make microbes safer	NATURE			English	Editorial Material									Univ Bradford, Dept Peace Studies, Bradford BD7 1DP, W Yorkshire, England; UK Chem & Biol Def Estab, Porton Down, England	University of Bradford	Pearson, GS (corresponding author), Univ Bradford, Dept Peace Studies, Bradford BD7 1DP, W Yorkshire, England.								0	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					217	218		10.1038/28260	http://dx.doi.org/10.1038/28260			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685152				2022-12-28	WOS:000074851900018
J	Scharenberg, AM; Kinet, JP				Scharenberg, AM; Kinet, JP			Ptdlns-3,4,5-P3: A regulatory nexus between tyrosine kinases and sustained calcium signals	CELL			English	Review							SHIP		Beth Israel Deaconess Med Ctr, Dept Pathol, Lab Allergy & Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Scharenberg, AM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Lab Allergy & Immunol, Boston, MA 02215 USA.							Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Chacko GW, 1996, J IMMUNOL, V157, P2234; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31	17	190	192	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					5	8		10.1016/S0092-8674(00)81214-3	http://dx.doi.org/10.1016/S0092-8674(00)81214-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674420	Bronze			2022-12-28	WOS:000074790800002
J	Stern, S; Altkorn, D; Levinson, W				Stern, S; Altkorn, D; Levinson, W			Detection of prostate and colon cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIGEN; SERUM		Univ Chicago, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA	University of Chicago	Levinson, W (corresponding author), Univ Chicago, Dept Med, Gen Internal Med Sect, 5841 S Maryland,MC 6098, Chicago, IL 60637 USA.	wendy@medicine.bsd.uchicago.edu						Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Coley CM, 1997, ANN INTERN MED, V126, P394, DOI 10.7326/0003-4819-126-5-199703010-00010; Coley CM, 1997, ANN INTERN MED, V126, P480; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Helfand M, 1997, JAMA-J AM MED ASSOC, V277, P44, DOI 10.1001/jama.277.1.44; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; Smart CR, 1997, CANCER, V80, P1835, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1835::AID-CNCR23>3.0.CO;2-5; US Preventive Services Task Force, 1998, GUID CLIN PREV SERV; VENTURA SJ, 1997, MON VITAL STAT RE S2, V46; vonEschenbach A, 1997, CANCER, V80, P1805, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1805::AID-CNCR17>3.3.CO;2-8; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594	16	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					117	118		10.1001/jama.280.2.117	http://dx.doi.org/10.1001/jama.280.2.117			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669770				2022-12-28	WOS:000074608400001
J	Petticrew, M				Petticrew, M			Uranus attacks! Herschel's legacy	BRITISH MEDICAL JOURNAL			English	Article													Petticrew, Mark/AAY-6274-2021					Hetherington Norriss S., 1988, SCI OBJECTIVITY EPIS; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					389	389						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694756				2022-12-28	WOS:000075409600027
J	Pierach, CA				Pierach, CA			A lesson learnt - Anaemia with a twist	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					400	400						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694760				2022-12-28	WOS:000075409600032
J	Nightingale, SL				Nightingale, SL			New warnings added to cisapride labeling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					410	410		10.1001/jama.280.5.410-b	http://dx.doi.org/10.1001/jama.280.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701062				2022-12-28	WOS:000075050200007
J	Diehl, RR; Linden, D				Diehl, RR; Linden, D			Neurocardiogenic syncope	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Alfried Krupp Krankenhaus, D-45117 Essen, Germany	Alfried Krupp Hospital	Diehl, RR (corresponding author), Alfried Krupp Krankenhaus, D-45117 Essen, Germany.								0	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1998	339	5					312	312		10.1056/NEJM199807303390505	http://dx.doi.org/10.1056/NEJM199807303390505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104TL	9682044				2022-12-28	WOS:000075031400005
J	Bushinsky, DA; Monk, RD				Bushinsky, DA; Monk, RD			Calcium	LANCET			English	Article							HYPOCALCEMIC EMERGENCIES; DRUG-THERAPY; HYPERCALCEMIA; MALIGNANCY; MANAGEMENT	Abnormalities in serum calcium concentration may have profound effects on neurological, gastrointestinal, and renal function. Maintenance of the normal serum calcium is a result of tightly regulated ion transport by the kidney, intestinal tract, and bone, mediated by calcaemic hormones especially parathyroid hormone and 1,25-dihydroxyvitamin D-3. Abnormalities in calcium transport that result in uncompensated influx into, or efflux from, the extracellular fluid, will result in hypercalcaemia or hypocalcaemia, respectively. When possible the biologically important ionised calcium concentration should be measured. A variety of common disorders are responsible for abnormalities in the serum calcium. Treatment of both hypercalcaemia and hypocalcaemia is dependent on the underlying disorder, the magnitude of the deviation of the serum calcium, and the severity of symptoms. Fortunately, in the case of hypercalcaemia, there is a broad selection of effective medications, especially the bisphosphonates. Treatment of hypocalcaemia relies on the provision of calcium and often vitamin D. In this article we review the mechanisms responsible for abnormalities in calcium homoeostatisis, the differential diagnosis of hypercalcaemia and hypocalcaemia and appropriate therapy.	Univ Rochester, Strong Mem Hosp, Sch Med & Dent, Rochester, NY 14642 USA; Univ Rochester, Strong Mem Hosp, Nephrol Unit, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bushinsky, DA (corresponding author), Univ Rochester, Strong Mem Hosp, Sch Med & Dent, Rochester, NY 14642 USA.							Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802; BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196; BILEZIKIAN JP, 1993, J CLIN ENDOCR METAB, V77, P1445, DOI 10.1210/jc.77.6.1445; Body JJ, 1996, CANCER TREAT REV, V22, P265, DOI 10.1016/S0305-7372(96)90020-1; Broadus Arthur E., 1996, P57; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; BUSHINSKY DA, 1995, KIDNEY INT, V47, P1816, DOI 10.1038/ki.1995.251; BUSHINSKY DA, 1992, DISORDERS BONE MINER, P417; BUSHINSKY DA, 1998, PRIMER KIDNEY DIS, P106; BUSHINSKY DA, 1992, KIDNEY PHYSL PATHOPH, P2395; *COMPL P CONS DEV, 1991, J BONE MINER RES S2, V6, pS1; FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495-199142060-00003; Hruska Keith A., 1996, P238; KOVACS CS, 1995, J PAIN SYMPTOM MANAG, V10, P224, DOI 10.1016/0885-3924(94)00127-7; MARCUS R, 1991, Journal of Bone and Mineral Research, V6, pS125; MONK RD, IN PRESS DISORDERS F; Monk RD, 1996, KIDNEY STONES MED SU, P759; Mundy GR, 1997, AM J MED, V103, P134, DOI 10.1016/S0002-9343(97)80047-2; PAK CYC, 1990, FLUIDS ELECTROLYTES, P596; Raue F, 1994, Recent Results Cancer Res, V137, P138; REBER PM, 1995, MED CLIN N AM, V79, P93, DOI 10.1016/S0025-7125(16)30086-4; SHANE E, 1991, Journal of Bone and Mineral Research, V6, pS131; Shane Elizabeth, 1996, P217; Shane Elizabeth, 1996, P177; Silverberg SJ, 1997, NEW ENGL J MED, V337, P1506, DOI 10.1056/NEJM199711203372104; Singer F R, 1995, Adv Endocrinol Metab, V6, P259; SUTTON RAL, 1996, KIDNEY, P1038; TOHME JF, 1993, ENDOCRIN METAB CLIN, V22, P363, DOI 10.1016/S0889-8529(18)30171-3	30	247	261	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					306	311		10.1016/S0140-6736(97)12331-5	http://dx.doi.org/10.1016/S0140-6736(97)12331-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690425	hybrid			2022-12-28	WOS:000074974500043
J	Sashidharan, SP; Smyth, M				Sashidharan, SP; Smyth, M			Care models for discharged psychiatric patients - Community based care is superior to conventional care	BRITISH MEDICAL JOURNAL			English	Letter									Univ Birmingham, Acad Unit, No Birmingham Mental Hlth Trust, Birmingham B23 7AL, W Midlands, England	University of Birmingham	Sashidharan, SP (corresponding author), Univ Birmingham, Acad Unit, No Birmingham Mental Hlth Trust, Birmingham B23 7AL, W Midlands, England.							MARSHALL M, 1997, COCHRANE LIB; Scott JE, 1995, SCHIZOPHRENIA BULL, V21, P657, DOI 10.1093/schbul/21.4.657; THOMPSON KS, 1990, HOSP COMMUNITY PSYCH, V41, P625; Tyrer P, 1998, BRIT MED J, V316, P106; Tyrer P, 1998, BRIT J PSYCHIAT, V172, P1, DOI 10.1192/bjp.172.1.1	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					283	283		10.1136/bmj.317.7153.283a	http://dx.doi.org/10.1136/bmj.317.7153.283a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677237	Green Published			2022-12-28	WOS:000075081900052
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Homing viruses	SCIENCE			English	Editorial Material									Medsite Commun, Boston, MA USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA USA.							Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; ITZHAKI JE, 1991, NUCLEIC ACIDS RES, V19, P3835, DOI 10.1093/nar/19.14.3835; Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1956	1957						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669951				2022-12-28	WOS:000074323800071
J	Hawton, K; Arensman, E; Townsend, E; Bremner, S; Feldman, E; Goldney, R; Gunnell, D; Hazell, P; van Heeringen, K; House, A; Owens, D; Sakinofsky, I; Traskman-Bendz, L				Hawton, K; Arensman, E; Townsend, E; Bremner, S; Feldman, E; Goldney, R; Gunnell, D; Hazell, P; van Heeringen, K; House, A; Owens, D; Sakinofsky, I; Traskman-Bendz, L			Deliberate self harm: systematic review of efficacy of psychosocial and pharmacological treatments in preventing repetition	BRITISH MEDICAL JOURNAL			English	Article							PARASUICIDAL BORDERLINE PATIENTS; ATTEMPTED-SUICIDE PATIENTS; FOLLOW-UP; TREATMENT INTERVENTIONS; SECONDARY PREVENTION; BEHAVIORAL TREATMENT; POISONING PATIENTS; CONTROLLED TRIAL; TRENDS; RATES	Objective: To identify and synthesise the findings from all randomised controlled trials that have examined the effectiveness of treatments of patients who have deliberately harmed themselves. Design: Systematic review of randomised controlled trials of psychosocial and physical treatments. Studies categorised according to type of treatment. When there was more than one investigation in a particular category a summary odds ratio was estimated with the Mantel-Haenszel method. Setting: Randomised trials available in electronic databases in 1996, in the Cochrane Controlled Trials Register in 1997, and from hand searching of journals to 1997, Subjects: Patients who had deliberately harmed themselves shortly before entry into the trials with information on repetition of behaviour. The included trials comprised 2452 randomised participants with outcome data. Main outcome measure: Repetition of self harm. Results: 20 trials reported repetition of self harm as an outcome variable, classified into 10 categories. Summary odds ratio (all for comparison with standard aftercare) indicated reduced repetition for problem solving therapy (0.73; 95% confidence interval 0.45 to 1.18) and for provision of an emergency contact card in addition to standard care (0.45; 0.19 to 1.07). The summary odds ratios were 0.83 (0.61 to 1.14) for trials of intensive aftercare plus outreach and 1.19 (0.53 to 2.67) for antidepressant treatment compared with placebo. Significantly reduced rates of further self harm were observed for depot flupenthixol versus placebo in multiple repeaters (0.09; 0.02 to 0.50) and for dialectical behaviour therapy versus standard aftercare (0.24; 0.06 to 0.93). Conclusion: There remains considerable uncertainty about which forms of psychosocial and physical treatments of patients who harm themselves are most effective. Further larger trials of treatments are needed.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Nepean Hosp, Penrith, NSW 2750, Australia; John Radcliffe Hosp, Dept Psychol Med, Oxford OX3 9DU, England; Univ Adelaide, Dept Psychiat, Adelaide, SA 5005, Australia; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Newcastle, Fac Med & Hlth Sci, Discipline Psychiat, Callaghan, NSW 2308, Australia; State Univ Ghent Hosp, Dept Psychiat, B-9000 Ghent, Belgium; Univ Leeds, Sch Med, Div Psychiat & Behav Sci, Leeds LS2 9LT, W Yorkshire, England; Clarke Inst Psychiat, Toronto, ON M5T 1R8, Canada; Univ Lund Hosp, Dept Psychiat, S-22185 Lund, Sweden	University of Oxford; Nepean Hospital; University of Sydney; University of Oxford; University of Adelaide; University of Bristol; University of Newcastle; Ghent University; Ghent University Hospital; University of Leeds; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Lund University; Skane University Hospital	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.		van Heeringen, Kees/H-2384-2013; Gunnell, David/ABE-6653-2020; Townsend, Ellen/M-6266-2015	van Heeringen, Kees/0000-0001-5801-194X; Gunnell, David/0000-0002-0829-6470; Townsend, Ellen/0000-0002-4677-5958; Arensman, Ella/0000-0003-0376-1203; House, Allan/0000-0001-8721-8026				ALLARD R, 1992, SUICIDE LIFE-THREAT, V22, P303; BANCROFT J, 1977, BRIT J PSYCHIAT, V131, P394, DOI 10.1192/bjp.131.4.394; Bialas MC, 1996, QJM-INT J MED, V89, P893; CHOWDHURY N, 1973, SOC PSYCHIATR, V8, P67, DOI 10.1007/BF00589238; *COCHR COLL, 1997, COCHR LIB; COTGROVE A, 1995, J ADOLESCENCE, V18, P569, DOI 10.1006/jado.1995.1039; DAVIS AT, 1991, MED J AUSTRALIA, V154, P666, DOI 10.5694/j.1326-5377.1991.tb121254.x; *DEP HLTH, 1992, CMND1986; DEW MA, 1987, J CONSULT CLIN PSYCH, V55, P229; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; Foster T, 1997, BRIT J PSYCHIAT, V170, P447, DOI 10.1192/bjp.170.5.447; GIBBONS JS, 1978, BRIT J PSYCHIAT, V133, P111, DOI 10.1192/bjp.133.2.111; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; HAWTON K, 1981, PSYCHOL MED, V11, P169, DOI 10.1017/S0033291700053381; HAWTON K, 1987, PSYCHOL MED, V17, P751, DOI 10.1017/S0033291700025988; HAWTON K, 1992, BRIT J PSYCHIAT, V161, P816, DOI 10.1192/bjp.161.6.816; Hawton K, 1988, BRIT J PSYCHIAT, V152, P751; HAWTON K, 1997, J PSYCHIAT, V171, P556; Hawton K., 1982, ATTEMPTED SUICIDE PR; Hawton K., 1989, COGNITIVE BEHAV THER, P406; HIRSCH SR, 1982, J AFFECT DISORDERS, V4, P299, DOI 10.1016/0165-0327(82)90027-1; LGIHT RJ, 1984, SUMMING UP SCI REVIE; LIBERMAN RP, 1981, ARCH GEN PSYCHIAT, V38, P1126; Linehan M., 1993, COGNITIVE BEHAV TREA; LINEHAN MM, 1993, ARCH GEN PSYCHIAT, V50, P971; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; MCLEAVEY BC, 1994, SUICIDE LIFE-THREAT, V24, P382; McLoone P, 1996, BRIT J PSYCHIAT, V169, P81, DOI 10.1192/bjp.169.1.81; Montgomery S, 1979, P 10 INT C SUIC PREV, P227; MONTGOMERY S, 1983, BR J CLIN PHARM, V15, P183; MORGAN HG, 1993, BRIT J PSYCHIAT, V163, P111, DOI 10.1192/bjp.163.1.111; NORDENTOFT M, 1993, BRIT MED J, V306, P1637, DOI 10.1136/bmj.306.6893.1637; OVENSTON.IM, 1974, BRIT J PSYCHIAT, V124, P336, DOI 10.1192/bjp.124.4.336; PATSIOKAS AT, 1985, PSYCHOTHERAPY, V22, P281, DOI 10.1037/h0085507; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Sackett D, 1997, COCHRANE COLLABORATI; SALKOVSKIS PM, 1990, BRIT J PSYCHIAT, V157, P871, DOI 10.1192/bjp.157.6.871; Schmidtke A, 1996, ACTA PSYCHIAT SCAND, V93, P327, DOI 10.1111/j.1600-0447.1996.tb10656.x; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SUOKAS J, 1991, ACTA PSYCHIAT SCAND, V84, P545, DOI 10.1111/j.1600-0447.1991.tb03191.x; Torhorst A, 1987, Crisis, V8, P53; Torhorst A, 1988, CURRENT ISSUES SUICI, P419; *UPD SOFTW, 1996, UPD SOFTW REVM 3 0; VanderSande R, 1997, BRIT J PSYCHIAT, V171, P35, DOI 10.1192/bjp.171.1.35; vanderSande R, 1997, ACTA PSYCHIAT SCAND, V96, P43; VANHEERINGEN C, 1995, PSYCHOL MED, V25, P963, DOI 10.1017/S0033291700037454; WATERHOUSE J, 1990, BRIT J PSYCHIAT, V156, P236, DOI 10.1192/bjp.156.2.236; WELU TC, 1977, SUICIDE LIFE-THREAT, V7, P17; WEXLER L, 1978, BRIT J PSYCHIAT, V132, P180, DOI 10.1192/bjp.132.2.180; *WHO, 1992, HLTH FOR ALL TARG HL; [No title captured]	51	279	284	0	34	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					441	447						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	112JF	9703526				2022-12-28	WOS:000075490200019
J	Jimenez-Lucho, V				Jimenez-Lucho, V			Images in clinical medicine - Verruga peruana	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Vet Adm Med Ctr, Northport, NY 11768 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Jimenez-Lucho, V (corresponding author), Vet Adm Med Ctr, Northport, NY 11768 USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					450	450		10.1056/NEJM199808133390706	http://dx.doi.org/10.1056/NEJM199808133390706			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700179				2022-12-28	WOS:000075342500006
J	Lewis, G				Lewis, G			A memorable patient - The dead fairy sign	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					396	396						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694758				2022-12-28	WOS:000075409600030
J	Singer, C; Shulmeister, J; McLea, B				Singer, C; Shulmeister, J; McLea, B			Evidence against a significant Younger Dryas cooling event in New Zealand	SCIENCE			English	Article							ICE CORE; AGE; GLACIER	Pollen records of deglacial sequences from northwest Nelson, New Zealand, demonstrate that there was no significant temperature decline associated with the Younger Dryas in New Zealand. Records of glacial advances at this time were either the product of increased snow accumulation under enhanced precipitation regimes or random variation ra ther than the result of a regional thermal decline. This finding supports those models of Younger Dryas initiation that require neither enhanced westerly circulation nor significant thermal decline in the Southern Hemisphere.	Univ Victoria, Res Sch Earth Sci, Wellington, New Zealand	Victoria University Wellington	Shulmeister, J (corresponding author), Univ Victoria, Res Sch Earth Sci, POB 600, Wellington, New Zealand.		Shulmeister, James/J-2859-2015	Shulmeister, James/0000-0001-5863-9462				BLANCHON P, 1995, GEOLOGY, V23, P4, DOI 10.1130/0091-7613(1995)023<0004:RDDTLD>2.3.CO;2; Broecker W, 1997, QUATERNARY SCI REV, V16, P821, DOI 10.1016/S0277-3791(97)00050-4; DEANGELIS M, 1987, NATURE, V325, P318, DOI 10.1038/325318a0; DENTON GH, 1994, SCIENCE, V264, P1434, DOI 10.1126/science.264.5164.1434; Fitzharris B. B., 1992, HOLOCENE, V2, P97, DOI DOI 10.1177/095968369200200201; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; HARVEY LDD, 1989, QUATERNARY SCI REV, V8, P137, DOI 10.1016/0277-3791(89)90002-4; HELLSTROM J, IN PRESS QUAT RES; HESSELL JWD, 1983, NEW ZEAL J SCI, V26, P315; KUTZBACH JE, 1987, N AM ADJACENT OCEANS, P425, DOI DOI 10.1130/DNAG-GNA-K3.425; Mabin MCG, 1996, SCIENCE, V271, P668, DOI 10.1126/science.271.5249.668; MARKGRAF V, 1991, BOREAS, V20, P63; McGlone MS, 1995, QUATERNARY SCI REV, V14, P867, DOI 10.1016/0277-3791(95)00068-2; MERCER JH, 1988, NEW ZEAL J GEOL GEOP, V31, P95, DOI 10.1080/00288306.1988.10417813; STEWART RB, 1984, NATURE, V311, P47, DOI 10.1038/311047a0; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46	17	73	80	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					812	814		10.1126/science.281.5378.812	http://dx.doi.org/10.1126/science.281.5378.812			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694650				2022-12-28	WOS:000075295600046
J	Arhi, MN; Batt, CK				Arhi, MN; Batt, CK			Mohammed Iftikar Akhter - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					353	353		10.1136/bmj.317.7154.353	http://dx.doi.org/10.1136/bmj.317.7154.353			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685300	Green Published			2022-12-28	WOS:000075409500063
J	Walberg, P; McKee, M; Shkolnikov, V; Chenet, L; Leon, DA				Walberg, P; McKee, M; Shkolnikov, V; Chenet, L; Leon, DA			Economic change, crime, and mortality crisis in Russia: regional analysis	BRITISH MEDICAL JOURNAL			English	Article								Objective: To identify which aspects of socioeconomic change were associated with the steep decline in life expectancy in Russia between 1990 and 1994. Design: Regression analysis of regional data, with percentage fall in male life expectancy as dependent variable and a range of socioeconomic measures reflecting transition, change in income, inequity, and social cohesion as independent variables. Determination of contribution of deaths from major causes and in each age group to changes in both male and female life expectancy at birth in regions with the smallest and largest declines. Setting: Regions (oblasts) of European Russia (excluding Siberia and those in the Caucasus affected by the Chechen war). Subjects: The population of European Russia. Results: The fall in life expectancy at birth varied widely between regions, with declines for men and women highly correlated. The regions with the largest falls were predominantly urban, with high rates of labour turnover, large increases in recorded crime, and a higher average but unequal distribution of household income. For both men and women increasing rates of death between the ages of 30 and 60 years accounted for most of the fall in life expectancy, with the greatest contributions being from conditions directly or indirectly associated with heavy alcohol consumption. Conclusions: The decline in life expectancy in Russia in the 1990s cannot be attributed simply to impoverishment Instead, the impact of social and economic transition, exacerbated by a lack of social cohesion, seems to have played a major part, The evidence that alcohol is an important proximate cause of premature death in Russia is strengthened.	Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1E 7HT, England; Univ Uppsala, Dept Publ Hlth & Caring Sci, S-75185 Uppsala, Sweden; Inst Econ Forecasting, Ctr Demog & Human Ecol, Lab Anal & Prognosis Populat Mortal, Moscow, Russia	University of London; London School of Hygiene & Tropical Medicine; Uppsala University	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, Keppel St, London WC1E 7HT, England.	m.mckee@ishun.ac.uk	Shkolnikov, Vladimir/D-2986-2017; McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018; Leon, David A/G-2195-2010	Shkolnikov, Vladimir/0000-0003-2259-5423; McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683; Leon, David A/0000-0001-9747-1762				Anderson B., 1997, PREMATURE DEATH NEW, P120; Bobak M, 1996, BRIT MED J, V312, P421; Chenet L, 1997, J EPIDEMIOL COMMUN H, V51, P510, DOI 10.1136/jech.51.5.510; CHENET L, IN PRESS J EPIDEMIOL; Coleman JS., 1990, FDN SOCIAL THEORY; CORNIA GA, 1995, EC POLITY STUDIES, V49; Durkheim Emile, 1897, SUICIDE STUDY SOCIOL; Hajdu P., 1995, EUR J PUBLIC HEALTH, V5, P259, DOI [DOI 10.1093/EURPUB/5.4.259, 10.1093/eurpub/5.4.259]; JIN RL, 1995, CAN MED ASSOC J, V153, P529; Jozan P, 1997, ATLAS LEADING AVOIDA; Kawachi I, 1997, BMJ-BRIT MED J, V314, P1037, DOI 10.1136/bmj.314.7086.1037; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; Mesle F., 1996, SERIE DONNEES STAT, V2; Mitchell F., 1997, PREMATURE DEATH NEW, P220; Pollard JH, 1982, J I ACTUARIES, V109, P225, DOI DOI 10.1017/S0020268100036258; POWELL B, 1998, NEWSWEEK, V131, P20; Putnam R.D., 1994, MAKING DEMOCRACY WOR, DOI DOI 10.2307/206637; RYAN M, 1995, BRIT MED J, V310, P646; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; SERVICE R, 1997, HIST 20 CENTURY RUSS, P467; SHAPIRO J, 1997, DEV RUSSIAN POLITICS; SHAPIRO J, 1995, RUSSIAN EC REFORM RI; SHKOLNIKOV V, 1995, POPULATION, V4, P907; Shkolnikov V. M., 1997, PREMATURE DEATH NEW, P239; SHKOLNIKOV VM, TRANSITIONS MORTALIT; VIKHERT AM, 1986, J AM COLL CARDIOL, V8, pA3, DOI 10.1016/S0735-1097(86)80023-7; Watson P, 1998, SOC SCI MED, V46, P549, DOI 10.1016/S0277-9536(97)00199-8; White S, 1996, RUSSIA GOES DRY; WILKINSON R, 1996, UNHEALTHY SOC AFFICT	30	240	254	2	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					312	318		10.1136/bmj.317.7154.312	http://dx.doi.org/10.1136/bmj.317.7154.312			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685275	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000075409500019
J	Sinelnikov, YD; Chen, GL; Neuville, DR; Vaughan, MT; Liebermann, RC				Sinelnikov, YD; Chen, GL; Neuville, DR; Vaughan, MT; Liebermann, RC			Ultrasonic shear wave velocities of MgSiO3 perovskite at 8 GPa and 800 K and lower mantle composition	SCIENCE			English	Article							SILICATE PEROVSKITE; EARTHS MANTLE; STRATIFICATION; HETEROGENEITY; CONSTRAINTS; DENSITY	Ultrasonic interferometric measurements of the shear elastic properties of MgSiO3 perovskite were conducted on three polycrystalline specimens at conditions up to pressures of 8 gigapascals and temperatures of 800 kelvin. The acoustic measurements produced the pressure (P) and temperature (T) derivatives of the shear modulus (G), namely (partial derivative G/partial derivative P)(T) = 1.8 +/- 0.4 and (partial derivative G/partial derivative T)(P) = -2.9 +/- 0.3 X 10(-2) gigapascals per kelvin. Combining these derivatives with the derivatives that were measured for the bulk modulus and thermal expansion of MgSiO3 perovskite provided data that suggest Lower mantle compositions between pyrolite and C1 carbonaceous chondrite and a Lower mantle potential temperature of 1500 +/- 200 kelvin.	SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Mineral Phys, Stony Brook, NY 11794 USA; Inst Phys Globe, Lab Phys Geomat, F-75252 Paris 05, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; UDICE-French Research Universities; Universite Paris Cite	Sinelnikov, YD (corresponding author), SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA.		Neuville, Daniel R./E-7074-2017	Neuville, Daniel R./0000-0002-8487-5001				Chen GL, 1998, SCIENCE, V280, P1913, DOI 10.1126/science.280.5371.1913; DUFFY TS, 1989, J GEOPHYS RES-SOLID, V94, P1895, DOI 10.1029/JB094iB02p01895; Fiquet G, 1998, PHYS EARTH PLANET IN, V105, P21, DOI 10.1016/S0031-9201(97)00077-0; Funamori N, 1996, J GEOPHYS RES-SOL EA, V101, P8257, DOI 10.1029/95JB03732; GASPARIK T, 1990, J GEOPHYS RES-SOLID, V95, P15751, DOI 10.1029/JB095iB10p15751; HALES AL, 1967, GEOPHYS J ROY ASTR S, V13, P403, DOI 10.1111/j.1365-246X.1967.tb03139.x; Jackson I, 1998, GEOPHYS J INT, V134, P291, DOI 10.1046/j.1365-246x.1998.00560.x; JEANLOZ R, 1989, PHILOS T R SOC A, V328, P377, DOI 10.1098/rsta.1989.0042; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; KNITTLE E, 1986, NATURE, V319, P214, DOI 10.1038/319214a0; KUNG J, 1997, EOS T AM GEOPHYS U S, V78, pF803; KUNG J, 1997, THESIS AUSTR NATL U; LI XD, 1991, GEOPHYS J INT, V105, P649, DOI 10.1111/j.1365-246X.1991.tb00802.x; MAO HK, 1991, J GEOPHYS RES-SOLID, V96, P8069, DOI 10.1029/91JB00176; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; MCMILLAN PF, 1996, MINERAL SPECTROSCOPY, P175; RINGWOOD AE, 1975, COMPOSITION EARTHS M, P295; ROBERTSON GS, 1995, GEOPHYS J INT, V123, P85, DOI 10.1111/j.1365-246X.1995.tb06663.x; STACEY FD, 1995, PHYS EARTH PLANET IN, V89, P219, DOI 10.1016/0031-9201(94)03005-4; STIXRUDE L, 1992, SCIENCE, V257, P1099, DOI 10.1126/science.257.5073.1099; UTSUMI W, 1995, GEOPHYS RES LETT, V22, P1005, DOI 10.1029/95GL00584; Wang YB, 1996, PURE APPL GEOPHYS, V146, P533, DOI 10.1007/BF00874732; WANG YB, 1994, PHYS EARTH PLANET IN, V83, P13, DOI 10.1016/0031-9201(94)90109-0; WOODHOUSE JH, 1989, PHILOS T R SOC A, V328, P291, DOI 10.1098/rsta.1989.0037; YEGANEHHAERI A, 1989, SCIENCE, V243, P787, DOI 10.1126/science.243.4892.787; ZHAO YS, 1994, PHYS EARTH PLANET IN, V85, P273, DOI 10.1016/0031-9201(94)90118-X; [No title captured]	27	60	62	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					677	679		10.1126/science.281.5377.677	http://dx.doi.org/10.1126/science.281.5377.677			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685256				2022-12-28	WOS:000075107900035
J	Lenton, TM				Lenton, TM			Gaia and natural selection	NATURE			English	Review							ATMOSPHERIC SULFUR; BIOTIC ENHANCEMENT; EARTHS ATMOSPHERE; MASS EXTINCTIONS; DIMETHYL SULFIDE; NUMERICAL-MODEL; FOSSIL RECORD; CLOUD ALBEDO; CLIMATE; HYPOTHESIS	Evidence indicates that the Earth self-regulates at a state that Is tolerated by rife, but why should the organisms that leave the most descendants be the ones that contribute to regulating their planetary environment? The evolving Gaia theory focuses on the feedback mechanisms, stemming from naturally selected traits of organisms, that could generate such self-regulation.	Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Lenton, TM (corresponding author), Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England.		Lenton, Tim M/X-1893-2018	Lenton, Tim M/0000-0002-6725-7498				ALVAREZ W, 1984, SCIENCE, V223, P1135, DOI 10.1126/science.223.4641.1135; Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; ANDREAE MO, 1986, ROLE AIR SEA EXCHANG, P331, DOI DOI 10.1007/978-94-009-4738-2_14; [Anonymous], GEOPHYS AMAZONIA VEG; AYERS GP, 1991, NATURE, V353, P834, DOI 10.1038/353834a0; Betts RA, 1997, NATURE, V387, P796, DOI 10.1038/42924; BONAN GB, 1992, NATURE, V359, P716, DOI 10.1038/359716a0; Brasseur G. P., 1991, TRACE GAS EMISSION P, P1; BUDYKO MI, 1969, TELLUS, V21, P611, DOI 10.3402/tellusa.v21i5.10109; CALDEIRA K, 1992, NATURE, V359, P226, DOI 10.1038/359226a0; CALDEIRA K, 1989, NATURE, V337, P732, DOI 10.1038/337732a0; Chapin FS, 1997, SCIENCE, V277, P500, DOI 10.1126/science.277.5325.500; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Darwin C., 1959, WHATS NEW, V67, P2; DAWKINS R, 1983, EXTENDED PHENOTYPE; DEDUVE C, 1995, VITAL DUST; Doolittle WF, 1981, COEVOLUTION Q, V29, P58; EHRLICH P, 1991, P19; Eisele FL, 1997, PHILOS T ROY SOC B, V352, P191, DOI 10.1098/rstb.1997.0014; Evans DA, 1997, NATURE, V386, P262, DOI 10.1038/386262a0; FALKOWSKI PG, 1992, SCIENCE, V256, P1311, DOI 10.1126/science.256.5061.1311; FOLEY JA, 1994, NATURE, V371, P52, DOI 10.1038/371052a0; Gage DA, 1997, NATURE, V387, P891, DOI 10.1038/43160; Gallimore RG, 1996, NATURE, V381, P503, DOI 10.1038/381503a0; Hamilton WD, 1998, ETHOL ECOL EVOL, V10, P1, DOI 10.1080/08927014.1998.9522867; Hamilton WD, 1996, NEW SCI, V151, P62; HAMILTON WD, 1995, J APPL ECOL, V32, P451, DOI 10.2307/2404643; Hansen J, 1996, GEOPHYS RES LETT, V23, P1665, DOI 10.1029/96GL01040; Harding SP, 1996, J THEOR BIOL, V182, P109, DOI 10.1006/jtbi.1996.0146; HARDING SP, UNPUB TELLUS; Hayes JM, 1994, NOBEL S, P220; HITCHCOCK DR, 1967, ICARUS, V7, P149, DOI 10.1016/0019-1035(67)90059-0; Holland H. D., 1978, CHEM ATMOSPHERE OCEA; Holland HD., 1984, CHEM EVOLUTION ATMOS; Jackson T.A., 1970, AM J SCI, V269, P446, DOI [10.2475/ajs.269.5.446, DOI 10.2475/AJS.269.5.446]; KEELING R, 1991, P118; KERR RA, 1988, SCIENCE, V240, P393, DOI 10.1126/science.240.4851.393; KIRCHNER JW, 1989, REV GEOPHYS, V27, P223, DOI 10.1029/RG027i002p00223; KLINGER L F, 1991, P247; KUMP IR, 1995, FUTURE CLIMATES WORL, P537; Laland KN, 1996, J EVOLUTION BIOL, V9, P293, DOI 10.1046/j.1420-9101.1996.9030293.x; LEGRAND M, 1991, NATURE, V350, P144, DOI 10.1038/350144a0; Legrand M, 1997, PHILOS T ROY SOC B, V352, P241, DOI 10.1098/rstb.1997.0019; Liss P.S., 1993, INTERACTIONS C N P S, P259, DOI [10.1007/978-3-642-76064-8_11, DOI 10.1007/978-3-642-76064-8_11]; Liss PS, 1997, PHILOS T R SOC B, V352, P159, DOI 10.1098/rstb.1997.0011; Lotka A. J., 1956, ELEMENTS MATH BIOL, DOI DOI 10.2307/1909476; Lovelock J, 1997, PHILOS T ROY SOC B, V352, P143, DOI 10.1098/rstb.1997.0009; Lovelock James, 1979, GAIA NEW LOOK LIFE E; Lovelock James, 1995, AGES GAIA; LOVELOCK JE, 1994, NATURE, V369, P732, DOI 10.1038/369732a0; LOVELOCK JE, 1973, NATURE, V241, P194, DOI 10.1038/241194a0; LOVELOCK JE, 1972, NATURE, V237, P452, DOI 10.1038/237452a0; LOVELOCK JE, 1974, TELLUS, V26, P2, DOI 10.1111/j.2153-3490.1974.tb01946.x; LOVELOCK JE, 1992, PHILOS T R SOC B, V338, P383, DOI 10.1098/rstb.1992.0156; LOVELOCK JE, 1982, PLANET SPACE SCI, V30, P795, DOI 10.1016/0032-0633(82)90112-X; LOVELOCK JE, 1974, ORIGINS LIFE EVOL B, V5, P93, DOI 10.1007/BF00927016; LOVELOCK JE, 1982, NATURE, V296, P561, DOI 10.1038/296561a0; LOVELOCK JE, 1986, B AM METEOROL SOC, V67, P392; LOVELOCK JE, 1990, NATURE, V344, P100, DOI 10.1038/344100a0; LOVELOCK JE, 1972, ATMOS ENVIRON, V6, P579, DOI 10.1016/0004-6981(72)90076-5; LOVELOCK JE, 1989, T RSE EARTH, V80, P169; LOVELOCK JE, 1989, REV GEOPHYS, V27, P215, DOI 10.1029/RG027i002p00215; LOVELOCK JE, 1975, PROC R SOC SER B-BIO, V189, P167, DOI 10.1098/rspb.1975.0051; LOVELOCK JE, 1965, NATURE, V207, P568, DOI 10.1038/207568a0; Lovelock JE, 1983, BIOMINERALIZATION BI, P15; Mackenzie F. T., 1993, INTERACTIONS C N P S, P1; MADDOCK L, 1991, TELLUS B, V43, P331, DOI 10.1034/j.1600-0889.1991.t01-2-00006.x; MARGULIS L, 1974, ICARUS, V21, P471, DOI 10.1016/0019-1035(74)90150-X; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; NEWMAN MJ, 1977, SCIENCE, V198, P1035, DOI 10.1126/science.198.4321.1035; OFFICER CB, 1987, NATURE, V326, P143, DOI 10.1038/326143a0; ORESKES N, 1994, SCIENCE, V263, P641, DOI 10.1126/science.263.5147.641; OttoBliesner BL, 1997, NATURE, V385, P804, DOI 10.1038/385804a0; PATTEN BC, 1981, AM NAT, V118, P886, DOI 10.1086/283881; RAMPINO MR, 1988, NATURE, V332, P63, DOI 10.1038/332063a0; RAMPINO MR, 1987, NATURE, V327, P468, DOI 10.1038/327468a0; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; Ravishankara AR, 1997, PHILOS T ROY SOC B, V352, P171, DOI 10.1098/rstb.1997.0012; ROEMMICH D, 1995, SCIENCE, V267, P1324, DOI 10.1126/science.267.5202.1324; RYE R, 1995, NATURE, V378, P603, DOI 10.1038/378603a0; SAUNDERS PT, 1994, J THEOR BIOL, V166, P365, DOI 10.1006/jtbi.1994.1033; Schneider Stephen, 1984, COEVOLUTION CLIMATE; Schrodinger E, 1944, WHAT IS LIFE; SCHWARTZMAN DW, 1989, NATURE, V340, P457, DOI 10.1038/340457a0; SCHWARTZMAN DW, 1991, GLOBAL PLANET CHANGE, V90, P357; SHUKLA J, 1990, SCIENCE, V247, P1322, DOI 10.1126/science.247.4948.1322; STOCKER S, 1995, J THEOR BIOL, V175, P495, DOI 10.1006/jtbi.1995.0156; Szathmary E, 1995, MAJOR TRANSITIONS EV; TURNER SM, 1988, LIMNOL OCEANOGR, V33, P364, DOI 10.4319/lo.1988.33.3.0364; vonBloh W, 1997, TELLUS B, V49, P249, DOI 10.1034/j.1600-0889.49.issue3.2.x; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776; WATSON A, 1978, BIOSYSTEMS, V10, P293, DOI 10.1016/0303-2647(78)90012-6; WATSON AJ, 1983, TELLUS B, V35, P284, DOI 10.1111/j.1600-0889.1983.tb00031.x; WATSON AJ, 1996, GAIA ACTION SCI LIVI, P65; WATSON AJ, 1991, NEW SCI INSIDE SCI, V48, P1; Wayne, 1991, CHEM ATMOSPHERES INT; WHITFIELD M, 1981, INTERDISCIPL SCI REV, V6, P12; Wolfe GV, 1997, NATURE, V387, P894, DOI 10.1038/43168	99	184	193	3	141	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					439	447		10.1038/28792	http://dx.doi.org/10.1038/28792			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697767				2022-12-28	WOS:000075080400041
J	Horton, R				Horton, R			The new new public health of risk and radical engagement	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							BEAGLEHOLE R, 1995, PUBLIC HLTH CROSSROA; Beck U., 1992, RISK SOC; Chadwick E., 1842, REPORT SANITARY COND; *DEP HLTH, 1998, OUR HLTH NAT; Giddens A., 1991, CONCEQUENCES MODERNI; Hamlin C., 1998, PUBLIC HLTH SOCIAL J; HERTZPICCIOTTO I, 1995, AM J PUBLIC HEALTH, V85, P484, DOI 10.2105/AJPH.85.4.484; Holland WalterW, 1998, PUBLIC HLTH VISION C; Lupton D., 1995, IMPERATIVE HLTH PUBL; Porter D., 1997, SOCIAL MED MED SOCIO; TAYLOR P, 1998, PUBLIC HLTH MODEL PR	11	36	36	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					251	252		10.1016/S0140-6736(05)60254-1	http://dx.doi.org/10.1016/S0140-6736(05)60254-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690400				2022-12-28	WOS:000074974500003
J	Haffner, SM; Lehto, S; Ronnemaa, T; Pyorala, K; Laakso, M				Haffner, SM; Lehto, S; Ronnemaa, T; Pyorala, K; Laakso, M			Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; MEN; POPULATIONS; IMPACT	Background Type 2 (non-insulin-dependent) diabetes is associated with a marked increase in the risk of coronary heart disease. It has been debated whether patients with diabetes who have not had myocardial infarctions should be treated as aggressively for cardiovascular risk factors as patients who have had myocardial infarctions. Methods To address this issue, we compared the seven-year incidence of myocardial infarction (fatal and nonfatal) among 1373 nondiabetic subjects with the incidence among 1059 diabetic subjects, all from a Finnish population-based study. Results The seven-year incidence rates of myocardial infarction in nondiabetic subjects with and without prior myocardial infarction at base line were 18.8 percent and 3.5 percent, respectively (P<0.001). The seven-year incidence rates of myocardial infarction in diabetic subjects with and without prior myocardial infarction at base line were 45.0 percent and 20.2 percent, respectively (P<0.001). The hazard ratio for death from coronary heart disease for diabetic subjects without prior myocardial infarction as compared with nondiabetic subjects with prior myocardial infarction was not significantly different from 1.0 (hazard ratio, 1.4; 95 percent confidence interval, 0.7 to 2.6) after adjustment for age and sex, suggesting similar risks of infarction in the two groups. After further adjustment for total cholesterol, hypertension, and smoking, this hazard ratio remained close to 1.0 (hazard ratio, 1.2; 95 percent confidence interval, 0.6 to 2.4). Conclusions Our data suggest that diabetic patients without previous myocardial infarction have as high a risk of myocardial infarction as nondiabetic patients with previous myocardial infarction. These data provide a rationale for treating cardiovascular risk factors in diabetic patients as aggressively as in nondiabetic patients with prior myocardial infarction. (N Engl J Med 1998;339:229-34.) (C) 1998, Massachusetts Medical Society.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland; Turku Univ, Dept Med, Turku, Finland	University of Texas System; University of Texas Health San Antonio; University of Eastern Finland; University of Turku	Haffner, SM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Northe, Hilda/I-1916-2012; Greiver, Michelle/N-8764-2015	Northe, Hilda/0000-0002-8873-5014; Greiver, Michelle/0000-0001-8957-0285; Lehto, Seppo/0000-0003-0414-5285				ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Amer Diabet Assoc, 1998, DIABETES CARE, V21, P179; [Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1998, AM HEART ASS 38 ANN; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V209, P3015; Haffner SM, 1997, DIABETES CARE, V20, P469, DOI 10.2337/diacare.20.4.469; HERLITZ J, 1992, CARDIOLOGY, V80, P237, DOI 10.1159/000175008; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; LAAKSO M, 1995, DIABETOLOGIA, V38, P487, DOI 10.1007/s001250050310; LAAKSO M, 1988, DIABETES CARE, V11, P449, DOI 10.2337/diacare.11.6.449; Lehto S, 1997, DIABETES, V46, P1354, DOI 10.2337/diabetes.46.8.1354; Miettinen H, 1998, DIABETES CARE, V21, P69, DOI 10.2337/diacare.21.1.69; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Pyorala K, 1997, DIABETES CARE, V20, P1048; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; Rosengren A, 1997, EUR HEART J, V18, P754; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Weinfeld, 1981, STROKE S1, V12, pI13; *WHO, 1983, PUBL WHO; Wingard DL., 1995, DIABETES AM, P429	26	4895	5117	0	193	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					229	234		10.1056/NEJM199807233390404	http://dx.doi.org/10.1056/NEJM199807233390404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673301	Bronze			2022-12-28	WOS:000074918700004
J	Shekelle, PG; Roland, M				Shekelle, PG; Roland, M			Measuring quality in the NHS: lessons from across the Atlantic	LANCET			English	Editorial Material									W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of Manchester	Shekelle, PG (corresponding author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.							Department of Health, 1997, CM3807 DEP HLTH; Department of Health, 1998, NEW NHS MOD DEP NAT; GRAY P, 1990, LANCET, V336, P517; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; Lohr K N, 1986, Med Care, V24, pS1; McKee M, 1998, BRIT MED J, V316, P322, DOI 10.1136/bmj.316.7128.322; SCOTT EA, 1992, ANN ROY COLL SURG, V74, P97	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					163	164		10.1016/S0140-6736(05)77801-6	http://dx.doi.org/10.1016/S0140-6736(05)77801-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683200				2022-12-28	WOS:000074859800004
J	Greenberg, DS				Greenberg, DS			Of human poundage	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					158	158		10.1016/S0140-6736(98)85078-2	http://dx.doi.org/10.1016/S0140-6736(98)85078-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672320				2022-12-28	WOS:000074775100071
J	Lorch, Y; Cairns, BR; Zhang, MC; Kornberg, RD				Lorch, Y; Cairns, BR; Zhang, MC; Kornberg, RD			Activated RSC-nucleosome complex and persistently altered form of the nucleosome	CELL			English	Article							YEAST SWI/SNF COMPLEX; DNA; TRANSCRIPTION; BINDING; DISPLACEMENT; DISRUPTION; INITIATION; HISTONES; PROTEIN	RSC, an abundant, essential chromatin-remodeling complex, related to SWI/SNF complex, binds nucleosomes and naked DNA with comparable affinities, as shown by gel shift analysis. The RSC-nucleosome complex is converted in the presence of ATP to a slower migrating form. This activated complex exhibits greatly increased susceptibility to endo- and exonucleases but retains a full complement of histones. Activation persists in the absence of ATP, and on removal of RSC, the nucleosome is released in an altered form, with a diminished electrophoretic mobility, greater sedimentation rate, and marked instability at elevated ionic strength. The reaction is reversible in the presence of RSC and ATP, with conversion of the altered form back to the nucleosome.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LORCH Y, 1994, P NATL ACAD SCI USA, V91, P11032, DOI 10.1073/pnas.91.23.11032; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PRUNELL A, 1977, COLD SPRING HARB SYM, V42, P103, DOI 10.1101/SQB.1978.042.01.011; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	22	174	174	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					29	34		10.1016/S0092-8674(00)81218-0	http://dx.doi.org/10.1016/S0092-8674(00)81218-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674424	Bronze			2022-12-28	WOS:000074790800006
J	Antonelli, M; Conti, G; Rocco, M; Bufi, M; De Blasi, RA; Vivino, G; Gasparetto, A; Meduri, GU				Antonelli, M; Conti, G; Rocco, M; Bufi, M; De Blasi, RA; Vivino, G; Gasparetto, A; Meduri, GU			A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOGENIC PULMONARY-EDEMA; FACE MASK; AIRWAY PRESSURE; PNEUMONIA; SUPPORT; TRIAL; DISEASE; THERAPY	Background and Methods The role of noninvasive positive-pressure ventilation delivered through a face mask in patients with acute respiratory failure is uncertain. We conducted a prospective, randomized trial of noninvasive positive-pressure ventilation as compared with endotracheal intubation with conventional mechanical ventilation in 64 patients with hypoxemic acute respiratory failure who required mechanical ventilation. Results Within the first hour of ventilation, 20 of 32 patients (62 percent) in the noninvasive-ventilation group and 15 of 32 (47 percent) in the conventional-ventilation group had an improved ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2:FiO(2)) (P=0.21). Ten patients in the noninvasive-ventilation group subsequently required endotracheal intubation. Seventeen patients in the conventional-ventilation group (53 percent) and 23 in the noninvasive-ventilation group (72 percent) survived their stay in the intensive care unit (odds ratio, 0.4; 95 percent confidence interval, 0.1 to 1.4; P = 0.19); 16 patients in the conventional-ventilation group and 22 patients in the noninvasive-ventilation group were discharged from the hospital. More patients in the conventional-ventilation group had serious complications (66 percent vs. 38 percent, P = 0.02) and had pneumonia or sinusitis related to the endotracheal tube (31 percent vs. 3 percent, P = 0.003). Among the survivors, patients in the noninvasive-ventilation group had shorter periods of ventilation (P = 0.006) and shorter stays in the intensive care unit (P = 0.002). Conclusions In patients with acute respiratory failure, noninvasive ventilation was as effective as conventional ventilation in improving gas exchange and was associated with fewer serious complications and shorter stays in the intensive care unit. (N Engl J Med 1998;339:429-35.) (C)1998, Massachusetts Medical Society.	Univ La Sapienza, Policlin Umberto I, Ist Anestesiol & Reanimaz, I-00161 Rome, Italy; Univ Tennessee, Dept Med, Lung Res Program, Div Pulm & Crit Care, Memphis, TN 38104 USA	Sapienza University Rome; University Hospital Sapienza Rome; University of Tennessee System; University of Tennessee Health Science Center	Antonelli, M (corresponding author), Univ La Sapienza, Policlin Umberto I, Ist Anestesiol & Reanimaz, Viale Policlin 155, I-00161 Rome, Italy.		Rocco, Monica/B-8407-2013; Antonelli, Massimo/K-9915-2016; De Blasi, Roberto A/B-6666-2013; Antonelli, Massimo/F-9848-2010; Conti, Giorgio/AAB-9546-2022	Rocco, Monica/0000-0001-8380-3607; Antonelli, Massimo/0000-0003-3007-1670; De Blasi, Roberto A/0000-0002-1069-2544; Conti, Giorgio/0000-0002-8566-9365				AHMED AH, 1992, THORAX, V47, P858; Antonelli M, 1996, CHEST, V110, P724, DOI 10.1378/chest.110.3.724; ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1989, AM REV RESPIR DIS, V139, P513, DOI 10.1164/ajrccm/139.2.513; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Cochran W.G., 1967, STAT METHODS; Daskalopoulou E, 1993, CHEST, V103, p271S; ESTES RJ, 1995, INTENS CARE MED, V21, P365, DOI 10.1007/BF01705418; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GREGORETTI C, 1992, American Review of Respiratory Disease, V145, pA75; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; MARTIN TJ, 1994, CRIT CARE MED, V23, pA129; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; Meduri GU, 1996, CLIN CHEST MED, V17, P513, DOI 10.1016/S0272-5231(05)70330-0; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	26	619	652	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					429	435		10.1056/NEJM199808133390703	http://dx.doi.org/10.1056/NEJM199808133390703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700176				2022-12-28	WOS:000075342500003
J	Diel, IJ; Solomayer, EF; Costa, SD; Gollan, C; Goerner, R; Wallwiener, D; Kaufmann, M; Bastert, G				Diel, IJ; Solomayer, EF; Costa, SD; Gollan, C; Goerner, R; Wallwiener, D; Kaufmann, M; Bastert, G			Reduction in new metastases in breast cancer with adjuvant clodronate treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELLS IN-VITRO; BONE METASTASES; MACROPHAGE-LIKE; BISPHOSPHONATE RISEDRONATE; PROPHYLACTIC TREATMENT; ORAL CLODRONATE; DOUBLE-BLIND; TUMOR; MARROW; GROWTH	Background Bisphosphonates are effective against the increased bone resorption caused by certain diseases because they inhibit the activity of osteoclasts. In patients who have breast cancer and metastatic bone disease, the bisphosphonate clodronate (clodronic acid) reduces the frequency of skeletal complications. Experiments in animals and preliminary clinical observations indicate that early clodronate therapy reduces the incidence of new bony metastases in breast cancer. We investigated the effects of clodronate on the incidence and extent of new metastases in patients with breast cancer. Methods Between 1990 and 1995, 302 patients with primary breast cancer and tumor cells in the bone marrow (the presence of which is a risk factor for the development of distant metastases) were randomly assigned to receive clodronate at a dose of 1600 mg per day orally for two years (157 patients) or standard follow-up (145 patients). The median length of observation was 36 months. All patients in both groups received standard surgical treatment and customary hormonal therapy or chemotherapy. Results Distant metastases were detected in 21 patients in the clodronate group and in 42 patients in the control group (P<0.001). The incidence of both osseous and visceral metastases was significantly lower in the clodronate group than in the control group (P=0.003 for both osseous and visceral metastases). Six patients in the clodronate group died, as did 22 in the control group (P=0.001), The mean number of bony metastases per patient in the clodronate group was roughly half that in the control group (3.1 vs. 6.3). Conclusions Clodronate can reduce the incidence and number of new bony and visceral metastases in women with breast cancer who are at high risk for distant metastases. (N Engl J Med 1998;339:357-63.) (C)1998, Massachusetts Medical Society.	Univ Hosp, Dept Obstet & Gynecol, D-69115 Heidelberg, Germany; Univ Frankfurt, Dept Obstet & Gynecol, D-6000 Frankfurt, Germany	Ruprecht Karls University Heidelberg; Goethe University Frankfurt	Diel, IJ (corresponding author), Univ Hosp, Dept Obstet & Gynecol, Voss Str 9, D-69115 Heidelberg, Germany.							AVERBUCH SD, 1993, CANCER-AM CANCER SOC, V72, P3443, DOI 10.1002/1097-0142(19931201)72:11+<3443::AID-CNCR2820721611>3.0.CO;2-3; Boissier S, 1997, CANCER RES, V57, P3890; COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13; COLEMAN RE, 1985, CANCER TREAT REV, V12, P251, DOI 10.1016/0305-7372(85)90008-8; DIEL IJ, 1992, J CLIN ONCOL, V10, P1534, DOI 10.1200/JCO.1992.10.10.1534; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; ELOMAA I, 1988, BIOMED PHARMACOTHER, V42, P111; ELOMAA I, 1987, BONE, V8, pS53; Fleisch H, 1989, Recent Results Cancer Res, V116, P1; HALL DG, 1994, J BONE MINER RES, V9, P221; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Kanis JA, 1996, BONE, V19, P663, DOI 10.1016/S8756-3282(96)00285-2; KANIS JA, 1994, INT J ONCOL, V5, P713; KNAIS JA, 1995, BONE S2, V17, pS101; KOSTENUIK PJ, 1993, CANCER RES, V53, P5452; KREMPIEN B, 1988, ONCOLOGY, V45, P41, DOI 10.1159/000226528; KREMPIEN B, 1993, CANCER, V72, P91, DOI 10.1002/1097-0142(19930701)72:1<91::AID-CNCR2820720118>3.0.CO;2-2; KREMPIEN B, 1996, BONE METASTASIS MECH, P221; MANSI JL, 1991, EUR J CANCER, V27, P1552, DOI 10.1016/0277-5379(91)90413-8; MONKKONEN J, 1993, CALCIFIED TISSUE INT, V53, P139, DOI 10.1007/BF01321893; MONKKONEN J, 1994, J DRUG TARGET, V2, P299, DOI 10.3109/10611869409015910; Mundy G. R., 1993, PHYSL PHARM BONE, P641; MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756-3282(91)90057-P; NEMOTO R, 1987, J CANCER RES CLIN, V113, P539, DOI 10.1007/BF00390862; OROURKE N, 1995, J CLIN ONCOL, V13, P929, DOI 10.1200/JCO.1995.13.4.929; PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59; REDDING WH, 1983, LANCET, V2, P1271; Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722; Rogers MJ, 1996, J BONE MINER RES, V11, P1482; SASAKI A, 1995, CANCER RES, V55, P3551; STEARNS ME, 1996, METASTASIS, V16, P116; THERIAULT RL, 1992, ANTI-CANCER DRUG, V3, P455, DOI 10.1097/00001813-199210000-00002; vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841; WINGEN F, 1986, J CANCER RES CLIN, V111, P35, DOI 10.1007/BF00402773; Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435	35	628	637	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1998	339	6					357	363		10.1056/NEJM199808063390601	http://dx.doi.org/10.1056/NEJM199808063390601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107MD	9691101				2022-12-28	WOS:000075212300001
J	Forrow, L; Sidel, VW				Forrow, L; Sidel, VW			Medicine and nuclear war - From Hiroshima to mutual assured destruction to abolition 2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSEQUENCES; PREVENTION; HEALTH; WINTER	To determine how physicians might participate in the prevention of nuclear war in the post-Cold War era, we review, from a medical perspective, the history of the nuclear weapons era since Hiroshima and the status of today's nuclear arsenals and dangers. In the 1950s, physicians were active partners in governmental civil defense planning. Since 1962, physicians have stressed prevention of nuclear war as the only effective medical intervention. Public advocacy by physicians helped end both atmospheric nuclear testing in the 1960s and superpower plans for fighting a nuclear war in the 1980s. Today's dangers include nuclear arms proliferation, an increasing risk of nuclear terrorism, and the 35000 warheads that remain in superpower nuclear arsenals, many still on hair-trigger alert. Physicians have recently joined with military and political leaders and over 1000 citizens' organizations in calling for the complete elimination of nuclear weapons. Global medical collaboration in support of a verifiable and enforceable Nuclear Weapons Convention would be a major contribution to safeguarding health in the 21st century.	Beth Israel Deaconess Med Ctr, Phys Social Responsibil, Albert Schweitzer Fellowship, Boston, MA 02215 USA; Montefiore Med Ctr, Dept Epidemiol & Social Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Beth Israel Deaconess Med Ctr, Int Phys Prevent Nucl War, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Forrow, L (corresponding author), Beth Israel Deaconess Med Ctr, Phys Social Responsibil, Albert Schweitzer Fellowship, 330 Brookline Ave, Boston, MA 02215 USA.	lforrow@igc.org						ABRAMS HL, 1981, NEW ENGL J MED, V305, P1226, DOI 10.1056/NEJM198111123052027; ABRAMS HL, 1984, JAMA-J AM MED ASSOC, V252, P653, DOI 10.1001/jama.252.5.653; ALLISON GT, 1985, HAWKS DOVES OWLS AGE, P230; ALLISON GT, 1996, AVOIDING NUCL ANARCH, P10; *AM COLL PHYS, 1996, M AM COLL PHYS OCT P; *AM MED ASS, 1981, POL 520 999 520 997; *AM PUBL HLTH ASS, 1997, AM J PUBLIC HEALTH, V87, P500; ANDERSON E, 1955, WORLD A SCHWEITZER; ARMSTRONG GE, 1948, JAMA-J AM MED ASSOC, V137, P105; ARONOW S, 1962, NEW ENGL J MED, V266, P1145, DOI 10.1056/NEJM196205312662206; BARTLETT J, 1980, FAMILIAR QUOTATIONS, P776; BOYER P, 1985, JAMA-J AM MED ASSOC, V254, P633, DOI 10.1001/jama.254.5.633; BOYER P, 1994, BOMBS EARLY LIGHT AM, P53; *BRIT MED ASS, 1986, REP BOARD SCI ED LON; *BRIT MED ASS, 1983, REP BOARD SCI ED MED; CASSEL CK, 1985, JAMA-J AM MED ASSOC, V254, P652, DOI 10.1001/jama.254.5.652; DAY B, 1985, JAMA-J AM MED ASSOC, V254, P644, DOI 10.1001/jama.254.5.644; DIAMOND J, 1994, BOSTON GLOBE    0716, P3; DRELL SD, 1985, READINGS SCI AM ARMS, P96; E Ishikawa, 1981, HIR NAG; ERVIN FR, 1962, NEW ENGL J MED, V266, P1127, DOI 10.1056/NEJM196205312662204; Forrow L, 1998, NEW ENGL J MED, V338, P1326, DOI 10.1056/NEJM199804303381824; FORROW L, 1995, ABOLITION 2000 HDB W; GARLAND J, 1962, NEW ENGL J MED, V266, P1174; GORBACHEV M, 1988, PERESTROIKA NEW THIN, P140; GRAY CS, 1984, NUCL WEAPONS NUCL WA, P49; HARWELL MA, 1986, MED IMPLICATIONS NUC, P117; Hersey John, 1989, HIROSHIMA; HERSHBERG J, 1993, JB CONANT HARVARD HI, P258; HIATT HH, 1981, JAMA-J AM MED ASSOC, V246, P2035, DOI 10.1001/jama.246.18.2035; HIATT HH, 1984, JAMA-J AM MED ASSOC, V252, P635, DOI 10.1001/jama.252.5.635; HIATT HH, 1980, JAMA-J AM MED ASSOC, V244, P2314, DOI 10.1001/jama.244.20.2314; *I MED, 1986, MED IMPL NUCL WAR; *INT PHYS PREV NUC, 1996, IPPNW GLOB HLTH WATC; *INT PHYS PREV NUC, 1991, RAD HEAV EARTH HLTH; JACK HA, 1988, A SCHWEITZER NUCL WA; *LAK SOS SNELL ASS, 1998, POLL COMM GRACE AB 2; LEAF A, 1986, NEW ENGL J MED, V315, P905, DOI 10.1056/NEJM198610023151437; LEANING J, 1984, COUNTERFEIT ARK CRIS, pR25; LEIDERMAN P. HERBERT, 1962, NEW ENGLAND JOUR MED, V266, P1149, DOI 10.1056/NEJM196205312662207; Leventhal Paul, 1986, NUCL TERRORISM DEFIN; LEVY BS, 1997, WAR PUBLIC HLTH, P82; LIFTON RJ, 1995, HIROSHIMA AM HALF CE, P168; LOWN B, 1981, NEW ENGL J MED, V304, P726, DOI 10.1056/NEJM198103193041210; LOWN B, 1981, JAMA-J AM MED ASSOC, V246, P2331, DOI 10.1001/jama.246.20.2331; LOWN B, 1995, JAMA-J AM MED ASSOC, V274, P416, DOI 10.1001/jama.274.5.416; LOWN B, 1986, NEW ENGL J MED, V314, P985, DOI 10.1056/NEJM198604103141509; LOWN B, 1993, NEVER WHISPER PRESEN, P26; LUNDBERG GD, 1983, JAMA-J AM MED ASSOC, V250, P617, DOI 10.1001/jama.250.5.617; Mack J.E., 1982, LAST AID MED DIMENSI; Makhijani Arjun, 1995, NUCL WASTELANDS GLOB; MASTERS D, 1971, ONE WORLD NONE REPOR; MCCULLOUGH D, 1992, TRUMAN, P454; MCNAMARA RS, 1967, B ATOMIC SCI     DEC, P26; MCNAMARA RS, 1996, RETROSPECT, P338; MUKHERJEE SS, 1998, BOSTON GLOBE    0524, pD2; *NAT AC SCI, 1997, FUT US NUCL WEAP POL; NATHAN DG, 1962, NEW ENGL J MED, V266, P1126; *NCI, 1998, CALC EST LIF RISK RA; Norris RS, 1996, B ATOM SCI, V52, P61; *NUCL AG PEAC FDN, 1998, AB 2000; PAINE CE, 1997, END RUN US GOVT PLAN; PIPES R, 1984, SURVIVAL IS NOT ENOU, P238; RELMAN AS, 1982, NEW ENGL J MED, V307, P744, DOI 10.1056/NEJM198209163071209; RELMAN AS, 1986, NEW ENGL J MED, V315, P889, DOI 10.1056/NEJM198610023151410; ROSENTHAL HL, 1963, SCIENCE, V140, P176, DOI 10.1126/science.140.3563.176; RUSSETT B, 1985, READINGS SCI AM ARMS, P10; SANTHOLZ.W, 1966, NATURE, V212, P820, DOI 10.1038/212820a0; SCHEER R, 1982, ENOUGH SHOVELS REAGA, V8, P104; Schell Jonathan, 1982, FATE EARTH; Schell Jonathan, 1998, GIFT TIME CASE ABOLI; Schwartz StephenI., 1998, ATOMIC AUDIT COSTS C; SCRIMSHAW NS, 1984, NEW ENGL J MED, V311, P272, DOI 10.1056/NEJM198407263110442; SIDEL VW, 1985, LANCET, V2, P1287; SIDEL VW, 1962, NEW ENGL J MED, V266, P1137, DOI 10.1056/NEJM196205312662205; SIDEL VW, 1989, JAMA-J AM MED ASSOC, V262, P680, DOI 10.1001/jama.262.5.680; STARKEY WE, 1969, ARCH ORAL BIOL, V14, P169, DOI 10.1016/0003-9969(69)90061-2; TURCO RP, 1990, SCIENCE, V247, P166, DOI 10.1126/science.11538069; TURCO RP, 1983, SCIENCE, V222, P1283, DOI 10.1126/science.222.4630.1283; TURNER S, 1997, CAGING NUCL GENIE AM, P125; TYROLER C, 1984, PAPERS COMMITTEE PRE, P183; VOLPITTO PP, 1950, JAMA-J AM MED ASSOC, V142, P1090; WARREN R, 1950, NEW ENGL J MED, V243, P696; WHO, 1987, EFF NUCL WAR HLTH HL; WINKLER AM, 1984, B ATOMIC SCI     JUN, P16; WITTNER LS, 1997, RESISTING BOMB HIST, V2, P118; WITTNER LS, 1993, ONE WORLD NONE STRUG, V1, P250; 1998, NUCL WEAP CONV; 1995, VITAL SIGNS, V8, P1; 1983, LANCET, V1, P565; 1998, NEWSWEEK        0525, pD32	91	17	17	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					456	461		10.1001/jama.280.5.456	http://dx.doi.org/10.1001/jama.280.5.456			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701082				2022-12-28	WOS:000075050200034
J	Munro, AJ				Munro, AJ			What now for postoperative radiotherapy for lung cancer?	LANCET			English	Editorial Material									Ninewells Hosp, Dept Radiotherapy, Dundee DD1 9SY, Scotland	University of Dundee	Munro, AJ (corresponding author), Ninewells Hosp, Dept Radiotherapy, Dundee DD1 9SY, Scotland.							BARENDSEN GW, 1982, INT J RADIAT ONCOL, V8, P1981, DOI 10.1016/0360-3016(82)90459-X; PHILIPS P, 1993, INT J RADIAT ONCOL, V27, P525, DOI 10.1016/0360-3016(93)90375-6; Saunders M, 1997, LANCET, V350, P161, DOI 10.1016/S0140-6736(97)06305-8	3	53	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					250	251		10.1016/S0140-6736(98)22030-7	http://dx.doi.org/10.1016/S0140-6736(98)22030-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690399				2022-12-28	WOS:000074974500002
J	Angel, JB; Walpita, P; Lerch, RA; Sidhu, MS; Masurekar, M; DeLellis, RA; Noble, JT; Snydman, DR; Udem, SA				Angel, JB; Walpita, P; Lerch, RA; Sidhu, MS; Masurekar, M; DeLellis, RA; Noble, JT; Snydman, DR; Udem, SA			Vaccine-associated measles pneumonitis in an adult with AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							VIRUS-INFECTED CHILDREN; IMMUNODEFICIENCY; STRAIN		Wyeth Lederle Vaccines & Pediat, Pearl River, NY 10965 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA	Pfizer; Tufts University; Tufts Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Udem, SA (corresponding author), Wyeth Lederle Vaccines & Pediat, 401 N Middletown Rd, Pearl River, NY 10965 USA.		Snydman, David R/O-3889-2014	Snydman, David R/0000-0003-0119-3978; Angel, Jonathan B/0000-0003-3102-4462	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020532, R01AI035286] Funding Source: NIH RePORTER; NCRR NIH HHS [2 SO7 RR05393] Funding Source: Medline; NIAID NIH HHS [AI 35286, AI20532] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FRENKEL LM, 1994, ARCH PEDIAT ADOL MED, V148, P57, DOI 10.1001/archpedi.1994.02170010059012; *IMM PRACT ADV COM, 1988, MMWR-MORBID MORTAL W, V37, P181; KAPLAN LJ, 1992, JAMA-J AM MED ASSOC, V267, P1237, DOI 10.1001/jama.267.9.1237; KATZ SL, 1960, NEW ENGL J MED, V263, P159, DOI 10.1056/NEJM196007282630402; Kawashima H, 1996, ARCH VIROL, V141, P877, DOI 10.1007/BF01718162; MCCRUMB FR, 1961, AM J DIS CHILD, V101, P45; MCLAUGHLIN M, 1988, PEDIATRICS, V82, P229; MONAFO WJ, 1994, J PEDIATR-US, V124, P273, DOI 10.1016/S0022-3476(94)70318-3; MORI T, 1993, VIRUS GENES, V7, P67, DOI 10.1007/BF01702349; ONORATO IM, 1988, PEDIATR INFECT DIS J, V7, P588; PALUMBO P, 1992, PEDIATR INFECT DIS J, V11, P1008, DOI 10.1097/00006454-199211120-00004; Peter G, 1997, 1997 RED BOOK REPORT, P344; [No title captured]; 1988, MMWR MORB MORTAL WKL, V37, P2352; 1988, MMWR MORB MORTAL WKL, V37, P183	15	61	61	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					104	106		10.7326/0003-4819-129-2-199807150-00007	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669968				2022-12-28	WOS:000074852000005
J	de Semir, V; Ribas, C; Revuelta, G				de Semir, V; Ribas, C; Revuelta, G			Press releases of science journal articles and subsequent newspaper stories on the same topic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			MEDICINES	Context.-Scientific journals issue press releases to disseminate scientific news about articles they publish. Objective.-To assess whether press releases about journal articles were associated with publication of subsequent newspaper stories. Design.-Retrospective content analysis of newspaper stories, journal press releases, and journal tables of contents. From December 1, 1996, to February 28, 1997, press releases and tables of contents were collected from BMJ, Nature, Science, and The Lancet, along with newspaper stories on scientific research published in The New York Times (United States), Le Figaro and Le Monde (France), El Pais and La Vanguardia (Spain), La Repubblica (Italy), and the International Herald Tribune. Main Outcome Measurements.-Number of newspaper stories that contained reference to articles appearing in the 4 scientific journals, number of newspaper stories that referred to journal articles described in press releases, and the order in which journal articles were mentioned in press releases. Results.-Of the 1060 newspaper stories analyzed, 142 referred to journal articles; of these, 119 (84%) referred to articles mentioned in press releases and 23 (16%) referred to journal articles not mentioned in press releases (comparison of proportions, P = .03), Articles described first or second were referenced in more newspapers than articles described later in the press release (P = .01 by chi(2) analysis). Conclusions.-Journal articles described in press releases, in particular those described first or second in the press release, are associated with the subsequent publication of newspaper stories on the same topic.	Pompeu Fabra Univ, Observ Comunicacio Cient, E-08002 Barcelona, Spain; Quark Ciencia Med Comunicac & Cultura, Barcelona, Spain	Pompeu Fabra University	de Semir, V (corresponding author), Pompeu Fabra Univ, Observ Comunicacio Cient, La Rambla 30-32, E-08002 Barcelona, Spain.		revuelta, gema/B-3382-2011; Revuelta, Gema/AAD-1081-2022	revuelta, gema/0000-0002-0701-2026; Revuelta, Gema/0000-0002-0701-2026				ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; VANTRIGT AM, 1994, SOC SCI MED, V38, P637, DOI 10.1016/0277-9536(94)90261-5; VANTRIGT AM, 1995, SOC SCI MED, V41, P893, DOI 10.1016/0277-9536(94)00389-B; Wilkie T, 1996, LANCET, V347, P1308, DOI 10.1016/S0140-6736(96)90947-2	4	76	77	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					294	295		10.1001/jama.280.3.294	http://dx.doi.org/10.1001/jama.280.3.294			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZZ204	9676688	Green Published			2022-12-28	WOS:000074706000033
J	Junker, CA				Junker, CA			Adherence to published standards of reporting - A comparison of placebo-controlled trials published in English or German	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			RANDOMIZED CONTROLLED TRIALS; MEDICAL JOURNALS; CLINICAL-TRIALS; CONSORT STATEMENT; QUALITY; METAANALYSIS; GUIDELINES	Context.-Although standards of reporting randomized controlled trials are well established internationally, essential study elements continue to be omitted, which hampers interpretation and systematic review of randomized controlled trials. Objective.-To identify deficiencies in the quality of reporting of placebo-controlled randomized trials published in German or English. Design.-Observational study comparing 32 German- and 89 English-language reports of placebo-controlled trials with parallel design, published by the same group of authors between 1985 and 1994. Main Outcome Measure.-High reporting quality,defined as adherence to published standards and measured by an 18-item scale based on 2 standard guidelines. Results.-The mean quality score was 8.4 (SD, 3.0; range, 1-16) of 18. The difference of the mean quality scores between English-language reports compared with German-language reports was small (0.27; 95% confidence interval, -0.97 to 1,52), More articles reported clinical aspects than trial methods or statistics. Conclusion.-There is room for improvement in the reporting of placebo-controlled randomized trials for both English and German reports.	Univ Bern, Dept Social & Prevent Med, Bern, Switzerland	University of Bern	Junker, CA (corresponding author), ISPM, Finkenhubelweg 11, CH-3012 Bern, Switzerland.	junker@ispm.unibe.ch						ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; [Anonymous], 1988, ANN INTERN MED, V108, P258, DOI 10.7326/0003-4819-108-2-258; [Anonymous], 1997, JAMA, V277, P927; [Anonymous], 1978, BRIT MED J, V1, P1334; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; Crosby P.B., 1979, QUALITY IS FREE ART; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Egger M, 1996, LANCET, V347, P1047, DOI 10.1016/S0140-6736(96)90188-9; EVANS M, 1984, ARCH SURG-CHICAGO, V119, P109; GARDNER MJ, 1986, BRIT MED J, V292, P810, DOI 10.1136/bmj.292.6523.810; GARDNER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1355, DOI 10.1001/jama.263.10.1355; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; IMPERIALE TF, 1990, ANN INTERN MED, V113, P299, DOI 10.7326/0003-4819-113-4-299; *INT COMM MED J ED, 1997, KLIN MONATSBL AUG S3, V211, P1; *INT COMM MED J ED, 1993, KLIN MONATSBL AUG S1, V203, P1; Junker C, 1996, JAMA-J AM MED ASSOC, V276, P1876; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; Mosteller F, 1996, ANNU REV PUBL HEALTH, V17, P1, DOI 10.1146/annurev.pu.17.050196.000245; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; RENNIE D, 1990, JAMA-J AM MED ASSOC, V263, P1317, DOI 10.1001/jama.1990.03440100011001; RENNIE D, 1994, JAMA-J AM MED ASSOC, V272, P79; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408	32	37	37	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					247	249		10.1001/jama.280.3.247	http://dx.doi.org/10.1001/jama.280.3.247			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZZ204	9676671				2022-12-28	WOS:000074706000016
J	Arias, IM				Arias, IM			New genetics of inheritable jaundice and cholestatic liver disease	LANCET			English	Editorial Material									Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Arias, IM (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.							BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Jansen P L, 1995, Prog Liver Dis, V13, P125; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; ZHANG X, 1997, HEPATOLOGY, V26, pA69	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1998	352	9122					82	83		10.1016/S0140-6736(98)85004-6	http://dx.doi.org/10.1016/S0140-6736(98)85004-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672268				2022-12-28	WOS:000074775100004
J	Walworth, NC				Walworth, NC			Cell cycle - Rad9 comes of age	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; S-PHASE; KINASE; YEAST; THREONINE; SERINE; GENE; TRANSCRIPTION; TYROSINE		Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Walworth, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA.	walworna@umdnj.edu		Walworth, Nancy/0000-0001-5940-8236				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Fay DS, 1997, CURR GENET, V31, P97, DOI 10.1007/s002940050181; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829	18	3	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					185	186		10.1126/science.281.5374.185	http://dx.doi.org/10.1126/science.281.5374.185			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9687277				2022-12-28	WOS:000074714200025
J	Burke, W; Thomson, E; Khoury, MJ; McDonnell, SM; Press, N; Adams, PC; Barton, JC; Beutler, E; Brittenham, G; Buchanan, A; Clayton, EW; Cogswell, ME; Meslin, EM; Motulsky, AG; Powell, LW; Sigal, E; Wilfond, BS; Collins, FS				Burke, W; Thomson, E; Khoury, MJ; McDonnell, SM; Press, N; Adams, PC; Barton, JC; Beutler, E; Brittenham, G; Buchanan, A; Clayton, EW; Cogswell, ME; Meslin, EM; Motulsky, AG; Powell, LW; Sigal, E; Wilfond, BS; Collins, FS			Hereditary hemochromatosis - Gene discovery and its implications for population-based screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IRON OVERLOAD; AFRICAN-AMERICANS; IDIOPATHIC HEMOCHROMATOSIS; COST-EFFECTIVENESS; HEALTH-INSURANCE; CYSTIC-FIBROSIS; MOLECULAR-BASIS; BLOOD-DONORS; PHENYLKETONURIA; PREVALENCE	Objective.-To evaluate the role of genetic testing in screening for hereditary hemochromatosis to help guide clinicians, policymakers, and researchers. Participants.-An expert panel was convened on March 3, 1997, by the Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI), with expertise in epidemiology, genetics, hepatology, iron overload disorders, molecular biology, public health, and the ethical, legal, and social implications surrounding the discovery and use of genetic information. Evidence.-The group reviewed evidence regarding the clinical presentation, natural history, and genetics of hemochromatosis, including current data on the candidate gene for hemochromatosis (HFE) and on the ethical and health policy implications of genetic testing for this disorder. Consensus Process.-Consensus was achieved by group discussion confirmed by a voice vote. A draft of the consensus statement was prepared by a writing committee and subsequently reviewed and revised by all members of the expert group over a 1-year period. Conclusions.-Genetic testing is not recommended at this time in population-based screening for hereditary hemochromatosis, due to uncertainties about prevalence and penetrance of HFE mutations and the optimal care of asymptomatic people carrying HFE mutations. In addition, use of a genetic screening test raises concerns regarding possible stigmatization and discrimination. Tests for HFE mutations may play a role in confirming the diagnosis of hereditary hemochromatosis in persons with elevated serum iron measures, but even this use is limited by uncertainty about genotype-phenotype correlations. To address these questions, the expert group accorded high priority to population-based research to define the prevalence of HFE mutations, age and sex-related penetrance of different HFE genotypes, interactions between HFE genotypes and environmental modifiers, and psychosocial outcomes of genetic screening for hemochromatosis.	Univ Washington, Dept Med, Seattle, WA 98105 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; NIH, Natl Ctr Human Genome Res, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Off Genet & Dis Prevent, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Med, Los Angeles, CA USA; Univ Western Ontario, Dept Med, London, ON, Canada; So Iron Disorders Ctr, Birmingham, AL USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Case Western Reserve Univ, Metrohlth Med Ctr, Dept Med, Cleveland, OH USA; Univ Wisconsin, Sch Business, Madison, WI 53706 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN USA; Vanderbilt Univ, Sch Law, Nashville, TN 37240 USA; Univ Queensland, Dept Med, Brisbane, Qld 4000, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; Mercator Genet, Menlo Park, CA USA; Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of California System; University of California Los Angeles; Western University (University of Western Ontario); Scripps Research Institute; Case Western Reserve University; MetroHealth System; University of Wisconsin System; University of Wisconsin Madison; Vanderbilt University; Vanderbilt University; University of Queensland; QIMR Berghofer Medical Research Institute; University of Arizona	Burke, W (corresponding author), Univ Washington, Dept Med, Box 354765,4245 Roosevelt Way NE, Seattle, WA 98105 USA.	wburke@u.washington.edu	Adams, Paul/G-2868-2011	Barton, James/0000-0003-2876-8276; Clayton, Ellen/0000-0002-0308-4110				Adams PC, 1996, HEPATOLOGY, V23, P724, DOI 10.1002/hep.510230411; ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; Adams PC, 1996, SEMIN LIVER DIS, V16, P47, DOI 10.1055/s-2007-1007218; Adams PC, 1998, GASTROENTEROLOGY, V114, P319, DOI 10.1016/S0016-5085(98)70483-4; Adams PC, 1997, HEPATOLOGY, V26, P986, DOI 10.1002/hep.510260428; Adams PC, 1997, HEPATOLOGY, V25, P162, DOI 10.1002/hep.510250130; Adams PC, 1997, GASTROENTEROLOGY, V112, pA1207; ADAMS PC, 1992, DIGEST DIS SCI, V37, P361, DOI 10.1007/BF01307728; Alper J S, 1994, J Public Health Policy, V15, P345, DOI 10.2307/3342910; Bacon BR, 1997, GASTROENTEROLOGY, V113, P995, DOI 10.1016/S0016-5085(97)70196-3; Baer D, 1996, AM J MED, V101, P5, DOI 10.1016/S0002-9343(96)00157-X; BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BARTON JC, 1995, AM J MED, V99, P616, DOI 10.1016/S0002-9343(99)80248-4; Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129; Beutler E, 1997, MOL MED, V3, P397, DOI 10.1007/BF03401686; Beutler E, 1997, AM J HUM GENET, V61, P762; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P95, DOI 10.1006/bcmd.1997.0125; Beutler E, 1997, LANCET, V349, P296, DOI 10.1016/S0140-6736(97)22005-2; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Bodmer JG, 1997, NAT GENET, V15, P234, DOI 10.1038/ng0397-234c; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; BOTHWELL TH, 1995, METABOLIC MOL BASES, pCH69; Bradley L A, 1996, J Med Screen, V3, P171; Carella M, 1997, AM J HUM GENET, V60, P828; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P991; COGSWELL ME, IN PRESS ANN INTERN; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1994, ADV EXP MED BIOL, V356, P303; Eisensmith Randy C., 1992, Human Mutation, V1, P13, DOI 10.1002/humu.1380010104; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Haddow J E, 1994, J Med Screen, V1, P16; Holtzman NA., 1998, PROMOTING SAFE EFFEC; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; *I MED, 1994, ASS GEN RISKS IMPL H; JAZWINSKA EC, 1996, NAT GENET, V13, P399; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kerem B, 1996, EUR J HUM GENET, V4, P65; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; LUDWIG J, 1993, MAYO CLIN PROC, V68, P263, DOI 10.1016/S0025-6196(12)60047-0; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; MOTULSKY AG, 1997, METABOLIC MOL BASES; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; Powell LW, 1996, SEMIN LIVER DIS, V16, P55, DOI 10.1055/s-2007-1007219; Robson KJH, 1997, GUT, V41, P841; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SCRIVER CR, 1980, NEW ENGL J MED, V303, P1394, DOI 10.1056/NEJM198012113032404; SIMON M, 1977, NEW ENGL J MED, V297, P1017, DOI 10.1056/NEJM197711102971901; SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332; Smith BN, 1997, HEPATOLOGY, V25, P1439, DOI 10.1002/hep.510250622; Tay GK, 1997, IMMUNOGENETICS, V45, P336; TYFIELD LA, 1995, J MED GENET, V32, P867, DOI 10.1136/jmg.32.11.867; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Wilson JMB, 1968, 34 WHO; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Wurapa RK, 1996, AM J MED, V101, P9, DOI 10.1016/S0002-9343(96)00053-8; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	61	236	240	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					172	178		10.1001/jama.280.2.172	http://dx.doi.org/10.1001/jama.280.2.172			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669792				2022-12-28	WOS:000074608400034
J	Bashford, JNR; Norwood, J; Chapman, SR				Bashford, JNR; Norwood, J; Chapman, SR			Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To establish the relation between new prescriptions for proton pump inhibitors and recorded upper gastrointestinal morbidity within a large computerised general practitioner database. Design: Retrospective survey of morbidity and prescribing data linked to new prescriptions for proton pump inhibitors and comparison with licensed indications between 1991 and 1995. Setting: General Practice Research Database and prescribing analysis and cost (PACT) data for the former West Midlands region. Subjects: Information for 612 700 patients in the General Practice Research Database. Anonymous PACT data for all general practitioners in West Midlands region. Main outcome measures: Diagnostic codes linked to the first prescriptions issued for proton pump inhibitors; relation between new prescriptions and licensed indications; yearly change in ratio of new to repeat prescriptions and prescribing volumes measured as defined daily doses. Results: Oesophagitis was the commonest recorded indication in 1991, accounting for 31% of new prescriptions, but was third in 1995 (14%). During the study new prescriptions increased substantially, especially for duodenal disease (780%) and non-ulcer dyspepsia (690%). In 1995 non-specific morbidity accounted for 46% of new prescriptions. The total volume of prescribing rose 10-fold between 1991 and 1995, when repeat prescribing accounted for 77% of the total. Conclusions: Changes in recorded morbidity associated with new prescriptions of proton pump inhibitors did not necessarily reflect changes in licensed indications. Although general practitioners seemed to respond to changes in licensing, particularly for duodenal and gastric disease, prescribing for unlicensed indications non-ulcer dyspepsia and non-specific abdominal pain increased.	Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England	Keele University	Chapman, SR (corresponding author), Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England.							Agreus L, 1997, BRIT MED J, V315, P1284, DOI 10.1136/bmj.315.7118.1284; Bateman DN, 1997, LANCET, V349, P1637, DOI 10.1016/S0140-6736(05)62629-3; Boath EH, 1997, SOC SCI MED, V45, P1571, DOI 10.1016/S0277-9536(97)00094-4; BRADLEY C, 1992, BR J GEN PRACT, V42, P458; *BRIT SOC GASTR, 1996, GUID GASTR, V1; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; EVANS SJW, 1991, BRIT MED J, V302, P302, DOI 10.1136/bmj.302.6772.302; Fleming D. M., 1994, Pharmaceutical Medicine (London), V8, P161; HALL G, 1992, PHARMACOEPIDEM DR S, V1, P33; Harris CM, 1996, BRIT J GEN PRACT, V46, P649; HEMINKI E, 1975, SOC SCI MED, V9, P111; HEPBURN A, 1991, PRESCRIBERS J, V31, P49; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Majeed A, 1997, BRIT MED J, V315, P1515, DOI 10.1136/bmj.315.7121.1515; MARINKER M, 1994, CONTROVERSIES HLTH C; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; *OFF NAT STAT, 1996, GEN PRACT RES DAT IN; Pryce AJ, 1996, BRIT MED J, V313, P1621, DOI 10.1136/bmj.313.7072.1621; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; STRICKLANDHODGE B, 1988, J ROY SOC MED, V81, P207, DOI 10.1177/014107688808100407; *WHO COLL CTR DRUG, 1991, GUID DDD	22	104	105	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					452	456						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703528				2022-12-28	WOS:000075490200021
J	Sturchio, NC; Antonio, MR; Soderholm, L; Sutton, SR; Brannon, JC				Sturchio, NC; Antonio, MR; Soderholm, L; Sutton, SR; Brannon, JC			Tetravalent uranium in calcite	SCIENCE			English	Article							ABSORPTION FINE-STRUCTURE; RADIONUCLIDES	X-ray absorption spectroscopy and x-ray fluorescence microprobe studies of 35-million-year-old calcite from a Mississippi Valley-type zinc ore deposit indicate substitution of tetravalent uranium for divalent calcium. Thus, tetravalent uranium has a stable location in calcite deposited under reducing conditions. This result validates uranium-series dating methods (including uranium/lead dating) for ancient calcite and shows that calcite provides a sink for uranium in deep groundwater aquifers and anoxic lacustrine and marine basins.	Argonne Natl Lab, Argonne, IL 60439 USA; Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL 60637 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA	United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago; University of Chicago; Washington University (WUSTL)	Sturchio, NC (corresponding author), Argonne Natl Lab, 9700 S Cass Ave, Argonne, IL 60439 USA.		Soderholm, Lynda/H-4432-2011; Antonio, Mark/AFV-0010-2022	Soderholm, Lynda/0000-0003-4435-2721; Sturchio, Neil/0000-0002-7581-9585; Antonio, Mark/0000-0002-1208-4534				BANNER JL, 1990, EARTH PLANET SC LETT, V101, P296, DOI 10.1016/0012-821X(90)90161-P; Brannon JC, 1996, CARBONATE HOSTED LEA, V4, P536; Burns PC, 1996, CAN MINERAL, V34, P845; DELEON JM, 1991, PHYS REV B, V44, P4146, DOI 10.1103/PhysRevB.44.4146; FUCHS LH, 1958, AM MINERAL, V43, P243; George G.N., 1995, EXAFSPAK SUITE COMPU; GRATZ JF, 1987, ECON GEOL, V82, P1790, DOI 10.2113/gsecongeo.82.7.1790; Greegor RB, 1997, SCIENCE, V275, P1452, DOI 10.1126/science.275.5305.1452; ISHIKAWA M, 1984, CHEM GEOL, V42, P137, DOI 10.1016/0009-2541(84)90010-X; Israelson C, 1996, EARTH PLANET SC LETT, V141, P153, DOI 10.1016/0012-821X(96)00071-4; LANGMUIR D, 1978, GEOCHIM COSMOCHIM AC, V42, P547, DOI 10.1016/0016-7037(78)90001-7; LARNBLE GM, 1997, J PHYS 4, V7; LUDWIG KR, 1992, SCIENCE, V258, P284, DOI 10.1126/science.258.5080.284; MAZZI F, 1983, AM MINERAL, V68, P2262; MEECE DE, 1993, GEOCHIM COSMOCHIM AC, V57, P1447, DOI 10.1016/0016-7037(93)90005-H; PARKS GA, 1988, GEOCHIM COSMOCHIM AC, V52, P863, DOI 10.1016/0016-7037(88)90357-2; REEDER RJ, 1983, CARBONATES MINERALOG, V23, P1; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; RUSSELL AD, 1994, GEOCHIM COSMOCHIM AC, V58, P671, DOI 10.1016/0016-7037(94)90497-9; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P757; Smith J. V., 1995, MICROPROBE TECHNIQUE, P163; SUTTON SR, 1993, NUCL INSTRUM METH B, V75, P5533; SZYMANSKI JT, 1982, CAN MINERAL, V20, P272; WASSERSTEIN B, 1954, NATURE, V174, P1004, DOI 10.1038/1741004b0; Zeh P, 1997, RADIOCHIM ACTA, V76, P37; ZUKIN JG, 1987, GEOCHIM COSMOCHIM AC, V51, P2719, DOI 10.1016/0016-7037(87)90152-9	26	126	127	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					971	973		10.1126/science.281.5379.971	http://dx.doi.org/10.1126/science.281.5379.971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703507				2022-12-28	WOS:000075412700040
J	Narod, SA; Risch, H; Moslehi, R; Dorum, A; Neuhausen, S; Olsson, H; Provencher, D; Radice, P; Evans, G; Bishop, S; Brunet, JS; Ponder, BAJ				Narod, SA; Risch, H; Moslehi, R; Dorum, A; Neuhausen, S; Olsson, H; Provencher, D; Radice, P; Evans, G; Bishop, S; Brunet, JS; Ponder, BAJ		Hereditary Ovarian Canc Clinical Study Grp	Oral contraceptives and the risk of hereditary ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; MUTATIONS; CARRIERS; BRCA1	Background Women with mutations in either the BRCA1 or the BRCA2 gene have a high lifetime risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they also protect against hereditary forms of ovarian cancer. Methods We enrolled 207 women with hereditary ovarian cancer and 161 of their sisters as controls in a case-control study. All the patients carried a pathogenic mutation in either BRCA1 (179 women) or BRCA2 (28 women). The control women were en rolled regardless of whether or not they had either mutation. Lifetime histories of oral-contraceptive use were obtained by interview or by written questionnaire and were compared between patients and control women, after adjustment for year of birth and parity. Results The adjusted odds ratio for ovarian cancer associated with any past use of oral contraceptives was 0.5 (95 percent confidence interval, 0.3 to 0.8). The risk decreased with increasing duration of use (P for trend, <0.001); use for six or more years was associated with a 60 percent reduction in risk. Oral-contraceptive use protected against ovarian cancer both for carriers of the BRCA1 mutation (odds ratio, 0.5; 95 percent confidence interval, 0.3 to 0.9) and for carriers of the BRCA2 mutation (odds ratio, 0.4; 95 percent confidence interval, 0.2 to 1.1). Conclusions Oral-contraceptive use may reduce the risk of ovarian cancer in women with pathogenic mutations in the BRCA1 or BRCA2 gene. (N Engl J Med 1998;339:424-8.) (C)1998, Massachusetts Medical Society.	Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada; Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; Norwegian Radium Hosp, Unit Med Genet, Oslo, Norway; Univ Utah, Dept Med Informat, Salt Lake City, UT 84112 USA; Univ Lund, Dept Oncol, Lund, Sweden; Univ Montreal, Notre Dame Hosp, Dept Obstet & Gynecol, Montreal, PQ H3C 3J7, Canada; Ist Nazl Tumori, I-20133 Milan, Italy; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Univ Cambridge, Canc Res Campaign Genet Epidemiol Unit, Cambridge, England; Rotterdam Canc Inst, Dept Med Oncol, Rotterdam, Netherlands	University of Toronto; University Toronto Affiliates; Womens College Hospital; Yale University; University of British Columbia; University of Oslo; Utah System of Higher Education; University of Utah; Lund University; Universite de Montreal; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Manchester; University of Cambridge; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Narod, SA (corresponding author), Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, 790 Bay St,Rm 750A, Toronto, ON M5G 1N8, Canada.		McLaughlin, John R/E-4577-2013; Narod, Steven A/AAA-6112-2022; Radice, Paolo/O-3119-2013; Evans, D Gareth/AAB-4308-2022	Radice, Paolo/0000-0001-6298-4111; Evans, D Gareth/0000-0002-8482-5784; Olsson, Hakan/0000-0002-8794-9635	NATIONAL CANCER INSTITUTE [R01CA063678, R01CA063682, R01CA057601] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA63682, CA57601, CA63678] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; EASTON DF, 1995, AM J HUM GENET, V56, P265; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRANCESCHI S, 1991, INT J CANCER, V49, P61, DOI 10.1002/ijc.2910490112; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; RISCH HA, 1994, AM J EPIDEMIOL, V139, P670, DOI 10.1093/oxfordjournals.aje.a117057; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; Ursin G, 1997, CANCER RES, V57, P3678; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427	11	401	408	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					424	428		10.1056/NEJM199808133390702	http://dx.doi.org/10.1056/NEJM199808133390702			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700175				2022-12-28	WOS:000075342500002
J	Bastian, H; Keirse, MJNC; Lancaster, PAL				Bastian, H; Keirse, MJNC; Lancaster, PAL			Perinatal death associated with planned home birth in Australia: population based study	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY	Objective: To assess the risk of perinatal death in planned home births in Australia. Design: Comparison of data an planned home births during 1985-90, notified to Homebirth Australia, with national data on perinatal deaths and outcomes of home births internationally. Results: 50 perinatal deaths occurred in 7002 planned home births in Australia during 1985-90: 7.1 per 1000 (95% confidence interval 5.2 to 9.1) according to Australian definitions and 6.4 per 1000 (4.6 to 8.3) according to World Health Organisation definitions. The perinatal death rate in infants weighing more than 2500 g was higher than the national average (5.7 versus 3.6 per 1000: relative risk 1.6; 1.1 to 2.4) as were intrapartum deaths not due to malformations or immaturity (2.7 versus 0.9 per 1000: 3.0; 1.9 to 4.8). More than half (52%) of the deaths were associated with intrapartum asphyxia. Conclusions: Australian home births carried a high death rate compared with both all Australian births ana home births elsewhere. The two largest contributors to the excess mortality were underestimation of the risks associated with post-term birth, twin pregnancy and breech presentation, and a lack of response to fetal distress.	Flinders Univ S Australia, Flinders Med Ctr, Dept Obstet & Gynaecol, Adelaide, SA 5100, Australia; Univ New S Wales, Australian Inst Hlth & Welf, Natl Perinatal Stat Unit, Sydney, NSW 2052, Australia	Flinders Medical Centre; Flinders University South Australia; University of New South Wales Sydney	Bastian, H (corresponding author), POB 569, Blackwood, SA 5051, Australia.	hilda.bastian@flinders.edu.au		Bastian, Hilda/0000-0001-8544-7386				Anderson RE, 1995, J NURSE-MIDWIFERY, V40, P483, DOI 10.1016/0091-2182(95)00051-8; Barron SL, 1996, BRIT MED J, V313, P1306; BASTIAN H, 1992, HOME BIRTHS AUSTR 19; BASTIAN H, 1990, HOME BIRTHS AUSTR 19; CHAMBERLAIN G, 1996, HOME BIRTHS REPORT 1; Gardner M. J., 1989, STAT CONFIDENCE; Gulbransen G, 1997, NEW ZEAL MED J, V110, P87; LECKYTHOMPSON M, 1989, CELEBRATING REVOLUTI, P43; Lumley J, 1985, Aust Fam Physician, V14, P1104; Macfarlane A, 1996, BRIT MED J, V312, P754; MEHLMADRONA L, 1997, NURSE MIDWIFERY, V42, P91; *MIDIRS NHS CTR RE, 1997, INF CHOIC WOM; *MIDIRS NHS CTR RE, 1997, INF CHOIC PROF; ODENT M, 1991, MOTHERING, V58, P80; TEW M, 1995, SAFER CHILDBIRTH CRI, P311; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; WIEGERS TA, 1996, BRIT MED J, V313, P1276; WOODCOCK HC, EPIDEMIOLOGICAL STUD; *ZIEK, 1987, VERL IND 1987 FIN RE	19	82	83	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					384	388						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694754				2022-12-28	WOS:000075409600025
J	Lilford, RJ; Pauker, SG; Braunholtz, DA; Chard, J				Lilford, RJ; Pauker, SG; Braunholtz, DA; Chard, J			Getting research findings into practice - Decision analysis and the implementation of research findings	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION		Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Tufts Univ, New England Med Ctr, Dept Med, Boston, MA 02111 USA; Univ Bristol, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England	University of Birmingham; Tufts Medical Center; Tufts University; University of Bristol	Lilford, RJ (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.	rlilford@doh.gov.uk						[Anonymous], 1988, LANCET, V2, P349; COL NF, 1991, JAMA-J AM MED ASSOC, V277, P1140; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; DONNER A, 1982, J CHRON DIS, V35, P429, DOI 10.1016/0021-9681(82)90057-1; Dowie J, 1996, HEALTH CARE ANAL, V4, P5, DOI 10.1007/BF02251141; Dowie J, 1996, J Health Serv Res Policy, V1, P104; French S, 1989, READINGS DECISION AN; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; JOHNSON N, 1992, BRIT J CANCER, V65, P717, DOI 10.1038/bjc.1992.151; Johnson N., 1994, Journal of Obstetrics and Gynaecology (Abingdon), V14, P35, DOI 10.3109/01443619409025967; Keeney R.L., 1976, DECISIONS MULTIPLE O; KELLETT J, 1995, MED DECIS MAKING, V15, P297, DOI 10.1177/0272989X9501500401; Lilford RJ, 1995, J ROY SOC MED, V88, P552; Lilford RJ, 1996, BRIT MED J, V313, P603; LILFORD RJ, 1990, LANCET, V336, P1303, DOI 10.1016/0140-6736(90)92977-P; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PAUKER SP, 1977, YALE J BIOL MED, V50, P275; Sculpher M, 1996, INT J TECHNOL ASSESS, V12, P104, DOI 10.1017/S0266462300009430; SON HC, 1988, MED DECISION MAKING; Swales JD, 1997, LANCET, V349, P1319, DOI 10.1016/S0140-6736(97)02260-5; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; Weinstein MC, 1980, CLIN DECISION ANAL	22	87	87	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1998	317	7155					405	409						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694762				2022-12-28	WOS:000075409600034
J	Pellegrini, V; Pinczuk, A; Dennis, BS; Plaut, AS; Pfeiffer, LN; West, KW				Pellegrini, V; Pinczuk, A; Dennis, BS; Plaut, AS; Pfeiffer, LN; West, KW			Evidence of soft-mode quantum phase transitions in electron double layers	SCIENCE			English	Article							MAGNETIC-FIELD; ENERGY-SPECTRUM; WELL; GAS; INSTABILITY; SYSTEMS	Inelastic Light scattering by low-energy spin-excitations reveals three distinct configurations of spin of electron double Layers in gallium arsenide quantum wells at even-integer quantum Hall states. The transformations among these spin states appear as quantum phase transitions driven by the interplay between Coulomb interactions and Zeeman splittings. One of the transformations correlates with the emergence of a spin-flip intersubband excitation at vanishingly Low energy and provides direct evidence of a Link between quantum phase transitions and soft collective excitations in a two-dimensional electron system.	AT&T Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Scuola Normale Super Pisa, Pisa, Italy; Ist Nazl Fis Mat, Pisa, Italy; Columbia Univ, Dept Phys, New York, NY 10027 USA; Columbia Univ, Dept Appl Phys, New York, NY 10027 USA; Univ Exeter, Dept Phys, Exeter EX4 4QL, Devon, England	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs; Scuola Normale Superiore di Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Columbia University; Columbia University; University of Exeter	Pellegrini, V (corresponding author), AT&T Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.							BOEBINGER GS, 1990, PHYS REV LETT, V64, P1793, DOI 10.1103/PhysRevLett.64.1793; BREY L, 1990, PHYS REV LETT, V65, P903, DOI 10.1103/PhysRevLett.65.903; Chakraborty T., 1995, QUANTUM HALL EFFECTS, V85; Das Sarma S., 1996, PERSPECTIVES QUANTUM; DasSarma S, 1997, PHYS REV LETT, V79, P917, DOI 10.1103/PhysRevLett.79.917; DOBERS M, 1988, PHYS REV B, V38, P5453, DOI 10.1103/PhysRevB.38.5453; Eisenstein J.P., 1997, PERSPECTIVES QUANTUM, DOI 10.1002/9783527617258.ch2; FERTIG HA, 1989, PHYS REV B, V40, P1087, DOI 10.1103/PhysRevB.40.1087; GIRVIN SM, 1986, PHYS REV B, V33, P2481, DOI 10.1103/PhysRevB.33.2481; GIULIANI GF, 1985, PHYS REV B, V31, P6228, DOI 10.1103/PhysRevB.31.6228; HU J, 1992, PHYS REV B, V46, P12554, DOI 10.1103/PhysRevB.46.12554; KALLIN C, 1984, PHYS REV B, V30, P5655, DOI 10.1103/PhysRevB.30.5655; Kamilla RK, 1997, PHYS REV B, V55, P13417, DOI 10.1103/PhysRevB.55.R13417; MACDONALD AH, 1990, PHYS REV LETT, V65, P775, DOI 10.1103/PhysRevLett.65.775; Pellegrini V, 1997, PHYS REV LETT, V78, P310, DOI 10.1103/PhysRevLett.78.310; PINCZUK A, 1996, B AM PHYS SOC, V41, P482; Plaut AS, 1997, PHYS REV B, V55, P9282, DOI 10.1103/PhysRevB.55.9282; Prange R. E., 1990, QUANTUM HALL EFFECT; Sawada A, 1998, PHYS REV LETT, V80, P4534, DOI 10.1103/PhysRevLett.80.4534; Shayegan M., 1996, PERSPECTIVES QUANTUM, P343; Sondhi SL, 1997, REV MOD PHYS, V69, P315, DOI 10.1103/RevModPhys.69.315; YAFET Y, 1966, PHYS REV, V152, P858, DOI 10.1103/PhysRev.152.858; Zheng L, 1997, PHYS REV LETT, V78, P2453, DOI 10.1103/PhysRevLett.78.2453	24	87	87	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					799	802		10.1126/science.281.5378.799	http://dx.doi.org/10.1126/science.281.5378.799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694645				2022-12-28	WOS:000075295600041
J	Smith, MA; Doliszny, KM; Shahar, E; McGovern, PG; Arnett, DK; Luepker, RV				Smith, MA; Doliszny, KM; Shahar, E; McGovern, PG; Arnett, DK; Luepker, RV			Delayed hospital arrival for acute stroke: The Minnesota stroke survey	ANNALS OF INTERNAL MEDICINE			English	Article						cerebrovascular disorders; time factors; patient education; Asian Americans; activities of daily living	ACUTE MYOCARDIAL-INFARCTION; ACUTE ISCHEMIC STROKE; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE-PROFESSIONALS; SPECIAL-WRITING-GROUP; PREHOSPITAL DELAY; TIME; INTERVENTION; THROMBOLYSIS; GUIDELINES	Background: Although recent advances have been made in the treatment of acute stroke, patients often arrive at the hospital too late to receive the maximum benefit from these new therapies. Objective: To investigate characteristics that influence the time from symptom onset to hospital arrival (delay time) for patients with acute stroke. Design: Retrospective medical record review. Setting: Minneapolis-St. Paul metropolitan hospitals. Patients: A 50% random sample of all patients 30 to 79 years of age who were hospitalized with acute stroke from 1991 to 1993. Measurements: Patients were identified through discharge diagnosis lists by using the International Classification of Diseases, 9th Revision. Trained nurses abstracted the medical records. Stroke events were validated by using neuroimaging reports and additional clinical criteria (1895 patients). An accelerated failure time model was used to identify patient characteristics that independently predicted delay time. For 70% of patients (n = 1334), delay time was calculated from the medical record by subtracting the recorded time of symptom onset from the admission time. For the remaining 30% of patients (n = 561), the time of symptom onset was not recorded, and an approximate delay time was estimated from all available information. Results: Among patients with a calculated delay time, half arrived within 3 hours of symptom onset and 90% arrived within 24 hours. Patients with approximated delay times tended to have longer delays, and less than 40% of these patients arrived within 24 hours of symptom onset. Some characteristics associated (P < 0.05) with longer delay included Asian/Pacific Islander ethnicity, dependence in any activities of daily living before stroke, and several symptoms at stroke onset. Characteristics associated (P < 0.05) with shorter delay included admission through the emergency department, presence of syncope or seizures at stroke onset, previous myocardial infarction, abnormal mental status, and greater disability at presentation (measured by the Rankin scale). Conclusions: Most patients arrive at the hospital too late to receive the maximum benefit from emerging stroke therapies. Efforts to reduce delays in hospital arrival after acute stroke can maximize the effectiveness of these thera pies by specifically targeting persons at risk for longer delay.	Univ Minnesota, Div Epidemiol, Sch Publ Hlth, Minneapolis, MN 55454 USA	University of Minnesota System; University of Minnesota Twin Cities	Luepker, RV (corresponding author), Univ Minnesota, Div Epidemiol, Sch Publ Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023727] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-23727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams HP, 1996, STROKE, V27, P1711; ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; ALBERTS MJ, 1990, JAMA-J AM MED ASSOC, V263, P65, DOI 10.1001/jama.263.1.65; ALONZO AA, 1986, SOC SCI MED, V22, P1297, DOI 10.1016/0277-9536(86)90093-6; Barinaga M, 1996, SCIENCE, V272, P664; BARSAN WG, 1993, ARCH INTERN MED, V153, P2558, DOI 10.1001/archinte.153.22.2558; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CLARK LT, 1992, J NATL MED ASSOC, V84, P931; DAVALOS A, 1995, STROKE, V26, P2233, DOI 10.1161/01.STR.26.12.2233; Dorman P, 1996, LANCET, V348, P1600, DOI 10.1016/S0140-6736(05)65688-7; Dracup K, 1997, ANN INTERN MED, V126, P645, DOI 10.7326/0003-4819-126-8-199704150-00010; DRACUP K, 1995, SOC SCI MED, V40, P379, DOI 10.1016/0277-9536(94)00278-2; Fogelholm R, 1996, STROKE, V27, P398, DOI 10.1161/01.STR.27.3.398; GALLERANI M, 1993, ACTA NEUROL SCAND, V87, P482; Gurwitz JH, 1997, ANN INTERN MED, V126, P593, DOI 10.7326/0003-4819-126-8-199704150-00001; Hachinski V, 1996, JAMA-J AM MED ASSOC, V276, P995, DOI 10.1001/jama.276.12.995; HARPER GD, 1992, STROKE, V23, P835, DOI 10.1161/01.STR.23.6.835; HARRISON I, 1971, HLTH FAMILY MED SOCI; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KENYON LW, 1991, CIRCULATION, V84, P1969, DOI 10.1161/01.CIR.84.5.1969; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; LEIBSON CL, 1994, STROKE, V25, P2348, DOI 10.1161/01.STR.25.12.2348; Mechanic D., 1978, MED SOCIOLOGY; MOSS AJ, 1969, AM J CARDIOL, V24, P659, DOI 10.1016/0002-9149(69)90453-6; MOSS AJ, 1970, CIRCULATION, V41, P737, DOI 10.1161/01.CIR.41.5.737; NORRIS JW, 1982, LANCET, V1, P328; Pincus MM, 1997, JAMA-J AM MED ASSOC, V277, P19, DOI 10.1001/jama.277.1.19; RANKIN J, 1957, Scott Med J, V2, P200; Rosamond WD, 1998, ACAD EMERG MED, V5, P45, DOI 10.1111/j.1553-2712.1998.tb02574.x; SAS Institute Inc, 1989, SAS STAT US GUID VER; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; Shahar E, 1997, STROKE, V28, P275, DOI 10.1161/01.STR.28.2.275; TURI ZG, 1986, AM J CARDIOL, V58, P203, DOI 10.1016/0002-9149(86)90047-0; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325	35	128	131	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					190	+		10.7326/0003-4819-129-3-199808010-00005	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696726				2022-12-28	WOS:000075032700003
J	Douglas, C				Douglas, C			Clinical governance made simple	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					287	287		10.1136/bmj.317.7153.287	http://dx.doi.org/10.1136/bmj.317.7153.287			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677243	Green Published			2022-12-28	WOS:000075081900066
J	Itescu, S; Tung, TCM; Burke, EM; Weinberg, AD; Mancini, D; Michler, RE; Suciu-Foca, NM; Rose, EA				Itescu, S; Tung, TCM; Burke, EM; Weinberg, AD; Mancini, D; Michler, RE; Suciu-Foca, NM; Rose, EA			An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients	LANCET			English	Article							SOLID-ORGAN TRANSPLANTATION; ANTI-HLA ANTIBODIES; HEART-TRANSPLANTATION; ALLOGRAFT-REJECTION; LUNG-TRANSPLANTATION; SURVIVAL; MICROCHIMERISM; CELLS	Background Transplant-related coronary-artery disease (TCAD) develops frequently in cardiac-allograft recipients, and limits long-term survival. We examined the relation between this disorder and cumulative frequency of high-grade rejection, and investigated whether concomitant use of three immunological factors at the time of a low-grade endomyocardial biopsy can predict progression to high-grade rejection. Methods We investigated the relation between the cumulative annual frequency of high-grade rejection and TCAD in 198 recipients of cardiac transplantation between 1992 and 1996 by means of Kaplan-Meier actuarial life-tables. Endomyocardial biopsy, lymphocyte-growth assays, and anti-HLA antibody measurements were compiled over 12 months in 102 patients during their first post-transplant year. We calculated predictive values for high-grade rejection within 90 days by chi(2), Kaplan Meier survival curves, and by multivariable logistic regression analyses. Findings We found a direct correlation between cumulative annual frequency of rejection and TCAD onset with highest risk in those with more than 0.75 rejections per year (p=0.0002). After a low-grade endomyocardial biopsy (0 or 1A), one or more donor-recipient HLA-DR matches protected against high-grade rejections (p<0.001). Among individuals with one or two DR matches, the negative predictive value for progression from a low-grade biopsy to a high-grade rejection was 87% in the presence of a negative lymphocyte-growth assay. Among individuals with no DR matches, the presence of either lymphocyte-growth assay or IgG anti-major-histocompatibility complex (MHC) class II antibodies was independently associated With high probability of progression to rejection (64% and 68%, respectively, p<0.0005). When both assays were positive, concomitantly with a low-grade endomyocardial biopsy, the positive predictive value for progression to a high-grade rejection was 86% (p<0.0001). For endomyocardial-biopsy grades 1B or 2, a positive lymphocyte-growth assay alone was associated with high-grade rejection in 100% of cases. Interpretation Use of an algorithm combining three immunological factors at the time of a low-grade endomyocardial biopsy enables prospective stratification of cardiac transplant recipients into risk categories for progression to high-grade rejection. Low-risk individuals require fewer biopsies, moderate-risk individuals require an ongoing schedule of surveillance biopsies, and high-risk individuals require rational organisation of interventional strategies aimed at preventing rejection. Additional predictive factors are needed to identify moderate-risk individuals who will progress to rejection. Ultimately, successful intervention may have an impact on the subsequent complication of TCAD.	Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10032 USA	Columbia University	Itescu, S (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Surg, 622 W 168th St,PH 14 W, New York, NY 10032 USA.	si5@columbia.edu						BILLINGHAM ME, 1990, J HEART TRANSPLANT, V9, P272; Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117; CONSTANZONORDIN MR, 1992, J HEART LUNG TRANSPL, V11, pS90; Creemers P, 1997, NEPHRON, V75, P166, DOI 10.1159/000189526; DEMATTOS AM, 1994, TRANSPLANTATION, V57, P626; FISCHER PE, 1995, J HEART LUNG TRANSPL, V14, P1156; GEORGE JF, 1995, J HEART LUNG TRANSPL, V14, P856; HALL T S, 1986, Journal of Heart Transplantation, V5, P419; HESS ML, 1983, CIRCULATION, V68, P94; Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; ITESCU S, 1998, IN PRESS CIRCULATION; JARCHO J, 1994, J HEART LUNG TRANSPL, V13, P583; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEMKES BM, 1992, J HEART LUNG TRANSPL, V11, pS221; KEOGH A, 1995, J HEART LUNG TRANSPL, V14, P444; KERMAN RH, 1994, TRANSPLANTATION, V57, P884, DOI 10.1097/00007890-199403270-00020; KORMOS R, 1992, J HEART LUNG TRANSPL, V11, pS104; Krieger NR, 1996, J EXP MED, V184, P2013, DOI 10.1084/jem.184.5.2013; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIU Z, 1993, J EXP MED, V177, P1643, DOI 10.1084/jem.177.6.1643; Liu ZR, 1996, J CLIN INVEST, V98, P1150, DOI 10.1172/JCI118898; MAMULA MJ, 1993, IMMUNOL TODAY, V14, P151, DOI 10.1016/0167-5699(93)90274-O; MARKUS PM, 1993, CELL TRANSPLANT, V2, P345, DOI 10.1177/096368979300200418; REED EF, 1996, TRANSPLANTATION, V61, P556; RIZEQ MN, 1994, J HEART LUNG TRANSPL, V13, P862; ROSE EA, 1992, J HEART LUNG TRANSPL, V11, pS120; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SMITH JD, 1992, TRANSPLANTATION, V53, P1358, DOI 10.1097/00007890-199206000-00034; SMITH JD, 1995, LANCET, V346, P1318, DOI 10.1016/S0140-6736(95)92341-1; Starzl T E, 1994, Prog Liver Dis, V12, P191; SUCIUFOCA N, 1991, TRANSPLANTATION, V51, P716, DOI 10.1097/00007890-199103000-00033; Tugulea S, 1997, TRANSPLANTATION, V64, P842, DOI 10.1097/00007890-199709270-00009; VALENTINE H, 1991, J HEART LUNG TRANSPL, V10, P757; Vanderlugt CJ, 1996, CURR OPIN IMMUNOL, V8, P831, DOI 10.1016/S0952-7915(96)80012-4; White JA, 1995, J HEART LUNG TRANSPL, V14, P1052; WINTERS GL, 1995, CIRCULATION, V91, P1975, DOI 10.1161/01.CIR.91.7.1975; WISENBERG G, 1987, AM J CARDIOL, V60, P130, DOI 10.1016/0002-9149(87)90999-4; ZAVAZAVA N, 1993, TISSUE ANTIGENS, V42, P20, DOI 10.1111/j.1399-0039.1993.tb02161.x; ZEEVI A, 1995, TRANSPLANTATION, V59, P616	40	48	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					263	270		10.1016/S0140-6736(98)09475-6	http://dx.doi.org/10.1016/S0140-6736(98)09475-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690405	hybrid			2022-12-28	WOS:000074974500008
J	Nelles, J; Fuhrer, A; Hirsbrunner, HP; Harding, TW				Nelles, J; Fuhrer, A; Hirsbrunner, HP; Harding, TW			Provision of syringes: the cutting edge of harm reduction in prison?	BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS-DRUG-USERS; HEPATITIS-C VIRUS; HIV-INFECTION; AUSTRALIAN PRISON; RISK BEHAVIOR; NEEDLE; AIDS; PREVALENCE; EXCHANGE; PENITENTIARY		Univ Bern, Psychiat Serv, Dept East, CH-3000 Bern 60, Switzerland; Univ Geneva, Inst Med Legale, CH-1211 Geneva, Switzerland	University of Bern; University of Geneva	Nelles, J (corresponding author), Univ Bern, Psychiat Serv, Dept East, CH-3000 Bern 60, Switzerland.							ANON C, 1995, REV ESP ENFERM DIG, V87, P505; BREWER TF, 1992, AIDS, V6, P623, DOI 10.1097/00002030-199207000-00002; Council of Europe, 1993, R936 COUNC EUR; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DOLAN K, 1995, AIDS, V9, P825, DOI 10.1097/00002030-199508000-00001; DOLAN K, 1994, MED J AUSTRALIA, V160, P734, DOI 10.5694/j.1326-5377.1994.tb125930.x; DOLAN K, 1997, STRATEGIES DRUGS AID, P213; DUBOISARBER F, 1991, EVALUATION AIDS PRAV; FORD PM, 1995, CAN MED ASSOC J, V153, P1605; Frischer M, 1996, LANCET, V347, P768, DOI 10.1016/S0140-6736(96)90121-X; Gaiter J, 1996, AM J PUBLIC HEALTH, V86, P1201, DOI 10.2105/AJPH.86.9.1201; Gaube J, 1993, Gesundheitswesen, V55, P246; HARDING TW, 1997, HARM REDUCTION PRISO, P161; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; Mahon N, 1996, AM J PUBLIC HEALTH, V86, P1211, DOI 10.2105/AJPH.86.9.1211; MARTIN G S, 1990, AIDS Care, V2, P275, DOI 10.1080/09540129008257740; MEYENBERG R, 1996, INFEKTIONSPROPHYLAXE; MYERS T, 1995, ADDICTION, V90, P217, DOI 10.1111/j.1360-0443.1995.tb01039.x; Nelles J., 1997, HARM REDUCTION PRISO, P239; NELLES J, 1997, KURZEVALUATION PILOT; NELLES J, 1997, HARM REDUCTION PRISO; Nelles J., 1995, DRUG HIV PREVENTION; NELLES J, 1997, INT J DRUG POLICY, V1, P2; PAPE U, 1996, 54 KRIM FORSCH NIED; Polych C, 1995, MENS HLTH ILLNESS GE, P139; STARK K, 1995, SCAND J INFECT DIS, V27, P331, DOI 10.3109/00365549509032726; STARK K, 1995, ADDICTION, V90, P1367, DOI 10.1111/j.1360-0443.1995.tb03554.x; STEPHENS RC, 1991, AM J PUBLIC HEALTH, V81, P568, DOI 10.2105/AJPH.81.5.568; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; THOMAS PA, 1994, AIDS PRISON; VLAHOV D, 1993, EUR J EPIDEMIOL, V9, P566, DOI 10.1007/BF00209538; *WHO, 1993, GLOB PROGR AIDS WHO; 1995, LANCET, V346, P1397	35	31	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					270	273		10.1136/bmj.317.7153.270	http://dx.doi.org/10.1136/bmj.317.7153.270			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PG	9677225	Green Published			2022-12-28	WOS:000075081900031
J	Brenner, RA; Simons-Morton, BG; Bhaskar, B; Mehta, N; Melnick, VL; Revenis, M; Berendes, HW; Clemens, JD				Brenner, RA; Simons-Morton, BG; Bhaskar, B; Mehta, N; Melnick, VL; Revenis, M; Berendes, HW; Clemens, JD			Prevalence and predictors of the prone sleep position among inner-city infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; PROGRAM; COHORT; HEALTH; RISK; SIDS; BACK; CARE	Context.-The prone sleep position is associated with an increased risk of sudden infant death syndrome (SIDS), but few studies have assessed factors associated with the choice of infant sleep position. Objectives.-To describe infant sleep position in a cohort of infants born to predominantly low-income, inner-city mothers and to identify predictors of the prone sleep position in this population. Design.-Prospective birth cohort study. Patients and Setting.-Three hundred ninety-four mother-infant dyads, systematically selected from 3 District of Columbia hospitals between August 1995 and September 1996, Mothers were interviewed shortly after delivery and again at 3 to 7 months postpartum. Main Outcome Measures.-Position in which infants were placed for sleep on the night prior to the 3- to 7-month interview. Results.-At 3 to 7 months of age, 157 infants (40%) were placed for sleep in the prone position. Independent predictors of prone sleep position included poverty (odds ratio [OR], 1.81; 95% confidence interval [CI], 1.10-2.99), black race (OR, 2.06; 95% CI, 1.05-4.04), presence of infant's grandmother in the home (OR, 1.83; 95% CI, 1.11-3.00), and intent, as measured shortly after delivery, to place the infant in the prone position (OR, 2.28; 95% CI, 1.44-3.60), Importantly, of the 43 mothers who observed their infants in the prone sleep position while in the hospital, 40 (93%) intended to place their infants prone at home. Conclusions.-A substantial proportion of infants in this predominantly low-income population were placed in the prone sleep position. Educational efforts should address both initial intentions and reinforcement of the correct sleep position, once initiated. Hospitals should ensure that healthy newborn infants are placed in the supine sleep position during the postpartum hospital stay.	NICHHD, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA; Res Triangle Inst, Rockville, MD USA; Georgetown Univ Hosp, Div Neonatol, Washington, DC 20007 USA; Univ Dist Columbia, Dept Biol & Environm Sci, Washington, DC USA; Childrens Natl Med Ctr, Dept Neonatol, Washington, DC 20010 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Research Triangle Institute; Georgetown University; University of the District of Columbia; Children's National Health System	Brenner, RA (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, 6100 Execut Blvd,Room 7B03, Bethesda, MD 20892 USA.	BrennerR@nih.gov		Simons-Morton, Bruce/0000-0003-1099-6617	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U18HD030447, U18HD030450, U18HD030458] Funding Source: NIH RePORTER; NICHD NIH HHS [U18-HD30458, U18-HD30450, U18-HD30447] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1996, FED REGISTER, V61, P8286; Bandura A., 1986, SOCIAL FDN THOUGHT A; BATES AS, 1995, JAMA-J AM MED ASSOC, V272, P1105; BURD L, 1994, PUBLIC HEALTH REP, V109, P446; CHESSARE JB, 1995, PEDIATRICS, V96, P893; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; ELLEN JM, 1995, PEDIATR EMERG CARE, V11, P223, DOI 10.1097/00006565-199508000-00008; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Hiley CMH, 1995, ARCH DIS CHILD, V73, P496, DOI 10.1136/adc.73.6.496; Johnson CM, 1996, PEDIATRICS, V98, P163; KAHN A, 1993, PEDIATRICS, V91, P1112; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; Kattwinkel J, 1996, PEDIATRICS, V98, P1216; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; Kemp JS, 1996, SLEEP, V19, pS263, DOI 10.1093/sleep/19.suppl_10.S263; MARKESTAD T, 1995, ACTA PAEDIATR, V84, P375, DOI 10.1111/j.1651-2227.1995.tb13653.x; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; NELSON EAS, 1989, LANCET, V1, P199; PONSONBY AL, 1994, PREV MED, V23, P402, DOI 10.1006/pmed.1994.1055; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; PONSONBY AL, 1995, ARCH DIS CHILD, V72, P204, DOI 10.1136/adc.72.3.204; Ray BJ, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e12; Rogers EM., 1983, DIFFUSION INNOVATION; Sawczenko A, 1996, SLEEP, V19, pS267; Taylor JA, 1996, ARCH PEDIAT ADOL MED, V150, P834, DOI 10.1001/archpedi.1996.02170330060010; Taylor JA, 1996, J PEDIATR-US, V128, P626, DOI 10.1016/S0022-3476(96)80126-0; TUOHY PG, 1993, ARCH DIS CHILD, V69, P664, DOI 10.1136/adc.69.6.664; WILLINGER M, 1995, PEDIATR ANN, V24, P358, DOI 10.3928/0090-4481-19950701-07; Willinger M, 1998, JAMA-J AM MED ASSOC, V280, P329, DOI 10.1001/jama.280.4.329; WILLINGER M, 1994, PEDIATRICS, V93, P814; WILLINGER M, 1995, JAMA-J AM MED ASSOC, V273, P818, DOI 10.1001/jama.273.10.818	34	85	86	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					341	346		10.1001/jama.280.4.341	http://dx.doi.org/10.1001/jama.280.4.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686551	Bronze			2022-12-28	WOS:000074804200034
J	Drenth, JPH				Drenth, JPH			Multiple authorship - The contribution of senior authors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			MEDICINE	Context.-The number of authors per article has increased markedly in recent years. Little is known about the hierarchical order of authorship and its change over time. Objective.-To assess the change in number and profile of authors of original articles published over a 20-year period in BMJ. It was hypothesized that the number of authors increased over this 20-year period and that it was the senior scientists who benefited most. Design.-Comparative descriptive analysis of the number and academic rank of authors who published original articles in BMJ volumes 270 (1975), 280 (1980), 290 (1985), 300 (1990), and 310 (1995). Main Outcome Measures.-The specific academic rank, order, and number of authors for each original article. Eight categories of authorship were distinguished as follows: 1, professor; 2, department chairperson; 3, consultant; 4, senior registrar; 5, lecturer and/or registrar; 6, medical student; 7, house officer; and 8, miscellaneous. Results.-The number of original articles published per year decreased from 262 (1975) to 125 (1995). The mean number (SD) of authors per article increased steadily from 3.21 (SD, 1.89) (1975) to 4.46 (SD, 2.04) (1995). Most authors belonged to category 3, and its proportion varied from 24.7% (1975) to 22.6% (1995), while category 1 grew from 13.2% to 20.3%. Category 5 authorship dropped from 24.3% (1975) to 15.8% (1995). With regard to first authorship, category 1 more than doubled from 8.0% (1975) to 16.8% (1995) compared with category 5 whose proportion decreased from 34.0% to 24.8%. Most last authors were from category 1, 20.4% (1975), growing to 29.0% (1995). Conclusion.-Over the last 20 years the number of BMJ authors of original articles increased, mainly because of the rise of authorship among professors and department chairpersons.	Univ Nijmegen St Radboud Hosp, Dept Med, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Drenth, JPH (corresponding author), Univ Nijmegen St Radboud Hosp, Dept Med, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Drenth, Joost/V-7436-2019; Drenth, J.P.H./H-8025-2014					Currie C, 1997, BRIT MED J, V315, P747; Drenth Joost P H, 1996, Sci Eng Ethics, V2, P469, DOI 10.1007/BF02583933; Ezsias A, 1997, BRIT MED J, V315, P746; MULLEE MA, 1995, BRIT MED J, V310, P869, DOI 10.1136/bmj.310.6983.869a; MURRAY GD, 1991, BRIT J SURG, V78, P777, DOI 10.1002/bjs.1800780704; MUSSUKARIS S, 1990, NEW ENGL J MED, V323, P488; ONWUDE JL, 1993, BRIT MED J, V306, P1345, DOI 10.1136/bmj.306.6888.1345; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; RIESENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1857, DOI 10.1001/jama.264.14.1857; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; SHULKIN DJ, 1993, ACAD MED, V68, P688, DOI 10.1097/00001888-199309000-00015; Slone RM, 1996, AM J ROENTGENOL, V167, P571, DOI 10.2214/ajr.167.3.8751654; SMITH J, 1994, BRIT MED J, V309, P1456, DOI 10.1136/bmj.309.6967.1456; WARD B, 1994, NATURE, V368, P579, DOI 10.1038/368579a0	14	139	146	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					219	221		10.1001/jama.280.3.219	http://dx.doi.org/10.1001/jama.280.3.219			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676660	Bronze			2022-12-28	WOS:000074706000005
J	Krimsky, S; Rothenberg, LS				Krimsky, S; Rothenberg, LS			Financial interest and its disclosure in scientific publications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Journal policies and requirements of funding agencies on financial disclosure of authors and grant applicants have divided editors and scientists who disagree on whether such policies can improve the integrity of science or manage conflicts of interest. Those opposed to such disclosure policies argue that financial interest is one of many interests held by scientists, is the least scientifically dangerous, and should not be singled out. Those who favor open reporting of financial interests argue that full disclosure removes the suspicion that something of relevance to objectivity is being hidden and allows readers to form their own opinions on whether a conflict of interest exists and what relevance that has to the study. The authors believe that the scientific community and the public will be best served by open publication of financial disclosures for readers and reviewers to evaluate.	Tufts Univ, Dept Urban & Environm Policy, Medford, MA 02155 USA; Univ Calif Los Angeles, Dept Med, Div Med Genet, Los Angeles, CA 90024 USA	Tufts University; University of California System; University of California Los Angeles	Krimsky, S (corresponding author), Tufts Univ, Dept Urban & Environm Policy, Medford, MA 02155 USA.	skrimsky@emerald.tufts.edu	Krimsky, Sheldon/F-3147-2010					ANGELL M, 1993, LANCET, V341, P742; Bernat JL, 1998, NEUROLOGY, V50, P327, DOI 10.1212/WNL.50.2.327; Blumenthal D, 1996, NEW ENGL J MED, V335, P1734, DOI 10.1056/NEJM199612053352305; CULLITON BJ, 1981, NEW ENGL J MED, V304, P1195, DOI 10.1056/NEJM198105143042003; Davidoff F, 1997, ANN INTERN MED, V126, P986, DOI 10.7326/0003-4819-126-12-199706150-00011; Davidson F, 1997, JAMA-J AM MED ASSOC, V277, P927; Donaldson M. S., 1991, PATIENT OUTCOMES RES, P61; HENDEE WR, 1990, JAMA-J AM MED ASSOC, V263, P2790; Horton R, 1997, LANCET, V349, P1112, DOI 10.1016/S0140-6736(97)22016-7; Krimsky S, 1996, Sci Eng Ethics, V2, P395, DOI 10.1007/BF02583927; KRIMSKY S, 1991, SCI TECHNOL HUM VAL, V16, P275, DOI 10.1177/016224399101600301; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; *US C, 1990, AR SCI MISC CONFL IN; WILKES MS, 1995, J GEN INTERN MED, V10, P443, DOI 10.1007/BF02599916; 1997, NATURE, V385, P469; 1995, FED REG, V60, P35810; 1995, FED REG, V60, P35820	18	57	57	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					225	226		10.1001/jama.280.3.225	http://dx.doi.org/10.1001/jama.280.3.225			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676662				2022-12-28	WOS:000074706000007
J	Gonzalez-Crespo, S; Abu-Shaar, M; Torres, M; Martinez, C; Mann, RS; Morata, G				Gonzalez-Crespo, S; Abu-Shaar, M; Torres, M; Martinez, C; Mann, RS; Morata, G			Antagonism between extradenticle function and Hedgehog signalling in the developing limb	NATURE			English	Article							HUMAN PROTOONCOGENE PBX1; LONG-RANGE ACTION; DISTAL-LESS; MORPHOGEN GRADIENT; DROSOPHILA EMBRYO; LEG DEVELOPMENT; GENE ACTIVITY; WINGLESS; PROTEIN; PATTERN	The Drosophila homeobox gene extradenticle (exd) encodes a highly conserved cofactor of Hox proteins(1-3). exd activity is regulated post-translationally by a mechanism involving nuclear translocation(4,5); only nuclear Exd protein is functional. The exd gene is required for patterning of the proximal region of the leg(6,7), whereas patterning of the distal region requires signalling by the Wingless (Wg) and Decapentaplegic (Dpp)(8,9) proteins, which are in turn activated by Hedgehog (Hh)(10). Here we show that exd function and Dpp/Wg signalling are antagonistic and divide the leg into two mutually exclusive domains. In the proximal domain, exd activity prevents cells from responding to Dpp and Wg, Conversely, in the distal domain, exd function is suppressed by the Dpp/Wg response gene Distal-less (Dll), which prevents the nuclear transport of Exd, We also found that the product of a murine homologue of exd (Pbx1) is regulated at the subcellular level, and that its pattern of nuclear localization in the mouse limb resembles that of Exd in the Drosophila leg. These findings suggest that the division of the limb into two antagonistic domains, as defined by exd (Pbx1) function and Hh signalling, may be a general feature of limb development.	Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28049 Madrid, Spain; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrat Program Cellular Mol & Biophys Stud, New York, NY 10032 USA; Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Columbia University; Columbia University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Morata, G (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28049 Madrid, Spain.		Torres, Miguel/CAG-0003-2022; Torres, Miguel/A-7388-2013	Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767; Morata, Gines/0000-0003-3274-5173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058575, R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058575, R01 GM054510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspland SE, 1997, DEVELOPMENT, V124, P741; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DIAZBENJUMES FJ, 1994, NATURE, V32, P175; Fuse N, 1996, DEVELOPMENT, V122, P1059; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; Goto S, 1997, DEVELOPMENT, V124, P125; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; MARDON G, 1994, DEVELOPMENT, V120, P3473; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Penton A, 1996, NATURE, V382, P162, DOI 10.1038/382162a0; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Torres M, 1995, DEVELOPMENT, V121, P4057; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	29	129	130	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					196	200		10.1038/28197	http://dx.doi.org/10.1038/28197			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671305				2022-12-28	WOS:000074705900058
J	Cavert, W; Hase, AT				Cavert, W; Hase, AT			A National Tissue Bank to track HIV eradication and immune reconstitution	SCIENCE			English	Editorial Material									Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Cavert, W (corresponding author), Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Hauptman PJ, 1997, NEW ENGL J MED, V336, P422, DOI 10.1056/NEJM199702063360607; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; McArthur JC, 1997, ANN NEUROL, V42, P689, DOI 10.1002/ana.410420504; *OFF AIDS RES ADV, 1996, REP NIH AIDS RES PRO; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PARKER NG, 1998, NAT MED, V4, P208; Price RW, 1997, ANN NEUROL, V42, P675, DOI 10.1002/ana.410420502; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	16	10	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1865	1866		10.1126/science.280.5371.1865	http://dx.doi.org/10.1126/science.280.5371.1865			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669943				2022-12-28	WOS:000074323800039
J	Carballo, E; Lai, WS; Blackshear, PJ				Carballo, E; Lai, WS; Blackshear, PJ			Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin	SCIENCE			English	Article							FINGER TRANSCRIPTION FACTOR; MESSENGER-RNA DEGRADATION; TNF-ALPHA; NUCLEOTIDE-SEQUENCE; TRANSGENIC MICE; PROTEIN; GENE; EXPRESSION; ARTHRITIS; DISEASE	Tumor necrosis factor-alpha (TNF-alpha) is a major mediator of both acute and chronic inflammatory responses in many diseases. Tristetraprolin (TTP), the prototype of a class of Cys-Cys-Cys-His (CCCH) zinc finger proteins, inhibited TNF-alpha production from macrophages by destabilizing its messenger RNA. This effect appeared to result from direct TTP binding to the AU-rich element of the TNF-alpha messenger RNA. TTP is a cytosolic protein in these cells, and its biosynthesis was induced by the same agents that stimulate TNF-alpha production. including TNF-alpha itself. These findings identify TTP as a component of a negative feedback Loop that interferes with TNF-alpha production by destabilizing its messenger RNA. This pathway represents a potential target for anti-TNF-alpha therapies.	NIEHS, Off Clin Res, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, Off Clin Res, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER B, 1991, J CLIN INVEST, V87, P1336, DOI 10.1172/JCI115137; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; CARBALLO E, UNPUB; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; JACOB CO, 1992, J AUTOIMMUN, V5, P133, DOI 10.1016/0896-8411(92)90028-O; Jorres A, 1997, CYTOKINE, V9, P119, DOI 10.1006/cyto.1996.0145; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Lai W.-Y., UNPUB; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506; LAI WS, 1990, J BIOL CHEM, V265, P16556; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; Lorenz HM, 1996, J IMMUNOL, V156, P1646; ODEH M, 1990, J INTERN MED, V228, P549, DOI 10.1111/j.1365-2796.1990.tb00278.x; Reimund JM, 1996, J CLIN IMMUNOL, V16, P144, DOI 10.1007/BF01540912; SHALABY MR, 1989, TRANSPLANTATION, V47, P1057, DOI 10.1097/00007890-198906000-00028; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shi Y, 1997, J BIOL CHEM, V272, P29290, DOI 10.1074/jbc.272.46.29290; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; Thompson MJ, 1996, GENE, V174, P225, DOI 10.1016/0378-1119(96)00084-4; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611	36	968	996	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1998	281	5379					1001	1005		10.1126/science.281.5379.1001	http://dx.doi.org/10.1126/science.281.5379.1001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703499	Green Submitted			2022-12-28	WOS:000075412700051
J	Rietti-Shati, M; Shemesh, A; Karlen, W				Rietti-Shati, M; Shemesh, A; Karlen, W			A 3000-year climatic record from biogenic silica oxygen isotopes in an equatorial high-altitude lake	SCIENCE			English	Article							OCEAN	A record of oxygen isotopes in biogenic opal, 4200 to 1200 calibrated years before the present, from a high-altitude proglacial Lake on Mount Kenya, East Africa, exhibits short-term fluctuations on a time scale of centuries as well as Long-term variations. The short-term fluctuations are attributed to changes in the glacier meltwater input, and the Long-term variations are related to changes in Lake temperature. The record indicates that the climate was warm in Equatorial East Africa from 2300 to 1500 years before the present.	Weizmann Inst Sci, Dept Environm Sci & Energy Res, IL-76100 Rehovot, Israel; Univ Stockholm, Dept Phys Geog, S-10691 Stockholm, Sweden	Weizmann Institute of Science; Stockholm University	Shemesh, A (corresponding author), Weizmann Inst Sci, Dept Environm Sci & Energy Res, IL-76100 Rehovot, Israel.							Bard E, 1997, NATURE, V385, P707, DOI 10.1038/385707a0; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; DENTON G H, 1973, Quaternary Research (Orlando), V3, P155, DOI 10.1016/0033-5894(73)90040-9; Hastenrath S., 1991, CLIMATE DYNAMICS TRO, V8; JOUZEL J, 1984, J GEOPHYS RES-ATMOS, V89, P1749, DOI 10.1029/JD089iD07p11749; JUILLETLECLERC A, 1987, EARTH PLANET SCI NEW, V84, P69, DOI DOI 10.1016/0012-821X(87)90177-4; KARLEN W, 1988, NATL GEOGR RES, V4, P219; MERLIVAT L, 1979, J GEOPHYS RES-OCEANS, V84, P5029, DOI 10.1029/JC084iC08p05029; Naidu PD, 1996, PALEOCEANOGRAPHY, V11, P129, DOI 10.1029/95PA03198; Nicholson S.E., 1996, LIMNOLOGY CLIMATOLOG, V1st ed., P25, DOI [DOI 10.1201/9780203748978-2, 10.1201/9780203748978-2]; SHEMESH A, 1995, PALEOCEANOGRAPHY, V10, P179, DOI 10.1029/94PA03060; SHEMESH A, 1992, SCIENCE, V256, P1434, DOI 10.1126/science.256.5062.1434; Stager JC, 1997, QUATERNARY RES, V47, P81, DOI 10.1006/qres.1996.1863; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; StreetPerrott FA, 1997, SCIENCE, V278, P1422, DOI 10.1126/science.278.5342.1422; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; THOMPSON LG, 1979, SEA LEVEL ICE CLIMAT, V131, P55	17	49	50	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					980	982		10.1126/science.281.5379.980	http://dx.doi.org/10.1126/science.281.5379.980			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703511				2022-12-28	WOS:000075412700044
J	Boer, R; de Koning, H; Threlfall, A; Warmerdam, P; Street, A; Friedman, E; Woodman, C				Boer, R; de Koning, H; Threlfall, A; Warmerdam, P; Street, A; Friedman, E; Woodman, C			Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study	BRITISH MEDICAL JOURNAL			English	Article								Objective: To compare the cost effectiveness of two possible modifications to the current UK screening programme: shortening the screening interval from three to true years and extending the age of invitation to a final screen from 64 to 69. Design: Computer simulation model which first simulates life histories for women in the absence of a screening programme for breast cancer and then assesses haw these life histories would be changed by introducing different screening policies. The model was informed by screening and cost data from the NHS breast screening programme. Setting: North West region of England. Main outcome measures: Numbers of deaths prevented, life years gained, and costs. Results: Compared with the current breast screening programme both modifications would increase the number of deaths prevented and the number of life years saved. The current screening policy costs pound 2522 per life year gained; extending the age range of the programme would cost pound 2612 and shortening the interval pound 2709 per life year gained: The marginal cost per life year gained of extending the age range of the screening programme is pound 2990 and of shortening the screening interval is pound 3545. Conclusions: If the budget for the NHS breast screening-programme were to allow for two more invitations per woman, substantial mortality reductions would follow from extending the age range screened or reducing the screening interval. The difference between the two policies is so small that either could be chosen.	Erasmus Univ, Dept Publ Hlth, Inst Maatschappelijke Gezondheidszorg, NL-3000 DR Rotterdam, Netherlands; Univ Manchester, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England; Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England; W Pennine Hlth Author, Dept Publ Hlth Med, Oldham OL1 2PN, England	Erasmus University Rotterdam; University of Manchester; University of York - UK	Boer, R (corresponding author), Erasmus Univ, Dept Publ Hlth, Inst Maatschappelijke Gezondheidszorg, POB 1738, NL-3000 DR Rotterdam, Netherlands.	boer@mgz.fgg.eur.nl	de+Koning, Harry/AAF-9062-2019; Boer, Robert/AAH-2901-2022; Boer, Robert/AFM-0525-2022; Boer, Rob/E-6473-2015	de+Koning, Harry/0000-0003-4682-3646; Boer, Robert/0000-0003-0680-001X; Boer, Robert/0000-0003-0680-001X; Boer, Rob/0000-0003-0680-001X				BEEMSTERBOER PMM, 1994, INT J CANCER, V58, P623, DOI 10.1002/ijc.2910580502; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHAMBERLAIN J, 1993, BRIT MED J, V307, P543; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; FORREST APM, 1987, REPORT HLTH MINISTER; PACI E, 1995, J CANC, V3, P348; *SCOTT CANC THER N, 1996, SCOTT BREAST CANC AU; Street AD, 1996, P2003 U YORK YORK HL; VANINEVELD BM, 1993, EUR J CANCER, V29A, P1663, DOI 10.1016/0959-8049(93)90100-T; VANOORTMARSSEN GJ, 1990, CANCER-AM CANCER SOC, V66, P1601, DOI 10.1002/1097-0142(19901001)66:7<1601::AID-CNCR2820660727>3.0.CO;2-O	12	53	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					376	379						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694752				2022-12-28	WOS:000075409600023
J	Horowitz, HW; Kilchevsky, E; Haber, S; Aguero-Rosenfeld, M; Kranwinkel, R; James, EK; Wong, SJ; Chu, F; Liveris, D; Schwartz, I				Horowitz, HW; Kilchevsky, E; Haber, S; Aguero-Rosenfeld, M; Kranwinkel, R; James, EK; Wong, SJ; Chu, F; Liveris, D; Schwartz, I			Perinatal transmission of the agent of human granulocytic ehrlichiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TICK-BORNE FEVER; LYME-DISEASE		Westchester Cty Med Ctr, Div Infect Dis, Dept Med, Valhalla, NY 10595 USA; Westchester Cty Med Ctr, Dept Pathol, Valhalla, NY 10595 USA; New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; Danbury Hosp, Dept Pediat, Sect Neonatol, Danbury, CT USA; Danbury Hosp, Dept Pathol, Danbury, CT USA; United Hosp, Dept Med, Port Chester, NY 10573 USA; New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA	Westchester Medical Center; Westchester Medical Center; New York Medical College; State University of New York (SUNY) System; Wadsworth Center	Horowitz, HW (corresponding author), Westchester Cty Med Ctr, Div Infect Dis, Dept Med, Rm 209,Macy Pavil SE, Valhalla, NY 10595 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041511] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR41511] Funding Source: Medline; PHS HHS [U50/CCU213698-01-1] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AgueroRosenfeld ME, 1996, ANN INTERN MED, V125, P904, DOI 10.7326/0003-4819-125-11-199612010-00006; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; Bakken JS, 1996, JAMA-J AM MED ASSOC, V275, P199, DOI 10.1001/jama.275.3.199; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; CRANWELL MP, 1986, VET REC, V119, P531, DOI 10.1136/vr.119.21.531; DUMLER JS, 1995, J CLIN MICROBIOL, V33, P1098, DOI 10.1128/JCM.33.5.1098-1103.1995; Egenvall AE, 1997, VET REC, V140, P222, DOI 10.1136/vr.140.9.222; Gardner T, 1995, INFECT DIS FETUS NEW, P447; Goodman JL, 1996, NEW ENGL J MED, V335, P361; Klein MB, 1997, ANTIMICROB AGENTS CH, V41, P76, DOI 10.1128/AAC.41.1.76; Liveris D, 1996, J CLIN MICROBIOL, V34, P1306, DOI 10.1128/JCM.34.5.1306-1309.1996; LONG MT, 1995, AM J VET RES, V56, P1307; Nadelman RB, 1997, NEW ENGL J MED, V337, P27, DOI 10.1056/NEJM199707033370105; Pusterla N, 1997, CLIN DIAGN LAB IMMUN, V4, P643, DOI 10.1128/CDLI.4.6.643-647.1997; Pusterla N, 1997, VET REC, V141, P101, DOI 10.1136/vr.141.4.101; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SCHUTZE GE, 1997, PEDIATRICS, V100, P127; Schwartz I, 1997, NEW ENGL J MED, V337, P49, DOI 10.1056/NEJM199707033370111; STAMP J T, 1950, Vet Rec, V62, P465; STUEN S, 1992, RES VET SCI, V52, P211, DOI 10.1016/0034-5288(92)90012-Q; Sumner JW, 1997, J CLIN MICROBIOL, V35, P2087, DOI 10.1128/JCM.35.8.2087-2092.1997; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042; Wormser GP, 1997, AM J CLIN PATHOL, V107, P142, DOI 10.1093/ajcp/107.2.142	25	78	79	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1998	339	6					375	378		10.1056/NEJM199808063390604	http://dx.doi.org/10.1056/NEJM199808063390604			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107MD	9691104				2022-12-28	WOS:000075212300004
J	Greenhalgh, T				Greenhalgh, T			Soundings - Is this anyone's brolly?	BRITISH MEDICAL JOURNAL			English	Editorial Material													Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					355	355		10.1136/bmj.317.7154.355	http://dx.doi.org/10.1136/bmj.317.7154.355			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685302	Green Published			2022-12-28	WOS:000075409500072
J	Mortimer, P				Mortimer, P			A memorable patient - Happy ending	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					342	342		10.1136/bmj.317.7154.342	http://dx.doi.org/10.1136/bmj.317.7154.342			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685287	Green Published			2022-12-28	WOS:000075409500037
J	Vanhala, M; Vanhala, P; Kumpusalo, E; Halonen, P; Takala, J				Vanhala, M; Vanhala, P; Kumpusalo, E; Halonen, P; Takala, J			Relation between obesity from childhood to adulthood and the metabolic syndrome: population based study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Pieksamaki Dist Hlth Ctr, Pieksamaki 76101, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland	University of Eastern Finland	Vanhala, M (corresponding author), Community Hlth Ctr City Imatra, Virastokatu 2, Imatra 55100, Finland.	Mauno.Vanhala@pp.inet.fi						BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; LAAKSO M, 1993, CARDIOVASC RISK FACT, V1, P55; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Vanhala M J, 1997, J Cardiovasc Risk, V4, P291, DOI 10.1097/00043798-199708000-00010	5	161	170	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					319	319		10.1136/bmj.317.7154.319	http://dx.doi.org/10.1136/bmj.317.7154.319			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685277	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000075409500021
J	Swanson, WJ; Vacquier, VD				Swanson, WJ; Vacquier, VD			Concerted evolution in an egg receptor for a rapidly evolving abalone sperm protein	SCIENCE			English	Article							SPECIES-SPECIFICITY; POSITIVE SELECTION; TRANSCRIPTION; FERTILIZATION; DIVERGENCE; MODULES; BINDING; LYSIN	Gamete interactions during fertilization exhibit species specificity. In abalone, the sperm protein Lysin species-specifically creates a hole in the egg envelope. Lysin evolves rapidly by positive Darwinian selection. Evolution of the egg receptor for Lysin provides the selective pressure for Lysin's divergence. The egg receptor for lysin is a tandemly repeated sequence that evolves by concerted evolution. Concerted evolution in the egg receptor could explain the rapid, adaptive evolution in sperm Lysin and may provide an underlying molecular mechanism that gives rise to species-specific fertilization.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Swanson, WJ (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.			Swanson, Willie/0000-0002-6553-0921	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12986] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; DOVER GA, 1993, CURR OPIN GENET DEV, V3, P902, DOI 10.1016/0959-437X(93)90012-E; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; Giudice G, 1973, DEV BIOL SEA URCHIN, P162; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; LEE YH, 1995, MOL BIOL EVOL, V12, P231; METZ EC, 1994, BIOL BULL-US, V187, P23, DOI 10.2307/1542162; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; MIESFELD R, 1984, MOL CELL BIOL, V4, P221, DOI 10.1128/MCB.4.2.221; MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7; Muse SV, 1996, MOL BIOL EVOL, V13, P105, DOI 10.1093/oxfordjournals.molbev.a025549; NEI M, 1986, MOL BIOL EVOL, V3, P418; NIKODEM V, 1979, ANAL BIOCHEM, V97, P382, DOI 10.1016/0003-2697(79)90089-7; OHTA T, 1984, GENETICS, V108, P501; OSANAI K, 1982, GAMETE RES, V5, P49, DOI 10.1002/mrd.1120050106; Owen B, 1971, Bull Los Ang City Mus Sci, VNo. 9, P1; PALUMBI SR, 1994, ANNU REV ECOL SYST, V25, P547, DOI 10.1146/annurev.es.25.110194.002555; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; ROLDAN ERS, 1989, J EXP ZOOL, V250, P321, DOI 10.1002/jez.1402500312; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SHAW A, 1993, SCIENCE, V262, P1864, DOI 10.1126/science.8266073; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; SUMMERS RG, 1975, EXP CELL RES, V96, P63, DOI 10.1016/S0014-4827(75)80037-1; Swanson WJ, 1997, P NATL ACAD SCI USA, V94, P6724, DOI 10.1073/pnas.94.13.6724; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; Vacquier VD, 1997, J MOL EVOL, V44, pS15, DOI 10.1007/PL00000049; Vacquier VD, 1993, ZYGOTE, V1, P181, DOI 10.1017/S0967199400001465; Yanagimachi R., 1988, P135	31	173	183	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					710	712		10.1126/science.281.5377.710	http://dx.doi.org/10.1126/science.281.5377.710			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685267				2022-12-28	WOS:000075107900046
J	Webster, MHC; MacFarlane, P				Webster, MHC; MacFarlane, P			Ian Alexander McGregor - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		MCGREGOR IS, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					285	285		10.1136/bmj.317.7153.285	http://dx.doi.org/10.1136/bmj.317.7153.285			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677241	Green Published			2022-12-28	WOS:000075081900057
J	England, LJ; Imperial, J; Jacobsen, R; Craig, AG; Gulyas, J; Akhtar, M; Rivier, J; Julius, D; Olivera, BM				England, LJ; Imperial, J; Jacobsen, R; Craig, AG; Gulyas, J; Akhtar, M; Rivier, J; Julius, D; Olivera, BM			Inactivation of a serotonin-gated ion channel by a polypeptide toxin from marine snails	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; FUNCTIONAL EXPRESSION; FAMILY; DIVERSITY; DISTINCT; PEPTIDE	The venom of predatory marine snails is a rich source of natural products that act on specific receptors and ion channels within the mammalian nervous system. A 41-amino acid peptide, sigma-conotoxin GVIIIA, was purified on the basis of its ability to inactivate the 5-HT3 receptor, an excitatory serotonin-gated ion channel. sigma-Conotoxin contains a brominated tryptophan residue, which may be important for peptide activity because the endogenous Ligand for the 5-HT3 receptor is a hydroxylated derivative of tryptophan. sigma-Conotoxin inactivates the 5-HT3 receptor through competitive antagonism and is a highly selective inhibitor of this receptor. Serotonin receptors can now be included among the molecular targets of natural polypeptide neurotoxins.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah; Salk Institute	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	julius@socrates.ucsf.edu			NIGMS NIH HHS [GM44298, GM48677] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677, R01GM044298] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Green T, 1998, NEURON, V20, P427, DOI 10.1016/S0896-6273(00)80986-1; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; LUCAS JJ, 1995, TRENDS PHARMACOL SCI, V16, P246, DOI 10.1016/S0165-6147(00)89034-3; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; OLIVERA BM, 1995, TRENDS BIOTECHNOL, V13, P422, DOI 10.1016/S0167-7799(00)88996-9; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; PATRICK J, 1987, ANN NY ACAD SCI, V505, P194; SAXENA PR, 1995, PHARMACOL THERAPEUT, V66, P339, DOI 10.1016/0163-7258(94)00005-N; Tecott L H, 1993, Curr Opin Neurobiol, V3, P310, DOI 10.1016/0959-4388(93)90122-F; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; ZIFA E, 1992, PHARMACOL REV, V44, P401	26	112	118	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					575	578		10.1126/science.281.5376.575	http://dx.doi.org/10.1126/science.281.5376.575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677203				2022-12-28	WOS:000075012300045
J	Calignano, A; La Rana, G; Giuffrida, A; Piomelli, D				Calignano, A; La Rana, G; Giuffrida, A; Piomelli, D			Control of pain initiation by endogenous cannabinoids	NATURE			English	Article							MOLECULAR CHARACTERIZATION; FORMALIN TEST; RECEPTOR; BRAIN; RATS; ANANDAMIDE; NEURONS; TISSUE	The potent analgesic effects of cannabis-like drugs(1-4) and the presence of CB1-type cannabinoid receptors in pain-processing areas of the brain and spinal cord(5,6) indicate that endogenous cannabinoids such as anandamide(7) may contribute to the control of pain transmission within the central nervous system (CNS)(8). Here we show that anandamide attenuates the pain behaviour produced by chemical damage to cutaneous tissue by interacting with CB1-like cannabinoid receptors located outside the CNS. Palmitylethanolamide (PEA), which is released together with anandamide from a common phospholipid precursor(9), exerts a similar effect by activating peripheral CB2-like receptors. When administered together, the two compounds act synergistically, reducing pain responses 100-fold more potently than does each compound alone. Gas-chromatography/mass-spectrometry measurements indicate that the levels of anandamide and PEA in the skin are enough to cause a tonic activation of local cannabinoid receptors. In agreement with this possibility, the CB1 antagonist SR141716A and the CB2 antagonist SR144528 prolong and enhance the pain behaviour produced by tissue damage. These results indicate that peripheral CB1-like and CBZ-like receptors participate in the intrinsic control of pain initiation and that locally generated anandamide and PEA may mediate this effect.	Univ Naples, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; Inst Neurosci, San Diego, CA 92121 USA	University of Naples Federico II	Piomelli, D (corresponding author), Univ Naples, Dipartimento Farmacol Sperimentale, 49 Via D Montesano, I-80131 Naples, Italy.	piomelli@nsi.edu	Giuffrida, Andrea/H-3770-2013	Giuffrida, Andrea/0000-0002-3773-0694; CALIGNANO, Antonio/0000-0002-1742-3179				ALOE L, 1993, AGENTS ACTIONS, V39, pC145, DOI 10.1007/BF01972748; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Cadas H, 1997, J NEUROSCI, V17, P1226; CODERRE TJ, 1992, J NEUROSCI, V12, P3665; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DICKENSON AH, 1987, PAIN, V30, P349, DOI 10.1016/0304-3959(87)90023-6; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Fields H. L., 1987, PAIN; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; JAGGAR SI, IN PRESS PAIN; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Lichtman AH, 1996, J PHARMACOL EXP THER, V276, P585; MARTIN BR, 1981, LIFE SCI, V29, P565, DOI 10.1016/0024-3205(81)90434-3; MARTIN WJ, 1993, BRAIN RES, V629, P300, DOI 10.1016/0006-8993(93)91334-O; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Richardson JD, 1998, J NEUROSCI, V18, P451; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; ROSLAND JH, 1990, PAIN, V42, P235, DOI 10.1016/0304-3959(90)91167-H; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Tsou K, 1996, NEUROSCIENCE, V70, P791, DOI 10.1016/S0306-4522(96)83015-6	29	871	907	1	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					277	281		10.1038/28393	http://dx.doi.org/10.1038/28393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685157	Green Submitted			2022-12-28	WOS:000074851900048
J	Dickersin, K; Fredman, L; Flegal, KM; Scott, JD; Crawley, B				Dickersin, K; Fredman, L; Flegal, KM; Scott, JD; Crawley, B			Is there a sex bias in choosing editors? Epidemiology journals as an example	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			SCIENTIFIC FIELDS; POLICIES; WOMEN	Context.-Editors, authors, and reviewers are influential in shaping science. The careers of women in public health have received less scrutiny than those of women in medicine and other branches of science. The performance of women as editors, authors, and reviewers in epidemiology has not been previously studied. Objective.-To examine changes over time in the representation of women at the editorial level in US epidemiology journals compared with the proportion of women authors and reviewers. Design and Setting.-Cross-sectional study of 4 US epidemiology journals, American Journal of Epidemiology, Annals of Epidemiology, Epidemiology, and the Journal of Clinical Epidemiology (formerly the Journal of Chronic Diseases), for 1982, 1987, 1992, and 1994. Subjects.-Editors, authors, and reviewers for the selected years. Main Outcome Measures.-Sex of editors, authors, and reviewers. Results.-We identified 2415 reports associated with 8005 authors. One of 7 editors in chief was a woman, a position she shared with a man. For all journals, the proportion of editors who were women ranged from 5 (6.5%) of 77 in 1982 to 42 (16.3%) of 258 in 1994. Over all journals and all years, women comprised a higher proportion of authors (28.7% [2225/7743]) compared with reviewers (26.7% [796/2982]) or editors (12.8% [89/696]). Conclusions.-Fewer women in public health hold editorial positions than are authors and reviewers. The reasons for this important discrepancy, including the possibility of a selection bias favoring men, should be further investigated.	Univ Maryland, Sch Med, Charles McC Mathias Natl Study Ctr Trauma & Emerg, Baltimore, MD 21201 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University System of Maryland; University of Maryland Baltimore	Dickersin, K (corresponding author), Brown Univ, Sch Med, Dept Community Hlth, Box G-A4, Providence, RI 02912 USA.	kay_dickersin@brown.edu	Dickersin, Kay/A-4576-2008; Flegal, Katherine M/A-4608-2013	Fredman, Lisa/0000-0001-5341-2955; Flegal, Katherine/0000-0002-0838-469X				BEYER JM, 1978, SOCIOL QUART, V19, P68, DOI 10.1111/j.1533-8525.1978.tb02172.x; Bielby W.T., 1991, OUTER CIRCLE WOMEN S, P171; Cole J.R., 1984, ADV MOTIVATION ACHIE, V2, P217; Cole JR., 1979, FAIR SCI WOMEN SCI C; Fox M. F., 1991, OUTER CIRCLE WOMEN S; GARROW J, 1997, 3 INT C PEER REV BIO; HATFIELD C, 1995, LANCET, V345, P662, DOI 10.1016/S0140-6736(95)90572-3; KATTERMAN L, 1996, SCIENTIST       0304, P1; KRONENFELD JJ, 1988, FEMINISM SCI HLTH PR; LEVIN M, 1993, US SCH PUBLIC HLTH D; LEVY JA, 1987, AM J PUBLIC HEALTH, V77, P1537, DOI 10.2105/AJPH.77.12.1537; MISAKIAN AL, 1997, 3 INT C PEER REV BIO; Parlette N, 1992, LONGITUDINAL STUDY G; Sonnert G., 1995, WHO SUCCEEDS SCI GEN; Tedeschi J., 1972, SOCIAL INFLUENCE PRO; TEDESCHI JT, 1974, PERSPECTIVES SOCIAL; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; WHITING B, 1995, US MED SCH FACULTY 1; WILKES MS, 1995, J GEN INTERN MED, V10, P443, DOI 10.1007/BF02599916; YOELS WC, 1974, SOCIOL QUART, V15, P264, DOI 10.1111/j.1533-8525.1974.tb00893.x; YOKOPENIC PA, 1975, SOC PROBL, V22, P493, DOI 10.1525/sp.1975.22.4.03a00050; ZUCKERMAN H, 1987, WOMEN THEIR UNDERREP	22	60	62	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					260	264		10.1001/jama.280.3.260	http://dx.doi.org/10.1001/jama.280.3.260			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676675				2022-12-28	WOS:000074706000020
J	Margaglione, M; Brancaccio, V; Giuliani, N; D'Andrea, G; Cappucci, G; Iannaccone, L; Vecchione, G; Grandone, E; Di Minno, G				Margaglione, M; Brancaccio, V; Giuliani, N; D'Andrea, G; Cappucci, G; Iannaccone, L; Vecchione, G; Grandone, E; Di Minno, G			Increased risk for venous thrombosis in carriers of the prothrombin G -> A(20210) gene variant	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	ACTIVATED PROTEIN-C; FACTOR-V LEIDEN; COAGULATION-FACTOR-V; ANTIPHOSPHOLIPID ANTIBODIES; DEFICIENT FAMILIES; RESISTANCE; THROMBOEMBOLISM; THROMBOPHILIA; MUTATION	Background: A mutation in the prothrombin gene (G-->A(20210)) has been associated with higher plasma prothrombin levels and an increased tendency for venous thrombosis. Objective: To determine whether the prothrombin A(20210) allele is independently associated with the occurrence of venous thrombosis. Design: Case-control study. Setting: Two thrombosis centers in southern Italy. Patients: 281 consecutive patients with venous thrombosis confirmed by objective tests and 850 controls. Measurements: Medical history was collected on standardized questionnaires. The presence of prothrombin G-->A(20210) and factor V Leiden mutations was determined by polymerase chain reaction. The presence of anticoagulant factors and prothrombin activity was determined by tests of function. Results: In 150 controls, increased prothrombin activity (P < 0.001) was associated with the prothrombin A(20210) allele. This allele was more frequent in patients than in controls (8.01% compared with 2.29%; P < 0.001) and was associated with an increased risk for thrombosis (odds ratio, 3.88 [95% CI, 2.23 to 6.74]). The increased prevalence of this allele was independent of the presence of the factor V Leiden mutation. After adjustment for sex, age, arterial thrombosis, and factor V Leiden mutation, the risk was still significantly elevated (odds ratio, 3.13 [CI, 1.89 to 5.21]). Moreover, the overall prevalence of inherited coagulation abnormalities was significantly higher in patients with thrombosis of the lower extremities than in patients with thrombosis of the upper extremities (odds ratio, 3.77 [CI, 1.10 to 12.93]). Fourteen patients carried both the prothrombin G-->A(20210) and factor V Leiden mutations. Conclusions: The prothrombin A(20210) allele is independently associated with the occurrence of venous thrombosis, particularly in patients with a history of thrombosis of the lower extremities.	IRCCS, Unita Aterosclerosi & Trombosi, I-71013 San Giovanni Rotondo, Italy; Osped Antonio Cardarelli, Naples, Italy; Univ Palermo, Palermo, Italy	IRCCS Casa Sollievo Della Sofferenza; Antonio Cardarelli Hospital; University of Palermo	Margaglione, M (corresponding author), IRCCS, Unita Aterosclerosi & Trombosi, Casa Sollievo Sofferenza,Viale Cappuccini, I-71013 San Giovanni Rotondo, Italy.		Grandone, Elvira/M-1127-2019	Grandone, Elvira/0000-0002-8980-9783; Di Minno, Giovanni/0000-0003-4235-7166; MARGAGLIONE, MAURIZIO/0000-0001-5627-9221				AMES PRJ, 1995, THROMB HAEMOSTASIS, V73, P768; Ames PRJ, 1996, THROMB HAEMOSTASIS, V76, P190; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Margaglione M, 1996, THROMB HAEMOSTASIS, V76, P814; MARGAGLIONE M, 1995, THROMB HAEMOSTASIS, V73, P579; Martinelli I, 1997, ANN INTERN MED, V126, P707, DOI 10.7326/0003-4819-126-9-199705010-00006; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417	19	199	205	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					89	93		10.7326/0003-4819-129-2-199807150-00003	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669991				2022-12-28	WOS:000074852000002
J	Misakian, AL; Bero, LA				Misakian, AL; Bero, LA			Publication bias and research on passive smoking - Comparison of published and unpublished studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			ENVIRONMENTAL TOBACCO-SMOKE; CLINICAL-TRIALS; LUNG-CANCER	Context.-The results of reviews may be biased by delays in publication and failure to publish nonsignificant results. Objective.-To determine the extent of unpublished results on the health effects of passive smoking and whether passive smoking studies with statistically nonsignificant results would have longer time to publication than those with statistically significant results. Design.-Semistructured telephone interviews of principal investigators of published or unpublished studies funded between 1981 and 1995, identified by information obtained from 76 (85%) of 89 organizations contacted that potentially funded research on passive smoking. Participants.-Seventy-eight investigators were eligible and could be located; 65 (83%) responded. They had conducted 61 studies of the health effects of passive smoke in humans or animals between 1981 and 1995 that met the criteria for the analysis of time to publication. Main Outcome Measure.-Time to publication for published studies and statistical significance of results of published and unpublished studies. Results.-Fourteen of the 61 studies were unpublished. Median time to publication was 5 years (95% confidence interval [CI], 4-7 years) for statistically nonsignificant studies and 3 years (95% CI, 3-5 years) for statistically significant studies (P=.004). Statistically significant results (P=.004), experimental study design (P=.01), study size less than or equal to 500 (P=.01), and animals as subjects (P=.03) were predictive of time to publication. When the studies with human participants were analyzed separately, only statistically significant data were predictive of publication (P=.007). Multivariate analysis of all studies indicated that statistical significance (P=.001) and study design (P=.01) were the only independent predictors of time to publication, while for the human studies only statistical significance was predictive of publication (P=.007). Conclusion.-There is a publication delay for passive smoking studies with nonsignificant results compared with those with significant results.	Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94109 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94109 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bero, LA (corresponding author), Univ Calif San Francisco, Dept Clin Pharm, 1388 Sutter St,11th Floor, San Francisco, CA 94109 USA.	bero@cardio.ucsf.edu						ARMITAGE AK, 1993, J SMOKING RELATED DI, V4, P27; Barnes D E, 1997, Tob Control, V6, P19; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; BERO LA, 1994, JAMA-J AM MED ASSOC, V272, P133, DOI 10.1001/jama.272.2.133; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; CALDWELL ADS, 1992, J SMOKING REL DISORD, V4, P1; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, ANAL SURVIVAL DATA, P123; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; Harrell FE, 1986, P 11 ANN SAS US GROU; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P319, DOI 10.1001/jama.279.4.319; KILPATRICK SJ, 1992, INT SURG, V77, P131; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; MANTEL N, 1989, INT CONGR SER, V860, P155; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; SUGITA M, 1992, JPN J CLIN ONCOL, V22, P354; *US DEP HHS, 1986, DHHS PUBL CDC, P332; *US EPA, 1992, EPA600690006F IND AI; VANDENBROUCKE JP, 1988, BRIT MED J, V296, P391, DOI 10.1136/bmj.296.6619.391	28	97	99	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					250	253		10.1001/jama.280.3.250	http://dx.doi.org/10.1001/jama.280.3.250			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZZ204	9676672	Bronze			2022-12-28	WOS:000074706000017
J	Usher, M; Donnelly, N				Usher, M; Donnelly, N			Visual synchrony affects binding and segmentation in perception	NATURE			English	Article							MACAQUE MONKEY; CORTEX; INFORMATION; MODELS	The visual system analyses information by decomposing complex objects into simple components (visual features) that are widely distributed across the cortex(1,2). When several objects are present simultaneously in the visual field, a mechanism is required to group (bind) together visual features that belong to each object and to separate (segment) them from features of other objects. An attractive scheme for binding visual features into a coherent percept consists of synchronizing the activity of their neural representations(3-6). If synchrony is important in binding, one would expect that binding and segmentation are facilitated by visual displays that are temporally manipulated to induce stimulus-dependent synchrony. Here we show that visual grouping is indeed facilitated when elements of one percept are presented at the same time as each other and are temporally separated (on a scale below the integration time of the visual system(7)) from elements of another percept or from background elements. Our results indicate that binding is due to a global mechanism of grouping caused by synchronous neural activation, and not to a local mechanism of motion computation.	Univ Kent, Dept Psychol, Canterbury CP2 7NP, Kent, England	University of Kent	Usher, M (corresponding author), Univ Kent, Dept Psychol, Canterbury CP2 7NP, Kent, England.	mu@ukc.ac.uk		Donnelly, Nick/0000-0002-3577-5434				BALL K, 1983, VISION RES, V23, P229, DOI 10.1016/0042-6989(83)90111-6; BECK J, 1908, ORG REPRESENTATION P, P285; BENAV MB, 1995, VISION RES, V35, P853, DOI 10.1016/0042-6989(94)00173-J; COLHEART M, 1980, PERCEPT PSYCHOPHYS, V27, P183; CRICK E, 1990, SEMIN NEUROSCI, V2, P263; FAHLE M, 1995, VISION RES, V35, P491, DOI 10.1016/0042-6989(94)00126-7; FAHLE M, 1993, P ROY SOC B-BIOL SCI, V254, P199, DOI 10.1098/rspb.1993.0146; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; Gregory R. L., 1997, EYE BRAIN PSYCHOL SE; KEELE SW, 1988, J EXP PSYCHOL HUMAN, V14, P444; Kiper DC, 1996, VISION RES, V36, P539, DOI 10.1016/0042-6989(95)00135-2; Leonards U, 1996, VISION RES, V36, P2689, DOI 10.1016/0042-6989(96)86829-5; Leonards U, 1998, VISION RES, V38, P101, DOI 10.1016/S0042-6989(97)00148-X; LOFTUS GR, 1993, PERCEPT PSYCHOPHYS, V54, P535, DOI 10.3758/BF03211776; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; OYAMA T, 1978, PSYCHOL RES-PSYCH FO, V40, P101, DOI 10.1007/BF00308406; ROELFSEMA PR, 1994, EUR J NEUROSCI, V6, P1645, DOI 10.1111/j.1460-9568.1994.tb00556.x; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; Singer W, 1997, TRENDS COGN SCI, V1, P252, DOI 10.1016/S1364-6613(97)01079-6; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; TSO DY, 1986, J NEUROSCI, V6, P1160; van Essen D.C., 1985, P259; von der Malsburg C., 1994, MODELS NEURAL NETWOR, P95, DOI [DOI 10.1007/978-1-4612-4320-5_2, 10.1007/978-1-4612-4320-5_2]; VONDERMALSBURG C, 1995, CURR OPIN NEUROBIOL, V5, P520, DOI 10.1016/0959-4388(95)80014-X	25	140	142	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					179	182		10.1038/28166	http://dx.doi.org/10.1038/28166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671300				2022-12-28	WOS:000074705900053
J	Blackwood, EM; Kadonaga, JT				Blackwood, EM; Kadonaga, JT			Going the distance: A current view of enhancer action	SCIENCE			English	Review							RNA-POLYMERASE-II; POSITION-EFFECT VARIEGATION; BETA-GLOBIN GENE; CHROMATIN STRUCTURE; DROSOPHILA EMBRYO; TRANSCRIPTION; EXPRESSION; ACTIVATION; ELEMENTS; DOMAIN	In eukaryotes, transcription of genes by RNA polymerase II yields messenger RNA intermediates from which protein products are synthesized. Transcriptional enhancers are discrete DNA elements that contain specific sequence motifs with which DNA-binding proteins interact and transmit molecular signals to genes. it Here, current models regarding the role of enhancers in the regulation of transcription !I by RNA polymerase II are presented.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM 41249, GM 46995] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonifer C, 1997, J BIOL CHEM, V272, P26075, DOI 10.1074/jbc.272.42.26075; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gerasimova TI, 1996, CURR OPIN GENET DEV, V6, P185, DOI 10.1016/S0959-437X(96)80049-9; Geyer PK, 1997, CURR OPIN GENET DEV, V7, P242, DOI 10.1016/S0959-437X(97)80134-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guy LG, 1997, NUCLEIC ACIDS RES, V25, P4400, DOI 10.1093/nar/25.21.4400; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HENIKOFF S, 1994, GENETICS, V138, P1; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; Jane SM, 1996, INT J BIOCHEM CELL B, V28, P1197, DOI 10.1016/S1357-2725(96)00058-1; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LI XL, 1994, EMBO J, V13, P400, DOI 10.1002/j.1460-2075.1994.tb06274.x; Liang CP, 1997, MOL CELL BIOL, V17, P2825, DOI 10.1128/MCB.17.5.2825; Magis W, 1996, P NATL ACAD SCI USA, V93, P13914, DOI 10.1073/pnas.93.24.13914; MAJUMDER S, 1993, EMBO J, V12, P1131, DOI 10.1002/j.1460-2075.1993.tb05754.x; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; PLON SE, 1986, CELL, V45, P575, DOI 10.1016/0092-8674(86)90289-8; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; WU CT, 1993, J CELL BIOL, V120, P587, DOI 10.1083/jcb.120.3.587	61	584	614	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					60	63		10.1126/science.281.5373.60	http://dx.doi.org/10.1126/science.281.5373.60			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9679020				2022-12-28	WOS:000074685800036
J	Tsien, RY; Miyawaki, A				Tsien, RY; Miyawaki, A			Seeing the machinery of live cells	SCIENCE			English	Article							EXCITATION; MICROSCOPY; PROTEINS		Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	rtsien@ucsd.edu	Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DEERINCK TJ, 1994, J CELL BIOL, V126, P901, DOI 10.1083/jcb.126.4.901; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Farinas J, 1998, BIOPHYS J, V74, pA184; GRIFFIN BA, IN PRESS SCIENCE; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; Liu DR, 1997, P NATL ACAD SCI USA, V94, P10092, DOI 10.1073/pnas.94.19.10092; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MIYAWAKI A, UNPUB; Murphy JT, 1997, CURR BIOL, V7, P870, DOI 10.1016/S0960-9822(06)00375-7; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; Tsien Roger Y., 1993, Trends in Cell Biology, V3, P242, DOI 10.1016/0962-8924(93)90124-J; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	28	142	147	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1954	1955		10.1126/science.280.5371.1954	http://dx.doi.org/10.1126/science.280.5371.1954			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669950				2022-12-28	WOS:000074323800069
J	Jones, D; Ballestas, ME; Kaye, KM; Gulizia, JM; Winters, GL; Fletcher, J; Scadden, DT; Aster, JC				Jones, D; Ballestas, ME; Kaye, KM; Gulizia, JM; Winters, GL; Fletcher, J; Scadden, DT; Aster, JC			Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN HERPESVIRUS-8 DNA; AIDS-RELATED LYMPHOMAS; CASTLEMANS DISEASE; SEQUENCES; VIRUS; KSHV; ESTABLISHMENT; TISSUE; TUMORS; CELLS		Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA; Massachusetts Gen Hosp, Ctr AIDS Res, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Aster, JC (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.		Aster, Jon C/B-6857-2009; Jones, Daniel/I-7399-2015	Ballestas, Mary/0000-0003-0660-9477	NCI NIH HHS [CA67380, CA66849, CA73580] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073580, R29CA066849, R01CA067380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkan S, 1997, BRIT J HAEMATOL, V96, P412, DOI 10.1046/j.1365-2141.1997.d01-2040.x; Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Bigoni B, 1996, J INFECT DIS, V173, P542, DOI 10.1093/infdis/173.3.542; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; Burger R, 1998, BLOOD, V91, P1858, DOI 10.1182/blood.V91.6.1858.1858_1858_1863; CATHOMAS G, 1996, TRANSPLANTATION, V80, P318; Cesarman, 1997, SEMIN DIAGN PATHOL, V14, P161; Cesarman E, 1996, AM J PATHOL, V149, P53; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chadburn A, 1997, CANCER-AM CANCER SOC, V80, P788, DOI 10.1002/(SICI)1097-0142(19970815)80:4&lt;788::AID-CNCR18&gt;3.0.CO;2-P; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Decker LL, 1996, J EXP MED, V184, P283, DOI 10.1084/jem.184.1.283; Dupin N, 1997, ARCH DERMATOL, V133, P537, DOI 10.1001/archderm.133.4.537; Dupin N, 1997, BRIT J DERMATOL, V136, P827, DOI 10.1111/j.1365-2133.1997.tb03920.x; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; Foreman K, 1997, ARCH DERMATOL, V133, P108, DOI 10.1001/archderm.133.1.108; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gessain A, 1997, LEUKEMIA, V11, P266, DOI 10.1038/sj.leu.2400549; Goedert JJ, 1997, LANCET, V349, P1368, DOI 10.1016/S0140-6736(05)63204-7; Horenstein MG, 1997, BLOOD, V90, P1186, DOI 10.1182/blood.V90.3.1186; Hsi ED, 1998, AM J SURG PATHOL, V22, P493, DOI 10.1097/00000478-199804000-00016; IBRAHIM RE, 1989, CANCER, V64, P1436; IBRAHIM RE, 1989, CANCER, V70, P2024; Jones D, 1996, AM J CLIN PATHOL, V106, P359; KARCHER DS, 1995, NEW ENGL J MED, V333, P797; Karcher DS, 1997, HUM PATHOL, V28, P801, DOI 10.1016/S0046-8177(97)90153-2; Kedda MA, 1996, CLIN TRANSPLANT, V10, P429; Luppi M, 1996, BLOOD, V87, P3903, DOI 10.1182/blood.V87.9.3903.bloodjournal8793903; Marchioli CC, 1996, J CLIN MICROBIOL, V34, P2635, DOI 10.1128/JCM.34.10.2635-2638.1996; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Oksenhendler E, 1996, AIDS, V10, P61, DOI 10.1097/00002030-199601000-00009; Parravicini C, 1997, AM J PATHOL, V151, P1517; Parravicini C, 1997, BLOOD, V90, P2826; PASTORE C, 1995, BRIT J HAEMATOL, V91, P918, DOI 10.1111/j.1365-2141.1995.tb05410.x; Pawson R, 1996, LANCET, V348, P1450, DOI 10.1016/S0140-6736(04)70095-1; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Renne R, 1996, J VIROL, V70, P8151, DOI 10.1128/JVI.70.11.8151-8154.1996; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Said JW, 1996, BLOOD, V88, P3124, DOI 10.1182/blood.V88.8.3124.bloodjournal8883124; Said JW, 1996, BLOOD, V87, P4937, DOI 10.1182/blood.V87.12.4937.bloodjournal87124937; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Takata M, 1997, BRIT J DERMATOL, V137, P156, DOI 10.1111/j.1365-2133.1997.tb03727.x	48	141	144	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					444	449		10.1056/NEJM199808133390705	http://dx.doi.org/10.1056/NEJM199808133390705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700178				2022-12-28	WOS:000075342500005
J	Levinson, W; Roach, K; Altkorn, D; Stern, S				Levinson, W; Roach, K; Altkorn, D; Stern, S			Update in general internal medicine	ANNALS OF INTERNAL MEDICINE			English	Article							TRIAL		Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA	University of Chicago	Levinson, W (corresponding author), Univ Chicago, Gen Internal Med Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.							Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Coley CM, 1997, ANN INTERN MED, V126, P394, DOI 10.7326/0003-4819-126-5-199703010-00010; Coley CM, 1997, ANN INTERN MED, V126, P480; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Feldhaus KM, 1997, JAMA-J AM MED ASSOC, V277, P1357, DOI 10.1001/jama.277.17.1357; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Helfand M, 1997, JAMA-J AM MED ASSOC, V277, P44, DOI 10.1001/jama.277.1.44; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Perrier A, 1997, AM J RESP CRIT CARE, V156, P492, DOI 10.1164/ajrccm.156.2.9702032; Perry G, 1997, NEW ENGL J MED, V336, P525; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; Sandercock P, 1997, LANCET, V349, P1569; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; Staessen JA, 1997, JAMA-J AM MED ASSOC, V278, P1065, DOI 10.1001/jama.278.13.1065; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; tenCate JW, 1997, NEW ENGL J MED, V337, P657; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; 1997, ARCH INTERN MED, V157, P2413	42	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					212	220		10.7326/0003-4819-129-3-199808010-00010	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696730				2022-12-28	WOS:000075032700007
J	Toka, HR; Bahring, S; Chitayat, D; Melby, JC; Whitehead, R; Jeschke, E; Wienker, TF; Toka, O; Schuster, H; Luft, FC				Toka, HR; Bahring, S; Chitayat, D; Melby, JC; Whitehead, R; Jeschke, E; Wienker, TF; Toka, O; Schuster, H; Luft, FC			Families with autosomal dominant brachydactyly type E, short stature, and severe hypertension	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Rare, monogenic forms of hypertension may give insight into novel mechanisms relevant to essential hypertension. Autosomal dominant hypertension with brachydactyly has been documented in a single Turkish kindred; the gene was mapped to chromosome 12p. Objective: To describe the molecular genetics of additional families with autosomal dominant hypertension and brachydactyly. Design: Case series. Setting: Tertiary care medical centers. Patients: An Ii-member Canadian family and a 7-member U.S. family, neither of Turkish background, with autosomal dominant hypertension and type E brachydactyly. Measurements: Clinical evaluation, genotyping, and haplotype analyses. Results: The mode of inheritance, the type E brachydactyly, and the propensity for stroke were consistent with autosomal dominant hypertension with brachydactyly. The same markers on chromosome 12p cosegregated with the phenotype in the families. A haplotype analysis strongly supported the conclusion that these families have a molecular defect in the same gene. Conclusions: The syndrome of autosomal dominant hypertension and brachydactyly is not confined to patients of Turkish origin. All persons with brachydactyly should have their blood pressure measured, and the syndrome should be considered if hypertension is found.	Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Boston Univ, Med Ctr, Endocrine Sect, Boston, MA 02118 USA; Humboldt Univ, Berlin, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Boston University; Humboldt University of Berlin	Luft, FC (corresponding author), Franz Volhard Clin, Wiltberg Str 50, D-13122 Berlin, Germany.		Toka, Hakan/AAQ-2162-2021	Luft, Friedrich/0000-0002-8635-1199				BRICKMAN AS, 1988, AM J MED, V85, P785; Chitayat D, 1997, AM J MED GENET, V73, P279, DOI 10.1002/(SICI)1096-8628(19971219)73:3<279::AID-AJMG10>3.0.CO;2-G; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Morimoto S, 1997, HYPERTENSION, V30, P77, DOI 10.1161/01.HYP.30.1.77; Naraghi R, 1997, STROKE, V28, P1749, DOI 10.1161/01.STR.28.9.1749; NARAGHI R, 1994, LANCET, V344, P1466, DOI 10.1016/S0140-6736(94)90289-5; RICCARDI VM, 1974, J PEDIATR-US, V84, P251, DOI 10.1016/S0022-3476(74)80614-1; Schuster H, 1996, NAT GENET, V13, P98, DOI 10.1038/ng0596-98; Schuster H, 1996, HYPERTENSION, V28, P1085, DOI 10.1161/01.HYP.28.6.1085; Schuster H, 1998, KIDNEY INT, V53, P167, DOI 10.1046/j.1523-1755.1998.00732.x; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85	11	28	28	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					204	208		10.7326/0003-4819-129-3-199808010-00008	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696728				2022-12-28	WOS:000075032700005
J	Klenerman, P; Zinkernagel, RM				Klenerman, P; Zinkernagel, RM			Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL RECEPTOR ANTAGONISTS; CHORIOMENINGITIS VIRUS; ESCAPE MUTANTS; SELECTION; RESISTANT	Some viruses, including human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in humans, and lymphocytic choriomeningitis virus (LCMV) in mice, are initially controlled by cytotoxic T lymphocytes (CTLs), but may subsequently escape through mutation of the relevant T-cell epitope(1-3), Some of these mutations preserve the normal binding to major histocompatibility complex class I molecules, but present an altered surface to the T-cell antigen receptor(4,5). The exact role of these so-called altered peptide ligands in vivo is not clear. Here we report that mice primed with LCMV-WE strain respond to a subsequent infection by WE-derived CTL epitope variants with a CTL response directed against the initial epitope rather than against the new variant epitope, This phenomenon of 'original antigenic sin' was initially described in influenza(6-8) and is an asymmetric pattern of protective antibody crossreactivity determined by exposure to previously existing strains, which may therefore extend to some CTL responses. Original antigenic sin by CTL leads to impaired clearance of variant viruses infecting the same individual and so may enhance the immune escape of mutant viruses evolving in an individual host.	Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland	University of Zurich	Zinkernagel, RM (corresponding author), Univ Zurich, Inst Expt Immunol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.			klenerman, paul/0000-0003-4307-9161				AEBISCHER T, 1991, P NATL ACAD SCI USA, V88, P11047, DOI 10.1073/pnas.88.24.11047; Bachmann MF, 1997, J VIROL, V71, P5764, DOI 10.1128/JVI.71.8.5764-5768.1997; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BERTOLETTI A, 1994, J EXP MED, V180, P933, DOI 10.1084/jem.180.3.933; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; DESTGROTH SF, 1966, J EXP MED, V124, P347, DOI 10.1084/jem.124.3.347; DESTGROTH SF, 1966, J EXP MED, V124, P331, DOI 10.1084/jem.124.3.331; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FRANCIS T, 1953, ANN INTERN MED, V39, P203, DOI 10.7326/0003-4819-39-2-203; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; GOOD MF, 1993, PARASITE IMMUNOL, V15, P187, DOI 10.1111/j.1365-3024.1993.tb00599.x; HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P470; JACOBSON S, 1980, NATURE, V283, P311, DOI 10.1038/283311a0; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; Kent SJ, 1997, J IMMUNOL, V158, P807; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; Klenerman P, 1997, NATURE, V390, P298, DOI 10.1038/36876; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; MCADAM S, 1995, J IMMUNOL, V155, P2729; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; WEINER D, 1995, P NATL ACAD SCI USA, V82, P2755; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	30	282	297	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					482	485		10.1038/28860	http://dx.doi.org/10.1038/28860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697771				2022-12-28	WOS:000075080400053
J	Beecham, L				Beecham, L			The review body's remit should not be changed	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					286	286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677242				2022-12-28	WOS:000075081900062
J	Blane, D; Drever, F				Blane, D; Drever, F			Inequality among men in standardised years of potential life lost, 1970-93	BRITISH MEDICAL JOURNAL			English	Article									Imperial Coll Sci Technol & Med, Sch Med, Dept Behav & Cognit Sci, London W6 8RP, England; Off Natl Stat, London SW1V 2QQ, England	Imperial College London	Blane, D (corresponding author), Imperial Coll Sci Technol & Med, Sch Med, Dept Behav & Cognit Sci, London W6 8RP, England.							BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; DREVER F, 1997, SERIES DS, V15; ROMEDER JM, 1977, INT J EPIDEMIOL, V6, P143, DOI 10.1093/ije/6.2.143; *WHO, 1991, STRAT HLTH ALL REV T	4	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					255	255		10.1136/bmj.317.7153.255	http://dx.doi.org/10.1136/bmj.317.7153.255			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677216	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000075081900023
J	Tucker, MO; Swan, CR				Tucker, MO; Swan, CR			The mango poison ivy connection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Joseph Hosp, Houston, TX 77002 USA		Tucker, MO (corresponding author), St Joseph Hosp, Houston, TX 77002 USA.								0	5	5	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					235	235		10.1056/NEJM199807233390405	http://dx.doi.org/10.1056/NEJM199807233390405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673302				2022-12-28	WOS:000074918700005
J	Wakayama, T; Perry, ACF; Zuccotti, M; Johnson, KR; Yanagimachi, R				Wakayama, T; Perry, ACF; Zuccotti, M; Johnson, KR; Yanagimachi, R			Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei	NATURE			English	Article							MOUSE OOCYTES; TRANSPLANTATION; FERTILIZATION; EMBRYOS; MICROINJECTION; INVITRO; GENE	Until recently, fertilization was the only way to produce viable mammalian offspring, a process implicitly involving male and female gametes, However, techniques involving fusion of embryonic or fetal somatic cells with enucleated oocytes have become steadily more successful in generating cloned young(1-3). Dolly the sheep(4) was produced by electrofusion of sheep mammary-derived cells with enucleated sheep oocytes. Here we investigate the factors governing embryonic development by introducing nuclei from somatic cells (Sertoli, neuronal and cumulus cells) taken from adult mice into enucleated mouse oocytes. We found that some enucleated oocytes receiving Sertoli or neuronal nuclei developed in vitro and implanted following transfer, but none developed beyond 8.5 days post coitum; however, a high percentage of enucleated oocytes receiving cumulus nuclei developed in vitro. Once transferred, many of these embryos implanted and, although most were subsequently resorbed, a significant proportion (2 to 2.8%) developed to term. These experiments show that for mammals, nuclei from terminally differentiated, adult somatic cells of known phenotype introduced into enucleated oocytes are capable of supporting full development.	Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA; Univ Tokyo, Fac Agr, Dept Vet Anat, Bunkyo Ku, Tokyo 113, Japan; Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England; Univ Pavia, Dipartimento Biol Anim, Lab Biol Sviluppo, I-27100 Pavia, Italy; Jackson Lab, Bar Harbor, ME 04609 USA	University of Hawaii System; University of Tokyo; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Pavia; Jackson Laboratory	Yanagimachi, R (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA.			Perry, Tony/0000-0003-3136-5355				BosMikich A, 1997, DEV BIOL, V182, P172, DOI 10.1006/dbio.1996.8468; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CHATOT CL, 1990, BIOL REPROD, V42, P432, DOI 10.1095/biolreprod42.3.432; COLLAS P, 1994, MOL REPROD DEV, V38, P264, DOI 10.1002/mrd.1080380306; CZOLOWSKA R, 1984, J CELL SCI, V69, P19; DIETRICH W, 1992, GENETICS, V131, P423; Eppig JJ, 1997, BIOL REPROD, V56, P976, DOI 10.1095/biolreprod56.4.976; Epstein C.J, 1986, CONSEQUENCES CHROMOS; ERICKSON RP, 1993, MOL REPROD DEV, V35, P114, DOI 10.1002/mrd.1080350203; JOHNSON KR, 1992, GENOMICS, V12, P503, DOI 10.1016/0888-7543(92)90441-T; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; KONO T, 1993, MOL REPROD DEV, V34, P43, DOI 10.1002/mrd.1080340107; Kono T, 1997, Rev Reprod, V2, P74; Kono Tomohiro, 1993, Journal of Reproduction and Development, V39, P301, DOI 10.1262/jrd.39.301; Kuretake S, 1996, BIOL REPROD, V55, P789, DOI 10.1095/biolreprod55.4.789; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; Schuetz AW, 1996, REPROD FERT DEVELOP, V8, P935, DOI 10.1071/RD9960935; TAYLOR BA, 1989, GENOMICS, V5, P221, DOI 10.1016/0888-7543(89)90050-5; TSUNODA Y, 1993, J REPROD FERTIL, V98, P537, DOI 10.1530/jrf.0.0980537; TSUNODA Y, 1989, DEVELOPMENT, V107, P407; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YANAGIDA K, 1991, BIOL REPROD, V44, P440, DOI 10.1095/biolreprod44.3.440	26	1733	2047	4	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					369	374		10.1038/28615	http://dx.doi.org/10.1038/28615			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690471				2022-12-28	WOS:000074968800051
J	Cooper, ME				Cooper, ME			Pathogenesis, prevention, and treatment of diabetic nephropathy	LANCET			English	Article							ANGIOTENSIN-CONVERTING ENZYME; URINARY ALBUMIN EXCRETION; NIDDM PATIENTS; RENAL-DISEASE; KIDNEY-FUNCTION; MICROALBUMINURIA; PROGRESSION; INHIBITION; MELLITUS; PROTEINURIA	It is likely that the pathophysiology of diabetic nephropathy involves an interaction of metabolic and haemodynamic factors. Relevant metabolic factors include glucose-dependent pathways such as advanced glycation, increased formation of polyols, and activation of the enzyme, protein kinase C. Specific inhibitors of the various pathways are now available, enabling investigation of the role of these processes in the pathogenesis of diabetic nephropathy and potentially to provide new therapeutic approaches for the prevention and treatment of diabetic nephropathy. Haemodynamic factors to consider include systemic hypertension, intraglomerular hypertension, and the role of vasoactive hormones, such as angiotensin II. The mainstay of therapy remains attaining optimum glycaemic control. Antihypertensive therapy has a major role in slowing the progression of diabetic nephropathy. Agents that interrupt the renin-angiotensin system such as angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists may be particularly useful as renoprotective agents in both the hypertensive and normotensive context.	Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, W Heidelberg, Vic 3081, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne	Cooper, ME (corresponding author), Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Repatriat Campus, W Heidelberg, Vic 3081, Australia.		Cooper, Mark E/E-8680-2010; Cooper, Mark/AAC-5326-2020	Cooper, Mark E/0000-0002-5953-642X; 				Agardh CD, 1996, J HUM HYPERTENS, V10, P185; Ahmad J, 1997, DIABETES CARE, V20, P1576, DOI 10.2337/diacare.20.10.1576; ALAVERAS AE, 1997, NEPHROL DIAL TRANSPL, V2, P71; Allen TJ, 1997, DIABETES, V46, P119, DOI 10.2337/diab.46.1.119; Allen TJ, 1996, KIDNEY INT, V50, P902, DOI 10.1038/ki.1996.390; Allen TJ, 1997, DIABETES, V46, P1612, DOI 10.2337/diabetes.46.10.1612; ANDERSON S, 1993, AM J PHYSIOL, V265, pF477, DOI 10.1152/ajprenal.1993.265.4.F477; BAKRIS GL, 1997, KIDNEY HYPERTENSION, P561; Berrut G, 1997, CLIN NEPHROL, V48, P92; Bjorck S, 1997, NEPHROL DIAL TRANSPL, V12, P67; Black HR, 1997, ARCH INTERN MED, V157, P2413; Boner G, 1996, DIABETOLOGIA, V39, P587; Bright R., 1836, GUYS HOSP REP, P338; Bucala R, 1995, AM J KIDNEY DIS, V26, P875, DOI 10.1016/0272-6386(95)90051-9; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; CHAVERS BM, 1989, NEW ENGL J MED, V320, P966, DOI 10.1056/NEJM198904133201503; CLOSE CF, 1995, BMJ-BRIT MED J, V311, P973; Cooper ME, 1997, CLIN EXP PHARMACOL P, V24, P770, DOI 10.1111/j.1440-1681.1997.tb02130.x; COOPER ME, 1998, KIDNEY HYPERTENSION, P427; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; Crepaldi G, 1998, DIABETES CARE, V21, P104, DOI 10.2337/diacare.21.1.104; Cutler JA, 1998, NEW ENGL J MED, V338, P679, DOI 10.1056/NEJM199803053381009; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; Fioretto P, 1996, DIABETOLOGIA, V39, P1569, DOI 10.1007/s001250050616; FORSBLOM CM, 1992, BRIT MED J, V305, P1051, DOI 10.1136/bmj.305.6861.1051; Fujisawa T, 1998, DIABETOLOGIA, V41, P47, DOI 10.1007/s001250050865; Gall MA, 1997, BMJ-BRIT MED J, V314, P783, DOI 10.1136/bmj.314.7083.783; GILBERT RE, 1993, KIDNEY INT, V44, P855, DOI 10.1038/ki.1993.322; Gilbert RE, 1998, DIABETES, V47, P414, DOI 10.2337/diabetes.47.3.414; Gilbert RE, 1997, DIABETES RES CLIN PR, V35, P57, DOI 10.1016/S0168-8227(96)01364-2; GILBERT RE, 1994, J AM SOC NEPHROL, V5, P377; GOLDFARB S, 1991, DIABETES, V40, P465, DOI 10.2337/diabetes.40.4.465; Gruden G, 1997, P NATL ACAD SCI USA, V94, P12112, DOI 10.1073/pnas.94.22.12112; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hendry BM, 1997, QJM-MON J ASSOC PHYS, V90, P277, DOI 10.1093/qjmed/90.4.277; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Kaplan N, 1998, LANCET, V351, P1748, DOI 10.1016/S0140-6736(98)22024-1; KELLY DJ, IN PRESS KIDNEY INT; Kimmelstiel P, 1936, AM J PATHOL, V12, P83; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LACOURCIERE Y, 1993, HYPERTENSION, V21, P786, DOI 10.1161/01.HYP.21.6.786; Lewis E.J, 1997, NEPHROLOGY, V3, P1222; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; Marre M, 1997, J CLIN INVEST, V99, P1585, DOI 10.1172/JCI119321; MATHIESEN ER, 1995, DIABETOLOGIA, V38, pA46; Mogensen CE, 1997, DIABETES, V46, pS104, DOI 10.2337/diab.46.2.S104; MOGENSEN CE, 1995, DIABETIC MED, V12, P756, DOI 10.1111/j.1464-5491.1995.tb02077.x; MOGENSEN CE, 1976, SCAND J CLIN LAB INV, V36, P383, DOI 10.3109/00365517609055274; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Nielsen FS, 1997, DIABETES, V46, P1182, DOI 10.2337/diabetes.46.7.1182; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Orchard TJ, 1997, ARCH INTERN MED, V157, P1851, DOI 10.1001/archinte.157.16.1851; Pahor M, 1998, LANCET, V351, P689, DOI 10.1016/S0140-6736(05)78489-0; Parving H H, 1994, Curr Opin Nephrol Hypertens, V3, P292, DOI 10.1097/00041552-199405000-00010; Parving HH, 1996, J AM SOC NEPHROL, V7, P2509; Parving HH, 1996, NEW ENGL J MED, V335, P1682, DOI 10.1056/NEJM199611283352212; Parving HH, 1996, BRIT MED J, V313, P591; Parving HH, 1996, KIDNEY INT, V49, P1778, DOI 10.1038/ki.1996.266; Passa P, 1996, DIABETOLOGIA, V39, P1662, DOI 10.1007/s001250050631; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; Pietruck F, 1998, DIABETOLOGIA, V41, P94, DOI 10.1007/s001250050872; POULSEN PL, 1994, DIABETES, V43, P1248, DOI 10.2337/diabetes.43.10.1248; Quinn M, 1996, DIABETOLOGIA, V39, P940; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; Rossing P, 1997, DIABETES, V46, P481, DOI 10.2337/diabetes.46.3.481; Rumble JR, 1997, J CLIN INVEST, V99, P1016, DOI 10.1172/JCI119229; SANO T, 1994, DIABETES CARE, V17, P420, DOI 10.2337/diacare.17.5.420; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sharma K, 1997, SEMIN NEPHROL, V17, P80; Soulis T, 1996, KIDNEY INT, V50, P627, DOI 10.1038/ki.1996.358; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; TIKKANEN T, IN PRESS HYPERTENSIO; TREVISAN R, 1997, KIDNEY HYPERTENSION, P215; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; Vedel P, 1996, DIABETOLOGIA, V39, P1584, DOI 10.1007/s001250050618; Velussi M, 1996, DIABETES, V45, P216, DOI 10.2337/diabetes.45.2.216; WEIDMANN P, 1995, NEPHROL DIAL TRANSPL, V10, P39; Williams B, 1997, DIABETES, V46, P1497, DOI 10.2337/diabetes.46.9.1497; Wuerth J.-P., 1997, Diabetologia, V40, pA548; YIP J, 1993, LANCET, V342, P883, DOI 10.1016/0140-6736(93)91943-G; 1988, LANCET, V1, P1433; 1951, LANCET, V2, P974	88	393	411	1	32	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					213	219		10.1016/S0140-6736(98)01346-4	http://dx.doi.org/10.1016/S0140-6736(98)01346-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683226				2022-12-28	WOS:000074859800042
J	Lever, AF; Hole, DJ; Gillis, CR; McCallum, IR; McInnes, GT; MacKinnon, PL; Meredith, PA; Murray, LS; Reid, JL; Robertson, JWK				Lever, AF; Hole, DJ; Gillis, CR; McCallum, IR; McInnes, GT; MacKinnon, PL; Meredith, PA; Murray, LS; Reid, JL; Robertson, JWK			Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?	LANCET			English	Article							GENE-EXPRESSION; BLOOD-PRESSURE; HYPERTENSION; PROLIFERATION; ANGIOGENESIS; INDUCTION; MORTALITY; MYOCYTES; GROWTH; TUMORS	Background Previous studies have reported an increased risk of cancer with calcium-channel blockers in man. Other work in animals suggests that inhibitors of angiotensin-1-converting enzyme (ACE) protect against cancer. We aimed to assess the risk of cancer in hypertensive patients receiving ACE inhibitors or other antihypertensive drugs. Methods Our retrospective cohort study was based on the records of 5207 patients who attended the Glasgow Blood Pressure Clinic between Jan 1, 1980, and Dec 31, 1995. The patients' records are linked with the Registrar General Scotland and the West of Scotland Cancer Registry. Findings Compared with the West of Scotland controls, the relative risks of incident and fatal cancer among the 1559 patients receiving ACE inhibitors were 0.72 (95% CI 0.55-0.92) and 0.65 (0.44-0.93). Among the 3648 patients receiving antihypertensive drugs other than ACE inhibitors (calcium-channel blockers 1416, diuretics 2099, beta-blockers 2681), the corresponding relative risks were 1.10 (0.97-1.22) and 1.03 (0.87-1.20). The relative risk of cancer was lowest in women on ACE inhibitors: 0.63 (0.41-0.93) for incident cancer; 0.48 (0.23-0.88) for fatal cancer; and 0.37 (0.12-0.87) for female-specific cancers. The reduced relative risk of cancer in patients on ACE inhibitors was greatest with follow-up of longer than 3 years. Calcium-channel blockers, diuretics, and beta-blockers had no apparent effect on risk of cancer. Interpretation Long-term use of ACE inhibitors may protect against cancer. The status of this finding is more that of hypothesis generation than of hypothesis testing; randomised controlled trials are needed.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Ruchill Hosp, W Scotland Canc Surveillance Unit, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow	Lever, AF (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.							Alderman M, 1997, J HYPERTENS, V15, P105; BOEHM T, 1997, NATURE, V390, P335; BROWN JJ, 1979, HYPERTENSION, V1, P159, DOI 10.1161/01.HYP.1.3.159; CHEN L, 1991, P SOC EXP BIOL MED, V196, P280; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DATTA M, 1993, LANCET, V342, P345, DOI 10.1016/0140-6736(93)91478-5; Elliott WJ, 1996, AM J HYPERTENS, V9, P409; FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141; Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GILLIS CR, 1987, CANC INCIDENCE 5 CON, V5, P704; Hamet P, 1996, HYPERTENSION, V28, P321, DOI 10.1161/01.HYP.28.3.321; HANSSON L, 1994, AM J HYPERTENS, V7, pS82; HAWTHORNE VM, 1974, BMJ-BRIT MED J, V3, P600, DOI 10.1136/bmj.3.5931.600; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P287; Hii SI, 1998, BRIT J CANCER, V77, P880, DOI 10.1038/bjc.1998.145; Hole DJ, 1998, J HYPERTENS, V16, P119, DOI 10.1097/00004872-199816010-00017; HOLE DJ, 1993, BRIT MED J, V306, P609, DOI 10.1136/bmj.306.6878.609; INWANG ER, 1997, BRIT J CANCER, V75, P79; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; leNoble FAC, 1996, J VASC RES, V33, P480, DOI 10.1159/000159187; LEON DA, 1993, LANCET, V342, P479, DOI 10.1016/0140-6736(93)91599-H; Lindop GBM, 1993, RENIN ANGIOTENSIN SY, P54; LYALL F, 1992, J HYPERTENS, V10, P1463, DOI 10.1097/00004872-199210120-00005; Marsigliante S, 1996, CANCER LETT, V110, P19, DOI 10.1016/S0304-3835(96)04449-7; MCINNES GT, 1995, J HUM HYPERTENS, V9, P429; *MEMB CLIN GLASG B, 1972, J R COLL PHYSICIANS, V7, P87; NEYSES L, 1993, J HYPERTENS, V11, P927, DOI 10.1097/00004872-199309000-00006; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; Reddy MK, 1995, P SOC EXP BIOL MED, V210, P221; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TAYLOR GM, 1988, AM J PATHOL, V130, P543; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; *WHO INT AG RES CA, 1991, IARC SCI PUBL, V95; Wing LMH, 1997, CLIN EXP PHARMACOL P, V24, P188; YEO WW, 1991, Q J MED, V293, P763	41	477	496	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					179	184		10.1016/S0140-6736(98)03228-0	http://dx.doi.org/10.1016/S0140-6736(98)03228-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683206				2022-12-28	WOS:000074859800010
J	Godlee, F; Gale, CR; Martyn, CN				Godlee, F; Gale, CR; Martyn, CN			Effect on the quality of peer review of blinding reviewers and asking them to sign their reports - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-Anxiety about bias, lack of accountability, and poor quality of peer review has led to questions about the imbalance in anonymity between reviewers and authors, Objective.-To evaluate the effect on the quality of peer review of blinding reviewers to the authors' identities and requiring reviewers to sign their reports. Design.-Randomized controlled trial. Setting.-A general medical journal. Participants.-A total of 420 reviewers from the journal's database, Intervention.-We modified a paper accepted for publication introducing 8 areas of weakness. Reviewers were randomly allocated to 5 groups. Groups 1 and 2 received manuscripts from which the authors' names and affiliations had been removed, while groups 3 and 4 were aware of the authors' identities. Groups 1 and 3 were asked to sign their reports, while groups 2 and 4 were asked to return their reports unsigned. The fifth group was sent the paper in the usual manner of the journal, with authors' identities revealed and a request to comment anonymously. Group 5 differed from group 4 only in that its members were unaware that they were taking part in a study. Main Outcome Measure.-The number of weaknesses in the paper that were commented on by the reviewers. Results.-Reports were received from 221 reviewers (53%). The mean number of weaknesses commented on was 2 (1.7, 2.1, 1.8, and 1.9 for groups 1, 2, 3, and 4 and 5 combined, respectively). There were no statistically significant differences between groups in their performance. Reviewers who were blinded to authors' identities were less likely to recommend rejection than those who were aware of the authors' identities (odds ratio, 0.5; 95% confidence interval, 0.3-1.0), Conclusions.-Neither blinding reviewers to the authors and origin of the paper nor requiring them to sign their reports had any effect on rate of detection of errors, Such measures are unlikely to improve the quality of peer review reports.	Univ Southampton, MRC, Environm Epidemiol Unit, Southampton SO9 6YD, Hants, England; BMJ, London, England	University of Southampton	Martyn, CN (corresponding author), Univ Southampton, MRC, Environm Epidemiol Unit, Southampton SO9 6YD, Hants, England.		Gale, Catharine R/B-1653-2012					BLANK RM, 1991, AM ECON REV, V81, P1041; FISHER M, 1994, JAMA-J AM MED ASSOC, V272, P143, DOI 10.1001/jama.272.2.143; Gale CR, 1996, BRIT MED J, V312, P608; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; NYLENNA M, 1994, JAMA-J AM MED ASSOC, V272, P149, DOI 10.1001/jama.272.2.149; VANROOYEN S, 1997, 3 INT C PEER REV BIO	6	235	241	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					237	240		10.1001/jama.280.3.237	http://dx.doi.org/10.1001/jama.280.3.237			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676667				2022-12-28	WOS:000074706000012
J	Gutman, S; Richter, K; Alpert, S				Gutman, S; Richter, K; Alpert, S			Update on FDA regulation of in vitro diagnostic devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Device Evaluat, Ctr Devices & Radiol Hlth, Rockville, MD 20850 USA	US Food & Drug Administration (FDA)	Gutman, S (corresponding author), US FDA, Off Device Evaluat, Ctr Devices & Radiol Hlth, 2098 Gaither Rd, Rockville, MD 20850 USA.							*FDA, 1988, ASS SAF EFF HOM US I; *INT STAND O, 1994, QUAL SYST MOD QUAL A; 1995, FED REG, V60, P237; 1996, FED REG, V61, P195	4	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					190	192		10.1001/jama.280.2.190	http://dx.doi.org/10.1001/jama.280.2.190			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669798				2022-12-28	WOS:000074608400039
J	Griffin, S				Griffin, S			Diabetes care in general practice: meta-analysis of randomised control trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SYSTEMATIC REVIEWS; COMMUNITY CARE; METAANALYSIS	Objective: To assess the effectiveness of care in general practice for people with diabetes. Design: Meta-analysis of randomised trials comparing general practice and shared care with follow up in hospital outpatient clinic. Identification: Trials were identified from searches of eight bibliographic and research databases. Results: Five trials identified included 1058 people with diabetes, overall mean age 58.4 years, receiving hospital outpatient follow up for their diabetes. Results were heterogeneous between trials. In shared care schemes featuring more intensive support through a computerised prompting system for general practitioners and patients, there was no difference in mortality between care in hospital and care in general practice (odds ratio 1.06, 95% confidence interval 0.53 to 2.11); glycated haemoglobin tended to be lower in primary care (weighted difference in means of -0.28%, -0.59% to 0.03%); and losses to follow up were significantly lower in primary care (odds ratio 0.37, 0.22 to 0.61). However, schemes with less well developed support for family doctors were associated with adverse outcomes for patients. Conclusions: Unstructured care in the community is associated with poorer follow up, worse glycaemic control, and greater mortality than in hospital care. Computerised central recall, with prompting for patients and their family doctors, can achieve standards of care as good as or better than hospital outpatient care, at least in the short term. The evidence supports provision of regular prompted recall and review of selected people with diabetes by willing general practitioners. This can be achieved if suitable organisation is in place.	Univ Southampton, Aldermoor Hlth Ctr, Primary Med Care Grp, Southampton SO16 5ST, Hants, England	University of Southampton	Griffin, S (corresponding author), Inst Publ Hlth, Dept Community Med, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England.	SJG49@medschl.cam.ac.uk	Griffin, Simon J/K-3106-2013	Griffin, Simon J/0000-0002-2157-4797	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Archibald LK., 1992, PRACTICAL DIABETES, V9, P13, DOI [DOI 10.1002/pdi.1960090104, 10.1002/pdi.1960090104]; DAVIS WK, 1988, DIABETES CARE, V11, P538, DOI 10.2337/diacare.11.7.538; DAY JL, 1987, BRIT MED J, V294, P1590, DOI 10.1136/bmj.294.6587.1590; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Doney B J, 1976, J R Coll Gen Pract, V26, P734; EYSENCK HJ, 1994, BRIT MED J, V309, P789, DOI 10.1136/bmj.309.6957.789; FARMER A, 1990, BRIT J GEN PRACT, V40, P56; FOULKES A, 1989, J ROY COLL GEN PRACT, V39, P444; GREENHALGH PM, 1994, 67 ROYAL COLL GEN PR; GRIFFIN S, 1997, TXB DIABETES; HAMMERSLEY MS, 1985, BRIT MED J, V291, P1330, DOI 10.1136/bmj.291.6505.1330; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HICKMAN M, 1994, J PUBLIC HEALTH MED, V16, P447, DOI 10.1093/oxfordjournals.pubmed.a043026; HOSKINS PL, 1993, DIABETIC MED, V10, P81, DOI 10.1111/j.1464-5491.1993.tb02001.x; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; KINMONTH AL, 1993, BRIT MED J, V306, P599, DOI 10.1136/bmj.306.6878.599; Marks L., 1996, COUNTING COST REAL I; NABARRO J, 1987, J ROY COLL GEN PRACT, V37, P389; NAJI S, 1994, BRIT MED J, V308, P1208; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; PORTER AMD, 1982, BRIT MED J, V285, P1121, DOI 10.1136/bmj.285.6348.1121; SILAGY C, 1993, BMJ-BRIT MED J, V306, P897, DOI 10.1136/bmj.306.6882.897; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; SPOOR R, 1996, BRIT MED J, V313, P342; STARFIELD B, 1994, DIABETES CARE, V17, P12; TASKER PRW, 1984, PRACTICAL DIABETES, V1, P21; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; TURNER RC, 1995, DIABETES, V44, P1249; *UPD SOFTW, 1996, REVM VERS 3 0 WIND; Wilkes E, 1980, J R Coll Gen Pract, V30, P199; Wilks J M, 1973, J R Coll Gen Pract, V23, P46; WILLIAMS DRR, 1990, DIABETIC MED, V7, P74, DOI 10.1111/j.1464-5491.1990.tb01312.x; WILLIAMS R, 1994, HLTH CARE NEEDS ASSE; Wood J, 1990, Health Trends, V22, P39	34	133	136	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1998	317	7155					390	395						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694757				2022-12-28	WOS:000075409600028
J	Grover, R; Sanders, R				Grover, R; Sanders, R			Recent advances - Plastic surgery	BRITISH MEDICAL JOURNAL			English	Review							BREAST RECONSTRUCTION; CLINICAL-EXPERIENCE; FLAP; DISTRACTION		Mt Vernon Hosp, RAFT Inst Plast Surg, Northwood HA6 2RN, Middx, England		Grover, R (corresponding author), Mt Vernon Hosp, RAFT Inst Plast Surg, Northwood HA6 2RN, Middx, England.							ACHAUER BM, 1993, PLAST RECONSTR SURG, V92, P1233; ALLEN RJ, 1994, ANN PLAS SURG, V32, P32, DOI 10.1097/00000637-199401000-00007; ALLEN RJ, 1995, PLAST RECONSTR SURG, V95, P1207, DOI 10.1097/00006534-199506000-00010; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; Blondeel PN, 1997, BRIT J PLAST SURG, V50, P315, DOI 10.1016/S0007-1226(97)90539-7; Blondeel PN, 1997, BRIT J PLAST SURG, V50, P322, DOI 10.1016/S0007-1226(97)90540-3; Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; CASANOVA R, 1995, 40 ANN M PLAST SURG; COHEN SR, 1995, J CRANIOFAC SURG, V6, P368, DOI 10.1097/00001665-199509000-00007; Compton Carolyn C., 1993, Journal of Burn Care and Rehabilitation, V14, P653, DOI 10.1097/00004630-199311000-00010; CUONO C, 1986, LANCET, V1, P1123, DOI 10.1016/S0140-6736(86)91838-6; FINE NA, 1994, ANN PLAS SURG, V33, P465, DOI 10.1097/00000637-199411000-00001; GAULT DT, 1997, T 2 INT C EAR REC NE, P34; Grover R, 1998, BRIT J PLAST SURG, V51, P8, DOI 10.1016/S0007-1226(97)90090-4; Grover R, 1998, BRIT J PLAST SURG, V51, P51; GROVER R, 1995, T 11 C INT CONF PLAS, P43; Habal M B, 1994, J Craniofac Surg, V5, P344, DOI 10.1097/00001665-199411000-00017; HARRISON DH, 1995, T 11 C INT CONF PLAS, P664; LORENZ HP, 1992, DEVELOPMENT, V114, P253; MCCARTHY JG, 1992, PLAST RECONSTR SURG, V89, P1, DOI 10.1097/00006534-199289010-00001; Mullner T, 1997, BRIT J PLAST SURG, V50, P194, DOI 10.1016/S0007-1226(97)91369-2; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Shah M, 1995, J CELL SCI, V108, P983	23	5	22	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					397	400						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694759				2022-12-28	WOS:000075409600031
J	Fienberg, AA; Hiroi, N; Mermelstein, PG; Song, WJ; Snyder, GL; Nishi, A; Cheramy, A; O'Callaghan, JP; Miller, DB; Cole, DG; Corbett, R; Haile, CN; Cooper, DC; Onn, SP; Grace, AA; Ouimet, CC; White, FJ; Hyman, SE; Surmeier, DJ; Girault, JA; Nestler, EJ; Greengard, P				Fienberg, AA; Hiroi, N; Mermelstein, PG; Song, WJ; Snyder, GL; Nishi, A; Cheramy, A; O'Callaghan, JP; Miller, DB; Cole, DG; Corbett, R; Haile, CN; Cooper, DC; Onn, SP; Grace, AA; Ouimet, CC; White, FJ; Hyman, SE; Surmeier, DJ; Girault, JA; Nestler, EJ; Greengard, P			DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission	SCIENCE			English	Article							NEOSTRIATAL NEURONS; BASAL GANGLIA; NUCLEUS-ACCUMBENS; CAUDATE-PUTAMEN; RAT STRIATUM; MUTANT MICE; RECEPTORS; COCAINE; D1; PHOSPHOPROTEIN	Dopaminergic neurons exert a major modulatory effect on the forebrain. Dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all neurons that receive a dopaminergic input, is converted in response to dopamine into a potent protein phosphatase inhibitor. Mice generated to contain a targeted disruption of the DARPP-32 gene showed profound deficits in their molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication. The results show that DARPP-32 plays a central role in regulating the efficacy of dopaminergic neurotransmission.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06519 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; Univ Tennessee, Dept Anat & Neurobiol, Coll Med, Memphis, TN 38163 USA; Coll France, INSERM, U114, F-75005 Paris, France; Ctr Dis Control & Prevent, NIOSH, Morgantown, WV 26505 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Hoechst Marion Roussel Inc, Somerville, NJ 08807 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Neurosci, N Chicago, IL 60064 USA; Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA	Rockefeller University; Yale University; University of Tennessee System; University of Tennessee Health Science Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Chicago Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; Florida State University	Fienberg, AA (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	fienba@rockvax.rockefeller.edu	Miller, Diane/O-2927-2013; Girault, Jean-Antoine/F-7518-2013; Hiroi, Noboru/E-2215-2013; anand, amit/A-7222-2009; O'Callaghan, James/O-2958-2013	Girault, Jean-Antoine/0000-0002-7900-1705; Hiroi, Noboru/0000-0002-6846-5969; Haile, Colin/0000-0001-8293-7291; Song, Wen-Jie/0000-0003-2909-3098	NIDA NIH HHS [DA 08227, DA10044, F31 DA005794] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005794, P01DA010044, P01DA008227] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKAIKE A, 1987, BRAIN RES, V418, P262, DOI 10.1016/0006-8993(87)90094-1; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; Blank T, 1997, P NATL ACAD SCI USA, V94, P14859, DOI 10.1073/pnas.94.26.14859; CALABRESI P, 1987, NEUROSCIENCE, V20, P757, DOI 10.1016/0306-4522(87)90239-9; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; COLE DC, UNPUB; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; CORBETT R, UNPUB; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FLORAN B, 1990, NEUROSCI LETT, V116, P136, DOI 10.1016/0304-3940(90)90399-T; GALLI T, 1992, NEUROSCIENCE, V50, P769, DOI 10.1016/0306-4522(92)90203-E; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIRAULT JA, 1986, NEUROSCIENCE, V19, P1109, DOI 10.1016/0306-4522(86)90127-2; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4486; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KONRADI C, 1994, J NEUROSCI, V14, P5623; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Langley KC, 1997, NEUROSCIENCE, V78, P977, DOI 10.1016/S0306-4522(96)00583-0; Levine MS, 1996, J NEUROSCI, V16, P5870; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nishi A, 1997, J NEUROSCI, V17, P8147; NISHI A, UNPUB; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; ONN SP, UNPUB; OUIMET CC, 1990, J NEUROCYTOL, V19, P39, DOI 10.1007/BF01188438; OUIMET CC, 1984, J NEUROSCI, V4, P114; OUIMET CC, UNPUB; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; SHCIFFMAN SN, 1994, J PHYSIOL-LONDON, V483, P95; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Snyder G., 1996, Society for Neuroscience Abstracts, V22, P380; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SVENNINGSSON P, UNPUB; UCHIMURA N, 1986, BRAIN RES, V375, P368, DOI 10.1016/0006-8993(86)90760-2; WALAAS SI, 1983, NATURE, V301, P69; WHITE SR, 1995, BRAIN RES, V681, P167, DOI 10.1016/0006-8993(95)00309-E; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	47	372	410	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					838	+		10.1126/science.281.5378.838	http://dx.doi.org/10.1126/science.281.5378.838			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694658				2022-12-28	WOS:000075295600054
J	Liu, Y; Merrow, M; Loros, JJ; Dunlap, JC				Liu, Y; Merrow, M; Loros, JJ; Dunlap, JC			How temperature changes reset a circadian oscillator	SCIENCE			English	Article							CLOCK MUTANTS; NEUROSPORA; LIGHT; PHASE; TIMELESS; ENTRAINMENT; FREQUENCY; PROTEIN; PERIOD	Circadian rhythms control many physiological activities. The environmental entrainment of rhythms involves the immediate responses of clock components. Levels of the clock protein FRQ were measured in Neurospora at various temperatures; at higher temperatures, the amount of FRQ oscillated around higher Levels. Absolute FRQ amounts thus identified different times at different temperatures, so temperature shifts corresponded to shifts in clock time without immediate synthesis or turnover of components. Moderate temperature changes could dominate Light-to-dark shifts in the influence of circadian timing. Temperature regulation of clock components could explain temperature resetting of rhythms and how single transitions can initiate rhythmicity from characteristic circadian phases.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Dunlap, JC (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	jay.c.dunlap@dartmouth.edu	Loros, Jennifer/B-6293-2014; Dunlap, Jay/L-6232-2013	Dunlap, Jay/0000-0003-1577-0457	NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH01186, MH44651] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001186, R01MH044651] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Aschoff J., 1981, BIOL RHYTHMS, P311; BARRETT RK, 1995, J NEUROSCI, V15, P5681; BellPedersen D, 1996, J GENET, V75, P387, DOI 10.1007/BF02966317; BRUCE VG, 1960, COLD SPRING HARB SYM, V25, P29, DOI 10.1101/SQB.1960.025.01.005; Bunning E, 1973, PHYSL CLOCK; BUNNING E, 1935, JB WISS BOT, V81, P411; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Czeisler C. A., 1978, THESIS STANFORD U; DHARMANANDA S, 1980, THESIS U CALIFORNIA; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Finlayson SA, 1998, PLANT PHYSIOL, V116, P17, DOI 10.1104/pp.116.1.17; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; GOOCH VD, 1994, J BIOL RHYTHM, V9, P83, DOI 10.1177/074873049400900108; GOOCH VD, 1985, TEMPORAL ORDER, P232; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Johnson C.H., 1990, ATLAS PHASE RESPONSE; KING PY, 1997, CELL, V89, P641; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; LAKINTHOMAS PI, 1991, J BIOL RHYTHM, V6, P281, DOI 10.1177/074873049100600401; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; MENAKER M, 1971, BIOCHRONOMETRY, P81; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; NAKASHIMA H, 1987, J INTERDISCIPL CYCLE, V18, P1; NJUS D, 1977, J COMP PHYSIOL, V117, P335, DOI 10.1007/BF00691559; PETERSON EL, 1980, J THEOR BIOL, V84, P281, DOI 10.1016/S0022-5193(80)80008-7; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; Pittendrigh CS, 1959, PHOTOPERIODISM RELAT, P475, DOI DOI 10.1177/0748730413516309; RENSING L, 1989, CHRONOBIOL INT, V6, P297, DOI 10.3109/07420528909056933; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Sidote D, 1998, MOL CELL BIOL, V18, P2004, DOI 10.1128/MCB.18.4.2004; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; SWEENEY B, 1968, INSECT PHYSL, V14, P669; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; UNDERWOOD H, 1987, Journal of Biological Rhythms, V2, P179, DOI 10.1177/074873048700200302; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Winfree A.T., 1980, GEOMETRY BIOL TIME, V8; Young MW, 1996, COLD SPRING HARB SYM, V61, P279	51	176	183	6	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					825	829		10.1126/science.281.5378.825	http://dx.doi.org/10.1126/science.281.5378.825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694654	Green Submitted			2022-12-28	WOS:000075295600050
J	Grotta, M				Grotta, M			Explorations of inner space: Cognitive neuroscience at the brink of the 21st century	ANNALS OF INTERNAL MEDICINE			English	Article									Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania	Grotta, M (corresponding author), Univ Penn, Med Ctr, Dept Neurol, 3 Gates,3400 Spruce St, Philadelphia, PA 19104 USA.				NIA NIH HHS [AG15116] Funding Source: Medline; NINDS NIH HHS [NS35867] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015116] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Damasio A.R., 2005, DESCARTES ERROR EMOT; Pinker S, 1994, LANGUAGE INSTINCT NE; PINKER S, 1997, HOW MIND WORKS; Schacter D. L., 1996, SEARCHING MEMORY BRA	4	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					255	258		10.7326/0003-4819-129-3-199808010-00027	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696742				2022-12-28	WOS:000075032700022
J	Rembold, CM				Rembold, CM			Number needed to screen: development of a statistic for disease screening	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER DETECTION; CORONARY HEART-DISEASE; MIDDLE-AGED MEN; MILD HYPERTENSION; DEATH RATES; TRIAL; PREVENTION; MORTALITY; MORBIDITY; OSLO	Objectives: To develop the number needed to screen, a new statistic to overcome inappropriate national strategies for disease screening. Number needed to screen is defined as the number of people that need to be screened for a given duration to prevent one death or adverse event. Design: Number needed to screen was calculated from clinical trials that directly measured the effect of a screening strategy. From clinical trials that measured treatment benefit, the number needed to screen nas estimated as the number needed to treat from the trial divided by the prevalence of heretofore unrecognised or untreated disease. Directly calculated values were then compared with estimate number needed to screen values. Subjects: Standard literature review. Results: For prevention of total mortality the most effective screening test was a lipid profile. The estimated number needed to screen for dyslipidaemia (low density lipoprotein cholesterol concentration > 4.14 mmol/1) was 418 if detection was followed by pravastatin treatment for 5 years. This indicates that one death in 5 years could be prevented by screening 418 people. The estimated number needed to screen for hypertension was between 274 and 1307 for 5 years (for 10 mm Hg and 6 mm Hg diastolic blood pressure reduction respectively) if detection was followed by treatment based on a diuretic. Screening with haemoccult testing and mammography significantly decreased cancer specific, but not total, mortality. The number needed to screen for haemoccult screening to prevent a death from colon cancer was 1374 for 5 years, and the number needed to screen for mammography to prevent a death from breast cancer was 2451 for 5 years for women aged 50-59. Conclusion: These data allow the clinician to prioritise screening strategies. Of the screening strategies evaluation, screening for, and treatment of, dyslipidaemia and hypertension seem to produce the largest clinical benefit.	Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA	University of Virginia	Rembold, CM (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA.	crembold@virginia.edu	Rembold, Christopher/K-8359-2013	Rembold, Christopher/0000-0003-0819-7488				AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1993, Am J Cardiol, V72, P1031; Armitage P., 2001, STAT METHODS MED RES; BUHLER FR, 1985, J HYPERTENS, V3, P379; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HOLME I, 1985, PREV MED, V14, P279, DOI 10.1016/0091-7435(85)90057-X; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; KINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; NIETO FJ, 1995, ARCH INTERN MED, V155, P677, DOI 10.1001/archinte.155.7.677; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PERRY HM, 1978, ANN NY ACAD SCI, V304, P267; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Rembold CM, 1996, J FAM PRACTICE, V42, P577; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH WM, 1977, CIRC RES, V40, P98; SOLOMON MJ, 1994, CAN MED ASSOC J, V150, P1961	31	241	248	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 1	1998	317	7154					307	312		10.1136/bmj.317.7154.307	http://dx.doi.org/10.1136/bmj.317.7154.307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685274	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075409500018
J	Chaudhry, R; Lall, SB; Mishra, B; Dhawan, B				Chaudhry, R; Lall, SB; Mishra, B; Dhawan, B			Lesson of the week - A foodborne outbreak of organophosphate poisoning	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTERMEDIATE SYNDROME		All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India; All India Inst Med Sci, Dept Pharmacol, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi	Chaudhry, R (corresponding author), All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India.	rchdhry@medinst.ernet.in						DEBLEECKER JL, 1995, J TOXICOL-CLIN TOXIC, V33, P683, DOI 10.3109/15563659509010628; FLANAGAN RJ, 1995, BASIC ANAL TOXICOLOG, P187; JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139; SENANAYAKE N, 1987, NEW ENGL J MED, V316, P761, DOI 10.1056/NEJM198703263161301	4	24	24	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					268	269		10.1136/bmj.317.7153.268	http://dx.doi.org/10.1136/bmj.317.7153.268			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677223	Green Published			2022-12-28	WOS:000075081900030
J	Gazzard, B; Moyle, G				Gazzard, B; Moyle, G		BHIVA	1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals	LANCET			English	Article								When the British HIV-1 Association (BHIVA) guidelines on the treatment of HIV-seropositive individuals with antiretrovirals were published in The Lancet in April 1997, It was clear that they would require updating on a frequent basis. The guidelines have been useful in ensuring that viral-load testing and combination therapy is widely available in the UK. However, standards of treatment are rapidly changing as new evidence becomes available. Since formulation of the guidelines, data from two large clinical endpoint studies have been presented that show superior clinical benefit for the use of triple therapy compared with dual therapy In treatment of both naive individuals and patients who have been given zidovudine. Here we update the BHIVA guidelines with a consensus drawn from a wide range of UK medical opinion. The guidelines include Input from groups representing individuals living with HIV-1. A more detailed reflection of these views may be found in publications such as the National AIDS Manual and the AIDS Treatment Project's Doctor fax.	Chelsea & Westminster Hosp, St Stephens Clin, London SW10 9NH, England	Imperial College London	Gazzard, B (corresponding author), Chelsea & Westminster Hosp, St Stephens Clin, London SW10 9NH, England.							BOUCHER CAB, 1998, 12 WORLD AIDS C GEN, P12267; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; COAKELY E, 1997, 4 C RETR OPP INF WAS, P575; DEEKS S, 1997, 37 INT C ANT AG CHEM, pLB2; DEMASI R, 1997, INT WORKSH HIV DRUG, P105; DEVER LL, 1997, 37 INT C ANT AG CHEM, pLB8; Gazzard B, 1997, Expert Opin Investig Drugs, V6, P99, DOI 10.1517/13543784.6.2.99; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; MOYLE G, 1998, 12 WORLD AIDS C GEN, P12222; Moyle G J, 1997, Expert Opin Investig Drugs, V6, P943, DOI 10.1517/13543784.6.8.943; Moyle GJ, 1998, DRUGS, V55, P383, DOI 10.2165/00003495-199855030-00005; OPRAVIL M, 1997, INT WORKSH HIV DRUG, P60; RABOUD J, 1998, 12 WORLD AIDS C GEN, P12361; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; STASZEWSKI S, 1998, 12 WORLD AIDS C GEN, P22336; STELLBRINK HJ, 1997, 6 EUR C CLIN ASP TRE; AIDS TREATMENT PROJE; NATL AIDS MANUAL	25	171	171	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					314	316		10.1016/S0140-6736(98)04084-7	http://dx.doi.org/10.1016/S0140-6736(98)04084-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690427				2022-12-28	WOS:000074974500045
J	Goodwin, N; Mays, N; McLeod, H; Malbon, G; Raftery, J				Goodwin, N; Mays, N; McLeod, H; Malbon, G; Raftery, J		Total Purchasing Natl Evaluation Team	Evaluation of total purchasing pilots in England and Scotland and implications for primary care groups in England: personal interviews and analysis of routine data	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To evaluate the reported achievements of the 52 first wave total purchasing pilot schemes in 1996-7 and the factors associated with these; and to 1996-7 and the factors associated with these; and to consider die implications of these findings for the development of the proposed primary care groups. Design: Face to face interviews with lead general practitioners, project managers, and health authority representatives responsible for each pilot; and analysis of hospital episode statistics. Setting: England and Scotland for evaluation of pilots; England only for consideration of implications for primary care groups. Main outcome measures: The ability of total purchasers to achieve their own objectives and their ability specifically to achieve objectives in the service areas beyond fundholding included in total purchasing. Results: The level of achievement between pilots varied widely. Achievement was more likely to be reported in primary than in secondary care. Reported achievements in reducing length of stay and emergency admissions were corroborated by analysis of hospital episode statistics. Single practice and small multipractice pilots were more likely than large multipractice projects to report achieving their objectives. Achievements were also associated with higher direct management costs per head and the ability to undertake independent contracting. Large multipractice pilots required considerable organisational development before progress could be made. Conclusion: The ability to create effective commissioning organisations the size of the proposed primary care groups should not be underestimated. To he effective commissioners, these care groups will need to invest heavily in their organisational development and in the short term are likely to need an additional development budget rather than the reduction in spending on NHS management that is planned by the government.	Kings Fund, Policy & Dev Directorate, Hlth Syst Programme, London W1M 0AN, England; Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Goodwin, N (corresponding author), Kings Fund, Policy & Dev Directorate, Hlth Syst Programme, London W1M 0AN, England.			Goodwin, Nicholas/0000-0003-4900-3352; McLeod, Hugh/0000-0002-2266-7303				MAHON A, 1998, DEV SUCCESS CRITERIA; Mays N, 1997, BRIT MED J, V315, P652, DOI 10.1136/bmj.315.7109.652; MAYS N, 1998, TOTAL PURCHASING STE; POSNETT J, 1998, T COSTS TOTAL PURCHA; 1997, CM3807	5	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					256	259		10.1136/bmj.317.7153.256	http://dx.doi.org/10.1136/bmj.317.7153.256			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677217	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075081900024
J	Sigal, LH; Zahradnik, JM; Lavin, P; Patella, SJ; Bryant, G; Haselby, R; Hilton, E; Kunkel, M; Adler-Klein, D; Doherty, T; Evans, J; Malawista, SE				Sigal, LH; Zahradnik, JM; Lavin, P; Patella, SJ; Bryant, G; Haselby, R; Hilton, E; Kunkel, M; Adler-Klein, D; Doherty, T; Evans, J; Malawista, SE		Recomb Outer-Surf Prot A Lyme Dis Vac	A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein a to prevent Lyme disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TREATMENT-RESISTANT; SCID MICE; OSPA; ARTHRITIS; IMMUNOGENICITY; PROTECTION; ANTIBODIES; INFECTION; RECOGNITION; SAFETY	Background Lyme disease is a multisystem inflammatory disease caused by infection with the tick-borne spirochete Borrelia burgdorferi and is the most common vector-borne infection in the United States. We assessed the efficacy of a recombinant vaccine consisting of outer-surface protein A (OspA) without adjuvant in subjects at risk for Lyme disease. Methods For this double-blind trial, 10,305 subjects 18 years of age or older were recruited at 14 sites in areas of the United States where Lyme disease was endemic; the subjects were randomly assigned to receive either placebo (5149 subjects) or 30 mu g of OspA vaccine (5156 subjects). The first two injections were administered 1 month apart, and 7515 subjects also received a booster dose at 12 months. The subjects were observed for two seasons during which the risk of transmission of Lyme disease was high. The primary end point was the number of new clinically and serologically confirmed cases of Lyme disease. Results The efficacy of the vaccine was 68 percent in the first year of the study in the entire population and 92 percent in the second year among the 3745 subjects who received the third injection. The vaccine was well tolerated. There was a higher incidence of mild, self-limited local and systemic reactions in the vaccine group, but only during the seven days after vaccination. There was no significant increase in the frequency of arthritis or neurologic events in vaccine recipients. Conclusions In this study, OspA vaccine was safe and effective in the prevention of Lyme disease. (N Engl J Med 1998;339:216-22.) (C) 1998, Massachusetts Medical Society.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, New Brunswick, NJ USA; Pasteur Merieux Connaught, Swiftwater, PA USA; Boston Biostat, Boston, MA USA; Gundersen Med Fdn, La Crosse, WI USA; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA; Long Isl Jewish Med Ctr, New Hyde Park, NY 11042 USA; Albert Einstein Coll Med, New York, NY USA; Danbury Hosp, Danbury, CT USA; Stamford Hosp, Stamford, CT USA; SE Connecticut Med Associates, Old Saybrook, CT USA; Yale Univ, Sch Med, New Haven, CT USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Marshfield Clinic; Northwell Health; Yeshiva University; Stamford Hospital; Yale University	Sigal, LH (corresponding author), 1 Robert Wood Johnson Pl,MEB 484, New Brunswick, NJ 08903 USA.							[Anonymous], 1997, MMWR MORB MORTAL WKL, V46, P1; Barthold SW, 1996, LAB INVEST, V74, P57; ERDILE LF, 1993, INFECT IMMUN, V61, P81, DOI 10.1128/IAI.61.1.81-90.1993; *EXP WORK GROUP, 1996, INT C HARM MED TERM; FAHRER H, 1991, J INFECT DIS, V163, P305, DOI 10.1093/infdis/163.2.305; FIKRIG E, 1994, J INFECT DIS, V169, P568, DOI 10.1093/infdis/169.3.568; FIKRIG E, 1992, INFECT IMMUN, V60, P773, DOI 10.1128/IAI.60.3.773-777.1992; Fikrig E, 1997, IMMUNITY, V6, P531, DOI 10.1016/S1074-7613(00)80341-6; FIKRIG E, 1992, INFECT IMMUN, V60, P657, DOI 10.1128/IAI.60.2.657-661.1992; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; FIKRIG E, 1995, J EXP MED, V181, P215, DOI 10.1084/jem.181.1.215; Gern L, 1997, VACCINE, V15, P1551, DOI 10.1016/S0264-410X(97)00066-2; KALISH RA, 1995, INFECT IMMUN, V63, P2228, DOI 10.1128/IAI.63.6.2228-2235.1995; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; KAMRADT T, 1995, MOL MED, V1, P486, DOI 10.1007/BF03401586; Kamradt T, 1996, INFECT IMMUN, V64, P1284, DOI 10.1128/IAI.64.4.1284-1289.1996; KELLER D, 1994, JAMA-J AM MED ASSOC, V271, P1764, DOI 10.1001/jama.271.22.1764; LENGLJANSSEN B, 1994, J EXP MED, V180, P2069, DOI 10.1084/jem.180.6.2069; LOVRICH SD, 1995, INFECT IMMUN, V63, P2113, DOI 10.1128/IAI.63.6.2113-2119.1995; PROBERT WS, 1994, INFECT IMMUN, V62, P1920, DOI 10.1128/IAI.62.5.1920-1926.1994; SADZIENE A, 1993, J INFECT DIS, V167, P165, DOI 10.1093/infdis/167.1.165; SCHAIBLE UE, 1990, P NATL ACAD SCI USA, V87, P3768, DOI 10.1073/pnas.87.10.3768; SCHAIBLE UE, 1993, VACCINE, V11, P1049, DOI 10.1016/0264-410X(93)90132-H; SCHOEN RT, 1995, J INFECT DIS, V172, P1324, DOI 10.1093/infdis/172.5.1324; Sigal LH, 1997, ANNU REV IMMUNOL, V15, P63, DOI 10.1146/annurev.immunol.15.1.63; SIMON MM, 1991, J INFECT DIS, V164, P123, DOI 10.1093/infdis/164.1.123; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; TELFORD SR, 1995, CLIN IMMUNOTHER, V4, P49, DOI 10.1007/BF03259070; VanHoecke C, 1996, VACCINE, V14, P1620, DOI 10.1016/S0264-410X(96)00146-6; WORMSER GP, 1995, CLIN INFECT DIS, V21, P1267, DOI 10.1093/clinids/21.5.1267; 1994, US PHARM CONV, P1696; 1990, MMWR MORB MORTAL WKL, V39, P19	32	286	304	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					216	222		10.1056/NEJM199807233390402	http://dx.doi.org/10.1056/NEJM199807233390402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673299				2022-12-28	WOS:000074918700002
J	Simmonds, P; Davidson, F; Lycett, C; Prescott, LE; MacDonald, DM; Ellender, J; Yap, PL; Ludlam, CA; Haydon, GH; Gillon, J; Jarvis, LM				Simmonds, P; Davidson, F; Lycett, C; Prescott, LE; MacDonald, DM; Ellender, J; Yap, PL; Ludlam, CA; Haydon, GH; Gillon, J; Jarvis, LM			Detection of a novel DNA virus (TTV) in blood donors and blood products	LANCET			English	Article							HEPATITIS-C VIRUS; NON-A; HEMOPHILIA; DETERGENT; OUTBREAK; GLOBULIN; SOLVENT	Background A newly discovered DNA virus, transfusion-transmitted virus (TTV), has been implicated as a cause of post-transfusion hepatitis. We investigated the frequency of TTV viraemia in UK blood donors, and the extent to which TTV contaminates blood products such as factor VIII and IX clotting factors. We also investigated the possible aetiological role of TTV in cryptogenic fulminant hepatic failure (FHF). Methods We extracted DNA from plasma of blood donors and patients with FHF, and from blood products (factor VIII and IX clotting-factor concentrates, immunoglobulin preparations). We detected TTV by PCR using primers from a conserved region in the TTV genome. Findings TTV viraemia was detected in 19 (1.9%) of 1000 non-remunerated regular blood donors. Infection occurred more frequently in older donors (mean age 53 years), compared with the age prolife of donors infected with hepatitis C virus and other parenterally-transmitted viruses. TTV contamination was found in ten (56%) of 18 batches of factor VIII and IX concentrate manufactured from such nonremunerated donors, and in seven (44%) of 16 batches of commercially available products. Whereas solvent or detergent treatment had little effect on the detection of TTV in factor VIII and IX by PCR, this virucidal step seemed to inactivate TTV infectivity. TTV infection was detected in four (19%) of 21 patients with FHF; in three cases, infection was detected at the onset of disease and could thus not be excluded from its aetiology. Interpretation TTV viraemia is frequent in the blood-donor population, and transmission of TTV through transfusion of blood components may have occurred extensively. Clinical assessment of infected donors and recipients of blood and blood products, and assessment of TTV's aetiological role in hepatic and extra-hepatic disease, are urgently needed.	Univ Edinburgh, Dept Med Microbiol, Edinburgh EH3 9HB, Midlothian, Scotland; Edinburgh & SE Scotland Blood Transfus Serv, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Royal Infirm Edinburgh, Dept Haematol, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Royal Infirm Edinburgh, Dept Med, Edinburgh EH3 9YW, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Simmonds, P (corresponding author), Univ Edinburgh, Dept Med Microbiol, Teviot Pl, Edinburgh EH3 9HB, Midlothian, Scotland.			Simmonds, Peter/0000-0002-7964-4700				Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; GARSON JA, 1990, LANCET, V335, P1473, DOI 10.1016/0140-6736(90)91510-H; Hanley JP, 1998, THROMB HAEMOSTASIS, V79, P291; Haydon GH, 1997, J VIRAL HEPATITIS, V4, P45, DOI 10.1046/j.1365-2893.1997.00122.x; JARVIS LM, 1994, J INFECT DIS, V170, P1018, DOI 10.1093/infdis/170.4.1018; Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X; KEDDA MA, 1995, HEPATOLOGY, V22, P1363, DOI 10.1002/hep.1840220504; KERNOFF PBA, 1985, BRIT J HAEMATOL, V60, P469, DOI 10.1111/j.1365-2141.1985.tb07444.x; Kumar S., 1993, MEGA MOL EVOLUTIONAR; LAWLOR E, 1994, VOX SANG, V67, P18, DOI 10.1111/j.1423-0410.1994.tb00968.x; LEFRERE JJ, 1994, LANCET, V343, P211, DOI 10.1016/S0140-6736(94)90993-8; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; Yap PL, 1996, CLIN EXP IMMUNOL, V104, P35, DOI 10.1111/cei.1996.104.s1.35	21	349	371	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					191	195		10.1016/S0140-6736(98)03056-6	http://dx.doi.org/10.1016/S0140-6736(98)03056-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683208				2022-12-28	WOS:000074859800012
J	Black, N; van Rooyen, S; Godlee, F; Smith, R; Evans, S				Black, N; van Rooyen, S; Godlee, F; Smith, R; Evans, S			What makes a good reviewer and a good review for a general medical journal?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			PEER REVIEWERS; QUALITY	Context.-Selecting peer reviewers who will provide high-quality reviews is a central task of editors of biomedical journals. Objectives.-To determine the characteristics of reviewers for a general medical journal who produce high-quality reviews and to describe the characteristics of a good review, particularly in terms of the time spent reviewing and turnaround time. Design, Setting, and Participants.-Surveys of reviewers of the 420 manuscripts submitted to BMJ between January and June 1997, Main Outcome Measures.-Review quality was assessed independently by 2 editors and by the corresponding author using a newly developed 7-item review quality instrument. Results.-Of the 420 manuscripts, 345 (82%) had 2 reviews completed, for a total of 690 reviews. Authors' assessments of review quality were available for 507 reviews. The characteristics of reviewers had little association with the quality of the reviews they produced (explaining only 8% of the variation), regardless of whether editors or authors defined the quality of the review. In a logistic regression analysis, the only significant factor associated with higher-quality ratings by both editors and authors was reviewers trained in epidemiology or statistics. Younger age also was an independent predictor for editors' quality assessments, while reviews performed by reviewers who were members of an editorial board were rated of poorer quality by authors. Review quality increased with time spent on a review, up to 3 hours but not beyond. Conclusions.-The characteristics of reviewers we studied did not identify those who performed high-quality reviews. Reviewers might be advised that spending longer than 3 hours on a review on average did not appear to increase review quality as rated by editors and authors.	Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; BMJ, London, England	University of London; London School of Hygiene & Tropical Medicine	Black, N (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.			Evans, Stephen/0000-0002-1474-2596				EVANS AT, 1993, J GEN INTERN MED, V8, P422, DOI 10.1007/BF02599618; LOCK S, 1990, JAMA-J AM MED ASSOC, V263, P1341, DOI 10.1001/jama.263.10.1341; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; NYLENNA M, 1994, JAMA-J AM MED ASSOC, V272, P149, DOI 10.1001/jama.272.2.149; STOSSEL TP, 1985, NEW ENGL J MED, V312, P658, DOI 10.1056/NEJM198503073121024; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; YANKAUER A, 1990, JAMA-J AM MED ASSOC, V263, P1338	7	169	178	1	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					231	233		10.1001/jama.280.3.231	http://dx.doi.org/10.1001/jama.280.3.231			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676665	Bronze			2022-12-28	WOS:000074706000010
J	Callaham, ML; Baxt, WG; Waeckerie, JF; Wears, RL				Callaham, ML; Baxt, WG; Waeckerie, JF; Wears, RL			Reliability of editors' subjective quality ratings of peer reviews of manuscripts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			POLICIES; ARTICLES	Context.-Quality of reviewers is crucial to journal quality, but there are usually too many for editors to know them all personally. A reliable method of rating them (for education and monitoring) is needed. Objective.-Whether editors' quality ratings of peer reviewers are reliable and how they compare with other performance measures. Design.-A 3.5-year prospective observational study. Setting.-Peer-reviewed journal. Participants.-All editors and peer reviewers who reviewed at least 3 manuscripts. Main Outcome Measures.-Reviewer quality ratings, individual reviewer rate of recommendation for acceptance, congruence between reviewer recommendation and editorial decision (decision congruence), and accuracy in reporting flaws in a masked test manuscript. Interventions.-Editors rated the quality of each review on a subjective 1 to 5 scale. Results.-A total of 4161 reviews of 973 manuscripts by 395 reviewers were studied. The within-reviewer intraclass correlation was 0.44 (P<.001), indicating that 20% of the variance seen in the review ratings was attributable to the reviewer. Intraclass correlations for editor and manuscript were only 0.24 and 0.12, respectively. Reviewer average quality ratings correlated poorly with the rate of recommendation for acceptance (R = -0.34) and congruence with editorial decision (R = 0.26). Among 124 reviewers of the fictitious manuscript, the mean quality rating for each reviewer was modestly correlated with the number of flaws they reported (R = 0.53). Highly rated reviewers reported twice as many flaws as poorly rated reviewers. Conclusions.-Subjective editor ratings of individual reviewers were moderately reliable and correlated with reviewer ability to report manuscript flaws. Individual reviewer rate of recommendation for acceptance and decision congruence might be thought to be markers of a discriminating (ie, high-quality) reviewer, but these variables were poorly correlated with editors' ratings of review quality or the reviewer's ability to detect flaws in a fictitious manuscript. Therefore, they cannot be substituted for actual quality ratings by editors.	Univ Calif San Francisco, Dept Med, Div Emergency Med, San Francisco, CA 94143 USA; Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; Univ Missouri, Dept Emergency Med, Kansas City, MO 64110 USA; Univ Florida, Dept Emergency Med, Jacksonville, FL USA	University of California System; University of California San Francisco; University of Pennsylvania; University of Missouri System; University of Missouri Kansas City; State University System of Florida; University of Florida	Callaham, ML (corresponding author), Univ Calif San Francisco, Dept Med, Div Emergency Med, Box 0208, San Francisco, CA 94143 USA.							BAXT WG, 1996, ACAD EMERG MED, V3, P504; BAXT WG, IN PRESS ANN EMERG M; CICCHETTI DV, 1991, BEHAV BRAIN SCI, V14, P119, DOI 10.1017/S0140525X00065675; EVANS AT, 1993, J GEN INTERN MED, V8, P422, DOI 10.1007/BF02599618; FEURER ID, 1994, JAMA-J AM MED ASSOC, V272, P98, DOI 10.1001/jama.272.2.98; NYLENNA M, 1994, JAMA-J AM MED ASSOC, V272, P149, DOI 10.1001/jama.272.2.149; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; SCHULMAN K, 1994, JAMA-J AM MED ASSOC, V272, P154, DOI 10.1001/jama.272.2.154; STRAYHORN J, 1993, AM J PSYCHIAT, V150, P947; WILKES MS, 1995, J GEN INTERN MED, V10, P443, DOI 10.1007/BF02599916	11	78	80	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					229	231		10.1001/jama.280.3.229	http://dx.doi.org/10.1001/jama.280.3.229			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676664				2022-12-28	WOS:000074706000009
J	Bero, LA; Grilli, R; Grimshaw, JM; Harvey, E; Oxman, AD; Thomson, MA				Bero, LA; Grilli, R; Grimshaw, JM; Harvey, E; Oxman, AD; Thomson, MA		Cochrane Effective Practice Org Care Review Grp	Getting research findings into practice - Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-PRACTICE; PRIMARY-CARE; PERFORMANCE; GUIDELINES; FEEDBACK		Dept Publ Hlth, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94109 USA; Ist Ric Farmacol Mario Negri, Lab Clin Epidemiol, Unit Clin Policy Anal, I-20157 Milan, Italy; Univ York, Dept Hlth Sci & Clin Evaluat, York YO1 5DD, N Yorkshire, England; Natl Inst Publ Hlth, Hlth Serv Res Unit, N-0462 Oslo, Norway	University of Aberdeen; University of California System; University of California San Francisco; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of York - UK	Grimshaw, JM (corresponding author), Dept Publ Hlth, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland.	j.m.grimshaw@abdn.ac.uk	Grilli, Roberto/K-1444-2016; Grimshaw, Jeremy/D-8726-2013; Oxman, Andrew/Y-3004-2019	Grilli, Roberto/0000-0001-9425-7170; Oxman, Andrew/0000-0002-5608-5061; Grimshaw, Jeremy/0000-0001-8015-8243				AUSTIN SM, 1994, J AM MED INFORM ASSN, P121; Beaudry JS, 1989, J CONTIN EDUC HEALTH, V9, P285, DOI DOI 10.1002/CHP.4750090414; BERO LA, 1997, COCHRANE LIB; BUNTINX F, 1993, FAM PRACT, V10, P219, DOI 10.1093/fampra/10.2.219; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; Freemantle N, 1995, Qual Health Care, V4, P45, DOI 10.1136/qshc.4.1.45; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; Grimshaw J, 1995, COMPLEXITY SYSTEMATI; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Grol R, 1992, Qual Health Care, V1, P184, DOI 10.1136/qshc.1.3.184; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS14; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; MANDELBLATT J, 1995, J FAM PRACTICE, V40, P162; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; *NHS RES DEV PROGR, 1995, METH PROM IMPL RES F; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; OXMAN AD, 1993, ANN NY ACAD SCI, V703, P123; Silagy C, 1994, Qual Health Care, V3, P193, DOI 10.1136/qshc.3.4.193; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; Waddell D L, 1991, J Contin Educ Nurs, V22, P113; Wensing M, 1994, Int J Qual Health Care, V6, P115; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005; YANO EM, 1995, ARCH INTERN MED, V155, P1146, DOI 10.1001/archinte.155.11.1146; 1994, EFFECTIVE HLTH CARE	31	1583	1604	1	82	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1998	317	7156					465	468						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703533				2022-12-28	WOS:000075490200028
J	Weerasuriya, K				Weerasuriya, K			Did I teach him survival skills and healthcare priorities?	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					461	461						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703531				2022-12-28	WOS:000075490200024
J	Van Peenen, HJ				Van Peenen, HJ			Hafiz Ali goes home	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Van Peenen, HJ (corresponding author), 1414 E Hartford,Unit 9, Ponca City, OK 74604 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					249	251		10.7326/0003-4819-129-3-199808010-00016	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696736				2022-12-28	WOS:000075032700012
J	Colavita, A; Krishna, S; Zheng, H; Padgett, RW; Culotti, JG				Colavita, A; Krishna, S; Zheng, H; Padgett, RW; Culotti, JG			Pioneer axon guidance by UNC-129, a C-elegans TGF-beta	SCIENCE			English	Article							GROWTH-FACTOR-BETA; DAUER LARVA DEVELOPMENT; CAENORHABDITIS-ELEGANS; TRANSFORMING GROWTH-FACTOR-BETA-2; 3-DIMENSIONAL STRUCTURE; COLORECTAL-CANCER; NETRIN CUES; GENE; RECEPTOR; ENCODES	The unc-129 gene, Like the unc-6 netrin gene, is required.to guide pioneer motoraxons along the dorsoventral axis of Caenorhabditis elegans. unc-129 encodes a member of the transforming growth factor-beta (TGF-beta) superfamily of secreted signaling molecules and is expressed in dorsal, but not ventral, rows of body wall muscles. Ectopic expression of UNC-129 from ventral body wall muscle disrupts growth cone and cell migrations that normally occur along the dorsoventral axis. Thus, UNC-129 mediates expression of dorsoventral polarity information required for axon guidance and guided cell migrations in C. elegans.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Rutgers State Univ, Waksman Inst, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Culotti, JG (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	culotti@mshri.on.ca	Culotti, Joseph/G-6467-2013	Colavita, Antonio/0000-0001-9391-5282; Culotti, Joseph/0000-0001-6325-4612				[Anonymous], [No title captured]; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; COLAVITA A, UNPUB; DURBIN RM, 1987, THESIS KINGS COLL CA; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NASH B, UNPUB; OKKEMA PG, 1993, GENETICS, V135, P385; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Su M.-D., UNPUB; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	27	185	199	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					706	709		10.1126/science.281.5377.706	http://dx.doi.org/10.1126/science.281.5377.706			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685266				2022-12-28	WOS:000075107900045
J	Ekwall, O; Hedstrand, H; Grimelius, L; Haavik, J; Perheentupa, J; Gustafsson, J; Husebye, E; Kampe, O; Rorsman, F				Ekwall, O; Hedstrand, H; Grimelius, L; Haavik, J; Perheentupa, J; Gustafsson, J; Husebye, E; Kampe, O; Rorsman, F			Identification of tryptophan hydroxylase as an intestinal autoantigen	LANCET			English	Article							AMINO-ACID DECARBOXYLASE; ADDISONS-DISEASE; OVARIAN FAILURE; AUTOIMMUNE; AUTOANTIBODIES; ANTIBODIES; TYROSINASE; SEROTONIN	Background Autoimmune polyendocrine syndrome type 1 (APS1) is an autosomal recessive disorder with both endocrine and non-endocrine features. Periodic gastrointestinal dysfunction occurs in 25-30% of APS1 patients. We aimed to identify an intestinal autoantigen. Methods A human duodenal cDNA library was immunoscreened with serum samples from APS1 patients. A positive clone was identified and used for in-vitro transcription and translation, followed by immunoprecipitation with serum samples from 80 APS1 patients from Norway, Finland, and Sweden. Sections of normal and APS1-affected small intestine were immunostained with serum from APS1 patients and specific antibodies. An enzyme-inhibition assay was used to characterise the autoantibodies. Findings We isolated a cDNA clone coding for tryptophan hydroxylase. 48% (38/80) of APS1 patients had antibodies to tryptophan hydroxylase, whereas no reactivity to this antigen was detected in patients with other autoimmune diseases (n=372) or healthy blood donors (n=70). 89% (17/19) of APS1 patients with gastrointestinal dysfunction were positive for antibodies to tryptophan hydroxylase, compared with 34% (21/61) of patients with no gastrointestinal dysfunction (p<0.0001). Serum from antibody-positive APSI patients specifically immunostained tryptophan-hydroxylase-containing enterochromaffin cells in normal duodenal mucosa. No serotonin-containing cells were seen in duodenal biopsy samples from APS1 patients. Serum from antibody-positive APS1 patients almost completely inhibited activity of tryptophan hydroxylase, Interpretation Tryptophan hydroxylase is an endogenous intestinal autoantigen in APS1, and there is an association between antibodies to the antigen and gastrointestinal dysfunction. Analysis of antibodies to tryptophan hydroxylase may be a valuable diagnostic tool to predict and monitor gastrointestinal dysfunction in APS1.	Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Pediat, S-75185 Uppsala, Sweden; Univ Bergen, Dept Biochem & Mol Biol, Bergen, Norway; Univ Bergen, Dept Med B, Bergen, Norway; Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; University of Bergen; University of Bergen; University of Helsinki	Ekwall, O (corresponding author), Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden.	olov.ekwall@medicin.uu.se	Haavik, Jan/AAI-3974-2020; Haavik, Jan/ABE-1535-2020	Haavik, Jan/0000-0001-7865-2808; Kampe, Olle/0000-0001-6091-9914; Ekwall, Olov/0000-0002-4506-9955				Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P933, DOI 10.1210/jc.80.3.933; BOADLEBIBER MC, 1993, PROG BIOPHYS MOL BIO, V60, P1, DOI 10.1016/0079-6107(93)90009-9; BOULARAND S, 1990, NUCLEIC ACIDS RES, V18, P4257, DOI 10.1093/nar/18.14.4257; Chen S, 1996, J CLIN ENDOCR METAB, V81, P1871, DOI 10.1210/jc.81.5.1871; Corazza GR, 1997, LANCET, V350, P106, DOI 10.1016/S0140-6736(97)01042-8; FRIEDMAN PA, 1972, MOL PHARMACOL, V8, P501; GebreMedhin G, 1997, FEBS LETT, V412, P439, DOI 10.1016/S0014-5793(97)00797-7; HAAN EA, 1987, BRAIN RES, V426, P19, DOI 10.1016/0006-8993(87)90420-3; HEUBI JE, 1983, DIGEST DIS SCI, V28, P124, DOI 10.1007/BF01315141; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; Husebye ES, 1997, J CLIN ENDOCR METAB, V82, P147, DOI 10.1210/jc.82.1.147; KOBAYASHI T, 1991, J PHARMACOL EXP THER, V256, P773; LENNON VA, 1991, GASTROENTEROLOGY, V100, P137, DOI 10.1016/0016-5085(91)90593-A; MANNS M, 1990, HEPATOLOGY, V12, P127, DOI 10.1002/hep.1840120120; MIRAKIAN R, 1986, BRIT MED J, V293, P1132, DOI 10.1136/bmj.293.6555.1132; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Neufeld M, 1980, Pediatr Ann, V9, P154; Peterson P, 1997, CLIN EXP IMMUNOL, V107, P335, DOI 10.1111/j.1365-2249.1997.282-ce1175.x; PortelaGomes GM, 1997, J HISTOCHEM CYTOCHEM, V45, P815, DOI 10.1177/002215549704500606; RAHMAN MK, 1981, BIOCHEM PHARMACOL, V30, P645, DOI 10.1016/0006-2952(81)90139-8; RORSMAN F, 1995, P NATL ACAD SCI USA, V92, P8626, DOI 10.1073/pnas.92.19.8626; Scire G, 1991, J Pediatr Gastroenterol Nutr, V13, P224, DOI 10.1097/00005176-199108000-00023; SONG YH, 1994, LANCET, V344, P1049, DOI 10.1016/S0140-6736(94)91709-4; Tuomi T, 1996, J CLIN ENDOCR METAB, V81, P1488, DOI 10.1210/jc.81.4.1488; VRANA SL, 1993, J NEUROSCI METH, V48, P123, DOI 10.1016/S0165-0270(05)80014-7; WINQVIST O, 1992, LANCET, V339, P1559, DOI 10.1016/0140-6736(92)91829-W; WINQVIST O, 1995, J CLIN ENDOCR METAB, V80, P1717, DOI 10.1210/jc.80.5.1717; Yee C, 1996, J IMMUNOL, V157, P4079	30	142	144	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					279	283		10.1016/S0140-6736(97)11050-9	http://dx.doi.org/10.1016/S0140-6736(97)11050-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690408				2022-12-28	WOS:000074974500011
J	Leon, DA; Lithell, HO; Vagero, D; Koupilova, I; Mohsen, R; Berglund, L; Lithell, UB; McKeigue, PM				Leon, DA; Lithell, HO; Vagero, D; Koupilova, I; Mohsen, R; Berglund, L; Lithell, UB; McKeigue, PM			Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915-29	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; ADULT LIFE; INFANCY	Objective: To establish whether fetal growth rate (as distinct from size at birth) is associated with mortality from ischaemic heart disease. Design: Cohort study based on uniquely detailed obstetric records with 97% follow up over the entire life course and linkage to census data in adult life. Subjects: All 14 611 babies delivered at the Uppsala Academic Hospital, Sweden, during 1915-29 followed up to end of 1995. Main outcome measures: Mortality from ischaemic heart disease and other causes. Results: Cardiovascular disease showed an inverse association with birth weight for both men and women, although this was significant only for men. In men a 1000 g increase in birth weight was associated with a proportional reduction in the rate of ischaemic heart disease of 0.77 (95% confidence interval 0.67 to 0.90). Adjustment for socioeconomic circumstances at birth and in adult life led to slight attenuation of this effect Relative to the lowest fourth of birth weight for gestational age, mortality from ischaemic heart disease in men in the second, third, and fourth fourths was 0.81 (0.66 to 0.98), 0.63 (0.50 to 0.78), and 0.67 (0.54 to 0.82), respectively The inclusion of birth weight per se and birth weight for gestational age in the same model strengthened the association with birth weight for gestational age but removed the association with birth weight Conclusion: This study provides by far the most persuasive evidence of a real association between size at birth and mortality from ischaemic heart disease in men, which cannot be explained by methodological artefact or socioeconomic confounding. It strongly suggests that it is variation in fetal growth rate rather than size at birth that is aetiologically important.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; Uppsala Univ, Inst Geriatr, S-75125 Uppsala, Sweden; Univ Stockholm, Dept Sociol, S-10691 Stockholm, Sweden	University of London; London School of Hygiene & Tropical Medicine; Uppsala University; Stockholm University	Leon, DA (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, Keppel St, London WC1E 7HT, England.	dleon@lshtm.ac.uk	Berglund, Lars/AAD-3856-2019; Leon, David A/G-2195-2010; Berglund, Lars/AAA-3188-2019; Koupil, Ilona/AAC-9067-2020	Berglund, Lars/0000-0002-7437-9047; Leon, David A/0000-0001-9747-1762; Koupil, Ilona/0000-0002-7034-1922; Vagero, Denny/0000-0002-1854-2292				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Erikson R., 1992, CONSTANT FLUX; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; Joseph KS, 1996, EPIDEMIOL REV, V18, P158, DOI 10.1093/oxfordjournals.epirev.a017923; KOUPILOVA I, 1996, J EPIDEMIOL COMMUNIT, V50, P592; KOUPILOVA I, 1997, J HYPERTENS       S4, V15, P46; KOUPILOVA I, 1997, ACTA U UPSAL, V698, P7; KRAMER MS, 1990, PEDIATRICS, V86, P707; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LEON DA, 1997, LIFE COURSE INFLUENC; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROTHWELL PM, 1994, LANCET, V343, P731, DOI 10.1016/S0140-6736(94)91610-1; *STAT CORP, 1997, STAT REF MAN REL 5; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; Vik T, 1997, EARLY HUM DEV, V48, P167, DOI 10.1016/S0378-3782(96)01852-X	24	574	584	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					241	245		10.1136/bmj.317.7153.241	http://dx.doi.org/10.1136/bmj.317.7153.241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677213	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000075081900020
J	Rockmann, T; Brenninkmeijer, CAM; Saueressig, G; Bergamaschi, P; Crowley, JN; Fischer, H; Crutzen, PJ				Rockmann, T; Brenninkmeijer, CAM; Saueressig, G; Bergamaschi, P; Crowley, JN; Fischer, H; Crutzen, PJ			Mass-independent oxygen isotope fractionation in atmospheric CO as a result of the reaction CO+OH	SCIENCE			English	Article							OH + CO; OZONE; CARBON	Atmospheric carbon monoxide (CO) exhibits mass-independent fractionation in the oxygen isotopes. An O-17 excess up to 7.5 per mil was observed in summer at high northern latitudes. The major source of this puzzling fractionation in this important trace gas is its dominant atmospheric removal reaction, CO + OH --> CO2 + H, in which the surviving CO gains excess O-17. The occurrence of mass-independent fractionation in the reaction of CO with OH raises fundamental questions about kinetic processes. At the same time the effect is a useful marker for the degree to which CO in the atmosphere has been reacting with OH.	Max Planck Inst Chem, Div Atmospher Chem, D-55020 Mainz, Germany	Max Planck Society	Rockmann, T (corresponding author), Max Planck Inst Chem, Div Atmospher Chem, Postfach 3060, D-55020 Mainz, Germany.		Crutzen, Paul J/F-6044-2012; Brenninkmeijer, Carl/B-6860-2013; Röckmann, Thomas/F-4479-2015	Röckmann, Thomas/0000-0002-6688-8968				Anderson SM, 1997, J CHEM PHYS, V107, P5385, DOI 10.1063/1.474247; BIGELEISEN J, 1965, SCIENCE, V147, P463, DOI 10.1126/science.147.3657.463; Brenninkmeijer CAM, 1997, J GEOPHYS RES-ATMOS, V102, P25477, DOI 10.1029/97JD02291; BRENNINKMEIJER CAM, 1993, J GEOPHYS RES-ATMOS, V98, P10595, DOI 10.1029/93JD00587; BRENNINKMELJER CAM, 1998, JRAPID COMMUN MASS S, V12, P479; Cliff SS, 1997, SCIENCE, V278, P1774, DOI 10.1126/science.278.5344.1774; Colman JJ, 1996, SCIENCE, V273, P774, DOI 10.1126/science.273.5276.774; DEMORE WB, 1994, JPL PUBLB, V11; Dubey MK, 1997, J PHYS CHEM A, V101, P1494, DOI 10.1021/jp962332p; Fulle D, 1996, J CHEM PHYS, V105, P983, DOI 10.1063/1.471991; Gellene GI, 1996, SCIENCE, V274, P1344, DOI 10.1126/science.274.5291.1344; GONFIANTINI R, 1978, NATURE, V271, P534, DOI 10.1038/271534a0; GREENBLATT GD, 1989, J PHYS CHEM-US, V93, P1035, DOI 10.1021/j100340a006; HODDER PS, 1994, 1107 US GEOL; HUFF AK, 1996, EOS S; Johnston JC, 1997, J GEOPHYS RES-ATMOS, V102, P25395, DOI 10.1029/97JD02075; KRANKOWSKY D, 1995, GEOPHYS RES LETT, V22, P1713, DOI 10.1029/95GL01436; MAUERSBERGER K, 1987, GEOPHYS RES LETT, V14, P80, DOI 10.1029/GL014i001p00080; MOZURKEWICH M, 1984, J PHYS CHEM-US, V88, P6435, DOI 10.1021/j150669a074; PARASKEVOPOULOS G, 1984, J CHEM PHYS, V80, P259, DOI 10.1063/1.446488; Rockmann T, 1998, J GEOPHYS RES-ATMOS, V103, P1463, DOI 10.1029/97JD02929; Smit H. G. J., 1982, STABLE ISOTOPES, P147; SMITH IWM, 1977, CHEM PHYS LETT, V49, P112, DOI 10.1016/0009-2614(77)80453-3; STEVENS CM, 1980, INT J CHEM KINET, V12, P935, DOI 10.1002/kin.550121205; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; THIEMENS MH, 1991, GEOPHYS RES LETT, V18, P669, DOI 10.1029/91GL00121; Yoo RK, 1996, J CHEM PHYS, V105, P177, DOI 10.1063/1.471855; Yung YL, 1997, J GEOPHYS RES-ATMOS, V102, P10857, DOI 10.1029/97JD00528	28	122	125	5	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					544	546		10.1126/science.281.5376.544	http://dx.doi.org/10.1126/science.281.5376.544			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677193				2022-12-28	WOS:000075012300035
J	Ron, E; Doddy, MM; Becker, DV; Brill, AB; Curtis, RE; Goldman, MB; Harris, BSH; Hoffman, DA; McConahey, WM; Maxon, HR; Preston-Martin, S; Warshauer, ME; Wong, FL; Boice, JD				Ron, E; Doddy, MM; Becker, DV; Brill, AB; Curtis, RE; Goldman, MB; Harris, BSH; Hoffman, DA; McConahey, WM; Maxon, HR; Preston-Martin, S; Warshauer, ME; Wong, FL; Boice, JD		Cooperative Thyrotoxicosis Therapy Follow Stud	Cancer mortality following treatment for adult hyperthyroidism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THYROID-CANCER; I-131 THERAPY; GRAVES-DISEASE; THYROTOXICOSIS; CARCINOMA; WOMEN; RISK	Context.-High-dose iodine 131 is the treatment of choice in the United States for most adults with hyperthyroid disease. Although there is little evidence to link therapeutic I-131 to the development of cancer, its extensive medical use indicates the need for additional evaluation. Objective.-To evaluate cancer mortality among hyperthyroid patients, particularly after I-131 treatment. Design.-A retrospective cohort study. Setting.-Twenty-five clinics in the United States and 1 clinic in England. Patients.-A total of 35 593 hyperthyroid patients treated between 1946 and 1964 in the original Cooperative Thyrotoxicosis Therapy Follow-up Study; 91% had Graves disease, 79% were female, and 65% were treated with I-131. Main Outcome Measure.-Standardized cancer mortality ratios (SMRs) after 3 treatment modalities for hyperthyroidism. Results.-Of the study cohort, 50.5% had died by the end of follow-up in December 1990. The total number of cancer deaths was close to that expected based on mortality rates in the general population (2950 vs 2857.6), but there was a small excess of mortality from cancers of the lung, breast, kidney, and thyroid, and a deficit of deaths from cancers of the uterus and the prostate gland. Patients with toxic nodular goiter had an SMR of 1.16 (95% confidence interval [CI], 1.03-1.30). More than 1 year after treatment, an increased risk of cancer mortality was seen among patients treated exclusively with antithyroid drugs (SMR, 1.31; 95% CI, 1.06-1.60). Radioactive iodine was not linked to total cancer deaths (SMR, 1.02; 95% CI, 0.98-1.07) or to any specific cancer with the exception of thyroid cancer (SMR, 3.94; 95% CI, 2.52-5.86). Conclusions.-Neither hyperthyroidism nor I-131 treatment resulted in a significantly increased risk of total cancer mortality. While there was an elevated risk of thyroid cancer mortality following I-131 treatment, in absolute terms the excess number of deaths was small, and the underlying thyroid disease appeared to play a role. Overall, I-131 appears to be a safe therapy for hyperthyroidism.	NCI, Radiat Epidemiol Branch, NIH, Bethesda, MD 20892 USA; Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA; Vanderbilt Univ, Nashville, TN USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; George Washington Univ, Washington, DC 20052 USA; Mayo Clin, Rochester, MN USA; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Univ So Calif, Los Angeles, CA 90089 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; NewYork-Presbyterian Hospital; Vanderbilt University; Harvard University; Harvard T.H. Chan School of Public Health; Research Triangle Institute; George Washington University; Mayo Clinic; University System of Ohio; University of Cincinnati; University of Southern California	Ron, E (corresponding author), NCI, Radiat Epidemiol Branch, NIH, Bethesda, MD 20892 USA.		Brill, Aaron/H-3732-2014	Brill, Aaron/0000-0001-7538-086X	NCI NIH HHS [N01-CP-41060] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP041060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		Becker David V., 1996, P943; BECKER DV, 1989, RAD THYROID, P57; BECKER DV, 1971, FURTHER ADV THYROID, P603; Cox DR, 1974, THEORETICAL STAT; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; DOBYNS BM, 1977, RAD ASS THYROID CARC, P459; FRANCESCHI S, 1989, INT J EPIDEMIOL, V18, P578, DOI 10.1093/ije/18.3.578; FURSZYFE.J, 1972, METABOLISM, V21, P197, DOI 10.1016/0026-0495(72)90041-8; GLOBEL B, 1989, RAD RISK PROTECTOIN, P565; GOLDMAN MB, 1990, CANCER RES, V50, P2283; GOLDMAN MB, 1988, AM J EPIDEMIOL, V127, P969, DOI 10.1093/oxfordjournals.aje.a114900; GRAHAM GD, 1986, ANN INTERN MED, V105, P900, DOI 10.7326/0003-4819-105-6-900; GREEN M, 1961, BRIT MED J, V1, P210; HALL P, 1991, BRIT J CANCER, V64, P159, DOI 10.1038/bjc.1991.261; HALL P, 1992, INT J CANCER, V50, P886, DOI 10.1002/ijc.2910500611; Hall P, 1996, RADIAT RES, V145, P86, DOI 10.2307/3579200; HALNAN KE, 1983, BMJ-BRIT MED J, V287, P8121; HANCOCK BW, 1977, CANCER, V39, P298, DOI 10.1002/1097-0142(197701)39:1<298::AID-CNCR2820390146>3.0.CO;2-C; HOFFMAN DA, 1982, AM J EPIDEMIOL, V115, P243, DOI 10.1093/oxfordjournals.aje.a113296; HOFFMAN DA, 1982, INT J EPIDEMIOL, V11, P218, DOI 10.1093/ije/11.3.218; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HOLM LE, 1988, JNCI-J NATL CANCER I, V80, P1132, DOI 10.1093/jnci/80.14.1132; *INT COMM RAD PROT, 1988, ANN ICRP, V18, P275; KLEIN I, 1994, ANN INTERN MED, V121, P281, DOI 10.7326/0003-4819-121-4-199408150-00010; LOEVINGER R, 1956, RAD DOSIMETRY, P870; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; PRESTON D. L., 1993, EPICURE USERS GUIDE; RON E, 1987, JNCI-J NATL CANCER I, V79, P1; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SAENGER EL, 1968, J AMER MED ASSOC, V205, P855, DOI 10.1001/jama.205.12.855; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; Tompkins E, 1970, MED RADIONUCLIDES RA, P431; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; *US DHEW, 1967, PHS PUBL, V1693; Volpe R, 1989, THYROID FUNCTION DIS, P214; WILLIAMS ED, 1986, LANCET, V2, P456; World Health Organization, 1957, MAN INT STAT CLASS D; ZANZONICO P B, 1989, Journal of Nuclear Medicine, V30, P833	39	247	268	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					347	355		10.1001/jama.280.4.347	http://dx.doi.org/10.1001/jama.280.4.347			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686552	Bronze			2022-12-28	WOS:000074804200035
J	Kumar, S; Berl, T				Kumar, S; Berl, T			Sodium	LANCET			English	Article							WATER CHANNEL EXPRESSION; INDUCED DOWN-REGULATION; ANTI-DIURETIC HORMONE; RAT-KIDNEY MEDULLA; DIABETES-INSIPIDUS; INAPPROPRIATE SECRETION; ARGININE-VASOPRESSIN; SEVERE HYPONATREMIA; MESSENGER-RNA; HEART-FAILURE	Disorders of serum sodium are both the most common and probably most the poorly understood electrolyte disorders in clinical medicine. In the past few years increased knowledge about the non-osmotic release of vasopressin and the cloning of vasopressin receptors and of vasopressin-regulated water channels (AQP2) has enhanced our understanding of these disorders. Also controversies surrounding the treatment of hyponatraemic patients have led to well-accepted therapeutic guidelines.	Univ Colorado, Sch Med, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Berl, T (corresponding author), Univ Colorado, Sch Med, Dept Med, 4200E 9th Ave, Denver, CO 80262 USA.	Tomas.Berl@uchsc.edu						ANDERSON RJ, 1986, KIDNEY INT, V29, P1237, DOI 10.1038/ki.1986.134; Apostol E, 1997, J AM SOC NEPHROL, V8, P15; BARRETT T, 1997, J MED GENET, V29, P1237; BENEDICT CR, 1994, J AM COLL CARDIOL, V23, P1410, DOI 10.1016/0735-1097(94)90385-9; Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; BERL T, 1990, KIDNEY INT, V37, P357; Bichet DG, 1997, J AM SOC NEPHROL, V8, P1951; DECAUX G, 1983, NEPHRON, V35, P82, DOI 10.1159/000183052; DURR JA, 1987, NEW ENGL J MED, V316, P1070, DOI 10.1056/NEJM198704233161707; Ecelbarger CA, 1997, J CLIN INVEST, V99, P1852, DOI 10.1172/JCI119352; FORREST JN, 1978, NEW ENGL J MED, V298, P173, DOI 10.1056/NEJM197801262980401; Fujita N, 1995, AM J PHYSIOL-RENAL, V269, pF926, DOI 10.1152/ajprenal.1995.269.6.F926; GOLDMAN MB, 1988, NEW ENGL J MED, V318, P397, DOI 10.1056/NEJM198802183180702; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HOWARD RL, 1992, AM J KIDNEY DIS, V19, P573, DOI 10.1016/S0272-6386(12)80837-7; Kim JK, 1996, MOL CELL ENDOCRINOL, V123, P179, DOI 10.1016/S0303-7207(96)03912-3; KITIYAKARA C, 1997, CURR OPIN NEPHROL HY, V35, P82; Lauriat SM, 1997, J AM SOC NEPHROL, V8, P1599; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LINAS SL, 1980, KIDNEY INT, V18, P58, DOI 10.1038/ki.1980.110; MACAULAY D, 1967, ARCH DIS CHILD, V42, P485, DOI 10.1136/adc.42.225.485; Marples D, 1996, J CLIN INVEST, V97, P1960, DOI 10.1172/JCI118628; MARPLES D, 1995, J CLIN INVEST, V95, P1838, DOI 10.1172/JCI117863; Martin PY, 1998, J CLIN INVEST, V101, P235, DOI 10.1172/JCI626; Rittig S, 1996, AM J HUM GENET, V58, P107; ROBERTSON GL, 1982, AM J MED, V72, P339, DOI 10.1016/0002-9343(82)90825-7; SANDS J, 1996, J CLIN INVEST, V97, P1906; SONNENBERCK M, 1993, CHEST, V193, P601; Soupart A, 1996, CLIN NEPHROL, V46, P149; Steele A, 1997, ANN INTERN MED, V126, P20, DOI 10.7326/0003-4819-126-1-199701010-00003; SZATALOWICZ VL, 1981, NEW ENGL J MED, V305, P263, DOI 10.1056/NEJM198107303050506; TANNEN RL, 1969, NEW ENGL J MED, V280, P1135, DOI 10.1056/NEJM196905222802101; TEITELBAUM I, 1995, J CLIN INVEST, V96, P378, DOI 10.1172/JCI118044; VANLIEBURG AF, 1994, AM J HUM GENET, V55, P648; VERBALIS JG, 1994, AM J PHYSIOL, V36, pR1617; Weigert AL, 1995, HEPATOLOGY, V22, P1856, DOI 10.1002/hep.1840220635; Zarinetchi F, 1996, ADV INTERNAL MED, V41, P251; ZU D, 1997, J CLIN INVEST, V99, P1500	38	227	233	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					220	228		10.1016/S0140-6736(97)12169-9	http://dx.doi.org/10.1016/S0140-6736(97)12169-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683227				2022-12-28	WOS:000074859800043
J	Martyn, CN; Gale, CR; Jespersen, S; Sherriff, SB				Martyn, CN; Gale, CR; Jespersen, S; Sherriff, SB			Impaired fetal growth and atherosclerosis of carotid and peripheral arteries	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; ADULT LIFE; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; IN-UTERO; DEATH; MEN; BIRTH; WEIGHT; SIZE	Background Although epidemiological studies suggest that people with low birthweight are at higher risk of coronary heart disease and stroke in adult life than those of higher birthweight, the mechanisms underlying this relation are unclear. We investigated whether impaired fetal growth leads to an increased risk of atherosclerosis by assessment of the carotid and lower-limb arteries in a group of people aged around 70 years for whom birthweight data were available. Methods 2232 singleton babies were born to married mothers at a maternity hospital in Sheffield, UK, between 1922 and 1926, and had complete birth records. We traced 829 survivors and invited 395 who still lived in Sheffield to take part in this study. 322 agreed; they were interviewed at home and 181 underwent duplex ultrasonographic examination of the extracranial parts of the carotid arteries. Atherosclerosis in the arteries of the lower limb was assessed in 186 people by the ankle brachial-pressure index (ABPI). Findings The prevalence and severity of carotid atherosclerosis was greatest in those with the lowest recorded birthweight. The risk of carotid stenosis was greater for people who had weighed 6.5 lb or less at birth than for those who weighed over 7.5 lb (odds ratio 5.3 [95% CI 2.0-14.0]), after adjustment for cardiovascular risk factors and gestational age at birth. The odds ratio for atherosclerotic disease in the lower limbs (low ABPI) was highest in people with the lowest recorded birthweight, but this relation was not significant (odds ratio 2.3 [1.0-5.6]). Interpretation Increased atherogenesis may be one mechanism mediating the observed epidemiological link between impaired fetal growth and cardiovascular disease. Adaptations made by the fetus in response to influences that retard its growth may have long-term consequences for the structure and metabolism of the vascular system.	Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; No Gen Hosp, Dept Med Phys, Sheffield S5 7AU, S Yorkshire, England	University of Southampton; Northern General Hospital	Martyn, CN (corresponding author), Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.	c.martyn@mrc.soton.ac.uk	Gale, Catharine R/B-1653-2012					ALLAN PLP, 1991, EPIDEMIOLOGY PERIPHE, P41; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; GIRAL P, 1991, ARCH INTERN MED, V151, P950, DOI 10.1001/archinte.151.5.950; JOENSUU T, 1994, J INTERN MED, V236, P79; KOUPILOVA I, 1996, J EPIDEMIOL COMMUNIT, V50, P592; Law CM, 1996, J HYPERTENS, V14, P935; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; Martyn CN, 1996, BRIT MED J, V312, P1393; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OGREN M, 1993, LANCET, V342, P1138, DOI 10.1016/0140-6736(93)92123-B; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Pasterkamp G, 1998, ATHEROSCLEROSIS, V137, P205, DOI 10.1016/S0021-9150(97)00255-4; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; RIZZO G, 1991, AM J OBSTET GYNECOL, V165, P876, DOI 10.1016/0002-9378(91)90431-P; SALONEN JT, 1993, CIRCULATION, V87, P56; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; SUTTON KC, 1987, STROKE, V18, P817, DOI 10.1161/01.STR.18.5.817	23	125	128	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1998	352	9123					173	178		10.1016/S0140-6736(97)10404-4	http://dx.doi.org/10.1016/S0140-6736(97)10404-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683205				2022-12-28	WOS:000074859800009
J	Buchel, C; Price, C; Friston, K				Buchel, C; Price, C; Friston, K			A multimodal language region in the ventral visual pathway	NATURE			English	Article							TEMPORAL-LOBE; CORTEX; EXTRASTRIATE; WORDS; ACTIVATION; IMPAIRMENT; ALEXIA; OBJECT; FACES; AREA	Reading words and naming pictures involves the association of visual stimuli with phonological and semantic knowledge. Damage to a region of the brain in the left basal posterior temporal lobe (BA37), which is strategically situated between the visual cortex and the more anterior temporal cortex, leads to reading and naming deficits(1,2). Additional evidence implicating this region in linguistic processing comes from functional neuroimaging studies of reading in normal subjects(3-7) and subjects with developmental dyslexia(8,9). Here we test whether the visual component of reading is essential for activation of BA37 by comparing cortical activations elicited by word processing in congenitally blind, late-blind and sighted subjects using functional neuroimaging. Despite the different modalities used (visual and tactile), all groups of subjects showed a common activation of BA37 by words relative to non-word letter-strings. These findings agree with the proposal that BA37 is an association area that integrates converging inputs from many regions(10). Our study confirms a prediction of theories of brain function that depend on convergence zones; the absence of one input (that is, visual) does not alter the response properties of such a convergence region.	Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England	University of London; University College London	Buchel, C (corresponding author), Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.		Friston, Karl/D-9230-2011	Friston, Karl/0000-0001-7984-8909; Price, Catherine/0000-0001-7448-4835	Wellcome Trust [051067] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLISON T, 1994, CEREB CORTEX, V4, P544, DOI 10.1093/cercor/4.5.544; Bookheimer SY, 1995, HUM BRAIN MAPP, V3, P93, DOI 10.1002/hbm.460030206; BRUNSWICK N, UNPUB BRAIN; Buchel C, 1998, BRAIN, V121, P409, DOI 10.1093/brain/121.3.409; BURNSTINE TH, 1990, NEUROLOGY, V40, P966, DOI 10.1212/WNL.40.6.966; Damasio A., 1994, LARGE SCALE NEURONAL, P61; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DEsposito M, 1997, NEUROPSYCHOLOGIA, V35, P725, DOI 10.1016/S0028-3932(96)00121-2; FARAH MJ, 1990, VISUAL AGNOSIA; FIEZ JA, 1995, J COGNITIVE NEUROSCI, V7, P357, DOI 10.1162/jocn.1995.7.3.357; Foundas AL, 1998, NEUROCASE, V4, P35, DOI 10.1093/neucas/4.1.35; Friedman RF, 1993, CLIN NEUROPSYCHOLOGY, P37; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; Kanwisher N, 1997, J NEUROSCI, V17, P4302; LUDERS H, 1986, NEUROLOGY, V36, P505, DOI 10.1212/WNL.36.4.505; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; Price CJ, 1997, NEUROIMAGE, V5, P261, DOI 10.1006/nimg.1997.0269; Puce A, 1996, J NEUROSCI, V16, P5205; RAPCSAK SZ, 1987, BRAIN LANG, V31, P109, DOI 10.1016/0093-934X(87)90063-0; Rumsey JM, 1997, ARCH NEUROL-CHICAGO, V54, P562, DOI 10.1001/archneur.1997.00550170042013; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; SUZUKI WA, 1993, J NEUROSCI, V13, P2430, DOI 10.1523/JNEUROSCI.13-06-02430.1993; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3	28	299	305	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					274	277		10.1038/28389	http://dx.doi.org/10.1038/28389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685156				2022-12-28	WOS:000074851900047
J	Grant, PA; Schieltz, D; Pray-Grant, MG; Steger, DJ; Reese, JC; Yates, JR; Workman, JL				Grant, PA; Schieltz, D; Pray-Grant, MG; Steger, DJ; Reese, JC; Yates, JR; Workman, JL			A subset of TAF(II)s are integral components of the SAGA complex required for nucleosome acetylation and transcriptional stimulation	CELL			English	Article							TATA-BINDING PROTEIN; YEAST SWI/SNF COMPLEX; HISTONE ACETYLATION; X-CHROMOSOME; ACTIVATION; CHROMATIN; H4; ENHANCEMENT; REPRESSION; CELLS	A number of transcriptional coactivator proteins have been identified as histone acetyltransferase (HAT) proteins, providing a direct molecular basis for the coupling of histone acetylation and transcriptional activation. The yeast Spt-Ada-Gcn5-acetyltransferase (SAGA) complex requires the coactivator protein Gcn5 for HAT activity. Identification of protein subunits by mass spectrometry and immunoblotting revealed that the TATA binding protein-associated factors (TAF(II)s) TAF(II)90, -68/61, -60, -25/23, and -20/17 are integral components of this complex. in addition, TAF(II)68 was required for both SAGA-dependent nucleosomal HAT activity and transcriptional activation from chromatin templates in vitro. These results illustrate a role for certain TAF(II) proteins in the regulation of gene expression at the level of chromatin modification that is distinct from the TFIID complex and TAF(II)145.	Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Washington, Hlth Sci Ctr, Dept Mol Biotechnol, Seattle, WA 98195 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Washington; University of Washington Seattle	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA.				PHS HHS [11823-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GAITLIN CL, 1998, IN PRESS J ANAL BIOC; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roberts SM, 1997, GENETICS, V147, P451; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; UTLEY RT, 1998, IN PRESS NATURE; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YATES JR, 1994, CELL BIOL LABORATORY, P380	59	376	395	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					45	53		10.1016/S0092-8674(00)81220-9	http://dx.doi.org/10.1016/S0092-8674(00)81220-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674426	Bronze			2022-12-28	WOS:000074790800008
J	Schnitzler, G; Sif, S; Kingston, RE				Schnitzler, G; Sif, S; Kingston, RE			Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state	CELL			English	Article							TRANSCRIPTIONAL ACTIVATORS; RETINOBLASTOMA PROTEIN; CHROMATIN STRUCTURE; COMPLEX; DNA; BINDING; DISRUPTION; SEQUENCES; RECEPTOR; FAMILY	The human SWI/SNF complex remodels nucleosome structure in an ATP-dependent manner, although the nature of this change has not been determined. Here we show that hSWI/SNF and ATP generate an altered nucleosomal structure that is stable in the absence of SWI/SNF. This product has an altered sensitivity to digestion by DNAse, restriction enzymes, and micrococcal nuclease, and an increased affinity for GAL4. It has the same protein composition but is approximately twice the size of a normal nucleosome. Incubation of the altered nucleosome with hSWI/SNF converts this structure back to a standard nucleosome in an ATP-dependent process. These results suggest that hSWI/SNF acts by facilitating an exchange between normal and altered, more accessible, nucleosome conformations.	Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA.		Sif, Said/AAE-5554-2019	Sif, Said/0000-0001-6268-1145				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Cao YX, 1997, MOL CELL BIOL, V17, P3323, DOI 10.1128/MCB.17.6.3323; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Harlow E., 1988, ANTIBODIES LAB MANUA; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; NOLL H, 1989, METHOD ENZYMOL, V170, P55; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Strober BE, 1996, MOL CELL BIOL, V16, P1576; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Utley RT, 1996, METHOD ENZYMOL, V274, P276; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU HM, 1979, BIOCHEMISTRY-US, V18, P3960, DOI 10.1021/bi00585a018	36	246	249	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					17	27		10.1016/S0092-8674(00)81217-9	http://dx.doi.org/10.1016/S0092-8674(00)81217-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674423	Bronze			2022-12-28	WOS:000074790800005
J	Anderson, RT; Chapelle, FH; Lovley, DR				Anderson, RT; Chapelle, FH; Lovley, DR			Evidence against hydrogen-based microbial ecosystems in basalt aquifers	SCIENCE			English	Article							DEEP; GEOCHEMISTRY; SUBSURFACE; SEDIMENTS; BIOSPHERE	It has been proposed that hydrogen produced from basalt-ground-water interactions may serve as an energy source that supports the existence of microorganisms in the deep subsurface on Earth and possibly on other planets. However, experiments demonstrated that hydrogen is not produced from basalt at an environmentally relevant, alkaline pH. Small amounts of hydrogen were produced at a lower pH in laboratory incubations, but even this hydrogen production was transitory. Furthermore, geochemical considerations suggest that previously reported rates of hydrogen production cannot be sustained over geologically significant time frames. These findings indicate that hydrogen production from basalt-ground-water interactions may not support microbial metabolism in the subsurface.	Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Civil & Environm Engn, Amherst, MA 01003 USA; US Geol Survey, Columbia, SC 29210 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; United States Department of the Interior; United States Geological Survey	Lovley, DR (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.							AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; ANDERSON SR, 1997, 974010 US GEOL SURV; BOSTON PJ, 1992, ICARUS, V95, P300, DOI 10.1016/0019-1035(92)90045-9; BURT RA, 1993, 2392 US GEOL SURV WA, P59; Chapelle F. H., 1993, GROUND WATER MICROBI; Chapelle FH, 1997, ENVIRON SCI TECHNOL, V31, P2873, DOI 10.1021/es970085c; CHAPELLE FH, 1990, APPL ENVIRON MICROB, V56, P1865, DOI 10.1128/AEM.56.6.1865-1874.1990; CHAPELLE FH, 1987, WATER RESOUR RES, V23, P1625, DOI 10.1029/WR023i008p01625; Claypool G.E., 1974, NATURAL GASES MARINE, P99, DOI DOI 10.1007/978-1-4684-2757-8_8; Fredrickson JK, 1996, SCI AM, V275, P68, DOI 10.1038/scientificamerican1096-68; Fry NK, 1997, APPL ENVIRON MICROB, V63, P1498, DOI 10.1128/AEM.63.4.1498-1504.1997; GHIORSE WC, 1988, ADV APPL MICROBIOL, V33, P107, DOI 10.1016/S0065-2164(08)70206-5; GOLD T, 1992, P NATL ACAD SCI USA, V89, P6045, DOI 10.1073/pnas.89.13.6045; HEARN PP, 1990, P US GEOL SURV WORKS, P63; KITA I, 1982, J GEOPHYS RES, V87, P789, DOI 10.1029/JB087iB13p10789; LEE RW, 1984, 84237 US GEOL SURV, P12; LOVLEY DR, 1988, GEOCHIM COSMOCHIM AC, V52, P2993, DOI 10.1016/0016-7037(88)90163-9; LOVLEY DR, 1995, REV GEOPHYS, V33, P365, DOI 10.1029/95RG01305; MADSEN EL, 1995, ADV AGRONOMY; Madsen Eugene L., 1993, P167; MCMAHON PB, 1991, NATURE, V349, P233, DOI 10.1038/349233a0; MURPHY EM, 1992, WATER RESOUR RES, V28, P723, DOI 10.1029/91WR02678; PEDERSEN K, 1993, EARTH-SCI REV, V34, P243, DOI 10.1016/0012-8252(93)90058-F; Stevens T, 1997, FEMS MICROBIOL REV, V20, P327, DOI 10.1016/S0168-6445(97)00015-6; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; Thurman E.M, 1985, ORGANIC CHEM NATURAL; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOOD WW, 1986, GEOL SOC AM BULL, V97, P1456, DOI 10.1130/0016-7606(1986)97<1456:AGADIT>2.0.CO;2; [No title captured]	29	64	66	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					976	977		10.1126/science.281.5379.976	http://dx.doi.org/10.1126/science.281.5379.976			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703509				2022-12-28	WOS:000075412700042
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Statistics notes - Generalisation and extrapolation	BRITISH MEDICAL JOURNAL			English	Article									Inst Hlth Sci, Ctr Stat Med, ICRF, Med Stat Grp, Oxford OX3 7LF, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	University of Oxford; St Georges University London	Altman, DG (corresponding author), Inst Hlth Sci, Ctr Stat Med, ICRF, Med Stat Grp, Oxford OX3 7LF, England.							Altman DG, 1996, BRIT MED J, V313, P486; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; CHITTY LS, 1994, BRIT J OBSTET GYNAEC, V101, P35, DOI 10.1111/j.1471-0528.1994.tb13007.x; ELLENBERG JH, 1994, STAT MED, V13, P557, DOI 10.1002/sim.4780130518; Heathcote JA, 1995, BRIT MED J, V311, P1668, DOI 10.1136/bmj.311.7021.1668; Sackett DL, 1997, EVIDENCE BASED MED P, P167; Zanetta G, 1996, BRIT MED J, V313, P1110, DOI 10.1136/bmj.313.7065.1110; 1980, LANCET, V1, P73	8	36	36	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					409	410						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694763				2022-12-28	WOS:000075409600035
J	Goldenberg, RL; Rouse, DJ				Goldenberg, RL; Rouse, DJ			Medical progress - Prevention of premature birth	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTRAUTERINE GROWTH-RETARDATION; RANDOMIZED CONTROLLED TRIALS; PRETERM BIRTH; PRENATAL-CARE; RISK-FACTORS; BACTERIAL VAGINOSIS; INDIGENT POPULATION; UTERINE ACTIVITY; CALCIUM SUPPLEMENTATION; ZINC SUPPLEMENTATION		Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Goldenberg, RL (corresponding author), Univ Alabama Birmingham, Dept Obstet & Gynecol, 618 S 20th St,OHB 560, Birmingham, AL 35294 USA.				PHS HHS [290-92-0055] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER S, 1989, EFFECTIVE CARE PREGN, V1, P345; Andrews WW, 1995, INFECT AGENT DIS, V4, P196; ATKINSON MW, 1995, AM J OBSTET GYNECOL, V173, P299, DOI 10.1016/0002-9378(95)90218-X; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BEROYZ G, 1994, LANCET, V343, P619; Bottoms SF, 1997, AM J OBSTET GYNECOL, V176, P960, DOI 10.1016/S0002-9378(97)70386-7; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1113, DOI 10.1001/jama.275.14.1113; BUCHER HC, 1996, JAMA-J AM MED ASSOC, V276, P1388; BUESCHER PA, 1988, AM J PUBLIC HEALTH, V78, P264, DOI 10.2105/AJPH.78.3.264; BUESCHER PA, 1991, AM J PUBLIC HEALTH, V81, P1625, DOI 10.2105/AJPH.81.12.1625; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; Carmichael SL, 1997, OBSTET GYNECOL, V89, P865, DOI 10.1016/S0029-7844(97)00047-1; COPPER RL, 1990, AM J OBSTET GYNECOL, V162, P748, DOI 10.1016/0002-9378(90)91000-3; COPPER RL, 1994, OBSTET GYNECOL, V84, P490; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; CREASY RK, 1993, AM J OBSTET GYNECOL, V168, P1223, DOI 10.1016/0002-9378(93)90373-Q; CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8; DEPP R, 1993, AM J OBSTET GYNECOL, V169, P352; DEVOE LD, 1995, AM J OBSTET GYNECOL, V173, P1120; DONALDSON PJ, 1984, MED CARE, V22, P177, DOI 10.1097/00005650-198402000-00009; Dyson DC, 1998, NEW ENGL J MED, V338, P15, DOI 10.1056/NEJM199801013380103; DYSON DC, 1991, AM J OBSTET GYNECOL, V164, P756, DOI 10.1016/0002-9378(91)90510-X; FINK A, 1992, OBSTET GYNECOL, V80, P867; Fiscella K, 1996, Obstet Gynecol Surv, V51, P60, DOI 10.1097/00006254-199601000-00022; FISCELLA K, 1995, OBSTET GYNECOL, V85, P468, DOI 10.1016/0029-7844(94)00408-6; FLOYD RL, 1993, ANNU REV PUBL HEALTH, V14, P379, DOI 10.1146/annurev.pu.14.050193.002115; Freda M C, 1996, J Perinatol, V16, P385; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; Goldenberg R L, 1996, Am J Obstet Gynecol, V174, P1618; GOLDENBERG RL, 1994, PREV MED, V23, P627, DOI 10.1006/pmed.1994.1103; GOLDENBERG RL, 1987, OBSTET GYNECOL, V70, P831; Goldenberg RL, 1996, AM J OBSTET GYNECOL, V175, P1317, DOI 10.1016/S0002-9378(96)70048-0; Goldenberg RL, 1997, CLIN PERINATOL, V24, P23, DOI 10.1016/S0095-5108(18)30182-9; GOLDENBERG RL, 1995, JAMA-J AM MED ASSOC, V274, P463, DOI 10.1001/jama.274.6.463; Goldenberg RL, 1998, AM J PUBLIC HEALTH, V88, P233, DOI 10.2105/AJPH.88.2.233; GOLDENBERG RL, 1995, REPROD HLTH CARE WOM, P391; GOLDENBERG RL, 1991, ROVINSKY GUTTMACHERS, P80; Grant A., 1989, EFFECTIVE CARE PREGN, VVolume 1, P633; GRIMES DA, 1992, OBSTET GYNECOL, V79, P137; GROOME LJ, 1992, AM J OBSTET GYNECOL, V167, P873, DOI 10.1016/S0002-9378(12)80004-4; GUINN DA, 1995, AM J OBSTET GYNECOL, V173, P1310, DOI 10.1016/0002-9378(95)91377-7; HACK M, 1991, PEDIATRICS, V87, P587; HARTIKAINENSORRI AL, 1980, OBSTET GYNECOL, V56, P692; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HEMMINKI E, 1991, J AM COLL NUTR, V10, P3; HIGBY K, 1993, AM J OBSTET GYNECOL, V168, P1247, DOI 10.1016/0002-9378(93)90376-T; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; HOBEL CJ, 1994, AM J OBSTET GYNECOL, V170, P54; IAMS JD, 1988, AM J OBSTET GYNECOL, V159, P595, DOI 10.1016/S0002-9378(88)80016-4; JOHNSON JWC, 1975, NEW ENGL J MED, V293, P675, DOI 10.1056/NEJM197510022931401; KATZ M, 1986, AM J OBSTET GYNECOL, V154, P44, DOI 10.1016/0002-9378(86)90390-X; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, V1, P694; KEIRSE MJNC, 1990, BRIT J OBSTET GYNAEC, V97, P149, DOI 10.1111/j.1471-0528.1990.tb01740.x; KLEBANOFF MA, 1989, JAMA-J AM MED ASSOC, V262, P511, DOI 10.1001/jama.262.4.511; KLEINMAN JC, 1987, NEW ENGL J MED, V317, P749, DOI 10.1056/NEJM198709173171207; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V271, P1340, DOI 10.1001/jama.271.17.1340; KRAMER MS, 1993, AM J CLIN NUTR, V58, P627, DOI 10.1093/ajcn/58.5.627; LAURIN J, 1987, ACTA OBSTET GYN SCAN, V66, P407, DOI 10.3109/00016348709022043; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Lewis DF, 1996, OBSTET GYNECOL, V88, P801, DOI 10.1016/0029-7844(96)00319-5; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; LU ZM, 1991, OBSTET GYNECOL, V77, P190; MACNAUGHTON MC, 1993, BRIT J OBSTET GYNAEC, V100, P516; MAIN DM, 1987, AM J OBSTET GYNECOL, V157, P789, DOI 10.1016/S0002-9378(87)80056-X; MAIN DM, 1985, AM J OBSTET GYNECOL, V151, P892, DOI 10.1016/0002-9378(85)90667-2; Maloni J A, 1991, Image J Nurs Sch, V23, P187; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCLAUGHLIN FJ, 1992, PEDIATRICS, V89, P128; Meis PJ, 1998, AM J OBSTET GYNECOL, V178, P562, DOI 10.1016/S0002-9378(98)70439-9; MEIS PJ, 1987, AM J OBSTET GYNECOL, V157, P550, DOI 10.1016/S0002-9378(87)80005-4; MERCER BM, 1992, AM J OBSTET GYNECOL, V166, P794, DOI 10.1016/0002-9378(92)91336-9; Mercer BM, 1997, JAMA-J AM MED ASSOC, V278, P989, DOI 10.1001/jama.278.12.989; METCOFF J, 1985, AM J CLIN NUTR, V41, P933, DOI 10.1093/ajcn/41.5.933; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; MOUTQUIN JM, 1992, NEW ENGL J MED, V327, P308; MUELLERHEUBACH E, 1989, AM J OBSTET GYNECOL, V160, P829, DOI 10.1016/0002-9378(89)90298-6; NICOLAIDES KH, 1987, LANCET, V1, P942; OHLSSON A, 1989, AM J OBSTET GYNECOL, V160, P890, DOI 10.1016/0002-9378(89)90306-2; OLDS, 1986, PEDIATRICS, V78, P138; OLDS DL, 1986, PEDIATRICS, V77, P16; OWEN, 1990, AM J OBSTET GYNECOL, V163, P2030; OWEN J, 1990, AM J OBSTET GYNECOL, V163, P873, DOI 10.1016/0002-9378(90)91086-R; PAINTIN D. B., 1966, Journal of Obstetrics and Gynaecology of the British Commonwealth, V73, P181, DOI 10.1111/j.1471-0528.1966.tb05144.x; PAUL RH, 1979, AM J OBSTET GYNECOL, V133, P503, DOI 10.1016/0002-9378(79)90284-9; PRANIKOFF J, 1991, American Journal of Obstetrics and Gynecology, V164, P387; PRENTICE AM, 1983, LANCET, V1, P489; ROBERTSON PA, 1992, AM J OBSTET GYNECOL, V166, P1629, DOI 10.1016/0002-9378(92)91551-K; ROMERO R, 1989, OBSTET GYNECOL, V73, P576; ROUSE DJ, 1994, OBSTET GYNECOL, V83, P483, DOI 10.1097/00006250-199404000-00001; RUSH D, 1989, EFFECTIVE CARE PREGN, P255; Scholl TO, 1997, AM J EPIDEMIOL, V146, P134, DOI 10.1093/oxfordjournals.aje.a009244; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; SIMMER K, 1991, EUR J CLIN NUTR, V45, P139; SIMMER K, 1987, AM J CLIN NUTR, V45, P122, DOI 10.1093/ajcn/45.1.122; SPENCER B, 1989, BRIT J OBSTET GYNAEC, V96, P281, DOI 10.1111/j.1471-0528.1989.tb02387.x; Tamura T, 1996, NUTR RES, V16, P139, DOI 10.1016/0271-5317(95)02068-3; TUCKER JM, 1991, OBSTET GYNECOL, V77, P343; VENTURA SJ, 1996, MON VITAL STAT REP S, V44, P75; VILLAR J, 1992, NEW ENGL J MED, V327, P1266, DOI 10.1056/NEJM199210293271803; WALSH SW, 1985, AM J OBSTET GYNECOL, V152, P335, DOI 10.1016/S0002-9378(85)80223-4; WEN SW, 1990, AM J OBSTET GYNECOL, V162, P213; 1994, AM J OBSTET GYNECOL, V173, P246	102	513	528	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1998	339	5					313	320		10.1056/NEJM199807303390506	http://dx.doi.org/10.1056/NEJM199807303390506			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104TL	9682045				2022-12-28	WOS:000075031400006
J	Cronenwett, SM; Oosterkamp, TH; Kouwenhoven, LP				Cronenwett, SM; Oosterkamp, TH; Kouwenhoven, LP			A tunable Kondo effect in quantum dots	SCIENCE			English	Article							ELECTRON-TRANSPORT; ANDERSON MODEL; EQUILIBRIUM; RESONANCE	A tunable Kondo effect has been realized in small quantum dots. A dot can be switched from a Kondo system to a non-Kondo system as the number of electrons on the dot is changed from odd to even. The Kondo temperature can be tuned by means of a gate voltage as a single-particle energy state nears the Fermi energy. Measurements of the temperature and magnetic field dependence of a Coulomb-blockaded dot show good agreement with predictions of both equilibrium and nonequilibrium Kondo effects.	Delft Univ Technol, Dept Appl Phys, NL-2600 GA Delft, Netherlands; Delft Univ Technol, DIMES, NL-2600 GA Delft, Netherlands; Stanford Univ, Dept Phys, Stanford, CA 94305 USA	Delft University of Technology; Delft University of Technology; Stanford University	Cronenwett, SM (corresponding author), Delft Univ Technol, Dept Appl Phys, POB 5046, NL-2600 GA Delft, Netherlands.							AVERIN DV, 1991, SINGLE CHARGE TUNN B, V294, P217; BICKERS NE, 1987, REV MOD PHYS, V59, P845, DOI 10.1103/RevModPhys.59.845; DOBERS M, 1988, PHYS REV B, V38, P5453, DOI 10.1103/PhysRevB.38.5453; Glazman L. I., 1988, PISMA ESKP TEOR FIZ, V47, P378; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; HERSHFIELD S, 1991, PHYS REV LETT, V67, P3720, DOI 10.1103/PhysRevLett.67.3720; INOSHIT AT, 1997, SUPERLATTICE MICROST, V22, P75; INOSHITA T, 1993, PHYS REV B, V48, P14725, DOI 10.1103/PhysRevB.48.14725; KAWABATA A, 1991, J PHYS SOC JPN, V60, P3222, DOI 10.1143/JPSJ.60.3222; Kondo J, 1970, SOLID STATE PHYS, V23, P183; Konig J, 1996, PHYS REV LETT, V76, P1715, DOI 10.1103/PhysRevLett.76.1715; Konig J, 1996, PHYS REV B, V54, P16820, DOI 10.1103/PhysRevB.54.16820; KOUWENHOVEN LP, 1997, MESOSCOPIC ELECT T E, V345, P105; MEIR Y, 1993, PHYS REV LETT, V70, P2601, DOI 10.1103/PhysRevLett.70.2601; NG TK, 1988, PHYS REV LETT, V61, P1768, DOI 10.1103/PhysRevLett.61.1768; Pohjola T, 1997, EUROPHYS LETT, V40, P189, DOI 10.1209/epl/i1997-00444-0; RALPH DC, 1994, PHYS REV LETT, V72, P3401, DOI 10.1103/PhysRevLett.72.3401; SCHOELLER H, 1997, MESOSCOPIC ELECT T E, V345, P291; Stewart DR, 1997, SCIENCE, V278, P1784, DOI 10.1126/science.278.5344.1784; VANDERVAART NC, 1995, PHYS REV LETT, V74, P4702, DOI 10.1103/PhysRevLett.74.4702; WAN Y, 1995, PHYS REV B, V51, P14782, DOI 10.1103/PhysRevB.51.14782	22	1454	1467	8	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					540	544		10.1126/science.281.5376.540	http://dx.doi.org/10.1126/science.281.5376.540			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677192	Green Submitted			2022-12-28	WOS:000075012300034
J	Evrard, YA; Lun, Y; Aulehla, A; Gan, L; Johnson, RL				Evrard, YA; Lun, Y; Aulehla, A; Gan, L; Johnson, RL			lunatic fringe is an essential mediator of somite segmentation and patterning	NATURE			English	Article							SIGNALING MOLECULE; GENE FAMILY; EXPRESSION; NOTCH1; REGION; CELLS	The gene lunatic fringe encodes a secreted factor with significant sequence similarity to the Drosophila gene fringe(1-5). fringe has been proposed to function as a boundary-specific signalling molecule in the wing imaginal disc, where it is required to localize signalling activity by the protein Notch to the presumptive wing margin(3,6). By targeted disruption in mouse embryos, we show here that lunatic fringe is likewise required for boundary formation. lunatic fringe mutants fail to form boundaries between individual GRAPHICS somites, the initial segmental unit of the vertebrate trunk. Hn addition, the normal alternating rostral-caudal pattern of the semitic mesoderm is disrupted, suggesting that intersomitic boundary formation and rostral-caudal patterning of somites are mechanistically Linked by a process that requires lunatic fringe activity. As a result, the derivatives of the somitic mesoderm, especially the axial skeleton, are severely disorganized in lunatic fringe mutants. Taken together our results demonstrate an essential function for a vertebrate fringe homologue and suggest a model in which lunatic fringe modulates Notch signalling in the segmental plate to regulate somitogenesis and rostral-caudal patterning of somites simultaneously.	Univ Texas, Md Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Johnson, RL (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.			Aulehla, Alexander/0000-0003-3487-9239				BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Christ B, 1998, ANAT EMBRYOL, V197, P1; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; CONLON RA, 1995, DEVELOPMENT, V121, P1533; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Gossler A, 1998, CURR TOP DEV BIOL, V38, P225; Hogan B, 1994, MANIPULATING MOUSE E; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Mansouri A, 1997, DEV DYNAM, V210, P53, DOI 10.1002/(SICI)1097-0177(199709)210:1<53::AID-AJA6>3.0.CO;2-0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; STERN CD, 1987, DEVELOPMENT, V99, P261; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; WILLIAMS R, 1995, MECH DEVELOP, V53, P357, DOI 10.1016/0925-4773(95)00451-3; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	28	340	350	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					377	381		10.1038/28632	http://dx.doi.org/10.1038/28632			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690473				2022-12-28	WOS:000074968800053
J	Hertz, M; Kouskoff, V; Nakamura, T; Nemazee, D				Hertz, M; Kouskoff, V; Nakamura, T; Nemazee, D			V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling	NATURE			English	Article							POSITIVE SELECTION; GERMINAL-CENTERS; CELLS; DEATH; THYMOCYTES; TOLERANCE; APOPTOSIS	In lymphocytes, DNA recombinations that generate the antigen-receptor genes can sometimes be reinduced in receptor-bearing cells in a process called receptor editing, which modifies the specificity of the receptor for antigen. In immature B lymphocytes, B-cell antigen receptor (BCR) signalling stimulates immune tolerance by receptor editing(1-5). More mature splenic B cells can also be induced to undergo V(D)J recombination, which generates diversity in the immune system, either by immunization with foreign proteins(6-9) or by stimulation in vitro with interleukin-4 and lipopolysaccharides(8-10). Here we show that immune tolerance is unlikely to induce V(D)J recombination in mature B cells, because BCR ligation actively inhibits V(D)J recombination induced by interleukin-ii and lipopolysaccharide. Furthermore, immunization of immunoglobulin transgenic mice with ligands of varying avidities for the BCR showed that low-avidity antigen could induce strong V(D)J recombination, whereas non-binding or high-avidity ligands could not. These data suggest that V(D)J recombination induced during the immune response modifies the antigen receptors of B cells with weak, but not strong, reactivity to antigen, potentially rescuing cells with improved receptor affinity and promoting their contribution to the immune response. Thus BCR signalling regulates V(D)J recombination in both tolerance and immunity, but in strikingly different ways.	Natl Jewish Med & Res Ctr, Div Basic Sci, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Tokyo, Inst Med Sci, Dept Infect Dis & Appl Immunol, Minato Ku, Tokyo 108, Japan	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Tokyo	Nemazee, D (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Sci, Dept Pediat, Denver, CO 80206 USA.				NIAID NIH HHS [R01 AI033608] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033608] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chen C, 1997, IMMUNITY, V6, P97, DOI 10.1016/S1074-7613(00)80673-1; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Hertz M, 1997, IMMUNITY, V6, P429, DOI 10.1016/S1074-7613(00)80286-1; Hikida M, 1997, J IMMUNOL, V158, P2509; Hikida M, 1998, J EXP MED, V187, P795, DOI 10.1084/jem.187.5.795; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KOUSKOFF V, UNPUB J EXP MED; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MARRACK P, 1993, IMMUNOL REV, V133, P119, DOI 10.1111/j.1600-065X.1993.tb01513.x; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; PAPAVASILIOU E, 1997, SCIENCE, V278, P298; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009	24	106	110	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					292	295		10.1038/28419	http://dx.doi.org/10.1038/28419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685161	Green Accepted			2022-12-28	WOS:000074851900052
J	Kavalier, F				Kavalier, F			Uganda: death is always just around the corner	LANCET			English	Article									Kentish Town Hlth Ctr, London NW5 2BX, England		Kavalier, F (corresponding author), Kentish Town Hlth Ctr, 2 Bartholomew Rd, London NW5 2BX, England.								0	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					141	142						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672295				2022-12-28	WOS:000074775100044
J	Senn, S				Senn, S			In the blood: proposed new requirements for registering generic drugs	LANCET			English	Editorial Material							BIOEQUIVALENCE		UCL, Dept Stat Sci, London WC1E 6BT, England; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Senn, S (corresponding author), UCL, Dept Stat Sci, Mortimer St, London WC1E 6BT, England.		Senn, Stephen J/A-8101-2008; Senn, Stephen/B-2903-2013	Senn, Stephen/0000-0002-7558-8473				ANDERSON S, 1990, J PHARMACOKINET BIOP, V18, P259, DOI 10.1007/BF01062202; *FDA, 1997, IN IV BIOEQ STUD BAS; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Senn S., 2021, THE BLIND DAT; Senn S, 1993, CROSS OVER TRIALS CL, V2nd; SHEINER LB, 1992, STAT MED, V11, P1777, DOI 10.1002/sim.4780111311; Steinijans V. W., 1993, Clinical Research and Regulatory Affairs, V10, P203, DOI 10.3109/10601339309079568; Steinijans V. W., 1995, DRUG INF J, V29, P1055	9	29	31	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1998	352	9122					85	86						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672271				2022-12-28	WOS:000074775100007
J	Phoolcharoen, W				Phoolcharoen, W			HIV/AIDS prevention in Thailand: Success and challenges	SCIENCE			English	Editorial Material							YOUNG MEN; NORTHERN THAILAND; INFECTION		Minist Publ Hlth, Dept Communicable Dis Control, Amphur Muang Nonthaburi 11000, Thailand	Ministry of Public Health - Thailand	Phoolcharoen, W (corresponding author), Minist Publ Hlth, Dept Communicable Dis Control, Tivanont Rd, Amphur Muang Nonthaburi 11000, Thailand.							*ARM MED SC RES I, 1998, REP HIV PREV RAT NEW; CARR JK, 1994, J ACQ IMMUN DEF SYND, V7, P1270; Celentano DD, 1996, JAMA-J AM MED ASSOC, V275, P122, DOI 10.1001/jama.275.2.122; CELENTANO DD, 1993, AIDS, V7, P1647, DOI 10.1097/00002030-199312000-00016; Epidemiology Division, 1998, REP HIV SER SENT SUR; FORD NJ, 1994, AIDS CARE, V6, P517, DOI 10.1080/09540129408258667; FRERICHS R, 1995, J PUBLIC HLTH, V8, P20; HAVANON N, 1993, STUD FAMILY PLANN, V24, P1, DOI 10.2307/2939210; KHAMBOONRUANG C, 1996, 10 INT C AIDS VANC C; Lyttleton C, 1996, Med Anthropol, V16, P363; Mills S, 1997, AIDS, V11, pS43; *NAT EC SOC DEV BO, 1998, EST UN RES 1997 EC C; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; PORAPAKKHAM Y, 1996, AIDSCAP POLICY WORKI; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; Sawanpanyalert P, 1996, J INFECT DIS, V174, P870, DOI 10.1093/infdis/174.4.870; SITTITRAL W, 1992, THAI SEXUAL BEHAV; Sugisaki Shigemitsu, 1998, 1998 HARV AS BUS C H; [No title captured]	19	50	53	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1873	1874		10.1126/science.280.5371.1873	http://dx.doi.org/10.1126/science.280.5371.1873			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669947				2022-12-28	WOS:000074323800043
J	Paterson-Brown, S				Paterson-Brown, S			Yes, as long as the woman is fully informed	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; VAGINAL DELIVERY; TERM; MORBIDITY		Queen Charlottes & Chelsea Hosp, London W6 0XG, England	Imperial College London	Paterson-Brown, S (corresponding author), Queen Charlottes & Chelsea Hosp, London W6 0XG, England.	s.paterson-brown@rpms.ac.uk						ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; AlMufti R, 1997, EUR J OBSTET GYN R B, V73, P1, DOI 10.1016/S0301-2115(96)02692-9; [Anonymous], 1997, LANCET, V349, P815; DRIFE J, 1997, EMJ, V314, P844; Expert Maternity Group Department of Health, 1993, CHANG CHILDB; FELDMAN GB, 1985, NEW ENGL J MED, V312, P1264, DOI 10.1056/NEJM198505093121926; GLAZENER CMA, 1995, BRIT J OBSTET GYNAEC, V102, P282, DOI 10.1111/j.1471-0528.1995.tb09132.x; Greene R, 1997, AM J OBSTET GYNECOL, V176, P254, DOI 10.1016/S0002-9378(97)80046-4; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; HALL MH, 1987, BRIT MED J, V294, P201, DOI 10.1136/bmj.294.6566.201; Hemminki E, 1996, AM J OBSTET GYNECOL, V174, P1569, DOI 10.1016/S0002-9378(96)70608-7; Hilder L, 1998, BRIT J OBSTET GYNAEC, V105, P169, DOI 10.1111/j.1471-0528.1998.tb10047.x; Lau TK, 1996, AUST NZ J OBSTET GYN, V36, P155, DOI 10.1111/j.1479-828X.1996.tb03274.x; Lescale KB, 1996, AM J PERINAT, V13, P171, DOI 10.1055/s-2007-994319; LILFORD RJ, 1990, BRIT J OBSTET GYNAEC, V97, P883, DOI 10.1111/j.1471-0528.1990.tb02442.x; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; Maternal and Child Health Research Consortium, 1997, CONF ENQ STILLB DEAT; McMahon MJ, 1996, NEW ENGL J MED, V335, P689, DOI 10.1056/NEJM199609053351001; MORRISON JJ, 1995, BRIT J OBSTET GYNAEC, V102, P101, DOI 10.1111/j.1471-0528.1995.tb09060.x; Mould TAJ, 1996, BRIT J OBSTET GYNAEC, V103, P1074, DOI 10.1111/j.1471-0528.1996.tb09585.x; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; Tranquilli AL, 1997, AM J OBSTET GYNECOL, V177, P245; 1996, REPORT CONFIDENTIAL; 1992, HLTH COMM MAT SERV	25	129	133	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1998	317	7156					462	463						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703532				2022-12-28	WOS:000075490200025
J	Garito, AF; Wang, J; Gao, R				Garito, AF; Wang, J; Gao, R			Effects of random perturbations in plastic optical fibers	SCIENCE			English	Review								The most important feature of an optical fiber waveguide is its bandwidth, which defines its information-carrying capacity. A major limitation on the bandwidth of multimode glass and plastic optical fibers is modal dispersion, in which different optical modes propagate at different velocities and the dispersion grows linearly with length. However, in plastic optical fibers, experimental and theoretical results indicate that the modes are not independent but are highly coupled, which leads to a characteristic square-root length dependence and an unanticipated large enhancement of the bandwidth to gigahertz levels. The ever increasing demands for low-cost, high-bandwidth communications media for voice, video, and data transmission in short- and medium-distance applications are generating a new assessment of multimode optical fibers to serve as high-speed fiber links.	Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA	University of Pennsylvania	Garito, AF (corresponding author), Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA.							BLYLER LI, 1996, ASIA PACIFIC FORUM 9, P58; GAMBLING WA, 1973, ELECTRON LETT, V9, P412, DOI 10.1049/el:19730303; GLOGE D, 1972, AT&T TECH J, V51, P1767, DOI 10.1002/j.1538-7305.1972.tb02682.x; Green PE, 1996, IEEE J SEL AREA COMM, V14, P764, DOI 10.1109/49.510902; Jiang G, 1997, IEEE PHOTONIC TECH L, V9, P1128, DOI 10.1109/68.605524; Kaino T., 1992, POLYM LIGHTWAVE INTE, P1; KAWAKAMI S, 1968, IEEE T MICROW THEORY, VMT16, P814, DOI 10.1109/TMTT.1968.1126797; KOIKE Y, 1995, IEEE J LIGHTWAVE TEC, V13, P1475; MARCUSE D, 1969, AT&T TECH J, V48, P3187, DOI 10.1002/j.1538-7305.1969.tb01742.x; MARCUSE D, 1973, AT&T TECH J, V52, P817, DOI 10.1002/j.1538-7305.1973.tb01992.x; Marcuse D., 1981, PRINCIPLES OPTICAL F; Okoshi T., 1982, OPTICAL FIBERS; PERSONICK SD, 1971, BELL SYST TECH J, V50, P843, DOI 10.1002/j.1538-7305.1971.tb01885.x; Shi RF, 1997, APPL PHYS LETT, V71, P3625, DOI 10.1063/1.120461	14	106	112	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					962	967		10.1126/science.281.5379.962	http://dx.doi.org/10.1126/science.281.5379.962			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703505				2022-12-28	WOS:000075412700038
J	Kay, A; Arenholz, E; Mun, S; de Abajo, FJG; Fadley, CS; Denecke, R; Hussain, Z; Van Hove, MA				Kay, A; Arenholz, E; Mun, S; de Abajo, FJG; Fadley, CS; Denecke, R; Hussain, Z; Van Hove, MA			Multi-atom resonant photoemission: A method for determining near-neighbor atomic identities and bonding	SCIENCE			English	Article							RAY; SPECTROSCOPY; 3D	Measurements and theoretical calculations are reported for an interatomic multi-atom resonant photoemission (MARPE) effect that permits direct determination of near-neighbor atomic identities (atomic numbers). MARPE occurs when the photon energy is tuned to a core-level absorption edge of an atom neighboring the emitting atom, with the emitting Level having a lower binding energy than the resonant level. Large peak-intensity enhancements of 33 to 105 percent and energy-integrated effects of 11 to 29 percent were seen in three metal oxides. MARPE should also be sensitive to bond distance, bonding type, and magnetic order, and be observable via the secondary processes of x-ray fluorescence and Auger decay.	Univ Calif Davis, Dept Phys, Davis, CA 95616 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA; Univ Basque Country, Dept CCIA, San Sebastian 20080, Spain; Univ Basque Country, Dept Fis Mat, San Sebastian 20080, Spain	University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Basque Country; University of Basque Country	Fadley, CS (corresponding author), Univ Calif Davis, Dept Phys, Davis, CA 95616 USA.	fadley@physics.ucdavis.edu	Van Hove, Michel A./A-9862-2008; García de Abajo, Javier/A-6095-2009; Mun, Bongjin/G-1701-2013	Van Hove, Michel A./0000-0002-8898-6921; García de Abajo, Javier/0000-0002-4970-4565; 				Billinge SJL, 1996, PHYS REV LETT, V77, P715, DOI 10.1103/PhysRevLett.77.715; BREWER MA, 1997, LBNL39981, P411; Butorin SM, 1996, PHYS REV B, V54, P4405, DOI 10.1103/PhysRevB.54.4405; Estrada H., UNPUB; Fadley CS, 1997, PROG SURF SCI, V54, P341, DOI 10.1016/S0079-6816(97)00013-0; FANO U, 1968, REV MOD PHYS, V40, P441, DOI 10.1103/RevModPhys.40.441; GARVIN LJ, 1983, J PHYS B-AT MOL OPT, V16, pL269, DOI 10.1088/0022-3700/16/9/004; GULLIKSON E, CTR XRAY OPTICS; Hove M.A., 1986, LOW ENERGY ELECT DIF; Hussain Z, 1996, J ELECTRON SPECTROSC, V80, P401, DOI 10.1016/0368-2048(96)03002-2; KAY AW, UNPUB; KORTRIGHT J, UNPUB; KRAUSE MO, 1984, PHYS REV A, V30, P1316, DOI 10.1103/PhysRevA.30.1316; KRISHNAN K, COMMUNICATION; KUIPER P, 1993, PHYS REV LETT, V70, P1549, DOI 10.1103/PhysRevLett.70.1549; NEWEILLE M, 1995, PHYSICA B, V208, P154; POWELL CJ, 1994, J ELECTRON SPECTROSC, V68, P605, DOI 10.1016/0368-2048(94)80023-5; POWELL CJ, COMMUNICATION; STERN EA, 1995, PHYSICA B, V208, P117, DOI 10.1016/0921-4526(94)00826-H; Stohr J, 1998, IBM J RES DEV, V42, P73, DOI 10.1147/rd.421.0073; TANAKA A, 1994, J PHYS SOC JPN, V63, P2788, DOI 10.1143/JPSJ.63.2788; THOLE BT, 1985, PHYS REV B, V32, P5107, DOI 10.1103/PhysRevB.32.5107; Weinelt M, 1997, PHYS REV LETT, V78, P967, DOI 10.1103/PhysRevLett.78.967	23	103	104	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					679	683		10.1126/science.281.5377.679	http://dx.doi.org/10.1126/science.281.5377.679			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685257				2022-12-28	WOS:000075107900036
J	Carmeliet, P; Dor, Y; Herbert, JM; Fukumura, D; Brusselmans, K; Dewerchin, M; Neeman, M; Bono, F; Abramovitch, R; Maxwell, P; Koch, CJ; Ratcliffe, P; Moons, L; Jain, RK; Collen, D; Keshet, E				Carmeliet, P; Dor, Y; Herbert, JM; Fukumura, D; Brusselmans, K; Dewerchin, M; Neeman, M; Bono, F; Abramovitch, R; Maxwell, P; Koch, CJ; Ratcliffe, P; Moons, L; Jain, RK; Collen, D; Keshet, E			Role of HIF-1 alpha or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis	NATURE			English	Article							GLUCOSE-REGULATED PROTEINS; INDUCIBLE FACTOR-1; ARREST; P21	As a result of deprivation of oxygen (hypoxia) and nutrients, the growth and viability of cells is reduced(1). Hypoxia-inducible factor (KIF)-1 alpha helps to restore oxygen homeostasis by inducing glycolysis, erythropoiesis and angiogenesis(2-4). Here we show that hypoxia and hypoglycaemia reduce proliferation and increase apoptosis in wild-type (HIF-1 alpha(+/+)) embryonic stem (ES) cells, but not in ES cells with inactivated HIF-1 alpha. genes (HIF-1 alpha(-/-)); however, a deficiency of HIF-1 alpha does not affect apoptosis induced by cytokines. We find that hypoxia/hypoglycaemia-regulated genes involved in controlling the cell cycle are either HIF-1 alpha-dependent (those encoding the proteins p53, p21, Bcl-2) or HLF-1 alpha-independent (p27, GADD153), suggesting that there are at least two different adaptive responses to being deprived of oxygen and nutrients, Loss of HIF-1 alpha. reduces hypoxia-induced expression of vascular endothelial growth factor, prevents formation of large vessels in ES-derived tumours, and impairs vascular function, resulting in hypoxic microenvironments within the tumour mass, However, growth of HIF-1 alpha. tumours was not retarded but was accelerated, owing to decreased hypoxia-induced apoptosis and increased stress-induced proliferation. As hypoxic stress contributes to many (patho)biological disorders(1,5), this new role for HIF-1 alpha in hypoxic control of cell growth and death may be of general pathophysiological importance.	Catholic Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Sanofi Rech, Haemobiol Res Dept, F-31036 Toulouse, France; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; John Radcliffe Hosp, Welcome Trust Ctr Human Genet, Inst Mol Med, Oxford OX3 7BN, England; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	Flanders Institute for Biotechnology (VIB); Hebrew University of Jerusalem; Sanofi-Aventis; Sanofi France; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Weizmann Institute of Science; University of Oxford; Wellcome Centre for Human Genetics; University of Pennsylvania	Carmeliet, P (corresponding author), Catholic Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.	Peter.Carmeliet@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020; Jain, Rakesh K/I-1384-2017; Maxwell, Patrick H/C-5557-2008; Neeman, Michal/A-8264-2008; Keshet, Eli/GQR-0445-2022; Neeman, Michal/AAH-9602-2019; Dor, Yuval/C-2405-2011	Carmeliet, Peter/0000-0001-7961-1821; Jain, Rakesh K/0000-0001-7571-3548; Maxwell, Patrick H/0000-0002-0338-2679; Neeman, Michal/0000-0002-6296-816X; Neeman, Michal/0000-0002-6296-816X; Ratcliffe, Peter/0000-0002-2853-806X; Moons, Lieve (Godelieve)/0000-0003-0186-1411	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abramovitch R, 1998, MAGN RESON MED, V39, P813, DOI 10.1002/mrm.1910390519; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COLLINS MKL, 1994, BIOESSAYS, V16, P133, DOI 10.1002/bies.950160210; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Dor Y, 1997, TRENDS CARDIOVAS MED, V7, P289, DOI 10.1016/S1050-1738(97)00091-1; EVANS SM, 1995, BRIT J CANCER, V72, P875, DOI 10.1038/bjc.1995.427; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Herbert JM, 1997, FEBS LETT, V413, P401, DOI 10.1016/S0014-5793(97)00915-0; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; KOBAYASHI N, 1994, AM J PHYSIOL, V266, pH1910, DOI 10.1152/ajpheart.1994.266.5.H1910; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; PRICE BD, 1992, CANCER RES, V52, P3814; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vaupel PW, 1997, KLIN PADIATR, V209, P243, DOI 10.1055/s-2008-1043957; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	30	2082	2202	5	303	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1998	394	6692					485	490		10.1038/28867	http://dx.doi.org/10.1038/28867			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697772				2022-12-28	WOS:000075080400054
J	Straus, WL; Qazi, SA; Kundi, Z; Nomani, NK; Schwartz, B				Straus, WL; Qazi, SA; Kundi, Z; Nomani, NK; Schwartz, B		Pakistan Co-Trimoxazole Study Grp	Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial	LANCET			English	Article							STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; COMMUNITY; PENICILLIN	Background Cotrimoxazole is widely used in treatment of paediatric pneumonia in developing countries, but drug resistance may decrease its effectiveness. We studied the effectiveness of co-trimoxazole compared with that of amoxycillin in pneumonia therapy, and assessed the clinical impact of co-trimoxazole resistance. Methods We recruited 595 children, aged 2-59 months, with non-severe or severe pneumonia (WHO criteria) diagnosed in the outpatient wards of two urban Pakistan hospitals. Patients were randomly assigned on a 2:1 basis co-trimoxazole (n=398) or amoxycillin (n=197) in standard WHO doses and dosing schedules, and were monitored in study wards. The primary outcome was inpatient therapy failure (clinical criteria) or clinical evidence of pneumonia at outpatient follow-up examination. Findings There were 92 (23%) therapy failures in the cotrimoxazole group and 30 (15%) in the amoxycillin group (p=0.03)-26 (13%) versus 12 (12%) among children with non-severe pneumonia (p=0.856) and 66 (33%) versus 18 (18%) among those with severe pneumonia (p=0.009). For patients with severe pneumonia, age under 1 year (p=0.056) and positive chest radiographs (p=0.005) also predicted therapy failure. There was no significant association between antimicrobial minimum inhibitory concentration and outcome among bacteraemic children treated with co-trimoxazole. Interpretation Co-trimoxazole provided effective therapy in non-severe pneumonia. For severe, life-threatening pneumonia, however, co-trimoxazole is less likely than amoxycillin to be effective.	Ctr Dis Control & Prevent, US PHS, US Dept HHS, Atlanta, GA USA; Childrens Hosp, Pakistan Inst Med Sci, Islamabad, Pakistan; Rawalpindi Gen Hosp, Rawalpindi, Pakistan; Natl Inst Hlth, Islamabad, Pakistan	Centers for Disease Control & Prevention - USA; United States Public Health Service; Pakistan Institute of Medical Sciences; Rawalpindi Medical College	Straus, WL (corresponding author), Merck & Co Inc, Outcomes Res & Management, POB 4,WP39-160, W Point, PA 19486 USA.							ALARIO AJ, 1987, J PEDIATR-US, V111, P187, DOI 10.1016/S0022-3476(87)80065-3; Bushby SR, 1973, J INFECT DIS S, V128, P442; CAMPBELL H, 1988, LANCET, V2, P1182; GAHFOOR A, 1990, REV INFECT DIS    S8, V12, pS907; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; ISAACS D, 1989, PEDIATR INFECT DIS J, V8, P143; JERNIGAN D, 1996, P INT C ANT AG CHEM; KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185; KHAN MA, 1993, ANN TROP PAEDIATR, V13, P73, DOI 10.1080/02724936.1993.11747627; MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; MCCARTHY PL, 1981, CLIN PEDIATR, V20, P686, DOI 10.1177/000992288102001101; *NAT COMM CLIN LAB, 1985, M7A NAT COMM CLIN LA; National Committee for Clinical Laboratory Standards, 1997, PERF STAND ANT DISK; ODEMPSEY TJ, 1993, ARCH DIS CHILD, V68, P429; Ostroff SM, 1996, CLIN INFECT DIS, V23, P1069, DOI 10.1093/clinids/23.5.1069; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9; SIMPSON W, 1974, PEDIATR RADIOL, V2, P155, DOI 10.1007/BF00972727; SIMPSON W, 1974, PEDIATR RADIOL, V2, P97, DOI 10.1007/BF01314938; TANWANI AK, 1995, QUALITY CONTROL CLIN, P108; WHO, 1990, AC RESP INF CHILDR C; *WHO, 1991, WHOARI9120; 1997, MORB MORTAL WKLY REP, V46, P62	24	98	102	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					270	274		10.1016/S0140-6736(97)10294-X	http://dx.doi.org/10.1016/S0140-6736(97)10294-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690406				2022-12-28	WOS:000074974500009
J	Fulop, V; Bocskei, Z; Polgar, L				Fulop, V; Bocskei, Z; Polgar, L			Prolyl oligopeptidase: An unusual beta-propeller domain regulates proteolysis	CELL			English	Article							PROLINE-SPECIFIC ENDOPEPTIDASE; ALPHA/BETA-HYDROLASE FOLD; FLAVOBACTERIUM-MENINGOSEPTICUM; CRYSTAL-STRUCTURE; G-PROTEIN; SECONDARY-STRUCTURE; ENZYME; SEQUENCE; CLONING; PURIFICATION	Prolyl oligopeptidase is a large cytosolic enzyme that belongs to a new class of serine peptidases. The enzyme is involved in the maturation and degradation of peptide hormones and neuropeptides, which relate to the induction of amnesia. The 1.4 Angstrom resolution crystal structure is presented here. The enzyme contains a peptidase domain with an alpha/beta hydrolase fold, and its catalytic triad (Ser554, His680, Asp641) is covered by. the central tunnel of an unusual beta propeller. This domain makes prolyl oligopeptidase an oligopeptidase by excluding large structured peptides from the active. site. In this way, the propeller protects larger peptides and proteins from proteolysis in the cytosol. The structure is also obtained with a transition state inhibitor, which may facilitate drug design to treat memory disorders.	Univ Oxford, Oxford Ctr Mol Sci, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Eotvos Lorand Univ, Dept Theoret Chem, H-117 Budapest, Hungary; Chinoin Chem & Pharmaceut Works Ltd, H-1325 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	University of Oxford; University of Warwick; Eotvos Lorand University; Sanofi-Aventis; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Fulop, V (corresponding author), Univ Oxford, Oxford Ctr Mol Sci, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.		Fulop, Vilmos/AAZ-7720-2021		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOCSKEI Z, 1998, IN PRESS ACTA CRYS D; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAMARGO ACM, 1979, J BIOL CHEM, V254, P5304; CHEVALLIER S, 1992, J BIOL CHEM, V267, P8192; CONNOLLY ML, 1985, J APPL CRYSTALLOGR, V18, P499, DOI 10.1107/S0021889885010779; CYGLER M, 1993, PROTEIN SCI, V2, P366; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIEFENTHAL T, 1993, APPL MICROBIOL BIOT, V40, P90, DOI 10.1007/BF00170434; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; FUKUNARI A, 1994, NEUROSCI LETT, V176, P201, DOI 10.1016/0304-3940(94)90082-5; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GARAVITO RM, 1977, BIOCHEMISTRY-US, V16, P5065, DOI 10.1021/bi00642a019; GOOSSENS F, 1995, EUR J BIOCHEM, V233, P432, DOI 10.1111/j.1432-1033.1995.432_2.x; ISHIURA S, 1990, FEBS LETT, V260, P131, DOI 10.1016/0014-5793(90)80084-V; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; Medrano FJ, 1998, EMBO J, V17, P1, DOI 10.1093/emboj/17.1.1; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIURA N, 1995, NEUROSCI LETT, V196, P128, DOI 10.1016/0304-3940(95)11821-D; MORIYAMA A, 1988, J BIOCHEM, V104, P112, DOI 10.1093/oxfordjournals.jbchem.a122404; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; POLGAR L, 1993, FEBS LETT, V322, P227, DOI 10.1016/0014-5793(93)81575-K; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1992, BIOCHEM J, V283, P647, DOI 10.1042/bj2830647; POLGAR L, 1991, EUR J BIOCHEM, V197, P441, DOI 10.1111/j.1432-1033.1991.tb15930.x; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; POLGAR L, 1989, MECHANISMS PROTEASE, P87; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; SCALONI A, 1994, J BIOL CHEM, V269, P15076; Shinoda M, 1997, BIOCHEM BIOPH RES CO, V235, P641, DOI 10.1006/bbrc.1997.6730; Smith L. C., 1992, CURR OPIN STRUC BIOL, V2, P490, DOI DOI 10.1016/0959-440X(92)90076-J; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; VANHOOF G, 1994, GENE, V149, P363, DOI 10.1016/0378-1119(94)90177-5; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730; YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786	60	443	454	2	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					161	170		10.1016/S0092-8674(00)81416-6	http://dx.doi.org/10.1016/S0092-8674(00)81416-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695945	Bronze			2022-12-28	WOS:000075020100005
J	Cho, MK; Justice, AC; Winker, MA; Berlin, JA; Waeckerle, JF; Callaham, ML; Rennie, D				Cho, MK; Justice, AC; Winker, MA; Berlin, JA; Waeckerle, JF; Callaham, ML; Rennie, D		PEER Investigators	Masking author identity in peer review - What factors influence masking success?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-In a previous study, we found that masking success was higher at a journal that masked reviewers to author identity. We hypothesized that masking policy or other factors could be associated with masking success. Objectives.-To evaluate differences in success of masking reviewers to author identity at 7 biomedical journals and to identify factors associated with these differences. Design.-Written questionnaire. Participants.-Reviewers at 3 journals with a long-standing policy of masking author identity (Annals of Emergency Medicine, Epidemiology, and Journal of the American Geriatrics Society) and 4 journals without a policy of masking author identity (Annals of Infernal Medicine, JAMA, Obstetrics & Gynecology, and Ophthalmology). Main Outcome Measures.-Masking success (percentage of reviewers successfully masked) and reviewer characteristics associated with masking. Results.-There was no significant difference in masking success between journals with a policy of masking (60%) and those without (58%) (P=.92). We found no association between masking success and a policy of masking when adjusted for the reviewer characteristics of age, sex, years of reviewing experience, number of articles published, number of articles reviewed, percentage of time spent in research, editorial experience, or academic rank (odds ratio [OR], 1.3; 95% confidence interval [CI], 0.64-2.8; P=.43). In multivariable analysis of reviewer characteristics, reviewers spending a greater percentage of time in research, the only significant predictor of masking success, were less likely to be successfully masked (OR, 1.01;95% CI, 1.00-1.02) (P=.04). Conclusions.-Masking success appears unrelated to a journal policy of masking, but is associated with reviewers' research experience and could be affected by other characteristics. Using reviewers with less research and reviewing experience might increase masking success, but the effect on review quality is unknown.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Dept Vet Affairs Med Ctr, Div Gen Internal Med, Cleveland, OH USA; Dept Vet Affairs Med Ctr, Program Hlth Care Res, Cleveland, OH USA; Case Western Reserve Univ, Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Div Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Missouri, Sch Med, Dept Emergency Med, Kansas City, MO 64108 USA; Univ Calif San Francisco, Sch Med, Div Emergency Med, San Francisco, CA USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Missouri System; University of Missouri Kansas City; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cho, MK (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.			Winker, Margaret/0000-0002-4708-5641; Callaham, Michael/0000-0003-2284-256X	AHRQ HHS [5T32 HS00009] Funding Source: Medline; PHS HHS [467-MZ-501163] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		FISHER M, 1994, JAMA-J AM MED ASSOC, V272, P143, DOI 10.1001/jama.272.2.143; Justice AC, 1998, JAMA-J AM MED ASSOC, V280, P240, DOI 10.1001/jama.280.3.240; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; MOOSSY J, 1985, J NEUROPATH EXP NEUR, V44, P225, DOI 10.1097/00005072-198505000-00001; YANKAUER A, 1991, AM J PUBLIC HEALTH, V81, P843, DOI 10.2105/AJPH.81.7.843	5	65	67	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					243	245		10.1001/jama.280.3.243	http://dx.doi.org/10.1001/jama.280.3.243			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZZ204	9676669				2022-12-28	WOS:000074706000014
J	Draguhn, A; Traub, RD; Schmitz, D; Jefferys, JGR				Draguhn, A; Traub, RD; Schmitz, D; Jefferys, JGR			Electrical coupling underlies high-frequency oscillations in the hippocampus in vitro	NATURE			English	Article							FIELD BURST ACTIVITY; RAT HIPPOCAMPAL; PYRAMIDAL NEURONS; SLICES; CELLS; MECHANISMS; POTENTIALS; NETWORKS; MODEL; PH	Coherent oscillations, in which ensembles of neurons fire in a repeated and synchronous manner, are thought to be important in higher brain functions. In the hippocampus, these discharges are categorized according to their frequency as theta (4-10 Hz)(1), gamma (20-80 Hz)(2) and high-frequency (similar to 200 Hz)(3-5) discharges, and they occur in relation to different behavioural states. The synaptic bases of theta and gamma rhythms have been extensively studied(6,7) but the cellular bases for high-frequency oscillations are not understood. Here we report that high-frequency network oscillations are present in rat brain slices in vitro, occurring as a brief series of repetitive population spikes at 150-200 Hz in all hippocampal principal cell layers. Moreover, this synchronous activity is not mediated through the more commonly studied modes of chemical synaptic transmission, but is in fact a result of direct electrotonic coupling of neurons, most Likely through gap-junctional connections. Thus high-frequency oscillations synchronize the activity of electrically coupled subsets of principal neurons within the well-documented synaptic network of the hippocampus.	Univ Birmingham, Sch Med, Dept Physiol, Birmingham B15 2TT, W Midlands, England; Humboldt Univ, Inst Physiol Charite, D-10117 Berlin, Germany	University of Birmingham; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Draguhn, A (corresponding author), Univ Birmingham, Sch Med, Dept Physiol, Birmingham B15 2TT, W Midlands, England.		Jefferys, John/E-6132-2012; Jefferys, John G R/AAF-1164-2021	Jefferys, John/0000-0003-0106-4412; Jefferys, John G R/0000-0003-0106-4412; Schmitz, Dietmar/0000-0003-2741-5241	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Chrobak JJ, 1996, J NEUROSCI, V16, P3056; CHURCH J, 1991, J NEUROSCI, V11, P3289; COBB SR, 1995, NATURE, V378, P612; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; JEFFERYS JGR, 1981, J PHYSIOL-LONDON, V319, P143, DOI 10.1113/jphysiol.1981.sp013897; JEFFERYS JGR, 1982, NATURE, V300, P448, DOI 10.1038/300448a0; LESLIE J, 1998, J PHYSIOL-LONDON, V146, pP506; LLINAS R, 1974, J NEUROPHYSIOL, V37, P560, DOI 10.1152/jn.1974.37.3.560; Logan SD, 1996, J PHYSIOL-LONDON, V495, P491, DOI 10.1113/jphysiol.1996.sp021609; MACVICAR BA, 1985, BRAIN RES, V330, P141, DOI 10.1016/0006-8993(85)90015-0; MACVICAR BA, 1981, SCIENCE, V213, P782, DOI 10.1126/science.6266013; Patrylo PR, 1996, NEUROSCIENCE, V74, P107, DOI 10.1016/0306-4522(96)00111-X; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; PINAULT D, 1995, BRAIN RES REV, V21, P42, DOI 10.1016/0165-0173(95)00004-M; Rash JE, 1997, J COMP NEUROL, V388, P265, DOI 10.1002/(SICI)1096-9861(19971117)388:2<265::AID-CNE6>3.0.CO;2-#; Simburger E, 1997, HISTOCHEM CELL BIOL, V107, P127, DOI 10.1007/s004180050097; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; Strata F, 1997, J NEUROSCI, V17, P1435; STUMPF C, 1965, ELECTROEN CLIN NEURO, V18, P477, DOI 10.1016/0013-4694(65)90128-8; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; THOMAS RC, 1984, J PHYSIOL-LONDON, V354, P3; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Traub RD, 1995, J COMPUT NEUROSCI, V2, P283, DOI 10.1007/BF00961440; VALIANTE TA, 1995, J NEUROSCI, V15, P6946; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; VANEY DI, 1993, P ROY SOC B-BIOL SCI, V252, P93, DOI 10.1098/rspb.1993.0051; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; YLINEN A, 1995, J NEUROSCI, V15, P30	30	526	535	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					189	192		10.1038/28184	http://dx.doi.org/10.1038/28184			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671303				2022-12-28	WOS:000074705900056
J	van Beek, I; Dwyer, R; Dore, GJ; Luo, KH; Kaldor, JM				van Beek, I; Dwyer, R; Dore, GJ; Luo, KH; Kaldor, JM			Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; PREVALENCE; HCV; TRANSMISSION; BEHAVIORS; AMSTERDAM; ANTIBODY; MARYLAND; HBV	Objectives: To estimate the incidence of HIV and hepatitis C virus and risk factors for seroconversion among a cohort of injecting drug users. Design: Retrospective cohort study. Setting: Primary healthcare facility in central Sydney. Subjects: Injecting drug users tested for HIV-1 antibody (n = 1179) and antibodies to hepatitis C virus (n = 1078) from February 1992 to October 1995. Main outcome measures: Incidence of HIV-1 and hepatitis C virus among seronegative subjects who injected drugs and underwent repeat testing. Demographic and behavioural risk factors for hepatitis seroconversion. Results: Incidence of HIV-1 among 426 initially seronegative injecting drug users was 0.17/100 person years (two seroconversions) compared with an incidence of hepatitis C virus of 20.9/100 person years (31 seroconversions) among 152 injecting drug users initially negative for hepatitis C virus. Incidence of hepatitis C virus among injecting drug users aged less than 20 years was 75.6/100 person years. Independent risk factors for hepatitis C virus seroconversion were age less than 20 years and a history of imprisonment. Conclusions: In a setting where prevention measures have contributed to the maintenance of low prevalence and incidence of HIV-1, transmission of hepatitis C virus continues at extremely high levels, particularly among young injecting drug users.	Kirketon Rd Ctr, Kings Cross, NSW 1340, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia	University of New South Wales Sydney; Kirby Institute	van Beek, I (corresponding author), Kirketon Rd Ctr, POB 22, Kings Cross, NSW 1340, Australia.	ivanbeek@oxemail.com.au	Dwyer, Robyn/K-9826-2019; Kaldor, John M/D-4545-2011; Dwyer, Robyn/K-3652-2013; Dore, Gregory John/ABD-5665-2021	Dwyer, Robyn/0000-0002-1886-0733; Dwyer, Robyn/0000-0002-1886-0733; Dore, Gregory John/0000-0002-4741-2622				BELL J, 1990, MED J AUSTRALIA, V153, P274, DOI 10.5694/j.1326-5377.1990.tb136900.x; BODSWORTH NJ, 1994, GENITOURIN MED, V70, P206; Breslow NE., 1987, STAT METHODS CANC RE, P81; CHAMOT E, 1992, AIDS, V6, P430, DOI 10.1097/00002030-199204000-00013; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; CROFTS N, 1994, EUR J EPIDEMIOL, V10, P687, DOI 10.1007/BF01719282; CROFTS N, 1993, MED J AUSTRALIA, V159, P237, DOI 10.5694/j.1326-5377.1993.tb137822.x; Crofts N, 1997, MED J AUSTRALIA, V167, P17, DOI 10.5694/j.1326-5377.1997.tb138757.x; DONAHUE JG, 1991, AM J EPIDEMIOL, V134, P1206, DOI 10.1093/oxfordjournals.aje.a116023; FRANCISCI D, 1995, EUR J EPIDEMIOL, V11, P123, DOI 10.1007/BF01719475; GALEAZZI B, 1995, LIVER, V15, P209; Gaube J, 1993, Gesundheitswesen, V55, P246; GIRARDI E, 1990, SCAND J INFECT DIS, V22, P751, DOI 10.3109/00365549009027133; Kaldor J, 1993, Drug Alcohol Rev, V12, P175, DOI 10.1080/09595239300185611; LOVE A, 1994, EPIDEMIOL INFECT, V113, P529, DOI 10.1017/S0950268800068540; MAJID A, 1995, J MED VIROL, V46, P48, DOI 10.1002/jmv.1890460111; NAKATA S, 1994, J GASTROEN HEPATOL, V9, P416, DOI 10.1111/j.1440-1746.1994.tb01265.x; PATTI AM, 1993, INT J EPIDEMIOL, V22, P135, DOI 10.1093/ije/22.1.135; QUARANTA JF, 1994, J MED VIROL, V42, P29, DOI 10.1002/jmv.1890420106; ROBINSON GM, 1995, NEW ZEAL MED J, V108, P103; THOMAS DL, 1995, MEDICINE, V74, P212, DOI 10.1097/00005792-199507000-00005; VANAMEIJDEN EJC, 1993, EUR J EPIDEMIOL, V9, P255, DOI 10.1007/BF00146260; VANBEEK I, 1994, GENITOURIN MED, V70, P321; VANBEEK I, 1994, SEX WORK SEX WORKERS; VANDENHOEK JAR, 1990, J INFECT DIS, V162, P823, DOI 10.1093/infdis/162.4.823; VLAHOV D, 1993, EUR J EPIDEMIOL, V9, P566, DOI 10.1007/BF00209538; WADDELL RG, 1994, MED J AUSTRALIA, V161, P286; YE S, 1993, CHIN J EPIDEMIOL, V14, P45; ZELDIS JB, 1992, WESTERN J MED, V156, P30	29	162	164	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1998	317	7156					433	437						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703523	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000075490200016
J	Aladjem, MI; Rodewald, LW; Kolman, JL; Wahl, GM				Aladjem, MI; Rodewald, LW; Kolman, JL; Wahl, GM			Genetic dissection of a mammalian replicator in the human beta-globin locus	SCIENCE			English	Article							BIDIRECTIONAL DNA-REPLICATION; CELL-CYCLE; FUNCTIONAL ELEMENTS; ANIMAL-CELLS; ORIGIN; INITIATION; XENOPUS; DOMAIN; IDENTIFICATION; CHROMOSOMES	The timing and localization of DNA replication initiation in mammalian cells are heritable traits, but it is not known whether initiation requires specific DNA sequences. A site-specific recombination strategy was used to show that DNA sequences previously identified as replication initiation sites could initiate replication when transferred to new chromosomal Locations. An 8-kilobase DNA sequence encompassing the origin of DNA replication in the human P-globin Locus initiated replication in the simian genome. Specific deletions within the globin origin did not initiate replication in these chromosomal sites. These data suggest that initiation of DNA replication in mammalian cells requires specific sequence information and extend the replicon hypothesis to higher eukaryotes.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Aladjem, Mirit/G-2169-2010	Aladjem, Mirit/0000-0002-1875-3110	NATIONAL CANCER INSTITUTE [R01CA048405, U01CA048405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051104] Funding Source: NIH RePORTER; NCI NIH HHS [CA48405] Funding Source: Medline; NIGMS NIH HHS [GM51104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 1997, MOL CELL BIOL, V17, P857, DOI 10.1128/MCB.17.2.857; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; BELL SP, 1993, COLD SPRING HARB SYM, V58, P435, DOI 10.1101/SQB.1993.058.01.050; BIELINSKY AK, 1998, MOL CELL BIOL, V279, P95; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BURHANS WC, 1994, SCIENCE, V263, P639, DOI 10.1126/science.8303270; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CARROLL SM, 1993, MOL CELL BIOL, V13, P2971, DOI 10.1128/MCB.13.5.2971; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Clyne RK, 1997, METHODS, V13, P221, DOI 10.1006/meth.1997.0522; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DePamphilis ML, 1993, CURR OPIN CELL BIOL, V5, P434, DOI 10.1016/0955-0674(93)90008-E; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; Diffley JFX, 1995, J CELL SCI, P67; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; EPNER E, 1991, P NATL ACAD SCI USA, V88, P153; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; GROSVELD F, 1993, COLD SPRING HARB SYM, V58, P7, DOI 10.1101/SQB.1993.058.01.004; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HAMLIN JL, COMMUNICATION; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HEINZEL SS, 1991, MOL CELL BIOL, V11, P2263, DOI 10.1128/MCB.11.4.2263; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kornberg A., 1992, DNA REPLICATION; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; NONET GH, 1993, SOMAT CELL MOLEC GEN, V19, P171, DOI 10.1007/BF01233532; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pasero P, 1997, GENE DEV, V11, P1504, DOI 10.1101/gad.11.12.1504; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; SAUER B, 1990, New Biologist, V2, P441; Shimizu N, 1998, J CELL BIOL, V140, P1307, DOI 10.1083/jcb.140.6.1307; Shimizu N, 1996, NAT GENET, V12, P65, DOI 10.1038/ng0196-65; SNAPKA RM, 1983, P NATL ACAD SCI-BIOL, V80, P7533, DOI 10.1073/pnas.80.24.7533; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Strehl S, 1997, MOL CELL BIOL, V17, P6157, DOI 10.1128/MCB.17.10.6157; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; YOON Y, 1995, MOL CELL BIOL, V15, P2482	57	172	181	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1998	281	5379					1005	1009		10.1126/science.281.5379.1005	http://dx.doi.org/10.1126/science.281.5379.1005			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703500				2022-12-28	WOS:000075412700052
J	Gennari, FJ				Gennari, FJ			Current concepts - Hypokalemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLASMA POTASSIUM CONCENTRATION; PSEUDO-BARTTERS SYNDROME; THERAPY; DISEASE; ALDOSTERONISM; DISTURBANCES; HYPERKALEMIA; METABOLISM; DEFICIENCY; SECRETION		Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA	University of Vermont	Gennari, FJ (corresponding author), Fletcher Allen Hlth Ctr, Burgess 315, Burlington, VT 05401 USA.							ADROGUE HJ, 1981, AM J MED, V71, P456, DOI 10.1016/0002-9343(81)90182-0; Atchley DW, 1933, J CLIN INVEST, V12, P297, DOI 10.1172/JCI100504; BASSER LS, 1979, MED J AUSTRALIA, V1, P47, DOI 10.5694/j.1326-5377.1979.tb111971.x; BLUMBERG A, 1992, KIDNEY INT, V41, P369, DOI 10.1038/ki.1992.51; BRADBERRY SM, 1995, J TOXICOL-CLIN TOXIC, V33, P295, DOI 10.3109/15563659509028915; BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BREMNER P, 1992, RESP MED, V86, P419, DOI 10.1016/S0954-6111(06)80009-0; BURGESS CD, 1989, EUR J CLIN PHARMACOL, V36, P415, DOI 10.1007/BF00558306; CHIOU CY, 1994, ENDOCRINOLOGY, V134, P2371, DOI 10.1210/en.134.6.2371; CLAUSEN T, 1989, KIDNEY INT, V35, P1, DOI 10.1038/ki.1989.1; EDWARDS CRW, 1993, J STEROID BIOCHEM, V45, P1, DOI 10.1016/0960-0760(93)90114-C; FIELD MJ, 1985, KIDNEY INT, V27, P379, DOI 10.1038/ki.1985.20; GEARHART MO, 1993, ANN PHARMACOTHER, V27, P285, DOI 10.1177/106002809302700304; GILL JR, 1967, CLIN SCI, V33, P577; HERNANDEZ RE, 1987, KIDNEY INT, V31, P1356, DOI 10.1038/ki.1987.150; HESP R, 1975, CLIN SCI MOL MED, V49, P77, DOI 10.1042/cs0490077; HOES AW, 1994, DRUGS, V47, P711, DOI 10.2165/00003495-199447050-00002; JAMISON RL, 1982, AM J MED, V73, P142, DOI 10.1016/0002-9343(82)90941-X; KASSIRER JP, 1977, KIDNEY INT, V11, P505, DOI 10.1038/ki.1977.67; KASSIRER JP, 1966, AM J MED, V40, P10, DOI 10.1016/0002-9343(66)90182-3; KATZ FH, 1972, ANN INTERN MED, V76, P85, DOI 10.7326/0003-4819-76-1-85; KOBRIN SM, 1990, SEMIN NEPHROL, V10, P525; KRISHNA GG, 1990, J AM SOC NEPHROL, V1, P43; LANTZ B, 1979, ACTA MED SCAND, V206, P45; LASO FJ, 1990, DRUG ALCOHOL DEPEN, V26, P183, DOI 10.1016/0376-8716(90)90126-Y; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MARTINEZ R, 1991, EXPERIENTIA, V47, P270, DOI 10.1007/BF01958157; Massry Shaul G, 1997, SUKI MASSRYS THERAPY, P53, DOI [10.1007/978-1-4757-6632-5_4, DOI 10.1007/978-1-4757-6632-5_4]; MCCLEAVE DJ, 1978, AUST NZ J MED, V8, P180, DOI 10.1111/j.1445-5994.1978.tb04508.x; MCCLEAVE DJ, 1997, KIDNEY INT, V51, P1867; MCKENNA TJ, 1978, ENDOCRINOLOGY, V103, P1411, DOI 10.1210/endo-103-4-1411; MEYERS AM, 1990, S AFR MED J, V78, P631; MINELLA RA, 1991, AM HEART J, V121, P1810, DOI 10.1016/0002-8703(91)90033-E; MIR MA, 1975, ANN INTERN MED, V82, P54, DOI 10.7326/0003-4819-82-1-54; NAPARSTEK Y, 1984, AM J MED SCI, V288, P175, DOI 10.1097/00000441-198411000-00005; OBER KP, 1992, MEDICINE, V71, P109, DOI 10.1097/00005792-199205000-00001; PAICE BJ, 1986, POSTGRAD MED J, V62, P187, DOI 10.1136/pgmj.62.725.187; PASSMORE AP, 1986, ANN INTERN MED, V105, P468, DOI 10.7326/0003-4819-105-3-468_1; RAO TLK, 1980, ANESTHESIOLOGY, V52, P170; RIMMER JM, 1987, ARCH INTERN MED, V147, P867, DOI 10.1001/archinte.147.5.867; ROWE JW, 1980, METABOLISM, V29, P498, DOI 10.1016/0026-0495(80)90074-8; SCHULMAN M, 1990, AM J CARDIOL, V65, pE4, DOI 10.1016/0002-9149(90)90244-U; SCHWARTZ AB, 1974, JAMA-J AM MED ASSOC, V230, P702; SEBASTIAN A, 1971, J CLIN INVEST, V50, P231, DOI 10.1172/JCI106479; SEBASTIAN A, 1971, J CLIN INVEST, V50, P677; SHANNON M, 1989, ARCH INTERN MED, V149, P2725, DOI 10.1001/archinte.149.12.2725; Sillen A, 1997, AM J MED GENET, V69, P102, DOI 10.1002/(SICI)1096-8628(19970303)69:1<102::AID-AJMG20>3.0.CO;2-S; Simon DB, 1996, AM J PHYSIOL-RENAL, V271, pF961, DOI 10.1152/ajprenal.1996.271.5.F961; SONG DJ, 1992, J LAB CLIN MED, V120, P792; SQUIRES RD, 1959, J CLIN INVEST, V38, P1134, DOI 10.1172/JCI103890; STEDWELL RE, 1992, AM J EMERG MED, V10, P143, DOI 10.1016/0735-6757(92)90048-3; STERNS RH, 1981, MEDICINE, V60, P339, DOI 10.1097/00005792-198109000-00002; STROM BL, 1987, ARCH INTERN MED, V147, P954, DOI 10.1001/archinte.147.5.954; SUGARMAN A, 1986, AM J PHYSIOL, V250, pF695, DOI 10.1152/ajprenal.1986.250.4.F695; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Tannen RI, 1996, FLUIDS ELECTROLYTES, P111; Whorwood CB, 1996, J HYPERTENS, V14, pS19	57	338	350	3	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					451	458		10.1056/NEJM199808133390707	http://dx.doi.org/10.1056/NEJM199808133390707			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700180				2022-12-28	WOS:000075342500007
J	Schnitzer, JE				Schnitzer, JE			Vascular targeting as a strategy for cancer therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOLID TUMORS		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Schnitzer, JE (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; SCHNITZER JE, 1997, VASCULAR ENDOTHELIUM, V3, P77	7	72	78	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					472	474		10.1056/NEJM199808133390711	http://dx.doi.org/10.1056/NEJM199808133390711			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9700184				2022-12-28	WOS:000075342500011
J	Schulte, JM; Nolt, BJ; Williams, RL; Spinks, CL; Hellsten, JJ				Schulte, JM; Nolt, BJ; Williams, RL; Spinks, CL; Hellsten, JJ			Violence and threats of violence experienced by public health field-workers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE WORKERS; SOCIAL-WORKERS; CRACK COCAINE; ASSAULTS; AMERICA; COUNTY; CLIENT; ABUSE	Context. - Public health workers may work with clients whose behaviors are risks for both infectious disease and violence. Objective. - To assess frequency of violent threats and incidents experienced by public health workers and risk factors associated with incidents. Design. - Anonymous, self-administered questionnaires. Setting. - Texas sexually transmitted disease (STD), human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), and tuberculosis (TB) programs. Participants. - Questionnaires were completed by 364 (95.5%) of 381 public health workers assigned to the programs. The STD program employed 131 workers (36%), the HIV/AIDS program, 121 workers (33%), and the TB program, 112 workers (31%). Main Outcome Measures. - The frequencies with which workers had ever experienced (while on the job) verbal threats, weapon threats, physical attacks, and rape, and risk factors associated with those outcomes. Results. - A total of 139 (38%) of 364 workers reported 611 violent incidents. Verbal threats were reported by 136 workers (37%), weapon threats by 45 (12%), physical attacks by 14 (4%), and rape by 3 (1%). Five workers (1%) carried guns and/or knives while working. In multiple logistic regression, receipt of verbal threats was associated with worker's male sex (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.5-4.0), white ethnicity (OR, 2.4; 95% CI, 1.4-4.1), experience of 5 years or longer (OR, 2.2; 95% CI, 1.3-3.8), weekend work (OR, 1.8; 95% CI, 1.1-3.1), and sexual remarks made to the worker by clients (OR, 2.0; 95% CI, 1.2-3.5). Receipt of weapon threats was associated with worker's male sex (OR, 5.7; 95% CI, 2.4-15.3), white ethnicity (OR, 4.0; 95% CI, 1.8-9.3), age of 40 years or older (OR, 2.5; 95% CI, 1.1-5.8), work experience of 5 years or longer (OR, 2.7; 95% CI, 1.2-6.0), rural work (OR, 3.6; 95% CI, 1.3-10.1), being alone with the opposite sex (OR, 3.7; 95% CI, 1.6-9.7), and interaction with homeless clients (OR, 5.2; 95% CI, 1.7-18.8). Physical attacks were associated with sexual remarks made to the worker by clients (OR, 4.2; 95% CI, 1.4-13.9). No risk factors predicting rape were identified. Conclusions. - Violence directed toward public field-workers is a common occupational hazard. An assessment of what situations, clients, and locations pose the risk of violence to public health workers is needed.	Texas Dept Hlth, Bur HIV STD Prevent, Austin, TX 78756 USA	Texas Department of State Health Services	Schulte, JM (corresponding author), Ctr Dis Control & Prevent, Surveillance & Epidemiol Branch, Div TB Eliminat, MS E10,1600 Clifton Rd NE, Atlanta, GA 30333 USA.							BENOWITZ NL, 1993, PHARMACOL TOXICOL, V72, P3, DOI 10.1111/j.1600-0773.1993.tb01331.x; BERNSTEIN HA, 1981, AM J PSYCHOTHER, V35, P542, DOI 10.1176/appi.psychotherapy.1981.35.4.542; BOOTH RE, 1993, AM J PUBLIC HEALTH, V83, P1144, DOI 10.2105/AJPH.83.8.1144; CHIRGWIN K, 1991, AM J PUBLIC HEALTH, V81, P1576, DOI 10.2105/AJPH.81.12.1576; DAS G, 1993, J CLIN PHARMACOL, V33, P296, DOI 10.1002/j.1552-4604.1993.tb04661.x; Dean A.G., 1994, EPI INFO VERSION 6 W; GOODMAN RA, 1994, JAMA-J AM MED ASSOC, V272, P1686, DOI 10.1001/jama.272.21.1686; GUNN RA, 1995, SEX TRANSM DIS, V22, P60, DOI 10.1097/00007435-199501000-00010; Jayaratne S., 1995, J APPL SOCIAL SCI, V20, P1; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; KOOP CE, 1994, JAMA-J AM MED ASSOC, V271, P1404; KOOP CE, 1992, JAMA-J AM MED ASSOC, V268, P3074; LANZA HL, 1985, HOSP COMMUNITY PSYCH, V34, P44; LAVOIE FW, 1988, ANN EMERG MED, V17, P1227, DOI 10.1016/S0196-0644(88)80076-3; LEONHARDT KK, 1994, AM J PUBLIC HEALTH, V84, P1834, DOI 10.2105/AJPH.84.11.1834; MADDEN DJ, 1976, AM J PSYCHIAT, V133, P422; MARZUK PM, 1995, NEW ENGL J MED, V332, P1753, DOI 10.1056/NEJM199506293322606; *NAT I OCC SAF HLT, 1996, NAT I OCC SAF HLTH B; Newhill CE, 1996, FAM SOC-J CONTEMP H, V77, P488, DOI 10.1606/1044-3894.958; Perlman DC, 1997, J SUBST ABUSE TREAT, V14, P3, DOI 10.1016/S0740-5472(96)00182-1; Poster E C, 1989, Arch Psychiatr Nurs, V3, P315; Rey LD, 1996, FAM SOC-J CONTEMP H, V77, P33, DOI 10.1606/1044-3894.839; *SAS I, 1994, PRINC REGR AN; *STAT CA, 1993, GUID SEC SAF HLTH CA; SULLIVAN C, 1995, AM J PUBLIC HEALTH, V85, P1011, DOI 10.2105/AJPH.85.7.1011; *US DEP LAB, 1996, OSHA B, V3148; YASSI A, 1994, CAN MED ASSOC J, V151, P1273	27	36	37	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					439	442		10.1001/jama.280.5.439	http://dx.doi.org/10.1001/jama.280.5.439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105AR	9701079	Bronze			2022-12-28	WOS:000075050200031
J	Kuzma, NN; Khandelwal, P; Barrett, SE; Pfeiffer, LN; West, KW				Kuzma, NN; Khandelwal, P; Barrett, SE; Pfeiffer, LN; West, KW			Ultraslow electron spin dynamics in GaAs quantum wells probed by optically pumped NMR	SCIENCE			English	Article							HETEROSTRUCTURES; EXCITATIONS; SKYRMIONS	Optically pumped nuclear magnetic resonance (OPNMR) measurements were performed in two different electron-doped multiple quantum Well samples near the fractional quantum Hall effect ground state nu = 1/3 Below 0.5 kelvin, the spectra provide evidence that spin-reversed charged excitations of the nu = 1/3 ground state are Localized over the NMR time scale of about 40 microseconds. Furthermore, by varying NMR pulse parameters, the electron spin temperature (as measured by the Knight shift) could be driven above the Lattice temperature, which shows that the value of the electron spin-lattice relaxation time tau(1s) is between 100 microseconds and 500 milliseconds at nu = 1/3.	Yale Univ, Dept Phys, New Haven, CT 06511 USA; Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA	Yale University; Alcatel-Lucent; Lucent Technologies; AT&T	Barrett, SE (corresponding author), Yale Univ, Dept Phys, New Haven, CT 06511 USA.		Barrett, Sean E/F-1274-2015; Kuzma, Nicholas/A-1117-2007	Barrett, Sean E/0000-0002-0498-2027; 				BARRETT SE, 1994, PHYS REV LETT, V72, P1368, DOI 10.1103/PhysRevLett.72.1368; BARRETT SE, 1995, PHYS REV LETT, V74, P5112, DOI 10.1103/PhysRevLett.74.5112; FERTIG HA, 1994, PHYS REV B, V50, P11018, DOI 10.1103/PhysRevB.50.11018; FISHMAN G, 1983, PHYS REV B, V27, P7611, DOI 10.1103/PhysRevB.27.7611; FRENKEL DM, 1991, PHYS REV B, V43, P14228, DOI 10.1103/PhysRevB.43.14228; Khandelwal P, 1998, PHYS REV LETT, V81, P673, DOI 10.1103/PhysRevLett.81.673; Kikkawa JM, 1998, PHYS REV LETT, V80, P4313, DOI 10.1103/PhysRevLett.80.4313; PFEIFFER LN, 1992, APPL PHYS LETT, V61, P1211, DOI 10.1063/1.107597; TYCKO R, 1995, SCIENCE, V268, P1460, DOI 10.1126/science.7539550	12	65	66	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					686	690		10.1126/science.281.5377.686	http://dx.doi.org/10.1126/science.281.5377.686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685259	Green Submitted			2022-12-28	WOS:000075107900038
J	De Deyn, PP; Orgogozo, JM; De Reuck, J				De Deyn, PP; Orgogozo, JM; De Reuck, J		PASS Grp	Acute treatment of stroke	LANCET			English	Letter									Univ Instelling Antwerp, Born Bunge Fdn, Dept Neurochem & Behav, B-2610 Antwerp, Belgium	University of Antwerp	De Deyn, PP (corresponding author), Univ Instelling Antwerp, Born Bunge Fdn, Dept Neurochem & Behav, B-2610 Antwerp, Belgium.							DeDeyn PP, 1997, STROKE, V28, P2347, DOI 10.1161/01.STR.28.12.2347; Lees KR, 1998, LANCET, V351, P1447, DOI 10.1016/S0140-6736(05)78865-6; ORGOGOZO JM, 1998, CEREBROVASC DIS S4, V8	3	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					326	326		10.1016/S0140-6736(05)60306-6	http://dx.doi.org/10.1016/S0140-6736(05)60306-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690444	Bronze			2022-12-28	WOS:000074974500066
J	Terwogt, JMM; Beijnen, JH; Huinink, WWT; Rosing, H; Schellens, JHM				Terwogt, JMM; Beijnen, JH; Huinink, WWT; Rosing, H; Schellens, JHM			Co-administration of cyclosporin enables oral therapy with paclitaxel	LANCET			English	Article									Netherlands Canc Inst, Siotervaart Hosp, NL-1066 EC Amsterdam, Netherlands; Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands	Netherlands Cancer Institute; Slotervaart Hospital; Netherlands Cancer Institute	Terwogt, JMM (corresponding author), Netherlands Canc Inst, Siotervaart Hosp, Louwesweg 6, NL-1066 EC Amsterdam, Netherlands.							Borst P, 1997, TRENDS GENET, V13, P217, DOI 10.1016/S0168-9525(97)01112-8; Huizing MT, 1997, J CLIN ONCOL, V15, P317, DOI 10.1200/JCO.1997.15.1.317; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Sparreboom A, 1997, P NATL ACAD SCI USA, V94, P2031, DOI 10.1073/pnas.94.5.2031; vanAsperen J, 1997, BRIT J CANCER, V76, P1181, DOI 10.1038/bjc.1997.530	5	104	105	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					285	285		10.1016/S0140-6736(98)24030-X	http://dx.doi.org/10.1016/S0140-6736(98)24030-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690410				2022-12-28	WOS:000074974500013
J	Boriack-Sjodin, PA; Margarit, SM; Bar-Sagi, D; Kuriyan, J				Boriack-Sjodin, PA; Margarit, SM; Bar-Sagi, D; Kuriyan, J			The structural basis of the activation of Ras by Sos	NATURE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EPIDERMAL GROWTH-FACTOR; GDP-GTP EXCHANGERS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL INTERACTION; MOLECULAR MECHANISM; EF-TU; PROTEIN; RESIDUES; COMPLEX	The crystal structure of human H-Ras complexed with the pas guanine-nucleotide-exchange-factor region of the Son of sevenless (Sos) protein has been determined at 2.8 Angstrom resolution. The normally tight interaction of nucleotides with pas is disrupted by Sos in two ways. First, the insertion into gas of an alpha-helix from Sos results in the displacement of the Switch 1 region of Ras, opening up the nucleotide-binding site. Second, side chains presented by this helix and by a distorted conformation of the Switch 2 region of pas alter title chemical environment of the binding site for the phosphate groups of the nucleotide and the associated magnesium ion, so that their binding is no longer favoured. Sos does not impede the binding sites for the base and the ribose of GTP or sop, so the Ras-Sos complex adopts a structure that allows nucleotide release and rebinding.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; BERNSTEIN FC, 1978, ARCH BIOCHEM BIOPHYS, V185, P584, DOI 10.1016/0003-9861(78)90204-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; BRUNGER AT, IN PRESS ACTA CRYS D; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; LAI SHY, 1993, COMPUT IND ENG, V25, P13, DOI 10.1016/0360-8352(93)90209-G; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Leonardsen L, 1996, ONCOGENE, V13, P2177; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	46	588	597	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					337	343		10.1038/28548	http://dx.doi.org/10.1038/28548			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690470				2022-12-28	WOS:000074968800041
J	Pitkin, RM; Branagan, MA				Pitkin, RM; Branagan, MA			Can the accuracy of abstracts be improved by providing specific instructions? A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			ORIGINAL RESEARCH ARTICLES; INTERNAL-MEDICINE; QUALITY; ANNALS	Context.-The most-read section of a research article is the abstract, and therefore it is especially important that the abstract be accurate. Objective.-To test the hypothesis that providing authors with specific instructions about abstract accuracy will result in improved accuracy. Design.-Randomized controlled trial of an educational intervention specifying 3 types of common defects in abstracts of articles that had been reviewed and were.being returned to the authors with an invitation to revise. Mean Outcome Measure.-Proportion of abstracts containing 1 or more of the following defects: inconsistency in data between abstract and body of manuscript (text, tables, and figures), data or other information given in abstract but not in body, and/or conclusions not justified by information in the abstract. Results.-Of 250 manuscripts randomized, 13 were never revised and 34 were lost to follow-up, leaving a final comparison between 89 in the intervention group and 114 in the control;group. Abstracts were defective in 25 (28%) and 30 (26%) cases, respectively (P =.78). Among 55 defective abstracts, 28 (51%) had inconsistencies, 16 (29%) contained data not present in the body, 8 (15%) had both types of defects, and 3 (5%) contained unjustified conclusions. Conclusions.-Defects in abstracts, particularly inconsistencies between abstract and body and the presentation of data in abstract but not in body, occur frequently. Specific instructions to authors who are revising their manuscripts are ineffective in lowering this rate. Journals should include in their editing processes specific and detailed attention to abstracts.	Obstet & Gynecol, Los Angeles, CA 90024 USA		Pitkin, RM (corresponding author), Obstet & Gynecol, 10921 Wilshire Blvd,Suite 403, Los Angeles, CA 90024 USA.	rpitkin@greenjournal.org						GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; HARTLEY J, IN PRESS BR J ED PSY; HAYNES RB, 1987, ANN INTERN MED, V106, P598; NARINE L, 1991, CAN MED ASSOC J, V144, P449; PITKIN RM, 1987, OBSTET GYNECOL, V70, P267; ROBERTS JC, 1994, JAMA-J AM MED ASSOC, V272, P119, DOI 10.1001/jama.272.2.119; TADDIO A, 1994, CAN MED ASSOC J, V150, P1611	7	86	86	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					267	269		10.1001/jama.280.3.267	http://dx.doi.org/10.1001/jama.280.3.267			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676677	Bronze			2022-12-28	WOS:000074706000022
J	Siegel, M				Siegel, M			Mass media antismoking campaigns: A powerful tool for health promotion	ANNALS OF INTERNAL MEDICINE			English	Article							CIGARETTE CONSUMPTION; SMOKING PREVENTION; TOBACCO; CALIFORNIA	Cigarette advertising and promotion have been shown to influence smoking in young persons, but the powerful effect of the mass media on behavior can also be used to promote health. Several states have earmarked a portion of their cigarette excise tax revenues to fund mass media antismoking campaigns, which have been effective in reducing cigarette consumption and in helping persons quit smoking. Despite their successes, the campaigns have been hindered by tobacco industry-supported attempts to cut their funding or restrict their scope. The most aggressive campaigns, which attack the tobacco industry and challenge social norms about tobacco use and promotion, are the most controversial but also the most effective. Mass media antismoking campaigns are a promising tool for health promotion, but only if sustained funding can be guaranteed and the development of the advertisements can be protected from intrusion by political forces.	Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02118 USA	Boston University	Siegel, M (corresponding author), Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, 715 Albany St,TW2, Boston, MA 02118 USA.			Siegel, Michael/0000-0002-2573-9616				[Anonymous], 1984, BEHAV HLTH HDB HLTH; *AR EP HLTH SERV, 1995, H6001 AR DEP HLTH SE; Austin E. W., 1995, DESIGNING HLTH MESSA, P114; BAL DG, 1990, JAMA-J AM MED ASSOC, V264, P1570, DOI 10.1001/jama.264.12.1570; DIFRANZA JR, 1992, J FAM PRACTICE, V34, P694; DORFMAN L, 1993, PUBLIC HEALTH REP, V108, P716; FEDER BJ, 1996, NY TIMES        0401, pA12; FLYNN BS, 1994, AM J PUBLIC HEALTH, V84, P1148, DOI 10.2105/AJPH.84.7.1148; GIBBONS J, 1986, CHILD DEV, V57, P1014, DOI 10.1111/j.1467-8624.1986.tb00262.x; Glantz S., 1993, TOB CONTROL, V2, P311, DOI DOI 10.1136/TC.2.4.311; Glantz SA, 1996, AM J PUBLIC HEALTH, V86, P156, DOI 10.2105/AJPH.86.2.156; Goldman LK, 1998, JAMA-J AM MED ASSOC, V279, P772, DOI 10.1001/jama.279.10.772; GOODMAN E, 1996, BOSTON GLOBE    0602, P77; GOODSTADT MS, 1990, DHHS PUBL, P7; HAMILTON JL, 1972, REV ECON STAT, V54, P401, DOI 10.2307/1924567; HEARN W, 1996, AM MED NEWS, V39, P64; *HOUST HERST FAV, 1997, ASS MASS TOB CONTR P; Hu T, 1995, TOBACCO CONTROL S1, V4, pS34; HU TW, 1995, AM J PUBLIC HEALTH, V85, P1218, DOI 10.2105/AJPH.85.9.1218; KASSEBAUM P, 1990, OSAP PREVENTION MONO, V5, P11; LEWIT EM, 1981, J LAW ECON, V24, P545, DOI 10.1086/466999; Lynch BS., 1994, GROWING TOBACCO FREE; McGuire R.J., 1969, HDB SOCIAL PSYCHOL, P136; MCKENNA JW, 1993, PUBLIC HEALTH REP, V108, P85; Novotny TE, 1996, HEALTH AFFAIR, V15, P58, DOI 10.1377/hlthaff.15.1.58; PACHMANN C, 1997, SOCIAL MARKETING THE, P189; PERRY CL, 1992, AM J PUBLIC HEALTH, V82, P1210, DOI 10.2105/AJPH.82.9.1210; PHILLIPS F, 1995, BOSTON GLOBE    1109, P15; PHILLIPS F, 1995, BOSTON GLOBE    1109, P1; POPHAM WJ, 1993, PUBLIC HEALTH REP, V108, P510; SCHNEIDER L, 1981, J LAW ECON, V24, P575, DOI 10.1086/467001; Siegel M, 1997, J SOC ISSUES, V53, P147, DOI 10.1111/0022-4537.10199710; *US DEP HHS, 1989, RED HLTH CONS SMOK 2; *US DEP HHS, 1994, PREV TOB US YOUNG PE; WARNER KE, 1977, AM J PUBLIC HEALTH, V67, P645, DOI 10.2105/AJPH.67.7.645; Worden JK, 1996, HEALTH EDUC QUART, V23, P453, DOI 10.1177/109019819602300406; 1996, MMWR MORB MORTAL WKL, V45, P966	37	55	55	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					128	132		10.7326/0003-4819-129-2-199807150-00013	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	101CL	9669972				2022-12-28	WOS:000074852000009
J	Meduri, GU; Headley, AS; Golden, E; Carson, SJ; Umberger, RA; Kelso, T; Tolley, EA				Meduri, GU; Headley, AS; Golden, E; Carson, SJ; Umberger, RA; Kelso, T; Tolley, EA			Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORTICOSTEROID RESCUE TREATMENT; ACUTE LUNG DAMAGE; INFLAMMATORY CYTOKINES; PERSISTENT ELEVATION; PULMONARY FIBROSIS; LATE ARDS; DEFINITIONS; SEPSIS; GLUCOCORTICOIDS; METAANALYSIS	Context.-No pharmacological therapeutic protocol has been found effective in modifying the clinical course of acute respiratory distress syndrome (ARDS) and mortality remains greater than 50%. Objective.-To determine the effects of prolonged methylprednisolone therapy on lung function and mortality in patients with unresolving ARDS. Design.-Randomized, double-blind, placebo-controlled trial. Setting.-Medical intensive care units of 4 medical centers. Participants.-Twenty-four patients with severe ARDS who had failed to improve lung injury score (LIS) by the seventh day of respiratory failure. Interventions.-Sixteen patients received methylprednisolone and 8 received placebo. Methylprednisolone dose was initially 2 mg/kg per day and the duration of treatment was 32 days. Four patients whose LIS failed to improve by at least 1 point after 10 days of treatment were blindly crossed over to the alternative treatment, Main Outcome Measures.-Primary outcome measures were improvement in lung function and mortality. Secondary outcome measures were improvement in multiple organ dysfunction syndrome (MODS) and development of nosocomial infections, Results.-Physiological characteristics at the onset of ARDS were similar in both groups. At study entry (day 9 [SD, 3] of ARDS), the 2 groups had similar LIS, ratios of PaO2 to fraction of inspired oxygen (FlO(2)), and MODS scores. Changes observed by study day 10 for methylprednisolone vs placebo were as follows: reduced LIS (mean [SEM], 1.7 [0.1] vs 3.0 [0.2]; P<.001); improved ratio of PaO2 to FlC(2) (mean [SEM], 262 [19] vs 148 [35]; P<.001); decreased MODS score (mean [SEM], 0.7 [0.2] vs 1.8 [0.3]; P<.001); and successful extubation (7 vs 0; P=.05). For the treatment group vs the placebo group, mortality associated with the intensive care unit was 0 (0%) of 16 vs 5 (62%) of 8 (P=.002) and hospital-associated mortality was 2 (12%) of 16 vs 5 (62%) of 8 (P=.03). The rate of infections per day of treatment was similar in both groups, and pneumonia was frequently detected in the absence of fever. Conclusions.-In this study, prolonged administration of methylprednisolone in patients with unresolving ARDS was associated with improvement in lung injury and MODS scores and reduced mortality.	Univ Tennessee, Lung Res Program, Baptist Mem Hosp, Memphis, TN 38163 USA; Univ Tennessee, Vet Affairs Med Ctr, Memphis, TN 38163 USA; Univ Tennessee, Dept Med, Coll Med, Memphis, TN 38163 USA; Univ Tennessee, Dept Prevent Med, Coll Med, Memphis, TN 38163 USA; Univ Tennessee, Coll Pharm, Memphis, TN 38163 USA	Baptist Memorial Hospital Memphis; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Meduri, GU (corresponding author), Univ Tennessee, Div Pulm & Crit Care Med, Coll Med, 956 Court Ave,Room H314, Memphis, TN 38163 USA.		Umberger, Reba/HHY-8227-2022	Umberger, Reba/0000-0002-4722-4031				ASHBAUGH DG, 1985, ARCH SURG-CHICAGO, V120, P530; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BARBER AE, 1993, J IMMUNOL, V150, P1999; BARNES PJ, 1997, LUNG SCI FDN, P37; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bernard GR, 1995, AM J RESP CRIT CARE, V151, pA323; BIFFL WL, 1995, AM J SURG, V170, P591, DOI 10.1016/S0002-9610(99)80022-1; Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010; BONE RC, 1989, CHEST, V96, P849, DOI 10.1378/chest.96.4.849; BONE RC, 1987, CHEST, V92, P1032, DOI 10.1378/chest.92.6.1032; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BRIEGEL J, 1994, CLIN INVESTIGATOR, V72, P782; CRONIN L, 1995, CRIT CARE MED, V23, P1430, DOI 10.1097/00003246-199508000-00019; HAKKINEN PJ, 1983, AM REV RESPIR DIS, V128, P648; Headley AS, 1997, CHEST, V111, P1306, DOI 10.1378/chest.111.5.1306; HESTERBERG TW, 1981, AM REV RESPIR DIS, V123, P47; HOOPER RG, 1990, CHEST, V97, P138, DOI 10.1378/chest.97.1.138; Hooper RG, 1996, SOUTHERN MED J, V89, P359, DOI 10.1097/00007611-199604000-00001; JONES RL, 1975, J TRAUMA, V15, P297, DOI 10.1097/00005373-197504000-00006; KEHRER JP, 1984, AM REV RESPIR DIS, V130, P256; KEW KH, 1993, CLIN PHARMACOL THER, V54, P402; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106; Krafft P, 1996, INTENS CARE MED, V22, P519, DOI 10.1007/s001340050125; LEFERING R, 1995, CRIT CARE MED, V23, P1294, DOI 10.1097/00003246-199507000-00021; MARX J, 1995, SCIENCE, V270, P232, DOI 10.1126/science.270.5234.232; Meduri G U, 1995, Semin Respir Infect, V10, P154; MEDURI GU, 1995, CHEST, V108, P1315, DOI 10.1378/chest.108.5.1315; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; MEDURI GU, 1994, CHEST, V105, P1516, DOI 10.1378/chest.105.5.1516; Meduri GU, 1996, EUR RESPIR J, V9, P2650, DOI 10.1183/09031936.96.09122650; MEDURI GU, 1991, CHEST, V100, P943, DOI 10.1378/chest.100.4.943; MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303; MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062; MEDURI GU, 1998, AM J RESP CRIT CARE, V157, pA460; MEDURI GU, 1992, CHEST, V102, P557; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; REDDY R, 1997, AM J RESP CRIT CARE, V155, pA393; SHEN AS, 1988, AM REV RESPIR DIS, V137, P564, DOI 10.1164/ajrccm/137.3.564; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; Sokal R R, 1981, BIOMETRY, P232; TORNATORE KM, 1994, J AM GERIATR SOC, V42, P1118, DOI 10.1111/j.1532-5415.1994.tb06219.x; Whitehead J., 1983, DESIGN ANAL SEQUENTI	44	595	651	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					159	165		10.1001/jama.280.2.159	http://dx.doi.org/10.1001/jama.280.2.159			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669790	Bronze			2022-12-28	WOS:000074608400032
J	Korber, B; Theiler, J; Wolinsky, S				Korber, B; Theiler, J; Wolinsky, S			Limitations of a molecular clock applied to considerations of the origin of HIV-1	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; ENVELOPE GENES; GAG GENES; SEQUENCE; ISOLATE; RECOMBINATION; TRANSMISSION; INFECTIONS; EVOLUTION		Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Univ Calif Los Alamos Natl Lab, Space & Remote Sensing Sci Grp NIS2, Los Alamos, NM 87545 USA; Univ Calif Los Alamos Natl Lab, Theoret Div T10, Los Alamos, NM 87545 USA	Northwestern University; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory	Wolinsky, S (corresponding author), Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA.		Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697; Korber, Bette/0000-0002-2026-5757	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI070001] Funding Source: NIH RePORTER; NIAID NIH HHS [3-Y01-AI-70001-13] Funding Source: Medline; NICHD NIH HHS [R01-HD-31756] Funding Source: Medline; PHS HHS [Y1-A1-4058-03] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BECKETT S, 1981, ILL SEEN ILL SAID, P76; Beddows S, 1998, J GEN VIROL, V79, P77, DOI 10.1099/0022-1317-79-1-77; BERMAN PW, 1992, J VIROL, V66, P4464, DOI 10.1128/JVI.66.7.4464-4469.1992; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Cao HY, 1997, J VIROL, V71, P8615, DOI 10.1128/JVI.71.11.8615-8623.1997; Carr JK, 1996, J VIROL, V70, P5935, DOI 10.1128/JVI.70.9.5935-5943.1996; CHARNEAU P, 1994, VIROLOGY, V205, P247, DOI 10.1006/viro.1994.1640; CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR R, 1998, AIDS RES HUM RETROV, V72, P1552; Cornelissen M, 1996, J VIROL, V70, P8209, DOI 10.1128/JVI.70.11.8209-8212.1996; Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997; DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995; DIGHE PK, 1997, HUMAN RETROVIRUSES A, P74; DOMS RW, 1997, HIV MOL IMMUNOLOGY D, P1; DSOUZA MP, 1997, INFECT DIS, V175, P1056; ELGEN M, 1996, TRENDS MICROBIOL, V4, P216; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GINSPARG P, 1905, COMMUNICATION; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; Gunthard HF, 1998, J VIROL, V72, P2422; HAMMOND J, 1997, HUMAN RETROVIRUSES 3, P206; Hillis David M., 1996, P515; HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0; Kanki P J, 1997, AIDS, V11 Suppl B, pS33; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1461, DOI 10.1089/aid.1992.8.1461; KORBER B, UNPUB; Korber B T, 1995, AIDS, V9 Suppl A, pS5; KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994; KUIKEN CL, MOL EVOLUTION HIV; Leitner T, 1996, P NATL ACAD SCI USA, V93, P10864, DOI 10.1073/pnas.93.20.10864; LEITNER T, 1997, HUMAN RETROVIRUSES 3, P25; LI WH, 1988, MOL BIOL EVOL, V5, P313; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; *LOS AL NAT LAB, 1997, THEOR BIOL BIOPH; LOUSSERTAJAKA I, 1995, J VIROL, V69, P5640, DOI 10.1128/JVI.69.9.5640-5649.1995; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995; McCutchan FE, 1996, AIDS, V10, pS13; McCutchan FE, 1998, AIDS RES HUM RETROV, V14, P329, DOI 10.1089/aid.1998.14.329; MCCUTCHAN FE, 1998, P 5 ANN HIV DYN EV M, V5, P23; Moore J P, 1995, AIDS, V9 Suppl A, pS117; NEWTON I, 1947, PRINCIPIA, P6; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; PEETERS M, 1998, P 5 ANN HIV DYN EV M, V5, P73; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Press W.H, 1992, NUMERICAL RECIPES C, P666; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; ROBERTSON DL, 1995, J MOL EVOL, V40, P249, DOI 10.1007/BF00163230; ROBERTSON DL, 1997, HUMAN RETROVIRUSES A, P25; SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994; Salminen MO, 1997, J VIROL, V71, P2647, DOI 10.1128/JVI.71.4.2647-2655.1997; SHARMA KD, 1994, HYDROL PROCESS, V8, P27, DOI 10.1002/hyp.3360080103; SHARP P, 1988, NATURE, V333, P315; Swofford David L., 1996, P407; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	64	68	72	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1868	1871		10.1126/science.280.5371.1868	http://dx.doi.org/10.1126/science.280.5371.1868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669945				2022-12-28	WOS:000074323800041
J	Ferris, G; Roderick, P; Smithies, A; George, S; Gabbay, G; Couper, N; Chant, A				Ferris, G; Roderick, P; Smithies, A; George, S; Gabbay, G; Couper, N; Chant, A			An epidemiological needs assessment of carotid endarterectomy in an English health region. Is the need being met?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANSIENT ISCHEMIC ATTACKS; STROKE; OXFORDSHIRE; MANAGEMENT; SURGERY	Objective: To compare the level of provision of carotid endarterectomy (an intervention of proved efficacy for prevention of stroke in patients with symptomatic high grade carotid artery stenosis) with estimates of need. Design: Comparison of regional, district, and age-sex specific operation rates derived from hospital episode statistics with estimates of need based on demographic and epidemiological data; interviews with regional vascular surgeons and a joint provider-purchaser workshop to discuss implications. Setting: Former Wessex Regional Health Authority, 1991-2 to 1995-6. Subjects: All residents covered by wessex region treated for carotid artery reconstruction. Main outcome measures: Regional, district, and age-sex operation rates as three year average 1993-6 (use) compared with respective estimates of need for carotid endarterectomy among those who presented with symptomatic carotid disease-transient ischaemic attack or minor stroke. Results: The operation rate more than doubled between 1991-2 and 1995-6, from 35 to 89 per million population, compared with an estimated level of need in the region's general population of 153 per million population (transient ischaemic attack 77, minor stroke 76). The ratio of use to need was 0.47 (95% confidence interval 0.4 to 0.54); district ratios were 0.28 (0.19-0.38) to 0.81 (0.62 to 1.06). The annual use:need ratio rose over the three years 1993-6 from 0.38 to 0.59. Use:need ratios were lower in elderly and female patients. Providers were keen to develop guidelines for referral and to increase access to diagnostic facilities; purchasers were more reluctant, given the limited impact of this intervention on the incidence of stroke and the relatively high cost of the operation. Conclusion: Although treatment rates increased in Wessex there is still unmet need. Further research is needed to determine the referral pathways of patients with symptomatic carotid disease for diagnosis and operation and to evaluate strategies to improve access to diagnostic facilities.	Univ Southampton, Southampton Gen Hosp, Wessex Inst Hlth Res & Dev, Southampton SO16 6YD, Hants, England; Southampton Univ Hosp Trust, Dept Vasc Surg, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust	Roderick, P (corresponding author), Univ Southampton, Southampton Gen Hosp, Wessex Inst Hlth Res & Dev, Mail Point 805,Level B,S Acad Block, Southampton SO16 6YD, Hants, England.	pjr@soton.ac.uk						BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BROWN MM, 1992, BMJ-BRIT MED J, V305, P1071, DOI 10.1136/bmj.305.6861.1071; CLAYTON D, 1995, STAT MODELS EPIDEMIO; DENNIS M, 1991, BRIT MED J, V303, P636, DOI 10.1136/bmj.303.6803.636; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; *DEP HLTH U SURR I, 1994, PUBL HLTH COMM DAT 1, V2; *EX COMM ASYMPT CA, 1995, JAMA-J AM MED ASSOC, V346, P209; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; HANKEY GJ, 1991, J NEUROL NEUROSUR PS, V54, P793, DOI 10.1136/jnnp.54.9.793; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; Hankey GJ, 1996, CEREBROVASC DIS, V6, P26, DOI 10.1159/000108068; LAMBERT M, 1995, BMJ-BRIT MED J, V310, P317, DOI 10.1136/bmj.310.6975.317; *OFF POP CENS SURV, 1991, TAB LIST CLASS SURG; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; Sanderson CFB, 1997, MED CARE, V35, P669, DOI 10.1097/00005650-199707000-00002; *SECR STAT HLTH, 1991, CM1523; SMITHIES A, 1997, REV CAROTID ENDARTER; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WADE DT, 1994, HLTH CARE NEEDS ASSE, V1, P111; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P	20	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1998	317	7156					447	451						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703527				2022-12-28	WOS:000075490200020
J	Su, XD; Gastinel, LN; Vaughn, DE; Faye, I; Poon, P; Bjorkman, PJ				Su, XD; Gastinel, LN; Vaughn, DE; Faye, I; Poon, P; Bjorkman, PJ			Crystal structure of hemolin: A horseshoe shape with implications for homophilic adhesion	SCIENCE			English	Article							CELL-ADHESION; IMMUNOGLOBULIN SUPERFAMILY; BINDING-SITES; MOLECULE L1; PROTEINS; RESOLUTION; MEMBER; IMMUNITY; COMPLEX; DOMAINS	Hemolin, an insect immunoglobulin superfamily member, is a Lipopolysaccharide-binding immune protein induced during bacterial infection. The 3.1 angstrom crystal structure reveals a bound phosphate and patches of positive charge, which may represent the Lipopolysaccharide binding site, and a new and unexpected arrangement of four immunoglobulin-like domains forming a horseshoe. Sequence analysis and analytical ultracentrifugation suggest that the domain arrangement is a feature of the L1 family of neural cell adhesion molecules related to hemolin. These results are relevant to interpretation of human L1 mutations in neurological diseases and suggest a domain swapping model for how L1 family proteins mediate homophilic adhesion.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Univ Stockholm, Dept Genet, S-10691 Stockholm, Sweden; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Stockholm University; University of California System; University of California Los Angeles	Bjorkman, PJ (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Abagyan RA, 1997, J MOL BIOL, V273, P355, DOI 10.1006/jmbi.1997.1287; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANDERSSON K, 1987, INSECT BIOCHEM, V17, P133, DOI 10.1016/0020-1790(87)90153-3; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bettencourt R, 1997, EUR J BIOCHEM, V250, P630, DOI 10.1111/j.1432-1033.1997.00630.x; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, IN PRESS ACTA CRYS D; *CCP4, 1994, COLL COMP PROJ; Chen CL, 1997, DEV BIOL, V181, P1, DOI 10.1006/dbio.1996.8437; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COPLEY RR, 1994, J MOL BIOL, V242, P321; Daffre S, 1997, FEBS LETT, V408, P127, DOI 10.1016/S0014-5793(97)00397-9; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Drescher B, 1996, EUR J NEUROSCI, V8, P2467, DOI 10.1111/j.1460-9568.1996.tb01541.x; ERICKSON H, UNPUB; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; FAYE I, 1997, MOL MECH IMMUNE RESP; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; HUBER AH, 1994, THESIS CALTECH PASAD; Hughes AL, 1998, IMMUNOGENETICS, V47, P283, DOI 10.1007/s002510050360; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P238, DOI 10.1016/0167-4781(91)90108-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LADENDORFF NE, 1991, ARCH INSECT BIOCHEM, V18, P285, DOI 10.1002/arch.940180410; LanzMendoza H, 1996, CELL IMMUNOL, V169, P47, DOI 10.1006/cimm.1996.0089; LINDSTROMDINNETZ I, 1995, EUR J BIOCHEM, V230, P920, DOI 10.1111/j.1432-1033.1995.tb20637.x; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUTHERFORD G, UNPUB; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stowell MHB, 1996, J APPL CRYSTALLOGR, V29, P608, DOI 10.1107/S0021889896004712; SU X, UNPUB; SUMMERS MD, 1987, MANUAL METHODS BACUL, P1; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Zhao L, 1996, J INSECT PHYSIOL, V42, P73, DOI 10.1016/0022-1910(95)00084-4	55	142	149	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					991	995		10.1126/science.281.5379.991	http://dx.doi.org/10.1126/science.281.5379.991			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703515				2022-12-28	WOS:000075412700048
J	Wu, MX; Ao, ZH; Prasad, KVS; Wu, RL; Schlossman, SF				Wu, MX; Ao, ZH; Prasad, KVS; Wu, RL; Schlossman, SF			IEX-1L, an apoptosis inhibitor involved in NF-kappa B-mediated cell survival	SCIENCE			English	Article							EARLY-RESPONSE GENE; MICE LACKING; DEATH; EXPRESSION; PROTEIN	Transcription factors of the nuclear factor-kappa B/rel (NF-kappa B) family may be important in cell survival by regulating unidentified, anti-apoptotic genes. One such gene that protects cells from apoptosis induced by pas or tumor necrosis factor type or (TNF), IEX-1L, is described here. Its transcription induced by TNF was decreased in cells with defective NF-kappa B activation, rendering them sensitive to TNF-induced apoptosis, which was abolished by transfection with IEX-1L. In support, overexpression of antisense IEX-1L partially blocked TNF-induced expression of IEX-1L and sensitized normal cells to killing. This study demonstrates a key role of IEX-1L in cellular resistance to TNF-induced apoptosis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Wu, MX (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Tumor Immunol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012069, R01AI012069, P30AI028691] Funding Source: NIH RePORTER; NIAID NIH HHS [P30AI28691, AI12069] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BALDWIN JAS, 1996, ANNU REV IMMUNOL, V4, P649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHARLES CH, 1993, ONCOGENE, V8, P797; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kondratyev AD, 1996, CANCER RES, V56, P1498; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Schafer H, 1996, CANCER RES, V56, P2641; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M.C., UNPUB	17	384	396	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					998	1001		10.1126/science.281.5379.998	http://dx.doi.org/10.1126/science.281.5379.998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703517				2022-12-28	WOS:000075412700050
J	Rubin, G; Garvican, L; Moss, S				Rubin, G; Garvican, L; Moss, S			Routine invitation of women aged 65-69 for breast cancer screening: results of first year of pilot study	BRITISH MEDICAL JOURNAL			English	Article									South East Inst Publ Hlth, Tunbridge Wells TN3 0XT, Kent, England; Royal Sussex Cty Hosp, E Sussex Brighton & Hove Breast Screening Serv, Brighton BN2 5BE, E Sussex, England; Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England	University of Brighton; University of London; Institute of Cancer Research - UK	Garvican, L (corresponding author), South East Inst Publ Hlth, Broomhill House,David Salomons Estate, Tunbridge Wells TN3 0XT, Kent, England.							Chen H H, 1995, J Med Screen, V2, P10; Forrest APM, 1986, BREAST CANC SCREENIN; Garvican L, 1996, J Med Screen, V3, P123; *NHS, 1997, NHS STAT B, V3	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					388	389						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694755				2022-12-28	WOS:000075409600026
J	May, A; Bahra, A; Buchel, C; Frackowiak, RSJ; Goadsby, PJ				May, A; Bahra, A; Buchel, C; Frackowiak, RSJ; Goadsby, PJ			Hypothalamic activation in cluster headache attacks	LANCET			English	Article							POSITRON EMISSION TOMOGRAPHY; ORBITAL PHLEBOGRAPHY; ANGINA-PECTORIS; PAIN; MIGRAINE; FIBERS; BRAIN	Background Cluster headache, one of the most severe pain syndromes in human beings, is usually described as a vascular headache. However, the striking circadian rhythmicity of this strictly half-sided pain syndrome cannot be readily explained by the vascular hypothesis. We aimed to assess changes in regional cerebral blood flow (rCBF) in patients with cluster headache. Methods We used positron emission tomography (PET) to assess the changes in rCBF, as an index of synaptic activity, during nitroglycerin-induced cluster headache attacks in nine patients who had chronic cluster headache. Eight patients who had cluster headache but were not in the bout acted as a control group. Findings In the acute pain slate, activation was seen in the ipsilateral inferior hypothalamic grey matter, the contralateral ventroposterior thalamus, the anterior cingulate cortex, and bilaterally in the insulae. Activation in the hypothalamus was seen solely in the pain state and was not seen in patients who have cluster headache but were out of the bout. Interpretation Our findings establish central nervous system dysfunction in the region of the hypothalamus as the primum movens in the pathophysiology of cluster headache. We suggest that a radical reappraisal of this type of headache is needed and that it should in general terms, be regarded as a neurovascular headache, to give equal weight to the pathological and physiological mechanisms that are at work.	UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; Univ London, Dept Clin Neurol, London, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London	May, A (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.	amay@ion.ucl.ac.uk	Goadsby, Peter J/Z-1970-2019; Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013; Goadsby, Peter J/B-2267-2009	Goadsby, Peter J/0000-0003-3260-5904; Frackowiak, Richard/0000-0002-3151-822X; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOVIM G, 1992, HEADACHE, V32, P408; BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CHAZOT G, 1984, CEPHALALGIA, V4, P213, DOI 10.1046/j.1468-2982.1984.0404213.x; EKBOM K, 1968, ARCH NEUROL-CHICAGO, V19, P487, DOI 10.1001/archneur.1968.00480050057005; EKBOM K, 1970, ACTA NEUROL SCAND, V46, P225, DOI 10.1111/j.1600-0404.1970.tb05618.x; EKEROT CF, 1991, J PHYSIOL-LONDON, V441, P257, DOI 10.1113/jphysiol.1991.sp018750; FANCIULLACCI M, 1995, PAIN, V60, P119, DOI 10.1016/0304-3959(94)00097-X; FRACKOWIAK RSJ, 1994, J ANAT, V184, P211; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GOADSBY PJ, 1987, AM J PHYSIOL, V253, pR270, DOI 10.1152/ajpregu.1987.253.2.R270; GOADSBY PJ, 1994, BRAIN, V117, P427, DOI 10.1093/brain/117.3.427; GOADSBY PJ, 1991, HEADACHE, V31, P365, DOI 10.1111/j.1526-4610.1991.hed3106365.x; GOADSBY PJ, 1997, HEADACHE; GOADSBY PJ, 1988, BASIC MECHANISMS HEA, P413; HANNERZ J, 1987, CEPHALALGIA, V7, P207, DOI 10.1046/j.1468-2982.1987.0703207.x; HARDEBO JE, 1994, HEADACHE, V34, P125, DOI 10.1111/j.1526-4610.1994.hed3403125.x; Hsieh JC, 1996, PAIN, V64, P303, DOI 10.1016/0304-3959(95)00129-8; Hsieh JC, 1996, PAIN, V67, P59, DOI 10.1016/0304-3959(96)03066-7; HSIEH JC, 1995, PAIN, V63, P225, DOI 10.1016/0304-3959(95)00048-W; ISLER H, 1993, CEPHALALGIA, V13, P172, DOI 10.1046/j.1468-2982.1993.1303172.x; KUDROW L, 1987, CEPHALALGIA, V7, P197, DOI 10.1046/j.1468-2982.1987.0703197.x; KUNKLE EC, 1952, T AM NEUROL ASSOC, P240; LEONE M, 1990, CEPHALALGIA, V10, P235, DOI 10.1046/j.1468-2982.1990.1005235.x; May A, 1998, PAIN, V74, P61, DOI 10.1016/S0304-3959(97)00144-9; Mesulam M. M., 1985, INSULA REIL MAN MONK; MINOSHIMA S, 1995, J CEREB BLOOD FLOW M, V15, P859; NELSON RF, 1978, HEADACHE, V18, P265, DOI 10.1111/j.1526-4610.1978.hed1805265.x; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Talairach J., 1988, COPLANAR STEREOTAXIC; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658	32	778	792	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					275	278		10.1016/S0140-6736(98)02470-2	http://dx.doi.org/10.1016/S0140-6736(98)02470-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690407				2022-12-28	WOS:000074974500010
J	Mirakian, R; Locatelli, M; Bottazzo, GF				Mirakian, R; Locatelli, M; Bottazzo, GF			Disclosure of novel autoantigens in human autoimmunity	LANCET			English	Editorial Material							GLUTAMATE-DECARBOXYLASE; ANTIGEN		St Bartholomews & Royal London, Sch Med & Dent, Dept Immunol, London E1 2AD, England	University of London; Queen Mary University London	Mirakian, R (corresponding author), St Bartholomews & Royal London, Sch Med & Dent, Dept Immunol, London E1 2AD, England.							Betterle C, 1997, J CLIN ENDOCR METAB, V82, P939, DOI 10.1210/jc.82.3.939; Betterle C, 1997, J CLIN ENDOCR METAB, V82, P932, DOI 10.1210/jc.82.3.932; Bonifacio E, 1997, ANN MED, V29, P405, DOI 10.3109/07853899708999370; BOTTAZZO GF, 1995, CLIN IMMUNOLOGY PRIN, V2, P1523; CHRISTIE MR, 1994, DIABETES, V43, P1254, DOI 10.2337/diabetes.43.10.1254; CORRAZZA GR, 1997, LANCET, V350, P106; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Kobayashi I, 1998, CLIN EXP IMMUNOL, V111, P527; Maki M, 1997, LANCET, V349, P1755, DOI 10.1016/S0140-6736(96)70237-4; MIRAKIAN R, 1986, BRIT MED J, V293, P1132, DOI 10.1136/bmj.293.6555.1132; MIRAKIAN R, 1980, CLIN EXP IMMUNOL, V41, P33; MIRAKIAN R, 1995, LANCET, V350, P959; Sepe V, 1997, FRONT HORM RES, V22, P68; VELLOSO LA, 1994, DIABETOLOGIA, V37, P61	14	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					255	256		10.1016/S0140-6736(05)60257-7	http://dx.doi.org/10.1016/S0140-6736(05)60257-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690403				2022-12-28	WOS:000074974500006
J	Slaytor, EK; Ward, JE				Slaytor, EK; Ward, JE			How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets	BRITISH MEDICAL JOURNAL			English	Article									Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Newtown, NSW 2042, Australia		Ward, JE (corresponding author), Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Locked Bag 8, Newtown, NSW 2042, Australia.	jward@nah.rpa.cs.nsw.gov.au						BAINES C, 1992, CAN MED J ASS, V142, P2147; CURRY SJ, 1993, PREV MED, V22, P350, DOI 10.1006/pmed.1993.1029; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; McCormick J, 1996, J CLIN EPIDEMIOL, V49, P619, DOI 10.1016/0895-4356(96)00039-X; ROBERTS MM, 1989, BRIT MED J, V299, P1153, DOI 10.1136/bmj.299.6708.1153	5	110	112	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					263	264		10.1136/bmj.317.7153.263	http://dx.doi.org/10.1136/bmj.317.7153.263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677220	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000075081900027
J	Stern, CD; Foley, AC				Stern, CD; Foley, AC			Molecular dissection of Hox gene induction and maintenance in the hindbrain	CELL			English	Review							EXPRESSION		Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Stern, CD (corresponding author), Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA.		Stern, Claudio/AAZ-7381-2021; Stern, Claudio D/C-6265-2008	Stern, Claudio/0000-0002-9907-889X; Stern, Claudio D/0000-0002-9907-889X				Arnone MI, 1997, DEVELOPMENT, V124, P1851; Cox WG, 1995, DEVELOPMENT, V121, P4349; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; Foley AC, 1997, DEVELOPMENT, V124, P2983; Garcia-Bellido A, 1998, Int J Dev Biol, V42, P233; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; ITASAKI N, 1991, DEVELOPMENT, V113, P1133; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; Knezevic V, 1998, DEVELOPMENT, V125, P1791; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; NIEUWKOOP PD, 1954, J EMBRYOL EXP MORPH, V2, P175; Pera EM, 1997, DEVELOPMENT, V124, P4153; Streit A, 1997, DEVELOPMENT, V124, P1191; Waddington CI, 1936, P K AKAD WET-AMSTERD, V39, P887	18	10	10	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					143	145		10.1016/S0092-8674(00)81412-9	http://dx.doi.org/10.1016/S0092-8674(00)81412-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695941	Bronze			2022-12-28	WOS:000075020100001
J	Gregg, EW; Cauley, JA; Seeley, DG; Ensrud, KE; Bauer, DC				Gregg, EW; Cauley, JA; Seeley, DG; Ensrud, KE; Bauer, DC		Study of Osteoporotic Fractures Res Grp	Physical activity and osteoporotic fracture risk in older women	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	BONE-MINERAL DENSITY; HIP FRACTURE; POSTMENOPAUSAL WOMEN; EXERCISE; CALCIUM	Background: Physical activity has been related to enhanced bone mass and improved physical functioning and thus may reduce the risk for osteoporotic fracture. Objective: To determine whether higher levels of physical activity are related to lower incidence of hip, wrist, and vertebral fractures. Design: Prospective cohort study. Setting: Four clinical centers in Baltimore, Maryland; Portland, Oregon; Minneapolis, Minnesota; and the Monongahela Valley, Pennsylvania. Participants: 9704 nonblack women 65 years of age or older. Measurements: Physical activity was assessed by questionnaire at baseline. Hip and wrist fractures were followed for an average of 7.6 years. The incidence of vertebral fracture was determined morphometrically by using radiography at baseline and an average of 3.7 years later. Results: Higher levels of leisure time, sport activity, and household chores and fewer hours of sitting daily were associated with a significantly reduced relative risk for hip fracture after adjustment for age, dietary factors, falls at baseline, and functional and health status. Very active women (fourth and fifth quintiles) had a statistically significant 36% reduction in hip fractures (relative risk, 0.64 [95% CI, 0.45 to 0.89]) compared with the least active women (lowest quintile). The intensity of physical activity was also related to fracture risk: Moderately to vigorously active women had statistically significant reductions of 42% and 33% in risk for hip and vertebral fractures, respectively, compared with inactive women. Total physical activity, hours of household chores per day, and hours of sitting per day were not significantly associated with wrist or vertebral fractures. Conclusions: Among older community-dwelling women, physical activity is associated with a reduced risk for hip fracture but not wrist or vertebral fracture.	Univ Vermont, Coll Med, Burlington, VT USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Minnesota, Vet Affairs Med Ctr, Minneapolis, MN USA	University of Vermont; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Gregg, EW (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Highway NE,Mailstop K-10, Atlanta, GA 30341 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036; Gregg, Edward/0000-0003-2381-6822	NIADDK NIH HHS [1-R01-AM35584] Funding Source: Medline; NIAMS NIH HHS [1-R01-AR35582, 1-R01-AR35583] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035583, R01AR035582] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baudoin C, 1996, BONE, V18, pS149, DOI 10.1016/8756-3282(95)00496-3; BLACK DM, 1995, J BONE MINER RES, V10, P890; BLACK DM, 1992, J BONE MINER RES, V7, P639; CAULEY JA, 1987, AM J CLIN NUTR, V45, P14, DOI 10.1093/ajcn/45.1.14; CHILIBECK PD, 1995, SPORTS MED, V19, P103, DOI 10.2165/00007256-199519020-00003; CHRISTIANSEN C, 1991, AM J MED, V90, P107; COUPLAND C, 1993, J EPIDEMIOL COMMUN H, V47, P441, DOI 10.1136/jech.47.6.441; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; ENSRUD KE, 1994, J AM GERIATR SOC, V42, P481, DOI 10.1111/j.1532-5415.1994.tb04968.x; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; Grisso JA, 1997, AM J EPIDEMIOL, V145, P786, DOI 10.1093/oxfordjournals.aje.a009171; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107, DOI 10.1093/oxfordjournals.aje.a116833; JOHNELL O, 1995, J BONE MINER RES, V10, P1802, DOI 10.1002/jbmr.5650101125; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LOOKER AC, 1995, J BONE MINER RES, V10, P796; MELTON LJ, 1995, J BONE MINER RES, V10, P175; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; NEVITT MC, 1992, FALLS BALANCE GAIT D; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Paganini-Hill A, 1991, Epidemiology, V2, P16; Pereira M A, 1997, Med Sci Sports Exerc, V29, pS1; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Smith EL, 1996, BONE, V18, pS45, DOI 10.1016/8756-3282(95)00379-7; Snow-Harter C, 1991, Exerc Sport Sci Rev, V19, P351; SOROCK GS, 1988, J GERONTOL, V43, pM134, DOI 10.1093/geronj/43.5.M134; Stevens JA, 1997, ANN EPIDEMIOL, V7, P54, DOI 10.1016/S1047-2797(96)00110-X; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889	33	246	251	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					81	88		10.7326/0003-4819-129-2-199807150-00002	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669990				2022-12-28	WOS:000074852000001
J	Pritchard, KI				Pritchard, KI			Is tamoxifen effective in prevention of breast cancer?	LANCET			English	Editorial Material									Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Pritchard, KI (corresponding author), Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada.		Pritchard, Kathleen I/I-2184-2014	Pritchard, Kathleen I/0000-0003-0758-9666				Clarke M, 1998, LANCET, V351, P1451; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; Goel V, 1998, CAN MED ASSOC J, V158, P1615; MAGOLESE RG, 1998, CMAJ, V158, P1613	4	81	81	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					80	81		10.1016/S0140-6736(98)85002-2	http://dx.doi.org/10.1016/S0140-6736(98)85002-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672266				2022-12-28	WOS:000074775100002
J	Levine, D; Grossberg, R; Tilton, R; Banks, P; Rosenfeld, A				Levine, D; Grossberg, R; Tilton, R; Banks, P; Rosenfeld, A			Are current regulations for approval of in vitro diagnostic devices adequate?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TESTS		New England Pediat LLP, Stamford, CT 06902 USA; Carolinas Med Ctr, New Britain, CT USA		Levine, D (corresponding author), New England Pediat LLP, 166 W Broad St,Suite 103, Stamford, CT 06902 USA.	ARosen45@aol.com						ALPERT S, 1998, SUBM 510K CHANG EX D; *AM AC PED, 1997, 1997 REED BOOK REP C, V199, P329; BANKS PM, 1993, HUM PATHOL, V24, P1153, DOI 10.1016/0046-8177(93)90208-X; BONE RC, 1995, CRIT CARE MED, V23, P1756; BURLINGTON DB, 1997, FDA PUBLIC HLTH ADVI; BURLINGTON DB, 1997, FDA SAFETY ALERT RIS; DOSHI ML, 1986, AM J PUBLIC HEALTH, V76, P512, DOI 10.2105/AJPH.76.5.512; Genel M, 1997, PEDIATRICS, V99, P597, DOI 10.1542/peds.99.4.597; LEVINE D, 1994, PEDIATRICS, V94, P892; Levine D, 1997, PEDIATRICS, V100, P267, DOI 10.1542/peds.100.2.267; RHEINSTEIN PH, 1993, AM FAM PHYSICIAN, V48, P636; SAVAGE RA, 1994, HUM PATHOL, V25, P548, DOI 10.1016/0046-8177(94)90131-7; *US DEP HHS, 1992, REV CRIT IN VITR DIA, P1; WAGNER L, 1997, ARCH PATHOL LAB MED, V121, P539; Wilson M, 1997, J CLIN MICROBIOL, V35, P3112, DOI 10.1128/JCM.35.12.3112-3115.1997; 1997, NY TIEMS        0724, pA20	16	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					187	189		10.1001/jama.280.2.187	http://dx.doi.org/10.1001/jama.280.2.187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669797				2022-12-28	WOS:000074608400038
J	Nightingale, SL				Nightingale, SL			New combination therapy approved for hepatitis C relapse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					410	410		10.1001/jama.280.5.410-b	http://dx.doi.org/10.1001/jama.280.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701062				2022-12-28	WOS:000075050200008
J	Rasekh, Z; Bauer, HM; Manos, MM; Iacopino, V				Rasekh, Z; Bauer, HM; Manos, MM; Iacopino, V			Women's health and human rights in Afghanistan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SOUTHEAST-ASIAN REFUGEES; DEPRESSION; TRAUMA	Context. - During the past 20 years, social and political upheavals have disrupted the way of life in Afghanistan. The Taliban regime, a radical Islamic movement that took control of Kabul in September 1996, has had extraordinary health consequences for Afghan women. Objective. - To assess the health and human rights concerns and conditions of women living in Kabul under the Taliban regime. Setting. - Residences in Kabul; refugee camps and residences in Pakistan. Design. - A cross-sectional survey of women who lived in Kabul, prior to September 1996, when the Taliban took control. Participants. - A total of 160 women participated, including 80 women currently living in Kabul and 80 Afghan women who had recently migrated to Pakistan. Main Outcome Measures. - Self-reported changes in physical and mental health, access to health care, war-related trauma, human rights abuses, and attitudes toward women's human rights. Results. - The median age of respondents was 32 years (range, 17-70 years); median formal education was 12 years, and 136 (85%) of respondents had lived in Kabul for at least 19 years. Sixty-two percent (99/180) reported that they were employed before the Taliban takeover; only 32 (20%) were employed during their last year in Kabul, The majority of all women reported a decline in physical and mental health status (71% [113/160] and 81% [129/160], respectively) and reported a decline in access to health care (62% [99/160]) during the last 2 years living in Kabul. Many of the women reported symptoms that met diagnostic criteria for posttraumatic stress disorder (42% [67/160]), demonstrated evidence of major depression (97% [155/160]), and had significant anxiety symptoms (86% [137/160]). Eighty-four percent (134/160) of women reported 1 family member or more killed in war. Sixty-nine percent (111/160) reported that they or a family member had been detained and abused by Taliban militia, and 68% (108/160) reported extremely restricted social activities. Almost all (96%) expressed support for women's human rights. Conclusions. - The current health and human rights status of women described in this report suggests that the combined effects of war-related trauma and human rights abuses by Taliban officials have had a profound effect on Afghan women's health. Moreover, support for women's human rights by Afghan women suggests that Taliban policies regarding women are incommensurate with the interests, needs, and health of Afghan women.	Physicians Human Rights, Boston, MA 02116 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Alameda Cty Med Ctr, Dept Internal Med, Oakland, CA USA	University of California System; University of California San Francisco	Iacopino, V (corresponding author), Physicians Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.	phrusa@phrusa.org	Eslami, Zohreh/AAL-3152-2020	Eslami, Zohreh/0000-0003-2969-5056				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1997, HUM DEV REP 1997; *AUSTR BROADC CORP, 1997, UNPUB TAL REP REV HO; BLOCK M, 1997, NATION          1124, P5; CARLSON EB, 1991, AM J PSYCHIAT, V148, P1548; CB World Health Organization (WHO) & UNICEF, 1978, DECL ALM ALT; *CONV EL ALL FORMS, 1994, 25 HUM RIGHTS DOC, P48; *CONV TORT OTH CRU, 1994, 25 HUM RIGHTS DOC, P71; CROSSETTE B, 1998, NY TIMES        1106, pA1; ERLANGER S, 1997, NY TIMES        0422, pA1; HINTON WL, 1994, J GEN INTERN MED, V9, P202, DOI 10.1007/BF02600124; IACOPINO V, 1995, MED HLTH CARE 21 CEN, P376; *INT COV CIV POL R, 1994, 25 HUM RIGHTS DOC, P17; *INT COV EC SOC CU, 1994, 25 HUM RIGHTS DOC, P10; KINZIE JD, 1990, AM J PSYCHIAT, V147, P913; Mann Jonathan M, 1994, Health Hum Rights, V1, P6; *MED, 1998, HOSP SURV 1997 KAB A; *MED SANS FRONT, 1998, ACT REP KART SHE; MGHIR R, 1995, J NERV MENT DIS, V183, P24, DOI 10.1097/00005053-199501000-00005; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P497; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P1567; Patton M., 2015, QUALITATIVE RES EVAL, V4th; *SECR GEN SIT AFGH, 1997, S1997897 UN COMM HUM; SPSS, 1997, SPSS BAS 7 5 WIND SP; *UN, **NON-TRADITIONAL**; *UN CHILDR FUND, 1997, AFGH 1997 MULT IND B, P2; *UN CHILDR FUND, 1997, STAT WORLDS CHILDR R; *UN COMM HUM RIGHT, 1996, ECN4199664 UN COMM H; *UN COMM HUM RIGHT, 1997, ECN4199759 UN COMM H; *UN DEP HUM AFF, 1997, REP DHA MISS AFGH, P1; United Nations High Commission for Refugees, 1997, REFUGEES, V108, P3; *US COMM REF, 1997, WORLD REF SURV 1997, P124; WESTERMEYER J, 1983, J OPER PSYCHIATR, V14, P36; *WHO, 1996, HOP; 1994, 25 HUMAN RIGHTS DOCU, P6; 1997, NY TIMES        1105, pA26; [No title captured]	37	57	57	3	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					449	455		10.1001/jama.280.5.449	http://dx.doi.org/10.1001/jama.280.5.449			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105AR	9701081				2022-12-28	WOS:000075050200033
J	Tarrier, N; Yusupoff, L; Kinney, C; McCarthy, E; Gledhill, A; Haddock, G; Morris, J				Tarrier, N; Yusupoff, L; Kinney, C; McCarthy, E; Gledhill, A; Haddock, G; Morris, J			Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia	BRITISH MEDICAL JOURNAL			English	Article							PSYCHOTIC SYMPTOMS	Objectives: To investigate whether intensive cognitive behaviour therapy results in significant improvement in positive psychotic symptoms in patients with chronic schizophrenia. Design: Patients with chronic schizophrenia were randomly allocated, stratified according to severity of symptoms and sex, to intensive cognitive behaviour therapy and routine care, supportive counselling and routine care, and routine care alone. Setting: Adjunct treatments were carried out in outpatient clinics or in the patient's home. Subjects: 87 patients with persistent positive symptoms who complied with medication; 72 completed treatment. Outcome measures: Assessments of positive psychotic symptoms before treatment and 3 months after treatment. Number of patients who showed a 50% or more improvement in symptoms. Exacerbation of symptoms and rates of readmission to hospital. Results: Significant improvements were found in the severity (F = 5.42, df = 2,86; P = 0.006) and number (F = 4.99, df = 2,86; P = 0.009) of positive symptoms in those treated with cognitive behaviour therapy. The supportive counselling group showed a non-significant improvement Significantly more patients treated with cognitive behaviour therapy showed an improvement of 50% or more in their symptoms (chi(2) = 5.18, df = 1; P = 0.02). Logistic regression indicated that receipt of cognitive behaviour therapy results in almost eight times greater odds (odds ratio 7.88) of showing this improvement The group receiving routine care alone also experienced more exacerbations and days spent in hospital. Conclusions: Cognitive behaviour therapy is a potentially useful adjunct treatment in the management of patients with chronic schizophrenia.	Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Dept Clin Psychol, Manchester M20 8LR, Lancs, England; Univ Manchester, Dept Med Stat, Manchester M20 8LR, Lancs, England	University of Manchester; University of Manchester	Tarrier, N (corresponding author), Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Dept Clin Psychol, Manchester M20 8LR, Lancs, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; CURSON DA, 1985, BRIT J PSYCHIAT, V146, P464, DOI 10.1192/bjp.146.5.464; Drury V, 1996, BRIT J PSYCHIAT, V169, P593, DOI 10.1192/bjp.169.5.593; FALLOON I, 1986, PSYCHOSOCIAL TREATME, P180; GARETY PA, 1994, BRIT J MED PSYCHOL, V67, P259, DOI 10.1111/j.2044-8341.1994.tb01795.x; HADDOCK G, 1994, BEHAV CHANGE, V11, P200, DOI 10.1017/S0813483900004472; HADDOCK G, 1996, COGNITIVE BEHAV INTE, P45; HADDOCK G, IN PRESS CLIN PSYCHO; KRAWIECKA M, 1977, ACTA PSYCHIAT SCAND, V55, P299, DOI 10.1111/j.1600-0447.1977.tb00174.x; Kuipers E, 1997, BRIT J PSYCHIAT, V171, P319, DOI 10.1192/bjp.171.4.319; LUKOFF D, 1986, SCHIZOPHRENIA BULL, V12, P578, DOI 10.1093/schbul/12.4.578; TARRIER N, 1993, BRIT J PSYCHIAT, V162, P524, DOI 10.1192/bjp.162.4.524; Tarrier N, 1992, SCHIZOPHRENIA OVERVI; *WHO, 1994, AN THER CHEM ATC CLA; Wing J. K. C., 1974, MEASUREMENT CLASSIFI	15	290	295	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					303	307		10.1136/bmj.317.7154.303	http://dx.doi.org/10.1136/bmj.317.7154.303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	110YQ	9685273	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075409500017
J	Casey, JM; Myers, RA				Casey, JM; Myers, RA			Near extinction of a large, widely distributed fish	SCIENCE			English	Article								Are extinctions of marine vertebrates as rare and unlikely as current data indicate? Long-term research surveys on the continental shelf between the Grand Banks of Newfoundland and southern New England reveal that one of the Largest skates in the northwest Atlantic, the barndoor skate (Raja laevis), is close to extinction. Forty-five years ago. research surveys on St. Pierre Bank (off southern Newfoundland) recorded barndoor skates in 10% of their tows; in the Last 20 years, none has been caught, and this pattern of decline is similar throughout the range of the species.	Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada; Mem Univ Newfoundland, Dept Biol, St Johns, NF A1C 5S7, Canada	Dalhousie University; Memorial University Newfoundland	Myers, RA (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada.							Anderson ED., 1990, ELASMOBRANCHS LIVING, V90, P473; Bigelow HB, 1953, FISHES W N ATLANTI 2; BIGELOW HB, 1953, FISH B, V53, P61; BRANDER K, 1981, NATURE, V290, P48, DOI 10.1038/290048a0; CASEY JM, IN PRESS CAN J FISH; Cochran W.G., 2007, SAMPLING TECHNIQUES; DOUBLEDAY WG, 1981, BOTTOM TRAWL SURVEYS; EDWARDS R. L., 1968, FUTURE FISHING IND U, P52; Fogarty MJ, 1998, ECOL APPL, V8, pS6, DOI 10.2307/2641359; Holden M.J., 1974, P117; HOLDEN MJ, 1973, CONSEIL INT EXPLORAT, V164, P360; HUNTSMAN GR, 1994, FISHERIES, V19, P8, DOI 10.1577/1548-8446(1994)019<0008:EMFNRO>2.0.CO;2; Murawski S. A., 1992, Journal of Northwest Atlantic Fishery Science, V14, P79; Myers RA, 1996, MAR ECOL PROG SER, V138, P293, DOI 10.3354/meps138293; Myers RA, 1997, FISH B-NOAA, V95, P762; SHACKELL N, 1995, MARINE PROTECTED ARE, P21; TEMPLEMAN W, 1966, MARINE RESOURCE NEWF; Templeman W., 1978, ICNAF RES B, V13, P31; Walker PA, 1998, ICES J MAR SCI, V55, P392, DOI 10.1006/jmsc.1997.0325	19	255	269	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					690	692		10.1126/science.281.5377.690	http://dx.doi.org/10.1126/science.281.5377.690			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685260				2022-12-28	WOS:000075107900039
J	Li, BS; Liebermann, RC; Weidner, DJ				Li, BS; Liebermann, RC; Weidner, DJ			Elastic moduli of wadsleyite (beta-Mg2SiO4) to 7 gigapascals and 873 Kelvin	SCIENCE			English	Article							X-RAY-DIFFRACTION; UPPER-MANTLE; SOUND VELOCITIES; TRANSITION ZONE; WAVE VELOCITIES; HIGH-P; OLIVINE; FORSTERITE; POLYMORPHS; PRESSURES	Simultaneous sound velocity measurements and x-ray diffraction studies were made on wadsleyite (beta-Mg2SiO4) to 7 gigapascals and 873 kelvin. The calculated adiabatic bulk (K) and shear (G) moduli yield K (at room conditions) = 172(2) gigapascals, dK/dP = 4.2(1), and dK/dT = -0.012(1) gigapascals per kelvin, and G (at room conditions) = 113(1) gigapascals, dG/dP = 1.5(1), and dG/dT = -0.017(1) gigapascals per kelvin, respectively. The data imply that the P and 5 wave velocity contrasts between olivine and wadsleyite require an olivine amount of 38 to 39 percent in the upper mantle to satisfy the observed 410-kilometer discontinuity, but 55 to 60 percent to account for the velocity increase through the transition zone.	SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Mineral Phys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Li, BS (corresponding author), SUNY Stony Brook, Ctr High Pressure Res, Stony Brook, NY 11794 USA.		Li, Baosheng/C-1813-2013					BASS JD, 1984, GEOPHYS RES LETT, V11, P237, DOI 10.1029/GL011i003p00229; BENZ HM, 1993, NATURE, V365, P147, DOI 10.1038/365147a0; BINA CR, 1987, J GEOPHYS RES-SOLID, V92, P4853, DOI 10.1029/JB092iB06p04853; DECKER DL, 1971, J APPL PHYS, V42, P3239, DOI 10.1063/1.1660714; DUFFY T, 1984, J GEOPHYS RES, V94, P1895; DUFFY TS, 1995, NATURE, V378, P170, DOI 10.1038/378170a0; FEI YW, 1992, J GEOPHYS RES-SOL EA, V97, P4489, DOI 10.1029/92JB00076; Flesch LM, 1998, AM MINERAL, V83, P444; GAHERTY JB, 1997, EOS, V78, pF486; GRAND SP, 1984, GEOPHYS J ROY ASTR S, V76, P399, DOI 10.1111/j.1365-246X.1984.tb05053.x; GWANMESIA GD, 1990, SCIENCE, V250, P794, DOI 10.1126/science.250.4982.794; ISAAK DG, 1989, J GEOPHYS RES-SOLID, V94, P5895, DOI 10.1029/JB094iB05p05895; ITA J, 1992, J GEOPHYS RES, V97, P6894; LEFEVRE LV, 1989, J GEOPHYS RES-SOLID, V94, P17749, DOI 10.1029/JB094iB12p17749; Li BS, 1996, GEOPHYS RES LETT, V23, P2259, DOI 10.1029/96GL02084; LIEBERMANN RC, 1997, EOS, V78, pF753; MENG Y, 1993, J GEOPHYS RES-SOL EA, V98, P22199, DOI 10.1029/93JB02383; NIESLER H, 1989, J ACOUST SOC AM, V86, P1573, DOI 10.1121/1.398717; NOLET G, 1994, J GEOPHYS RES-SOL EA, V99, P23753, DOI 10.1029/94JB01892; REVENAUGH J, 1991, J GEOPHYS RES-SOL EA, V96, P19781, DOI 10.1029/91JB01487; Rigden S.M, 1992, HIGH PRESSURE RES AP, P167; RIGDEN SM, 1991, NATURE, V354, P143, DOI 10.1038/354143a0; RIGDEN SM, 1994, PHYS EARTH PLANET IN, V86, P35, DOI 10.1016/0031-9201(94)05060-0; SAWAMOTO H, 1984, SCIENCE, V224, P749, DOI 10.1126/science.224.4650.749; Stixrude L, 1997, J GEOPHYS RES-SOL EA, V102, P14835, DOI 10.1029/97JB00550; WALCK MC, 1984, GEOPHYS J ROY ASTR S, V76, P697, DOI 10.1111/j.1365-246X.1984.tb01918.x; Weidner D.J., 1992, HIGH PRESSURE RES AP, V67, P13; WEIDNER DJ, 1987, HIGH PRESSURE RES MI, P439; ZAUG JM, 1993, SCIENCE, V260, P1487, DOI 10.1126/science.260.5113.1487; Zha CS, 1997, EARTH PLANET SC LETT, V147, pE9, DOI 10.1016/S0012-821X(97)00010-1; Zha CS, 1996, J GEOPHYS RES-SOL EA, V101, P17535, DOI 10.1029/96JB01266	31	105	112	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					675	677		10.1126/science.281.5377.675	http://dx.doi.org/10.1126/science.281.5377.675			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685255				2022-12-28	WOS:000075107900034
J	Wessely, S				Wessely, S			Peer review of grant applications: what do we know?	LANCET			English	Review							NATIONAL-SCIENCE-FOUNDATION; PROPOSALS		Kings Coll, Sch Med, Dept Psychol Med, London SE5 8AF, England; Inst Psychiat, London SE5 8AF, England	University of London; King's College London; University of London; King's College London	Wessely, S (corresponding author), Kings Coll, Sch Med, Dept Psychol Med, London SE5 8AF, England.		Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929				ABRAMS PA, 1991, SOC STUD SCI, V21, P111, DOI 10.1177/030631291021001006; BUNCH DS, 1989, METHOD INFORM MED, V28, P168; CAMPANARIO JM, 1993, SOC STUD SCI, V23, P342, DOI 10.1177/030631293023002005; Carter GM, 1978, R2229NIH RAND; Chubin DE, 1990, PEERLESS SCI PEER RE, P83; CICCHETTI DV, 1991, BEHAV BRAIN SCI, V14, P119, DOI 10.1017/S0140525X00065675; Cole S, 1992, MAKING SCI NATURE SO; DAS NK, 1985, J CLIN IMMUNOL, V5, P220, DOI 10.1007/BF00929456; FONSECA L, 1994, BRAZ J MED BIOL RES, V27, P2709; FUHRER MJ, 1985, ARCH PHYS MED REHAB, V66, P318; GAVAGHAN H, 1994, NATURE, V369, P269, DOI 10.1038/369269a0; Gillespie GW, 1985, SCI TECHNOL, V10, P44; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V272, P114, DOI 10.1001/jama.272.2.114; GREEN JG, 1989, FASEB J, V3, P1987, DOI 10.1096/fasebj.3.8.2721858; GROENEVELD L, 1975, SOC STUD SCI, V5, P343, DOI 10.1177/030631277500500305; HARTMANN I, 1990, SCIENTOMETRICS, V19, P419, DOI 10.1007/BF02020704; Hensler D, 1976, PERCEPTIONS NATL HEA; HODGSON C, 1995, CAN J CARDIOL, V11, P864; Horrobin DF, 1996, LANCET, V348, P1293, DOI 10.1016/S0140-6736(96)08029-4; Hull D. L., 1988, SCI PROCESS; Kahneman D., 1982, JUDGEMENT UNCERTAINT; KALBERER JT, 1979, J NATL CANCER I, V63, P1097; KLAHR D, 1985, AM PSYCHOL, V40, P148, DOI 10.1037/0003-066X.40.2.148; MARSHALL E, 1994, SCIENCE, V265, P20, DOI 10.1126/science.8016650; MCCULLOUGH J, 1989, SCI TECHNOL HUM VAL, V14, P78, DOI 10.1177/016224398901400107; MCCULLOUGH J, 1997, 54 NAT BOARD EMPL ED, P125; MCGARITY TO, 1994, HIGH TECH LJ, V9, P1; NOBLE JH, 1974, SCIENCE, V185, P916, DOI 10.1126/science.185.4155.916; NORMAN KL, 1986, J APPL PSYCHOL, V71, P156, DOI 10.1037/0021-9010.71.1.156; OLSSON CA, 1995, J UROLOGY, V154, P1866, DOI 10.1016/S0022-5347(01)66806-X; PORTER AL, 1985, SCI TECHNOL, V10, P33, DOI DOI 10.1177/016224398501000304; POURIS A, 1988, R&D MANAGE, V18, P333, DOI 10.1111/j.1467-9310.1988.tb00608.x; RUSSELL AS, 1983, J RHEUMATOL, V10, P479; Sobel D., 1995, LONGITUDE; TRAVIS GDL, 1991, SCI TECHNOL HUM VAL, V16, P322, DOI 10.1177/016224399101600303; VANDENBEEMT F, 1997, 54 AUSTR RES COUNC, P153; vanRaan AFJ, 1996, SCIENTOMETRICS, V36, P397, DOI 10.1007/BF02129602; WEINER S, 1977, CLIN RES, V25, P306; Wenneras C, 1997, NATURE, V387, P341, DOI 10.1038/387341a0; WESSELY S, 1998, PEER REV HLTH CARE; WESTHEAD EW, 1975, SCIENCE, V188, P204, DOI 10.1126/science.188.4185.204-a; WOOD F, 1997, PEERE REV PROCESS; YALOW RS, 1982, B SCI TECHNOL SOC, V2, P401; 1994, PEER REV REFORMS NEE; 1997, PEERS PEERS ALLOCATI; 1977, REPORT NAT SCI BOARD	46	94	94	0	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					301	305		10.1016/S0140-6736(97)11129-1	http://dx.doi.org/10.1016/S0140-6736(97)11129-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	103TT	9690424				2022-12-28	WOS:000074974500042
J	Catalano, SM; Shatz, CJ				Catalano, SM; Shatz, CJ			Activity-dependent cortical target selection by thalamic axons	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; VISUAL-CORTEX; RETINOTECTAL PROJECTION; SUBPLATE NEURONS; CONNECTIONS; RAT; TETRODOTOXIN; MORPHOLOGY; NEOCORTEX; CIRCUITS	Connections in the developing nervous system are thought to be formed initially by an activity-independent process of axon pathfinding and target selection and subsequently refined by neural activity. Blockade of sodium action potentials by intracranial infusion of tetrodotoxin in cats during the early period when axons from the Lateral geniculate nucleus (LCN) were in the process of selecting visual cortex as their target altered the pattern and precision of this thalamocortical projection. The majority of LCN neurons, rather than projecting to visual cortex, elaborated a significant projection within the subplate of cortical areas normally bypassed. Those axons that did project to their correct target were topographically disorganized. Thus, neural activity is required for initial targeting decisions made by thalamic axone as they traverse the subplate,	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Catalano, SM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Catalano, Susan/0000-0001-7278-3233	NEI NIH HHS [EY02838, EY06491] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; BOLZ J, 1992, J NEUROSCI, V12, P3054, DOI 10.1523/JNEUROSCI.12-08-03054.1992; Campbell G, 1997, VISUAL NEUROSCI, V14, P779, DOI 10.1017/S0952523800012724; CATALANO SM, UNPUB; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; DALVA MB, 1994, J NEUROSCI, V14, P3588; DECARLOS JA, 1992, J NEUROSCI, V12, P1194; FRIAUF E, 1990, J NEUROSCI, V10, P2601; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; GHOSH A, 1992, J NEUROSCI, V12, P39; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GOODMAN CS, 1993, NEURON S, V10, P77; HERRMANN K, 1995, P NATL ACAD SCI USA, V92, P11244, DOI 10.1073/pnas.92.24.11244; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KONIG N, 1975, ANAT EMBRYOL, V148, P73, DOI 10.1007/BF00315564; KOSTOVIC I, 1980, J NEUROCYTOL, V9, P219, DOI 10.1007/BF01205159; KRISTT DA, 1979, ANAT EMBRYOL, V157, P217, DOI 10.1007/BF00305161; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; OLSON MD, 1994, J NEUROSCI, V14, P208; SCHMIDT JT, 1990, J NEUROBIOL, V21, P900, DOI 10.1002/neu.480210608; SHATZ CJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P472, DOI 10.1001/archopht.1993.01090040064031; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; VALVERDE F, 1989, J COMP NEUROL, V290, P118, DOI 10.1002/cne.902900108	27	194	200	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					559	562		10.1126/science.281.5376.559	http://dx.doi.org/10.1126/science.281.5376.559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677198				2022-12-28	WOS:000075012300040
J	Johnson, PR; Swanson, R; Rakhilina, L; Hochstrasser, M				Johnson, PR; Swanson, R; Rakhilina, L; Hochstrasser, M			Degradation signal masking by heterodimerization of MAT alpha 12 and MATa1 blocks their mutual destruction by the ubiquitin-proteasome pathway	CELL			English	Article							HOMEO DOMAIN; HOMEODOMAIN PROTEINS; IN-VIVO; YEAST; REPRESSOR; ALPHA-2; DNA; MUTAGENESIS; SEQUENCES; CHAINS	Proteolysis by the ubiquitin-proteasome pathway is often regulated, but the mechanisms underlying such regulation remain ill-defined. In Saccharomyces cerevisiae, cell type is controlled by the MAT transcription factors. The alpha 2 repressor is a known ubiquitin pathway substrate in cu haploid cells. We show that a1 is rapidly degraded in a haploids. In a/alpha diploids, alpha 2 and a1 are stabilized by heterodimerization. Association depends on N-terminal coiled-coil interactions between al and alpha 2. Residues in alpha 2 important for these interactions overlap a critical determinant of an alpha 2 degradation signal, which we delimit by extensive mutagenesis. Our data provide a detailed description of a natural ubiquitin-dependent degradation signal and point to a molecular mechanism for regulated turnover in which proteolytic signals are differentially masked in alternative multiprotein complexes.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Hochstrasser, M (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA.			Hochstrasser, Mark/0000-0002-1131-5484	NIGMS NIH HHS [GM07183, GM46904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183, R01GM046904, R37GM046904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HARASHIMA S, 1989, MOL CELL BIOL, V9, P4523, DOI 10.1128/MCB.9.10.4523; HO YC, 1994, EMBO J, V13, P1403; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Kopski KM, 1997, GENETICS, V147, P409; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486	35	136	139	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					217	227		10.1016/S0092-8674(00)81421-X	http://dx.doi.org/10.1016/S0092-8674(00)81421-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695950	Bronze			2022-12-28	WOS:000075020100010
J	Chen, QJ; Fernandez, V; Sundstrom, A; Schlichtherle, M; Datta, S; Hagblom, P; Wahlgren, M				Chen, QJ; Fernandez, V; Sundstrom, A; Schlichtherle, M; Datta, S; Hagblom, P; Wahlgren, M			Developmental selection of var gene expression in Plasmodium falciparum	NATURE			English	Article							HUMAN CEREBRAL MALARIA; INFECTED ERYTHROCYTES; ANTIGENIC VARIATION; PROTEINS; CYTOADHERENCE; PHENOTYPES; ADHERENCE; DIVERSE; FAMILY	The protozoan Plasmodium falciparum causes lethal malaria(1). Adhesion of erythrocytes infected with P. falciparum to vascular endothelium and to uninfected red blood cells (rosetting) maybe involved in the pathogenesis of severe malaria(2-4). The binding is mediated by the antigenically variant erythrocyte-membrane-protein-1 (PfEMP-1)(5-8), which is encoded by members of the P. falciparum var gene famjily(9,10). The control of expression and switching of var genes seems to lack resemblance.to mechanisms operating in variant gene families of other microbial pathogens(11,12). Here we show that multiple, distinct var gene transcripts (about 24 or more) can be detected by reverse transcription and polymerase chain reaction in bulk cultures of the rosetting parasite FCR3S1.2, despite the adhesive homogeneity of the cultures. We also detected several var transcripts in single erythrocytes infected with a ring-stage parasite of FCR3S1.2, and found that different var genes are transcribed simultaneously from several chromosomes in the same cell. In contrast, we detected only one var transcript, FCR3S1.2 var-1, which encodes the rosetting PfEMP-1 protein(13), in individual rosette-adhesive trophozoite-infected cells, and we found only one PfEMP-1 type at the erythrocyte surface by labelling with (125)iodine and immunoprecipitation. We conclude that a single P. falciparum parasite simultaneously transcribes multiple var genes but, through a developmentally regulated process, selects only one PfEMP-1 to reach the surface of the host cell.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Swedish Inst Infect Dis Control, S-17177 Stockholm, Sweden; Changchun Univ Agr & Anim Sci, Changchun 130062, Peoples R China; Astra Res Ctr, Bangalore, Karnataka, India	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Jilin University	Wahlgren, M (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.							Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; Fernandez V, 1998, INFECT IMMUN, V66, P2969, DOI 10.1128/IAI.66.6.2969-2975.1998; GUPTA S, 1994, P NATL ACAD SCI USA, V91, P3715, DOI 10.1073/pnas.91.9.3715; HernandezRivas R, 1997, MOL CELL BIOL, V17, P604, DOI 10.1128/MCB.17.2.604; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; PIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835; VANSCHRAVENDIJK MR, 1991, BLOOD, V78, P226	24	259	265	3	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					392	395		10.1038/28660	http://dx.doi.org/10.1038/28660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690477				2022-12-28	WOS:000074968800057
J	Mauceri, HJ; Hanna, NN; Beckett, MA; Gorski, DH; Staba, MJ; Stellato, KA; Bigelow, K; Heimann, R; Gately, S; Dhanabal, M; Soff, GA; Sukhatme, VP; Kufe, DW; Weichselbaum, RR				Mauceri, HJ; Hanna, NN; Beckett, MA; Gorski, DH; Staba, MJ; Stellato, KA; Bigelow, K; Heimann, R; Gately, S; Dhanabal, M; Soff, GA; Sukhatme, VP; Kufe, DW; Weichselbaum, RR			Combined effects of angiostatin and ionizing radiation in antitumour therapy	NATURE			English	Article							ANGIOGENESIS; CANCER; SUPPRESSION; CARCINOMA; DISEASE; AGENTS	Angiogenesis, the formation of new capillaries from pre-existing vessels, is essential for tumour progression(1-5). Angiostatin, a proteolytic fragment of plasminogen(6) that was first isolated from the serum and urine of tumour-bearing mice(7), inhibits angiogenesis and thereby growth of primary(8) and metastatic(7,9,10) tumours. Radiotherapy is important in the treatment of many human cancers, but is often unsuccessful because of tumour cell radiation resistance(11,12). Here we combine radiation with angiostatin to target tumour vasculature that is genetically stable and therefore less likely to develop resistance(13-15). The results show an antitumour interaction between ionizing radiation and angiostatin for four distinct tumour types, at doses of radiation that are used in radiotherapy. The combination produced no increase in toxicity towards normal tissue. In vitro studies show that radiation and angiostatin have combined cytotoxic effects on endothelial cells, but not tumour cells. In vivo studies show that these agents, in combination, target the tumour vasculature. Our results provide support for combining ionizing radiation with angiostatin to improve tumour eradication without increasing deleterious effects.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Chicago; University of Chicago; University of Chicago; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Weichselbaum, RR (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.	rrw@rover.uchicago.edu	Sukhatme, Vikas/W-2776-2019; Gorski, David/AAE-6399-2022	Gorski, David/0000-0002-9805-6699				Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOULDS G, 1985, INT J CLIN PHARM RES, V2, P79; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HANAHAN D, 1996, J NATL CANCER I, V88, P1091; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kakeji Y, 1997, INVEST NEW DRUG, V15, P39, DOI 10.1023/A:1005718628223; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; Sim BKL, 1997, CANCER RES, V57, P1329; TEICHER BA, 1992, CANCER RES, V52, P6702; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V14, P907, DOI 10.1016/0360-3016(88)90013-2; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684	15	608	639	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					287	291		10.1038/28412	http://dx.doi.org/10.1038/28412			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685160				2022-12-28	WOS:000074851900051
J	Shih, DM; Gu, LJ; Xia, YR; Navab, M; Li, WF; Hama, S; Castellani, LW; Furlong, CE; Costa, LG; Fogelman, AM; Lusis, AJ				Shih, DM; Gu, LJ; Xia, YR; Navab, M; Li, WF; Hama, S; Castellani, LW; Furlong, CE; Costa, LG; Fogelman, AM; Lusis, AJ			Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; POLYMORPHISM	Serum paraoxonase (PON1) is an esterase that is associated with high-density lipoproteins (HDLs) in the plasma; it is involved in the detoxification of organophosphate insecticides such as parathion and chlorpyrifos(1-3). PON1 may also confer protection against coronary artery disease by destroying pro-inflammatory oxidized lipids present in oxidized low-density lipoproteins (LDLs)(4-8). To study the role of PON1 in vivo we created PON1-knockout mice by gene targeting. Compared with their wild-type littermates, PON1-deficient mice were extremely sensitive to the toxic effects of chlorpyrifos oxon, the activated form of chlorpyrifos, and were more sensitive to chlorpyrifos itself. HDLs isolated from PON1-deficient mice were unable to prevent LDL oxidation in a co-cultured cell model of the artery wall, and both HDLs and LDLs isolated from PON1-knockout mice were more susceptible to oxidation by co-cultured cells than the lipoproteins from wild-type littermates. When fed on a high-fat, high-cholesterol diet, PON1-null mice were more susceptible to atherosclerosis than their wild-type littermates.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lusis, AJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, 47-123 CHS, Los Angeles, CA 90095 USA.							COSTA LG, 1990, TOXICOL APPL PHARM, V103, P66, DOI 10.1016/0041-008X(90)90263-T; Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; Heinecke JW, 1998, AM J HUM GENET, V62, P20, DOI 10.1086/301691; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; LI WF, 1993, J TOXICOL ENV HEALTH, V40, P337, DOI 10.1080/15287399309531798; LI WF, 1995, TOXICOL LETT, V76, P219, DOI 10.1016/0378-4274(95)80006-Y; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; MURPHY SD, 1980, TOXICOLOGY BASIC SCI, P357; Navab M, 1997, J CLIN INVEST, V99, P2005, DOI 10.1172/JCI119369; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589; SMOLEN A, 1991, DRUG METAB DISPOS, V19, P107; TAFURI J, 1987, ANN EMERG MED, V16, P193, DOI 10.1016/S0196-0644(87)80015-X; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	17	913	950	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					284	287		10.1038/28406	http://dx.doi.org/10.1038/28406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685159				2022-12-28	WOS:000074851900050
J	Budd, JM; Sievert, ME; Schultz, TR				Budd, JM; Sievert, ME; Schultz, TR			Phenomena of retraction - Reasons for retraction and citations to the publications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-This study examined the impact of retracted articles on biomedical communication. Objective.-To examine publications identified in the biomedical literature as having been retracted, to ascertain why and by whom the publications were retracted and to what extent citations of later-retracted articles continue to be incorporated in subsequent work. Design.-A search of MEDLINE from 1966 through August 1997 for articles that had been retracted. Main Outcome Measures.-Characteristics of retractions and citations to articles after retraction. Results.-A total of 235 articles had been retracted. Error was acknowledged in relation to 91 articles; results could not be replicated in 38; misconduct was evident in 86; and no clear reason was given in 20. Of the 235 articles, 190 were retracted by some or all of the authors; 45 were retracted by a person or organization other than the author(s). The 235 retracted articles were cited 2034 times after the retraction notice. Examination of 299 of those citations reveals that in only 19 instances was the retraction noted; the remaining 280 citations treated the retracted article either explicitly (n = 17) or implicitly (n = 263) as though it were valid research. Conclusion.-Retracted articles continue to be cited as valid work in the biomedical literature after publication of the retraction; these citations signal potential problems for biomedical science.	Univ Missouri, Sch Informat Sci & Learning Technol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Budd, JM (corresponding author), Univ Missouri, Sch Informat Sci & Learning Technol, 217 Townsend Hall, Columbia, MO 65211 USA.	libsjmb@showme.missouri.edu		Budd, John/0000-0002-5000-0303				KOCHAN CA, 1992, J AM SOC INFORM SCI, V43, P488, DOI 10.1002/(SICI)1097-4571(199208)43:7<488::AID-ASI3>3.0.CO;2-7; LaFollette MarcelC., 1992, STEALING PRINT FRAUD, DOI 10.1525/9780520917804; LOCK S, 1993, FRAUD MISCONDUCT MED; STEWART WW, 1987, NATURE, V325, P207, DOI 10.1038/325207a0; WHITELY WP, 1994, JAMA-J AM MED ASSOC, V272, P170, DOI 10.1001/jama.272.2.170	5	137	141	8	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					296	297		10.1001/jama.280.3.296	http://dx.doi.org/10.1001/jama.280.3.296			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZZ204	9676689	Bronze			2022-12-28	WOS:000074706000034
J	Wilcox, LJ				Wilcox, LJ			Authorship - The coin of the realm, the source of complaints	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-Disputes associated with achieving recognition for work done may affect both morale and subsequent resource allocation to medical researchers. Objective.-To assess authorship disputes brought to the Ombuds Office. Setting.-The Ombuds Office, Harvard Medical School, Dental School, School of Public Health, and affiliated hospitals. Main Outcome Measure.-Change in number of queries related to authorship between 1991 to 1992 and 1996 to 1997. Results.-Disputes increased from 8 (2.3%) of 355 issues brought to the office in 1991 to 1992 to 59 (10.7%) of 551 issues in 1996 to 1997. They also increased from involving 0.06% of the total population of faculty, staff, and students affiliated with the schools in 1991 to 1992 to 0.33% of the total population in 1996 to 1997. Such problems appear to occur more often for women (53% of complaints in 1994-1995 through 1996-1997) and for non-US citizens (21% of complaints in 1991-1992 through 1996-1997). Conclusions.-Authorship disputes are increasingly frequent. Institutions should increase enforcement of published authorship standards and place more emphasis on managerial skills for laboratory and research department heads.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard School of Dental Medicine	Wilcox, LJ (corresponding author), Harvard Univ, Sch Publ Hlth, 164 Longwood Ave,Room 304, Boston, MA 02115 USA.	linda_wilcox@hms.harvard.edu						BAILAR JC, 1990, ETHICS POLICY SCI PU; Davidson F, 1997, JAMA-J AM MED ASSOC, V277, P927; JONES AH, 1997, 3 INT C PEER REV BIO; *NAT AC SCI, 1995, BEING SCI; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; RIESENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1857, DOI 10.1001/jama.264.14.1857; 1998, SCIENCE         0623	7	76	81	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					216	217		10.1001/jama.280.3.216	http://dx.doi.org/10.1001/jama.280.3.216			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676658	Bronze			2022-12-28	WOS:000074706000003
J	Vaizey, CJ; Kamm, MA; Gold, DM; Bartram, CI; Halligan, S; Nicholls, RJ				Vaizey, CJ; Kamm, MA; Gold, DM; Bartram, CI; Halligan, S; Nicholls, RJ			Clinical, physiological, and radiological study of a new purpose-designed artificial bowel sphincter	LANCET			English	Article							FECAL INCONTINENCE; ANAL INCONTINENCE	Background Studies of the use of artificial urinary sphincters for faecal incontinence have led to refinement and adaptation of such sphincters to the anatomy of the anal region. We aimed to test this new device. Methods Six women, median age 53 (range 32-58) years, who were unsuitable for sphincter repair, had an artificial bowel sphincter implanted as a one-stage procedure without colostomy cover. Clinical assessment, physiological testing, and endosonography were done before and after the operation. Plain radiography, three-dimensional endosonography, and magnetic-resonance imaging were done after the operation, to define its anatomical location. Results Median follow-up was 10 (range 5-13) months and the device was functional in five patients. In one patient, the device was removed after ulceration through the skin, Of the patients with intact devices, Wexner incontinence scores improved from a median of 19 (18-20) of 20 before the operation, to 3 (0-6) of 20 after the operation, Median anal pressure at rest significantly increased from 60 (range 30-80) cm H2O to 110 (100-120) cm H2O, Functional anal-canal length varied after the operation from 3.3 cm to 3.8 cm. There was no significant change in the maximum tolerated volume of the rectum (140 [80-230] vs 100 [75-250] mt), or rectal compliance (2.9 [2.8-6.0] cm H2O/mL vs 3.5 [2.3-7.3] cm H2O/mL). All the imaging techniques accurately located the implant relative to the anal canal and pelvic floor in each patient. Interpretation The new artificial bowel sphincter provided a good functional result in five of the six patients, the surgical procedure was straightforward, and the maximum resting anal pressure rose without affecting rectal function. The ease of visualisation of such implants in situ should aid simple management of complications, should they arise.	St Marks Hosp, Dept Physiol, London EC1V 2PS, England; St Marks Hosp, Dept Radiol, London EC1V 2PS, England; St Marks Hosp, Dept Surg, London EC1V 2PS, England	Imperial College London; Imperial College London; Imperial College London	Nicholls, RJ (corresponding author), St Marks Hosp, Dept Surg, Northwick Pk,Watford Rd, Harrow HA1 3UJ, Middx, England.		Halligan, Steve/C-5875-2009	Halligan, Steve/0000-0003-0632-5108; Gold, Darren/0000-0003-4478-9747				BAETEN CGMI, 1995, NEW ENGL J MED, V332, P1600, DOI 10.1056/NEJM199506153322403; CHRISTIANSEN J, 1989, DIS COLON RECTUM, V32, P432, DOI 10.1007/BF02563699; CHRISTIANSEN J, 1987, LANCET, V1, P244; Geerdes BP, 1996, DIS COLON RECTUM, V39, P912, DOI 10.1007/BF02053991; JORGE JMN, 1993, SOUTH MED J, V86, P924, DOI 10.1097/00007611-199308000-00016; KAMM MA, 1990, DIS COLON RECTUM, V33, P419, DOI 10.1007/BF02156270; KIFF ES, 1984, BRIT J SURG, V71, P614, DOI 10.1002/bjs.1800710817; Lehur PA, 1996, DIS COLON RECTUM, V39, P1352, DOI 10.1007/BF02054523; LEO ME, 1993, J UROLOGY, V150, P1412, DOI 10.1016/S0022-5347(17)35793-2; MARCIO J, 1993, DIS COLON RECTUM, V36, P77; NEILL ME, 1981, BRIT J SURG, V68, P531, DOI 10.1002/bjs.1800680804; Scott F B, 1973, Urology, V1, P252; Wong WD, 1996, DIS COLON RECTUM, V39, P1345	13	82	85	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					105	109		10.1016/S0140-6736(97)11427-1	http://dx.doi.org/10.1016/S0140-6736(97)11427-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672276				2022-12-28	WOS:000074775100014
J	Smith, JL				Smith, JL			Structural biology - Secret life of cytochrome bc(1)	SCIENCE			English	Editorial Material							COMPLEX		Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Smith, JL (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	smithj@bragg.bio.purdue.edu						Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; KIM HY, IN PRESS P NATL ACAD; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	6	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					58	59		10.1126/science.281.5373.58	http://dx.doi.org/10.1126/science.281.5373.58			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9679019				2022-12-28	WOS:000074685800035
J	Hall, A				Hall, A			Signal transduction - G proteins and small GTPases: Distant relatives keep in touch	SCIENCE			English	Editorial Material									UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem, Canc Res Campaign Oncogene, London WC1E 6BT, England; UCL, Signal Transduct Grp, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Hall, A (corresponding author), UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England.	Alan.Hall@ucl.ac.uk						Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Brock J, 1996, J CELL BIOL, V135, P1097, DOI 10.1083/jcb.135.4.1097; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295	17	170	172	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2074	2075		10.1126/science.280.5372.2074	http://dx.doi.org/10.1126/science.280.5372.2074			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9669963				2022-12-28	WOS:000074435900033
J	Psenner, R; Sattler, B				Psenner, R; Sattler, B			Microbial communities - Life at the freezing point	SCIENCE			English	Editorial Material									Univ Innsbruck, Inst Zool & Limnol, A-6020 Innsbruck, Austria	University of Innsbruck	Psenner, R (corresponding author), Univ Innsbruck, Inst Zool & Limnol, A-6020 Innsbruck, Austria.	roland.psenner@uibk.ac.at						Balter M, 1998, SCIENCE, V280, P31, DOI 10.1126/science.280.5360.31; DeLong E, 1998, SCIENCE, V280, P542, DOI 10.1126/science.280.5363.542; FELIP M, 1995, APPL ENVIRON MICROB, V61, P2394, DOI 10.1128/AEM.61.6.2394-2401.1995; FELIP M, 1996, APPL ENVIRON MICROB, V62, P2138; MARGESIN R, 1998, IN PRESS COLD ADAPTE; POMEROY LR, 1986, SCIENCE, V233, P359, DOI 10.1126/science.233.4761.359; Priscu JC, 1998, SCIENCE, V280, P2095, DOI 10.1126/science.280.5372.2095; SATTLER B, UNPUB	8	47	50	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2073	2074		10.1126/science.280.5372.2073	http://dx.doi.org/10.1126/science.280.5372.2073			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9669962				2022-12-28	WOS:000074435900032
J	Metcalfe, D				Metcalfe, D			Doctors and patients should be fellow travellers	BRITISH MEDICAL JOURNAL			English	Article									Westgate Barn, Milburn CA10 1TW, Cumbria, England; Univ Manchester, Manchester M13 9PL, Lancs, England	University of Manchester	Metcalfe, D (corresponding author), Westgate Barn, Milburn CA10 1TW, Cumbria, England.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1892	1893						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9669847				2022-12-28	WOS:000074686500034
J	Epstein, E				Epstein, E			How calcium enhances plant salt tolerance	SCIENCE			English	Article									Univ Calif Davis, Dept Land Air & Water Resources Soils & Biogeoche, Davis, CA 95616 USA	University of California System; University of California Davis	Epstein, E (corresponding author), Univ Calif Davis, Dept Land Air & Water Resources Soils & Biogeoche, Davis, CA 95616 USA.	eqepstein@ucdavis.edu						Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EPSTEIN E, 1961, PLANT PHYSIOL, V36, P437, DOI 10.1104/pp.36.4.437; EPSTEIN E, 1973, INT REV CYTOL, V34, P123, DOI 10.1016/S0074-7696(08)61936-1; Fu HH, 1998, PLANT CELL, V10, P63, DOI 10.1105/tpc.10.1.63; HASEGAWA PM, UNPUB; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; Hoth S, 1997, J EXP BOT, V48, P415, DOI 10.1093/jxb/48.Special_Issue.415; Kim EJ, 1998, PLANT CELL, V10, P51, DOI 10.1105/tpc.10.1.51; KOCHIAN LV, 1993, DEV PLANT SOIL SCI, V45, P121; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; Santa-Maria GE, 1997, PLANT CELL, V9, P2281, DOI 10.1105/tpc.9.12.2281; Smart CJ, 1996, PLANT SOIL, V187, P81, DOI 10.1007/BF00011659; Wegner LH, 1997, PLANTA, V203, P506, DOI 10.1007/s004250050220; Winicov I, 1997, ACTA PHYSIOL PLANT, V19, P435, DOI 10.1007/s11738-997-0040-7; Zimmermann S, 1998, PLANT PHYSIOL, V116, P879, DOI 10.1104/pp.116.3.879	17	105	123	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1906	1907		10.1126/science.280.5371.1906	http://dx.doi.org/10.1126/science.280.5371.1906			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669949				2022-12-28	WOS:000074323800054
J	Hein, K				Hein, K			Aligning science with politics and policy in HIV prevention	SCIENCE			English	Article									Natl Acad Sci, Inst Med, Washington, DC 20418 USA	National Academies of Sciences, Engineering & Medicine	Hein, K (corresponding author), Natl Acad Sci, Inst Med, Washington, DC 20418 USA.	khein@nas.edu						Celentano DD, 1998, SCIENCE, V280, P1889, DOI 10.1126/science.280.5371.1889; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P309; *HIH CONS STAT, 1997, INT PREV HIV RISK BE, V14; Kahn JG, 1997, AIDS PUBLIC POLICY J, V12, P21; Phoolcharoen W, 1998, SCIENCE, V280, P1873, DOI 10.1126/science.280.5371.1873	5	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1905	1906		10.1126/science.280.5371.1905	http://dx.doi.org/10.1126/science.280.5371.1905			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZV618	9669948				2022-12-28	WOS:000074323800053
J	Ohno, H				Ohno, H			Making nonmagnetic semiconductors ferromagnetic	SCIENCE			English	Review							III-V SEMICONDUCTORS; GAAS	Semiconductor devices generally take advantage of the charge of electrons, whereas magnetic materials are used for recording information involving electron spin. To make use of both charge and spin of electrons in semiconductors, a high concentration of magnetic elements can be introduced in nonmagnetic III-V semiconductors currently in use for devices. Low solubility of magnetic elements was overcome by Low-temperature nonequilibrium molecular beam epitaxial growth, and ferromagnetic (Ca,Mn)As was realized. Magnetotransport measurements revealed that the magnetic transition temperature can be as high as 110 kelvin. The origin of the ferromagnetic interaction is discussed. Multilayer heterostructures including resonant tunneling diodes (RTDs) have also successfully been fabricated. The magnetic coupling between two ferromagnetic (Ga,Mn)As films separated by a nonmagnetic layer indicated the critical role of the holes in the magnetic coupling. The magnetic coupling in all semiconductor ferromagnetic/nonmagnetic Layered structures, together with the possibility of spin filtering in RTDs, shows the potential of the present material system for exploring new physics and for developing new functionality toward future electronics.	Tohoku Univ, Elect Commun Res Inst, Lab Elect Intelligent Syst, Sendai, Miyagi 9808577, Japan	Tohoku University	Ohno, H (corresponding author), Tohoku Univ, Elect Commun Res Inst, Lab Elect Intelligent Syst, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.	ohno@riec.tohoku.ac.jp	Ma, Jun/D-8971-2011; Ohno, Hideo/E-6453-2010	Ohno, Hideo/0000-0001-9688-8259				AKIBA N, UNPUB; ALVARADO SF, 1995, PHYS REV LETT, V75, P513, DOI 10.1103/PhysRevLett.75.513; DIETL T, 1994, DILUTED MAGNETIC S B, V3; DIVINCENZO DP, 1995, SCIENCE, V270, P255, DOI 10.1126/science.270.5234.255; Furdyna J. K., 1988, DILUTED MAGNETIC SEM, V25; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Haury A, 1997, PHYS REV LETT, V79, P511, DOI 10.1103/PhysRevLett.79.511; HEINRICH B, 1994, ULTRATHIN MAGNETIC S, V2, pCH2; KASUYA T, 1956, PROG THEOR PHYS, V16, P45, DOI 10.1143/PTP.16.45; Kikkawa JM, 1998, PHYS REV LETT, V80, P4313, DOI 10.1103/PhysRevLett.80.4313; Koshihara S, 1997, PHYS REV LETT, V78, P4617, DOI 10.1103/PhysRevLett.78.4617; Matsukura F, 1998, PHYS REV B, V57, pR2037, DOI 10.1103/PhysRevB.57.R2037; Matsukura F, 1997, APPL SURF SCI, V113, P178, DOI 10.1016/S0169-4332(96)00790-8; Monsma DJ, 1998, SCIENCE, V281, P407, DOI 10.1126/science.281.5375.407; MUNEKATA H, 1989, PHYS REV LETT, V63, P1849, DOI 10.1103/PhysRevLett.63.1849; MUNEKATA H, 1993, APPL PHYS LETT, V63, P2929, DOI 10.1063/1.110276; Ohno H, 1996, APPL PHYS LETT, V69, P363, DOI 10.1063/1.118061; Ohno H, 1998, APPL PHYS LETT, V73, P363, DOI 10.1063/1.121835; OHNO H, 1992, PHYS REV LETT, V68, P2664, DOI 10.1103/PhysRevLett.68.2664; OHNO H, 1996, P 23 INT C PHYS SEM, P405; Oiwa A, 1997, SOLID STATE COMMUN, V103, P209, DOI 10.1016/S0038-1098(97)00178-6; OKABAYASHI J, IN PRESS PHYS REV B; SATOH Y, 1997, 3 S PHYS APPL SPIN R, P23; Shen A, 1997, APPL PHYS LETT, V71, P1540, DOI 10.1063/1.119973; Shen A, 1997, J CRYST GROWTH, V175, P1069, DOI 10.1016/S0022-0248(96)00967-0; Shen AD, 1997, JPN J APPL PHYS 2, V36, pL73, DOI 10.1143/JJAP.36.L73; Shioda R, 1998, PHYS REV B, V58, P1100, DOI 10.1103/PhysRevB.58.1100; Shirai M, 1998, J MAGN MAGN MATER, V177, P1383, DOI 10.1016/S0304-8853(97)00350-8; STORY T, 1986, PHYS REV LETT, V56, P777, DOI 10.1103/PhysRevLett.56.777; Szczytko J, 1996, SOLID STATE COMMUN, V99, P927, DOI 10.1016/0038-1098(96)00315-8; VanEsch A, 1997, PHYS REV B, V56, P13103, DOI 10.1103/PhysRevB.56.13103; VONMOLNAR S, 1991, J MAGN MAGN MATER, V93, P356, DOI 10.1016/0304-8853(91)90361-D; VONMOLNAR S, 1968, PHYS REV LETT, V21, P1757, DOI 10.1103/PhysRevLett.21.1757	34	4490	4618	24	732	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1998	281	5379					951	956		10.1126/science.281.5379.951	http://dx.doi.org/10.1126/science.281.5379.951			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703503				2022-12-28	WOS:000075412700036
J	Masters, EJ				Masters, EJ			Loxoscelism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Reg Primary Care, Cape Girardeau, MO 63703 USA		Masters, EJ (corresponding author), Reg Primary Care, Cape Girardeau, MO 63703 USA.								0	10	11	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1998	339	6					379	379		10.1056/NEJM199808063390605	http://dx.doi.org/10.1056/NEJM199808063390605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107MD	9691105				2022-12-28	WOS:000075212300005
J	Spiller, DA; Losos, JB; Schoener, TW				Spiller, DA; Losos, JB; Schoener, TW			Impact of a catastrophic hurricane on island populations	SCIENCE			English	Article							EXTINCTION; DIVERSITY; PREDATORS; LIZARDS; SIZE	Lizard and spider populations were censused immediately before and after Hurricane Lili on islands differentially affected by the storm surge. The results support three general propositions. First, the larger organisms, Lizards, are more resistant to the immediate impact of moderate disturbance, whereas the more prolific spiders recover faster. Second, extinction risk is related to population size when disturbance is moderate but not when it is catastrophic. Third, after catastrophic disturbance, the recovery rate among different types of organisms is related to dispersal ability. The absence of the poorer dispersers. Lizards, from many suitable islands is probably the result of long-lasting effects of catastrophes.	Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA	University of California System; University of California Davis; University of California System; University of California Davis; Washington University (WUSTL)	Spiller, DA (corresponding author), Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA.							Carew J.L, 1995, TERRESTRIAL SHALLOW, P5; Conneil J.H., 1975, P460; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; CONNELL JH, 1997, ECOL MONOGR, V67, P489; FEINBERG SE, 1972, BIOMETRIKA, V59, P591; HECKEL DG, 1979, ECOLOGY, V60, P966, DOI 10.2307/1936865; Holt Robert D., 1993, P77; Lawrence MB., 1996, PRELIMINARY REPORT H; LEVI H, COMMUNICATION; LEVI HW, 1995, B MUS COMP ZOOL HARV, V154, P81; LOSOS JB, IN PRESS ECOLOGY; MAC ARTHUR ROBERT H., 1967; Pimm S.L., 1991, BALANCE NATURE; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; REAGAN DP, 1991, BIOTROPICA, V23, P468, DOI 10.2307/2388268; REY JR, 1981, ECOL MONOGR, V51, P237, DOI 10.2307/2937265; Schoener T.W., 1986, COMMUNITY ECOLOGY, P556; SCHOENER TW, 1992, AM NAT, V139, P1176, DOI 10.1086/285381; SCHOENER TW, 1983, NATURE, V302, P332, DOI 10.1038/302332a0; Schoener TW, 1996, NATURE, V381, P691, DOI 10.1038/381691a0; SCHOENER TW, 1987, NATURE, V330, P474, DOI 10.1038/330474a0; SCHOENER TW, 1983, SCIENCE, V219, P1353, DOI 10.1126/science.219.4590.1353; SIMBERLOFF DS, 1969, ECOLOGY, V50, P278, DOI 10.2307/1934856; THORNTON I, 1996, KRAKATOA; WHITTAKER RJ, 1995, TRENDS ECOL EVOL, V10, P421, DOI 10.1016/S0169-5347(00)89164-8; WUNDERLE JM, 1992, AUK, V109, P148, DOI 10.2307/4088275	26	131	141	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					695	697		10.1126/science.281.5377.695	http://dx.doi.org/10.1126/science.281.5377.695			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685262				2022-12-28	WOS:000075107900041
J	Kokori, H; Giannakopoulou, C; Paspalaki, P; Tsatsakis, A; Sbyrakis, S				Kokori, H; Giannakopoulou, C; Paspalaki, P; Tsatsakis, A; Sbyrakis, S			An anaemic infant in a coma	LANCET			English	Article									Univ Crete, Dept Gen Paediat, Heraklion 71110, Greece	University of Crete	Giannakopoulou, C (corresponding author), Univ Crete, Dept Gen Paediat, POB 1352, Heraklion 71110, Greece.		Tsatsakis, Aristidis M./H-2890-2013	Tsatsakis, Aristidis M./0000-0003-3824-2462				Abadin HG, 1997, TOXICOL IND HEALTH, V13, P495, DOI 10.1177/074823379701300403; COFFIN R, 1966, PEDIATRICS, V69, P198; GRAEF JW, 1992, PEDIATRICS, V90, P131; MARAVELIAS C, 1994, SCI TOTAL ENVIRON, V158, P79, DOI 10.1016/0048-9697(94)04221-8; Tellier L, 1994, Wis Med J, V93, P257	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					284	284		10.1016/S0140-6736(98)03214-0	http://dx.doi.org/10.1016/S0140-6736(98)03214-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690409				2022-12-28	WOS:000074974500012
J	Birck, C; Poch, O; Romier, C; Ruff, M; Mengus, G; Lavigne, AC; Davidson, I; Moras, D				Birck, C; Poch, O; Romier, C; Ruff, M; Mengus, G; Lavigne, AC; Davidson, I; Moras, D			Human TAF(II)28 and TAF(II)18 interact through a histone fold encoded by atypical evolutionary conserved motifs also found in the SPT3 family	CELL			English	Article							RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; TFIID COMPLEX; MULTIPLE INTERACTIONS; BINDING PROTEIN; TBP; ACTIVATION; SUBUNITS	Determination of the crystal structure of the human Tap-associated factor (hTAF(II))28/hTAF(II)18 heterodimer shows that these TAF(II)s form a novel histone-like pair in the TFIID complex. The histone folds in hTAF(II)28 and hTAF(II)18 were not predicted from their primary sequence, indicating that these TAF(II)s define a novel family of atypical histone fold sequences. The TAF(II)18 and TAF(II)28 histone fold moths are also present in the N- and C-terminal regions of the SPT3 proteins, suggesting that the histone fold in SPT3 may be reconstituted by intramolecular rather than classical intermolecular interactions. The;existence of additional histone-like pairs in both the TFIID and SAGA complexes shows that the histone fold is a more commonly used motif for mediating TAF-TAF interactions than previously believed.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163,CU Strasbourg, F-67404 Illkirch, France.		ruff, marc/J-3011-2013; Lavigne, Anne-Claire/O-8805-2015	ruff, marc/0000-0001-5451-6377; Romier, Christophe/0000-0002-3680-935X; Davidson, Irwin/0000-0001-5533-1171; MENGUS, Gabrielle/0000-0002-2844-1778				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; BRUNGER AT, 1992, XPLOR VERSION 3 1; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Burley SK, 1997, CURR OPIN STRUC BIOL, V7, P94, DOI 10.1016/S0959-440X(97)80012-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Collart MA, 1996, MOL CELL BIOL, V16, P6668; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gribskov M, 1996, METHOD ENZYMOL, V266, P198; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klebanow ER, 1997, J BIOL CHEM, V272, P9436; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Roberts SM, 1997, GENETICS, V147, P451; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SLESAREV AI, 1998, NUCLEIC ACIDS RES, V26, P247; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	53	118	130	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					239	249		10.1016/S0092-8674(00)81423-3	http://dx.doi.org/10.1016/S0092-8674(00)81423-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695952	Bronze			2022-12-28	WOS:000075020100012
J	Kersh, EN; Shaw, AS; Allen, PM				Kersh, EN; Shaw, AS; Allen, PM			Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation	SCIENCE			English	Article							PROTEIN-TYROSINE KINASES; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; MICE LACKING; TCR-ZETA; MURINE THYMOCYTES; CYTOPLASMIC TAIL; PARTIAL AGONISTS; MHC COMPLEXES; CHAIN	The T cell receptor (TCR) alpha beta heterodimer interacts with its ligands with high specificity, but surprisingly Low affinity. The role of the zeta component of the murine TCR in contributing to the Fidelity of antigen recognition was examined. With sequence-specific phosphotyrosine antibodies, it was found that zeta undergoes a series of ordered phosphorylation events upon TCR engagement. Completion of phosphorylation steps is dependent on the nature of the TCR ligand. Thus, the phosphorylation steps establish thresholds for T cell activation. This study documents the sophisticated molecular events that follow the engagement of a low-affinity receptor.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Allen, PM (corresponding author), Washington Univ, Sch Med, Ctr Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	allen@immunology.wustl.edu						Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Combadiere B, 1996, J EXP MED, V183, P2109, DOI 10.1084/jem.183.5.2109; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GERMAIN RN, 1995, IMMUNOLOGIST, V3, P113; GRAKOUI A, UNPUB; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; KERSH EN, UNPUB; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LaFace DM, 1997, J IMMUNOL, V158, P2057; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Lin SY, 1997, J EXP MED, V185, P707, DOI 10.1084/jem.185.4.707; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SHINKAI Y, 1995, IMMUNITY, V2, P401; Shores EW, 1997, J EXP MED, V185, P893, DOI 10.1084/jem.185.5.893; SHORES EW, 1994, SCIENCE, V266, P1047, DOI 10.1126/science.7526464; SHORES EW, 1963, CURR OPIN IMMUNOL, V9380, P97; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; Sousa CRE, 1996, J EXP MED, V184, P149, DOI 10.1084/jem.184.1.149; Stone JD, 1997, J IMMUNOL, V158, P5773; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; van Oers NSC, 1998, J IMMUNOL, V160, P163; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; Vely F, 1997, EUR J IMMUNOL, V27, P3010, DOI 10.1002/eji.1830271138; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; Wiest DL, 1996, IMMUNITY, V4, P495, DOI 10.1016/S1074-7613(00)80415-X; Yamazaki T, 1997, J IMMUNOL, V158, P1634	59	266	275	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					572	575		10.1126/science.281.5376.572	http://dx.doi.org/10.1126/science.281.5376.572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677202				2022-12-28	WOS:000075012300044
J	Xie, T; Spradling, AC				Xie, T; Spradling, AC			decapentaplegic is essential for the maintenance and division of germline stem cells in the Drosophila ovary	CELL			English	Article							BETA SIGNALING PATHWAY; BAG-OF-MARBLES; DPP RECEPTORS; THICK VEINS; I RECEPTORS; PROTEIN; GENE; PATTERN; TRANSCRIPTION; MELANOGASTER	Stem cells are thought to occupy special local environments, or niches, established by neighboring cells that give them the capability for self-renewal. Each ovariole in the Drosophila ovary contains two germline stem cells surrounded by a group of differentiated somatic cells that express hedgehog and wingless. Here we show that the BMP2/4 homolog decapentaplegic (dpp) is specifically required to maintain female germline stem cells and promote their division. Overexpression of dpp blocks germline stem cell differentiation. Conversely, mutations in dpp or its receptor (saxophone) accelerate stem cell loss and retard stem cell division. We constructed mutant germline stem cell clones to show that the dpp signal is directly received by germline stem cells. Thus, dpp signaling helps define a niche that controls germline stem cell proliferation.	Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, Baltimore, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute	Spradling, AC (corresponding author), Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, 115 W Univ Pkwy, Baltimore, MD 21210 USA.				Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BAKER D, 1992, GENE DEV, V6, P2312; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Burke R, 1996, DEVELOPMENT, V122, P2261; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen EH, 1997, DEVELOPMENT, V124, P205; Das P, 1998, DEVELOPMENT, V125, P1519; de Cuevas M, 1997, ANNU REV GENET, V31, P405, DOI 10.1146/annurev.genet.31.1.405; DECUEVAS M, 1998, IN PRESS DEVELOPMENT; DOE CQ, 1995, NEURON, V15, P991, DOI 10.1016/0896-6273(95)90088-8; Forbes A, 1998, DEVELOPMENT, V125, P679; Forbes AJ, 1996, DEVELOPMENT, V122, P3283; Forbes AJ, 1996, DEVELOPMENT, V122, P1125; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hudson JB, 1998, DEVELOPMENT, V125, P1407; HURSH DA, 1993, DEVELOPMENT, V117, P1211; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIANG L, 1994, DEVELOPMENT, V120, P1201; Lin HF, 1997, ANNU REV GENET, V31, P455, DOI 10.1146/annurev.genet.31.1.455; Lin HF, 1997, DEVELOPMENT, V124, P2463; Manseau L, 1997, DEV DYNAM, V209, P310, DOI 10.1002/(SICI)1097-0177(199707)209:3<310::AID-AJA6>3.0.CO;2-L; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Matunis E, 1997, DEVELOPMENT, V124, P4383; MCKEARIN D, 1995, DEVELOPMENT, V121, P2937; MCKEARIN DM, 1990, GENE DEV, V4, P2242, DOI 10.1101/gad.4.12b.2242; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Ohlstein B, 1997, DEVELOPMENT, V124, P3651; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Penton A, 1997, SCIENCE, V275, P203, DOI 10.1126/science.275.5297.203; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Spradling AC, 1997, COLD SPRING HARB SYM, V62, P25; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Twombly V, 1996, DEVELOPMENT, V122, P1555; Wharton K, 1996, GENETICS, V142, P493; WIESCHAUS E, 1979, DEV BIOL, V68, P29, DOI 10.1016/0012-1606(79)90241-0; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; XU T, 1993, DEVELOPMENT, V117, P1223; Zaccai M, 1996, ZYGOTE, V4, P159, DOI 10.1017/S096719940000304X; Zhao GQ, 1996, GENE DEV, V10, P1657, DOI 10.1101/gad.10.13.1657; Zhao GQ, 1998, DEVELOPMENT, V125, P1103	61	511	524	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					251	260		10.1016/S0092-8674(00)81424-5	http://dx.doi.org/10.1016/S0092-8674(00)81424-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695953	Bronze			2022-12-28	WOS:000075020100013
J	Garrett, TPJ; McKern, NM; Lou, MZ; Frenkel, MJ; Bentley, JD; Lovrecz, GO; Elleman, TC; Cosgrove, LJ; Ward, CW				Garrett, TPJ; McKern, NM; Lou, MZ; Frenkel, MJ; Bentley, JD; Lovrecz, GO; Elleman, TC; Cosgrove, LJ; Ward, CW			Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor	NATURE			English	Article							ALANINE-SCANNING MUTAGENESIS; ALPHA-SUBUNIT; BINDING DOMAIN; GENE; DETERMINANTS; SPECIFICITY; SITE	The type-1 insulin-like growth-factor receptor (IGF-1R) and insulin receptor (IR) are closely related members of the tyrosine-kinase receptor superfamily. IR is essential for glucose homeostasis, whereas IGF-1R is involved in both normal growth and development and malignant transformation. Homologues of these receptors are found in animals as simple as cnidarians. The epidermal growth-factor receptor (EGFR) family is closely related to the IR family and has significant sequence identity to the extracellular portion we describe here. We now present the structure of the first three domains of IGF-1R (L1-Cys-rich-L2) determined to a 2.4 Angstrom resolution. The L domains each consist of a single-stranded right-handed beta-helix. The Cys-rich region is composed of eight disulphide-bonded modules, seven of which form a rod-shaped domain with modules associated in an unusual manner. The three domains surround a central space of sufficient size to accommodate a ligand molecule. Although the fragment (residues 1-462) does not bind ligand, many of the determinants responsible for hormone binding and ligand specificity map to this central site. This structure therefore shows how the IR subfamily might interact with their ligands.	CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia; Biomol Res Inst, Parkville, Vic 3052, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Ward, CW (corresponding author), CSIRO, Div Mol Sci, 343 Royal Parade, Parkville, Vic 3052, Australia.	tom.barrett@bioresi.com.au; colin.ward@molsci.csiro.au	Lovrecz, George/H-8602-2013; Cosgrove, Leah J/A-7764-2010	Cosgrove, Leah J/0000-0002-8340-4291				BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; BAYNE ML, 1988, J BIOL CHEM, V264, P11004; BRUNGER AT, 1996, XPLOR REFERENCE MANU; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HOLM I, 1993, J MOL BIOL, V233, P125; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KUROSE T, 1994, J BIOL CHEM, V269, P29190; McKern NM, 1997, PROTEIN SCI, V6, P2663; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; NAKAE J, 1995, J BIOL CHEM, V270, P22017, DOI 10.1074/jbc.270.37.22017; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROACH P, 1994, DIABETES, V43, P1096, DOI 10.2337/diabetes.43.9.1096; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1993, J BIOL CHEM, V268, P3044; Steele RE, 1996, DEV GENES EVOL, V206, P247, DOI 10.1007/s004270050050; STEIGEMAN W, 1974, THESIS TU MUNICH; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; TAYLOR S, 1994, ENDOCR REV, V2, P58; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7	30	221	244	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					395	399		10.1038/28668	http://dx.doi.org/10.1038/28668			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690478				2022-12-28	WOS:000074968800058
J	Steere, AC; Sikand, VK; Meurice, F; Parenti, DL; Fikrig, E; Schoen, RT; Nowakowski, J; Schmid, CH; Laukamp, S; Buscarino, C; Krause, DS				Steere, AC; Sikand, VK; Meurice, F; Parenti, DL; Fikrig, E; Schoen, RT; Nowakowski, J; Schmid, CH; Laukamp, S; Buscarino, C; Krause, DS		Lyme Dis Vaccine Study Grp	Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; PROTEIN-A; TREATMENT-RESISTANT; ERYTHEMA MIGRANS; OSPA; ARTHRITIS; MICE; INFECTION; EPIDEMIC; AGENT	Background The risk of acquiring Lyme disease is high in areas in which the disease is endemic, and the development of a safe and effective vaccine is therefore important. Methods We conducted a multicenter, double-blind, randomized trial involving 10,936 subjects who lived in areas of the United States in which Lyme disease is endemic. Participants received an injection of either recombinant Borrelia burgdorferi outer-surface lipoprotein A (OspA) with adjuvant or placebo at enrollment and 1 and 12 months later. In cases of suspected Lyme disease, culture of skin lesions, polymerase-chain-reaction testing, or serologic testing was done. Serologic testing was performed 12 and 20 months after study entry to detect asymptomatic infections. Results In the first year, after two injections, 22 subjects in the vaccine group and 43 in the placebo group contracted definite Lyme disease (P=0.009); vaccine efficacy was 49 percent (95 percent confidence interval, 15 to 69 percent). In the second year, after the third injection, 16 vaccine recipients and 66 placebo recipients contracted definite Lyme disease (P<0.001); vaccine efficacy was 76 percent (95 percent confidence interval, 58 to 86 percent). The efficacy of the vaccine in preventing asymptomatic infection was 83 percent in the first year and 100 percent in the second year. Injection of the vaccine was associated with mild-to-moderate local or systemic reactions lasting a median of three days. Conclusions Three injections of vaccine prevented most definite cases of Lyme disease or asymptomatic B. burgdorferi infection. (N Engl J Med 1998; 339:209-15.) (C)1998, Massachusetts Medical Society.	Tufts Univ, Sch Med, New England Med Ctr, Tupper Res Inst,Div Rheumatol & Immunol, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Med Ctr, Tupper Res Inst,Div Clin Care Res, Boston, MA 02111 USA; SmithKline Beecham Pharmaceut, Res & Dev, Collegeville, PA USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA; Kendle Gmi, Munich, Germany	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; GlaxoSmithKline; Yale University; New York Medical College	Steere, AC (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Tupper Res Inst,Div Rheumatol & Immunol, Box 406,750 Washington St, Boston, MA 02111 USA.		Schmid, Christopher H./J-2398-2014	Schmid, Christopher H./0000-0002-0855-5313; Steere, Allen/0000-0002-5268-9853				[Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; CHANG YF, 1995, INFECT IMMUN, V63, P3543, DOI 10.1128/IAI.63.9.3543-3549.1995; EDELMAN R, 1991, VACCINE, V9, P531, DOI 10.1016/0264-410X(91)90236-Y; FEDER HM, 1995, AM J MED, V99, P412, DOI 10.1016/S0002-9343(99)80190-9; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; FIKRIG E, 1992, P NATL ACAD SCI USA, V89, P5418, DOI 10.1073/pnas.89.12.5418; GOLDSTEIN MD, 1990, AM J PUBLIC HEALTH, V80, P1225, DOI 10.2105/AJPH.80.10.1225; GROSS DM, IN PRESS SCIENCE; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; Klein JP., 2003, SURVIVAL ANAL TECHNI; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LENGLJANSSEN B, 1994, J EXP MED, V180, P2069, DOI 10.1084/jem.180.6.2069; LOVRICH SD, 1995, INFECT IMMUN, V63, P2113, DOI 10.1128/IAI.63.6.2113-2119.1995; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Nocton JJ, 1996, J INFECT DIS, V174, P623, DOI 10.1093/infdis/174.3.623; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; ONEILL RT, 1988, STAT MED, V7, P1279, DOI 10.1002/sim.4780071208; PHILIPP MT, 1996, J SPIROCHETAL TICKBO, V3, P1; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SCHAIBLE UE, 1990, P NATL ACAD SCI USA, V87, P3768, DOI 10.1073/pnas.87.10.3768; SCHOEN RT, 1995, J INFECT DIS, V172, P1324, DOI 10.1093/infdis/172.5.1324; SEARS JE, 1991, J IMMUNOL, V147, P1995; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; VanHoecke C, 1996, VACCINE, V14, P1620, DOI 10.1016/S0264-410X(96)00146-6; Wormser GP, 1997, AM J CLIN PATHOL, V107, P142, DOI 10.1093/ajcp/107.2.142; 1996, MMWR MORB MORTAL WKL, V45, P481	31	509	536	0	36	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					209	215		10.1056/NEJM199807233390401	http://dx.doi.org/10.1056/NEJM199807233390401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673298				2022-12-28	WOS:000074918700001
J	Cossart, Y				Cossart, Y			TTV a common virus, but pathogenic?	LANCET			English	Editorial Material							PARVOVIRUS		Univ Sydney, Dept Infect Dis, Sydney, NSW 2006, Australia	University of Sydney	Cossart, Y (corresponding author), Univ Sydney, Dept Infect Dis, Sydney, NSW 2006, Australia.							Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101; COSSART YE, 1975, LANCET, V1, P72; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X; PATTISON JR, 1981, LANCET, V1, P664	6	40	44	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1998	352	9123					164	164		10.1016/S0140-6736(05)77802-8	http://dx.doi.org/10.1016/S0140-6736(05)77802-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683201				2022-12-28	WOS:000074859800005
J	de Groen, PC; Barry, JA; Schaller, WJ				de Groen, PC; Barry, JA; Schaller, WJ			Applying World Wide Web technology to the study of patients with rare diseases	ANNALS OF INTERNAL MEDICINE			English	Article								Randomized, controlled trials of sporadic diseases are rarely conducted. Recent developments in communication technology, particularly the World Wide Web, allow efficient dissemination and exchange of information. However, software for the identification of patients with a ra re disease and subsequent data entry and analysis in a secure Web database are currently not available. To study cholangiocarcinoma, a rare cancer of the bile ducts, we developed a computerized disease tracing system coupled with a database accessible on the Web. The tracing system scans computerized information systems on a daily basis and forwards demographic information on patients with bile duct abnormalities to an electronic mailbox. If informed consent is given, the patient's demographic and preexisting medical information available in medical database servers are electronically forwarded to a UNIX research database. Information from further patient-physician interactions and procedures is also entered into this database. The database is equipped with a Web user interface that allows data entry from various platforms (PC-compatible, Macintosh, and UNIX workstations) anywhere inside or outside our institution. To ensure patient confidentiality and data security, the database includes all security measures required for electronic medical records. The combination of a Web-based disease tracing system and a database has broad applications, particularly for the integration of clinical research within clinical practice and for the coordination of multicenter trials.	Mayo Clin & Mayo Fdn, Div Gastroenterol, Rochester, MN 55905 USA	Mayo Clinic	de Groen, PC (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol, 200 1st St SW, Rochester, MN 55905 USA.							Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Sirica A. E., 1997, BILIARY PANCREATIC D, P229; WALL L, 1996, PROGRAMMING PERL	3	20	29	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					107	113		10.7326/0003-4819-129-2-199807150-00009	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669969				2022-12-28	WOS:000074852000006
J	Olson, CM; Glass, RM; Thacker, SB; Stroup, DF				Olson, CM; Glass, RM; Thacker, SB; Stroup, DF			Ethical issues in studying submissions to a medical journal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				A protocol to prospectively study characteristics of meta-analyses submitted to a weekly medical journal raised several ethical issues. In submitting a manuscript for publication, authors do not implicitly consent to have their work used for research. Authors must be free to refuse to consent, without it affecting their chances for publication. Systematically analyzing data on manuscript characteristics might influence the decision to publish. Having investigators who are not on the editorial staff or peer reviewers extract the manuscripts' characteristics breaks the confidentiality of the author-editor-reviewer relationship. In response to these issues, we added a statement to our journal's instructions for authors that submitted manuscripts may be systematically analyzed to improve the quality of the editorial or peer review process. Authors had to actively consent to participate, but editors and external reviewers were unaware of which authors were participating. The manuscript characteristics were not shared with authors, editors, or external reviewers. The investigators were blinded to each manuscript's author and institution. After we addressed ethical issues encountered in studying manuscripts submitted to a medical journal, 99 of 105 authors submitting a meta-analysis during the study's first 24 months agreed to participate.	Univ Washington, Seattle, WA 98195 USA; Univ Chicago, Chicago, IL 60637 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA USA	University of Washington; University of Washington Seattle; University of Chicago; Centers for Disease Control & Prevention - USA	Olson, CM (corresponding author), JAMA, 515 N State St, Chicago, IL 60610 USA.							*COUNC BIOL ED ED, 1997, CBE VIEWS, V20, P183; IVERSON C, 1998, AM MED ASS MANUAL ST, P136; WILLIAMS ES, 1998, JAMA-J AM MED ASSOC, V279, P1116; 1998, JAMA, V279, P67	4	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					290	291		10.1001/jama.280.3.290	http://dx.doi.org/10.1001/jama.280.3.290			2	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676686	Bronze			2022-12-28	WOS:000074706000031
J	Enver, T; Greaves, M				Enver, T; Greaves, M			Loops, lineage, and leukemia	CELL			English	Review							DIFFERENTIATION; GATA-1		Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Enver, T (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, 237 Fulham Rd, London SW3 6JB, England.							Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; BROWN G, 1988, DIFFERENTIATION, V39, P83, DOI 10.1111/j.1432-0436.1988.tb00084.x; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; GREAVES MF, 1986, BLOOD, V67, P1; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ronchi Antonella, 1997, Genes and Function, V1, P245; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3	21	165	169	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					9	12		10.1016/S0092-8674(00)81215-5	http://dx.doi.org/10.1016/S0092-8674(00)81215-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674421	Bronze			2022-12-28	WOS:000074790800003
J	Versteege, I; Sevenet, N; Lange, J; Rousseau-Merck, MF; Ambros, P; Handgretinger, R; Aurias, A; Delattre, O				Versteege, I; Sevenet, N; Lange, J; Rousseau-Merck, MF; Ambros, P; Handgretinger, R; Aurias, A; Delattre, O			Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer	NATURE			English	Article							MALIGNANT RHABDOID TUMOR; SWI/SNF COMPLEX; BINDING; STIMULATION; PROTEIN; KIDNEY; SNF5	Malignant rhabdoid tumours (MRTs) are extremely aggressive cancers of early childhood. They can occur in various locations, mainly the kidney, brain and soft tissues(1,2). Cytogenetic and molecular analyses have shown that the deletion of region 11.2 of the long arm of chromosome 22 (22q11.2) is a recurrent genetic characteristic of MRTs, indicating that this locus may encode a tumour suppressor gene(3-8). Here we map the most frequently deleted part of chromosome 22q11.2 from a panel of 13 MRT cell lines. We observed six homozygous deletions that delineate the smallest region of overlap between the cell lines. This region is found in the hSNF5/3INI1 gene, which encodes a member of the chromatin-remodelling SWI/SNF multiprotein complexes(9-12). We analysed the sequence of hSNF5/INI1 and found frameshift or nonsense mutations of this gene in six other cell lines. These truncating mutations of one allele were associated with the loss of the other allele. Identical alterations were observed in corresponding primary tumour DNAs but not in matched constitutional DNAs, indicating that they had been acquired somatically. The observation of bi-allelic alterations of hSNF5/INI1 in MRTs suggests that loss-of-function mutations of hSNF5/INI1 contribute to oncogenesis.	Inst Curie, Sect Rech, Lab Pathol Mol Canc, F-75248 Paris 05, France; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Tubingen, Kinderklin, D-72070 Tubingen, Germany	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Saint Anna Children's Hospital; Eberhard Karls University of Tubingen	Delattre, O (corresponding author), Inst Curie, Sect Rech, Lab Pathol Mol Canc, 26 Rue Ulm, F-75248 Paris 05, France.	delattre@curie.fr	Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; delattre, olivier/0000-0002-8730-2276				Biegel JA, 1996, GENE CHROMOSOME CANC, V16, P94, DOI 10.1002/(SICI)1098-2264(199606)16:2<94::AID-GCC3>3.0.CO;2-Y; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOUGLASS EC, 1990, GENE CHROMOSOME CANC, V2, P210, DOI 10.1002/gcc.2870020308; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FORT DW, 1994, GENE CHROMOSOME CANC, V11, P146, DOI 10.1002/gcc.2870110303; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; HANDGRETINGER R, 1990, CANCER RES, V50, P2177; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LYNCH HT, 1983, CANCER-AM CANCER SOC, V52, P290, DOI 10.1002/1097-0142(19830715)52:2<290::AID-CNCR2820520216>3.0.CO;2-L; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1998, EMBO J, V16, P101; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARHAM DM, 1994, AM J SURG PATHOL, V18, P1010, DOI 10.1097/00000478-199410000-00005; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Rosty C, 1998, GENE CHROMOSOME CANC, V21, P82, DOI 10.1002/(SICI)1098-2264(199802)21:2<82::AID-GCC2>3.0.CO;2-3; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; SHASHI V, 1994, GENE CHROMOSOME CANC, V10, P49, DOI 10.1002/gcc.2870100108; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SOULIE J, 1986, CANCER GENET CYTOGEN, V21, P117, DOI 10.1016/0165-4608(86)90037-3; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; WICK MR, 1995, SEMIN DIAGN PATHOL, V12, P233	28	1117	1161	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					203	206		10.1038/28212	http://dx.doi.org/10.1038/28212			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671307				2022-12-28	WOS:000074705900060
J	Gureje, O; Von Korff, M; Simon, GE; Gater, R				Gureje, O; Von Korff, M; Simon, GE; Gater, R			Persistent pain and well-being - A World Health Organization study in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BACK-PAIN; PSYCHOLOGICAL-PROBLEMS; DEPRESSION; DISABILITY; SYMPTOMS; ILLNESS	Context.-There is little information on the extent of persistent pain across cultures. Even though pain is a common reason for seeking health care, information on the frequency and impacts of persistent pain among primary care patients is inadequate. Objective.-To assess the prevalence and impact of persistent pain among primary care patients. Design and Setting.-Survey data were collected from representative samples of primary care patients as part of the World Health Organization Collaborative Study of Psychological Problems in General Health Care, conducted in 15 centers in Asia, Africa, Europe, and the Americas. Participants.-Consecutive primary care attendees between the age of majority (typically 18 years) and 65 years were screened (n = 25 916) and stratified random samples interviewed (n = 5438). Main Outcome Measures.-Persistent pain, defined as pain present most of the time for a period of 6 months or more during the prior year, and psychological illness were assessed by the Composite International Diagnostic interview, Disability was assessed by the Groningen Social Disability Schedule and by activity-limitation days in the prior month. Results.-Across all 15 centers, 22% of primary care patients reported persistent pain, but there was wide variation in prevalence rates across centers (range, 5.5%-33.0%). Relative to patients without persistent pain, pain sufferers were more likely to have an anxiety or depressive disorder (adjusted odds ratio [OR], 4, 14, 95% confidence interval [CI], 3.52-4.86), to experience significant activity limitations (adjusted OR, 1.63; 95% CI, 1.41-1.89), and to have unfavorable health perceptions (adjusted OR, 1.26; 95% CI, 1.07-1.49), The relationship between psychological disorder and persistent pain was observed in every center, while the relationship between disability and persistent pain was inconsistent across centers. Conclusions.-Persistent pain was a commonly reported health problem among primary care patients and was consistently associated with psychological illness across centers. Large variation in frequency and the inconsistent relationship between persistent pain and disability across centers suggests caution in drawing conclusions about the role of culture in shaping responses to persistent pain when comparisons are based on patient samples drawn from a limited number of health care settings in each culture.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Coll Hosp, Dept Psychiat, Ibadan, Nigeria; Withington Hosp, Dept Psychiat, Manchester M20 8LR, Lancs, England	Group Health Cooperative; University of Ibadan; University College Hospital, Ibadan	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave, Seattle, WA 98101 USA.		Gureje, Oye/J-1183-2014	Gureje, Oye/0000-0003-0094-5947; VonKorff, Michael/0000-0001-5386-8477	NIDCR NIH HHS [DE08773-10] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008773] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSSON HI, 1993, CLIN J PAIN, V9, P174, DOI 10.1097/00002508-199309000-00004; Bates M S, 1995, Med Anthropol, V16, P141; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; LERESCHE L, IN PRESS HDB PAIN SY; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; MOORE R, 1990, PSYCHOSOM MED, V52, P171, DOI 10.1097/00006842-199003000-00005; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; POLATIN PB, 1993, SPINE, V18, P66, DOI 10.1097/00007632-199301000-00011; ROMANO JM, 1985, PSYCHOL BULL, V97, P18, DOI 10.1037/0033-2909.97.1.18; ROY R, 1984, COMPR PSYCHIAT, V25, P96, DOI 10.1016/0010-440X(84)90027-0; SANDERS SH, 1992, CLIN J PAIN, V8, P317, DOI 10.1097/00002508-199212000-00006; SARTORIUS N, 1993, ARCH GEN PSYCHIAT, V50, P819; SCHAPPERT SM, 1992, VITAL HLTH STAT, V18; TURK DC, 1988, J CONSULT CLIN PSYCH, V56, P233, DOI 10.1037/0022-006X.56.2.233; USTN TB, 1995, MENTAL ILLNESS GEN H; Von Korff M., 1995, MENTAL ILLNESS GEN H; VONKORFF A, 1988, PAIN, V32, P173; VONKORFF M, 1993, PAIN, V55, P251, DOI 10.1016/0304-3959(93)90154-H; VonKorff M, 1996, J CLIN EPIDEMIOL, V49, P297, DOI 10.1016/0895-4356(95)00512-9; VonKorff M, 1996, BRIT J PSYCHIAT, V168, P101, DOI 10.1192/S0007125000298474; VONKORFFM, 1992, PAIN, V50, P133; *WHO, 1989, WHO PUBL; WIERSMA D, 1988, INT J REHABIL RES, V11, P213, DOI 10.1097/00004356-198809000-00001; World Health Organization, 1992, INT STAT CLASS DIS	24	967	1002	0	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					147	151		10.1001/jama.280.2.147	http://dx.doi.org/10.1001/jama.280.2.147			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZY321	9669787	Bronze			2022-12-28	WOS:000074608400029
J	Martinsen, BJ; Bronner-Fraser, M				Martinsen, BJ; Bronner-Fraser, M			Neural crest specification regulated by the helix-loop-helix repressor Id2	SCIENCE			English	Article							DNA-BINDING; RETINOBLASTOMA PROTEIN; NEGATIVE REGULATOR; GENE; DIFFERENTIATION; EXPRESSION; CELLS; DROSOPHILA; GROWTH; EXTRAMACROCHAETAE	Vertebrate neural crest cells, derived from the neural folds, generate a variety of tissues, such as cartilage, ganglia, and cranial.(intramembranous) bone, The chick homolog of the helix-loop-helix transcriptional regulator Id2 is expressed in cranial but not trunk neural folds and subsequently in some migrating cranial neural crest cells. Ectopic expression of Id2 with recombinant retroviruses converted ectodermal cells to a neural crest fate, demonstrating that proper regulation of Id2 is important for sustaining epidermal traits. In addition, overexpression of Id2 resulted in overgrowth and premature neurogenesis of the dorsal neural tube. These results suggest that Id2 may allocate ectodermal precursors into neural rather than epidermal lineages.	CALTECH, Beckman Inst 139 74, Div Biol, Pasadena, CA 91125 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA	California Institute of Technology; University of California System; University of California Irvine	Bronner-Fraser, M (corresponding author), CALTECH, Beckman Inst 139 74, Div Biol, Pasadena, CA 91125 USA.			Bronner, Marianne/0000-0003-4274-1862	NINDS NIH HHS [NS36585, NS34671] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034671, R01NS036585, R37NS036585] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hara E, 1996, DEV GENET, V18, P161; Homburger SA, 1996, DEV DYNAM, V206, P112, DOI 10.1002/(SICI)1097-0177(199605)206:1<112::AID-AJA10>3.0.CO;2-7; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; LEBLANC GG, 1990, DEV BIOL, V137, P318, DOI 10.1016/0012-1606(90)90257-J; LEDOUARI.NM, 1974, DEV BIOL, V41, P162, DOI 10.1016/0012-1606(74)90291-7; LEDOUARIN NM, 1982, DEV CELL BIOL SERIES, V12; MORGAN BA, 1996, METHOD CELL BIOL, V51, P186; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; NAKAMURA H, 1982, J EMBRYOL EXP MORPH, V70, P1; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; NODEN DM, 1975, DEV BIOL, V42, P106, DOI 10.1016/0012-1606(75)90318-8; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Sawai S, 1997, MECH DEVELOP, V65, P175, DOI 10.1016/S0925-4773(97)00071-3; Sechrist J, 1995, DEVELOPMENT, V121, P4103; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; ZHANG H, 1995, MECH DEVELOP, V50, P119, DOI 10.1016/0925-4773(94)00329-L	33	126	128	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					988	991		10.1126/science.281.5379.988	http://dx.doi.org/10.1126/science.281.5379.988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703514				2022-12-28	WOS:000075412700047
J	Penn, RL; Banfield, JF				Penn, RL; Banfield, JF			Imperfect oriented attachment: Dislocation generation in defect-free nanocrystals	SCIENCE			English	Article							GROWTH	Dislocations are common defects in solids, yet all crystals begin as dislocation-free nuclei. The mechanisms by which dislocations form during early growth are poorly understood. When nanocrystalline materials grow by oriented attachment at crystallographically specific surfaces and there is a small misorientation at the interface, dislocations result. Spiral growth at two or more closely spaced screw dislocations provides a mechanism for generating complex polytypic and polymorphic structures. These results are of fundamental importance to understanding crystal growth.	Univ Wisconsin, Mat Sci Program, Madison, WI 53706 USA; Univ Tokyo, Grad Sch Sci, Inst Mineral, Tokyo 113, Japan	University of Wisconsin System; University of Wisconsin Madison; University of Tokyo	Banfield, JF (corresponding author), Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA.	jill@min.s.u-tokyo.ac.jp		Banfield, Jill/0000-0001-8203-8771				Alivisatos AP, 1997, BER BUNSEN PHYS CHEM, V101, P1573, DOI 10.1002/bbpc.19971011104; AMELINCKX S, 1953, CR HEBD ACAD SCI, V237, P1726; AVERBACK RS, 1996, SYNTHESIS PROCESSING; Banfield JF, 1996, AM MINERAL, V81, P79; BANFIELD JF, 1997, REV MINERAL, V35, P86; BARONNET A, 1978, PROG CRYST GROWTH CH, V1, P151, DOI 10.1016/0146-3535(78)90009-6; BHID VG, 1957, ZS KRIST, V109, P81; BURTON WK, 1949, NATURE, V163, P398, DOI 10.1038/163398a0; BURTON WK, 1951, PHILOS T R SOC S-A, V243, P299, DOI 10.1098/rsta.1951.0006; DEKEYSER W, 1955, C DEF CRYST SOL JUL; Friedel G, 1904, B SOC IND MINERALE, VIII; Friedel J., 1964, DISLOCATIONS; Gribb AA, 1997, AM MINERAL, V82, P717, DOI 10.2138/am-1997-7-809; GRIBB AA, UNPUB; Griffin L., 1950, PHILOS MAG, V41, P196; HOFLER HJ, 1990, SCRIPTA METALL MATER, V24, P2401, DOI 10.1016/0956-716X(90)90101-L; ITO T, 1950, XRAY STUDIES POLYM; Kirkpatrick RJ, 1981, REV MINERAL, V8, P321, DOI DOI 10.1017/CBO9781107415324.004; Lasaga A.C., 1981, REV MINERALOGY, V8, P261; MITCHELL RS, 1957, Z KRISTALLOGR, V109, P1; NIEH TG, 1991, SCRIPTA METALL MATER, V25, P955, DOI 10.1016/0956-716X(91)90256-Z; PANDEY D, 1982, PHYS CHEM MINER, V8, P268, DOI 10.1007/BF00308248; PENN RL, IN PRESS AM MINERAL; [No title captured]; [No title captured]	25	2126	2177	20	795	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1998	281	5379					969	971		10.1126/science.281.5379.969	http://dx.doi.org/10.1126/science.281.5379.969			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703506				2022-12-28	WOS:000075412700039
J	Kuroda, S; Fukata, M; Nakagawa, M; Fujii, K; Nakamura, T; Ookubo, T; Izawa, I; Nagase, T; Nomura, N; Tani, H; Shoji, I; Matsuura, Y; Yonehara, S; Kaibuchi, K				Kuroda, S; Fukata, M; Nakagawa, M; Fujii, K; Nakamura, T; Ookubo, T; Izawa, I; Nagase, T; Nomura, N; Tani, H; Shoji, I; Matsuura, Y; Yonehara, S; Kaibuchi, K			Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion	SCIENCE			English	Article							BINDING PROTEIN; ALPHA-CATENIN; BETA-CATENIN; IDENTIFICATION; FAMILY; RHO; INTERLEUKIN-3; PLAKOGLOBIN; ACTIVATION; FILOPODIA	The small guanosine triphosphatases (GTPases) Cdc42 and Rad regulate E-cadherin-mediated cell-cell adhesion. IQGAP1, a target: of Cdc42 and Rac1,was localized with E-cadherin and beta-catenin at sites of cell-cell contact in mouse L Fibroblasts expressing E-cadherin (EL cells), and interacted with E-cadherin and beta-catenin both in vivo and in vitro. IQGAP1 induced the dissociation of alpha-catenin from a cadherin-catenin complex in vitro and in vivo. Overexpression of IQGAP1 in EL cells, but not in L cells expressing an E-cadherin-alpha-catenin chimeric protein, resulted in a decrease in E-cadherin-mediated cell-cell adhesive activity. Thus, IQGAP1, acting downstream of Cdc42 and Rac1, appears to regulate cell-cell adhesion through the cadherin-catenin pathway.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Japan Sci & Technol, PRESTO, Inheritance & Variat Grp, Kyoto 6190237, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Hiroshima 7348551, Japan; Cent Lab Key Technol, Kirin Brewery, Yokohama 2360004, Japan; Kazusa DNA Res Inst, Kazusa CDNA Res Grp, Kisarazu 2920812, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 1620052, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068397, Japan	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); Hiroshima University; Kirin Brewery Company Limited; Kazusa DNA Research Institute; National Institute of Infectious Diseases (NIID); Kyoto University	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan.		KURODA, SHINYA/G-4961-2014; Shoji, Ikuo/Y-7079-2019; Fukata, Masaki/AAZ-2476-2021	Shoji, Ikuo/0000-0002-0730-4379; Fukata, Masaki/0000-0001-5200-9806				Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; KURODA S, UNPUB; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; YONEHARA S, 1990, INT IMMUNOL, V2, P143, DOI 10.1093/intimm/2.2.143	27	410	426	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					832	835		10.1126/science.281.5378.832	http://dx.doi.org/10.1126/science.281.5378.832			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694656				2022-12-28	WOS:000075295600052
J	Corrado, D; Basso, C; Schiavon, M; Thiene, G				Corrado, D; Basso, C; Schiavon, M; Thiene, G			Screening for hypertrophic cardiomyopathy in young athletes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AGE-RELATED-CHANGES; NORMAL HUMAN HEARTS; 1ST 10 DECADES; SUDDEN-DEATH; CARDIOVASCULAR-DISEASE; SPECIMENS; ADULTS; LIFE; OLD	Background For more than 20 years in Italy, young athletes have been screened before participating in competitive sports. We assessed whether this strategy results in the prevention of sudden death from hypertrophic cardiomyopathy, a common cardiovascular cause of death in young athletes. Methods We prospectively studied sudden deaths among athletes and nonathletes (35 years of age or less) in the Veneto region of Italy from 1979 to 1996. The causes of sudden death in both populations were compared, and the pathological findings in the athletes were related to their clinical histories and electrocardiograms. Cardiovascular reasons for disqualification from participation in sports were investigated and follow-up was performed in a consecutive series of 33,735 young athletes who underwent preparticipation screening in Padua, Italy, during the same period. Results Of 269 sudden deaths in young people, 49 occurred in competitive athletes (44 male and 5 female athletes; mean [+/-SD] age, 23+/-7 years). The most common causes of sudden death in athletes were arrhythmogenic right ventricular cardiomyopathy (22.4 percent), coronary atherosclerosis (18.4 percent), and anomalous origin of a coronary artery (12.2 percent). Hypertrophic cardiomyopathy caused only 1 sudden death among the athletes (2.0 percent) but caused 16 sudden deaths in the nonathletes (7.3 percent). Hypertrophic cardiomyopathy was detected in 22 athletes (0.07 percent) at preparticipation screening and accounted for 3.5 percent of the cardiovascular reasons for disqualification. None of the disqualified athletes with hypertrophic cardiomyopathy died during a mean follow-up period of 8.2+/-5 years. Conclusions The results show that hypertrophic cardiomyopathy was an uncommon cause of death in these young competitive athletes and suggest that the identification and disqualification of affected athletes at screening before participation in competitive sports may have prevented sudden death. (N Engl J Med 1998;339:364-9.) (C)1998, Massachusetts Medical Society.	Univ Padua, Ist Anat Patol, I-35121 Padua, Italy; Univ Padua, Dept Cardiol, I-35121 Padua, Italy; Natl Hlth Serv, Ctr Sports Med, Padua, Italy	University of Padua; University of Padua	Thiene, G (corresponding author), Univ Padua, Ist Anat Patol, Via A Gabelli 61, I-35121 Padua, Italy.		Schiavon, Maurizio/AAU-9558-2021	CORRADO, DOMENICO/0000-0003-1487-0392; basso, cristina/0000-0002-0195-9753				[Anonymous], 1994, J Am Coll Cardiol, V24, P845; Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; BUDDINGTON RS, 1974, AM J CARDIOL, V33, P129, DOI 10.1016/0002-9149(74)90779-6; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CHESLER E, 1983, CIRCULATION, V67, P632, DOI 10.1161/01.CIR.67.3.632; *COM ORG CARD ID A, 1989, G ITAL CARDIOL, V19, P250; CORRADO D, 1994, CIRCULATION, V90, P2315, DOI 10.1161/01.CIR.90.5.2315; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; DAVIES MJ, 1995, HISTOPATHOLOGY, V26, P493, DOI 10.1111/j.1365-2559.1995.tb00267.x; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; Friedman HH, 1971, DIAGNOSTIC ELECTROCA; KITZMAN DW, 1988, MAYO CLIN PROC, V63, P137, DOI 10.1016/S0025-6196(12)64946-5; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1985, J AM COLL CARDIOL, V6, P1189; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1979, AM J CARDIOL, V43, P1242, DOI 10.1016/0002-9149(79)90160-7; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MORRIS JJ, 1964, CIRCULATION, V29, P242, DOI 10.1161/01.CIR.29.2.242; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; PELLICCIA A, 1995, AM J CARDIOL, V75, P827, DOI 10.1016/S0002-9149(99)80421-4; PELLICCIA A, 1993, AM J CARDIOL, V72, P1048, DOI 10.1016/0002-9149(93)90861-6; POMERANCE A, 1975, PATHOLOGY HEART, P42; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SAVAGE DD, 1978, CIRCULATION, V58, P402, DOI 10.1161/01.CIR.58.3.402; SCHLANT RC, 1986, CIRCULATION, V74, pA653; SCHOLZ DG, 1988, MAYO CLIN PROC, V63, P126, DOI 10.1016/S0025-6196(12)64945-3; SHAPIRO LM, 1983, BRIT HEART J, V50, P534; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; THOMPSON PD, 1979, JAMA-J AM MED ASSOC, V242, P1265, DOI 10.1001/jama.242.12.1265; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; VANDCAMP SP, 1995, MED SCI SPORTS EXERC, V27, P641; VIRMANI R, 1982, AM J MED, V72, P874, DOI 10.1016/0002-9343(82)90845-2; WALLER BF, 1980, AM J CARDIOL, V45, P1292, DOI 10.1016/0002-9149(80)90491-9; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; 1982, GAZZETTA UFFICI 0305, P1715; 1971, GAZZETTA UFFICI 1223, P8162	41	659	696	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1998	339	6					364	369		10.1056/NEJM199808063390602	http://dx.doi.org/10.1056/NEJM199808063390602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107MD	9691102	Bronze			2022-12-28	WOS:000075212300002
J	Thomsen, OO; Cortot, A; Jewell, D; Wright, JP; Winter, T; Veloso, FT; Vatn, M; Persson, T; Pettersson, E				Thomsen, OO; Cortot, A; Jewell, D; Wright, JP; Winter, T; Veloso, FT; Vatn, M; Persson, T; Pettersson, E		Int Budesonide Mesalamine Study Grp	A comparison of budesonide and mesalamine for active Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PENTASA; TRIAL; ACID	Background Crohn's disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release budesonide capsules and slow-release mesalamine tablets in patients with active Crohn's disease affecting the ileum, the ascending colon, or both. Methods In a double-blind, multicenter trial, we enrolled 182 patients with scores of 200 to 400 on the Crohn's Disease Activity Index (with higher scores indicating greater disease activity) and randomly assigned 93 to receive 9 mg of budesonide once daily and 89 to receive 2 g of mesalamine twice daily for 16 weeks. The primary efficacy variable was clinical remission, defined as a score of 150 or less on the Crohn's Disease Activity Index. Results In the analysis of all patients who received at least one dose of study drug, the rates of remission after 8 weeks of treatment were 69 percent in the budesonide group and 45 percent in the mesalamine group (P=0.001); the respective rates after 16 weeks of treatment were 62 percent and 36 percent (P<0.001). Seventy-seven patients in the budesonide group completed the 16 weeks of treatment, as compared with 50 patients in the mesalamine group (P<0.001). The numbers of patients with adverse events were similar in the two groups, but those assigned to budesonide had fewer severe adverse events. Among patients who completed 16 weeks of treatment, the morning plasma cortisol value was normal in 67 percent of budesonide-treated patients and 83 percent of mesalamine-treated patients (P=0.06); 90 percent and 100 percent, respectively, had normal increases in cortisol in response to cosyntropin (P=0.02). Conclusions In patients with active Crohn's disease affecting the ileum, the ascending colon, or both, a controlled-ileal-release formulation of budesonide was more effective in inducing remission than a slow-release formulation of mesalamine. (N Engl J Med 1998;339:370-4.) (C)1998, Massachusetts Medical Society.	Univ Copenhagen, Herlev Hosp, Dept Med Gastroenterol C, DK-2730 Herlev, Denmark; Hop Claude Huriez, Serv Gastroenterol, Lille, France; John Radcliffe Hosp, Gastroenterol Unit, Oxford OX3 9DU, England; Groote Schuur Hosp, Dept Gastroenterol, ZA-7925 Cape Town, South Africa; Kingsbury Hosp, Gastrointestinal Clin, Cape Town, South Africa; Hosp S Joao, Dept Gastroenterol, Porto, Portugal; Univ Oslo, Rikshosp, Dept Med, N-0027 Oslo, Norway; Astro Draco AB, Dept Clin Res, Lund, Sweden	University of Copenhagen; Herlev & Gentofte Hospital; Universite de Lille - ISITE; CHU Lille; University of Oxford; University of Cape Town; Sao Joao Hospital; University of Oslo; National Hospital Norway	Thomsen, OO (corresponding author), Univ Copenhagen, Herlev Hosp, Dept Med Gastroenterol C, DK-2730 Herlev, Denmark.		CORTOT, Antoine/I-5796-2015; CORTOT, ANTOINE/I-7739-2016	CORTOT, ANTOINE/0000-0002-1067-8996				BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Brattsand R, 1990, CAN J GASTROENTEROL, V4, P407; Campieri M, 1997, GUT, V41, P209, DOI 10.1136/gut.41.2.209; Dupuy H.J., 1984, ASSESSMENT QUALITY L, P170; GREENBERG GR, 1994, NEW ENGL J MED, V331, P836, DOI 10.1056/NEJM199409293311303; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P144; MAHIDA YR, 1990, DIGESTION, V45, P88, DOI 10.1159/000200228; MEYERS S, 1990, HEPATO-GASTROENTEROL, V37, P42; RASMUSSEN SN, 1987, SCAND J GASTROENTERO, V22, P877, DOI 10.3109/00365528708991929; RUTGEERTS P, 1994, NEW ENGL J MED, V331, P842, DOI 10.1056/NEJM199409293311304; Scholmerich J, 1990, CAN J GASTROENTEROL, V4, P446; SINGLETON J, 1994, GASTROENTEROLOGY, V107, P632, DOI 10.1016/0016-5085(94)90210-0; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1293, DOI 10.1016/0016-5085(93)90337-C; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847	14	237	248	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1998	339	6					370	374		10.1056/NEJM199808063390603	http://dx.doi.org/10.1056/NEJM199808063390603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	107MD	9691103				2022-12-28	WOS:000075212300003
J	Kleck, G				Kleck, G			What are the risks and benefits of keeping a gun in the home?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							OWNERSHIP		Florida State Univ, Sch Criminol & Criminal Justice, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University	Kleck, G (corresponding author), Florida State Univ, Sch Criminol & Criminal Justice, Tallahassee, FL 32306 USA.							Beautrais AL, 1996, AUST NZ J PSYCHIAT, V30, P741, DOI 10.3109/00048679609065040; BLOCK CR, 1994, 8941 ICPSR; Cook PJ, 1997, GUNS AM; Cummings P, 1997, AM J PUBLIC HEALTH, V87, P974, DOI 10.2105/AJPH.87.6.974; FOX J, 1994, 6787 ICPSR; Hemenway D, 1997, J CRIM LAW CRIM, V87, P1430, DOI 10.2307/1144020; KELLERMANN AL, 1990, AM J EPIDEMIOL, V131, P1080, DOI 10.1093/oxfordjournals.aje.a115600; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KELLERMANN AL, 1997, 6898 ICPSR; Kleck G, 1997, J CRIM LAW CRIM, V87, P1446, DOI 10.2307/1144021; Kleck G, 1995, J CRIM LAW CRIM, V86, P150, DOI 10.2307/1144004; Kleck G., 1997, TARGETING GUNS; KLECK G, 1996, 1996 M AM SOC CRIM N; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P56; US Bureau of Justice Statistics, 1996, CRIM VICT US 1993; WEBSTER DW, 1992, PEDIATRICS, V89, P902	17	17	18	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					473	475		10.1001/jama.280.5.473	http://dx.doi.org/10.1001/jama.280.5.473			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105AR	9701088				2022-12-28	WOS:000075050200042
J	Diamond, HS; Goldberg, E; Janosky, JE				Diamond, HS; Goldberg, E; Janosky, JE			The effect of full-time faculty hospitalists on the efficiency of care at a community teaching hospital	ANNALS OF INTERNAL MEDICINE			English	Article						hospitalists; quality of health care; cost-benefit analysis; patient readmission; length of stay	UNIT	Background: Hospitalists are increasingly being used for inpatient care. Objective: To investigate whether the use of hospitalists is beneficial. Design: Retrospective cohort study. Setting: Inpatient medical service of a 500-bed community teaching hospital. Participants: 1620 patients in the study group, seen during the hospitalist year; 1679 patients from the same outpatient practice as the study group, seen during the previous year (prehospitalist year); an unselected comparison group of 3413 patients seen during the prehospitalist year and 3223 patients seen during the hospitalist year; and a subset of the unselected comparison group, cared for by outpatient practices, who had a prehospitalist length of stay similar to that of the study group (743 patients in the prehospitalist year and 786 in the hospitalist year). Interventions: Full-time faculty hospitalists cared for the study group, were in the hospital during normal working hours, and made decisions throughout the day. In the prehospitalist year and in the comparison groups, primary care physicians managed their own hospitalized patients. Measurements: Length of stay; cost of care; costs of hematology and chemistry evaluation, pharmacy, and radiology; and readmissions were determined for the prehospitalist and hospitalist years. Results: In the study group, median length of stay decreased from 6.01 to 5.01 days (P < 0.001). Median cost of care decreased from $4139 to $3552 (P < 0.001), and the 14-day readmission rate decreased from 9.9 to 4.64 readmissions per 100 admissions (P < 0.001). In the comparison groups, length of stay decreased but both cost of care and readmission rates increased. Conclusion: Hospitalists may improve the efficiency of inpatient care. Further study in various settings is needed to verify these findings.	Western Penn Hosp, Dept Med, Pittsburgh, PA 15224 USA; Univ Pittsburgh, Sch Med, Div Biostat, Dept Med & Clin Epidemiol, Pittsburgh, PA 15261 USA	West Penn Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Diamond, HS (corresponding author), Western Penn Hosp, Dept Med, 4800 Friendship Ave, Pittsburgh, PA 15224 USA.							BRANDNER J, 1995, MANAGED CARE     JUL, P19; BROOK RH, 1987, HLTH CARE FINANCE RE, P39; CAMERON JM, 1985, NEW ENGL J MED, V312, P1233, DOI 10.1056/NEJM198505093121906; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; DIAMOND HS, 1993, J GEN INTERN MED, V8, P614, DOI 10.1007/BF02599717; GIPE B, 1996, COST QUALITY, V2, P6; HORN SD, 1983, AM J PUBLIC HEALTH, V73, P25, DOI 10.2105/AJPH.73.1.25; JENCKS SF, 1987, NEW ENGL J MED, V317, P679, DOI 10.1056/NEJM198709103171106; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; LUFT HS, 1987, HEALTH SERV RES, V22, P157; Moore J D Jr, 1997, Mod Healthc, V27, P54; Moore J D Jr, 1997, Mod Healthc, V27, P58; NELSON JR, 1997, HOSPITALIST, V1, P1; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	16	135	135	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					197	+		10.7326/0003-4819-129-3-199808010-00006	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	104UA	9696727				2022-12-28	WOS:000075032700004
J	Straus, SE; Sackett, DL				Straus, SE; Sackett, DL			Getting research findings into practice - Using research findings in clinical practice	BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE BASED MEDICINE		Oxford Radcliffe Hosp NHS Trust, NHS Res Ctr Evidence Based Med, Nuffield Dept Clin Med, Oxford OX3 9DU, England	Oxford University Hospitals NHS Foundation Trust; University of Oxford	Straus, SE (corresponding author), Oxford Radcliffe Hosp NHS Trust, NHS Res Ctr Evidence Based Med, Nuffield Dept Clin Med, Oxford OX3 9DU, England.							*AM COLL PHYS, 1996, BEST EV; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; *COCHR COLL OXF, 1998, COCHR LIBR; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Geddes JR, 1996, QUAL HEALTH CARE, V5, P215, DOI 10.1136/qshc.5.4.215; Gill P, 1996, BRIT MED J, V312, P819; GOTZSCHE PC, 1998, COCHRANE LIBR; Kenny SE, 1997, ARCH DIS CHILD, V76, P50, DOI 10.1136/adc.76.1.50; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; Sackett D. L., 1997, EVIDENCE BASED MED P; SACKETT D. L., 1996, SERIALS, V9, P178; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SACKETT DL, 1997, EVIDENCE BASED MED, V2, P101; SAUVE JS, 1995, ANN R COLL PHYS SURG, V28, P396	16	130	135	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					339	342		10.1136/bmj.317.7154.339	http://dx.doi.org/10.1136/bmj.317.7154.339			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685286	Green Published			2022-12-28	WOS:000075409500036
J	Hecht, FM; Grant, RM; Petropoulos, CJ; Dillon, B; Chesney, MA; Tian, H; Hellmann, NS; Bandrapalli, NI; Digilio, L; Branson, B; Kahn, JO				Hecht, FM; Grant, RM; Petropoulos, CJ; Dillon, B; Chesney, MA; Tian, H; Hellmann, NS; Bandrapalli, NI; Digilio, L; Branson, B; Kahn, JO			Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; OLIGONUCLEOTIDE ARRAYS; CONFIDENCE-LIMITS; PHYLOGENIES; SENSITIVITY; BOOTSTRAP; SELECTION		Univ Calif San Francisco, AIDS Program, San Francisco, CA 94110 USA; San Francisco Gen Hosp, AIDS Program, San Francisco, CA 94110 USA; Gladstone Inst Virol & Immunol, San Francisco, CA USA; ViroLog, S San Francisco, CA USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Calif San Francisco, Ctr Aids Prevent Studies, San Francisco, CA USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco	Hecht, FM (corresponding author), Univ Calif San Francisco, AIDS Program, 995 Potrero Ave,Ward 84, San Francisco, CA 94110 USA.			Grant, Robert/0000-0002-0851-7085; Hecht, Frederick/0000-0002-5782-1171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI 27763] Funding Source: Medline; PHS HHS [U64/CCU913941, UO1 41531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ANGARANO G, 1994, AIDS, V8, P1013, DOI 10.1097/00002030-199407000-00023; Barrie KA, 1996, VIROLOGY, V219, P407, DOI 10.1006/viro.1996.0266; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HECHT FM, 1998, 5 C RETR OPP INF CHI; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; IPPOLITO G, 1994, JAMA-J AM MED ASSOC, V272, P433, DOI 10.1001/jama.272.6.433; Ives KJ, 1997, J ANTIMICROB CHEMOTH, V39, P771, DOI 10.1093/jac/39.6.771; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; LIPSHUTZ RJ, 1995, BIOTECHNIQUES, V19, P442; McDonald CK, 1997, ARCH INTERN MED, V157, P951, DOI 10.1001/archinte.157.9.951; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; PUDNEY J, 1992, LANCET, V340, P1470, DOI 10.1016/0140-6736(92)92659-4; Rayner MM, 1997, VIROLOGY, V236, P85, DOI 10.1006/viro.1997.8620; SANDERSON MJ, 1989, CLADISTICS, V5, P113, DOI 10.1111/j.1096-0031.1989.tb00559.x; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VEENSTRA J, 1995, CLIN INFECT DIS, V21, P556, DOI 10.1093/clinids/21.3.556; WAHLBERG J, 1994, J INFECT DIS, V169, P611, DOI 10.1093/infdis/169.3.611; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YAMAGUCHI K, 1995, BBA-PROTEIN STRUCT M, V1253, P136, DOI 10.1016/0167-4838(95)00167-1; Zhang YM, 1997, J VIROL, V71, P6662, DOI 10.1128/JVI.71.9.6662-6670.1997	30	375	380	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1998	339	5					307	311		10.1056/NEJM199807303390504	http://dx.doi.org/10.1056/NEJM199807303390504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104TL	9682043	Bronze			2022-12-28	WOS:000075031400004
J	White, A; Ding, XC; vanderSpek, JC; Murphy, JR; Ringe, D				White, A; Ding, XC; vanderSpek, JC; Murphy, JR; Ringe, D			Structure of the metal-ion-activated diphtheria toxin repressor tox operator complex	NATURE			English	Article							REGULATORY ELEMENT DTXR; CORYNEBACTERIUM-DIPHTHERIAE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURES; BINDING; RESOLUTION; SITE; REFINEMENT; REVEALS; ERRORS	The virulent phenotype of the pathogenic bacterium Corynebacterium diphtheriae is conferred by diphtheria toxin, whose expression is an adaptive response to low concentrations of iron. The expression of the toxin gene (tox) is regulated by the repressor DtxR (ref. 1), which is activated by transition metal ions. X-ray crystal structures of DtxR with(2-5) and without (apo-form(2)) its coordinated transition metal ion have established the general architecture of the repressor, identified the location of the metal-binding sites, and revealed a metal-ion-triggered subunit-subunit 'caliper-like' conformational change, Here we report the three-dimensional crystal structure of the complex between a biologically active Ni(II)-bound DtxR(C102D) mutant, in which a cysteine is replaced by an aspartate at residue 102, and a 33-base-pair DNA segment containing the toxin operator toxO. This structure shows that DNA interacts with two dimeric repressor proteins bound to opposite sides of the tox operator. We propose that a metal-ion-induced helix-to-coil structural transition in the amino-terminal region of the protein is partly responsible for the unique mode of repressor activation by transition metal ions.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr MS029, Waltham, MA 02454 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Brandeis Univ, Dept Chem, Waltham, MA 02454 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Brandeis University; Brandeis University; Brandeis University; Boston University	Ringe, D (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr MS029, Waltham, MA 02454 USA.	ringe@binah.cc.brandeis.edu						Albright RA, 1998, P NATL ACAD SCI USA, V95, P3431, DOI 10.1073/pnas.95.7.3431; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOYD J, 1990, P NATL ACAD SCI USA, V87, P5968, DOI 10.1073/pnas.87.15.5968; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Ding X, 1996, NAT STRUCT BIOL, V3, P382, DOI 10.1038/nsb0496-382; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kercher MA, 1997, CURR OPIN STRUC BIOL, V7, P76, DOI 10.1016/S0959-440X(97)80010-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; MUST LM, BACTERIAL PROTIN TOX, V6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiu XY, 1996, BIOCHEMISTRY-US, V35, P12292, DOI 10.1021/bi960861d; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHIERING N, 1995, P NATL ACAD SCI USA, V92, P9843, DOI 10.1073/pnas.92.21.9843; SCHMITT MP, 1993, MOL MICROBIOL, V9, P173, DOI 10.1111/j.1365-2958.1993.tb01679.x; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; TAO X, 1995, P NATL ACAD SCI USA, V92, P6803, DOI 10.1073/pnas.92.15.6803; TAO X, 1993, P NATL ACAD SCI USA, V90, P8524, DOI 10.1073/pnas.90.18.8524; TAO X, 1994, MOL MICROBIOL, V14, P191, DOI 10.1111/j.1365-2958.1994.tb01280.x; WANG ZO, 1994, INFECT IMMUN, V62, P1600, DOI 10.1128/IAI.62.5.1600-1608.1994; XU T, 1992, J BIOL CHEM, V267, P21761; ZHANG H, 1994, J MOL BIOL, V238, P592, DOI 10.1006/jmbi.1994.1317	30	135	145	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					502	506		10.1038/28893	http://dx.doi.org/10.1038/28893			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697776				2022-12-28	WOS:000075080400058
J	Brown, P				Brown, P			On the origins of BSE	LANCET			English	Editorial Material									NINDS, NIH, CNS Studies Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Brown, P (corresponding author), NINDS, NIH, CNS Studies Lab, Bethesda, MD 20892 USA.							Taylor DM, 1998, VET REC, V143, P6, DOI 10.1136/vr.143.1.6; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					252	253		10.1016/S0140-6736(05)60255-3	http://dx.doi.org/10.1016/S0140-6736(05)60255-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690401				2022-12-28	WOS:000074974500004
J	Kaneko, T; Wang, PY; Tawata, M; Sato, A				Kaneko, T; Wang, PY; Tawata, M; Sato, A			Low carbohydrate intake before oral glucose-tolerance tests	LANCET			English	Article									Med Univ Yamanashi, Dept Environm Hlth, Yamanashi, Japan; Med Univ Yamanashi, Dept Internal Med 3, Yamanashi, Japan	University of Yamanashi; University of Yamanashi	Kaneko, T (corresponding author), Med Univ Yamanashi, Dept Environm Hlth, Yamanashi, Japan.							[Anonymous], 1985, TECHN REP SER WHO; Conn JW, 1940, AM J MED SCI, V199, P555, DOI 10.1097/00000441-194004000-00014; Gavin JR, 1997, DIABETES CARE, V20, P1183; RANDLE PJ, 1963, LANCET, V1, P785; WILKERSON HLC, 1960, NEW ENGL J MED, V262, P1047, DOI 10.1056/NEJM196005262622101	5	27	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					289	289		10.1016/S0140-6736(05)60263-2	http://dx.doi.org/10.1016/S0140-6736(05)60263-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690416				2022-12-28	WOS:000074974500019
J	Olsen, JH				Olsen, JH			Interpretation in drug epidemiology	LANCET			English	Editorial Material							CANCER		Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Olsen, JH (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen, Denmark.			Olsen, Jorgen Helge/0000-0001-9633-5662				Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; Hole DJ, 1998, J HYPERTENS, V16, P119, DOI 10.1097/00004872-199816010-00017; HOLE DJ, 1993, BRIT MED J, V306, P609, DOI 10.1136/bmj.306.6878.609; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; Ottenbacher KJ, 1998, AM J EPIDEMIOL, V147, P615; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; Rosenberg L, 1998, JAMA-J AM MED ASSOC, V279, P1000, DOI 10.1001/jama.279.13.1000	9	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					162	163		10.1016/S0140-6736(05)77800-4	http://dx.doi.org/10.1016/S0140-6736(05)77800-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683199				2022-12-28	WOS:000074859800003
J	Roland, M; van Tulder, M				Roland, M; van Tulder, M			Should radiologists change the way they report plain radiography of the spine?	LANCET			English	Editorial Material									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 6PL, Lancs, England; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands	University of Manchester; Vrije Universiteit Amsterdam	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Williamson Bldg,Oxford Rd, Manchester M13 6PL, Lancs, England.		van Tulder, Maurits/AAB-9785-2022	van Tulder, Maurits/0000-0002-7589-8471				*AG HLTH CAR POL R, 1994, AC LOW BACK PROBL AD; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; DEYO RA, 1987, ARCH INTERN MED, V147, P141, DOI 10.1001/archinte.147.1.141; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P783, DOI 10.1093/oxfordjournals.aje.a117326; HAPLIN SF, 1991, BRIT MED J, V303, P813; KELLGREN JH, 1963, ATLAS STANDARD RADIO, V2, P20; ROSEN M, 1995, BACK PAIN; *ROYAL COLL RAD, 1995, MAK BEST US DEP RAD; SuarezAlmazor ME, 1997, JAMA-J AM MED ASSOC, V277, P1782, DOI 10.1001/jama.277.22.1782; vanTulder MW, 1997, SPINE, V22, P427, DOI 10.1097/00007632-199702150-00015; WADDELL G, 1996, LOW BACK PAIN EVIDEN	13	41	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					229	230		10.1016/S0140-6736(97)11499-4	http://dx.doi.org/10.1016/S0140-6736(97)11499-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683228				2022-12-28	WOS:000074859800044
J	Soni, PN; Reddy, I; Rauff, S				Soni, PN; Reddy, I; Rauff, S			Pneumonia and severe haemoptysis	LANCET			English	Article							AMEBIC LIVER-ABSCESS		Univ Natal, Dept Med, ZA-4013 Congella, Durban, South Africa	University of Kwazulu Natal	Soni, PN (corresponding author), Univ Natal, Dept Med, Private Bag 7, ZA-4013 Congella, Durban, South Africa.							ADAMS EB, 1977, MEDICINE, V56, P325, DOI 10.1097/00005792-197707000-00004; JACKSON TFHG, 1984, T ROY SOC TROP MED H, V78, P342, DOI 10.1016/0035-9203(84)90115-9; MACLEOD IN, 1964, THORACIC AMOEBIASIS; POWELL SJ, 1965, LANCET, V2, P602; SIMJEE AE, 1985, CLIN RADIOL, V36, P61, DOI 10.1016/S0009-9260(85)80027-1	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					198	198		10.1016/S0140-6736(98)04498-5	http://dx.doi.org/10.1016/S0140-6736(98)04498-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683210				2022-12-28	WOS:000074859800014
J	Joyce, J; Rabe-Hesketh, S; Wessely, S				Joyce, J; Rabe-Hesketh, S; Wessely, S			Reviewing the reviews - The example of chronic fatigue syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			PUBLICATION; TRIALS; BIAS	Objective;-To test the hypothesis that the selection of literature in review articles is unsystematic and is influenced by the authors' discipline and country of residence. Data Sources.-Reviews in English published between 1980 and March 1996 in MEDLINE, EMBASE (BIDS), PSYCHLIT, and Current Contents were searched. Study Selection.-Reviews of chronic fatigue syndrome (CFS) were selected. Articles explicitly concerned with a specialty aspect of CFS and unattributed, unreferenced, or insufficiently referenced articles were discarded. Data Extraction.-Record of data sources in each review was noted as was the departmental specialty of the first author and his or her country of residence. The references cited in each index paper were tabulated by assigning them to 6 specialty categories, by article title, and by assigning them to 8 categories, by country of journal publication. Data Synthesis.-Of 89 reviews, 3 (3.4%) reported on literature search and described search method. Authors from laboratory-based disciplines preferentially cited laboratory references, while psychiatry-based disciplines preferentially cited psychiatric literature (P =.01). A total of 71.6% of references cited by US authors were from US journals, while 54.9% of references cited by United Kingdom authors were published in United Kingdom journals (P =.001). Conclusion.-Citation of the literature is influenced by review authors' discipline and nationality.	Kings Coll Hosp London, Dept Psychol Med, London SE5 9RS, England; Kings Coll London, Sch Med, Inst Psychiat, London SE5 9PJ, England; Maudsley Hosp & Inst Psychiat, London SE5 8AZ, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London	Wessely, S (corresponding author), Kings Coll Hosp London, Dept Psychol Med, Denmark Hill, London SE5 9RS, England.	sphascw@iop.bpmf.ac.uk	Rabe-Hesketh, Sophia/B-1643-2008; Wessely, Simon C/A-8713-2008	Rabe-Hesketh, Sophia/0000-0002-5257-4837; Wessely, Simon Charles/0000-0002-6743-9929				CAMPBELL F, 1996, B MED LIB ASS, V78, P376; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; DAWSON NV, 1987, J GEN INTERN MED, V2, P183, DOI 10.1007/BF02596149; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; GOER JC, 1996, BIPLOTS; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; INGELFINGER FJ, 1974, AM J MED, V56, P686, DOI 10.1016/0002-9343(74)90635-4; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P91, DOI 10.1016/0895-4356(91)90205-N; OXMAN AD, 1992, ANN NY ACAD SCI, V703, P125	13	34	36	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					264	266		10.1001/jama.280.3.264	http://dx.doi.org/10.1001/jama.280.3.264			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZZ204	9676676	Green Published, Bronze			2022-12-28	WOS:000074706000021
J	de Beaufort, AJ; Pelikan, DMV; Elferink, JGR; Berger, HM				de Beaufort, AJ; Pelikan, DMV; Elferink, JGR; Berger, HM			Effect of interleukin 8 in meconium on in-vitro neutrophil chemotaxis	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; ASPIRATION SYNDROME; INHIBITION; IL-8; INFLAMMATION; FLUID	Background Pneumonitis, characterised by large numbers of neutrophils in the lung, is an important feature of the meconium aspiration syndrome. The mechanism underlying the neutrophil influx is not known. We have investigated whether meconium has chemotactic activity and whether such activity is related to the presence of interleukin 8. Methods The chemotactic activity of meconium on neutrophils from newborn infants was assessed in a Boyden-chamber assay. Interleukin 8 and formyl-methionyl-leucyl-phenylalanine (f-MLP) served as positive controls. Inhibition of chemotaxis was assessed with monoclonal antibody to interleukin 8. The interleukin-8 concentration was measured by ELISA. Findings Sterile meconium suspension from seven unrelated newborn babies increased migration of neutrophils from neonates in comparison with random migration (79, 72, 70, 50, 58, 88 mu m vs 46 mu m; p<0,001). This effect was greatest at a meconium concentration of 5 g/L, although differences between samples from individual babies were observed. Interleukin 8 was present in all meconium suspensions (480-3980 ng/L). Anti-interleukin-8 inhibited neutrophil migration. Interpretation Interleukin 8 is present in meconium and it induces chemotaxis of neutrophils in vitro. This mechanism may have a role in the pathogenesis of pneumonitis in meconium aspiration syndrome.	Leiden Univ, Med Ctr, Dept Pediat, Neonatal Unit, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Biochem Med, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Beaufort, AJ (corresponding author), Leiden Univ, Med Ctr, Dept Pediat, Neonatal Unit, POB 9600, NL-2300 RC Leiden, Netherlands.			de Beaufort, Arnout Jan/0000-0003-1990-2672				BERGER HM, 1994, J R COLL PHYSICIANS, V1, P24; CLARK P, 1995, AM J OBSTET GYNECOL, V173, P1301, DOI 10.1016/0002-9378(95)91375-0; DAVEY AM, 1993, PEDIATR PULM, V16, P101, DOI 10.1002/ppul.1950160205; DIRKES K, 1995, J PEDIATR SURG, V30, P979, DOI 10.1016/0022-3468(95)90325-9; Elferink JGR, 1997, BRIT J PHARMACOL, V121, P643, DOI 10.1038/sj.bjp.0701167; ELFERINK JGR, 1993, EUR J PHARM-MOLEC PH, V246, P157, DOI 10.1016/0922-4106(93)90093-O; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Jones CA, 1996, PEDIATR RES, V39, P966, DOI 10.1203/00006450-199606000-00007; KATZ VL, 1992, AM J OBSTET GYNECOL, V166, P171, DOI 10.1016/0002-9378(92)91856-6; Miller EJ, 1996, CRIT CARE MED, V24, P1448, DOI 10.1097/00003246-199609000-00004; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; Olah KS, 1996, J REPROD IMMUNOL, V32, P89, DOI 10.1016/S0165-0378(96)00990-4; Perks B., 1997, European Respiratory Journal Supplement, V10, p303S; PERLMAN EJ, 1989, HUM PATHOL, V20, P701, DOI 10.1016/0046-8177(89)90159-7; RAPPAPORT S, 1950, SCIENCE, V85, P715; Soukka H, 1997, PEDIATR PULM, V23, P205, DOI 10.1002/(SICI)1099-0496(199703)23:3<205::AID-PPUL6>3.0.CO;2-M; SUN B, 1993, ACTA PAEDIATR, V82, P182, DOI 10.1111/j.1651-2227.1993.tb12635.x; TYLER DC, 1978, PEDIATRICS, V62, P454; Yokoi K, 1997, LAB INVEST, V76, P375; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	21	65	65	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					102	105		10.1016/S0140-6736(98)85013-7	http://dx.doi.org/10.1016/S0140-6736(98)85013-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672275				2022-12-28	WOS:000074775100013
J	Katayama, T; Kubota, T; Kurokawa, K; Crooke, E; Sekimizu, K				Katayama, T; Kubota, T; Kurokawa, K; Crooke, E; Sekimizu, K			The initiator function of DnaA protein is negatively regulated by the sliding clamp of the E-coli chromosomal replicase	CELL			English	Article							POLYMERASE-III HOLOENZYME; IN-VITRO REPLICATION; ESCHERICHIA-COLI; BETA-SUBUNIT; ENZYMATIC REPLICATION; ORIGIN REGION; MUTANT; SEQA; GENE; PURIFICATION	The beta subunit of DNA polymerase III is essential far negative regulation of the initiator protein, DnaA. DnaA inactivation occurs through accelerated hydrolysis of ATP bound to DnaA; the resulting ADP-DnaA fails to initiate replication. The ability of beta subunit to promote DnaA inactivation depends on its assembly as a sliding clamp on DNA and must be accompanied by a partially purified factor, IdaB protein. DnaA inactivation in the presence of IdaB and DNA polymerase III is further stimulated by DNA synthesis, indicating close linkage between initiator inactivation and replication. In vivo, DnaA predominantly takes on the ADP form in a beta subunit-dependent manner. Thus, the initiator is negatively regulated by action of the replicase, a mechanism that may be key to effective control of the replication cycle.	Kyushu Univ, Fac Pharmaceut Sci, Dept Microbiol, Fukuoka 8128582, Japan; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Kyushu University; Georgetown University	Katayama, T (corresponding author), Kyushu Univ, Fac Pharmaceut Sci, Dept Microbiol, Fukuoka 8128582, Japan.			Katayama, Tsutomu/0000-0001-9994-1684	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM049700, R01GM049700] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49700, R01 GM049700] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRENDLER T, 1995, EMBO J, V14, P4083, DOI 10.1002/j.1460-2075.1995.tb00080.x; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CROOKE E, 1995, CELL, V82, P877, DOI 10.1016/0092-8674(95)90020-9; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; Crooke E, 1995, METHOD ENZYMOL, V262, P500; CROOKE E, 1992, J BIOL CHEM, V267, P16779; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; ECHOLS H, 1961, J MOL BIOL, V3, P425, DOI 10.1016/S0022-2836(61)80055-7; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Garner J, 1996, EMBO J, V15, P2313, DOI 10.1002/j.1460-2075.1996.tb00585.x; Herendeen DR, 1996, CELL, V84, P5, DOI 10.1016/S0092-8674(00)80069-0; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1997, MOL MICROBIOL, V25, P661, DOI 10.1046/j.1365-2958.1997.5001872.x; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kornberg A., 1992, DNA REPLICATION; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; Kurokawa K, 1998, BIOCHEM BIOPH RES CO, V243, P90, DOI 10.1006/bbrc.1997.8069; LASKEN RS, 1987, J BIOL CHEM, V262, P1720; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; MIKI T, 1978, MOL GEN GENET, V158, P217, DOI 10.1007/BF00267192; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; NOZAKI N, 1988, J BIOL CHEM, V263, P14176; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; SAKAKIBARA Y, 1980, MOL GEN GENET, V178, P541, DOI 10.1007/BF00337859; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOSHIKAWA H, 1991, MOL MICROBIOL, V5, P2589, DOI 10.1111/j.1365-2958.1991.tb01967.x; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	66	262	264	0	80	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					61	71		10.1016/S0092-8674(00)81222-2	http://dx.doi.org/10.1016/S0092-8674(00)81222-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674428	hybrid			2022-12-28	WOS:000074790800010
J	Roberts, G; Sherratt, TN				Roberts, G; Sherratt, TN			Development of cooperative relationships through increasing investment	NATURE			English	Article							TIT-FOR-TAT; PRISONERS-DILEMMA; RECIPROCAL ALTRUISM; EVOLUTION; IMPALA	Reciprocal altruism(1) can become established among selfish, unrelated individuals if they use responsive strategies such as 'tit-for-tat'(2-4). This result raises the fundamental question: how altruistic should one be? The problem is difficult to solve using current 'prisoner's dilemma' based models because they allow only the discrete choice of cooperating or defecting. In reality, however, cooperation is rarely all-or-nothing. Furthermore, if cooperative investment is variable, a new and more subtle kind of cheating becomes possible: individuals may invest slightly less than their partner. A concern is that this 'short-changing' will erode cooperative ventures. Here we show that cooperation can thrive despite variable investment through the new strategy of 'raise-the-stakes'. This strategy offers a small amount on first meeting and then, if matched, raises its investment, something that no strategy in the discrete model can do. We show that such behaviour can readily invade a population of non-altruists and cannot be effectively exploited. The practice of 'testing the water' rather than making sudden cooperative 'leaps of faith' powerfully reinforces the stability and effectiveness of reciprocity.	Newcastle Univ, Dept Psychol, Evolut & Behav Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England	Newcastle University - UK; Durham University	Roberts, G (corresponding author), Newcastle Univ, Dept Psychol, Evolut & Behav Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	gilbert.roberts@ncl.ac.uk						AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Benedict Ruth, 1935, PATTERNS CULTURE; CLEMENTS KC, 1995, ANIM BEHAV, V50, P527, DOI 10.1006/anbe.1995.0267; CONNOR RC, 1995, ANIM BEHAV, V49, P528, DOI 10.1006/anbe.1995.0070; de Waal FBM, 1997, EVOL HUM BEHAV, V18, P375, DOI 10.1016/S1090-5138(97)00085-8; Frean M, 1996, J THEOR BIOL, V182, P549, DOI 10.1006/jtbi.1996.0194; FREAN MR, 1994, P ROY SOC B-BIOL SCI, V257, P75, DOI 10.1098/rspb.1994.0096; Halpern JJ, 1997, J CONFLICT RESOLUT, V41, P835, DOI 10.1177/0022002797041006006; HART BL, 1992, ANIM BEHAV, V44, P1073, DOI 10.1016/S0003-3472(05)80319-7; HEINSOHN R, 1995, SCIENCE, V269, P1260, DOI 10.1126/science.7652573; Maynard Smith J., 1982, pi; MESTERTONGIBBONS M, 1992, B MATH BIOL, V54, P423, DOI 10.1007/BF02464842; MILINSKI M, 1987, NATURE, V325, P433, DOI 10.1038/325433a0; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; NOWAK MA, 1994, J THEOR BIOL, V168, P219, DOI 10.1006/jtbi.1994.1101; PECK JR, 1993, J THEOR BIOL, V162, P195, DOI 10.1006/jtbi.1993.1083; Roberts G, 1998, P ROY SOC B-BIOL SCI, V265, P427, DOI 10.1098/rspb.1998.0312; SEYFARTH RM, 1984, NATURE, V308, P541, DOI 10.1038/308541a0; SHERRATT TN, IN PRESS J THEOR BIO; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; WILKINSON GS, 1984, NATURE, V308, P181, DOI 10.1038/308181a0	23	194	196	2	37	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					175	179		10.1038/28160	http://dx.doi.org/10.1038/28160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671299				2022-12-28	WOS:000074705900052
J	Lachs, MS; Williams, CS; O'Brien, S; Pillemer, KA; Charlson, ME				Lachs, MS; Williams, CS; O'Brien, S; Pillemer, KA; Charlson, ME			The mortality of elder mistreatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER ADULTS	Context. - Although elder mistreatment is suspected to be life threatening in some instances, little is known about the survival of elderly persons who have been mistreated. Objective. - To estimate the independent contribution of reported elder abuse and neglect to all-cause mortality in an observational cohort of community-dwelling older adults. Design. - Prospective cohort study with at least 9 years of follow-up. Setting and Patients. - The New Haven Established Population for Epidemiologic Studies in the Elderly cohort, which included 2812 community-dwelling adults who were older than 65 years in 1982, a subset of whom were referred to protective services for the elderly. Main Outcome Measures. - All-cause mortality among (1) elderly persons for whom protective services were used for corroborated elder mistreatment (elder abuse, neglect, and/or exploitation), or (2) elderly persons for whom protective services were used for self-neglect. Results. - In the first 9 years after cohort inception, 176 cohort members were seen by elderly protective services for verified allegations; 10 (5.7%) of these were for abuse, 30 (17.0%) for neglect, 8 (4.5%) for exploitation, and 128 (72.7%) for self-neglect. At the end of a 13-year follow-up period from cohort inception, cohort members seen for elder mistreatment at any time during the follow-up had poorer survival (9%) than either those seen for self-neglect (17%) or other noninvestigated cohort members (40%) (P < .001), In a pooled logistic regression that adjusted for demographic characteristics, chronic diseases, functional status, social networks, cognitive status, and depressive symptomatology, the risk of death remained elevated for cohort members experiencing either elder mistreatment (odds ratio, 3.1; 95% confidence interval, 1.4-6.7) or self-neglect (odds ratio, 1.7; 95% confidence interval, 1.2-2.5), when compared with other members of the cohort. Conclusions. - Reported and corroborated elder mistreatment and self-neglect are associated with shorter survival after adjusting for other factors associated with increased mortality in older adults.	Cornell Univ, Coll Med, Div Geriatr & Gerontol, New York, NY USA; Cornell Univ, Coll Med, Div Gen Internal Med, New York, NY USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol, New Haven, CT 06510 USA; Connecticut Dept Social Serv, Hartford, CT USA; Cornell Coll Human Ecol, Ithaca, NY USA	Cornell University; Cornell University; Yale University; Yale University; Cornell University	Lachs, MS (corresponding author), Cornell Univ, Med Ctr, Coll Med, New York Hosp,Div Geriatr & Gerontol, 525 E 68th St,Box 46, New York, NY 10021 USA.			Pillemer, Karl/0000-0002-7700-3563	NIA NIH HHS [N01-AG-0-2105] Funding Source: Medline; PHS HHS [K0800580] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG002105] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; FIORE J, 1983, AM J COMMUN PSYCHOL, V11, P423, DOI 10.1007/BF00894057; JOHNSON TF, 1991, ELDER MISTREATMENT D; Lachs MS, 1997, GERONTOLOGIST, V37, P469, DOI 10.1093/geront/37.4.469; LACHS MS, 1994, J AM GERIATR SOC, V42, P169, DOI 10.1111/j.1532-5415.1994.tb04947.x; Lachs MS, 1996, ARCH INTERN MED, V156, P449, DOI 10.1001/archinte.156.4.449; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; *NAT I AG, 1986, NIA PUBL; OKUN MA, 1990, GERONTOLOGIST, V30, P193, DOI 10.1093/geront/30.2.193; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; PILLEMER K, 1992, J GERONTOL, V47, pS165, DOI 10.1093/geronj/47.4.S165; PILLEMER K, 1988, GERONTOLOGIST, V28, P51, DOI 10.1093/geront/28.1.51; Pillemer K., 1996, HDB SOCIAL SUPPORT F, P467; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROOK KS, 1984, J PERS SOC PSYCHOL, V46, P1097, DOI 10.1037/0022-3514.46.5.1097; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; Shah BV, 1996, SUDAAN USERS MANUAL; VINOKUR AD, 1993, J PERS SOC PSYCHOL, V65, P350, DOI 10.1037/0022-3514.65.2.350	19	401	410	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					428	432		10.1001/jama.280.5.428	http://dx.doi.org/10.1001/jama.280.5.428			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105AR	9701077	Bronze			2022-12-28	WOS:000075050200029
J	Ofri, D				Ofri, D			Autopsy room	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Ofri, Danielle/0000-0001-9865-7104					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					402	402		10.1001/jama.280.5.402	http://dx.doi.org/10.1001/jama.280.5.402			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701057				2022-12-28	WOS:000075050200001
J	Hopkinson, ZEC; Sattar, N; Fleming, R; Greer, IA				Hopkinson, ZEC; Sattar, N; Fleming, R; Greer, IA			Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology	BRITISH MEDICAL JOURNAL			English	Review							GROWTH FACTOR-I; INSULIN-RESISTANCE; RISK-FACTORS; OBESE WOMEN; BODY-FAT; DISEASE		Univ Glasgow, Glasgow Royal Infirm NHS Trust, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm NHS Trust, Dept Clin Biochem, Glasgow G31 2ER, Lanark, Scotland	University of Glasgow; University of Glasgow	Hopkinson, ZEC (corresponding author), Univ Glasgow, Glasgow Royal Infirm NHS Trust, Dept Obstet & Gynaecol, Glasgow G31 2ER, Lanark, Scotland.							Acbay O, 1996, FERTIL STERIL, V65, P946, DOI 10.1016/S0015-0282(16)58266-1; BERGH C, 1993, FERTIL STERIL, V59, P323; Birdsall MA, 1997, ANN INTERN MED, V126, P32, DOI 10.7326/0003-4819-126-1-199701010-00005; CAREY AH, 1993, CLIN ENDOCRINOL, V38, P653, DOI 10.1111/j.1365-2265.1993.tb02150.x; CASSIMIRRI F, 1997, INT J OBES S, V21, pS61; CATALDO NA, 1997, ENDOCRINOLOGY, V15, P123; CONWAY GS, 1992, CLIN ENDOCRINOL, V37, P119, DOI 10.1111/j.1365-2265.1992.tb02295.x; CRAVE JC, 1995, J CLIN ENDOCR METAB, V80, P2057, DOI 10.1210/jc.80.7.2057; DAHLGREN E, 1992, ACTA OBSTET GYN SCAN, V71, P599, DOI 10.3109/00016349209006227; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; DOUCHI T, 1995, OBSTET GYNECOL, V86, P516, DOI 10.1016/0029-7844(95)00250-U; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P524, DOI 10.1210/jc.82.2.524; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; Erenus M, 1996, FERTIL STERIL, V66, P216, DOI 10.1016/S0015-0282(16)58441-6; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Gonzalez F, 1997, SEMIN REPROD ENDOCR, V15, P137, DOI 10.1055/s-2007-1016296; Kettel LM, 1996, SEMIN REPROD ENDOCR, V14, P309, DOI 10.1055/s-2008-1067976; Nestler J. E., 1997, HUM REPROD         S, V12, P52; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; Nestler JE, 1997, J CLIN ENDOCR METAB, V82, P4075, DOI 10.1210/jc.82.12.4075; NOBELS F, 1992, FERTIL STERIL, V58, P655; PIRWANI I, 1997, J SOC GYNECOL INVE S, V4, pA90; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; SHEU WHH, 1994, CLIN ENDOCRINOL, V40, P249, DOI 10.1111/j.1365-2265.1994.tb02476.x; TALBOTT E, 1995, ARTERIOSCL THROM VAS, V15, P821, DOI 10.1161/01.ATV.15.7.821; VANDERSPUY ZM, 1996, HUM REPROD, V11, P167; Velazquez E, 1997, OBSTET GYNECOL, V90, P392; Velazquez EM, 1997, METABOLISM, V46, P454, DOI 10.1016/S0026-0495(97)90066-4; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; Wild RA, 1997, SEMIN REPROD ENDOCR, V15, P105, DOI 10.1055/s-2007-1016293	33	82	89	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					329	332		10.1136/bmj.317.7154.329	http://dx.doi.org/10.1136/bmj.317.7154.329			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685283	Green Published			2022-12-28	WOS:000075409500027
J	Soto, J; Toledo, J; Rodriquez, M; Sanchez, J; Herrera, R; Padilla, J; Berman, J				Soto, J; Toledo, J; Rodriquez, M; Sanchez, J; Herrera, R; Padilla, J; Berman, J			Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: Efficacy and toxicity - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Primaquine had a prophylactic efficacy of 90% to 95% against infection with Plasmodium falciparum and P. vivax in Indonesian settlers. Objective:To evaluate the efficacy of primaquine prophylaxis for protecting nonimmune persons from malaria. Design: Randomized, double-blind, placebo-controlled field study. Setting: A malaria-endemic area in Colombia. Patients: 176 healthy, young, nonimmune adult male soldiers. Intervention: Primaquine, 30 mg/d, or matching placebo during 15 weeks of patrol in the endemic area and 1 week afterward. Measurements: Symptomatic parasitemia was determined over the 16-week intervention period and for 3 weeks in base camp. Results: Protective efficacy in the primaquine group (122 participants) was 89% (95% CI, 75% to 96%) against all types of malaria, 94% (CI, 78% to 99%) against P. falciparum malaria, and 85% (CI, 57% to 95%) against P. vivax malaria. Six primaquine recipients had mild to moderate gastrointestinal distress, and three had severe distress. Conclusions: For prophylaxis against P. falciparum malaria, primaquine has an efficacy and toxicity competitive with those of standard agents. A;potential advantage of primaquine is that prophylaxis may be discontinued 1 week after the recipient has left the endemic area.	Univ Mil Nueva Granada, Bogota, DC, Colombia; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; Minist Salud, Bogota, Colombia; Consorcio Invest Bioclin, Direcc Sanidad Ejercito, Bogota, Colombia	Universidad Militar Nueva Granada; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center	Soto, J (corresponding author), Univ Mil Nueva Granada, Calle 100 Con Cra 11, Bogota, DC, Colombia.			SOTO, JAIME/0000-0002-0330-1242				ARNOLD J, 1954, J LAB CLIN MED, V44, P429; ARNOLD J, 1955, J LAB CLIN MED, V46, P391; EDERER F, 1974, AM J EPIDEMIOL, V100, P165, DOI 10.1093/oxfordjournals.aje.a112024; FRYAUFF DJ, 1995, LANCET, V346, P1190, DOI 10.1016/S0140-6736(95)92898-7; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; WEBSTER LT, 1985, GOODMAN GILMANS PHAR, P1038; Wolfe MS, 1997, CLIN INFECT DIS, V25, P177, DOI 10.1086/514540	7	54	55	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					241	244		10.7326/0003-4819-129-3-199808010-00013	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696733				2022-12-28	WOS:000075032700009
J	Simonsen, A; Lippe, R; Christoforidis, S; Gaullier, JM; Brech, A; Callaghan, J; Toh, BH; Murphy, C; Zerial, M; Stenmark, H				Simonsen, A; Lippe, R; Christoforidis, S; Gaullier, JM; Brech, A; Callaghan, J; Toh, BH; Murphy, C; Zerial, M; Stenmark, H			EEA1 links PI(3)K function to Rab5 regulation of endosome fusion	NATURE			English	Article							ENDOCYTIC MEMBRANE-FUSION; SMALL GTPASE RAB5; PHOSPHATIDYLINOSITOL 3-KINASE; PATHWAY; LOCALIZATION; WORTMANNIN	GTPases and lipid kinases regulate membrane traffic along the endocytic pathway by mechanisms that are not completely understood(1-4). Fusion between early endosomes requires phosphatidyl-inositol-3-OH kinase (PI(3)K) activity(5-7) as well as the small GTPase Rab5 (ref. 8). Excess Rab5-GTP complex restores endosome fusion when PI(3)K is inhibited(5,9), Here we identify the early-endosomal autoantigen EEA1 (refs 10-12) which binds the PI(3)K product phosphatidylinositol-3-phosphate, as a new Rab5 effector that is required for endosome fusion. The association of EEA1 with the endosomal membrane requires Rab5-GTP and PI(3)K activity, and excess Rab5-GTP stabilizes the membrane association of EEA1 even when PI(3)K is inhibited. The identification of EEA1 as a direct Rab5 effector provides a molecular link between PI(3)K and Rab5, and its restricted distribution to early endosomes(10) indicates that EEA1 may confer directionality to Rab5-dependent endocytic transport.	Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway; European Mol Biol Lab, D-69012 Heidelberg, Germany; Inst Biol, EM Unit, N-0316 Oslo, Norway; Monash Univ Sch Med, Dept Pathol & Immunol, Melbourne, Vic 3181, Australia; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	University of Oslo; European Molecular Biology Laboratory (EMBL); Monash University; Max Planck Society	Stenmark, H (corresponding author), Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway.	stenmark@ulrik.uio.no	Stenmark, Harald/B-8868-2008; Murphy, Carol/ABE-4282-2021	Murphy, Carol/0000-0003-1353-8558; Brech, Andreas/0000-0002-9803-1774; Lippe, Roger/0000-0001-5066-3070; Christoforidis, Savvas/0000-0002-0210-0713; Simonsen, Anne/0000-0003-4711-7057				BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DArrigo A, 1997, EUR J CELL BIOL, V72, P95; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Jones AT, 1998, MOL BIOL CELL, V9, P323, DOI 10.1091/mbc.9.2.323; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; OIKKONEN VM, 1997, INT REV CYTOL, V176, P1; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	26	884	903	2	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					494	498		10.1038/28879	http://dx.doi.org/10.1038/28879			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697774				2022-12-28	WOS:000075080400056
J	Roberts, I				Roberts, I		Cochrane Injuries Grp Albumin Reviewers	Human albumin administration in critically ill patients: systematic review of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							COLLOID OSMOTIC-PRESSURE; PARENTERAL-NUTRITION; MAJOR SURGERY; ONCOTIC PRESSURE; RESUSCITATION; PULMONARY; SHOCK; SUPPLEMENTATION; BYPASS; WATER	Objective: To quantify effect on mortality of administering human albumin or plasma protein fraction during management of critically ill patients. Design: Systematic review of randomised controlled trials comparing administration of albumin or plasma protein fraction with no administration or with administration of crystalloid solution in critically ill patients with hypovolaemia, bums, or hypoalbuminaemia. Subjects: 30 randomised controlled trials including 1419 randomised patients. Main outcome measure: Mortality from all causes at end of follow up for each trial. Results: For each patient category the risk of death in the albumin treated group was higher than in the comparison group. For hypovolaemia the relative risk of death after albumin administration was 1.46 (95% confidence interval 0.97 to 2.22), for burns the relative risk was 2.40 (1.11 to 5.19), and for hypoalbuminaemia it was 1.69 (1.07 to 2.67). Pooled relative risk of death with albumin administration was 1.68 (1.26 to 2.23). Pooled difference in the risk of death with albumin was 6% (95% confidence interval 3% to 9%) with a fixed effects model. These data suggest that for every 17 critically ill patients treated with albumin there is one additional death. Conclusions: There is no evidence that albumin administration reduces mortality in critically ill patients with hypovolaemia, burns, or hypoalbuminaemia and a strong suggestion that it may increase mortality. These data suggest that use of human albumin in critically ill patients should be urgently reviewed and that it should not be used outside the context of rigorously conducted, randomised controlled trials.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, Cochrane Injuries Grp, Child Hlth Monitoring Unit, London WC1N 1EH, England; UK Cochrane Ctr, Oxford, England; Univ Nottingham, Ctr Evidence Based Pharmacotherapy, Nottingham NG7 2RD, England	University of London; London School of Hygiene & Tropical Medicine; University College London; Cochrane Centre; University of Nottingham	Roberts, I (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, Cochrane Injuries Grp, Child Hlth Monitoring Unit, 30 Guilford St, London WC1N 1EH, England.	Ian.Roberts@ich.ucl.ac.uk						*ASS BRIT PHARM IN, 1998, ABPI COMP DAT SHEETS; BLAND RD, 1976, AM J OBSTET GYNECOL, V124, P263, DOI 10.1016/0002-9378(76)90154-X; BOLDT J, 1993, ANESTH ANALG, V76, P1185, DOI 10.1213/00000539-199376060-00002; BOUTROS AR, 1979, CRIT CARE MED, V7, P9, DOI 10.1097/00003246-197901000-00003; BROWN RO, 1988, CRIT CARE MED, V16, P1177, DOI 10.1097/00003246-198812000-00002; CLIFT DR, 1982, J SURG RES, V32, P449, DOI 10.1016/0022-4804(82)90125-1; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FLECK A, 1985, LANCET, V1, P781; FOLEY EF, 1990, ARCH SURG-CHICAGO, V125, P739; GALLAGHER JD, 1985, ANESTH ANALG, V64, P753; Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2; GOLUB R, 1994, CRIT CARE MED, V22, P613, DOI 10.1097/00003246-199404000-00017; GOODWIN CW, 1983, ANN SURG, V197, P520, DOI 10.1097/00000658-198305000-00004; GREENHALGH DG, 1995, J TRAUMA, V39, P67, DOI 10.1097/00005373-199507000-00009; GREENOUGH A, 1993, EUR J PEDIATR, V152, P157, DOI 10.1007/BF02072495; GRUNDMANN R, 1982, INTENS CARE MED, V8, P179, DOI 10.1007/BF01725735; JELENKO C, 1979, CRIT CARE MED, V7, P157, DOI 10.1097/00003246-197904000-00003; JOHNSON SD, 1979, ARCH SURG-CHICAGO, V114, P379; KANAREK KS, 1992, JPEN-PARENTER ENTER, V16, P49, DOI 10.1177/014860719201600149; LOWE RJ, 1977, SURGERY, V81, P676; LUCAS CE, 1980, J TRAUMA, V20, P47, DOI 10.1097/00005373-198020010-00006; LUCAS CE, 1978, J TRAUMA, V18, P564, DOI 10.1097/00005373-197808000-00002; MCCLELLAND DBL, 1990, BRIT MED J, V300, P35, DOI 10.1136/bmj.300.6716.35; MCNULTY SE, 1993, ANESTH ANALG, V76, P830; *MED ED TRIAL AMN, 1998, COCHR LIB; NIELSEN OM, 1985, ACTA CHIR SCAND, V151, P221; NILSSON E, 1980, ACTA CHIR SCAND, V146, P619; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; POCKAJ BA, 1994, J IMMUNOTHER, V15, P22, DOI 10.1097/00002371-199401000-00003; Prien T, 1990, J Clin Anesth, V2, P317; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; Rubin H, 1997, CRIT CARE MED, V25, P249, DOI 10.1097/00003246-199702000-00009; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SHAH DM, 1977, ARCH SURG-CHICAGO, V112, P1161; SKILLMAN JJ, 1975, SURGERY, V78, P291; So KW, 1997, ARCH DIS CHILD-FETAL, V76, pF43, DOI 10.1136/fn.76.1.F43; SONI N, 1995, BRIT MED J, V310, P887, DOI 10.1136/bmj.310.6984.887; TOLLOFSRUD S, 1995, ACTA ANAESTH SCAND, V39, P671, DOI 10.1111/j.1399-6576.1995.tb04146.x; VIRGILIO RW, 1979, SURGERY, V85, P129; WEAVER DW, 1978, ARCH SURG-CHICAGO, V113, P387; WOITTIEZ AJ, 1998, COCHRANE LIB; WOJTYSIAK SL, 1992, CRIT CARE MED, V20, P164, DOI 10.1097/00003246-199202000-00005; WOODS MS, 1993, AM SURGEON, V59, P758; ZETTERSTROM H, 1981, ACTA ANAESTH SCAND, V25, P125, DOI 10.1111/j.1399-6576.1981.tb01622.x; ZETTERSTROM H, 1981, ACTA ANAESTH SCAND, V25, P133, DOI 10.1111/j.1399-6576.1981.tb01623.x	45	750	778	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					235	240						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677209				2022-12-28	WOS:000075081900017
J	Justice, AC; Cho, MK; Winker, MA; Berlin, JA; Rennie, D				Justice, AC; Cho, MK; Winker, MA; Berlin, JA; Rennie, D		PEER Investigators	Does masking author identity improve peer review quality? - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-All authors may not be equal in the eyes of reviewers. Specifically, well-known authors may receive less objective (poorer quality) reviews. One study at a single journal found a small improvement in review quality when reviewers were masked to author identity. Objectives.-To determine whether masking reviewers to author identity is generally associated with higher quality of review at biomedical journals, and to determine the success of routine masking techniques. Design and Setting.-A randomized controlled trial performed on external reviews of manuscripts submitted to Annals of Emergency Medicine, Annals of Internal Medicine, JAMA, Obstetrics & Gynecology, and Ophthalmology. Interventions.-Two peers reviewed each manuscript. In one study arm, both peer reviewers received the manuscript according to usual masking practice. In the other arm, one reviewer was randomized to receive a manuscript with author identity masked, and the other reviewer received an unmasked manuscript. Main Outcome Measure.-Review quality on a 5-point Likert scale as judged by manuscript author and editor. A difference of 0.5 or greater was considered important. Results.-A total of 118 manuscripts were randomized, 26 to usual practice and 92 to intervention. In the intervention arm, editor quality assessment was complete for 77 (84%) of 92 manuscripts. Author quality assessment was complete on 40 (54%) of 74 manuscripts. Authors and editors perceived no significant difference in quality between masked (mean difference, 0.1; 95% confidence interval [CI], -0.2 to 0.4) and unmasked (mean difference, -0.1;95% CI, -0.5 to 0.4) reviews. We also found no difference in the degree to which the review influenced the editorial decision (mean difference, -0.1;95% CI,-0.3 to 0.3). Masking was often unsuccessful (overall, 68% successfully masked; 95% CI, 58%-77%), although 1 journal had significantly better masking success than others (90% successfully masked; 95% CI, 73%-98%). Manuscripts by generally known authors were less likely to be successfully masked (odds ratio, 0.3; 95% CI, 0.1-0.8). When analysis was restricted to manuscripts that were successfully masked, review quality as assessed by editors and authors still did not differ. Conclusions.-Masking reviewers to author identity as commonly practiced does not improve quality of reviews. Since manuscripts of well-known authors are more difficult to mask, and those manuscripts may be more likely to benefit from masking, the inability to mask reviewers to the identity of well-known authors may have contributed to the lack of effect.	Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; Dept Vet Affairs Med Ctr, Div Gen Internal Med, Cleveland, OH USA; Dept Vet Affairs Med Ctr, Program Hlth Care Res, Cleveland, OH USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Div Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; University Hospitals of Cleveland; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of California System; University of California San Francisco	Justice, AC (corresponding author), Case Western Reserve Univ, Sch Med, WG-29,10900 Euclid Ave, Cleveland, OH 44106 USA.			Winker, Margaret/0000-0002-4708-5641	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000009] Funding Source: NIH RePORTER; AHRQ HHS [5T32 HS00009] Funding Source: Medline; PHS HHS [467-MZ-501163] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CLEARY JD, 1988, DRUG INTEL CLIN PHAR, V22, P601, DOI 10.1177/106002808802200720; Fletcher R. H., 1997, SCI ENG ETHICS, V3, P35, DOI [DOI 10.1007/S11948-997-0015-5, 10.1007/s11948-997-0015-5]; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; MOOSSY J, 1985, J NEUROPATH EXP NEUR, V44, P225, DOI 10.1097/00005072-198505000-00001; PITKIN RM, 1995, OBSTET GYNECOL, V85, P781; YANKAUER A, 1991, AM J PUBLIC HEALTH, V81, P843, DOI 10.2105/AJPH.81.7.843	6	184	187	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					240	242		10.1001/jama.280.3.240	http://dx.doi.org/10.1001/jama.280.3.240			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676668				2022-12-28	WOS:000074706000013
J	Shin, DM; Walsh, GL; Komaki, R; Putnam, JB; Nesbitt, J; Ro, JY; Shin, HJC; Ki, KH; Wimberley, A; Pisters, KMW; Schrump, D; Gregurich, MA; Cox, JD; Roth, JA; Hong, WK				Shin, DM; Walsh, GL; Komaki, R; Putnam, JB; Nesbitt, J; Ro, JY; Shin, HJC; Ki, KH; Wimberley, A; Pisters, KMW; Schrump, D; Gregurich, MA; Cox, JD; Roth, JA; Hong, WK			A multidisciplinary approach to therapy for unresectable malignant thymoma	ANNALS OF INTERNAL MEDICINE			English	Article							INVASIVE THYMOMA; NEOADJUVANT CHEMOTHERAPY; CLINICAL STAGES; CISPLATIN; SURVIVAL; CYCLOPHOSPHAMIDE; INTERGROUP; RESECTION; PHASE	Background: The therapeutic outcome for unresectable, locally advanced, malignant thymoma has been poor. Objective: To improve tumor resectability and patient survival rates by studying a multimodal approach to therapy for unresectable malignant thymoma. Design: Prospective cohort study. Setting: Tertiary care cancer center. Participants: All eligible patients had newly diagnosed, histologically proven, unresectable malignant thymoma. Intervention: The treatment regimen consisted of induction chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone), surgical resection, postoperative radiation therapy, and consolidation chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone). Tissue samples were taken at the time of surgical resection for assessment of tumor necrosis and Ki-67 expression. Measurements: Tumor response and resectability (both overall and after induction chemotherapy) and disease-free survival rate in patients who received multimodal therapy. Results: 13 patients were consecutively enrolled from February 1990 to December 1996, and 12 evaluable patients were assessed for response. Disease responded to induction chemotherapy completely in 3 patients (25%) and partially in 8 patients (67%); 1 patient had a minor response (8%). Eleven patients had surgical resection; 1 refused surgery. Tumors were removed completely in 9 (82%) and incompletely in 2 (18%) of 11 patients who had been receiving radiation therapy and consolidation chemotherapy. All 12 patients are alive (100% at 7 years), with a median follow-up of 43 months, and 10 patients are disease free (73 % disease-free survival at 7 years). A high correlation was seen between tumor necrosis after induction chemotherapy and Ki-67 expression (r = -0.88). Conclusions: Aggressive multimodal treatment is highly effective and may cure locally advanced, unresectable malignant thymoma.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Shin, DM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Ray, Dana M/C-3470-2013; Shin, Dong Moon/G-9649-2013	Shin, Dong Moon/0000-0002-8245-4174; Putnam, Joe/0000-0002-7504-2104				BERRUTI A, 1993, ANN ONCOL, V4, P429, DOI 10.1093/oxfordjournals.annonc.a058527; BLUMBERG D, 1995, ANN THORAC SURG, V60, P908, DOI 10.1016/0003-4975(95)00669-C; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; COWEN D, 1995, RADIOTHER ONCOL, V34, P9, DOI 10.1016/0167-8140(94)01493-M; Giaccone G, 1996, J CLIN ONCOL, V14, P814, DOI 10.1200/JCO.1996.14.3.814; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOMAKI R, 1994, MOSS RAD ONCOLOGY RA, P320; LOEHRER PJ, 1990, ANN INTERN MED, V113, P520, DOI 10.7326/0003-4819-113-7-520; LOEHRER PJ, 1994, J CLIN ONCOL, V12, P1164, DOI 10.1200/JCO.1994.12.6.1164; Loehrer PJ, 1997, J CLIN ONCOL, V15, P3093, DOI 10.1200/JCO.1997.15.9.3093; MACCHIARINI P, 1991, CANCER, V68, P706, DOI 10.1002/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H; MAGGI G, 1986, CANCER-AM CANCER SOC, V58, P765, DOI 10.1002/1097-0142(19860801)58:3<765::AID-CNCR2820580326>3.0.CO;2-S; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; MCCART JA, 1993, J SURG ONCOL, V54, P233, DOI 10.1002/jso.2930540409; PARK HS, 1994, CANCER-AM CANCER SOC, V73, P2491, DOI 10.1002/1097-0142(19940515)73:10<2491::AID-CNCR2820731007>3.0.CO;2-6; REA F, 1993, J THORAC CARDIOV SUR, V106, P543; THOMAS C R JR, 1990, Current Opinion in Oncology, V2, P359; Uematsu M, 1996, INT J RADIAT ONCOL, V35, P357, DOI 10.1016/0360-3016(96)00086-7; VERLEY JM, 1985, CANCER, V55, P1074, DOI 10.1002/1097-0142(19850301)55:5<1074::AID-CNCR2820550524>3.0.CO;2-T; Yang WI, 1996, HUM PATHOL, V27, P70, DOI 10.1016/S0046-8177(96)90140-9	20	92	96	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					100	104		10.7326/0003-4819-129-2-199807150-00006	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669967				2022-12-28	WOS:000074852000004
J	Powles, T; Eeles, R; Ashley, S; Easton, D; Chang, J; Dowsett, M; Tidy, A; Viggers, J; Davey, J				Powles, T; Eeles, R; Ashley, S; Easton, D; Chang, J; Dowsett, M; Tidy, A; Viggers, J; Davey, J			Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial	LANCET			English	Article							THERAPY; RISK	Background Tamoxifen, a drug with antioestrogenic effects, is predicted to prevent the occurrence of breast cancer, We have undertaken a trial of tamoxifen in healthy women who are at increased risk of breast cancer because of family history. We report a planned interim analysis, Methods Between October, 1986, and April, 1996, we accrued 2494 healthy women aged between 30 and 70 with a family history of breast cancer, They have been randomised (double blind) to receive tamoxifen 20 mg per day orally or placebo for up to 8 years. Follow-up included clinical assessment, annual mammography, and assessment of toxicity and compliance. The primary endpoint was the occurrence of breast cancer, which was analysed on an intention-to-treat basis with a survival curve. Findings With a median follow-up of 70 months, 2471 women (tamoxifen 1238, placebo 1233) were suitable for analysis, The groups were evenly matched at baseline, and compliance was good. The overall frequency of breast cancer is the same for women on tamoxifen or placebo (tamoxifen 34, placebo 36, relative risk 1.06 [95% CI 0.7-1.7], p=0.8). Participants who were already on hormone-replacement therapy when they entered the study had an increased risk of breast cancer compared with nonusers. Those participants who started such therapy while on trial had a significantly reduced risk. The safety profile of tamoxifen was as expected. Interpretation We have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction in healthy women given tamoxifen versus placebo. Differences in the study populations for the two trials may underlie these conflicting findings: eligibility in our trial was based predominantly on a strong family history of breast cancer whereas in the NSABP trial was mostly based on non-genetic risk factors. The importance of oestrogen promotion may vary between such populations.	Royal Marsden NHS Trust, London, England; Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England; Strangeways Lab, CRC, Canc Genet Team, Cambridge, England; Inst Canc Res, Canc Genet Team, Sutton, Surrey, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Powles, T (corresponding author), Royal Marsden NHS Trust, London, England.	trevor.powles@rmh.nthames.nhs.uk	; chang, jenny/G-7614-2015	Eeles, Rosalind/0000-0002-3698-6241; chang, jenny/0000-0002-0890-9302				[Anonymous], 1988, NEW ENGL J MED, V319, P1681; BAUM M, 1983, LANCET, V1, P257; Clarke M, 1998, LANCET, V351, P1451; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COHN JS, 1988, CLIN CHEM, V34, P2456; CUZICK J, 1985, LANCET, V2, P282; JOHNSTON SRD, 1993, BREAST CANCER RES TR, V28, P241, DOI 10.1007/BF00666585; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; JORDAN VC, 1976, EUR J CANCER, V12, P419, DOI 10.1016/0014-2964(76)90030-X; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; Osin P, 1998, LANCET, V351, P1487, DOI 10.1016/S0140-6736(98)24020-7; Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78; POWLES T, IN PRESS BR J CANC; POWLES TJ, 1995, J NATL CANCER I, V87, P1343, DOI 10.1093/jnci/87.18.1343; POWLES TJ, 1989, BRIT J CANCER, V60, P126, DOI 10.1038/bjc.1989.235; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; 1990, J NAT CANC I, V90, P648	18	710	727	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1998	352	9122					98	101						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672274				2022-12-28	WOS:000074775100012
J	Ho, DD				Ho, DD			Toward HIV eradication or remission: The tasks ahead	SCIENCE			English	Editorial Material							LIFE-SPAN; IN-VIVO; T-CELLS; LYMPHOCYTES; TURNOVER; NAIVE		Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Rockefeller University	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@adarc.org						Cao Y., UNPUB; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; HAVLIR DV, 1998, 5 C RETR OPP INF CHI, pLB16; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; MORRIS L, IN PRESS J EXP MED; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PERELSON AS, UNPUB; RAFFI F, 1998, 5 C RETR OPP INF CHI, pLB15; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; VESANEN M, 1997, INT WORKSH HIV DRUG; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	23	149	159	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1866	1867		10.1126/science.280.5371.1866	http://dx.doi.org/10.1126/science.280.5371.1866			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669944				2022-12-28	WOS:000074323800040
J	Marx, SO; Ondrias, K; Marks, AR				Marx, SO; Ondrias, K; Marks, AR			Coupled gating between individual skeletal muscle Ca2+ release channels (ryanodine receptors)	SCIENCE			English	Article							II-III-LOOP; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; DIHYDROPYRIDINE RECEPTOR; REGIONS	Excitation-contraction coupling in skeletal muscle requires the release of intracellular calcium ions (Ca2+) through ryanodine receptor (RyR1) channels in the sarcoplasmic reticulum. Half of the RyR1 channels are activated by voltage-dependent Ca2+ channels in the plasma membrane, In planar Lipid bilayers, RyR1 channels exhibited simultaneous openings and closings, termed "coupled gating." Addition of the channel accessory protein FKBP12 induced coupled gating, and removal of FKBP12 uncoupled channels, Coupled gating provides a mechanism by which RyR1 channels that are not associated with voltage-dependent Ca2+ channels can be regulated.	Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Cardiol,Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Circulatory Physiol,Dept Med, New York, NY 10032 USA; Slovak Acad Sci, Inst Mol Physiol & Genet, SK-83334 Bratislava, Slovakia; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Slovak Academy of Sciences; Columbia University	Marks, AR (corresponding author), Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Cardiol,Dept Med, New York, NY 10032 USA.			Ondrias, Karol/0000-0001-8329-3563	FOGARTY INTERNATIONAL CENTER [R03TW000949] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056180] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW00949] Funding Source: Medline; NHLBI NIH HHS [R01HL56180] Funding Source: Medline; PHS HHS [R01A139794] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CORONADO R, 1992, METHOD ENZYMOL, V207, P699; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; MARX SO, UNPUB; MILLER C, 1986, ION CHANNL RECONSTIT, P3; Ondrias K, 1996, SOC GEN PHY, V51, P29; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0	20	350	362	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					818	821		10.1126/science.281.5378.818	http://dx.doi.org/10.1126/science.281.5378.818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694652				2022-12-28	WOS:000075295600048
J	Fraenkel, L; Zhang, YQ; Chaisson, CE; Evans, SR; Wilson, PWF; Felson, DT				Fraenkel, L; Zhang, YQ; Chaisson, CE; Evans, SR; Wilson, PWF; Felson, DT			The Association of Estrogen Replacement Therapy and the Raynaud Phenomenon in Postmenopausal Women	ANNALS OF INTERNAL MEDICINE			English	Article							MENSTRUAL-CYCLE; HEALTHY WOMEN; DIAGNOSIS; PROGESTERONE; POPULATION; ESTRADIOL	Background: Hormonal factors may play an important role in the pathophysiology of the Raynaud phenomenon. Experimental studies have shown an increased vasoconstrictor response to estrogen, a response that can be prevented by the addition of progesterone. Objective: To measure the association between estrogen replacement therapy (alone and with progesterone) and the Raynaud phenomenon. Design: Cross-sectional study. Setting: Framingham Offspring Study. Participants: 497 postmenopausal women. Measurements: Prevalence of the Raynaud phenomenon according to hormone use. Covariates measured included age, body mass index, smoking, alcohol consumption, and p-blocker use. Results: Forty-nine women were classified as having the Raynaud phenomenon (9.9%). The prevalence of this phenomenon was 8.4% among women who did not receive estrogen, 19.1% among women receiving estrogen alone, and 9.8% among women receiving estrogen plus progesterone. The adjusted odds ratio for the Raynaud phenomenon was 2.5 (95% CI, 1.2 to 5.3) for unopposed estrogen and 0.9 (CI, 0.3 to 2.6) for estrogen plus progesterone, with nonusers as the reference group. Conclusions: Unopposed estrogen therapy was associated with the Raynaud phenomenon in postmenopausal women. This association was not present in women who were receiving combined hormone therapy.	Boston Univ, Ctr Arthritis, Boston, MA 02118 USA; Boston Univ, Med Ctr, Boston, MA USA; NHLBI, Bethesda, MD USA	Boston University; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Fraenkel, L (corresponding author), Boston Univ, Ctr Arthritis, A203,715 Albany St, Boston, MA 02118 USA.		Wilson, Peter W.F./J-2455-2016	Felson, David/0000-0002-2668-2447; Chaisson, Christine/0000-0002-3207-9257; Zhang, Yuqing/0000-0001-7954-1149	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIAMS NIH HHS [AR20613] Funding Source: Medline; NIA NIH HHS [AG09300] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTURA BM, 1975, J PHARMACOL EXP THER, V193, P403; BARTELINK ML, 1994, EUR J CLIN PHARMACOL, V46, P557, DOI 10.1007/BF00196115; BRENNAN P, 1993, BRIT J RHEUMATOL, V32, P357; COFFMAN JD, 1990, J VASC MED BIOL, V2; EASTCOTT HH, 1976, BRIT MED J, V2, P477, DOI 10.1136/bmj.2.6033.477-c; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; FELSON DT, 1995, AM J EPIDEMIOL, V142, P485, DOI 10.1093/oxfordjournals.aje.a117664; Greenstein D, 1996, ANGIOLOGY, V47, P427, DOI 10.1177/000331979604700501; HAMLET MA, 1980, AM J PHYSIOL, V239, pH450, DOI 10.1152/ajpheart.1980.239.4.H450; KEIL JE, 1991, INT J EPIDEMIOL, V20, P221, DOI 10.1093/ije/20.1.221; LEPPERT J, 1987, ANGIOLOGY, V38, P871, DOI 10.1177/000331978703801201; LEVINE JD, 1989, BRAIN RES, V487, P143, DOI 10.1016/0006-8993(89)90949-9; MARICQ HR, 1988, J RHEUMATOL, V15, P454; OKEEFFE ST, 1992, J RHEUMATOL, V19, P1415; ROBERTS JM, 1977, NATURE, V270, P624, DOI 10.1038/270624a0; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; SOLERTE SB, 1988, BRIT J OBSTET GYNAEC, V95, P1305, DOI 10.1111/j.1471-0528.1988.tb06822.x; TERREGINO CA, 1985, ANGIOLOGY, V36, P88, DOI 10.1177/000331978503600204; Valter I, 1998, J RHEUMATOL, V25, P697; WILLIAMS LT, 1977, J CLIN INVEST, V60, P815, DOI 10.1172/JCI108835	20	43	45	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					208	211		10.7326/0003-4819-129-3-199808010-00009	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696729				2022-12-28	WOS:000075032700006
J	Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R				Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R			Identification of patients with atrial fibrillation in general practice: a study of screening methods	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle Upon Tyne, Sch Clin Med Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England	Newcastle University - UK	Sudlow, M (corresponding author), Univ Newcastle Upon Tyne, Sch Clin Med Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	Mark.Sudlow@ncl.ac.uk		Kenny, Rose Anne/0000-0002-9336-8124				Cuckle HS, 1984, ANTENATAL NEONATAL S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	5	51	52	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					327	328		10.1136/bmj.317.7154.327	http://dx.doi.org/10.1136/bmj.317.7154.327			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685281	Green Published			2022-12-28	WOS:000075409500025
J	Villers, D; Espaze, E; Coste-Burel, M; Giauffret, F; Ninin, E; Nicolas, F; Richet, H				Villers, D; Espaze, E; Coste-Burel, M; Giauffret, F; Ninin, E; Nicolas, F; Richet, H			Nosocomial Acinetobacter baumannii infections: Microbiological and clinical epidemiology	ANNALS OF INTERNAL MEDICINE			English	Article						Acinetobacter infections; drug resistance, multiple; opportunistic infections; cross infection; anti-infective agents, fluoroquinolone	QUINOLONE-RESISTANT MUTANTS; HOSPITAL OUTBREAKS; ESCHERICHIA-COLI; TYPING METHODS; RISK-FACTORS; IN-VITRO; STRAINS; DNA; CIPROFLOXACIN; PHARMACOKINETICS	Background: Acinetobacter baumannii is an important opportunistic pathogen that is rapidly evolving toward multidrug resistance and is involved in various nosocomial infections that are often severe. It is difficult to prevent A. baumannii infection because A. baumannii is ubiquitous and the epidemiology of the infections it causes is complex. Objective: To study the epidemiology of A. baumannii infections and assess the relation between fluoroquinolone use and the persistence of multidrug-resistant clones. Design: Three case-control studies and a retrospective cohort study. Setting: A 20-bed medical and surgical intensive care unit. Patients: Acinetobacter baumannii was isolated from 45 patients in urine (31%), the lower respiratory tract (26.7%), wounds (17.8%), blood (11.1%), skin (6.7%), cerebrospinal fluid (4.4%), and sinus specimens (2.2%). One death was due to A. baumannii infection. Measurements: Antimicrobial resistance pattern and molecular typing were used to characterize isolates. The incidence of A. baumannii infection and the use of fluoroquinolones were calculated annually. Results: Initially, 28 patients developed A. baumannii infection. Eleven isolates had the same antimicrobial susceptibility profile, genotypic profile, or both (epidemic cases), and 17 were heterogeneous (endemic cases). A surgical procedure done in an emergency operating room was the main risk factor for epidemic cases, whereas previous receipt of a fluoroquinolone was the only risk factor for endemic cases. The opening of a new operating room combined with the restriction of fluoroquinolone use contributed to a transitory reduction in the incidence of infection. When a third epidemiologic study was done, previous receipt of a fluoroquinolone was again an independent risk factor and a parallel was seen between the amount of intravenous fluoroquinolones prescribed and the incidence of endemic infection. Conclusion: Epidemic infections coexisted with endemic infections favored by the selection pressure of intravenous fluoroquinolones.	Hop Nantes, Bacteriol Lab, Inst Biol, F-44035 Nantes, France; Hop Hotel Dieu, Nantes, France	Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Villers, D (corresponding author), CHU Nantes, Serv Reanimat Med, Hotel Dieu, F-44035 Nantes 01, France.							ANDREWS HJ, 1986, J HOSP INFECT, V7, P169, DOI 10.1016/0195-6701(86)90060-5; BECKSAGUE CM, 1990, AM J EPIDEMIOL, V132, P723, DOI 10.1093/oxfordjournals.aje.a115714; BergogneBerezin E, 1996, CLIN MICROBIOL REV, V9, P148, DOI 10.1128/CMR.9.2.148; BOUVET PJM, 1987, ANN INST PASTEUR MIC, V138, P569, DOI 10.1016/0769-2609(87)90042-1; BROSIUS J, 1981, PLASMID, V6, P112, DOI 10.1016/0147-619X(81)90058-5; BRUMFITT W, 1984, ANTIMICROB AGENTS CH, V26, P757, DOI 10.1128/AAC.26.5.757; CEFAI C, 1990, J HOSP INFECT, V15, P177, DOI 10.1016/0195-6701(90)90128-B; CHRISTIE C, 1995, INFECT CONT HOSP EP, V16, P590; DIJKSHOORN L, 1993, J CLIN MICROBIOL, V31, P702, DOI 10.1128/JCM.31.3.702-705.1993; DOLZANI L, 1995, J CLIN MICROBIOL, V33, P1108, DOI 10.1128/JCM.33.5.1108-1113.1995; Fung-Tomc J, 1990, ANTIMICROB NEWSLETT, V7, P17; GO ES, 1994, LANCET, V344, P1329, DOI 10.1016/S0140-6736(94)90694-7; GRUNDMANN H, 1995, J MED MICROBIOL, V43, P446, DOI 10.1099/00222615-43-6-446; HORREVORTS A, 1995, J CLIN MICROBIOL, V33, P1567, DOI 10.1128/JCM.33.6.1567-1572.1995; JOLYGUILLOU ML, 1990, J HOSP INFECT, V16, P49, DOI 10.1016/0195-6701(90)90048-S; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KROPEC A, 1993, J HOSP INFECT, V23, P133, DOI 10.1016/0195-6701(93)90017-T; Levin ASS, 1996, INFECT CONT HOSP EP, V17, P366, DOI 10.1086/647319; LORTHOLARY O, 1995, CLIN INFECT DIS, V20, P790, DOI 10.1093/clinids/20.4.790; MULIN B, 1995, EUR J CLIN MICROBIOL, V14, P569, DOI 10.1007/BF01690727; PETERSON LR, 1993, DIAGN MICR INFEC DIS, V17, P97, DOI 10.1016/0732-8893(93)90019-4; PIDDOCK LJV, 1991, J ANTIMICROB CHEMOTH, V28, P185, DOI 10.1093/jac/28.2.185; RICHARD P, 1994, J INFECT DIS, V170, P377, DOI 10.1093/infdis/170.2.377; ROHWEDDER RW, 1990, DIAGN MICR INFEC DIS, V13, P127, DOI 10.1016/0732-8893(90)90095-D; SAMADPOUR M, 1988, J CLIN MICROBIOL, V26, P2319, DOI 10.1128/JCM.26.11.2319-2323.1988; SCERPELLA EG, 1995, INFECT CONT HOSP EP, V16, P92, DOI 10.1086/647063; SEIFERT H, 1994, INFECT CONT HOSP EP, V15, P520; SEIFERT H, 1995, J CLIN MICROBIOL, V33, P1402, DOI 10.1128/JCM.33.5.1402-1407.1995; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SOUSSY CJ, 1994, EUR J CLIN MICROBIOL, V13, P238, DOI 10.1007/BF01974543; STRUELENS MJ, 1993, J HOSP INFECT, V25, P15, DOI 10.1016/0195-6701(93)90005-K; TJERNBERG I, 1989, APMIS, V97, P595, DOI 10.1111/j.1699-0463.1989.tb00449.x; TRAUB WH, 1989, J CLIN MICROBIOL, V27, P2713, DOI 10.1128/JCM.27.12.2713-2716.1989; VANCEBRYAN K, 1990, CLIN PHARMACOKINET, V19, P434, DOI 10.2165/00003088-199019060-00003; VANDEECHOUTTE M, 1995, RES MICROBIOL, V146, P457; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; VILA J, 1989, J CLIN MICROBIOL, V27, P1086, DOI 10.1128/JCM.27.5.1086-1089.1989; VOLLAARD EJ, 1990, J ANTIMICROB CHEMOTH, V26, P847, DOI 10.1093/jac/26.6.847; WATANABE M, 1990, ANTIMICROB AGENTS CH, V34, P173, DOI 10.1128/AAC.34.1.173	39	169	185	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1998	129	3					182	+		10.7326/0003-4819-129-3-199808010-00003	http://dx.doi.org/10.7326/0003-4819-129-3-199808010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104UA	9696725				2022-12-28	WOS:000075032700002
J	Nitta, I; Kamada, Y; Noda, H; Ueda, T; Watanabe, K				Nitta, I; Kamada, Y; Noda, H; Ueda, T; Watanabe, K			Reconstitution of peptide bond formation with Escherichia coli 23S ribosomal RNA domains	SCIENCE			English	Article							TRANSFERASE CENTER; SITE; SECONDARY; SUBUNITS; PROTEIN; MODEL	It was recently demonstrated that peptide bond formation can occur using an Escherichia coli naked 23S ribosomal RNA without any of the ribosomal proteins. Here, the six domains of the 23S ribosomal RNA were individually synthesized and shown to be capable, when complexed together, of stimulating the reaction. Omission and addition experiments indicated that the activity could be reconstituted solely by domain V at a concentration 10 times higher than that of the intact 23S ribosomal RNA, whereas domain VI could enhance the activity in trans. These findings suggest that fragments of an RNA molecule have the ability to associate into a functional whole.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.		Ueda, Takuya/K-5217-2014	Ueda, Takuya/0000-0002-7760-8271				AZAD AA, 1979, NUCLEIC ACIDS RES, V7, P1913, DOI 10.1093/nar/7.7.1913; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; CUNDLIFFE E, 1981, ANTIBIOTIC INHIBITOR, P402; DABROWSKI M, 1995, EMBO J, V14, P4872, DOI 10.1002/j.1460-2075.1995.tb00168.x; DOUDNA JA, 1995, RNA, V1, P36; FRANCESCHI FJ, 1990, J BIOL CHEM, V265, P16676; Green R, 1997, J MOL BIOL, V266, P40, DOI 10.1006/jmbi.1996.0780; Green R, 1996, RNA, V2, P1011; GREEN R, 1997, ANNU REV BIOCHEM, V66, P191; HAUSNER TP, 1988, J BIOL CHEM, V263, P13103; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; MCCLAIN WH, 1973, J MOL BIOL, V81, P157, DOI 10.1016/0022-2836(73)90186-1; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; Nitta I, 1998, RNA, V4, P257; NITTA I, UNPUB; NOLLER HF, 1981, NUCLEIC ACIDS RES, V9, P6167, DOI 10.1093/nar/9.22.6167; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Porse BT, 1996, J MOL BIOL, V264, P472, DOI 10.1006/jmbi.1996.0655; RAUE HA, 1988, PROG BIOPHYS MOL BIO, V51, P77, DOI 10.1016/0079-6107(88)90011-9; RAUE HA, 1990, RIBOSOME, P217; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SEIDMAN JG, 1975, J MOL BIOL, V99, P733, DOI 10.1016/S0022-2836(75)80182-3; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; Spahn CMT, 1996, J BIOL CHEM, V271, P32857, DOI 10.1074/jbc.271.51.32857; Spahn CMT, 1996, J BIOL CHEM, V271, P32849, DOI 10.1074/jbc.271.51.32849; STIEGE W, 1983, NUCLEIC ACIDS RES, V11, P1687, DOI 10.1093/nar/11.6.1687; Tan GT, 1996, J MOL BIOL, V261, P222, DOI 10.1006/jmbi.1996.0454; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VANDERHORST G, 1991, P NATL ACAD SCI USA, V88, P184, DOI 10.1073/pnas.88.1.184; Vazquez D., 1979, INHIBITORS PROTEIN B; Woese C, 1967, GENETIC CODE, P179; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z	34	64	69	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					666	669		10.1126/science.281.5377.666	http://dx.doi.org/10.1126/science.281.5377.666			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685252				2022-12-28	WOS:000075107900031
J	Beecham, L				Beecham, L			NHS helpline will cover 10 million people	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					286	286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677242				2022-12-28	WOS:000075081900064
J	Burdett, S; Parmar, MKB; Stewart, LA; Souhami, RL; Arriagada, R; Girling, DJ; Pignon, JP; Torri, V; Brichet, AH; Lafitte, JJ; Dautzenberg, B; Debevec, M; Kovac, V; Stephens, RJ; Gregor, A; Piantadosi, S; Rocmans, P; Van Houtte, P; Wang, M				Burdett, S; Parmar, MKB; Stewart, LA; Souhami, RL; Arriagada, R; Girling, DJ; Pignon, JP; Torri, V; Brichet, AH; Lafitte, JJ; Dautzenberg, B; Debevec, M; Kovac, V; Stephens, RJ; Gregor, A; Piantadosi, S; Rocmans, P; Van Houtte, P; Wang, M		PORT Meta-Anal Trialists Grp	Postoperative radiotherapy in nonsmall-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials	LANCET			English	Article							RADIATION	Background The role of postoperative radiotherapy in treatment of patients with completely resected non-small-cell lung cancer (NSCLC) remains unclear. We undertook a systematic review and meta-analysis of the available evidence from randomised trials. Methods Updated data were obtained on individual patients from all available randomised trials of postoperative radiotherapy versus surgery alone. Data on 2128 patients from nine randomised trials (published and unpublished) were analysed by intention to treat. There were 707 deaths among 1056 patients assigned postoperative radiotherapy and 661 among 1072 assigned surgery alone. Median follow-up was 3.9 years (2.3-9.8 for individual trials) for surviving patients. Findings The results show a significant adverse effect of postoperative radiotherapy on survival (hazard ratio 1.21 [95% CI 1.08-1.34]). This 21% relative increase in the risk of death is equivalent to an absolute detriment of 7% (3-11) at 2 years, reducing overall survival from 55% to 48%. Subgroup analyses suggest that this adverse effect was greatest for patients with stage I/II, N0-N1 disease, whereas for those with stage III, N2 disease there was no clear evidence of an adverse effect. Interpretation Postoperative radiotherapy is detrimental to patients with early-stage completely resected NSCLC and should not be used routinely for such patients. The role of postoperative radiotherapy in the treatment of N2 tumours is not clear and may warrant further research.	MRC, Canc Trials Off, Cambridge CB2 2BW, England; UCL, Sch Med, London, England; Inst Radiomed, Santiago, Chile; Inst Gustave Roussy, Villejuif, France; Ist Ric Farmacol Mario Negri, Milan, Italy; CHRU, Hop Calmette, Lille, France; Inst Oncol, Ljubljana, Slovenia; European Org Res Treatment Canc, Brussels, Belgium; Hop St Pierre & Erasme, Brussels, Belgium; Inst Jules Bordet, B-1000 Brussels, Belgium; Chinese Acad Med Sci, Beijing 100037, Peoples R China	University of London; University College London; UCL Medical School; UNICANCER; Gustave Roussy; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Universite de Lille - ISITE; CHU Lille; Institute of Oncology - Slovenia; European Organisation for Research & Treatment of Cancer; Universite Libre de Bruxelles; Institut Jules Bordet; Chinese Academy of Medical Sciences - Peking Union Medical College	Stewart, LA (corresponding author), MRC, Canc Trials Off, 5 Shaftesbury Rd, Cambridge CB2 2BW, England.	ls@cto.mrc.ac.uk	Torri, Valter/H-7550-2015	Torri, Valter/0000-0001-9541-9354; Stewart, Lesley/0000-0003-0287-4724; PIGNON, Jean-Pierre/0000-0003-2047-1582				ALBERTI W, 1995, BRIT MED J, V311, P899; BANGMA PJ, 1972, CARCINOMA BRONCHUS M, P163; BASSORICCI S, 1991, LUNG CANCER, V7, P99; Debevec M, 1996, LUNG CANCER, V14, P99, DOI 10.1016/0169-5002(95)00515-3; Dickersin K, 1995, SYSTEMATIC REV, P17; *EAR BREAST CANC T, 1990, TRATM EARL BREAST CA; ISRAEL L, 1979, LUNG CANC PROGR THER, P443; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lafitte JJ, 1996, ANN THORAC SURG, V62, P830, DOI 10.1016/S0003-4975(96)00507-3; Parkin DM, 1993, LUNG CANCER, V9, P1; PARMAR M, 1995, SURVIVAL ANAL PRACTI; PATERSON R, 1962, Clin Radiol, V13, P141, DOI 10.1016/S0009-9260(62)80036-1; Rankin EM, 1986, RANDOMISED TRIALS CA, P447; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SmolleJuettner FM, 1996, EUR J CARDIO-THORAC, V10, P947, DOI 10.1016/S1010-7940(96)80395-2; Stephens RJ, 1996, BRIT J CANCER, V74, P632, DOI 10.1038/bjc.1996.413; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; VANHOUTTE P, 1980, INT J RADIAT ONCOL, V6, P983, DOI 10.1016/0360-3016(80)90105-4; WANG M, 1994, CHIN J RAD ONCOL, V3, P39; WEISENBURGER TH, 1986, NEW ENGL J MED, V315, P1377; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	21	644	654	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					257	263						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690404				2022-12-28	WOS:000074974500007
J	Neuberger, J				Neuberger, J			Primary care: core values - Patients' priorities	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; SATISFACTION; PRACTITIONERS; COSTS; NIGHT		Kings Fund, London W1M 0AN, England		Neuberger, J (corresponding author), Kings Fund, London W1M 0AN, England.	j.neuberger@kehf.org.uk	Neuberger, James/ABG-3010-2020					BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Baker R, 1996, BRIT J GEN PRACT, V46, P601; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; Brown JS, 1997, BRIT J GEN PRACT, V47, P205; CALNAN M, 1994, FAM PRACT, V11, P468, DOI 10.1093/fampra/11.4.468; Campbell JL, 1996, BRIT J GEN PRACT, V46, P465; CROGG D, 1997, BMJ-BRIT MED J, V314, P187; Hearnshaw H, 1996, FAM PRACT, V13, P52, DOI 10.1093/fampra/13.1.52; HEATH I, 1995, BRIT MED J, V311, P466, DOI 10.1136/bmj.311.7003.466; HEATH I, 1994, BRIT MED J, V308, P993, DOI 10.1136/bmj.308.6935.993; Jessopp L, 1997, BRIT MED J, V314, P199, DOI 10.1136/bmj.314.7075.199; KENDRICK D, 1994, BRIT J GEN PRACT, V44, P372; Lattimer V, 1996, BRIT MED J, V312, P352; MAESENEER J, 1996, EUR J GEN PRACT, V2, P3; McKinley RK, 1997, BMJ-BRIT MED J, V314, P190, DOI 10.1136/bmj.314.7075.190; ODOWD T, 1994, BRIT MED J, V308, P1386, DOI 10.1136/bmj.308.6941.1386; PRINGLE M, 1996, EUR J GEN PRACT, V2, P5; Salisbury C, 1997, BRIT MED J, V314, P182, DOI 10.1136/bmj.314.7075.182; Salisbury C, 1997, BRIT MED J, V314, P1598, DOI 10.1136/bmj.314.7094.1598; Salisbury C, 1997, BRIT MED J, V314, P1594, DOI 10.1136/bmj.314.7094.1594; SPIERS R, 1995, BR J GEN PRACT, V45, P31	21	28	29	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					260	262		10.1136/bmj.317.7153.260	http://dx.doi.org/10.1136/bmj.317.7153.260			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677218	Green Published			2022-12-28	WOS:000075081900025
J	Schoenen, J				Schoenen, J			Cluster headaches - central or peripheral in origin?	LANCET			English	Editorial Material							NITROGLYCERIN; ATTACKS		Univ Liege, Dept Neurol, B-4000 Liege, Belgium	University of Liege	Schoenen, J (corresponding author), Univ Liege, Dept Neurol, B-4000 Liege, Belgium.							AFRA J, IN PRESS CEPHALALGIA; ATACK JR, 1995, TRENDS NEUROSCI, V18, P343, DOI 10.1016/0166-2236(95)93926-O; DEBELLEROCHE J, 1986, CEPHALALGIA, V6, P147, DOI 10.1046/j.1468-2982.1986.0603147.x; EKBOM K, 1991, NEW ENGL J MED, V325, P322, DOI 10.1056/nejm199108013250505; FANCIULLACCI M, 1988, CLIN NEUROPHARMACOL, V11, P56, DOI 10.1097/00002826-198802000-00005; FRANCESCHINI R, 1995, J NEUROL NEUROSUR PS, V59, P381, DOI 10.1136/jnnp.59.4.381; GILLETTE MU, 1998, NEW NEUROETHOLOGY MO, P105; GOADSBY PJ, 1994, BRAIN, V117, P427, DOI 10.1093/brain/117.3.427; Hannerz J, 1996, HEADACHE, V36, P174, DOI 10.1046/j.1526-4610.1996.3603174.x; Hardebo Jan Erik, 1993, P569; Hsieh JC, 1996, PAIN, V67, P59, DOI 10.1016/0304-3959(96)03066-7; LEONE M, 1993, CEPHALALGIA, V13, P309, DOI 10.1046/j.1468-2982.1993.1305309.x; Lozza A, 1997, PAIN, V71, P81, DOI 10.1016/S0304-3959(97)03342-3; May A, 1998, PAIN, V74, P61, DOI 10.1016/S0304-3959(97)00144-9; NAPPI G, 1981, CHRONOBIOLOGIA, V8, P140; SAPER CB, 1998, HUMAN NERVOUS SYSTEM, P389; SICUTERI F, 1990, HEADACHE, V30, P69, DOI 10.1111/j.1526-4610.1990.hed3002069.x; SJAASTAD O, 1992, IN PRESS CEPHALALGIA; Strittmatter M, 1996, CEPHALALGIA, V16, P476, DOI 10.1046/j.1468-2982.1996.1607476.x; SWAAB DF, 1985, SCIENCE, V228, P1112, DOI 10.1126/science.3992248; WALDENLIND E, 1987, J NEUROL NEUROSUR PS, V50, P207, DOI 10.1136/jnnp.50.2.207	21	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					253	255		10.1016/S0140-6736(05)60256-5	http://dx.doi.org/10.1016/S0140-6736(05)60256-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690402				2022-12-28	WOS:000074974500005
J	Smith, H; Gooding, S; Brown, R; Frew, A				Smith, H; Gooding, S; Brown, R; Frew, A			Evaluation of readability and accuracy of information leaflets in general practice for patients with asthma	BRITISH MEDICAL JOURNAL			English	Article									Univ Southampton, Wessex Primary Care Res Network, Southampton SO16 5ST, Hants, England; Wilton Hlth Ctr, Wilton SP2 0HT, England; Univ Med, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Smith, H (corresponding author), Univ Southampton, Wessex Primary Care Res Network, Southampton SO16 5ST, Hants, England.		Kelly, Frank J/C-6125-2009; Smith, Helen E/M-2449-2016	Kelly, Frank J/0000-0003-2558-8392; Smith, Helen E/0000-0003-1883-6124				*BAS SKILLS AG, 1992, MAK READ EAS; Carey S, 1997, ADULT LITERACY BRITA; ESTEY A, 1991, PATIENT EDUC COUNS, V18, P165, DOI 10.1016/0738-3991(91)90008-S; ESTEY A, 1996, PATIENT EDUC COUNS, V30, P205; MCLAUGHLIN GH, 1969, J READING, V12, P639; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	6	60	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					264	265		10.1136/bmj.317.7153.264	http://dx.doi.org/10.1136/bmj.317.7153.264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PG	9677221	Green Published, Green Accepted			2022-12-28	WOS:000075081900028
J	Dobbins, AC; Jeo, RM; Fiser, J; Allman, JM				Dobbins, AC; Jeo, RM; Fiser, J; Allman, JM			Distance modulation of neural activity in the visual cortex	SCIENCE			English	Article							RESPONSE PROPERTIES; PRESTRIATE CORTEX; VIEWING DISTANCE; EYE POSITION; NEURONS; MONKEY; AREA; DEPTH; SIZE; STEREOPSIS	Humans use distance information to scale the size of objects. Earlier studies demonstrated changes in neural response as a function of gaze direction and gaze distance in the dorsal visual cortical pathway to parietal cortex. These findings have been interpreted as evidence of the parietal pathway's role in spatial representation. Here, distance-dependent: changes in neural response were also found to be common in neurons in the ventral pathway leading to inferotemporal cortex of monkeys, This result implies that the information necessary for object and spatial scaling is common to all visual cortical areas.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ So Calif, Los Angeles, CA 90089 USA	California Institute of Technology; University of Southern California	Dobbins, AC (corresponding author), Univ Alabama, Dept Biomed Engn, Vis Sci Res Ctr, Birmingham, AL 35294 USA.		Fiser, József/A-2877-2009	Fiser, Jozsef/0000-0002-7064-0690				Aguirre GK, 1997, J NEUROSCI, V17, P2512; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; BARBUR JL, 1987, CLIN VISION SCI, V2, P131; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; COLLETT TS, 1991, PERCEPTION, V20, P733, DOI 10.1068/p200733; DOBBINS E, UNPUB; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; GALLETTI C, 1989, J NEUROSCI, V9, P1112; GENTILUCCI M, 1983, EXP BRAIN RES, V50, P464; GNADT JW, 1995, J NEUROPHYSIOL, V73, P280, DOI 10.1152/jn.1995.73.1.280; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Holway AH, 1941, AM J PSYCHOL, V54, P21, DOI 10.2307/1417790; HUMPHREY N, 1969, Q J EXP PSYCHOL, V21, P255; LEIBOWIT.H, 1966, J OPT SOC AM, V56, P1120, DOI 10.1364/JOSA.56.001120; Milner A. D., 1995, VISUAL BRAIN ACTION; NAKAYAMA K, 1990, VISION RES, V30, P1811, DOI 10.1016/0042-6989(90)90161-D; PETERSEN SE, 1980, BRAIN RES, V197, P507, DOI 10.1016/0006-8993(80)91137-3; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SAKATA H, 1980, J NEUROPHYSIOL, V43, P1654, DOI 10.1152/jn.1980.43.6.1654; Trotter Y, 1996, J NEUROPHYSIOL, V76, P2872, DOI 10.1152/jn.1996.76.5.2872; TROTTER Y, 1992, SCIENCE, V257, P1279, DOI 10.1126/science.1519066; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1977, EXP BRAIN RES, V27, P251; WALLACH H, 1963, AM J PSYCHOL, V76, P404, DOI 10.2307/1419781; WEYAND TG, 1993, J NEUROPHYSIOL, V69, P2258, DOI 10.1152/jn.1993.69.6.2258; WISE SP, 1988, SCIENCE, V242, P736, DOI 10.1126/science.3187520; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	27	86	86	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					552	555		10.1126/science.281.5376.552	http://dx.doi.org/10.1126/science.281.5376.552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677196				2022-12-28	WOS:000075012300038
J	Annas, GJ				Annas, GJ			Partial-birth abortion, Congress, and the constitution	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas C L, 1996, J Contemp Health Law Policy, V12, P325; ANNAS GJ, 1992, NEW ENGL J MED, V327, P651, DOI 10.1056/NEJM199208273270920; GIANCELLI DM, 1997, AM MED NEWS     0707, P30; GIANELLI DM, 1997, AM MED NEWS     0303, P28; GIANELLI DM, 1997, AM MED NEWS     0303, P3; HSU S, 1998, WASHINGTON POST 0626, pC1; JETER J, 1998, WASHINGTON POST 0520, pA8; Kassirer JP, 1997, NEW ENGL J MED, V336, P1747, DOI 10.1056/NEJM199706123362409; KLEIN J, 1998, NEW YORKER      0105, P30; LEWIN T, 1998, NY TIMES        0515, pA16; Massie AM, 1998, U PITT LAW REV, V59, P301; SANTORUM R, 1997, NATL RIGHT LIFE 0523, P6; SEELYE KQ, 1997, NY TIMES        0509, pA32; Vobejda Barbara, 1996, WASHINGTON POST 0912, pA01; Wolinsky H, 1994, SERPENT STAFF UNHEAL; 1996, WEEKLY COMPILATI 041, P643; 1997, WEEKLY COMPILAT 1010, P1545	17	10	10	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					279	283		10.1056/NEJM199807233390420	http://dx.doi.org/10.1056/NEJM199807233390420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673308	Green Published			2022-12-28	WOS:000074918700031
J	Mannucci, PM				Mannucci, PM			Hemostatic drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EPSILON-AMINOCAPROIC ACID; REDUCE BLOOD-LOSS; ORTHOTOPIC LIVER-TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL; VIII-VONWILLEBRAND-FACTOR; PLACEBO-CONTROLLED TRIAL; PROLONGED BLEEDING-TIME; OPEN-HEART SURGERY; TRANEXAMIC ACID; CARDIOPULMONARY BYPASS		Maggiore Hosp, Ist Ricovero & Cura Carattere Sci, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy; Univ Milan, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Mannucci, PM (corresponding author), Via Pace 9, I-20122 Milan, Italy.							ADAMS HP, 1987, NEUROLOGY, V37, P1586, DOI 10.1212/WNL.37.10.1586; ANDERSSON L, 1968, ANN NY ACAD SCI, V146, P642, DOI 10.1111/j.1749-6632.1968.tb20322.x; ANDERSSON L, 1965, SCAND J HAEMATOL, V2, P230; [Anonymous], 1989, LANCET, V1, P938; ANSELL J, 1992, J THORAC CARDIOV SUR, V104, P117; BARTHOLOMEW JR, 1989, ARCH INTERN MED, V149, P1959, DOI 10.1001/archinte.149.9.1959; Benoni G, 1996, J BONE JOINT SURG BR, V78B, P434, DOI 10.1302/0301-620X.78B3.0780434; BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364; BLAUHUT B, 1994, J THORAC CARDIOV SUR, V108, P1083, DOI 10.1016/S0022-5223(12)70192-7; Bonnar J, 1996, BRIT MED J, V313, P579; Boylan JF, 1996, ANESTHESIOLOGY, V85, P1043, DOI 10.1097/00000542-199611000-00012; BURROUGHS AK, 1985, BRIT MED J, V291, P1377, DOI 10.1136/bmj.291.6506.1377; CATTANEO M, 1995, THROMB HAEMOSTASIS, V74, P1064; Cicek S, 1996, J THORAC CARDIOV SUR, V112, P1462, DOI 10.1016/S0022-5223(96)70004-1; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; COSGROVE DM, 1992, ANN THORAC SURG, V54, P1031, DOI 10.1016/0003-4975(92)90066-D; COX HT, 1969, GUT, V10, P404, DOI 10.1136/gut.10.5.404; DAILY PO, 1994, J THORAC CARDIOV SUR, V108, P99; DEFRANCHIS R, 1993, HEPATOLOGY, V18, P1102; DELAFUENTE B, 1985, ANN INTERN MED, V103, P6, DOI 10.7326/0003-4819-103-1-6; DELROSSI AJ, 1989, CHEST, V96, P27, DOI 10.1378/chest.96.1.27; DIETRICH W, 1990, ANESTHESIOLOGY, V73, P1119, DOI 10.1097/00000542-199012000-00009; Dietrich W, 1997, J THORAC CARDIOV SUR, V113, P194, DOI 10.1016/S0022-5223(97)70415-X; DIMICHELE DM, 1990, AM J HEMATOL, V33, P39, DOI 10.1002/ajh.2830330108; FORBES CD, 1972, BMJ-BRIT MED J, V2, P311, DOI 10.1136/bmj.2.5809.311; FRAEDRICH G, 1989, THORAC CARDIOV SURG, V37, P89, DOI 10.1055/s-2007-1013914; FREMES SE, 1994, ANN THORAC SURG, V58, P1580, DOI 10.1016/0003-4975(94)91636-5; FRITZ H, 1983, ARZNEIMITTELFORSCH, V33-1, P479; GAMBA G, 1979, BLUT, V39, P89, DOI 10.1007/BF01008084; GARDNER FH, 1980, JAMA-J AM MED ASSOC, V243, P35, DOI 10.1001/jama.243.1.35; GROH J, 1992, LANCET, V340, P173, DOI 10.1016/0140-6736(92)93246-J; HACKMANN T, 1989, NEW ENGL J MED, V321, P1437, DOI 10.1056/NEJM198911233212104; HARDER MP, 1991, ANN THORAC SURG, V51, P936, DOI 10.1016/0003-4975(91)91009-K; HAVEL M, 1994, J THORAC CARDIOV SUR, V107, P807; Hayes A, 1996, J CLIN ANESTH, V8, P357, DOI 10.1016/0952-8180(96)00080-3; HENRY DA, 1989, BMJ-BRIT MED J, V298, P1142, DOI 10.1136/bmj.298.6681.1142; Hiippala ST, 1997, ANESTH ANALG, V84, P839, DOI 10.1097/00000539-199704000-00026; Hoffmann H, 1989, Adv Exp Med Biol, V247B, P35; HORROW JC, 1995, ANESTHESIOLOGY, V82, P383, DOI 10.1097/00000542-199502000-00009; HOYLAERTS M, 1981, BIOCHIM BIOPHYS ACTA, V673, P75; KALANGOS A, 1994, EUR J CARDIO-THORAC, V8, P651, DOI 10.1016/S1010-7940(05)80140-X; KARSKI JM, 1995, J THORAC CARDIOV SUR, V110, P835, DOI 10.1016/S0022-5223(95)70118-4; Katsaros D, 1996, ANN THORAC SURG, V61, P1131, DOI 10.1016/0003-4975(96)00022-7; KAWASUJI M, 1993, ANN THORAC SURG, V55, P1205, DOI 10.1016/0003-4975(93)90035-G; KLUFT C, 1991, BLOOD USE IN CARDIAC SURGERY, P10; KOBRINSKY NL, 1984, LANCET, V1, P1145; KOHLER M, 1986, THROMB HAEMOSTASIS, V55, P108; Kurdy NMG, 1996, ANN CHIR GYNAECOL FE, V85, P86; LASS M, 1995, EUR J CARDIO-THORAC, V9, P206; LEMMER JH, 1994, J THORAC CARDIOV SUR, V107, P543, DOI 10.1016/S0022-5223(94)70101-6; Lemmer JH, 1996, ANN THORAC SURG, V62, P1659, DOI 10.1016/S0003-4975(96)00451-1; LETHAGEN S, 1987, THROMB HAEMOSTASIS, V58, P1033; LEVY JH, 1995, CIRCULATION, V92, P2236, DOI 10.1161/01.CIR.92.8.2236; LIU YK, 1984, LANCET, V2, P887; LIVIO M, 1986, NEW ENGL J MED, V315, P731, DOI 10.1056/NEJM198609183151204; MALLETT SV, 1990, LANCET, V336, P886, DOI 10.1016/0140-6736(90)92404-6; MANNUCCI PM, 1977, LANCET, V1, P869; MANNUCCI PM, 1992, BRIT J HAEMATOL, V82, P87, DOI 10.1111/j.1365-2141.1992.tb04598.x; MANNUCCI PM, 1981, BRIT J HAEMATOL, V47, P283, DOI 10.1111/j.1365-2141.1981.tb02789.x; MANNUCCI PM, 1986, BLOOD, V67, P1148; MANNUCCI PM, 1975, BRIT J HAEMATOL, V30, P81, DOI 10.1111/j.1365-2141.1975.tb00521.x; MANNUCCI PM, 1976, J LAB CLIN MED, V88, P662; MANNUCCI PM, 1983, NEW ENGL J MED, V308, P8, DOI 10.1056/NEJM198301063080102; MANNUCCI PM, 1994, THROMB HAEMOSTASIS, V71, P154; Martinowitz U, 1997, THROMB HAEMOSTASIS, V78, P661; Menichetti A, 1996, J CARDIOVASC SURG, V37, P401; MILLER RA, 1980, BRIT J UROL, V52, P26, DOI 10.1111/j.1464-410X.1980.tb02914.x; MOIA M, 1987, LANCET, V2, P1227; NEUHAUS P, 1989, LANCET, V2, P924; OKAMOTO SHOKUKE, 1959, KEIO JOUR MED, V8, P247; ORCHARD MA, 1993, BRIT J HAEMATOL, V85, P533; Prendergast TW, 1996, ANN THORAC SURG, V62, P670; RAO AK, 1995, THROMB HAEMOSTASIS, V74, P1071; ROCHA E, 1994, CIRCULATION, V90, P921, DOI 10.1161/01.CIR.90.2.921; ROCHA E, 1988, CIRCULATION, V77, P1319, DOI 10.1161/01.CIR.77.6.1319; ROYSTON D, 1989, Anesthesiology (Hagerstown), V71, pA6, DOI 10.1097/00000542-198909001-00006; ROYSTON D, 1987, LANCET, V2, P1289; RUGGERI ZM, 1982, BLOOD, V59, P1272; SAKARIASSEN KS, 1984, BLOOD, V64, P229; SALZMAN EW, 1986, NEW ENGL J MED, V314, P1402, DOI 10.1056/NEJM198605293142202; SHEMIN D, 1990, AM J MED, V89, P436, DOI 10.1016/0002-9343(90)90372-K; SHEPHERD LL, 1989, J PEDIATR-US, V114, P470, DOI 10.1016/S0022-3476(89)80575-X; SINDETPEDERSEN S, 1989, NEW ENGL J MED, V320, P840, DOI 10.1056/NEJM198903303201305; SINDETPEDERSEN S, 1987, J CLIN PHARMACOL, V27, P1005, DOI 10.1002/j.1552-4604.1987.tb05605.x; SINDETPEDERSEN S, 1986, J ORAL MAXIL SURG, V44, P703, DOI 10.1016/0278-2391(86)90039-X; Smith PK, 1996, ANN THORAC SURG, V62, P1575; STEFANINI M, 1990, J UROLOGY, V143, P559, DOI 10.1016/S0022-5347(17)40018-8; STEINER RW, 1979, AM J HEMATOL, V7, P107, DOI 10.1002/ajh.2830070203; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; TOVI D, 1972, ACTA NEUROL SCAND, V48, P393, DOI 10.1111/j.1600-0404.1972.tb07561.x; VanderSalm TJ, 1996, J THORAC CARDIOV SUR, V112, P1098, DOI 10.1016/S0022-5223(96)70112-5; VANOEVEREN W, 1988, LANCET, V1, P644; VERMEULEN M, 1984, NEW ENGL J MED, V311, P432, DOI 10.1056/NEJM198408163110703; VERSTRAETE M, 1985, DRUGS, V29, P236, DOI 10.2165/00003495-198529030-00003; VERSTRAETE M, 1994, HAEMOSTASIS THROMBOS, V2, P1057; Wahba A, 1996, THROMB HAEMOSTASIS, V75, P844; WALSH PN, 1971, BRIT J HAEMATOL, V20, P463, DOI 10.1111/j.1365-2141.1971.tb07061.x; Wildevuur C R, 1989, Eur J Cardiothorac Surg, V3, P533, DOI 10.1016/1010-7940(89)90114-0; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6	99	430	463	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					245	253		10.1056/NEJM199807233390407	http://dx.doi.org/10.1056/NEJM199807233390407			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673304				2022-12-28	WOS:000074918700007
J	Wang, LY; Kaczmarek, LK				Wang, LY; Kaczmarek, LK			High-frequency firing helps replenish the readily releasable pool of synaptic vesicles	NATURE			English	Article							AUDITORY BRAIN-STEM; TRAPEZOID BODY; TRANSMITTER RELEASE; MEDIAL NUCLEUS; DEPRESSION; CELLS; ORGANIZATION; HIPPOCAMPUS; PARVALBUMIN; CALRETININ	Synapses in the central nervous system undergo various short- and long-term changes in their strength(1-3), but it is often difficult to distinguish whether presynaptic or postsynaptic mechanisms are responsible for these changes. Using patch-clamp recording from giant synapses in the mouse auditory brainstem(4-7), we show here that short-term synaptic depression can be largely attributed to rapid depletion of a readily releasable pool of vesicles. Replenishment of this pool is highly dependent on the recent history of synaptic activity. High-frequency stimulation of presynaptic terminals significantly enhances the rate of replenishment. Broadening the presynaptic action potential with the potassium-channel blocker tetraethylammonium, which increases Ca2+ entry, further enhances the rate of replenishment. As this increase can be suppressed by the Ca2+-channel blocker Cd2+ or by the Ca2+ buffer EGTA, we conclude that Ca2+ influx through voltage-gated Ca2+ channels is the key signal that dynamically regulates the refilling of che releasable pool of synaptic vesicles in response to different patterns of inputs.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Toronto, Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada	Yale University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	Kaczmarek@Yale.edu						BARNESDAVIES M, 1995, J PHYSIOL-LONDON, V488, P387, DOI 10.1113/jphysiol.1995.sp020974; BETZ WJ, 1970, J PHYSIOL-LONDON, V206, P629, DOI 10.1113/jphysiol.1970.sp009034; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; Borst JGG, 1996, NATURE, V383, P431, DOI 10.1038/383431a0; BROWNELL WE, 1975, BRAIN RES, V94, P413, DOI 10.1016/0006-8993(75)90226-7; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; FORSYTHE ID, 1994, J PHYSIOL-LONDON, V479, P381, DOI 10.1113/jphysiol.1994.sp020303; GUINAN JJ, 1972, INT J NEUROSCI, V4, P147, DOI 10.3109/00207457209164756; HANKEL AW, 1996, CURR OPIN NEUROBIOL, V6, P350; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; Isaacson JS, 1996, J NEUROPHYSIOL, V76, P1566, DOI 10.1152/jn.1996.76.3.1566; KUSANO K, 1975, J PHYSIOL-LONDON, V245, P13, DOI 10.1113/jphysiol.1975.sp010832; KUWABARA N, 1991, J COMP NEUROL, V314, P684, DOI 10.1002/cne.903140405; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Lohmann C, 1996, J COMP NEUROL, V367, P90, DOI 10.1002/(SICI)1096-9861(19960325)367:1<90::AID-CNE7>3.0.CO;2-E; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MOREST D K, 1968, Zeitschrift fuer Anatomie und Entwicklungsgeschichte, V127, P201, DOI 10.1007/BF00526129; PARKER D, 1995, J NEUROPHYSIOL, V74, P529, DOI 10.1152/jn.1995.74.2.529; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; Takahashi T, 1996, SCIENCE, V274, P594, DOI 10.1126/science.274.5287.594; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; VATER M, 1994, J COMP NEUROL, V341, P534, DOI 10.1002/cne.903410409; vonGersdorff H, 1997, J NEUROSCI, V17, P8137; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WANG LY, 1997, SOC NEUR ABSTR, V25, P365; WU SH, 1993, HEARING RES, V68, P189, DOI 10.1016/0378-5955(93)90123-I; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	456	463	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					384	388		10.1038/28645	http://dx.doi.org/10.1038/28645			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690475				2022-12-28	WOS:000074968800055
J	Cowburn, PJ; Cleland, JGF; McArthur, JD; MacLean, MR; McMurray, JJV; Dargie, HJ				Cowburn, PJ; Cleland, JGF; McArthur, JD; MacLean, MR; McMurray, JJV; Dargie, HJ			Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure	LANCET			English	Article									Univ Glasgow, MRC, Clin Res Initiat Heart Failure, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; University of Glasgow	Cleland, JGF (corresponding author), Univ Glasgow, MRC, Clin Res Initiat Heart Failure, Glasgow G12 8QQ, Lanark, Scotland.		mcmurray, John/B-2467-2013; Cleland, John G./AAZ-4185-2020	mcmurray, John/0000-0002-6317-3975; Cleland, John G./0000-0002-1471-7016; MacLean, Margaret/0000-0001-8214-7759				CLELAND JGF, 1985, BRIT MED J, V291, P1309, DOI 10.1136/bmj.291.6505.1309; COWBURN PJ, 1998, IN PRESS CARDIOVASC; Dupuis J, 1996, J APPL PHYSIOL, V81, P1510, DOI 10.1152/jappl.1996.81.4.1510; KIOWSKI W, 1995, LANCET, V346, P732, DOI 10.1016/S0140-6736(95)91504-4; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0	5	61	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					201	202		10.1016/S0140-6736(05)77807-7	http://dx.doi.org/10.1016/S0140-6736(05)77807-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683214				2022-12-28	WOS:000074859800018
J	Jadad, AR; Cook, DJ; Jones, A; Klassen, TP; Tugwell, P; Moher, M; Moher, D				Jadad, AR; Cook, DJ; Jones, A; Klassen, TP; Tugwell, P; Moher, M; Moher, D			Methodology and reports of systematic reviews and meta-analyses - A comparison of COCHRANE reviews with articles published in paper-based journals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE				Context.-Review articles are important sources of information to help guide decisions by clinicians, patients, and other decision makers. Ideally, reviews should include strategies to minimize bias and to maximize precision and be reported so explicitly that any interested reader would be able to replicate them. Objective.-To compare the methodological and reporting aspects of systematic reviews and meta-analyses published by the Cochrane Collaboration with those published in paper-based journals indexed in MEDLINE. Data Sources.-The Cochrane Library, issue 2 of 1995, and a search of MEDLINE restricted to 1995. Study Selection.-All 36 completed reviews published in the Cochrane Database of Systematic Reviews and a randomly selected sample of 39 meta-analyses or systematic reviews published in journals indexed by MEDLINE in 1995. Data Extraction.-Number of authors, trials, and patients; trial sources; inclusion and exclusion criteria; language restrictions; primary outcome; trial quality assessment; heterogeneity testing; and effect estimates. Updating by 1997 was evaluated. Results.-Reviews found in MEDLINE included more authors (median, 3 vs 2; P < .001), more trials (median, 13.5 vs 5; P < .001), and more patients (median, 1280 vs 528; P < .001) than Cochrane reviews. More Cochrane reviews, however, included a description of the inclusion and exclusion criteria (35/36 vs 18/39; P < .001) and assessed trial quality (36/36 vs 12/39; P < .001). No Cochrane reviews had language restrictions (0/36 vs 7/39; P < .01), There were no differences in sources of trials, heterogeneity testing, or description of effect estimates. By June 1997, 18 of 36 Cochrane reviews had been updated vs 1 of 39 reviews listed in MEDLINE. Conclusions.-Cochrane reviews appear to have greater methodological rigor and are more frequently updated than systematic reviews or meta-analyses published in paper-based journals.	McMaster Univ, Dept Clin Epidemiol & Biostat, Hlth Informat Res Unit, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; Childrens Hosp Eastern Ontario, Thomas C Chalmers Ctr Systemat Reviews, Res Inst, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1N 6N5, Canada; Univ Oxford, Dept Primary Hlth Care, Oxford, England	McMaster University; McMaster University; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Oxford	Jadad, AR (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hlth Informat Res Unit, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	jadada@fhs.mcmaster.ca	Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Moher, David/0000-0003-2434-4206				ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; JADAD AR, 1998, MED DECIS MAKING, V279, P611; Sacks HS, 1996, MT SINAI J MED, V63, P216	7	367	394	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					278	280		10.1001/jama.280.3.278	http://dx.doi.org/10.1001/jama.280.3.278			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676681				2022-12-28	WOS:000074706000026
J	Halperin, ML; Kamel, KS				Halperin, ML; Kamel, KS			Potassium	LANCET			English	Article							ANGIOTENSIN-II; HYPERKALEMIA; MODULATION; DISORDERS; SECRETION; TUBULE	In a logical, stepwise approach to patients presenting with hypokalaemia or hyperkalaemia the clinician must first recognise circumstances in which the dyskalaemia represents a clinical emergency because therapy then takes precedence over diagnosis. If a dyskalaemia has been present for a long time, there is an abnormal renal handling of K+. The next step to analyse is the rate of excretion of K+ and, if necessary, its two components (urine flow rate and K+ concentration in the cortical collecting duct [CCD]) analysed independently. If the K+ concentration in the CCD is not in the expected range, its basis should be defined at the ion-channel level in the CCD from clinical information that can be used to deduce the relative rates of reabsorption of Na+ and Cl- in the CCD. This analysis provides the basis for diagnosis and may indicate where non-emergency therapy should then be directed.	Univ Toronto, St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1A6, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Halperin, ML (corresponding author), Univ Toronto, St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1A6, Canada.							ADROGUE HJ, 1981, AM J MED, V71, P456, DOI 10.1016/0002-9343(81)90182-0; ALLON M, 1993, KIDNEY INT, V43, P1197, DOI 10.1038/ki.1993.170; CARLISLE EJF, 1991, KIDNEY INT, V39, P1206, DOI 10.1038/ki.1991.152; CLAUSEN T, 1989, KIDNEY INT, V35, P1, DOI 10.1038/ki.1989.1; COGAN MG, 1990, HYPERTENSION, V15, P451, DOI 10.1161/01.HYP.15.5.451; ETHIER JH, 1990, AM J KIDNEY DIS, V15, P309, DOI 10.1016/S0272-6386(12)80076-X; HALPERIN ML, 1997, ACID TRUTH BASIC FAC; Kamel K., 1996, BRENNER RECTORS KIDN, P999; Kamel KS, 1997, AM J KIDNEY DIS, V29, P136, DOI 10.1016/S0272-6386(97)90021-4; KAMEL KS, 1994, AM J KIDNEY DIS, V24, P597, DOI 10.1016/S0272-6386(12)80220-4; KAMEL KS, IN PRESS DISORDERS F; Levine DZ, 1996, J CLIN INVEST, V97, P120, DOI 10.1172/JCI118378; Lin SH, 1997, AM J PHYSIOL-RENAL, V273, pF796, DOI 10.1152/ajprenal.1997.273.5.F796; MAGNER PO, 1988, AM J KIDNEY DIS, V11, P220, DOI 10.1016/S0272-6386(88)80153-7; PORTE D, 1969, ARCH INTERN MED, V123, P252, DOI 10.1001/archinte.123.3.252; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; Rosa RM, 1992, KIDNEY PHYSL PATHOPH, P2165; Rossier BC, 1997, J AM SOC NEPHROL, V8, P980; SALEM MM, 1991, AM J KIDNEY DIS, V18, P421, DOI 10.1016/S0272-6386(12)80110-7; Schreiber M, 1996, KIDNEY INT, V49, P82, DOI 10.1038/ki.1996.11; STEELE A, 1994, AM J PHYSIOL, V36, pR554; STERNS RH, 1981, MEDICINE, V60, P339, DOI 10.1097/00005792-198109000-00002; SWAN RC, 1955, J CLIN INVEST, V34, P205, DOI 10.1172/JCI103073; VELAZQUEZ H, 1982, AM J PHYSIOL, V242, pF46, DOI 10.1152/ajprenal.1982.242.1.F46; WEST ML, 1986, MINER ELECTROL METAB, V12, P234; WILLIAMS ME, 1985, NEW ENGL J MED, V312, P823, DOI 10.1056/NEJM198503283121304; Wright FS, 1992, KIDNEY PHYSL PATHOPH, P2209; ZIERLER K, 1987, DIABETES, V36, P1035, DOI 10.2337/diabetes.36.9.1035	28	140	148	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					135	140						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672294				2022-12-28	WOS:000074775100043
J	Mach, F; Schonbeck, U; Sukhova, GK; Atkinson, E; Libby, P				Mach, F; Schonbeck, U; Sukhova, GK; Atkinson, E; Libby, P			Reduction of atherosclerosis in mice by inhibition of CD40 signalling	NATURE			English	Article							ENDOTHELIAL-CELLS; LIGAND INTERACTIONS; LYMPHOCYTES-T; GP39; HYPERCHOLESTEROLEMIA; PATHOGENESIS; MACROPHAGES; PREVENTION; EXPRESSION; LESIONS	Increasing amounts of evidence support the involvement of inflammation and immunity in atherogenesis(1-4), but mediators of communication between the major cell types in atherosclerotic plaques are poorly defined. Cells in human atherosclerotic lesions express the immune mediator CD40 and its ligand CD40L (also known as CD154 or gp39)(5). The interaction of CD40 with CD40L figures prominently in both humoral and cell-mediated immune responses(6). CD4OL-positive T cells accumulate in atheroma(5), and, by virtue of their early appearance, persistence and localization at sites of lesion growth and complication, activated T cells may coordinate important aspects of atherogenesis(7-9). Interruption of CD40L-CD40 signalling by administration of an anti-CD40L antibody Limits experimental autoimmune diseases such as collagen-induced arthritis, lupus nephritis, acute or chronic graft-versus-host disease, multiple sclerosis and thyroiditis(10-14). Ligation of CD40 on atheroma-associated cells in vitro activates functions related to atherogenesis, including induction of proinflammatory cytokines(5), matrix metalloproteinases(15,16), adhesion molecules(17-19) and tissue factor(16,20). However, the role of CD40 signalling in atherogenesis in vivo remains unknown. Here we determine whether interruption of CD40 signalling influences atherogenesis in vivo in hyperlipidaemic mice, Treatment with antibody against mouse CD40L limited atherosclerosis in mice lacking the receptor for low-density lipoprotein that had been fed a high-cholesterol diet for 12 weeks. This antibody reduces the size of aortic atherosclerotic lesions by 59% and their lipid content by 79%, Furthermore, atheroma of mice treated with anti-CD40L antibody contained significantly fewer macrophages (64%) and T lymphocytes (70%), and exhibited decreased expression of vascular cell adhesion molecule-1. These data support the involvement of inflammatory pathways in atherosclerosis and indicate a role for CD40 signalling during atherogenesis in hyperlipidaemic mice.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Cardiovasc Div,Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Libby, P (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Cardiovasc Div,Vasc Med & Atherosclerosis Unit, 221 Longwood Ave, Boston, MA 02115 USA.	plibby@rics.bwh.harvard.edu	Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X				Carayanniotis G, 1997, IMMUNOLOGY, V90, P421, DOI 10.1111/j.1365-2567.1997.00421.x; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; EMESON EE, 1988, AM J PATHOL, V130, P369; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; HANSSON GK, 1988, ATHEROSCLEROSIS, V72, P135, DOI 10.1016/0021-9150(88)90074-3; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kennedy MK, 1996, EUR J IMMUNOL, V26, P370, DOI 10.1002/eji.1830260216; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lichtman A. H., 1997, FASEB Journal, V11, pA154; Lichtman AH, 1996, AM J PATHOL, V149, P351; Lu LN, 1997, TRANSPLANTATION, V64, P1808, DOI 10.1097/00007890-199712270-00031; Mach F, 1997, CIRCULATION, V96, P396; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MACH F, IN PRESS ATHEROSCLER; MOHAN C, 1995, J IMMUNOL, V154, P1470; Roselaar SE, 1996, ARTERIOSCL THROM VAS, V16, P1013, DOI 10.1161/01.ATV.16.8.1013; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schonbeck U, 1997, CIRC RES, V81, P448, DOI 10.1161/01.RES.81.3.448; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; Zhou XH, 1996, AM J PATHOL, V149, P359	29	723	784	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					200	203		10.1038/28204	http://dx.doi.org/10.1038/28204			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671306				2022-12-28	WOS:000074705900059
J	Nabarro, DN; Tayler, EM				Nabarro, DN; Tayler, EM			The "Roll Back Malaria" campaign	SCIENCE			English	Editorial Material									Dept Int Dev, London SW1E 5JL, England		Nabarro, DN (corresponding author), Dept Int Dev, 94 Victoria St, London SW1E 5JL, England.	d-nabarro@dfid.gtnet.gov.uk						Butler D, 1997, NATURE, V390, P209, DOI 10.1038/36663; Mons B, 1998, SCIENCE, V279, P498, DOI 10.1126/science.279.5350.498; *WHO HLTH ORG, 1993, GLOB STRAT MAL CONTR; *WHO HLTH ORG AFR, AFR IN MAL CONTR 21, P98	4	114	120	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2067	2068		10.1126/science.280.5372.2067	http://dx.doi.org/10.1126/science.280.5372.2067			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9669961				2022-12-28	WOS:000074435900028
J	Barrett-Connor, E				Barrett-Connor, E			Fortnightly review - Hormone replacement therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							QUALITY-OF-LIFE; ESTROGEN REPLACEMENT; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; CONTROLLED TRIAL; RISK; BONE; METAANALYSIS; OSTEOPOROSIS; MORTALITY		Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Barrett-Connor, E (corresponding author), Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.	ebarrettconnor@ucsd.edu						Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Cauley JA, 1997, ARCH INTERN MED, V157, P2181, DOI 10.1001/archinte.157.19.2181; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, IN PRESS CONTR CLIN; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Kanis JA, 1996, BONE, V19, pS185, DOI 10.1016/S8756-3282(96)00257-8; Laya MB, 1996, J NATL CANCER I, V88, P643, DOI 10.1093/jnci/88.10.643; LIMOUZINLAMOTHE MA, 1994, AM J OBSTET GYNECOL, V170, P618, DOI 10.1016/S0002-9378(94)70239-X; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NEWCOMB PA, 1995, JNCI-J NATL CANCER I, V87, P1067, DOI 10.1093/jnci/87.14.1067; Newnham H.H., 1997, LANCET S1, V349, pS13; Newton KM, 1997, AM J EPIDEMIOL, V145, P269; Nieves JW, 1998, AM J CLIN NUTR, V67, P18, DOI 10.1093/ajcn/67.1.18; OBrien JE, 1996, J AM COLL CARDIOL, V28, P1111, DOI 10.1016/S0735-1097(96)00306-3; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; Porter M, 1996, BRIT J OBSTET GYNAEC, V103, P1025, DOI 10.1111/j.1471-0528.1996.tb09555.x; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; STEVENSON JC, 1996, MENOPAUSE, P243; Torgerson DJ, 1997, ARCH INTERN MED, V157, P2121, DOI 10.1001/archinte.157.18.2121; Tunstall-Pedoe H, 1998, LANCET, V351, P1425, DOI 10.1016/S0140-6736(97)11321-6; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; *WHO, 1996, WHO TECH REP SER, V866; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688	40	125	132	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1998	317	7156					457	461						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703530				2022-12-28	WOS:000075490200023
J	Fisk, MR; Giovannoni, SJ; Thorseth, IH				Fisk, MR; Giovannoni, SJ; Thorseth, IH			Alteration of oceanic volcanic glass: Textural evidence of microbial activity	SCIENCE			English	Article							BASALTIC GLASS; RIDGE	The subsurface biosphere may constitute as much as 50 percent of Earth's biomass. Direct and indirect evidence suggests that an extensive biosphere exists in the rocks below the sea floor. This survey of basalts of the Atlantic, Pacific, and Indian Oceans supports the hypothesis that bacteria have colonized much of the upper oceanic crust, which has a volume estimated at 10(18) cubic meters. Although this is the Largest habitat on Earth, its Low abundance of bacteria constitutes much Less than 1 percent of Earth's biomass.	Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Univ Bergen, Inst Geol, N-5007 Bergen, Norway	Oregon State University; Oregon State University; University of Bergen	Fisk, MR (corresponding author), Oregon State Univ, Coll Ocean & Atmospher Sci, 104 Ocean Adm Bldg, Corvallis, OR 97331 USA.							CROVISIER JL, 1987, GEOCHIM COSMOCHIM AC, V51, P2977, DOI 10.1016/0016-7037(87)90371-1; FISK MR, 1994, EOS T AGU, V75, P706; FISK MR, 1997, EOS S, V78, P740; Fumes H., 1996, P ODP SCI RESULTS, V148, P191, DOI DOI 10.2973/0DP.PR0C.SR; Giovannoni S.J., 1996, P OCEAN DRILLING PRO, V148, P207, DOI DOI 10.2973/0DP; HAYMON RM, 1993, EARTH PLANET SC LETT, V119, P85, DOI 10.1016/0012-821X(93)90008-W; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; JUNIPER SK, 1995, GEOPHYS RES LETT, V22, P179, DOI 10.1029/94GL02436; Liu SV, 1997, SCIENCE, V277, P1106, DOI 10.1126/science.277.5329.1106; LOVELY DR, 1995, REV GEOPHYS, V33, P365; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; Taylor CD, 1997, SCIENCE, V277, P1483, DOI 10.1126/science.277.5331.1483; THORSETH IH, 1995, CHEM GEOL, V119, P139, DOI 10.1016/0009-2541(94)00098-S; Thorseth IH, 1995, CHEM GEOL, V126, P137, DOI 10.1016/0009-2541(95)00114-8; TORSVIK T, IN PRESS EARTH PLANE; Zhang CL, 1997, GEOCHIM COSMOCHIM AC, V61, P4621, DOI 10.1016/S0016-7037(97)00257-3	17	266	283	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					978	980		10.1126/science.281.5379.978	http://dx.doi.org/10.1126/science.281.5379.978			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9703510				2022-12-28	WOS:000075412700043
J	Boyd, R				Boyd, R			A memorable meeting - A view from the man in the seat opposite	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, London, England	St Georges University London	Boyd, R (corresponding author), Univ London St Georges Hosp, Sch Med, London, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					410	410						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694764				2022-12-28	WOS:000075409600036
J	Schoffski, P; Freund, M; Wunder, R; Petersen, D; Kohne, CH; Hecker, H; Schubert, U; Ganser, A				Schoffski, P; Freund, M; Wunder, R; Petersen, D; Kohne, CH; Hecker, H; Schubert, U; Ganser, A			Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study	BRITISH MEDICAL JOURNAL			English	Article							FAT EMULSION; DELIVERY SYSTEM; RENAL TOXICITY; LIPID EMULSION; AIDS PATIENTS; TOLERANCE; CANDIDIASIS; OVERLOAD; EFFICACY; TRIAL	Objective: To compare the feasibility of treatment, safety, and toxicity of intravenous amphotericin B deoxycholate prepared in either glucose or intralipid for empirical antimycotic treatment of neutropenic cancer patients. Design: Single centre stratified, randomised non-blinded phase II study. Setting: University hospital providing tertiary clinical care. Subjects: 51 neutropenic patients (leukaemia (35), lymphoma (11), solid tumours (5)) with refractory fever of unknown origin (24) or pneumonia (27). Interventions: Amphotericin B 0.75 mg/kg/day in 250 ml glucose 5% solution or mixed with 250 ml intralipid 20%, given an eight consecutive days then alternate days, as a 1-4 hour infusion. Main outcome measures: Feasibility of treatment, subjective tolerance (questionnaire), and objective toxicity (common toxicity criteria sf the National Cancer Institute). Results: Study arms were balanced for age, sex, underlying malignancy, renal and liver function, and pre- and concomitant treatment with antibiotics and nephrotoxic agents. No statistically significant or clinically relevant differences were found between the treatment groups for: daily or cumulative dose and duration sf treatment with amphotericin B; incidence and time of dose modifications or infusion duration changes related to toxicity; dose or duration of symptomatic support with opiates, antipyretics, or antihistamines; renal function; subjective tolerance; most common toxicity scores; course of infection; and incidence of treatment failures. Patients treated with amphotericin B in intralipid were given fewer diuretics (P < 0.05) and therefore had more peripheral oedema (P < 0.01) and needed less potassium supplementation (P < 0.05) than patients given amphotericin in glucose. Acute respiratory events were more common in the intralipid ann (P < 0.05). Conclusions: Amphotericin B 0.75 mg/kg/day in intralipid given on eight consecutive days then alternate days provides no benefit and is associated with Potential pulmonary side effects possibly because of fat overload or an incompatibility of the two drugs.	Univ Hannover, Sch Med, Dept Haematol Oncol, D-30625 Hannover, Germany; Univ Rostock, Dept Haematol Oncol, D-18055 Rostock, Germany; Univ Rostock, Dept Clin Chem, D-18055 Rostock, Germany; Univ Rostock, Biometr Dept, D-18055 Rostock, Germany	Leibniz University Hannover; University of Rostock; University of Rostock; University of Rostock	Schoffski, P (corresponding author), Univ Hannover, Sch Med, Dept Haematol Oncol, D-30625 Hannover, Germany.							ANDERSON RP, 1995, ANN PHARMACOTHER, V29, P496, DOI 10.1177/106002809502900509; ARNING M, 1995, EUR J CLIN MICROBIOL, V14, P41, DOI 10.1007/BF02112616; BELIN RP, 1976, ARCH SURG-CHICAGO, V111, P1391; BODEY G, 1992, EUR J CLIN MICROBIOL, V11, P99, DOI 10.1007/BF01967060; CAILLOT D, 1994, J ANTIMICROB CHEMOTH, V33, P603, DOI 10.1093/jac/33.3.603; CAILLOT D, 1993, J ANTIMICROB CHEMOTH, V31, P161, DOI 10.1093/jac/31.1.161; CAILLOT D, 1992, EUR J CLIN MICROBIOL, V11, P722, DOI 10.1007/BF01989977; CHAVANET PY, 1992, BRIT MED J, V305, P921, DOI 10.1136/bmj.305.6859.921; GREENE HL, 1976, AM J CLIN NUTR, V29, P127, DOI 10.1093/ajcn/29.2.127; HEIDE PE, 1996, OESTERREICHISCHE KRA, V10, P36; Joly V, 1996, J ANTIMICROB CHEMOTH, V38, P117, DOI 10.1093/jac/38.1.117; JOLY V, 1994, ANTIMICROB AGENTS CH, V38, P177, DOI 10.1128/AAC.38.2.177; KHOO SH, 1994, J ANTIMICROB CHEMOTH, V33, P203, DOI 10.1093/jac/33.2.203; KIRSH R, 1988, J INFECT DIS, V158, P1065, DOI 10.1093/infdis/158.5.1065; LINDHOLM M, 1991, J DRUG DEV S3, V4, P40; LYMAN CA, 1992, DRUGS, V44, P9, DOI 10.2165/00003495-199244010-00002; MACEDO MCMA, 1994, CLIN INFECT DIS, V19, P366, DOI 10.1093/clinids/19.2.366; MEYER OC, 1992, CLIN EXP RHEUMATOL, V10, P1; MOREAU P, 1992, J ANTIMICROB CHEMOTH, V30, P535, DOI 10.1093/jac/30.4.535; SCHOFFSKI P, 1994, ARZNEIMITTELTHERAPIE, V12, P115; SUNDSTROM G, 1973, J APPL PHYSIOL, V34, P816, DOI 10.1152/jappl.1973.34.6.816; THAKUR CP, 1994, T ROY SOC TROP MED H, V88, P698, DOI 10.1016/0035-9203(94)90236-4; Villani P, 1996, ARZNEIMITTELFORSCH, V46, P445; WESSON DE, 1984, J PEDIATR SURG, V19, P777, DOI 10.1016/S0022-3468(84)80367-X; WRIGHT DG, 1981, NEW ENGL J MED, V304, P1185, DOI 10.1056/NEJM198105143042001	25	48	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					379	384						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694753	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075409600024
J	Backstrom, BT; Muller, U; Hausmann, B; Palmer, E				Backstrom, BT; Muller, U; Hausmann, B; Palmer, E			Positive selection through a motif in the alpha beta T cell receptor	SCIENCE			English	Article							NEGATIVE SELECTION; CD4+8+ THYMOCYTES; TRANSGENIC MICE; ANTIGEN; CHAIN; THYMUS; TOLERANCE; MOLECULES; DELETION; IMMATURE	The two Lineages of T cells, alpha beta and gamma delta, differ in their developmental requirements: only alpha beta cells require major histocompatibility complex recognition, a process known as positive selection, The alpha beta T cell receptor (TCR), but not its gamma delta counterpart, contains a motif within the alpha-chain connecting peptide domain (alpha-CPM) that has been conserved over the Last 500 million years. In transgenic mice expressing an alpha beta TCR Lacking the alpha-CPM, thymocytes were blocked in positive selection but could undergo negative selection. Thus, the alpha-CPM seems to participate in the generation of signals required for positive selection.	Basel Inst Immunol, CH-4005 Basel, Switzerland		Palmer, E (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.							AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Backstrom BT, 1997, EUR J IMMUNOL, V27, P1433; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BACKSTROM BT, UNPUB; BIGBY M, 1993, J IMMUNOL, V151, P4465; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; COHN M, 1982, BEHRING I MITT, V70, P219; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; CURNOW SJ, 1994, CYTOMETRY, V16, P41, DOI 10.1002/cyto.990160107; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DIGIUSTO DL, 1994, MOL IMMUNOL, V31, P693, DOI 10.1016/0161-5890(94)90179-1; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; PAGE DM, 1993, J IMMUNOL, V151, P1868; Partula S, 1996, J IMMUNOL, V157, P207; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; ROZDZIAL MM, 1994, J IMMUNOL, V153, P1563; Schweighoer E, 1996, J EXP MED, V183, P2033, DOI 10.1084/jem.183.5.2033; SHIOHARA T, 1987, J IMMUNOL, V138, P1979; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	30	97	98	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					835	838		10.1126/science.281.5378.835	http://dx.doi.org/10.1126/science.281.5378.835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694657				2022-12-28	WOS:000075295600053
J	Cummings, P; Koepsell, TD				Cummings, P; Koepsell, TD			Does owning a firearm increase or decrease the risk of death?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADOLESCENT SUICIDE; GUN OWNERSHIP; CRIME; HOMICIDE; VICTIMS; HOME		Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cummings, P (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.							Beautrais AL, 1996, AUST NZ J PSYCHIAT, V30, P741, DOI 10.3109/00048679609065040; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; BRENT DA, 1993, AM J DIS CHILD, V147, P1066, DOI 10.1001/archpedi.1993.02160340052013; Cook P.J., 1997, GUNS AM NATL SURVEY; Cummings P, 1997, AM J PUBLIC HEALTH, V87, P974, DOI 10.2105/AJPH.87.6.974; Cummings P, 1998, Inj Prev, V4, P54; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; Kleck G, 1995, J CRIM LAW CRIM, V86, P150, DOI 10.2307/1144004; KLECK G, 1988, SOC PROBL, V35, P1, DOI 10.1525/sp.1988.35.1.03a00010; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; MCDOWALL D, 1994, AM J PUBLIC HEALTH, V84, P1982, DOI 10.2105/AJPH.84.12.1982; RAND MR, 1994, GUNS CRIME HANDGUN V; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; ZIMRING FE, 1993, HEALTH AFFAIR, V12, P109, DOI 10.1377/hlthaff.12.4.109	17	17	18	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					471	473		10.1001/jama.280.5.471	http://dx.doi.org/10.1001/jama.280.5.471			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105AR	9701087				2022-12-28	WOS:000075050200041
J	Herman, J				Herman, J			Conflict of interest - Equanimity upset	BRITISH MEDICAL JOURNAL			English	Article																		OSLER W, AEQUINIMITAS	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					318	318		10.1136/bmj.317.7154.318	http://dx.doi.org/10.1136/bmj.317.7154.318			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685276	Green Published			2022-12-28	WOS:000075409500020
J	Gross, DM; Forsthuber, T; Tary-Lehmann, M; Etling, C; Ito, K; Nagy, ZA; Field, JA; Steere, AC; Huber, BT				Gross, DM; Forsthuber, T; Tary-Lehmann, M; Etling, C; Ito, K; Nagy, ZA; Field, JA; Steere, AC; Huber, BT			Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis	SCIENCE			English	Article							SURFACE PROTEIN-A; BORRELIA-BURGDORFERI; RHEUMATOID-ARTHRITIS; ANTIGEN EXPRESSION; ASSOCIATION; DISEASE; PEPTIDE; RECOGNITION; PREDICTION; DISTINCT	Treatment-resistant Lyme arthritis is associated with immune reactivity to outer surface protein A (OspA) of Borrelia burgdorferi, the agent of Lyme disease, and the major histocompatibility complex class II allele DRB1*0401. The immunodominant epitope of OspA for T helper cells was identified. A homology search revealed a peptide from human leukocyte function-associated antigen-1 (hLFA-1) as a candidate autoantigen. Individuals with treatment-resistant Lyme arthritis, but not other forms of arthritis, generated responses to OspA, hLFA-1, and their highly related peptide epitopes. Identification of the initiating bacterial antigen and a cross-reactive autoantigen may provide a model for development of autoimmune disease.	Tufts Univ, Dept Pathol, Boston, MA 02111 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Hoffmann La Roche Inc, Dept Immunol, Nutley, NJ 07110 USA; New England Med Ctr, Dept Rheumatol, Boston, MA 02111 USA	Tufts University; Case Western Reserve University; Roche Holding; Tufts Medical Center	Gross, DM (corresponding author), Tufts Univ, Dept Pathol, Boston, MA 02111 USA.		Forsthuber, Thomas/AID-8080-2022	/0000-0003-0692-7125; Steere, Allen/0000-0002-5268-9853	NIAMS NIH HHS [R01 AR20358] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020358] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BRADLEY JF, 1994, ANN INTERN MED, V120, P487, DOI 10.7326/0003-4819-120-6-199403150-00007; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; FENG SL, 1995, J INFECT DIS, V172, P286, DOI 10.1093/infdis/172.1.286; Golde WT, 1998, INFECT MED, V15, P38; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Gross D., UNPUB; Gross DM, 1998, J IMMUNOL, V160, P1022; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; Kamradt T, 1996, INFECT IMMUN, V64, P1284, DOI 10.1128/IAI.64.4.1284-1289.1996; LAHESMAA R, 1993, J IMMUNOL, V150, P4125; LANCHBURY JSS, 1991, HUM IMMUNOL, V32, P56, DOI 10.1016/0198-8859(91)90117-R; LENGLJANSSEN B, 1994, J EXP MED, V180, P2069, DOI 10.1084/jem.180.6.2069; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARSHALL KW, 1995, J IMMUNOL, V154, P5927; MORENO J, 1991, J IMMUNOL, V147, P3306; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; STEEG PS, 1982, J EXP MED, V156, P1780, DOI 10.1084/jem.156.6.1780; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, UNPUB; SZTEIN MB, 1984, J CLIN INVEST, V73, P556, DOI 10.1172/JCI111243; WELSH J, 1992, INT J SYST BACTERIOL, V42, P370, DOI 10.1099/00207713-42-3-370; WILSKE B, 1992, RES MICROBIOL, V143, P583, DOI 10.1016/0923-2508(92)90116-6	28	371	408	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					703	706		10.1126/science.281.5377.703	http://dx.doi.org/10.1126/science.281.5377.703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685265				2022-12-28	WOS:000075107900044
J	Madaule, P; Eda, M; Watanabe, N; Fujisawa, K; Matsuoka, T; Bito, H; Ishizaki, T; Narumiya, S				Madaule, P; Eda, M; Watanabe, N; Fujisawa, K; Matsuoka, T; Bito, H; Ishizaki, T; Narumiya, S			Role of citron kinase as a target of the small GTPase Rho in cytokinesis	NATURE			English	Article							BINDING PROTEIN-RHO; SERINE/THREONINE KINASE; CYTOSKELETON; CELLS	During mitosis, a ring containing actin and myosin appears beneath the equatorial surface of animal cells. This ring then contracts, forms a cleavage furrow and divides the cell(1-3), a step known as cytokinesis, The two daughter cells often remain connected by an intercellular bridge which contains a refringent structure known as the midbody(4,5). How the appearance of this ring is regulated is unclear, although the small GTPase Rho, which controls the formation of actin structures(6,7), is known to be essential(8-10). Protein kinases are also thought to participate in cytokinesis(8-10). We now show that a splice variant of a Rho target protein, named citron(13), contains a protein kinase domain that is related to the Rho-associated kinases ROCK14 and ROK15-17, which regulate myosin-based contractility(18-21). Citron kinase localizes to the cleavage furrow and midbody of HeLa cells; Rho is also localized in the midbody. We find that overexpression of citron mutants results in the production of multinucleate cells and that a kinase-active mutant causes abnormal contraction during cytokinesis, We propose that citron kinase regulates cytokinesis at a step after Rho in the contractile process.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan	Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				ANDREASSEN PR, 1991, J CELL SCI, V99, P523; BYERS B, 1968, PROTOPLASMA, V66, P413, DOI 10.1007/BF01255868; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MULLINS JM, 1977, J CELL BIOL, V73, P672, DOI 10.1083/jcb.73.3.672; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044	28	329	345	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1998	394	6692					491	494		10.1038/28873	http://dx.doi.org/10.1038/28873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	105NT	9697773				2022-12-28	WOS:000075080400055
J	Saag, KG; Emkey, R; Schnitzer, TJ; Brown, JP; Hawkins, F; Goemaere, S; Thamsborg, G; Liberman, UA; Delmas, PD; Malice, MP; Czachur, M; Daifotis, AG				Saag, KG; Emkey, R; Schnitzer, TJ; Brown, JP; Hawkins, F; Goemaere, S; Thamsborg, G; Liberman, UA; Delmas, PD; Malice, MP; Czachur, M; Daifotis, AG		Glucocorticoid-Induced Osteopor Interven	Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	61st National Scientific Meeting of the American-College-of-Rheumatology	NOV 08-12, 1997	WASHINGTON, D.C.	Amer Coll Rheumatol			CORTICOSTEROID-INDUCED OSTEOPOROSIS; RHEUMATOID-ARTHRITIS PATIENTS; INDUCED BONE LOSS; VERTEBRAL FRACTURES; INDUCED OSTEOPENIA; CONTROLLED TRIAL; CALCIUM; ETIDRONATE; CALCITONIN; SECONDARY	Background Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment. Methods We carried out two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women, 17 to 83 years of age, who were receiving glucocorticoid therapy. The primary end point was the difference in the mean percent change in lumbar-spine bone density from base line to week 48 between the groups. Secondary outcomes included changes in bone density of the hip, biochemical markers of bone turnover, and the incidence of new vertebral fractures. Results The mean (+/-SE) bone density of the lumbar spine increased by 2.1+/-0.3 percent and 2.9+/-0.3 percent, respectively, in the groups that received 5 and 10 mg of alendronate per day (P<0.001) and decreased by 0.4+/-0.3 percent in the placebo group. The femoral-neck bone density increased by 1.2+/-0.4 percent and 1.0+/-0.4 percent in the respective alendronate groups (P<0.01) and decreased by 1.2+/-0.4 percent in the placebo group (P<0.01). The bone density of the trochanter and total body also increased significantly in the patients treated with alendronate. There were proportionally fewer new vertebral fractures in the alendronate groups (overall incidence, 2.3 percent) than in the placebo group (3.7 percent) (relative risk, 0.6; 95 percent confidence interval, 0.1 to 4.4). Markers of bone turnover decreased significantly in the alendronate groups (P<0.001). There were no differences in serious adverse effects among the three groups, but there was a small increase in nonserious upper gastrointestinal effects in the group receiving 10 mg of alendronate. Conclusions Alendronate increases bone density in patients receiving glucocorticoid therapy. (N Engl J Med 1998;339:292-9.) (C)1998, Massachusetts Medical Society.	Univ Iowa, Coll Med, Dept Internal Med, Div Rheumatol, Iowa City, IA USA; Univ Iowa, Coll Med, Dept Prevent Med & Environm Hlth, Iowa City, IA USA; Bone Res Ctr, W Reading, PA USA; CHU Quebec, Ste Foy, PQ, Canada; Northwestern Univ, Chicago, IL 60611 USA; Hosp 12 Octubre, Serv Endocrinol, E-28041 Madrid, Spain; Univ Hosp Ghent, Ghent, Belgium; Kommune Hosp Copenhagen, Osteoporose Centret, Copenhagen, Denmark; Beilinson Med Ctr, Petah Tiqwa, Israel; Hop Edouard Herriot, Lyon, France; Merck Res Labs, Rahway, NJ USA	University of Iowa; University of Iowa; Laval University; Northwestern University; Hospital Universitario 12 de Octubre; Ghent University; Ghent University Hospital; Rabin Medical Center; CHU Lyon; Merck & Company	Saag, KG (corresponding author), Univ Iowa Hosp & Clin, Dept Internal Med, Div Rheumatol, 200 Hawkins Dr, Iowa City, IA 52242 USA.			Brown, Jacques/0000-0003-1910-788X	NCRR NIH HHS [RR00059] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adachi JD, 1996, J RHEUMATOL, V23, P995; Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; ADACHI JD, 1994, J RHEUMATOL, V21, P1922; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Buckley LM, 1996, ANN INTERN MED, V125, P961, DOI 10.7326/0003-4819-125-12-199612150-00004; CAPIZZI T, 1992, BIOMETRICAL J, V34, P275, DOI 10.1002/bimj.4710340303; CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002-9343(99)80134-X; CUMMINGS SR, 1995, J BONE MINER RES, V10, P518; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; CUMMINGS SR, 1995, J BONE MINER RES, V10, P1605; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; DEQUEKER J, 1995, J RHEUMATOL, V22, P1013; DIAMOND T, 1995, AM J MED, V98, P459, DOI 10.1016/S0002-9343(99)80345-3; DYKMAN TR, 1984, ARTHRITIS RHEUM, V27, P1336, DOI 10.1002/art.1780271203; FLEISCH H, 1993, OSTEOPOROSIS INT, V3, pS15; GARNERO P, 1993, J CLIN ENDOCR METAB, V77, P1046, DOI 10.1210/jc.77.4.1046; GARNERO P, 1995, BONE, V16, P499, DOI 10.1016/8756-3282(95)00075-O; Genant HK, 1996, J BONE MINER RES, V11, P984; HAHN TJ, 1979, J CLIN INVEST, V64, P655, DOI 10.1172/JCI109506; HALL GM, 1994, ARTHRITIS RHEUM, V37, P1499, DOI 10.1002/art.1780371014; Healey JH, 1996, CALCIFIED TISSUE INT, V58, P73, DOI 10.1007/s002239900014; JERGAS M, 1995, VERTEBRAL FRACTURE O, P163; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MICHEL BA, 1991, J RHEUMATOL, V18, P804; REID IR, 1988, LANCET, V1, P143; Roux C, 1998, J CLIN ENDOCR METAB, V83, P1128, DOI 10.1210/jc.83.4.1128; Saag KG, 1997, AM J MED, V103, P31, DOI 10.1016/S0002-9343(97)90006-1; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; STRUYS A, 1995, AM J MED, V99, P235, DOI 10.1016/S0002-9343(99)80154-5; TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666; VERSTRAETEN A, 1989, CLIN EXP RHEUMATOL, V7, P351; Walsh LJ, 1996, BRIT MED J, V313, P344, DOI 10.1136/bmj.313.7053.344	34	915	940	1	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1998	339	5					292	299		10.1056/NEJM199807303390502	http://dx.doi.org/10.1056/NEJM199807303390502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	104TL	9682041				2022-12-28	WOS:000075031400002
J	Haynes, B; Haines, A				Haynes, B; Haines, A			Getting research findings into practice - Barriers and bridges to evidence based clinical practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; GENERAL-PRACTICE; PERFORMANCE; GUIDELINES; TRIALS		McMaster Univ, Fac Hlth Sci, Hamilton, ON L8N 3Z5, Canada; Royal Free Hosp, Sch Med, Dept Primary Care & Populat, London NW3 2PF, England; UCL, Sch Med, London NW3 2PF, England	McMaster University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School	Haynes, B (corresponding author), McMaster Univ, Fac Hlth Sci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	bhaynes@fhs.mcmaster.ca		Haines, Andy/0000-0002-8053-4605				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ASZKENASY OM, 1994, J ROY SOC MED, V87, P588; CARTER A, 1993, CAN MED ASSOC J, V148, P383; *COCHR COLL, 1996, COCHR LIB; Davis David A., 1995, JAMA (Journal of the American Medical Association), V274, P700, DOI 10.1001/jama.274.9.700; DOOREY AJ, 1992, JAMA-J AM MED ASSOC, V268, P3108, DOI 10.1001/jama.268.21.3108; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; HAYNES RB, 1990, ANN INTERN MED, V113, P724, DOI 10.7326/0003-4819-113-9-724; HAYNES RB, 1997, COCHRANE LIB; HAYNES RB, 1991, ACP J CLUB, V114, pA18; Hersh W, 1996, ACP J Club, V125, pA14; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KARUZA J, 1995, ARCH INTERN MED, V155, P625, DOI 10.1001/archinte.155.6.625; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; KRAHN M, 1991, ANN INTERN MED, V115, P248, DOI 10.7326/0003-4819-115-4-248; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; Mashru M, 1997, BMJ-BRIT MED J, V314, P942, DOI 10.1136/bmj.314.7085.942; MICHAUD C, 1996, INVESTING HLTH RES D, P217; Muir-Gray J, 1997, EVIDENCE BASED MED, V2, P36; Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443; Sackett D. L., 1997, EVIDENCE BASED MED P; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Shepperd S, 1995, FAM PRACT, V12, P443, DOI 10.1093/fampra/12.4.443; Stewart MA, 1995, PATIENT CTR MED TRAN, P185; STOCKING B, 1993, MILBANK Q, V71, P497, DOI 10.2307/3350412; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Sutton M, 1997, BMJ-BRIT MED J, V315, P47, DOI 10.1136/bmj.315.7099.47; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P	29	318	330	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					273	276		10.1136/bmj.317.7153.273	http://dx.doi.org/10.1136/bmj.317.7153.273			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677226	Green Published			2022-12-28	WOS:000075081900032
J	Chou, JJ; Matsuo, H; Duan, H; Wagner, G				Chou, JJ; Matsuo, H; Duan, H; Wagner, G			Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment	CELL			English	Article							DEATH DOMAIN; PROTEINS; NMR; RESONANCE; FADD; C-13; FAS	Apoptosis requires recruitment of caspases by receptor-associated adaptors through homophilic interactions between the CARDs (caspase recruitment domains) of adaptor proteins and prodomains of caspases. We have solved the CARD structure of the RAIDD adaptor protein that recruits ICH-1/caspase-2. It consists of six tightly packed helices arranged in a topology homologous to the Fas death domain. The surface contains a basic and an acidic patch on opposite sides. This polarity is conserved in the ICH-1 CARD as indicated by homology modeling. Mutagenesis data suggest that these patches mediate CARD/CARD interaction between RAIDD and ICH-1. Subsequent modeling of the CARDs of Apaf-1 and caspase-9, as well as Ced-4 and Ced-3, showed that the basic/acidic surface polarity is highly conserved, suggesting a general mode for CARD/CARD interaction.	Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA	Harvard University; Harvard University; Harvard Medical School; Pfizer	Wagner, G (corresponding author), Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA.		Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344	NIGMS NIH HHS [GM 47467, GM 38608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047467, R01GM038608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker SJ, 1996, ONCOGENE, V12, P1; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUNGER AT, 1994, XPLOR 3851 SYSTEM XR; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chou KC, 1997, FEBS LETT, V419, P49, DOI 10.1016/S0014-5793(97)01246-5; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; DELRIOPORTILLA F, 1994, J MAGN RESON SER A, V111, P132, DOI 10.1006/jmra.1994.1238; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LEVITT M, 1995, LOOK VERSION 2 0 MOL; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Matsuo H, 1996, J MAGN RESON SER B, V110, P112, DOI 10.1006/jmrb.1996.0018; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; WISHART DS, 1994, J BIOMOL NMR, V4, P171; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	36	275	281	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					171	180		10.1016/S0092-8674(00)81417-8	http://dx.doi.org/10.1016/S0092-8674(00)81417-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695946	Bronze			2022-12-28	WOS:000075020100006
J	Farrell, BD				Farrell, BD			"Inordinate fondness" explained: Why are there so many beetles?	SCIENCE			English	Article							INSECT DIVERSITY; COLEOPTERA; MORPHOLOGY	The phylogeny of the Phytophaga, the Largest and oldest radiation of herbivorous beetles, was reconstructed from 115 complete DNA sequences for the 18S nuclear ribosomal subunit and from 212 morphological characters. The results of these analyses were used to interpret the role of angiosperms in beetle diversification. Jurassic fossils represent basal Lineages that are still associated with conifers and cycads. Repeated origins of angiosperm-feeding beetle Lineages are associated with enhanced rates of beetle diversification, indicating a series of adaptive radiations. Collectively, these radiations represent nearly half of the species in the order Coleoptera and a similar proportion of herbivorous insect species.	Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA	Harvard University	Farrell, BD (corresponding author), Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA.	bfarrell@oeb.harvard.edu						ARNOLDII LV, 1991, MESOZOIC COLEOPTERA; Bily S., 1989, FAUNA ENTOMOLOGICA S, V22; BRUNDIN L, 1965, EVOLUTION, V19, P496, DOI 10.2307/2406246; Carpenter F. M., 1992, TREATISE INVERTEBR R, V4; CROWSON R A, 1985, Entomologist's Monthly Magazine, V121, P144; Crowson Roy A., 1991, P13; DOYLE JA, 1987, REV PALAEOBOT PALYNO, V50, P63, DOI 10.1016/0034-6667(87)90040-6; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.2307/2406212; FARRELL BD, 1991, AM NAT, V138, P881, DOI 10.1086/285258; Farrell BD, 1998, BIOL J LINN SOC, V63, P553, DOI 10.1006/bijl.1997.0207; GRIMALDI DA, 1990, B AM MUS NAT HIST, P1; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; Jernvall J, 1996, SCIENCE, V274, P1489, DOI 10.1126/science.274.5292.1489; JOLIVET P, BIOL CHRYSOMELIDAE, P88; JOLIVET P, 1995, HOST PLANTS CHRYSOME; Kuschel G., 1996, New Zealand Entomologist, V19, P1; Kuschel G., 1983, GeoJournal, V7, P499; Kuschel G., 1995, Memoirs of the Entomological Society of Washington, V14, P5; KUSCHEL G, 1993, ENTOMOL SCAND, V24, P143; Kuschel G., 1954, Revista Chilena de Historia Natural Santiago, V54, P97; KUSCHEL G, 1994, AUSTR WEEVILS, P569; KUSCHEL G, 1993, INVERTEBR TAXON, V3, P697; KUSCHEL G, 1994, AUSTR WEEVILS, P244; KUSCHEL GUILLERMO, 1959, INVEST ZOOL CHILENAS, V5, P229; LABANDEIRA CC, 1993, SCIENCE, V261, P310, DOI 10.1126/science.11536548; Lawrence J.F., 1982, P482; LINSLEY E. GORTON, 1961, UNIV CALIFORNIA PUBL ENT, V18, P1; MANN JS, 1981, J NAT HIST, V15, P727, DOI 10.1080/00222938100770531; Reid C.A.M., 1995, P559; Stockey R. A., 1978, PALAEONTOGR ABT B, V166, P1; STOCKEY RA, 1994, J PLANT RES, V107, P493, DOI 10.1007/BF02344070; STORK NE, 1988, BIOL J LINN SOC, V35, P321, DOI 10.1111/j.1095-8312.1988.tb00474.x; STRONG DR, 1984, INSECTS PLANTS; Taylor T.N., 1996, PALYNOLOGY PRINCIPLE, P427; THOMPSON RT, 1992, J NAT HIST, V26, P835, DOI 10.1080/00222939200770511; Whiting MF, 1997, SYST BIOL, V46, P1, DOI 10.1093/sysbio/46.1.1; Zherikhin V. V., 1995, PALEONTOL ZH, V29, P112; Zherikhin V.V., 1995, BIOL PHYLOGENY CLASS, P633; ZHERIKHIN VV, 1995, BIOL CLASSIFICATION, P646; ZIMMERMAN E, 1994, AUSTR WEEVILS, P504	40	597	627	4	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					555	559		10.1126/science.281.5376.555	http://dx.doi.org/10.1126/science.281.5376.555			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677197				2022-12-28	WOS:000075012300039
J	Hua, J; Meyerowitz, EM				Hua, J; Meyerowitz, EM			Ethylene responses are negatively regulated by a receptor gene family in Arabidopsis thaliana	CELL			English	Article							2-COMPONENT HISTIDINE KINASE; SIGNAL-TRANSDUCTION; PLANTS; PATHWAY; ETR1; INSENSITIVITY; DICTYOSTELIUM; PROTEINS; HOMOLOG; BINDING	A family of genes including ETR1, ETR2, EIN4, ERS1, and ERS2 is implicated in ethylene perception in Arabidopsis thaliana. As only dominant mutations were previously available for these genes, it was unclear whether all of them are components in the ethylene signaling pathway and whether they code for positive or negative regulators of ethylene responses. In this study, we have isolated loss-of-function mutations of four of these genes (ETR1, ETR2, EIN4, and ERS2) and identified an ethylene-independent role of ETR1 in promoting cell elongation. Quadruple mutants had constitutive ethylene responses, revealing that these proteins negatively regulate ethylene responses and that the induction of ethylene response in Arabidopsis is through inactivation rather than activation of these proteins.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009					Abeles F, 1992, ETHYLENE PLANT BIOL; Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; BEYER EM, 1976, PLANT PHYSIOL, V58, P268, DOI 10.1104/pp.58.3.268; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CALLIS J, 1990, J BIOL CHEM, V265, P12486; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Clark KL, 1998, P NATL ACAD SCI USA, V95, P5401, DOI 10.1073/pnas.95.9.5401; Conover JC, 1997, REV NEUROSCIENCE, V8, P13; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; HUA J, 1998, IN PRESS PLANT CELL; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUMAR PP, 1998, IN PRESS IN VITRO CE; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Neljubow D., 1901, BEIHEFTE ZUM BOT ZEN, V10, P128; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; ROMAN G, 1995, GENETICS, V139, P1393; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Schuster SC, 1996, EMBO J, V15, P3880, DOI 10.1002/j.1460-2075.1996.tb00762.x; Tanimoto M, 1995, PLANT J, V8, P943, DOI 10.1046/j.1365-313X.1995.8060943.x; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Wang N, 1996, EMBO J, V15, P3890, DOI 10.1002/j.1460-2075.1996.tb00763.x; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; Zhou DB, 1996, PLANT MOL BIOL, V30, P1331, DOI 10.1007/BF00019564	40	789	877	7	145	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					261	271		10.1016/S0092-8674(00)81425-7	http://dx.doi.org/10.1016/S0092-8674(00)81425-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695954	Bronze			2022-12-28	WOS:000075020100014
J	Cunningham, ET; Margolis, TP				Cunningham, ET; Margolis, TP			Ocular manifestations of HIV infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY-SYNDROME; ADNEXAL KAPOSIS-SARCOMA; RETINAL MICROVASCULOPATHY; VIRUS INFECTION; PATIENT; AIDS; TOXOPLASMOSIS; KERATITIS; LESIONS		Univ Calif San Francisco, Med Ctr, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Ophthalmol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cunningham, ET (corresponding author), Univ Calif San Francisco, Med Ctr, Francis I Proctor Fdn, San Francisco, CA 94143 USA.							Akduman L, 1995, Semin Ophthalmol, V10, P111, DOI 10.3109/08820539509059987; ANTLE CM, 1990, OPHTHALMOLOGY, V97, P1494; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BARDENSTEIN DS, 1995, OPHTHALMOLOGY, V102, P1031; Berenbaum F, 1996, BRIT J RHEUMATOL, V35, P295; BRYAN RT, 1995, CLIN INFECT DIS, V21, pS62, DOI 10.1093/clinids/21.Supplement_1.S62; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Cunningham ET, 1996, ARCH OPHTHALMOL-CHIC, V114, P834, DOI 10.1001/archopht.1996.01100140048006; Cunningham ET, 1997, ARCH OPHTHALMOL-CHIC, V115, P559; Currie J, 1995, Curr Opin Ophthalmol, V6, P34, DOI 10.1097/00055735-199512000-00006; Davis JL, 1997, ARCH OPHTHALMOL-CHIC, V115, P733, DOI 10.1001/archopht.1997.01100150735008; DENNEHY PJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P978, DOI 10.1001/archopht.1989.01070020040025; DUGEL PU, 1990, AM J OPHTHALMOL, V110, P500, DOI 10.1016/S0002-9394(14)77872-9; DUGEL PU, 1992, OPHTHALMOLOGY, V99, P1127; ENGSTROM RE, 1990, AM J OPHTHALMOL, V109, P153, DOI 10.1016/S0002-9394(14)75980-X; ENGSTROM RE, 1994, OPHTHALMOLOGY, V101, P1488; FREEMAN WR, 1989, AM J OPHTHALMOL, V107, P229, DOI 10.1016/0002-9394(89)90304-8; FREEMAN WR, 1984, AM J OPHTHALMOL, V97, P133, DOI 10.1016/S0002-9394(14)76082-9; GLASGOW BJ, 1994, AM J OPHTHALMOL, V118, P46, DOI 10.1016/S0002-9394(14)72841-7; Glasgow BJ, 1997, OPHTHALMOLOGY, V104, P753, DOI 10.1016/S0161-6420(97)30237-1; Gonzalez CR, 1996, RETINA-J RET VIT DIS, V16, P305, DOI 10.1097/00006982-199616040-00005; HEMADY RK, 1995, OPHTHALMOLOGY, V102, P1026; Hodge WG, 1997, OPHTHALMOLOGY, V104, P120, DOI 10.1016/S0161-6420(97)30351-0; HOLLAND GN, 1988, AM J OPHTHALMOL, V106, P653, DOI 10.1016/0002-9394(88)90697-6; HOLLAND GN, 1982, AM J OPHTHALMOL, V93, P393, DOI 10.1016/0002-9394(82)90127-1; Jabs DA, 1997, AM J OPHTHALMOL, V124, P227, DOI 10.1016/S0002-9394(14)70789-5; Jabs DQT, 1996, OCULAR INFECT IMMUNI, P289; Jacobson MA, 1997, NEW ENGL J MED, V337, P105, DOI 10.1056/NEJM199707103370207; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Jacobson MA, 1997, NEW ENGL J MED, V337, P1019; KARBASSI M, 1992, SURV OPHTHALMOL, V36, P395, DOI 10.1016/S0039-6257(05)80021-9; Kronish JW, 1996, OPHTHALMOLOGY, V103, P1483, DOI 10.1016/S0161-6420(96)30479-X; Lewallen S, 1997, ARCH OPHTHALMOL-CHIC, V115, P1291, DOI 10.1001/archopht.1997.01100160461014; LOPEZ JS, 1992, AM J OPHTHALMOL, V113, P331, DOI 10.1016/S0002-9394(14)71588-0; Lowder CY, 1996, AM J OPHTHALMOL, V121, P715, DOI 10.1016/S0002-9394(14)70642-7; LUCCA JA, 1990, OPHTHALMOLOGY, V97, P1008; MARION RW, 1987, AM J DIS CHILD, V141, P429, DOI 10.1001/archpedi.1987.04460040087022; Miller NR, 1995, WALSH HOYTS CLIN N 2, V5, P4107; Moorthy RS, 1997, BRIT J OPHTHALMOL, V81, P189, DOI 10.1136/bjo.81.3.189; MORINELLI EN, 1993, OPHTHALMOLOGY, V100, P1014; Mueller AJ, 1997, AM J OPHTHALMOL, V124, P158, DOI 10.1016/S0002-9394(14)70780-9; Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203; Nichols CW, 1996, CLIN INFECT DIS, V22, pS43, DOI 10.1093/clinids/22.Supplement_1.S43; Ormerod LD, 1996, OPHTHALMOLOGY, V103, P899, DOI 10.1016/S0161-6420(96)30589-7; Reed JB, 1997, AM J OPHTHALMOL, V124, P199, DOI 10.1016/S0002-9394(14)70784-6; SHAH GK, 1995, AM J OPHTHALMOL, V120, P669, DOI 10.1016/S0002-9394(14)72216-0; Shalaby IA, 1997, ARCH OPHTHALMOL-CHIC, V115, P469, DOI 10.1001/archopht.1997.01100150471003; Silverstein BE, 1997, AM J OPHTHALMOL, V123, P254, DOI 10.1016/S0002-9394(14)71044-X; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P614, DOI 10.1001/jama.277.8.614; TEICH SA, 1987, AM J OPHTHALMOL, V103, P332; Tschachler E, 1996, LANCET, V348, P659, DOI 10.1016/S0140-6736(96)01032-X; TURNER BJ, 1994, ARCH INTERN MED, V154, P1561, DOI 10.1001/archinte.154.14.1561; *UNAIDS WHO, 1997, UNAIDS WHO REP GLOB; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; WHITCUP SM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1594, DOI 10.1001/archopht.1994.01090240100033; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519; WILHELMUS KR, 1995, AM J OPHTHALMOL, V119, P14, DOI 10.1016/S0002-9394(14)73808-5; Wilhelmus KR., 1996, OCULAR INFECT IMMUNI, P1088; Wiznia AA, 1996, MED CLIN N AM, V80, P1309, DOI 10.1016/S0025-7125(05)70492-2; YOUNG TL, 1989, OPHTHALMOLOGY, V96, P1476; Zegans M. E., 1997, Investigative Ophthalmology and Visual Science, V38, pS739; 1997, MMWR MORB MORTAL WKL, V46, P165	62	107	114	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					236	244		10.1056/NEJM199807233390406	http://dx.doi.org/10.1056/NEJM199807233390406			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673303				2022-12-28	WOS:000074918700006
J	Kobayashi, K; Nakahori, Y; Miyake, M; Matsumura, K; Kondo-Iida, E; Nomura, Y; Segawa, M; Yoshioka, M; Saito, K; Osawa, K; Hamano, K; Sakakihara, Y; Nonaka, I; Nakagome, Y; Kanazawa, I; Nakamura, Y; Tokunaga, K; Toda, T				Kobayashi, K; Nakahori, Y; Miyake, M; Matsumura, K; Kondo-Iida, E; Nomura, Y; Segawa, M; Yoshioka, M; Saito, K; Osawa, K; Hamano, K; Sakakihara, Y; Nonaka, I; Nakagome, Y; Kanazawa, I; Nakamura, Y; Tokunaga, K; Toda, T			An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy	NATURE			English	Article							LINKAGE-DISEQUILIBRIUM; GLYCOPROTEIN COMPLEX; LOCALIZATION; GENE; PROTEINS; FCMD	Fukuyama-type congenital muscular dystrophy (FCMD), one of the most common autosomal recessive disorders in Japan (incidence is 0.7-1.2 per 10,000 births), is characterized by congenital muscular dystrophy associated with brain malformation (micropolygria) due to a defect in the migration of neurons(1). We previously mapped the FCMD gene to a region of less than 100 kilobases which included the marker locus D9S2107 on chromosome 9q31 (refs 2-4). We have also described a haplotype that is shared by more than 80% of FCMD chromosomes, indicating that most chromosomes bearing the FCMD mutation could be derived hom a single ancestor(5). Here we report that there is a retrotransposal insertion of tandemly repeated sequences within this candidate-gene interval in all FCMD chromosomes carrying the founder haplotype (87%). The inserted sequence is about 3 kilobases long and is located in the 3' untranslated region of a gene encoding a new 461-amino-acid protein. This gene is expressed in various tissues in normal individuals, but not in FCMD patients who carry the insertion. Two independent point mutations confirm that mutation of this gene is responsible for FCMD. The predicted protein, which we term fukutin, contains an amino-terminal signal sequence, which together with results from transfection experiments suggests that fukutin is a secreted protein. To our knowledge, FCMD is the first human disease to be caused by an ancient retrotransposal integration.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Med,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Med, Dept Human Genet, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Neurol, Tokyo 1130033, Japan; Univ Tokushima, Sch Med, Dept Publ Hlth, Tokushima 7708503, Japan; Teikyo Univ, Sch Med, Dept Neurol, Tokyo 1738605, Japan; Tokyo Womens Med Coll, Dept Pediat, Tokyo 1628666, Japan; Segawa Neurol Clin Children, Tokyo 1010062, Japan; Kobe Gen Hosp, Dept Pediat, Kobe, Hyogo 6500046, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 3058576, Japan; Natl Inst Neurosci, NCNP, Dept Ultrastruct Res, Tokyo 1878502, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Tokushima University; Teikyo University; Tokyo Women's Medical University; Kobe City Medical Center General Hospital; University of Tsukuba; National Center for Neurology & Psychiatry - Japan	Toda, T (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	toda@ims.u-tokyo.ac.jp	Kobayashi, Kazuhiro/AAH-8638-2021	Kobayashi, Kazuhiro/0000-0001-7801-147X; Saito, Kayoko/0000-0003-2632-0873; Toda, Tatsushi/0000-0002-0717-1123				BANNAI M, 1994, EUR J IMMUNOGENET, V21, P1, DOI 10.1111/j.1744-313X.1994.tb00170.x; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; des Portes V, 1998, CELL, V92, P51; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FUKUYAMA Y, 1981, BRAIN DEV-JPN, V3, P1; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; HAYASHI YK, 1993, J NEUROL SCI, V119, P53, DOI 10.1016/0022-510X(93)90191-Z; Ishii H, 1997, NEUROMUSCULAR DISORD, V7, P191, DOI 10.1016/S0960-8966(97)00462-8; KOBAYASHI K, IN PRESS HUM GENET; MATSUMURA K, 1993, LANCET, V341, P521, DOI 10.1016/0140-6736(93)90279-P; Miyake M, 1997, GENOMICS, V40, P284, DOI 10.1006/geno.1996.4584; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakano I, 1996, ACTA NEUROPATHOL, V91, P313, DOI 10.1007/s004010050431; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TODA T, 1993, NAT GENET, V5, P283, DOI 10.1038/ng1193-283; Toda T, 1996, AM J HUM GENET, V59, P1313; TODA T, 1994, AM J HUM GENET, V55, P946; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; [No title captured]	22	621	636	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					388	392		10.1038/28653	http://dx.doi.org/10.1038/28653			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690476				2022-12-28	WOS:000074968800056
J	Bray, GA				Bray, GA			Obesity: a time bomb to be defused	LANCET			English	Editorial Material									Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Bray, GA (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.							BRAY G, 1996, ORIGINS CONSEQUENCES, P228; Bray GA, 1998, RECENT PROG HORM RES, V53, P95; Chagnon YC, 1998, OBES RES, V6, P76, DOI 10.1002/j.1550-8528.1998.tb00318.x; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Jeffcoate W, 1996, LANCET, V347, P451, DOI 10.1016/S0140-6736(96)90018-5; Kassirer JP, 1998, NEW ENGL J MED, V338, P52, DOI 10.1056/NEJM199801013380109; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Quesenberry CP, 1998, ARCH INTERN MED, V158, P466, DOI 10.1001/archinte.158.5.466; RAVUSSIN E, 1993, DIABETES CARE, V16, P232, DOI 10.2337/diacare.16.1.232; Sjostrom CD, 1997, OBES RES, V5, P519; THOMAS PR, 1995, WEIGHTING OPTIONS CR; Wilding J, 1997, BRIT MED J, V315, P997, DOI 10.1136/bmj.315.7114.997; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; Wolf AM, 1998, OBES RES, V6, P97, DOI 10.1002/j.1550-8528.1998.tb00322.x; World Health Organization, 1997, OB PREV MAN GLOB EP; YOUNG LM, 1985, J HEALTH SOC BEHAV, V26, P233, DOI 10.2307/2136755; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	17	91	101	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					160	161		10.1016/S0140-6736(98)22029-0	http://dx.doi.org/10.1016/S0140-6736(98)22029-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683198				2022-12-28	WOS:000074859800002
J	Callaham, ML; Wears, RL; Weber, EJ; Barton, C; Young, G				Callaham, ML; Wears, RL; Weber, EJ; Barton, C; Young, G			Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			PUBLICATION BIAS; CLINICAL RESEARCH; QUALITY; TRIALS; FATE	Context.-Studies with positive results are more likely to be published in biomedical journals than are studies with negative results. However, many studies submitted for consideration at scientific meetings are never published in full; bias in this setting is poorly studied. Objective.-To identify features associated with the fate of research abstracts submitted to a scientific meeting. Design and Setting.-Prospective observational cohort, with 5-year follow-up of all research submitted for consideration to the major annual 1991 US research meeting in the specialty of emergency medicine. Participants.-All research abstracts submitted for consideration at the meeting for possible presentation. Main Outcome Measures.-Characteristics associated with acceptance for presentation at the meeting and subsequent publication as a full manuscript. Results.-A total of 492 research abstracts were submitted from programs in emergency medicine and other specialies affiliated with 103 US medical schools, A total of 179 (36%) were accepted for presentation and 214 (43%) were published in 44 journals. Of the 179 abstracts accepted for presentation, 111 studies were published. Scientific quality of abstracts or prestige of the journal in which the study was eventually published did not predict either of these outcomes. The best predictors (by logistic regression) of meeting acceptance were a subjective "originality" factor (odds ratio [OR], 2.07; 95% confidence interval [CI], 1.13-3.89) and positive results (OR, 1.99; 95% CI, 1.07-3.84), and, for publication, meeting acceptance (OR, 2.49; 95% CI, 1.49-4.35) and large sample size (OR, 2.26; 95% CI, 1,23-4.31). Forty-nine percent (241) of abstracts did not report on blinding, and 24% (118) did not report on randomization. Acceptance and publication were both more likely for positive outcomes (P=.03). Funnel plots showed the classic distribution of positive-outcome ("publication") bias at each of the submission, acceptance, and publication phases. Meeting acceptance predicted publication with a sensitivity of only 51%, specificity of 71%, positive predictive value of 57%, and negative predictive value of 66%. Conclusions.-Positive-outcome bias was evident when studies were submitted for consideration and was amplified in the selection of abstracts for both presentation and publication, neither of which was strongly related to study design or quality.	Univ Calif San Francisco, Div Emergency Med, San Francisco, CA 94143 USA; Univ Florida, Div Emergency Med, Gainesville, FL USA; Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA; Highland Hosp, Alameda Cty Med Ctr, Dept Emergency Med, Alameda, CA USA	University of California System; University of California San Francisco; State University System of Florida; University of Florida; University of North Carolina; University of North Carolina Chapel Hill	Callaham, ML (corresponding author), Univ Calif San Francisco, Div Emergency Med, Box 0208, San Francisco, CA 94143 USA.	mlc@itsa.ucsf.edu	Weber, Ellen/GRR-9967-2022; Wears, Robert/N-5959-2014	Wears, Robert/0000-0001-9826-954X; Callaham, Michael/0000-0003-2284-256X; Weber, Ellen/0000-0002-0094-1973				BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; BERLIN JA, 1992, ONLINE J CURR CLIN T; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; DEBELLEFEUILLE C, 1992, ANN ONCOL, V3, P187, DOI 10.1093/oxfordjournals.annonc.a058147; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Dickersin K., 1993, ONLINE J CURR CLIN T, pDoc No 50; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Gallagher E J, 1994, Acad Emerg Med, V1, P41; Garfield E., 1993, SCI J CITATION REPOR; GARFIELD E, 1992, SCI J CITATION REPOR; GARFIELD E, 1991, SCI J CITATION REPOR; GARFIELD E, 1994, SCI J CITATION REPOR; GARFUNKEL JM, 1994, JAMA-J AM MED ASSOC, V272, P137, DOI 10.1001/jama.272.2.137; GOLDMAN L, 1980, NEW ENGL J MED, V303, P255, DOI 10.1056/NEJM198007313030504; HOSMER DW, 1989, APPL LOGISTIC REGRES; KOREN G, 1989, LANCET, V2, P1440; MCCORMICK MC, 1985, AM J DIS CHILD, V139, P122, DOI 10.1001/archpedi.1985.02140040020017; MERANZE J, 1982, ANESTH ANALG, V61, P445; Moscati R, 1994, Acad Emerg Med, V1, P267; NEWCOMBE RG, 1987, BRIT MED J, V295, P656, DOI 10.1136/bmj.295.6599.656; Olson C M, 1994, Acad Emerg Med, V1, P207; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; SCHERER RW, 1994, JAMA-J AM MED ASSOC, V272, P158, DOI 10.1001/jama.272.2.158; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Weber EJ, 1998, JAMA-J AM MED ASSOC, V280, P257, DOI 10.1001/jama.280.3.257; WEINTRAUB WH, 1987, J PEDIATR SURG, V22, P11, DOI 10.1016/S0022-3468(87)80005-2; WUERZ R, 1994, ACAD EMERG MED, V1, pA59; [No title captured]	31	197	199	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					254	257		10.1001/jama.280.3.254	http://dx.doi.org/10.1001/jama.280.3.254			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZZ204	9676673	Bronze			2022-12-28	WOS:000074706000018
J	Grigsby, J; Sanders, JH				Grigsby, J; Sanders, JH			Telemedicine: Where it is and where it's going	ANNALS OF INTERNAL MEDICINE			English	Article								The term telemedicine encompasses a wide range of telecommunications and information technologies and many clinical applications, although interactive video may be the most common medium. The first telemedicine programs were established almost 40 years ago, but the technology has grown considerably in the past decade. Despite the expansion of telemedicine, the volume of patients receiving services that use the technology remains relatively low (about 21 000 in 1996). In part, this reflects the lack of a consistent coverage and payment policy and concerns about licensure, liability, and other issues. A considerable amount of federal funding has supported telemedicine in recent years, and legislators and federal, regional, and state policymakers are struggling with several crucial policy matters. Research on the effectiveness of telemedicine is somewhat limited, although the work that has been done thus far supports the hypothesis that, in general, the technology is medically effective. The cost-effectiveness of specific telemedicine applications has not yet been rigorously demonstrated.	Univ Colorado, Hlth Sci Ctr, Ctr Hlth Serv & Policy Res, Denver, CO 80222 USA; Global Telemed Grp, Mclean, VA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Grigsby, J (corresponding author), Univ Colorado, Hlth Sci Ctr, Ctr Hlth Serv & Policy Res, 1355 S Colorado Blvd 306, Denver, CO 80222 USA.							Alboliras E T, 1996, Telemed J, V2, P251, DOI 10.1089/tmj.1.1996.2.251; ARMSTRONG PA, 1975, TELEMEDICINE EXPLORA, P309; Bashshur R L, 1995, Telemed J, V1, P19, DOI 10.1089/tmj.1.1995.1.19; BASHSHUR RL, 1979, TECHNOLOGY SERVES PE; Belmont J M, 1995, Telemed J, V1, P133, DOI 10.1089/tmj.1.1995.1.133; BENSCHOTER RA, 1967, ANN NY ACAD SCI, V142, P471, DOI 10.1111/j.1749-6632.1967.tb14360.x; Bruderman I, 1997, Telemed J, V3, P127, DOI 10.1089/tmj.1.1997.3.127; CAWTHON MA, 1991, INVEST RADIOL, V26, P854, DOI 10.1097/00004424-199110000-00002; CONRATH DW, 1977, BEHAV SCI, V22, P12, DOI 10.1002/bs.3830220103; Dunn B E, 1997, Telemed J, V3, P1, DOI 10.1089/tmj.1.1997.3.1; DWYER TF, 1973, AM J PSYCHIAT, V130, P865, DOI 10.1176/ajp.130.8.865; Field MJ, 1996, TELEMEDICINE GUIDE A; Gellman R, 1995, Telemed J, V1, P189, DOI 10.1089/tmj.1.1995.1.189; Gilbert F, 1995, Telemed J, V1, P91, DOI 10.1089/tmj.1.1995.1.91; Gomez E, 1996, Telemed J, V2, P201, DOI 10.1089/tmj.1.1996.2.201; Granade P F, 1995, Telemed J, V1, P87, DOI 10.1089/tmj.1.1995.1.87; Grigsby B, 1997, Telemed Today, V5, P30; GRIGSBY B, 1997, TELEMED TODAY, V5, P42; Grigsby J, 1995, Health Care Financ Rev, V17, P115; GRIGSBY J, 1993, TELEMEDICINE LIT REV; Hassol A, 1996, Telemed J, V2, P43, DOI 10.1089/tmj.1.1996.2.43; HOUSE AM, 1977, CAN MED ASSOC J, V117, P386; Houtchens BA, 1993, PREHOSP DISASTER MED, V8, P57; JUSTICE JW, 1979, ADV BIOMED ENG, V7, P101; Kaye L W, 1997, Telemed J, V3, P243, DOI 10.1089/tmj.1.1997.3.243; LIPSON L, 1995, STATE INITIATIVES PR; MOORE GT, 1975, NEW ENGL J MED, V292, P729, DOI 10.1056/NEJM197504032921406; MURPHY RLH, 1973, CHEST, V63, P578, DOI 10.1378/chest.63.4.578; MURPHY RLH, 1974, AM J PUBLIC HEALTH, V64, P113, DOI 10.2105/AJPH.64.2.113; Nitzkin J L, 1997, Telemed J, V3, P141, DOI 10.1089/tmj.1.1997.3.141; *OFF TECHN ASS US, 1995, BRING HLTH CAR ONL; PEDERSEN S, 1994, ARCH OTOLARYNGOL, V120, P133; PEREDNIA DA, 1995, JAMA-J AM MED ASSOC, V273, P483, DOI 10.1001/jama.273.6.483; *PHYS PAYM REV COM, 1995, PHYS PAYM REV COMM A; Sanders J H, 1995, Telemed J, V1, P115, DOI 10.1089/tmj.1.1995.1.115; SATAVA RM, 1992, MINIM INVASIV THER, V1, P357; Shannon G W, 1997, Telemed J, V3, P269, DOI 10.1089/tmj.1.1997.3.269; WITTSON CL, 1972, AM J PSYCHIAT, V129, P624, DOI 10.1176/ajp.129.5.624; Zincone L H Jr, 1997, Telemed J, V3, P247, DOI 10.1089/tmj.1.1997.3.247; 1995, TELEMED J, V1, P321	40	109	120	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					123	127		10.7326/0003-4819-129-2-199807150-00012	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669971				2022-12-28	WOS:000074852000008
J	Rennie, D				Rennie, D			Freedom and responsibility in medical publication - Setting the balance right	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	3rd International Congress on Peer Review in Biomedical Publication	SEP, 1997	PRAGUE, CZECH REPUBLIC	Journal of the Amer Med Assoc, British Med J, Project HOPE			ANONYMITY; REVIEWERS; HEALTH		JAMA, Chicago, IL 60610 USA		Rennie, D (corresponding author), JAMA, 515 N State St, Chicago, IL 60610 USA.							ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P166, DOI 10.1001/jama.272.2.166; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; BERO L, 1997, C PEER REV GLOB COMM; CANTEKIN EI, 1990, JAMA-J AM MED ASSOC, V263, P1427, DOI 10.1001/jama.263.10.1427; Cho MK, 1998, JAMA-J AM MED ASSOC, V280, P243, DOI 10.1001/jama.280.3.243; Davidoff F, 1998, ANN INTERN MED, V128, P66, DOI 10.7326/0003-4819-128-1-199801010-00011; FABIATO A, 1994, CARDIOVASC RES, V28, P1134, DOI 10.1093/cvr/28.8.1134; Godlee F, 1998, JAMA-J AM MED ASSOC, V280, P237, DOI 10.1001/jama.280.3.237; HEARSE DJ, 1994, CARDIOVASC RES, V28, P1133, DOI 10.1093/cvr/28.8.1133; HORROBIN D, 1994, CARDIOVASC RES, V28, P1141; HORROBIN DF, 1990, JAMA-J AM MED ASSOC, V263, P1438, DOI 10.1001/jama.263.10.1438; Horton R, 1998, LANCET, V351, P688, DOI 10.1016/S0140-6736(98)22010-1; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; Justice AC, 1998, JAMA-J AM MED ASSOC, V280, P240, DOI 10.1001/jama.280.3.240; LOCK S, 1994, CARDIOVASC RES, V28, P1141; MARSHALL E, 1995, SCIENCE, V270, P1912, DOI 10.1126/science.270.5244.1912; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; Northridge M, 1998, AM J PUBLIC HEALTH, V88, P733, DOI 10.2105/AJPH.88.5.733; OSMOND DH, 1983, J NEUROBIOL, V14, P95, DOI 10.1002/neu.480140202; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; Rennie D, 1998, AM J PUBLIC HEALTH, V88, P828, DOI 10.2105/AJPH.88.5.828; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; RENNIE D, 1991, JAMA-J AM MED ASSOC, V266, P3333, DOI 10.1001/jama.266.23.3333; RENNIE D, 1994, CARDIOVASC RES, V28, P1142; RENNIE D, 1991, BALANCING ACT ESSAYS, P9; SIMS I, 1997, THESIS STANFORD U ST; Smith R, 1997, BRIT MED J, V315, P696, DOI 10.1136/bmj.315.7110.696; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; VANDERWEYDEN M, 1997, MED J AUSTR; 1998, ANN INTERN MED, V128, P11	30	42	44	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1998	280	3					300	302		10.1001/jama.280.3.300	http://dx.doi.org/10.1001/jama.280.3.300			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ204	9676691	Bronze			2022-12-28	WOS:000074706000036
J	Grasland, A; Pouchot, J; Regnard, JF; Vinceneux, P				Grasland, A; Pouchot, J; Regnard, JF; Vinceneux, P			A 20-year-old with severe arm pain	LANCET			English	Article									Univ Paris 07, Hop Louis Mourier, Serv Med Interne, F-92700 Colombes, France; Hop Marie Lannelongue, Serv Chirurg Thorac & Vasc, F-92350 Le Plessis Robinson, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Marie Lannelongue	Grasland, A (corresponding author), Univ Paris 07, Hop Louis Mourier, Serv Med Interne, 178 Rue Renouillers, F-92700 Colombes, France.							JIRIK FR, 1982, ANN INTERN MED, V97, P48, DOI 10.7326/0003-4819-97-1-48; KAHN MF, 1995, J RHEUMATOL, V22, P2017; Mackinnon S E, 1996, Semin Thorac Cardiovasc Surg, V8, P176; Mackinnon S E, 1996, Semin Thorac Cardiovasc Surg, V8, P190; VANHOLSBEECK M, 1989, SKELETAL RADIOL, V18, P1	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					110	110						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672277				2022-12-28	WOS:000074775100015
J	Perrin, L; Telenti, A				Perrin, L; Telenti, A			HIV treatment failure: Testing for HIV resistance in clinical practice	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; PREVALENCE; ZIDOVUDINE		CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva	Perrin, L (corresponding author), Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland.		Telenti, Amalio/AAY-1674-2021					Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1133, DOI 10.1126/science.279.5354.1133; DEEKS S, 1998, 5 C RETR OPP INF CHI; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; GERVAIX A, COMMUNICATION; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; HAVLIR DV, 1998, 5 C RETR OPP INF CHI; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Jellinger RM, 1997, J INFECT DIS, V175, P561, DOI 10.1093/infdis/175.3.561; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lorenzi P, 1997, AIDS, V11, pF95, DOI 10.1097/00002030-199712000-00002; MAYERS D, 1997, INT WORKSH HIV DRUG; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Nijhuis M, 1997, J INFECT DIS, V176, P398, DOI 10.1086/514056; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PERRIN L, UNPUB; Quigg M, 1997, AIDS, V11, P835; RAFFI R, 1998, 5 C RETR OPP INF CHI; Roberts NA, 1998, AIDS, V12, P453, DOI 10.1097/00002030-199805000-00005; Roederer M, 1998, NAT MED, V4, P145, DOI 10.1038/nm0298-145; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; Schinazi R. F., 1997, International Antiviral News, V5, P129; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; Stuyver L, 1997, ANTIMICROB AGENTS CH, V41, P284, DOI 10.1128/AAC.41.2.284; Winters MA, 1997, ANTIMICROB AGENTS CH, V41, P757, DOI 10.1128/AAC.41.4.757; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; YERLY S, COMMUNICATION; Zhang YM, 1997, J VIROL, V71, P6662, DOI 10.1128/JVI.71.9.6662-6670.1997	38	172	179	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1871	1873		10.1126/science.280.5371.1871	http://dx.doi.org/10.1126/science.280.5371.1871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669946				2022-12-28	WOS:000074323800042
J	Nightingale, SL				Nightingale, SL			New mammography screening aid approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					410	410		10.1001/jama.280.5.410-b	http://dx.doi.org/10.1001/jama.280.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701062				2022-12-28	WOS:000075050200006
J	Nightingale, SL				Nightingale, SL			New prescribing information about standardized grass pollen extracts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1998	280	5					410	410		10.1001/jama.280.5.410-b	http://dx.doi.org/10.1001/jama.280.5.410-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105AR	9701062				2022-12-28	WOS:000075050200009
